<SEC-DOCUMENT>0001193125-24-215436.txt : 20240909
<SEC-HEADER>0001193125-24-215436.hdr.sgml : 20240909
<ACCEPTANCE-DATETIME>20240909060634
ACCESSION NUMBER:		0001193125-24-215436
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		27
FILED AS OF DATE:		20240909
DATE AS OF CHANGE:		20240909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MBX Biosciences, Inc.
		CENTRAL INDEX KEY:			0001776111
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281764
		FILM NUMBER:		241285721

	BUSINESS ADDRESS:	
		STREET 1:		12406 HORESHAM STREET
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
		BUSINESS PHONE:		3179893100

	MAIL ADDRESS:	
		STREET 1:		12406 HORESHAM STREET
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d790774ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>As filed with the Securities and Exchange Commission on September 9, 2024. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Registration No.&nbsp;333&#150;281764 </B></P>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>Amendment No. 2
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:20pt; font-family:arial" ALIGN="center"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center">(Exact name of
registrant as specified in its charter) </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">84-1882872</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>MBX Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>11711 N. Meridian Street, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Carmel, Indiana 46032 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(317) <FONT
STYLE="white-space:nowrap">659-0200</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>P. Kent Hawryluk </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>President and Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>MBX Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>11711 N. Meridian Street, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Carmel, Indiana 46032 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(317) <FONT
STYLE="white-space:nowrap">659-0200</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for
service) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Mitchell S. Bloom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Edwin O&#146;Connor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Daniel Hughes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>100 Northern
Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Boston, Massachusetts 02210</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Richard D. Truesdell, Jr.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Yasin Keshvargar</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Davis Polk&nbsp;&amp;
Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>450 Lexington Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>New York, New York 10017</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">450-4000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public</B>: As soon as practicable after the effective date of this registration statement.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as
amended, check the following box.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Exchange Act.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant files a further
amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such
date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT COLOR="#8b3f4e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the Securities and Exchange Commission declares our registration statement effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><FONT COLOR="#8b3f4e"><B>Subject to completion, dated September 9, 2024 </B></FONT></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>PRELIMINARY PROSPECTUS </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B><I>8,500,000 Shares </I></B></P>
 <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g00m01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This is
an initial public offering of shares of common stock of MBX Biosciences, Inc. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering 8,500,000 shares of our common stock. We expect that the initial
public offering price will be between $14.00 and $16.00 per share. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock. We have
applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; We believe that upon the completion of this offering, we will meet the standards for listing on the Nasdaq Global Select Market, and the closing of
this offering is contingent upon such listing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; under the federal
securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and for future filings. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investing in our common stock involves a high degree of risk. Before buying any shares, you should read carefully the discussion of the material risks of investing in
our common stock under the heading &#147;<A HREF="#toc790774_4">Risk factors</A>&#148; starting on page 16 of this prospectus. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Underwriting discounts and commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds, before expenses, to MBX Biosciences, Inc.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; beginning on page&nbsp;212 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted the underwriters an option for a period of 30 days to purchase an additional 1,275,000 shares of our common stock from us at the initial public offering
price, less underwriting discounts and commissions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At our request, the underwriters have reserved up to 5% of the shares offered by this prospectus for sale, at
the initial public offering price, to our directors, officers, certain employees and certain other persons associated with us. See &#147;Underwriting&#151;Directed share program.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to deliver the shares against payment in New York, New York on &#8195;&#8195;&#8195;&#8195;, 2024. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="top"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Stifel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Guggenheim&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Prospectus dated&#8195;&#8195;&#8195;&#8195;, 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc"></A>Table of contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_1">Prospectus summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_2">The offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_3">Summary financial data</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_4">Risk factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_5">Special note regarding forward-looking statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_6">Use of proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_7">Dividend policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_10">Management&#146;s discussion and analysis of financial condition and results of operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_13">Executive compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_14">Certain relationships and related person transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_15">Principal stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_16">Description of capital stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_17">Shares eligible for future sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_18">Material U.S. federal income tax considerations for <FONT STYLE="white-space:nowrap">non-U.S.
</FONT> holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_20">Legal matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_22">Where you can find more information</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_23">Index to financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than
those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide
no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so.
The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our
business, financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For investors outside the United States: We have not, and the
underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States
who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Market data and certain other statistical information used throughout this prospectus are based on independent
industry publications, governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys, and studies generally indicate that
their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this prospectus, and we believe that
these sources are reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates,
in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled &#147;Risk factors&#148; and
elsewhere in this prospectus. Some data are also based on our good faith estimates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to apply for various trademarks that we use in connection with the
operation of our business. This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#146; trademarks, service marks, trade
names or products in this prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear
without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or
the right of the applicable owner of these trademarks, service marks and trade names. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_1"></A>Prospectus summary </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>This summary highlights information contained in greater detail elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes thereto included elsewhere in this prospectus. You should also
consider, among other things, the information set forth under the sections entitled &#147;Risk factors,&#148; &#147;Special note regarding forward-looking statements,&#148; and &#147;Management&#146;s discussion and analysis of financial condition
and results of operations,&#148; in each case included elsewhere in this prospectus. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and
metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or PEP<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and
simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically
validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>MBX 2109:</B> Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a
potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous,
infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. In a Phase 1 clinical trial, MBX 2109 demonstrated a low ratio between the highest concentration of active drug observed after a dose and the
concentration of active drug observed immediately prior to the next dose, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio, which is consistent with a continuous, infusion-like profile, and an
extended half-life, potentially enabling the first once-weekly PTH dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2
clinical trial in patients with HP and dosed our first patient in this trial in August 2024. We anticipate reporting topline data in the third quarter of 2025. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>MBX 1416:</B> We are advancing MBX 1416, which is designed to be a long-acting glucagon-like peptide-1, or <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, or PBH, a chronic complication of bariatric surgery. MBX 1416 is designed as a convenient once-weekly therapy to reduce insulin
secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events. In our ongoing Phase&nbsp;1 clinical trial, preliminary data regarding the way the compound is absorbed, distributed, metabolized and excreted, or
pharmacokinetics, from the single ascending dose portion demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional
single ascending dose and multiple ascending dose data from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Obesity portfolio:</B> Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent <FONT
STYLE="white-space:nowrap">GLP-1</FONT> and glucose-dependent insulinotropic polypeptide, or GIP, receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> prodrug with the goal of reducing dosing frequency and improving efficacy and tolerability
relative to existing standards of </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
care. In our preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component of MBX 4291, supporting the potential for once-monthly administration. During our preclinical
studies, the concentration of the active component of MBX 4291 was significantly lower than the concentration of tirzepatide during the comparison period. Although we believe MBX 4291 has the potential to be dosed less frequently, less frequent
dosing would necessarily require a higher dose of MBX 4291. The results observed from our preclinical studies may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. In addition, the study supporting
potential duration of MBX 4291 was conducted separately from studies evaluating its effects. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an anticipated investigational new drug, or IND, submission in
the second quarter of 2025. Beyond MBX 4291, we have a robust discovery pipeline including multiple programs in the lead optimization stage of development. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate their function and maintain homeostasis, which impact metabolism,
growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. In addition to using peptides as hormone replacement therapies, peptide-based
drugs have been developed as pharmacologic agents to treat endocrine and other diseases. However, whether as replacement therapies or novel pharmacological actions, these therapeutic peptides often have significant drawbacks. Unmodified peptides
often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours<B> </B>by<B><I> </I></B>the liver and kidney. This often necessitates frequent, daily injections of these peptides, which can result in wide
fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high levels of the peptide. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens. Although these convenient, patient-friendly therapies
could increase compliance and result in improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios, which can lead to side effects and limit potential
efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent injections and have the potential to provide improved
efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we are designing and developing novel peptide therapeutics with the goal of achieving four key, distinct attributes: 1) high potency, 2) high target
selectivity, 3) half-lives that allow for dosing at weekly or less frequent intervals, and 4) low or flat <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios to improve tolerability, thereby
facilitating higher dosing and greater potential efficacy. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our platform </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have built our proprietary PEP platform to develop innovative precision peptide therapies that are designed to overcome key limitations of current peptide therapies.
We were founded by leaders in the field of peptide discovery and development with the goal of transforming the treatment landscape for endocrine and metabolic diseases with novel, efficacious, safe and convenient treatments. Our PEP platform builds
upon the expertise and chemical technologies originally discovered at the Indiana University laboratory of our scientific <FONT STYLE="white-space:nowrap">co-founder,</FONT> Dr.&nbsp;Richard DiMarchi, who is globally recognized for translational
breakthroughs in endocrine pharmacology, including the discovery of the first <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist</FONT> as well as other dual and triple incretin agonists. Our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art,</FONT></FONT></FONT> proprietary PEP platform has enabled us to engineer novel product candidates that are designed to have optimized
pharmaceutical properties, including a longer duration of action, consistent drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios, and less frequent dosing, which support
our goals of improved tolerability, efficacy </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and potency. We currently rely on the discovery capabilities of Dr. DiMarchi through the Indiana University laboratory, but are continuing to grow and develop our internal discovery and
development capacity, including having hired an experienced <FONT STYLE="white-space:nowrap">cross-functional</FONT> discovery team and building a peptide synthesis laboratory that will fully launch in the third quarter of 2024. We have developed a
proprietary platform of tools that we believe will allow us to continually design transformative therapies. These proprietary tools and <FONT STYLE="white-space:nowrap">know-how</FONT> include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advanced chemical modifications</B> with a goal to provide enhanced physical properties including stability and
solubility, increased potency, and multiple mechanisms of action in a single peptide </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Programmable prodrug technologies</B> that are designed to precisely time the chemical conversion of the prodrug into an
active form to reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios and improve clinical outcomes </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Fatty acylation</B> that aims to provide increased duration of action for more convenient dosing regimens and
compatibility with <FONT STYLE="white-space:nowrap">non-injectable</FONT> formulations </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our PEP platform is designed to improve clinical outcomes
and simplify disease management for patients. Our PEPs are engineered to potentially optimize pharmaceutical properties yielding peptides with extended time-action profiles, convenient dosing regimens and the potential to enhance compliance and
improve treatment effectiveness in a real-world setting. PEPs may improve efficacy and reduce adverse events by providing a more continuous, infusion-like exposure to the peptide. We believe that our PEP technology, along with our significant <FONT
STYLE="white-space:nowrap">know-how</FONT> in the synergistic application of these tools, provides the opportunity to discover novel, highly selective and efficacious peptides with extended time-action profiles and low
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios that may improve on the shortcomings of existing peptide therapies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our pipeline </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are leveraging our PEP platform to advance a pipeline
of programs to treat both endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet needs and large potential market opportunities. Developing product candidates, including
conducting preclinical studies and clinical trials, is a time consuming, expensive and uncertain process. We have not yet demonstrated an ability to obtain regulatory approvals. We retain exclusive, worldwide development and commercialization rights
to all of our product candidates and discovery programs. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g82i98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyond MBX 4291, we have a robust discovery pipeline including multiple obesity programs in the lead optimization stage of
development. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MBX 2109: Potential treatment for chronic hypoparathyroidism </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment
of HP. HP is a rare endocrine disease where parathyroid glands fail to produce sufficient amounts of PTH, which is a hormone that regulates calcium levels in the blood through its effects on bone, kidneys and intestines. We estimate that HP affects
approximately 120,000 people in the United States and more than 250,000 in the United States and Europe. HP&nbsp;is caused by damage to or removal of the parathyroid glands during neck surgery in approximately 75% of cases or, less commonly, from an
autoimmune disease or a genetic disorder. A deficiency of PTH results in lower blood calcium levels, or hypocalcemia, which can result in a variety of acute symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as
depression, confusion and cognitive impairment. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To avoid hypocalcemia and its symptoms, patients are treated with high dose calcium supplements and prescription
strength active vitamin D therapy, which can require the daily ingestion of approximately seven or more pills taken at multiple times throughout the day. This treatment does not address PTH deficiency and symptom relief can be suboptimal. Once-daily
injectable PTH therapies have been shown in clinical studies to reduce the need for high doses of calcium and active vitamin D supplements, decrease urinary calcium excretion and, by patient-reported-outcome assessments, result in improvements in
patients&#146; quality of life. However, these therapies can have significant fluctuations in drug concentrations that require daily subcutaneous injections, which impacts the potential outcomes for patients. Palopegteriparatide, manufactured by
Ascendis Pharma, is a once-daily PTH replacement therapy that is approved in the United States and European Union, marketed as Yorvipath&reg;, for the treatment of HP in adults. In Phase 3 trials, palopegteriparatide treatment rendered the majority
of patients independent of active vitamin D and calcium supplements (which reduced pill burden), reduced urinary calcium excretion and, by patient-reported-outcome assessments, improved quality of life. We believe there is a need for a more
effective therapy, which can ultimately normalize serum and urine calcium levels with a sustained PTH pharmacology, with a more convenient, once-weekly dosing regimen for patients with HP. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP. MBX 2109 is a prodrug, which is a compound engineered to be
biologically inactive at the time of subcutaneous injection that then converts to an active peptide in an intrinsically controlled, time-dependent fashion. The prodrug design is supplemented by fatty acylation, the addition of fatty acids to the
compound, which facilitates binding to proteins and extends the time of the compound in circulation. This combination is meant to provide an extended time-action profile that allows a once-weekly administration and provides a continuous,
infusion-like PTH exposure with lower daily <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios than observed with daily PTH dosing regimens. This continuous, infusion-like exposure to MBX 2109 may
reduce the frequency and severity of events of excessive blood calcium, or hypercalcemia, and insufficient blood calcium, or hypocalcemia. The once-weekly MBX 2109 dosing regimen may improve compliance relative to daily PTH dosing regimens, which we
believe improves effectiveness in a real-world setting. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In a Phase 1 clinical trial in 76 healthy adults, weekly subcutaneous injections of MBX 2109 led to
sustained and dose-dependent elevations of serum calcium and the suppression of endogenous PTH. The half-life of the MBX 2109 active drug across all doses was approximately 7.7 to 8.9 days, supporting a once-weekly dosing regimen. MBX 2109 was
generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating the safety, tolerability and efficacy of three fixed doses of MBX 2109 in a randomized, double-blind, placebo-controlled Phase 2 clinical
trial in approximately 48 patients with HP. The primary endpoint of the Phase 2 clinical trial is the proportion of patients who can discontinue active vitamin D and reduce calcium </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
supplements after 12 weeks of treatment while maintaining normal serum calcium levels. We expect to report topline data from our Phase 2 clinical trial in the third quarter of 2025. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MBX 1416: Potential treatment for post-bariatric hypoglycemia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX
1416, our potential treatment for PBH, is designed to be a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist, which is a molecule that binds to the applicable receptor to prevent the native molecule that would otherwise
activate the receptor from binding. PBH is a rare, serious and chronic complication of bariatric surgery typically occurring six months or later after surgery. We estimate PBH affects more than 90,000 people in the United States. In PBH, pathologic
increases in <FONT STYLE="white-space:nowrap">GLP-1</FONT> are released following a meal leading to hyperinsulinemia, or excessive levels of insulin, that may result in hypoglycemia, or low blood glucose. Hypoglycemic symptoms may include confusion,
weakness, dizziness, blurred vision, loss of consciousness and seizures. While <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT><B> </B>therapies have been recently approved to treat obesity and its <FONT
STYLE="white-space:nowrap">co-morbidities,</FONT> people with severe obesity, defined as a BMI <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>40 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, often can require a greater degree
of weight loss than these current therapies can achieve. According to the CDC, the prevalence of severe obesity in the United States in adults over 20 years increased from 4.7% in 2000 to 9.2% in 2018. Bariatric surgery still remains the most
efficacious means of treating severe obesity, with bariatric surgeries increasing by approximately 23% since 2017 to approximately 280,000 in the United States in 2022, according to the American Society for Metabolic and Bariatric Surgery. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are currently no U.S. Food and Drug Administration, or FDA, approved pharmacologic therapies for PBH. The current treatment options to reduce the frequency and
severity of hypoglycemic episodes focus on dietary interventions and, secondarily, on the use of <FONT STYLE="white-space:nowrap">off-label</FONT> medications with significant side effect profiles and unproven effectiveness in patients with PBH.
While glucagon is used as a rescue therapy to treat severe hypoglycemic events, it does not prevent hypoglycemia from occurring. In certain patients with severe, intractable hypoglycemia, surgical reversal of the bariatric procedure may be
considered. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416 is designed as a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist to prevent
<FONT STYLE="white-space:nowrap">GLP-1</FONT> from augmenting insulin release to cause hyperinsulinemia following a meal and thereby prevent the occurrence of severe hypoglycemia in patients with PBH. Leveraging our PEP platform, we aim to improve
the pharmaceutical properties of the <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence required to inhibit <FONT STYLE="white-space:nowrap">GLP-1</FONT> action by chemically modifying the amino acid backbone to achieve enhanced potency,
stability and solubility, relative to the corresponding, unmodified <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence. We are evaluating the safety, tolerability, pharmacokinetics and the effects that the drug has on the body, or
pharmacodynamics, of MBX 1416 in an ongoing randomized double-blind, placebo-controlled single- and multiple- ascending dose, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 clinical trial in
healthy adults. Preliminary pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial demonstrated that subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life
supporting once-weekly dosing. We anticipate topline results from our Phase 1 clinical trial in the fourth quarter of 2024. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our obesity portfolio
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our PEP platform, we are discovering and developing candidates with optimized pharmacokinetic profiles and pharmacologic attributes to
potentially improve on the current treatments for obesity and related <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We are engineering our candidates to extend the time-action profile and to potentially improve tolerability, thereby
providing the potential for higher doses leading to greater weight loss than can be achieved with existing therapies. We are prioritizing candidates targeting clinically validated mechanisms for weight loss and are focusing on discovering peptides
that target multiple unique receptors. Our obesity </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
portfolio currently includes one product candidate, MBX 4291, in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and a robust discovery pipeline with multiple development programs
in lead optimization. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>MBX 4291: Long-acting and highly potent potential treatment for obesity </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist</FONT> prodrug. Obesity is a common and costly chronic condition leading to significant morbidity and mortality. According to the CDC, an estimated 42% of U.S. adults aged 20 and over have obesity, or BMI<FONT
STYLE="font-family:Times New Roman">&#8805;</FONT>30 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, as of 2018, including 9% of adults with severe obesity, and another 31% of adults who are overweight, or BMI between 25.0 and 29.9 kg/m<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP>. Based on the CDC&#146;s 2018 prevalence rates, we estimate that at least 190 million adults in the United States are obese or overweight. While the current, approved GLP-1-based agonists represent
significant and clinically meaningful advances in the treatment of obesity, they require weekly injections and can be associated with significant gastrointestinal, or GI, side effects. These side effects often lead to reduced adherence and increased
discontinuation, thereby limiting a patient&#146;s ability to lose weight. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe MBX 4291 has the potential to be a safe and efficacious therapy that will help
people achieve their weight loss goals and improve their overall health. MBX 4291 is designed to achieve the extended time-action profile using two of our proprietary technologies, programmable prodrug and fatty acylation. In our preclinical
studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist,</FONT>
and an extended duration of action of the active component of MBX&nbsp;4291 supporting the potential for once-monthly administration. We believe that our proprietary PEP platform and <FONT STYLE="white-space:nowrap">know-how</FONT> also provide
significant optionality in devising dosing regimens that could lead to clinically meaningful improvements in tolerability and increase the maximally attained weight loss, relative to existing, approved <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an IND submission in the second quarter of 2025. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our company and team </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX was founded by pioneers in the endocrine
drug development field and is led by a team of seasoned industry veterans with a common goal to transform the treatment of endocrine and metabolic disorders and improve patients&#146; lives. Members of our leadership team have collaborated
successfully over several decades on the discovery, development and commercialization of endocrine therapeutics including Forteo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,
Humalog<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and Byetta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Our <FONT STYLE="white-space:nowrap">co-founders,</FONT> Dr.&nbsp;DiMarchi and Kent Hawryluk, were central to
the success of MB2 and Marcadia Biotech in advancing multiple <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-</FONT></FONT> and glucagon-based product candidates in clinical development through strategic transactions with
Eli Lilly, Merck, Novo Nordisk, and Roche. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our team is led by executives who have deep experience in drug development and company-building in the biopharmaceutical
industry. Key members of our executive and leadership team include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Kent Hawryluk, President, Chief Executive Officer and <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> has spent more
than 20 years as a life sciences entrepreneur, leader and investor, and prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> MBX held biopharma executive leadership roles at Avidity Biosciences, MB2, and Marcadia Biotech.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Salomon (Sam) Azoulay, M.D., Chief Medical Officer, has over 35 years of experience in drug development and operations,
including as the Chief Medical Officer at Sumitovant Biopharma and Pfizer Essential Health. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Richard Bartram, Chief Financial Officer, has over 15 years of financial leadership experience spanning strategic and
operational finance roles, including serving as the Chief Financial Officer of Esperion Therapeutics and as a public accountant at PricewaterhouseCoopers LLP. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Michelle Graham, Chief Human Resources Officer, has over 25 years of experience in human resources, talent management, and
organizational development across various sectors of the healthcare industry, including as the Chief Human Resources Officer at Albireo Pharma, Tesaro, and Parexel. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Steven J. Prestrelski, Ph.D., Chief Scientific Officer, is a seasoned biopharmaceutical executive with over 30 years of
scientific and operational expertise who has led successful endocrine and metabolism product development programs from discovery through regulatory approval, including Byetta, Bydureon<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
Gvoke<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our platform technology includes patent rights and proprietary technology
exclusively licensed from Indiana University and developed in the Indiana University laboratory of our scientific founder, Dr.&nbsp;DiMarchi. Dr.&nbsp;DiMarchi developed the original PEP technology, and is the inventor of the first dual and triple
incretin agonists. Dr.&nbsp;DiMarchi is known as a world class innovator and inventor, a member of the National Inventor Hall of Fame and the National Academy of Medicine, and one of the world&#146;s leading peptide chemists. He is a former
decade-long chairman of the Peptide Therapeutics Foundation and is widely recognized as an international spokesperson for macromolecular medicines. He has an extensive track record of drug development in big pharma, early-stage biotech, and
academia, and is a successful repeat entrepreneur. In particular, he is recognized for his contributions to the discovery and development of rDNA-derived Humalog, rGlucagon, and Forteo, which he shepherded through development and commercialization.
His research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity. A former officer and director, Dr.&nbsp;DiMarchi is not currently an employee of
the Company, but acts as the principal investigator under our research agreement with the Trustees of Indiana University, pursuant to which we have the option to license intellectual property developed on our behalf by Dr.&nbsp;DiMarchi.
Dr.&nbsp;DiMarchi is not required to devote any specified number of hours to the Company. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have raised approximately $214&nbsp;million in
funding from leading healthcare investors, including Deep Track Capital, Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management, and Wellington Management. Prospective investors should not rely on
the investment decisions of our existing investors, as these investors may have different risk tolerances and in certain cases received their shares in prior offerings at prices lower than the price offered to the public in this offering. See the
sections titled &#147;Certain relationships and related person transactions&#148; and &#147;Principal stockholders&#148; for more information. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our strategy
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are building a leading biopharmaceutical company with a focus on endocrine and metabolic disorders. Our mission is to enable patients with these disorders to
live fuller and healthier lives through the discovery and development of transformative precision peptide therapies. We are leveraging our propriety PEP platform to significantly improve clinical outcomes by discovering novel treatments that
overcome key limitations of current peptide therapies. The key pillars of our business strategy to achieve this mission include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Advance MBX 2109, a potential PTH peptide prodrug therapy, through clinical development to improve outcomes for patients
with HP. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Advance MBX 1416, a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist, through clinical
development to potentially address the unmet medical need in patients with PBH. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Advance our obesity portfolio, including our lead obesity candidate, MBX 4291, with a focus on improving efficacy,
tolerability and dosing frequency compared to existing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Leverage our proprietary PEP technology platform and the capabilities of our experienced discovery team to expand our
pipeline in endocrine, metabolic and other disease areas. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Build a fully-integrated biopharmaceutical company and selectively evaluate strategic opportunities to maximize the value
of our pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Maintain an entrepreneurial, scientifically rigorous, and inclusive corporate culture where employees are fully engaged and
strive to bring improved therapeutic options to patients. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks associated with our business </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never
achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The results observed from preclinical studies or early-stage clinical trials of our product candidates, including, but not
limited to, our preclinical studies of MBX 4291, may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. Similarly, positive results from such preclinical studies or early-stage clinical trials may not be
replicated in our subsequent preclinical studies or clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have never generated revenue from product sales and may never become profitable. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We will need substantial additional funding in addition to the net proceeds we receive from this offering. If we are unable
to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future commercialization efforts or other operations.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our business is highly dependent on the success of our product candidates. If we are unable to successfully complete
clinical development, obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If we fail to discover, develop and commercialize other product candidates, or successfully build out our own internal
discovery capacities, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their
regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may find it difficult to enroll patients in our future clinical trials given the limited number of patients who have the
diseases some of our product candidates are intended to target. Additionally, we also compete for trial participants with other clinical trials for product candidates that are in the same areas as our product candidates. If we experience delays or
difficulties in the enrollment of patients in clinical trials, our clinical development activities and our receipt of necessary regulatory approvals could be delayed or prevented. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our estimates as to prevalence may not be accurate, and the actual prevalence or addressable patient population for some or
all of those indications, or any other indication that we elect to pursue, may be significantly smaller than our estimates. The actual number of patients with these disease indications may, however, be significantly lower than we believe, which may
delay enrollment in our clinical trials and delay or prevent development of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Even if any of our product candidates receives regulatory approval, it may fail to achieve the degree of market acceptance
by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may be unsuccessful in obtaining or may be unable to maintain the benefits associated with Orphan Drug Designation,
including the potential for market exclusivity. Furthermore, Orphan Drug Designation does not shorten the development time or regulatory review time of a product candidate and does not provide any guarantee of approval in the regulatory review or
approval process. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We face significant competition in an environment of rapid change, and there is a possibility that our competitors may
achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, or that we are unable to compete with existing entities that have made substantial investment into novel treatments for disease, which
may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently
unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We have not yet demonstrated an ability to obtain regulatory approvals. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Unless we can demonstrate that MBX 2109 is either not a similar medicinal product to Yorvipath<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a once-daily PTH replacement therapy that is approved in the European Union, or EU, for the treatment of HP, or, if it is, that MBX 2109 is safer, more effective or otherwise clinically
superior, we may not be able to gain approval for MBX 2109 in the European Union until expiry of the market exclusivity period for Yorvipath. The exclusivity period could run until 2035 at the latest. Yorvipath is approved in the United States for
the treatment of HP in adults. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may in the future conduct clinical trials for drug candidates outside the United States, and the FDA and comparable
foreign regulatory authorities may not accept data from such trials. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may
have to alter our development and commercialization plans.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may not be
able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our use of third parties to manufacture our product candidates may increase the risk that we will not have sufficient
quantities of our product candidates, raw materials, active pharmaceutical ingredients, or APIs, or drug products when needed or at an acceptable cost. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to
retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property
and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products and product candidates similar to ours and our
ability to successfully develop and commercialize our product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third
parties or otherwise experience disruptions to our business relationships with our current and future licensors, we could lose license rights that are important to our business. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We will need to continue to significantly increase the size of our organization and we may have difficulties in managing
our growth and expanding our operations successfully. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We do not know whether a market will develop for our common stock or what the market price of our common stock will be,
and, as a result, it may be difficult for you to sell your shares of our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate information </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were founded as MBX Biosciences LLC, an Indiana limited liability company, in August 2018. We converted to a Delaware corporation in April 2019 and incorporated under
the name MBX Biosciences, Inc. Our principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032, and our telephone number is (317) <FONT STYLE="white-space:nowrap">659-0200.</FONT> Our website address is
https://www.mbxbio.com. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as
an inactive textual reference. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Implications of being an emerging growth company and a smaller reporting company </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth
company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">being permitted to present only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden
parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting
pursuant to the Sarbanes-Oxley Act of 2002; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may take advantage of these exemptions for up
to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC. We may choose to take advantage of some but not
all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold
stock. Additionally, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of
certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised
accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of other public companies that
comply with new or revised accounting pronouncements as of public company </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoptions is permitted for private companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our shares held by nonaffiliates plus the proposed aggregate amount of gross
proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering
if either (i)&nbsp;the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal
year and the market value of our shares held by nonaffiliates is less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_2"></A>The offering </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; line-height:0.0pt; font-size:10pt; font-family:arial"><B><I>Shares of common stock offered by us </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">8,500,000 shares. </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; line-height:0.0pt; font-size:10pt; font-family:arial"><B><I>Underwriters&#146; option to purchase additional shares </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 1,275,000 additional shares of our common
stock at the initial public offering price, less underwriting discounts and commissions on the same terms as set forth in this prospectus. </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B><I>Shares of our common stock to be outstanding after this offering </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">30,153,698 shares (or 31,428,698 shares if the underwriters exercise their option to purchase additional shares in full). </P></TD></TR></TABLE>
 <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; line-height:0.0pt; font-size:10pt; font-family:arial"><B><I>Use of proceeds </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">We estimate that the net proceeds to us from the sale of 8,500,000 shares of our common stock in this offering will be approximately
$114.8&nbsp;million, or $132.6 million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $15.00&nbsp;per share, the midpoint of the price range set forth on the cover page
of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents and
short-term investments, to fund the continued development of MBX 2109 and MBX 1416, our two clinical stage programs, MBX 4291, our preclinical stage program, our discovery research and development activities and additional clinical development and
for general corporate purposes and working capital. See &#147;Use of proceeds.&#148; </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; line-height:0.0pt; font-size:10pt; font-family:arial"><B><I>Directed share program </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">At our request, the underwriters have reserved up to 5% of the shares of common stock being offered by this prospectus for sale at the initial
public offering price to our directors, officers, certain employees and certain other persons associated with us. The sales will be made by J.P. Morgan Securities LLC, an underwriter of this offering, through a directed share program. We do not know
if these persons will choose to purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public. Any reserved shares not so purchased will be
offered by the underwriters to the general public on the same terms as the other shares of </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="47%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
common stock. Except for reserved shares purchased by our executive officers and directors, these reserved shares will not be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT>
restrictions described elsewhere in this prospectus.&#148; See &#147;Underwriting&#151;Directed share program&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; line-height:0.0pt; font-size:10pt; font-family:arial"><B><I>Proposed Nasdaq Global Select Market symbol </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; The closing of this offering is
contingent upon such listing. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; line-height:0.0pt; font-size:10pt; font-family:arial"><B><I>Risk factors </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">Investment in our common stock involves substantial risks. You should read this prospectus carefully, including the section entitled &#147;Risk
factors&#148; and the financial statements and the related notes to those statements included in this prospectus, before investing in our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common outstanding after this offering is based on 21,653,698 shares of our common stock (which includes 35,703 shares underlying unvested
restricted stock awards subject to a repurchase option by us) outstanding as of June 30, 2024, after giving effect to the conversion of all outstanding shares of our convertible Series A preferred stock, Series B preferred stock, and Series C
preferred stock, or the preferred stock, into an aggregate of 20,336,599 shares of our common stock, which will occur immediately upon the closing of this offering, or the Preferred Stock Conversion, and excludes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,864,410 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2024, with a
weighted-average exercise price of $6.68 per share under our 2019 Stock Option and Grant Plan, or the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">357,544 shares of common stock issuable upon the exercise of stock options granted after June 30, 2024, with a
weighted-average exercise price of $10.46 per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">783,287 shares of common stock reserved for issuance under the 2019 Plan, as amended, as of August 15, 2024, which shares
will cease to be available for issuance at the time our 2024 Stock Option and Incentive Plan, or the 2024 Plan, becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">3,065,000 shares of common stock reserved for future issuance under our 2024 Plan, which will become effective upon the
date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">289,436 shares of common stock reserved for future issuance under our 2024 Employee Stock Purchase Plan, or the 2024 ESPP,
which will become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise noted, all information in this prospectus assumes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise of the underwriters&#146; option to purchase up to 1,275,000 additional shares of common stock in this
offering; </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no vesting of the restricted common stock described above; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no purchases by existing stockholders or their affiliates pursuant to the directed share program; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a 1 -for- 12.0221 reverse stock split of our common stock effected on September 6, 2024; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the filing and effectiveness of our fourth amended and restated certificate of incorporation immediately prior to the
closing of this offering and the adoption of our amended and restated bylaws upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><A NAME="toc790774_3"></A>Summary financial data </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>You should read the
following summary financial data together with our financial statements and the related notes appearing at the end of this prospectus and the &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148;
section of this prospectus. We have derived the statement of operations and comprehensive loss data for the years ended December 31, 2022 and 2023 from our audited financial statements appearing at the end of this prospectus. We have derived the
statement of operations and comprehensive loss data for the six months ended June&nbsp;30, 2023 and 2024 and the summary balance sheet data as of June&nbsp;30, 2024, except for pro forma amounts, from our unaudited condensed interim financial
statements and related notes as of and for the six months ended June&nbsp;30, 2023 and 2024 appearing at the end of this prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period.
</I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands, except per share and per share data)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Statement of operations:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized gain (loss) on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reclassification of net (gains) losses included in net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per common share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares
outstanding used in computation of net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right">667,018</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,018,757</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right">923,696</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,229,473</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>As of June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Pro&nbsp;forma,&nbsp;as</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>adjusted(3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; line-height:10.0pt; font-size:10pt; font-family:arial"><B>Balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8196;118,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8196;233,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(97,885</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">117,972</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">232,797</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See notes 2 and 15 to our audited financial statements and note 14 to our unaudited condensed interim financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate the
net loss per share attributable to common stockholders, basic and diluted, and the weighted average number of shares used in the computation of the per share amounts. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma column above gives effect to (i) our issuance in August 2024 of an aggregate of 61,650,480 shares of Series C preferred stock for gross proceeds of $63.5&nbsp;million, or the Series C Financing, (ii) the
filing and effectiveness of our fourth amended and restated certificate of incorporation in Delaware immediately prior to the closing of this offering and the adoption of our amended and restated bylaws upon the effectiveness of the registration
statement of which this prospectus forms a part and (iii) the automatic conversion of all of our convertible preferred stock into an equal number of shares of common stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma, as adjusted column gives effect to the pro forma adjustments set forth in footnote (2) above and gives further effect to the sale of 8,500,000 shares of common stock in this offering at an assumed initial
public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting fees and commissions and estimated offering expenses payable by us. This pro
forma as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of
$15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total
stockholders&#146; equity by $7.9 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Each increase or decrease of 1,000,000 in the number of shares we are offering would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and
stockholders&#146; equity by $14.0 million, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital is defined as total current assets less total current liabilities. See our financial statements and the related notes thereto included elsewhere in this prospectus for further details regarding our
current assets and current liabilities. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_4"></A>Risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other
information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus, before deciding to invest in our common stock. If any of the events or developments described below were to
occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties described below are
not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to financial position and need for capital </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have
incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since
inception, we have incurred significant operating losses. Our net loss was $26.1&nbsp;million and $32.6&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively. Our net loss was $28.2 million for the six months ended June 30,
2024. As of December&nbsp;31, 2023, we had an accumulated deficit of $75.6&nbsp;million. As of June 30, 2024, we had an accumulated deficit of $103.8&nbsp;million. We have financed our operations primarily through issuing convertible preferred stock
and convertible promissory notes. Substantially all of our losses have resulted from expenses incurred in connection with our research and development and from general and administrative costs associated with our operations. We expect to continue to
incur significant expenses and increasing operating losses for the foreseeable future. Our ability to generate revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our
current product candidates and potential future product candidates. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially for the foreseeable future if and as we:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance our current research activities and further develop our platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue preclinical development and progress clinical trials for our product candidates and any future product candidates
we may identify; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approval for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish our manufacturing capacity capabilities to supply our clinical trials in our pipeline and eventually for
commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">commercialize our product candidates, if approved, which will require significant marketing, sales, and distribution
infrastructure expenses; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">hire additional research and development, clinical, commercial, and general and administration personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain, expand, protect, and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">confirm, maintain or obtain freedom to operate for any of our owned or licensed technologies and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add operational, financial and management information systems and personnel; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, audit, accounting, compliance, insurance, investor relations and other expenses to operate as a
public company that we did not incur as a private company. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result, we will need substantial additional funding to support our continuing
operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which may
include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or
enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of our platform, product candidates or delay our pursuit of potential
<FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not yet demonstrated an ability to successfully complete any pivotal clinical trials,
advance any product candidate beyond Phase 2, obtain regulatory approvals, manufacture our product candidates at commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for
successful product commercialization. To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize a therapy or therapies with market potential. This will require us to be successful in a
range of challenging activities, including completing preclinical studies and clinical trials of product candidates, obtaining regulatory approval for these product candidates, manufacturing, marketing and selling those therapies for which we may
obtain regulatory approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because of the numerous risks and uncertainties associated with developing our technology, platform and our product candidates, we are unable to predict the extent of
any future losses or when we will become profitable, if at all. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the
value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your
investment. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have never generated revenue from product sales and may never become profitable. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the
development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We may not generate revenues from product sales for many years, if ever. Our ability to generate future revenues from product sales depends
heavily on our or our collaborators&#146; ability to successfully: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">complete research and development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identify new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek and obtain regulatory approvals for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">launch and commercialize any product candidates for which we may obtain regulatory approval by establishing a sales force,
marketing and distribution infrastructure, or alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which
we may obtain regulatory approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in both amount
and quality, products and services to support clinical development and the market demand for any product candidates for which we obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for the product
candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">address competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our
obligations in such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">receive market acceptance by physicians, patients, healthcare payors, and others in the medical community;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">maintain, protect, enforce, defend and expand our portfolio of intellectual property and other proprietary rights,
including patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">defend against third-party intellectual property claims of infringement, misappropriation or other violation; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attract, hire and retain qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration, or the FDA, or other regulatory authorities to perform
preclinical studies or clinical trials in addition to those that we currently anticipate. Even if one or more of our product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any
approved product candidate. Additionally, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives. Even if we are able to generate revenues from the sale of any
approved product candidates, we may not become profitable and may need to obtain additional funding to continue operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will need substantial
additional funding in addition to the net proceeds we receive from this offering. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and
product development programs, future commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Developing product candidates, including conducting preclinical studies
and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our
ongoing activities, particularly as we continue the research and development of, continue, initiate and conduct clinical trials of, and seek regulatory approval for, our product candidates. In addition, if we obtain regulatory approval for our
product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, manufacturing, and distribution are not the responsibility
of a collaborator. Other unanticipated costs may also arise. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce, or eliminate our research and product development programs, future
commercialization efforts or other operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, our cash, cash equivalents and marketable securities were $55.3&nbsp;million, exclusive of
approximately $63.5 million in gross proceeds from the Series C Financing received in August 2024. We expect that the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
securities, including the proceeds from our Series C Financing, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027. However, our operating plan may
change as a result of factors currently unknown to us, and we may need to seek funding sooner than planned. Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of research and development, preclinical and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our product candidates for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of preparing, filing and prosecuting our patent applications, maintaining and enforcing our patents and other
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any product liability or other lawsuits related to our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of economic uncertainty, global health crises and geopolitical tensions, which may exacerbate the magnitude of
the factors discussed above. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming,
expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not
achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing
to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we
believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these
securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures, declaring dividends, and possibly other restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. We have no committed sources of additional capital and, if we are unable to raise additional
capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our future product candidates or other research and development initiatives. Without
sufficient funding, our license agreements and any future collaboration agreements may also be terminated if we are unable to meet the payment or other obligations under such agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product
development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Additionally, if we raise funds through additional collaborations, strategic
alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or we may have to grant licenses on terms that may not be
favorable to us and/or that may reduce the value of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our short operating history may make it difficult for you to evaluate the success of our
business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an early-stage company. We commenced our operations in August 2018. Our operations to date have
been limited to organizing and staffing our company, business planning, raising capital, and research and development activities such as developing our platform and technology and identifying and beginning to advance preclinical and clinical testing
of our product candidates. Two of our product candidates, MBX 2109 and MBX 1416 are in clinical development, while MBX 4291 is in the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> phase and our other development programs in our obesity
portfolio remain in the research or lead optimization stage of development. We have not yet demonstrated an ability to complete any large-scale, pivotal clinical trials, advance any product candidate beyond Phase 2, obtain regulatory approvals,
manufacture our product candidates at commercial scale, arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful commercialization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our limited operating history, particularly in light of the evolving field of peptide therapies, may make it difficult to evaluate our platform, technology and industry
and predict our future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by very early
stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, as a new business that is rapidly
growing, we may encounter other unforeseen expenses, difficulties, complications, and delays in our product development. We will need to transition from a company with a focus on research and conducting clinical trials to a company capable of
supporting commercial activities if any of our product candidates are approved. We may not be successful in such a transition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our future ability to utilize
our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have incurred losses and we may never achieve
profitability. As of December&nbsp;31, 2023, we had U.S. federal net operating loss carryforwards of $30.1&nbsp;million which are not subject to expiration and state net operating loss carryforwards of $71.3&nbsp;million which begin to expire in
various amounts in 2039, and $4.7&nbsp;million of U.S. federal research and development carryforwards which begin to expire in various amounts in 2039, and $1.2&nbsp;million of research credit carryforwards for state income tax purposes which begin
to expire in various amounts in 2029. To the extent that we continue to generate taxable losses, under current law, our unused U.S. federal net operating losses, or NOLs, may be carried forward to offset a portion of future taxable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
income, if any. Additionally, we continue to generate business tax credits, including research and development tax credits, which generally may be carried forward to offset a portion of future
taxable income, if any, subject to expiration of such credit carryforwards. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership change,&#148; generally defined as
one or more shareholders or groups of shareholders who own at least 5&nbsp;percent of the corporation&#146;s equity increasing their equity ownership in the aggregate by more than 50 percentage points (by value) over a three-year period, the
corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax credits) to offset its post-change income
or taxes may be limited. Similar rules may apply under state tax laws. To date, we have not completed an analysis under Section&nbsp;382 of the Code. It is possible that our prior equity offerings and other changes in our stock ownership could have
resulted in such ownership changes in the past. In addition, we may experience ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we
earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs or other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset U.S. federal taxable income may be subject to limitations,
which could potentially result in increased future tax liability to us. There is a risk that due to changes under the tax law, regulatory changes or other unforeseen reasons, our existing NOLs or business tax credits could expire or otherwise be
unavailable to offset future income tax liabilities. At the state level, there may also be periods during which the use of NOLs or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes
owed. For these reasons, we may not be able to realize a tax benefit from the use of our NOLs or tax credits, even if we attain profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in tax
laws or in their implementation or interpretation may adversely affect our business and financial condition. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The rules dealing with U.S. federal, state and
local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could
adversely affect our business and our financial condition. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, under Section&nbsp;174 of the Code, currently, in taxable years
beginning after December&nbsp;31, 2021, expenses that are incurred for research and development in the U.S. are capitalized and amortized, which may have an adverse effect on our cash flow. More recently, however, there have been proposals to
retroactively reinstate deductibility under Section&nbsp;174 of the Code. In addition, it is unclear how changes in U.S. federal income tax laws will affect state and local taxation. We cannot predict whether, when, in what form or with what
effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided or whether they could increase our or our shareholders&#146; tax liability or require changes in the manner in which we operate in order to minimize any
adverse effects of changes in tax laws or in the interpretation thereof. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our business and industry </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our business is highly dependent on the success of our product candidates. If we are unable to successfully complete clinical development, obtain regulatory
approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
in the early stages of our development efforts and have only two product candidates, MBX 2109 and MBX 1416, in clinical development. All of our other development programs are still in the preclinical or drug discovery stage. To date, as an
organization, we have not completed the development of any product candidates. Our future success and ability to generate revenue from our product candidates is dependent on our ability to successfully develop, obtain regulatory approval for and
commercialize one or more of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
product candidates. All of our product candidates will require substantial additional investment for clinical development, regulatory review and approval in one or more jurisdictions. If any of
our product candidates encounters safety or efficacy problems, development delays or regulatory issues or other problems, our development plans and business would be materially harmed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not have the financial resources to continue development of our product candidates if we experience any issues that delay or prevent regulatory approval of, or
our ability to commercialize, our product candidates, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product
candidates are safe and effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">insufficiency of our financial and other resources to complete the necessary clinical trials and preclinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">negative or inconclusive results from our clinical trials, preclinical studies or the clinical trials of others for product
candidates similar to ours, leading to a decision or requirement to conduct additional clinical trials or preclinical studies or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product-related adverse events experienced by subjects in our clinical trials, including unexpected toxicity results or
drug-drug interactions, or by individuals using drugs or therapeutic biologics similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in submitting an Investigational New Drug, or IND, application or comparable foreign applications or delays or
failure in obtaining the necessary approvals from regulators to commence a clinical trial or a suspension or termination, or hold, of a clinical trial once commenced; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">conditions imposed by the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">poor effectiveness of our product candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive
results from our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in enrolling or inability to enroll subjects in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of subjects from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">higher than anticipated clinical trial or manufacturing costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to timely or adequately finalize the design or formulation of any product candidate or demonstrate that a
formulation of any product candidate will be stable for commercially reasonable time periods; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unfavorable FDA or comparable regulatory authority inspection and review of our clinical trial sites;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or the clinical trial
protocol or otherwise meet their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure to acquire patent rights over our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays and changes in regulatory requirements, policies and guidelines, including the imposition of additional regulatory
oversight around clinical testing generally or with respect to our therapies in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">varying interpretations of data by the FDA and comparable foreign regulatory authorities.<B><I><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to discover, develop and commercialize other product candidates, or
successfully build out our own internal discovery capacities, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although the development and commercialization of MBX 2109, MBX 1416 and MBX 4291 and the other development candidates in our obesity portfolio are our initial focus, as
part of our longer-term growth strategy, we plan to continue to develop our additional assets in earlier stages of development and to build fully functional internal discovery capabilities to develop other product candidates. We intend to evaluate
internal opportunities from our existing product candidates or other potential product candidates. We have historically relied on the discovery capabilities of our <FONT STYLE="white-space:nowrap">co-founder,</FONT> Dr.&nbsp;Richard DiMarchi, but we
are currently continuing to build fully functional internal discovery capabilities, including laboratory space, and internalizing our ability to develop other product candidates. Dr. DiMarchi is a current consultant to the Company, as well as the
principal investigator under our research agreement with the Trustees of Indiana University, under which we retain intellectual property developed on our behalf by Dr. DiMarchi, but the consulting agreement and research agreement are both terminable
by either party. We have leased laboratory and office space at a research facility suitable for peptide chemistry, <I>in vitro</I> pharmacology and bioanalytical chemistry. We have built a team devoted to peptide chemistry and <I>in vitro</I>
pharmacology, and are continuing to expand that team. The peptide chemistry lab will be based around a state-of-the-art peptide synthesizer capable of synthesizing up to 106 peptides of variable scales and chemistries simultaneously. We are
equipping the laboratories currently and expect to have our internal discovery efforts established in the third quarter of 2024. If we are unable to complete this expansion and internalization, we may not be able to add internally-developed product
candidates to our pipeline and will have to rely on our existing product candidates, additional product candidates we may in-license, or additional candidates we may develop through third-party research partners. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also may choose to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product candidates to treat patients suffering from other disorders with
significant unmet medical needs and limited treatment options. These <FONT STYLE="white-space:nowrap">in-licensed</FONT> or internally developed potential product candidates will require additional, time-consuming development efforts prior to
commercial sale, including preclinical studies, clinical trials and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development,
including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or
produced economically, successfully commercialized or widely accepted in the marketplace or be more effective than other commercially available alternatives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These
research programs to discover and identify additional product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified, and all efforts are as of now completed
externally as we continue our efforts to internalize certain of our discovery capabilities. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development
for many reasons, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the research methodology used may not be successful in identifying potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">competitors may develop alternatives that render our product candidates obsolete; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product candidates that we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a product candidate may, on further study, be shown to have harmful side effects, interactions with other drugs, or other
characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a product candidate may not be sufficiently differentiated or offer substantial improvement over the currently available
treatment options or standard of care in a given therapeutic category; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the future, we may also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire product candidates or the underlying technology.
The process of proposing, negotiating and implementing a license or acquisition is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or
acquisition of product candidates. We have limited resources to identify and execute the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of third-party products, businesses and technologies and integrate them into our current
infrastructure. Moreover, we may devote resources to potential acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may
not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, future acquisitions may entail numerous
operational and financial risks, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">exposure to unknown liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disruption of our business and diversion of management&#146;s time and attention to develop acquired products or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">higher than expected acquisition and integration costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty assimilating or integrating acquired or licensed technologies, products, employees or business operations;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issues maintaining uniform standards, procedures, controls and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or contingent
liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increased amortization expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">risks associated with entering new markets in which we have limited or no experience; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential losses related to investments in other companies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and
ownership; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inability to motivate key employees of any acquired businesses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unsuccessful in identifying and developing additional product candidates, either through internal
development or licensing or acquisition from third parties, our potential for growth and achieving our strategic objectives may be impaired and we may not be able to increase our revenues in future periods, which could harm our business, results of
operations and prospects, and the value of our shares.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The successful development of
pharmaceutical products is highly uncertain. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Successful development of pharmaceutical products is highly uncertain and is dependent on numerous factors,
many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">clinical trial results may show the product candidates to be less effective than expected (for example, a clinical trial
could fail to meet its primary or key secondary endpoint(s)) or have an unacceptable safety or tolerability profile; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among other things,
may be caused by patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost to <FONT STYLE="white-space:nowrap">follow-up,</FONT> length of time to achieve trial endpoints,
additional time requirements for data analysis or New Drug Application, or NDA, preparation, discussions with the FDA, an FDA request for additional preclinical or clinical data (such as long-term toxicology studies) or unexpected safety or
manufacturing issues; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful side effects;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">post-marketing approval requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the proprietary rights of others and their competing products and technologies that may prevent our product candidates from
being commercialized. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The length of time necessary to complete clinical trials and submit an application for marketing approval for a final
decision by a regulatory authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult to predict. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we are successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the availability of coverage and
adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations in the United States or country-specific governmental organizations in foreign countries, which may
be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a
product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were not to provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial
success would be reduced. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, if any of our product candidates receive marketing approval, we will be subject to significant regulatory obligations
regarding the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our third-party providers comply) with current Good Manufacturing Practices, or cGMPs, and Good
Clinical Practices, or GCPs, for any clinical trials that we conduct post-approval. In addition, there is always the risk that we, a regulatory authority or a third-party might identify previously unknown problems with a product post-approval, such
as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates post-approval could adversely affect our business, financial condition and
results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we
must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. We may experience delays in completing our clinical trials or preclinical studies and initiating or completing
additional clinical trials or preclinical studies, including as a result of regulators not allowing or delay in allowing clinical trials to proceed under an IND, or not approving or delaying approval for any clinical trial grant or similar approval
we need to initiate a clinical trial. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators, institutional review boards, or IRBs, or other reviewing bodies may not authorize us or our investigators to
commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical
trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may experience challenges or delays in recruiting principal investigators or study sites to lead our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of subjects or patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be insufficient or slower than we anticipate, including because of the small number of patients for certain of our rare disease indications, and the number of clinical trials being conducted at any given time
may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our
behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies to reflect
changes to incorporate adjustments in our planned analysis or in regulatory requirements or guidance, which may be required to resubmit to an IRB and regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators or other reviewing bodies may find deficiencies with, fail to approve or subsequently find fault with the
manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for clinical and commercial supplies, or the supply or quality of any product candidate or other materials necessary to conduct clinical trials of
our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regulators or IRBs of the institutions in which clinical
trials are being conducted may suspend, limit or terminate a clinical trial, or data monitoring committees may recommend that we suspend or terminate a clinical trial, due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side
effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Negative or inconclusive results
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from our clinical trials or preclinical studies could mandate repeated or additional clinical trials and, to the extent we choose to conduct clinical trials in other indications, could result in
changes to or delays in clinical trials of our product candidates in such other indications. We do not know whether any clinical trials that we conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our
product candidates for the indications that we are pursuing. If later-stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates will be adversely impacted. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our failure to successfully initiate and complete clinical trials and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market our
product candidates would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds to complete clinical
trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure or otherwise modify our trials after they have begun. For instance, we have adjusted our
protocol for MBX 2109 to take into account feedback from our CRO. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring
products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials
may ultimately lead to the denial of regulatory approval of our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we complete the necessary preclinical studies and clinical trials,
the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product candidate we develop and the activities associated with its development and commercialization, including its design, testing, manufacture, safety, efficacy,
recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries.
Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any
jurisdiction and it is possible that none of the product candidates we are developing or may seek to develop in the future will ever obtain regulatory approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
have no experience in submitting and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the
submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy. Securing regulatory approval also
requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately
effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude its obtaining marketing approval or prevent or limit commercial use. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if
approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in
or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries
have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval that
we may ultimately obtain could be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we
experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial
profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Undesirable side effects caused by
any of our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory
authorities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain side effects and potential drug-drug interactions have been observed in our product candidates to date. For example, in our Phase 1 clinical
trial of MBX 2109, injection site adverse events were the most common treatment-related adverse event, and events of hypercalcemia were observed at the top doses in three subjects each in the single and multiple ascending dose cohort. Although these
events were not serious adverse events and resolved without intervention, if we were unable to identify a dose with a tolerable side-effect profile, or were limited in our ability for our product candidates to be used with certain other drugs, the
commercial success of our product candidates, if approved, could be limited. Injection site adverse events were observed in the single and multiple ascending dose cohorts of the Phase 1 clinical trial of MBX 1416 and we have added a drug interaction
cohort to our Phase 1 clinical trial of MBX 1416 to evaluate interactions between MBX 1416 and certain other common drugs, which could be costly and time-consuming. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also observe additional safety or tolerability issues with our product candidates in ongoing or future clinical trials. Many compounds that initially showed
promise in clinical or earlier-stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. Results of future clinical trials of our product candidates could reveal a high and
unacceptable severity and prevalence of side effects or unexpected characteristics, despite a favorable tolerability profile observed in earlier-stage testing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If
unacceptable side effects arise in the development of our product candidates, we, the FDA or comparable foreign regulatory authorities, the IRBs, or independent ethics committees at the institutions in which our trials are conducted, could suspend,
limit or terminate our clinical trials, or the independent safety monitoring committee could recommend that we suspend, limit or terminate our trials, or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or
deny approval of our product candidates for any or all targeted indications. Treatment-emergent side effects that are deemed to be drug-related could delay recruitment of clinical trial subjects or may cause subjects that enroll in our clinical
trials to discontinue participation in our clinical trials. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may need to train medical personnel using our product candidates to
understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in harm to
patients that are administered our product candidates. Any of these occurrences may adversely affect our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it
is possible that our clinical trials may indicate an apparent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to
successfully develop, obtain regulatory approval for or commercialize our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The results observed from preclinical studies or early-stage
clinical trials of our product candidates may not necessarily be predictive of the results of later-stage clinical trials that we conduct. Similarly, positive results from such preclinical studies or early-stage clinical trials may not be replicated
in our subsequent preclinical studies or clinical trials. Furthermore, our product candidates may not be able to demonstrate similar activity or adverse event profiles as other product candidates that we believe may have similar profiles. For
example, our future preclinical or clinical trials for our existing and future product candidates may not continue to demonstrate the extended half lives and low
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios that we have seen so far in our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
addition, in our planned future clinical trials, we may utilize clinical trial designs or dosing regimens that have not been tested in prior clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There
can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs proceeding through clinical trials. Many companies in
the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These
setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we may utilize an &#147;open-label&#148; clinical trial design. An &#147;open-label&#148; clinical trial is one where both the patient and investigator
know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose
levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a
&#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#147;investigator bias&#148; where
those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an
open-label trial may not be predictive of future clinical trial results of a product candidate when studied in a controlled environment with a placebo or active control. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed
satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the
final data.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may publish interim, topline or preliminary data from our clinical
trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline
data also remain subject to audit and verification procedures that may result in the final data being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse
differences between preliminary or interim data and final data could significantly harm our reputation and business prospects.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may find it difficult to enroll patients in our future clinical trials given the limited number of patients who have the diseases some of our product candidates
are intended to target. Additionally, we also compete for trial participants with other clinical trials for product candidates that are in the same areas as our product candidates. If we experience delays or difficulties in the enrollment of
patients in clinical trials, our clinical development activities and our receipt of necessary regulatory approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As we
progress our programs, we may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or
other comparable regulatory authorities outside the United States, or as needed to provide appropriate statistical power for a given trial. Enrollment may be particularly challenging for some of the rare diseases we are targeting in our programs
such as MBX 2109 and MBX 1416. For instance, in our Phase 1 trial of MBX 2109, we added one new site to the trial following slow enrollment at the originally selected sites, in order to meet our enrollment requirements. Enrollment may also be
challenging for product candidates targeting prevalent diseases, such as MBX 4291 or other product candidates in our obesity portfolio, due to the intense competition in the field. In addition, if patients are unwilling to participate in our trials
because of negative publicity from adverse events, competitive clinical trials for similar patient populations, clinical trials in competing product candidates or for other reasons, the timeline for recruiting patients, conducting studies and
obtaining regulatory approval of our product candidates may be delayed. Moreover, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as our product candidates, and patients who would
otherwise be eligible for our future clinical trials may instead enroll in clinical trials of our competitors&#146; product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patient enrollment is also
affected by other factors, some of which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">size of the patient population and process for identifying patients, including proximity and availability of clinical trial
sites for prospective patients with conditions that have small patient pools; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">effects of global health crises, such as those related to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> on enrollment
and/or completion of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">design of the trial protocol, including efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">availability and efficacy of approved medications for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ability to obtain and maintain patient informed consent; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">risk that enrolled patients will drop out before completion of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">eligibility and exclusion criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">perceived risks and benefits of the product candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patient referral practices of physicians. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, if we are unable to enroll a sufficient number of eligible patients in these trials in the United States,
we may look to enroll in sites outside of the United States. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, some of
which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty in establishing or managing relationships with CROs and physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">different standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">different <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for patients
with a particular disease; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty in locating qualified local consultants, physicians and partners; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the
regulation of pharmaceutical and biotechnology products. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Enrollment delays in our clinical trials may result in increased development costs for
our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct our clinical trials,
we may need to delay, limit or terminate ongoing or planned clinical trials or entire clinical programs, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The number of patients with the diseases and disorders for which we are developing our product candidates has not been established with precision. If the actual
number of patients with the diseases or disorders we elect to pursue with our product candidates is smaller than we anticipate, we may have difficulties in enrolling patients in our clinical trials, which may delay or prevent development of our
product candidates. Even if such product candidates are successfully developed and approved, the markets for our products may be smaller than we expect and our revenue potential and ability to achieve profitability may be materially adversely
affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pipeline includes product candidates for both endocrine and metabolic diseases, with our lead product candidates targeting chronic
hypoparathyroidism, or HP, post-bariatric hypoglycemia, or PBH, and obesity. There is no precise method of establishing the actual number of patients with any of these disorders in any geography over any time period. With respect to many of the
indications in which we have developed, are developing, or plan to develop our product candidates, we have estimates of the prevalence of the disease or disorder. The process we have used in developing an estimated incidence and prevalence for the
indications we are targeting has involved collating limited data from multiple sources. Our estimates as to prevalence may not be accurate, and the actual prevalence or addressable patient population for some or all of those indications, or any
other indication that we elect to pursue, may be significantly smaller than our estimates. For example, the estimated patient population for HP, a rare endocrine disease, already tends to be small, and may be even smaller than our current estimates.
Moreover, the patient population for PBH may decrease due to the development of novel treatments for obesity, reducing the potential need for bariatric surgery, and the patient population for obesity may decrease as novel treatments for obesity are
introduced. In estimating the potential prevalence of indications we are pursuing, or may in the future pursue, including our estimates as to the prevalence of HP, PBH and obesity, we apply assumptions to available information that may not prove to
be accurate. In each case, there is a range of estimates in the published literature and in marketing studies, which include estimates within the range that are lower than our estimates. The actual number of patients with these disease indications
may, however, be significantly lower than we believe. Even if our prevalence estimates are correct, our product candidates may be developed for only a subset of patients with the relevant disease or </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
disorder or our products, if approved, may be indicated for or used by only a subset. In the event the number of patients with the diseases and disorders we are studying is significantly lower
than we expect, we may have difficulties in enrolling patients in our clinical trials, which may delay or prevent development of our product candidates. If any of our product candidates are approved and our prevalence estimates with respect to any
indication or our other market assumptions are not accurate, the markets for our product candidates for these indications may be smaller than we anticipate, which could limit our revenues and our ability to achieve profitability or to meet our
expectations with respect to revenues or profits.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if any of our product candidates
receives regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant
revenues or become profitable. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never commercialized a product, and even if any of our product candidates is approved by the appropriate regulatory
authorities for marketing and sale, it may nonetheless fail to achieve sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Many of the indications for our product candidates have
well-established standards of care that physicians, patients and payors are familiar with. Even if our product candidates are successful in registrational clinical trials, they may not be successful in displacing these current standards of care if
we are unable to demonstrate superior efficacy, safety, ease of administration and/or cost-effectiveness. For example, physicians may be reluctant to take their patients off their current medications and switch their treatment regimen to our product
candidates. Further, patients often acclimate to the treatment regimen that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch due to lack of coverage and adequate
reimbursement. Even if we are able to demonstrate our product candidates&#146; safety and efficacy to the FDA and other regulators, safety or efficacy concerns in the medical community may hinder market acceptance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, including management time
and financial resources, and may not be successful. If any product candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market
acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efficacy and safety of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential advantages of the product compared to competitive therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the product&#146;s convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the willingness of the target patient population to try, and of physicians to prescribe, the product;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations or warnings, including interactions with other drugs or distribution or use restrictions contained in the
product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the strength of sales, marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the standard of care for the targeted indications for the product; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">availability and adequacy of coverage and reimbursement from government payors, managed care plans and other third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any failure by one or more of our product candidates that obtains regulatory approval to achieve market acceptance or commercial success
would adversely affect our business prospects.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face significant competition in an
environment of rapid change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, or that we are unable to compete with existing
entities that have made substantial investment into novel treatments for disease, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.</I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The development and commercialization of new drug products is highly competitive. We will face competition with respect to our product candidates and any product
candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government
agencies and other public and private research organizations that conduct research, seek patent or other intellectual property protection and establish collaborative arrangements for research, development, manufacturing and commercialization. There
are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we have research programs. Some of these
competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, while others are based on entirely different approaches. For more information, see &#147;Business&#150;Competition.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future that
are approved to treat the same diseases for which we may obtain approval for any product candidates we may develop. This may include other types of therapies, such as small molecule, antibody and/or protein therapies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in
research and development, manufacturing, conducting preclinical studies and clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may
result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are
more convenient, or are less expensive than any product candidates that we may develop or that would render any product candidates that we may develop obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may
obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally,
technologies developed by our competitors may render our product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, as a result of the expiration or successful challenge of our patent or other intellectual property rights, we could face risks relating to our ability to
successfully prevent or delay launch of competitors&#146; products. The availability of our competitors&#146; products could limit the demand and the price we are able to charge for any product candidates that we may develop and commercialize. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Due to the significant resources required for the development of our pipeline, and depending on our ability to
access capital, we must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product candidates or indications that may have been more profitable or for which there is a
greater likelihood of success. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently have three product candidates as well as several other programs at various stages of discovery and development.
We seek to advance discovery and development for product candidates with an initial focus on both endocrine and metabolic disorders with high unmet need. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to the
significant resources required for the development of our product candidates, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of
research, development, collaboration, management and financial resources toward particular product candidates, therapeutic areas or indications may not lead to the development of viable commercial products and may divert resources away from better
opportunities. For instance, we have elected to evaluate MBX 1416 as a treatment for PBH, but there may be better indications for which to evaluate MBX 1416, and this decision may divert resources away from better opportunities for MBX 1416. If we
make incorrect determinations regarding the viability or market potential of any of our product candidates or misread trends in the pharmaceutical industry, in particular for the rare diseases we are pursuing, our business, financial condition and
results of operations could be materially and adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product
candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or royalty
arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We currently have no commercial marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest
significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately
receives regulatory approval, we expect to establish a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time
consuming. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and
incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our
internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either
to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing
and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any
products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in
commercializing our products, either on our own or through arrangements with one or more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the development and commercialization of our
product candidates may be delayed, and our business and results of operations may be harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For planning purposes, we sometimes estimate the timing of the
accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of
regulatory filings or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt
of marketing approval or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which, if not realized as expected, may cause the
timing of achievement of the milestones to vary considerably from our estimates, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including the
extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our receipt of approvals by the FDA and other regulatory authorities and the timing thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing
activities. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we fail to achieve announced milestones in the timeframes we expect, the development and commercialization of our product
candidates may be delayed, and our business and results of operations may be harmed.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks
related to regulatory, legal, and clinical trials </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy,
time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining regulatory approval from the FDA. Foreign
regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and comparable foreign authorities is inherently unpredictable, but typically takes many years following the commencement of clinical trials and
depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product
candidate&#146;s clinical development and may vary among jurisdictions. Jurisdictions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
outside of the United States, such as the European Union or Japan, may have different requirements for regulatory approval, which may require us to conduct additional clinical, nonclinical or
chemistry, manufacturing and control studies. To date, we have not submitted an NDA to the FDA or similar drug approval submissions to comparable foreign regulatory authorities for any product candidate. We must complete additional preclinical
studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
addition, a product known as Yorvipath has received orphan medicine designation for hypoparathyroidism in the EU and was granted a marketing authorization in November 2023. In the EU, orphan medicines benefit from 10 years of market exclusivity once
they receive a marketing authorization in the EU (which may be extended by two additional years when the results of specific studies are reflected in the summary of product characteristics, or SmPC, addressing the paediatric population and completed
in accordance with a fully compliant paediatric investigation plan). This market exclusivity prevents the EMA and all EU Member States from accepting an application or granting a marketing authorization for a &#147;similar medicinal product&#148;
for the same therapeutic indication as the authorized orphan medicine, subject to certain specific derogations. Regulation (EC) 847/2000 defines a &#147;similar medicinal product&#148; as one which contains a similar active substance or substances
as contained in an authorized orphan medicinal product and which is intended for the same therapeutic indication. A &#147;similar active substance&#148; is defined in the same Regulation as an identical active substance, or an active substance with
the same principal molecular structural features (but not necessarily all of the same molecular structural features) and which acts via the same mechanism. There are some limited derogations to the market exclusivity granted to orphan medicinal
products in the EU. Specifically, a company may be able to market a similar medicinal product to an authorized orphan product if: (i)&nbsp;the marketing authorization holder for the authorized orphan product consents to the grant of a marketing
authorization for the similar product; (ii)&nbsp;the marketing authorization holder for the authorized orphan product is unable to supply sufficient quantities of its product; or (iii)&nbsp;the later applicant can establish that its product,
although similar to the authorized orphan product, is safer, more effective or otherwise clinically superior. Regulation (EC) 847/2000 provides details on what would constitute clinical superiority in this context, including that direct comparative
clinical trials may be required to demonstrate greater efficacy or safety to the authorized orphan product. As a result, we may not be able to gain approval for MBX 2109 in the EU until expiry of the market exclusivity period for Yorvipath (which
could run until 2035 at the latest), unless we can demonstrate that MBX 2109 is either not a similar medicinal product to Yorvipath (i.e. the active substance in MBX 2109, if not identical to Yorvipath, does not have the same principal molecular
structural features and act via the same mechanism as Yorvipath) or, if it is, that MBX 2109 is safer, more effective or otherwise clinically superior. Any comparative studies required to demonstrate clinical superiority could be costly and
time-consuming, and there is no certainty that we would succeed in adequately demonstrating that our product is clinically superior to Yorvipath. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Yorvipath is
also approved in the United States for the treatment of HP in adults. In Phase 3 trials, palopegteriparatide treatment rendered the majority of patients independent of active vitamin D and calcium supplements (which reduced pill burden), reduced
urinary calcium excretion and, by patient-reported-outcome assessments, improved quality of life. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current and future product candidates could fail to
receive regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product
candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign
regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or
preclinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA
to the FDA or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing
processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">another company may benefit from market exclusivity for their product which prevents us from obtaining marketing
authorization for our product in the same indication during such exclusivity period (as described above). </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This lengthy approval process as well as
the unpredictability of clinical trial results and market exclusivity issues described above may result in our failing to obtain regulatory approval to market any product candidate we develop, which would substantially harm our business, results of
operations and prospects. The FDA and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we
believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request,
may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our product candidates require specific shipping, storage, handling and administration, which in some cases, may require cold-chain logistics and subject our
product candidates to risk of loss or damage if failures occur. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our product candidates are sensitive to temperature, storage and handling conditions. They
must be stored at very low temperatures in specialized freezers or specialized shipping containers until immediately prior to use. The handling and administration of the therapy product, if approved, may need to be performed according to specific
instructions and in some steps within specific time periods. Failure to correctly handle our product could negatively impact the efficacy and or safety of our product, or cause a loss of product. In addition, if approved, certain of our products may
need to be frozen using specialized equipment and maintained following specific procedures in order to be stored without damage in a cost-efficient manner and without degradation. We will need to <FONT STYLE="white-space:nowrap">scale-up</FONT> a
cost-effective and reliable cold-chain distribution and logistics network, which we may be unable to accomplish. Failure to effectively <FONT STYLE="white-space:nowrap">scale-up</FONT> our cold-chain supply logistics, by us or third
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
parties, could in the future lead to additional manufacturing costs and delays in our ability to supply required quantities for commercial supply. For these and other reasons, we may not be able
to manufacture our current or future product candidates at commercial scale or in a cost-effective manner. Even if we are able to manufacture and distribute the product candidates, if our products require specific procedures to maintain and use
them, we may be limited in commercial opportunity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Any drug delivery device that we potentially use to deliver our product candidates may have its own
regulatory, development, supply and other risks. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to deliver our product candidates via a drug delivery device, such as an injector or other
delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Our product candidates may
not be approved or may be substantially delayed in receiving approval if the devices that we choose to utilize or develop do not gain and/or maintain their own regulatory approvals or clearances, if required. Where approval of the drug product and
device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent on the
sustained cooperation and effort of those third-party companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be
dependent on those third-party companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party companies to supply the devices, to successfully complete studies on the devices in a timely manner, or
to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or
clearance for expanded labels for new indications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The FDA or comparable foreign regulatory authorities may disagree with our regulatory plan for our product
candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The general approach for FDA approval of a new drug is dispositive data from two or more adequate and well-controlled clinical trials of the
product candidate in the relevant patient population. Adequate and well-controlled clinical trials typically involve a large number of patients, have significant costs and take years to complete. The FDA or other regulatory authorities may disagree
with us about whether a clinical trial is adequate and well-controlled or may request that we conduct additional clinical trials prior to regulatory approval. In addition, there is no assurance that the doses, endpoints and trial designs that we
intend to use for our planned clinical trials, including those that we have developed based on feedback from regulatory agencies or those that have been used for the approval of similar drugs, will be acceptable for future approvals. For instance,
if our ongoing Phase 1 trial of MBX 1416 is successful, we plan to run a combined Phase 2/3 to evaluate MBX 1416 in PBH. If the FDA disagrees with our approach, we may have to evaluate MBX 1416 in two separate trials, which would be costly and
time-consuming. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our clinical trial results may not support approval of our product candidates. In addition, our product candidates could fail to receive regulatory
approval, or regulatory approval could be delayed, for many reasons, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may not file or accept our NDA or marketing application for
substantive review; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the dosing regimen, design or implementation of our
clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our
product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of our clinical trials may not meet the level of statistical significance required by the FDA or comparable
foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate that our product candidates&#146; clinical and other benefits outweigh their safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from our preclinical
studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or
comparable foreign regulatory authorities to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing
processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may in the future conduct clinical trials for drug candidates outside the
United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may in the future choose to conduct one or
more additional clinical trials outside the United States, including, among other places, in the EU, South America, Australia and/or Asia. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction
by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for regulatory approval in the United
States, the FDA will generally not approve the application based on foreign data alone unless: (i)&nbsp;the data is applicable to the U.S. population and U.S. medical practice; and (ii)&nbsp;the trials were performed by clinical investigators of
recognized competence and pursuant to GCP regulations. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar
approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority
will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could
be costly and time-consuming, and which may result in drug candidates that we may develop not receiving approval for commercialization in such jurisdiction.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory
approval of our product candidates in other jurisdictions.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obtaining and maintaining regulatory
approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may
have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable foreign regulatory authorities must also approve the manufacturing and marketing of the
product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the
United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of
product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and
could delay or prevent the introduction of our products in certain countries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>While we may in the future seek designations for our product candidates with the
FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can be no assurance that we will successfully obtain such
designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of
product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and
priority review. However, there can be no assurance that we will successfully obtain such designations for our product candidates. In addition, while such designations could expedite the development or approval process, they generally do not change
the standards for approval. Even if we obtain such designations for our product candidates, there can be no assurance that we will realize their intended benefits. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, we may seek a Fast Track Designation for future product candidates we develop. If a product is intended for the treatment of a serious or life-threatening
condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this
designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development
process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may seek Breakthrough Therapy Designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in
combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more
clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial
can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for accelerated approval
and priority review. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop meets
the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a product candidate may not result in a faster
development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
ultimate approval by the FDA. In addition, even if any product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for
qualification and rescind the designation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even in the absence of obtaining Fast Track and/or Breakthrough Therapy Designations, a sponsor can seek priority review
at the time of submitting a marketing application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when
compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented
enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation
of such applications, and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be unsuccessful in obtaining or may be unable to maintain the benefits associated with Orphan Drug
Designation, including the potential for market exclusivity.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Orphan Drug Act, the FDA may
designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S., or a patient population greater than 200,000
in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the U.S., Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding
towards clinical trial costs, tax advantages and user fee waivers. In July 2022, the FDA granted MBX 2109 Orphan Drug Designation for the treatment of hypoparathyroidism. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, in the EU, the EC grants orphan medicinal product designation after receiving the opinion of the EMA&#146;s Committee for Orphan Medicinal Products on an
orphan medicinal product designation application. Orphan medicinal product designation is intended to promote the development of medicinal products that are intended for the diagnosis, prevention or treatment of life threatening or chronically
debilitating conditions affecting not more than five (5)&nbsp;in ten thousand (10,000) persons in the EU or for products intended for the diagnosis, prevention, or treatment of a life threatening, seriously debilitating or serious and chronic
condition when, without incentives, it is unlikely that sales of the product in the EU would generate sufficient return to justify the necessary investment in developing the product. In each case, there must be no satisfactory method of diagnosis,
prevention, or treatment authorized for marketing in the EU (or, if such a method exists, the product would be of significant benefit to those affected by the condition). In the EU, orphan medicinal product designation entitles a party to financial
incentives such as reduction of fees or fee waivers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the
indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the EC or the FDA from approving another marketing application for the same drug and indication for that time period, except in
limited circumstances. The applicable period is seven years in the U.S. and ten years in the EU. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan medicinal product designation or if the drug is
sufficiently profitable so that market exclusivity is no longer justified. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not
effectively protect the designated drug from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA
concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Where appropriate, we plan to secure approval from the FDA or comparable foreign regulatory authorities through
the use of expedited approval pathways, such as accelerated approval. If we are unable to obtain such approvals, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase
the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not
comply with rigorous post-marketing requirements, the FDA or such other regulatory authorities may seek to withdraw the accelerated approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where
possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated approval pathway for one or more of our therapeutic candidates from the FDA or comparable foreign regulatory authorities. Under
the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#146;s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate designed to treat a serious or life-threatening condition
that provides meaningful therapeutic benefit over available therapies upon a determination that the therapeutic candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.
The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is
a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint
that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases
in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on
the sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#146;s clinical benefit. Under the Food and Drug Omnibus Reform Act, or FDORA, the FDA is permitted to
require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased
authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly
posted by the agency, or if such post-approval studies fail to verify the drug&#146;s predicted clinical benefit. The FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval
confirmatory study or submit timely reports to the agency on their progress. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to seeking accelerated approval, we would seek feedback from the FDA or
comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or
submit an NDA or BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, or comparable foreign regulatory authorities, we will
continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can be no
assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our
application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated approval or any other form of
expedited development, review or approval for our therapeutic candidate would result in a longer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
time period to commercialization of such therapeutic candidate, could increase the cost of development of such therapeutic candidate and could harm our competitive position in the marketplace.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or
case law interpreting applicable fraud and abuse or other healthcare laws and regulations. Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of
pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which we conduct research and would sell, market and distribute our products. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to
Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations that may affect our ability to operate may apply. See the section titled, &#147;Business&#150;Government regulation&#150;Other healthcare laws.&#148;
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the
lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations,
prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare and privacy laws, as well as responding to possible investigations by government authorities, can be time and
resource-consuming and can divert a company&#146;s attention from the business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ensuring that our internal operations and future business arrangements with third
parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency
guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be
subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational harm and the
curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful
in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws,
they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could
be adversely affected.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Coverage and reimbursement may be limited or unavailable in certain
market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The success of our
product candidates, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. We cannot be sure that coverage and reimbursement will be available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. See the section
titled, &#147;Business&#150;Government regulation&#150;Coverage and reimbursement.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients who are provided medical treatment for their conditions generally
rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new
product acceptance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining
coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the
use of our products on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. In the United States, the principal decisions
about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to
follow CMS to a substantial degree. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require
<FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations
required following the use of product candidates, once approved. Patients are unlikely to use our product candidates, once approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost. There is
significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product
candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future
relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts
from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In
addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and
timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, increasing efforts by governmental and other third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the
United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing,
including price or patient reimbursement constraints, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward
pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether
the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals or clearances of our product candidates, if any, may be. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary
widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of
medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available
therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no
assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the
European Union do not follow price structures of the United States and generally prices tend to be significantly lower.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example, (1)&nbsp;changes to our
manufacturing arrangements, (2)&nbsp;additions or modifications to product labeling, (3)&nbsp;the recall or discontinuation of our products or (4)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could
adversely affect the operation of our business. See the sections titled, &#147;Business&#150;Government regulation&#150;Current and future U.S. healthcare reform.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. There
have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other
changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic
products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenue generated from the sale of any approved products.
Even if we do receive a favorable coverage determination for our products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery
models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and
proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated
that it will continue to seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict the initiatives that may be adopted in the future. The continuing
efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the demand for our product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to set a price that we believe is fair for our approved products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other
healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Off-label</FONT> use or misuse of our product candidates may harm our reputation in the marketplace or result in injuries that
lead to costly product liability suits. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our product candidates are approved by the FDA, we may only promote or market our product candidates in a manner
consistent with their <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. We will train our marketing and sales force against promoting our product candidates for uses outside of the approved indications for use, known as <FONT
STYLE="white-space:nowrap">&#147;off-label</FONT> uses.&#148; We cannot, however, prevent a physician from using our product candidates <FONT STYLE="white-space:nowrap">off-label,</FONT> when in the physician&#146;s independent professional medical
judgment he or she deems it appropriate. Furthermore, the use of our product candidates for indications other than those approved by the FDA may not effectively treat such conditions. Any such <FONT STYLE="white-space:nowrap">off-label</FONT> use of
our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our product candidates for these uses for which they are not
approved, which could lead to product liability suits that might require significant financial and management resources and that could harm our reputation.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Inadequate funding for the FDA or other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products
and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability
to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government
agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA or other government agencies may also
slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, including as a result of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
reaching the debt ceiling, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our
business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.<B><I><SUP STYLE="font-size:75%; vertical-align:top">
</SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Failure to access or a significant delay in accessing animal research models may materially adversely affect our ability to advance our
preclinical programs and successfully develop any product candidates, which could result in significant harm to our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Consistent with various rules,
regulations and cGMP, our ability to advance our preclinical and clinical programs for our product candidates requires access to animal research models sufficient to assess safety and in some cases to establish the rationale for therapeutic use.
Failure to access or a significant delay in accessing animal research models that meet our needs or that fulfill regulatory requirements may materially adversely affect our ability to advance our preclinical programs and successfully develop any
product candidates and this could result in significant harm to our business. During the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, researchers and CROs (including those engaged by us) experienced significant limitations in their
access to animal research models, specifically including a sharp reduction in the availability of <FONT STYLE="white-space:nowrap">non-human</FONT> primates, or NHPs, originating from breeding farms in Southeast Asia and limited access to the
generation of genetically-modified rodent models used in efficacy evaluations. Prior to the pandemic, China was the leading exporter of NHPs employed in basic and applied research; however, early in 2020, China ceased exportation of cynomolgus
monkeys, the species most commonly involved in pharmaceutical product development. This change in the world supply of a critical research model has resulted in increased demand from breeding farms principally located in Cambodia, Vietnam, and
Mauritius Island, with a resultant marked increase in unit pricing. Consequently, this has further exacerbated an already constrained NHP supply for research purposes. If we are unable to obtain NHPs in sufficient quantities and in a timely manner
to meet the needs of our preclinical research programs, if the price of NHPs that are available increases significantly, or if our suppliers are unable to ship the NHPs in their possession that are reserved for us, our ability to advance our
preclinical programs and successfully develop any additional preclinical candidates we may identify may be materially adversely affected or significantly delayed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may
result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising,
promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign
regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring
that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess
compliance with cGMP and adherence to commitments made in any NDA, other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all
areas of regulatory compliance, including manufacturing, production and quality control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved
indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of
the product candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA may also
require a risk evaluation and mitigation strategies, or REMS, program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide,
physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our
product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product
candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add
new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or
withdrawal of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product seizure or detention or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, under FDORA, sponsors of approved drugs and biologics must provide 6 months&#146; notice to the FDA of any changes in marketing status, such as the
withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#146;s ability to be marketed. The FDA strictly regulates marketing, labeling, advertising and
promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The policies of the FDA and comparable foreign regulatory authorities may
change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are and will continue to be subject to U.S. and certain foreign export and import controls, sanctions,
embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious
consequences for violations, which can harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to export control and import laws and regulations, including the U.S. Export
Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Control, the U.S. Foreign Corrupt Practices Act of 1977, as amended,
or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.
Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of
value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory
approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of
our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal
fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and any contract manufacturers and suppliers
we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and
disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. We cannot eliminate the risk of contamination or injury from hazardous
materials, including chemical and biological materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under
certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and
penalties. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws, regulations, and permitting
requirements. These current or future laws, regulations, and permitting requirements may impair our research, development, or production efforts. Failure to comply with these laws, regulations, and permitting requirements also may result in
substantial fines, penalties, or other sanctions or business disruption, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health, and safety laws and regulations.
Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other
improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
exposed to the risk of fraud or other misconduct by our employees, consultants and commercial partners, and, if we commence clinical trials, our principal investigators. Misconduct by these parties could include intentional failures to comply with
FDA regulations and other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data
accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could
involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We are also exposed
to risks in connection with any insider trading violations by employees or others affiliated with us. Upon the effectiveness of this registration statement, we will adopt a code of conduct and an insider trading policy applicable to all of our
employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may
develop. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face
an even greater risk if we commercially sell such product candidates. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual
outcome, liability claims may result in: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">decreased demand for any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">loss of revenue; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inability to commercialize any of our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that we will need to increase our insurance coverage when we begin clinical trials and if we successfully commercialize any product candidate. Insurance
coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our internal computer and information technology systems, or those of our third-party vendors, collaborators,
contractors, consultants or other third parties, may fail, become unavailable, or suffer security incidents, compromises, or data breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our product
development programs, compromise confidential, sensitive or personal information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our internal computer and information technology systems and those of our current and any future
third-party vendors, collaborators, contractors, consultants or other third parties, are vulnerable to damage or interruption from, among other things, computer viruses, computer hackers, phishing attacks, ransomware, malware, social engineering,
service interruptions, system malfunction, malicious code, employee theft, fraud, misconduct or misuse, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, sophisticated nation-state and
nation-state-supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we seek to protect our information technology systems from system failure, accident and security breach, we
have in the past and may in the future experience phishing and other security incidents which could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary,
personal or confidential information or other disruptions. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we have implemented cybersecurity measures designed to protect our information technology systems as well as the confidential and
sensitive data in our possession, there can be no assurance that these measures will be adequate to detect, prevent, or adequately address any cybersecurity incident or data breach that we may face. Controls employed by our information technology
department and other third parties could prove inadequate, and our ability to monitor such third parties&#146; data security practices is limited. Due to applicable laws, rules, regulations and standards or contractual obligations, we may be held
responsible for any information security failure or cybersecurity incident or compromise attributed to our third-party vendors as they relate to the information we share with them. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we were to experience a cybersecurity incident, breach, compromise or other security event relating to our information systems or data, the costs, time and effort
associated with the investigation, remediation and potential notification of the breach to counterparties, regulators and data subjects could be material. We may incur significant costs in an effort to detect and prevent security incidents or
compromises, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security incident or compromise. In addition, techniques used to sabotage or to obtain unauthorized access to
networks in which data is stored or through which data is transmitted change frequently, become more complex over time and generally are not recognized until launched against a target. The risk of a cybersecurity breach, incident, compromise or
disruption, particularly through cyberattacks including supply chain attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of
attempted attacks and intrusions from around the world have increased. As a result, we and our third-party vendors may be unable to anticipate these techniques or implement adequate preventative measures quickly enough to prevent either an
electronic intrusion into our systems or services or a compromise of critical information. We cannot guarantee that we will be able to detect or prevent any such incidents, and, our remediation efforts may not be successful or timely. Our efforts to
improve our cybersecurity and protect data from compromise may also identify previously undiscovered instances of data breaches, compromises or other cybersecurity incidents. If we do not allocate and effectively manage the resources necessary to
build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of
or damage to intellectual property or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
proprietary, personal or confidential information. Although we currently maintain cybersecurity insurance, the insurance we maintain against the risk of this type of loss may not be sufficient to
cover actual losses, or may not apply to the circumstances relating to any particular loss. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that any disruption or security breach were to result in a
loss of, or damage to, our or our third-party vendors&#146;, collaborators&#146;, contractors&#146;, employees&#146;, consultants&#146; or other third parties&#146; data, including personal data, or applications or inappropriate disclosure, loss,
destruction or alteration of, or access to, confidential, personal or proprietary information, we could incur significant liability including litigation exposure, substantial penalties and fines, we could become the subject of regulatory action,
inquiry or investigation, our competitive position could be harmed, we could incur significant reputational damage and the further development and commercialization of any product candidates we may develop could be delayed. Any of the above could
have a material adverse effect on our business, financial condition, results of operations or prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Laws and regulations governing any international
operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates we may identify outside of the United States and require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will be subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate in the future. The creation, implementation and
maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign
official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are
listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise
and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records
provisions of the FCPA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, the U.K. Bribery Act 2010 has extra-territorial effect for companies and individuals having a connection with the United Kingdom.
The U.K. Bribery Act prohibits inducements both to public officials and private individuals and organizations. Compliance with the FCPA and the U.K. Bribery Act is expensive and difficult, particularly in countries in which corruption is a
recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials.
Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and
will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain drugs and drug candidates outside of the United States, which could limit our
growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA
can result in significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a
violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international
business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the
FCPA&#146;s accounting provisions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to stringent and often unsettled laws, rules, regulations, policies, standards and contractual obligations
related to data privacy and security and changes in such laws, rules, regulations, policies, standards and contractual obligations could adversely affect our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to data privacy and protection laws, rules, regulations, policies, standards and contractual obligations that apply to the collection, transmission,
storage, use, disclosure, transfer, maintenance and other processing of sensitive, personal and personally-identifying information, which, among other things, impose certain requirements relating to the privacy, security, transmission and other
processing of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the
potential to affect our business. However, our data privacy program is in its early stages and we have not yet assessed the applicability of and our compliance with data privacy-related laws, rules and regulations. As a result, we cannot guarantee
that we are and have been in compliance with all applicable data privacy and protection laws, rules, regulations, policies and standards, and we may need to expend significant resources to implement privacy compliance measures. Additionally, we rely
on certain third-party vendors to process certain confidential, sensitive or personal information on our behalf. Failure by us or our third-party vendors to comply with any of these laws, rules, regulations, contractual obligations or standards
could result in notification obligations, enforcement actions, regulatory investigations or inquiries, significant fines, imprisonment of company officials and public censure, litigation and claims for damages by affected individuals, customers or
business partners, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are numerous U.S. federal and state laws, rules and regulations related to the privacy and security of personal information. In particular, regulations promulgated
pursuant to the Health Insurance Portability and Accountability Act of 1996, or HIPAA, establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and
require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. The
Genetic Information Nondiscrimination Act of 2008, or GINA, which clarified that genetic information is protected under HIPAA and restricts the use and disclosure of genetic information. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a
cybersecurity incident or data breach. These laws are not consistent, and compliance in the event of a widespread cybersecurity incident or data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws,
requiring attention to changing regulatory requirements. We also may be contractually required to notify patients or other counterparties of a cybersecurity breach, incident, or compromise. Although we may have contractual protections with our
service providers, any actual or perceived security breach, cybersecurity incident, or other information system compromise could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data
security and in responding to any such actual or perceived breach, incident, or compromise. Any contractual protections we may have from our service providers may not be sufficient to adequately protect us from any such liabilities and losses, and
we may be unable to enforce any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory information technology system
standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards. Determining whether personal information has been handled in compliance with applicable privacy
standards and our contractual obligations can be complex and may be subject to changing interpretation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to properly protect the privacy and
security of personal information, we could be alleged or actually found to have breached our contracts. Furthermore, if we fail to comply with applicable privacy laws, we could face significant administrative, civil and criminal penalties. We cannot
be sure how these laws, rules and regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with
evolving laws, rules and regulations at the international, federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We make public statements about our use, collection, disclosure and other processing of personal information through our privacy policies and information provided on our
website. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The publication of our privacy policies and other statements that provide promises and
assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Data privacy remains an evolving landscape at both the domestic and international level, with new laws, rules and regulations coming into effect and continued legal
challenges. At the state level, numerous states have enacted or are in the process of enacting or considering comprehensive data privacy and security laws, rules and regulations while other states have focused on more narrow aspects of privacy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, Washington state passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of
action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or
security of certain specific types of information. For example, a number of states have passed laws that regulate biometric data specifically. These various privacy and security laws may impact our business activities, including our identification
of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to
which we may likely become subject, if enacted. The existence of different privacy laws in various jurisdictions in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to
enforcement actions or otherwise incur liability for noncompliance. Although many of the existing state privacy laws exempt clinical trial information and health information governed by HIPAA, future privacy and data protection laws may be broader
in scope. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that these laws are or become applicable, all of these evolving compliance and operational requirements may impose significant costs, such
as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. In addition, such requirements may require us to
modify our data processing practices and policies, utilize management&#146;s time and/or divert resources from other initiatives and projects. Our efforts to comply with these evolving data protection laws, rules and regulations may be unsuccessful.
It is possible that these laws, rules and regulations may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
laws are not consistent, and compliance in the event of a widespread cybersecurity incident or data breach is costly and time-consuming. States are also frequently amending existing laws,
requiring attention to frequently changing regulatory requirements. We must devote significant resources to understanding and complying with this changing landscape. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any failure or perceived failure by us or our third-party vendors to comply with laws, rules and regulations regarding data privacy and protection could result in damage
to our reputation or expose us to risk of enforcement actions taken by data protection authorities and/or other third parties, including class action privacy litigation in certain jurisdictions, which carry the potential for significant penalties if
we are found to be <FONT STYLE="white-space:nowrap">non-compliant.</FONT> Similarly, failure to comply with federal and state laws, rules and regulations in the United States regarding privacy and security of personal information could expose us to
penalties under such laws, rules and regulations. Any such failure, or perceived failure, by us or our third-party vendors to comply with data protection and privacy laws, rules and regulations could result in significant government-imposed fines or
orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we
are not determined to have violated these laws, rules or regulations, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial
condition, results of operations or prospects. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The use of new and evolving technologies, such as artificial intelligence, or AI, in our operations may require us to expend material resources and may present
risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, any of which may result in reputational harm and liability, or
otherwise adversely affect our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may choose to integrate AI into our operations, and this innovation presents risks and challenges that could
affect its adoption, and therefore our business. There are significant risks involved in utilizing AI and no assurance can be provided that the usage of AI will enhance our business or assist our business in becoming more efficient or profitable.
The use of certain AI technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement and misappropriation. Other known risks of AI currently include
inaccuracy, bias, toxicity, data privacy and cybersecurity issues, and data provenance disputes. In addition, AI may have errors or inadequacies that are not easily detectable. AI may also be subject to data herding and interconnectedness (i.e.,
multiple market participants utilizing the same data), which may adversely impact our business. If the data used to train AI or the content, analyses, or recommendations that AI applications assist in producing are or are alleged to be deficient,
inaccurate, incomplete, overbroad or biased, our business, financial condition, and results of operations may be adversely affected. Additionally, we expect to see increasing government and supranational regulation and ethical concerns related to AI
use which may also significantly increase the burden and cost of research, development and compliance in this area. For example, the EU&#146;s Artificial Intelligence Act, or AI Act &#151; the world&#146;s first comprehensive AI law &#151; entered
into force on August 1, 2024 and, with some exceptions, will become fully applicable 24 months thereafter. This legislation imposes significant obligations on providers and deployers of high risk AI systems, and encourages providers and deployers of
AI systems to account for certain ethical principles in their design, development and use of these systems. The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain our technology and
products to help ensure that AI is implemented in accordance with applicable laws and regulations and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. The legal landscape and subsequent legal
protection for the use of AI remains uncertain, and development of the law in this area </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
could impact our ability to enforce our proprietary rights or protect against infringing uses. If we do not have sufficient rights to use the data on which AI relies or to the outputs produced by
AI applications, we may incur liability through the violation of certain laws, third-party privacy or other rights or contracts to which we are a party. Our use of AI applications may also, in the future, result in cybersecurity incidents that
implicate the personal data of customers or patients. Any such cybersecurity incidents related to our use of AI applications could adversely affect our reputation and results of operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our vendors may also incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry
standards, including with respect to intellectual property, privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and
misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and
adversely impact our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to third-party relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are reliant on a license agreement with Indiana University Research and Technology Corporation. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are reliant on a License Agreement, or the IURTC License Agreement, with Indiana University Research and Technology Corporation, or IURTC, pursuant to which we have
been granted an exclusive, royalty-bearing license to certain IURTC patent rights, or the Licensed Intellectual Property, developed by Dr.&nbsp;DiMarchi and other collaborators to further scientific research, for new product development, and for
other applications in public interest. In particular, we have been granted an exclusive, royalty-bearing license to make, have made, use, have used, offer to sell, have offered for sale, sell, have sold, import and have imported products that are
covered by the Licensed Intellectual Property. Termination of our IURTC License Agreement or reduction or elimination of our licensed rights may require us to negotiate new or reinstated licenses with less favorable terms or to cease all development
and commercialization of our current product candidates. In addition, delay in appointing or finding a suitable replacement provider, if one exists, could make it difficult for us to operate our business for that period. If any such events were to
occur, they could have a material adverse effect on our business prospects, financial condition and results of operations. For more information, see &#147;Business&#151;License agreement&#148;. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical studies and clinical trials that
were previously conducted for our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have relied on third parties, including Indiana University, to conduct certain preclinical studies
and clinical trials. Therefore, we are dependent on these third parties having conducted their research and development in accordance with the applicable protocols, legal and regulatory requirements, and scientific standards; having accurately
reported the results of all preclinical studies and clinical trials conducted with respect to such product candidates and having correctly collected and interpreted the data from these studies and trials. These risks also apply to any additional
product candidates that we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. If these activities were not compliant, accurate or correct, the clinical development, regulatory approval or commercialization of our
product candidates will be adversely affected.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If conflicts arise between us and our
collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If conflicts
arise between our collaborators and corporate or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our collaborators
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners, however, may
develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that are the subject of these collaborations with us. Competing products, either developed by the collaborators or
strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for any product candidates we may develop. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop
competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, prevent us from obtaining timely regulatory approvals, terminate their agreements with us prematurely or fail to
devote sufficient resources to the collaboration efforts, including development, delivery, manufacturing and commercialization of products. Any of these developments could harm our company and product development efforts. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and
commercialization plans.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The advancement of our product candidates and development programs and the
potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our programs, we may decide to collaborate with other pharmaceutical and biotechnology companies with
respect to development and potential commercialization. Likely collaborators may include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.
In addition, if we are able to obtain regulatory approval for product candidates from foreign regulatory authorities, we may enter into collaborations with international biotechnology or pharmaceutical companies for the commercialization of such
product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend,
among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the
potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such
approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates
or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or
bring them to market and generate product revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Collaborations are complex and time-consuming to negotiate and document. Further, there have been a significant
number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration agreements that we enter into in the future may contain restrictions on our
ability to enter into potential collaborations or to otherwise develop specified product candidates. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail
the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or
marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we
may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have relied upon and plan to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators,
to conduct our clinical trials and expect to rely on these third parties to conduct clinical trials of any other product candidate that we develop. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These
factors include protocol design, regulatory and IRB approval, patient enrollment rates and compliance with GCPs. We have opened clinical trial sites and may in the future enroll patients in a number of countries where our experience is limited. In
most cases, we use the services of third parties, including CROs, to carry out our clinical trial-related activities and rely on such parties to accurately report their results. Our reliance on third parties for clinical development activities may
impact or limit our control over the timing, conduct, expense and quality of our clinical trials. Moreover, the FDA requires us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and
reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of clinical trial sponsors, principal investigators, clinical
trial sites and IRBs. For certain commercial prescription drug products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking
and tracing and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific
standards. Our failure or the failure of third parties to comply with the applicable protocol, legal and regulatory requirements and scientific standards can result in rejection of our clinical trial data or other sanctions. If we or our third-party
clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful. Additionally, if we or our
third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which
would delay the regulatory approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. We are also required to register certain clinical trials and post the results of
completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements with such
contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. Moreover, many CROs, including some of those that we have engaged to conduct our clinical trials, are experiencing
enrollment challenges as a result of, among other things, high employee turnover driven by the post-COVID macroeconomic environment and the inexperience of new employees. Furthermore, at clinical trial sites, the availability of staff and trial
participants has been limited due to a decrease in the number of clinical investigative sites across the globe. These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be
conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators, do not successfully carry out their
contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the
commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay
clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any of the third-party organizations we utilize may terminate their engagements with us under certain circumstances. The replacement of an existing CRO or other third
party may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates. For example, although we believe there are a number of other CROs we could
engage, we may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, while we believe there may be suitable replacements for one or more of these service providers, there is a natural transition
period when a new service provider begins work. As a result, delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects.<B><I><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs
or delay. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is
common that various aspects of the development program, such as the vendors used to manufacture drug product or manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the
risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials
manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. Moreover, if the formulation of our product candidates requires the use of delivery methods such as cold-chain distribution
provided by third parties, whereby the product must be maintained between specified temperatures, we will be subject to reliance on our distribution partners to maintain the temperature of the formulation or else risk it being adulterated and
rendered unusable. Any of the above could delay or prevent completion of clinical trials, require conducting bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay or prevent approval of our
product candidates and jeopardize our ability to commence sales and generate revenue.<I> </I> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our use of third parties to manufacture our product candidates
may increase the risk that we will not have sufficient quantities of our product candidates, raw materials, active pharmaceutical ingredients, or APIs, or drug products when needed or at an acceptable cost.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities
of our product candidates, and we lack the resources and the capabilities to do so. Our current strategy is to outsource all manufacturing of our product candidates to third parties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently rely on and engage third-party manufacturers to provide all of the API and the final drug product formulation of all of our product candidates that are
being used in our clinical trials and preclinical studies. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying
any such replacement. In addition, we typically order raw materials, API and drug product and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
manufacturer. We may not be able to timely secure needed supply arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have a material adverse
effect on our ability to complete the development of our product candidates or, to commercialize them, if approved. We may be unable to conclude agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable
terms. There may be difficulties in scaling up to commercial quantities and formulation of our product candidates, and the costs of manufacturing could be prohibitive. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our manufacturers have difficulty or suffer delays in successfully manufacturing material that meets our specifications, it may limit supply of our product candidates
and could delay our clinical trials. Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third parties
for manufacturing process development, regulatory compliance and quality assurance; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our
product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations on supply availability resulting from capacity and scheduling constraints of third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible breach of manufacturing agreements by third parties because of factors beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements by the
third party, at a time that is costly or inconvenient to us; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we do not maintain our key manufacturing relationships, we may fail to find replacement
manufacturers or develop our own manufacturing capabilities, which could delay or impair our ability to obtain regulatory approval for our product candidates. If we do find replacement manufacturers, we may not be able to enter into agreements with
them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA and other foreign regulatory authorities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, if any third-party manufacturer with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which
we may not have the capabilities or resources, or enter into an agreement with a different manufacturer. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the
technical skills required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a <FONT
STYLE="white-space:nowrap">back-up</FONT> or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change third-party manufacturers for any reason, we will be required to verify that the new
manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will
produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. We may be unsuccessful in demonstrating the comparability of clinical supplies, which could require the conduct of
additional clinical trials. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget.
Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidate that such third party owns independently. This would increase our reliance on such third-party manufacturer or require us to obtain a
license from such third-party manufacturer in order to have another third party manufacture our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any of our product candidates is approved by any regulatory agency, we intend to utilize arrangements with
third-party contract manufacturers for the commercial production of those products. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract
manufacturers operating under cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some of our manufacturers may be located outside of the United States. There is currently significant uncertainty about the future relationship between the United States
and various other countries, including China, with respect to trade policies, treaties, government regulations and tariffs. Increased tariffs could potentially disrupt our existing supply chains and impose additional costs on our business.
Additionally, it is possible further tariffs may be imposed that could affect imports of APIs used in our product candidates, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including
restricted access to such raw materials used in our product candidates. Given the unpredictable regulatory environment in China and the United States and uncertainty regarding how the U.S. or foreign governments will act with respect to tariffs,
international trade agreements and policies, further governmental action related to tariffs, additional taxes, regulatory changes or other retaliatory trade measures in the future could occur with a corresponding detrimental impact on our business
and financial condition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed
on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of product candidates, operating restrictions and criminal prosecutions, any of which could
significantly affect supplies of our product candidates. The facilities used by our contract manufacturers to manufacture our product candidates must be evaluated by the FDA. We do not control the manufacturing process of, and are completely
dependent on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we
may not be able to secure and/or maintain regulatory approval for our product candidates manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality
assurance and qualified personnel. If the FDA finds deficiencies or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may
need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Contract manufacturers may face manufacturing or quality
control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA and
comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products, if approved. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA and other foreign regulatory authorities require manufacturers to register manufacturing facilities. The FDA and corresponding foreign regulators also inspect
these facilities to confirm compliance with cGMPs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Contract manufacturers may face manufacturing or quality control problems causing drug substance production and
shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA and comparable foreign regulatory requirements could
adversely affect our clinical research activities and our ability to develop our product candidates and market our products following approval, if obtained.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If any third-party manufacturer of our product candidates is unable to increase the scale of its production of
our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates, our
third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of our product candidates. The transition to larger scale production could prove difficult. In addition,
if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the same
quality then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operations.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may need to maintain licenses for APIs from third parties to develop and commercialize some of our
product candidates, which could increase our development costs and delay our ability to commercialize those product candidates.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Should we decide to use any APIs in any of our product candidates that are proprietary to one or more third parties, we would need to maintain licenses to those APIs
from those third parties. If we are unable to gain or continue to access rights to these APIs prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these
programs by either accessing or developing alternate APIs, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued access rights to the desired APIs on
commercially reasonable terms or develop suitable alternate APIs, we may not be able to commercialize product candidates from these programs.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to personnel, operations, and growth </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are dependent on
the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly
dependent upon our senior management, including our President and Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the
successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our
senior management team, these agreements are terminable at will with notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or
any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will need
to continue to significantly increase the size of our organization and we may have difficulties in managing our growth and expanding our operations successfully. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of August&nbsp;15, 2024, we had 36 full-time employees. As we advance our products and product candidates through the development and commercialization process, we
will need to expand managerial, operational, financial, sales and marketing and other resources to manage our operations, preclinical and clinical trials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities or contract with other organizations to provide
these capabilities for us. As operations expand, we expect that we will need to manage additional relationships with various suppliers and other organizations. Our ability to manage our operations and growth requires us to continue to improve our
operational, financial and management controls, reporting systems and procedures across a global organization. Such growth could place a strain on our administrative and operational infrastructure. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, we may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical
personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we may not be able to make improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in
existing systems and controls. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we either internally, together
with collaboration partners or through third-party contractors, as applicable: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expand our general and administrative functions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identify, recruit, screen, retain, incentivize and integrate additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manage our internal development efforts effectively while carrying out our contractual obligations to third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and build a marketing and commercial organization; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue to improve our operational, legal, financial, compliance and management controls, reporting systems and
procedures. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience
constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our commercial success
depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other
third parties could develop and commercialize products and product candidates similar to ours and our ability to successfully develop and commercialize our product candidates may be adversely affected. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends, in large part, on our ability to obtain and maintain intellectual property rights protection through patents, trademarks, and trade
secrets in the United States and other countries with respect to our technology and product candidates. If we do not adequately protect our intellectual property rights, competitors or other third parties may be able to erode, negate or preempt any
competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have filed patent applications and may file other patent applications in the United States or abroad
related to our product candidates that are important to our business; we also license and may purchase patents or patent applications filed by others. In particular, we are heavily reliant on patent rights we have exclusively <FONT
STYLE="white-space:nowrap">in-licensed</FONT> from IURTC pursuant to the IURTC License Agreement. The patent application process is expensive, time-consuming and complex. We may not be able to file, prosecute, maintain, enforce or license all
necessary or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
desirable patent applications at a reasonable cost or in a timely manner. Our owned and in-licensed patent portfolio is generally at a very early stage. In particular, we do not currently own or <FONT
STYLE="white-space:nowrap">in-license</FONT> any issued patents relating to any of our product candidates and we also do not own or <FONT STYLE="white-space:nowrap">in-license</FONT> any issued U.S. patents relating to our PEP technology or
otherwise. Further, the only pending patent applications we currently own are two U.S. provisional patent applications relating to one of our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
may not be able to obtain patents on certain inventions if those inventions are publicly disclosed prior to our filing a patent application covering them. We enter into nondisclosure and confidentiality agreements with parties who have access to
confidential information, including confidential information regarding inventions not yet disclosed in patent applications. We cannot guarantee that any of these parties will not breach these confidentiality agreements and publicly disclose any of
our inventions before a patent application is filed covering such inventions. If such confidential information is publicly disclosed, we may not be able to successfully patent it and consequently, we may not be able to prevent third parties from
using such inventions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Composition of matter patents for pharmaceutical and biological product candidates can provide a strong form of intellectual property
protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our or our licensors&#146; pending patent applications directed to the composition of matter of
our product candidates will be considered patentable by the United States Patent and Trademark Office, or USPTO, or by patent offices in foreign countries, or that the claims in any of the issued patents we may own or license will be considered
valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is
identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe such products <FONT
STYLE="white-space:nowrap">&#147;off-label.&#148;</FONT> Although <FONT STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement
is difficult to prevent or prosecute. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the scope of the patent protection we obtain is not sufficiently broad, we may not be able to prevent others from
developing and commercializing technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately
protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents have, or that any of our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications that mature into issued patents will include claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage. Other
parties have developed or may develop technologies that may be related or competitive with our approach, and may have filed or may file patent applications and may have been issued or may be issued patents with claims that overlap or conflict with
our patent portfolio, either by claiming the same compounds, formulations or methods or by claiming subject matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our rights to the same extent as
the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Various extensions may be available; however, the life of a patent,
and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting such product candidates might expire before or shortly after such product
candidates are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if they are unchallenged, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and pending patent applications, if issued, may not provide us
with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patent portfolio by developing similar or alternative product candidates in a <FONT STYLE="white-space:nowrap">non-infringing</FONT>
manner. For example, a third party may develop a product candidate that provides benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
similar to one of our product candidates but falls outside the scope of our patent protection or license rights. If the patent protection provided by the patent and patent applications we hold or
pursue with respect to such product candidate is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidate could be negatively affected, which would harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization
activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is
possible that defects of form in the preparation or filing of our patent portfolio may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we
or our partners, collaborators, or licensees whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or
licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or
enforcement of our patent portfolio, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Periodic maintenance fees, renewal fees, annuity fees and various other government fees on
patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and patent applications. We rely on our outside counsel or our
licensing partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with several
procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules,
there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT
STYLE="white-space:nowrap">Non-compliant</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our
business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent position of biotechnology and pharmaceutical companies carries uncertainty. As a result, the issuance, scope, validity, enforceability and
commercial value of our patent rights are characterized by uncertainty. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending patent applications cannot be enforced against third parties practicing the
technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent.
However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United
States and other jurisdictions are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patent portfolio, or that we were the first to
file for patent protection of such inventions. If third parties have filed prior patent applications on inventions claimed in our patent portfolio that were filed on or before March&nbsp;15, 2013, an interference proceeding in the United States can
be initiated by such third parties to determine who was the first to invent any of the subject matter covered by our patent portfolio. If third parties have filed such prior applications after March&nbsp;15, 2013, a derivation proceeding in the
United States can be initiated by such third parties to determine whether our invention was derived from theirs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or
enforceability, any patents we may own or license may be challenged in the courts or patent offices in the United States and abroad. There is no assurance that all the potentially relevant prior art relating to our patent portfolio has been found.
Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at
all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patent portfolio, or that we were the first to file for patent protection of such inventions. If such prior art exists, it may be used to
invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party submission of prior art to the USPTO, or to other patent offices around the world.
Alternately or additionally, we may become involved in post-grant review procedures, oppositions, derivation proceedings, ex parte reexaminations, inter partes review, supplemental examinations, or interference proceedings or challenges before the
USPTO or in district court in the United States, or similar proceedings in various foreign jurisdictions, including both national and regional, challenging patents or patent applications in which we have rights, including patents on which we rely to
protect our business. An adverse determination in any such challenges may result in loss of the patent or claims in the patent portfolio being narrowed, invalidated or held unenforceable, in whole or in part, or in denial of the patent application
or loss or reduction in the scope of one or more claims of the patent portfolio, any of which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent
protection of our technology and products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our or our licensors&#146; pending and future patent applications may not result in patents being issued that protect our
business, in whole or in part, or which effectively prevent others from commercializing competitive products. For example, our or our licensors&#146; provisional applications may never result in issued patents. A provisional patent application is
not eligible to become an issued patent until, among other things, we or our licensors file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of filing the related provisional patent application. If we or
our licensors do not timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we or our licensors may lose the priority dates with respect to such provisional patent applications and any patent protection on the
inventions disclosed in such provisional patent applications. While we intend to timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications relating to our current and future provisional patent applications, we cannot
predict whether any of our or our licensors&#146; patent applications for our technology and product candidates will result in the issuance of patents that effectively protect our technology and product candidates. Further, competitors may be able
to design around our patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries also may diminish the value of our patents or narrow the scope of our patent protection. In addition, the
laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various jurisdictions, including jurisdiction covering significant commercial markets, such
as the European Patent Office, China, and Japan, restrict the patentability of methods of treatment of the human body more than United States law does. If these developments were to occur, they could have a material adverse effect on our ability to
generate revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future
development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other provisions during the patent process. There are situations in which noncompliance, whether intentional or not, can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">company-owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that have been issued or may be issued in the
future may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors, many of whom have substantially greater resources and many of whom have made significant investments in
competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing products; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">countries other than the U.S. may, under certain circumstances, force us to grant a license under our patents to a
competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Issued patents that we may own or license may not provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any
competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Our competitors may also seek approval to
market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of
proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors do not infringe our patents. Thus, even if we have valid and enforceable patents, these patents still may not provide
protection against competing products or processes sufficient to achieve our business objectives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain certain information as company trade secrets. This
information may relate to inventions that are not patentable or not optimally protected with patents. We use commercially acceptable practices to protect this information, including, for example, limiting access to the information and requiring
passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom we may provide access to the information and with our employees, consultants, scientific advisors, collaborators, vendors, contractors,
and advisors. We cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. It is possible that technology relevant
to our business will be independently developed by a person who is not a party to such a confidentiality or invention assignment agreement. If any of our trade secrets were to be independently developed by a competitor or other third party, we would
have no right to prevent such competitor or third party, or those to whom they communicate such independently developed information, from using that information to compete with us. We may not be able to prevent the unauthorized disclosure or use of
our technical knowledge or trade secrets by contract manufacturers, consultants, collaborators, vendors, advisors, former employees and current employees. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps
we have taken to protect our proprietary technologies will be effective. Furthermore, if the parties to our confidentiality agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or
violation, and we could lose our trade secrets as a consequence of such breaches or violations. Our trade secrets could otherwise become known or be independently discovered by our competitors. Additionally, if the steps taken to maintain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose
protection for our trade secrets, our business, financial condition, results of operation and prospects may be materially and adversely harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to
comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our current and future licensors, we could lose license
rights that are important to our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are heavily reliant upon the IURTC License Agreement pursuant to which we have been granted an exclusive,
royalty-bearing license to certain patent rights that are important or necessary to the development of our proprietary technology and product candidates. Termination of the IURTC License Agreement or reduction or elimination of our licensed rights
could lead to the loss of our ability to develop and commercialize our proprietary technology and product candidates. Further development of our proprietary technology and product candidates may require us to enter into additional license or
collaboration agreements. Our future licenses may not provide us with exclusive rights to use the licensed intellectual property and technology, or may not provide us with exclusive rights to use such intellectual property and technology in all
relevant fields of use and in all territories in which we may wish to develop or commercialize our product candidates and proprietary technology in the future. Additionally, the IURTC License Agreement imposes, and future agreements may impose,
various development, diligence, commercialization and other obligations on us and require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the
licenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disputes may arise between us and our current or future licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual
property of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our current or future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be
susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we
believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual
property that we have licensed, or license in the future, prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite our best efforts, our current or future licensors might conclude that we materially breached our license
agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products, if approved, and technology covered by these license agreements. As a result, we may be required to cease our
development and commercialization of our product candidates and use of our proprietary technologies covered by the patent rights owned by the licensors. Furthermore, if the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights fail to
provide the intended exclusivity, competitors will have the freedom to seek regulatory approval of, and to market, products identical to ours. These events could have a material adverse effect on our competitive position, business, financial
condition, results of operations, and prospects.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>It is difficult and costly to protect our
intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success will depend in part on
obtaining and maintaining patent protection and trade secret protection for our product candidates, as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our product candidates from
unauthorized making, using, selling, offering to sell or importing by third parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which
important legal principles remain unresolved and have in recent years been the subject of much litigation. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our
intellectual property. Over the past decade, U.S. federal courts have increasingly invalidated pharmaceutical and biotechnology patents during litigation often based on changing interpretations of patent law. Further, the determination that a patent
application or patent claim meets all the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the USPTO or by a court or other trier of fact in the United
States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party publications, patents and other information that
may affect the patentability of claims in our patent portfolio, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our own patent portfolio.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> pending patent applications relating to our MBX 2109, MBX 1416, and MBX 4291 product
candidates and we own two pending provisional patent applications relating to our MBX 2109 product candidate, we cannot provide assurances that any of our patent applications will be found to be patentable, including over our own prior art
publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims that may issue from our pending and future patent applications nor to the outcome of any proceedings by any potential third
parties that could challenge the patentability, validity or enforceability of our patent portfolio in the United States or foreign jurisdictions. Any such challenge, if successful, could limit patent protection for our product candidates and/or
materially harm our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to challenges during litigation, third parties can challenge the validity of our patents in the United States using
post-grant review and inter partes review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent filed March&nbsp;16, 2013 or later, a petition for
post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for inter partes review can be filed immediately following the issuance of a patent if the patent has an effective filing date prior to
March&nbsp;16, 2013. A petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with an effective filing date of March&nbsp;16, 2013 or later. Post-grant review
proceedings can be brought on any ground of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
invalidity, whereas inter partes review proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review patent claims
without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third
party to have a U.S. patent invalidated in a USPTO post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there
is no guarantee that we will be successful in defending the patent, which may result in a loss of the challenged patent right to us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection
for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of
developments in one or more of our programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the
patent claims will not have sufficient scope to protect our technology, provide us with commercially viable patent protection or provide us with any competitive advantages; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable under
United States or foreign laws; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not successfully commercialize our product candidates, if approved, before our relevant patents expire;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not be the first to file patent applications for the inventions covered by our patent portfolio; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not develop additional proprietary technologies that are separately patentable. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, to the extent that we are unable to obtain and maintain patent protection for our product candidates, or in the event that such patent protection expires,
it may no longer be cost-effective to extend our portfolio by pursuing additional development of any of our product candidates for <FONT STYLE="white-space:nowrap">follow-on</FONT> indications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its
earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and
Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent having an earlier expiration date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Various
extensions may be available, but the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting such product candidates
might expire before or shortly after such product candidates are commercialized. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the Drug Price Competition and Patent Term Restoration Act of
1984 permits a Patent Term Extension, or PTE, of up to five years beyond the normal expiration of the patent to compensate patent owners for loss of enforceable patent term due to the lengthy regulatory approval process. A PTE grant cannot extend
the remaining term of a patent beyond a total of 14 years from the date of the product approval. Further, PTE may only be applied once per product, and only with respect to an approved indication&#151;in other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
words, only one patent (for example, covering the product itself, an approved use of said product, or a method of manufacturing said product) can be extended by PTE. Moreover, the scope of
protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. We anticipate applying for PTE in the United States. Similar extensions may be available in other
countries where we are prosecuting patents and we likewise anticipate applying for such extensions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The granting of such patent term extensions is not guaranteed
and is subject to numerous requirements. We might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents, failure to exercise due diligence during
the testing phase or regulatory review process or any other failure to satisfy any of the numerous applicable requirements. In addition, to the extent we wish to pursue patent term extension based on a patent that we
<FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of that third party. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory
authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be
able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse
effect on our ability to generate revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value
of patents in general, thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The United States Congress is responsible for passing laws establishing
patentability standards. As with any laws, implementation is left to federal agencies and the federal courts based on their interpretations of the laws. Interpretation of patent standards can vary significantly within the USPTO, and across the
various federal courts, including the U.S. Supreme Court. Recently, the Supreme Court has ruled on several patent cases, generally limiting the types of inventions that can be patented. Further, there are open questions regarding interpretation of
patentability standards that the Supreme Court has yet to decisively address. Absent clear guidance from the Supreme Court, the USPTO has become increasingly conservative in its interpretation of patent laws and standards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to increasing uncertainty with regard to our ability to obtain patents in the future, the legal landscape in the U.S. has created uncertainty with respect to
the value of patents. Depending on any actions by Congress, and future decisions by the lower federal courts and the U.S. Supreme Court, along with interpretations by the USPTO, the laws and regulations governing patents could change in
unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patent
reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our future issued patents. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted,
redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional
procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant
proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even
though the same evidence would be insufficient to invalidate the claim if first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged
by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
future issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After
March&nbsp;16, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to
the patent on an invention regardless of whether this inventor was the first to invent the claimed invention. As a result, a third party that files a patent application in the USPTO on or after March&nbsp;16 2013, but before we file an application
covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to
filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing until publication or issuance, we cannot be certain that we or our licensors were the first to
file any patent application related to our product candidates and other proprietary technologies we may develop. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the
other party can show that they used the invention in commerce before our filing date. Accordingly, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our future issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other
countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. The U.S. Supreme Court
has ruled on several patent cases in recent years; these cases often narrow the scope of patent protection available to inventions in the biotechnology and pharmaceutical spaces. For example, in <I>Amgen Inc. v. Sanofi</I>, or <I>Amgen</I>, the U.S.
Supreme Court held that certain of Amgen&#146;s patent claims defined a class of antibodies by their function of binding to a particular antigen. The U.S. Supreme Court further wrote that because the patent claims defined the claimed class of
antibodies only by their function of binding to a particular antigen, a skilled artisan would have to use significant trial and error to identify and make all of the molecules in that class. The U.S. Supreme Court ultimately held that Amgen failed
to properly enable its patent claims. In the 2013 case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents
owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. In 2023, the Federal Circuit issued a decision in <I>In
re Cellect, LLC</I> involving the interaction of patent term adjustment, or PTA, terminal disclaimers, and obviousness-type double patenting which may affect the patent term of any issued patents that rely on any PTA. In 2022, Congress passed the
Inflation Reduction Act, or IRA, which authorizes the Secretary of the Department of Health and Human Services, or HHS, to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines
are protected by an existing patent. For small molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we
cannot be certain that it will not affect our patent strategy in the long run. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, a new court system recently became operational in the European Union. The Unified Patent Court, or UPC, began
accepting patent cases on June&nbsp;1, 2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple member states of the European Union. The broad geographic reach of the UPC
could enable third parties to seek revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual European Union member states in which the European patent is validated.
Under the UPC, a successful revocation proceeding for a European Patent under the UPC would result in loss of patent protection in those European Union countries. Accordingly, a single proceeding under the UPC could result in the partial or complete
loss of patent protection in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our
business, financial condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and we cannot predict what the outcomes of cases tried before the UPC will be. The case law of the
UPC may adversely affect our ability to enforce or defend the validity of our European patents. Patent owners have the option to <FONT STYLE="white-space:nowrap">opt-out</FONT> their European Patents from the jurisdiction of the UPC, defaulting to <FONT
STYLE="white-space:nowrap">pre-UPC</FONT> enforcement mechanisms. We have decided to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents could be
subject to the jurisdiction of the UPC. We cannot be certain that our European patents will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Filing, prosecuting, enforcing, and defending patents protecting our product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in
countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, our ability to
protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual
property protection to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This could make it
difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third
parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe or from selling or importing products made from our inventions in and into the United States
or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and market their own products and, further, may export otherwise infringing products to territories where we have
patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Proceedings to enforce our patent rights, whether successful or not, could result in substantial costs and divert our efforts and resources
from other aspects of our business. Further, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly; put our pending patent applications at risk of not issuing; and provoke third parties to
assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all
jurisdictions in which we may wish to market our products, if approved. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent
applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, further to the United States and foreign government actions related
to Russia&#146;s invasion of Ukraine, the Kremlin issued Decree 299 stating that Russian companies and individuals can use patented inventions without the owner&#146;s permission or compensation, if the patent is held by owners from &#147;unfriendly
countries,&#148; which include the United States. As a result, we would not be able to enforce our otherwise valid patent rights against an infringer in Russia. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the
degree of future protection that we will have on our technologies, products and product candidates. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents, as
appropriate, the process of obtaining patents is time consuming, expensive and unpredictable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>In order to protect our competitive position around our product
candidates, we may become involved in lawsuits to enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our patents being found invalid or unenforceable. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Competitors may seek to commercialize competitive products to our product candidates. In order to protect our competitive position, we may become involved in lawsuits
asserting infringement of our patents, or misappropriation or other violations of other of our intellectual property rights. Litigation is expensive and time consuming and would likely divert the time and attention of our management and scientific
personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the
monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we file a patent infringement lawsuit against a perceived infringer, such a lawsuit could provoke the defendant to counterclaim that we infringe their patents and/or
that our patents are invalid and/or unenforceable. In patent litigation in the United States, it is commonplace for a defendant to counterclaim alleging invalidity and/or unenforceability. In any patent litigation there is a risk that a court will
decide that the asserted patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the defendant from using the invention at issue. With respect to a counterclaim of invalidity, we cannot be certain that
there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent claims narrowly or decide that we
do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. If any of our patents are found invalid or unenforceable, or construed narrowly, our ability to stop
the other party from launching a competitive product would be materially impaired. Further, such adverse outcomes could limit our ability to assert those patents against future competitors. Loss of patent protection would have a material adverse
impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we establish infringement of any of our patents by a competitive product, a court may decide not to grant an
injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should
instead pay us a &#147;reasonable royalty&#148; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related
product would have a material adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Litigation often involves significant amounts of public disclosures. Such disclosures could have a
materially adverse impact on our competitive position or our stock prices. During U.S. litigation we would be required to produce voluminous records related to our patents and our research and development activities in a process called discovery.
The discovery process may result in the disclosure of some of our confidential information. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could adversely affect the price of our common shares. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Litigation is inherently expensive, and the outcome is
often uncertain. Any litigation likely would substantially increase our operating costs and reduce our resources available for development activities. Further, we may not have sufficient financial or other resources to adequately conduct such
litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. As a result, we may conclude that even if
a competitor is infringing any of our patents, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent
course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If in
the future, we <FONT STYLE="white-space:nowrap">in-license</FONT> any patent rights, we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for us. If we are not able to directly
assert our licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where such potential infringers conduct their business,
and our commercialization efforts may suffer as a result. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with an infringement litigation, third parties may also be able to challenge the validity of
our patents before administrative bodies in the United States or abroad. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post grant review and equivalent proceedings in foreign jurisdictions, e.g., opposition
proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our products, potentially negatively impacting any concurrent litigation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from
developing or commercializing our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our
product candidates without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that
we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Third parties may have U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent
applications relating to compounds, methods of manufacturing compounds and/or methods of use for the treatment of the disease indications for which we are developing our product candidates. If any third-party patents or patent applications are found
to cover our product candidates, or their methods of use or manufacture, we may not be free to manufacture or market such product candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at
all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries,
and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates, including patent infringement lawsuits in the U.S. or abroad. There may be
third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture of our product candidates. Third parties may assert infringement claims
against us based on existing patents that they own or <FONT STYLE="white-space:nowrap">in-license</FONT> or patents that may grant to them (or which they may <FONT STYLE="white-space:nowrap">in-license)</FONT> in the future, regardless of the merit
of such patents or infringement claims. If our defenses to such assertions of infringement were unsuccessful, we could be liable for a court-determined reasonable royalty on our existing sales and further damages to the patent owner (or licensee),
such as lost profits. Such royalties and damages could be significant. If we are found to have willfully infringed the claims of a third party&#146;s patent, the third party could be awarded treble damages and attorney&#146;s fees. Further, unless
we obtain a license to such patent, we may be precluded from commercializing the infringing product candidate. Any of the aforementioned could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we perform periodic searches for relevant patents and patent applications with respect to our product candidates, including MBX 2109, MBX 1416, and MBX 4291,
we cannot guarantee the completeness or thoroughness of any of our patent searches or analyses including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, nor can we be
certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of any of our product candidates in any jurisdiction. Patent applications in the
United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will
not be filed outside the U.S. can remain confidential until patents issue. As a result, we may be unable to identify such patents or patent applications despite our best efforts. In addition, patent applications can take many years to issue, there
may be currently pending patent applications which may later result in issued patents that any of our product candidates may be accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future. The outcome of intellectual property litigation is subject to
uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover
various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need
to demonstrate that the relevant product or methods of using the product either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is
difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur
substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, parties making claims against us
may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources, and we may not have sufficient resources to bring these actions to a successful conclusion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are found to infringe, misappropriate or otherwise violate a third party&#146;s intellectual property rights, we could be forced, including by court order, to
cease developing, manufacturing or commercializing the infringing product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the
infringing product. If we were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
required to obtain a license to continue to manufacture or market the affected product, we may be required to pay substantial royalties or grant cross-licenses to our patents. Even if we were
able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We cannot assure you that any such license will be available on acceptable terms, if at all.
Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights, Further, the outcome of
intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property
cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to
obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our
ability to compete successfully in the commercial marketplace. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding
of infringement could prevent us from commercializing a product or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our
confidential information could be compromised by disclosure. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to
be negative, it could adversely affect the price of our common shares. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or
otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Others may challenge inventorship or claim
an ownership interest in our intellectual property which could expose it to litigation and have a significant adverse effect on its prospects. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may be
subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper
inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors or the effects of foreign
laws where foreign nationals are involved in the development of the subject matter of the patent. Furthermore, ownership disputes may arise from alleged contributions of third parties involved in developing our product candidates and may result in
joint ownership of our inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Any disagreement over inventorship could result in our being forced to defend our determination of
inventorship in a legal action which could result in substantial costs and be a distraction to our senior management and scientific personnel. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such
intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an
outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we typically require employees, consultants and contractors who may develop intellectual property on our behalf to execute agreements assigning such intellectual
property to us, we may be unsuccessful in obtaining execution of assignment agreements with each party who in fact develops intellectual property that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment
agreements may be breached. In either case, we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals
executing agreements with us may have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. If we
are unsuccessful in obtaining assignment agreements from an employee, consultant or contractor who develops intellectual property on our behalf, the employee, consultant or contractor may later claim ownership of the invention. Any disagreement over
ownership of intellectual property could result in our losing ownership, or exclusive ownership, of the contested intellectual property, paying monetary damages and/or being enjoined from clinical testing, manufacturing and marketing of the affected
product candidate(s). Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or by third parties asserting that our employees or we have misappropriated
their intellectual property or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our current and former employees and our
licensors&#146; current and former employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential competitors. Although
we take commercially reasonable steps to ensure that our employees do not use the proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, including incorporating such intellectual
property into our product candidates, we may be subject to claims that we or these employees have misappropriated the intellectual property of a third party. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we
or any of our employees are accused of misappropriating the proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of a third party, we may be forced to defend such claims in litigation. If we are found to have
misappropriated the intellectual property rights of a third party, we may be forced to pay monetary damages, sustain reputational damage, lose key personnel, or lose valuable intellectual property rights. Further, it may become necessary for us to
obtain a license from such third party to commercialize any of our product candidates. Such a license may not be available on commercially reasonable terms or at all. Any of the aforementioned could materially affect the commercialization of any of
our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may rely on trade secrets and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> which can be difficult to trace and enforce and, if we are unable to
protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We consider proprietary trade secrets or
confidential <FONT STYLE="white-space:nowrap">know-how</FONT> and unpatented <FONT STYLE="white-space:nowrap">know-how</FONT> to be important to our business. We may rely on trade secrets or confidential
<FONT STYLE="white-space:nowrap">know-how</FONT> to protect our technology, especially where patent protection is believed by us to be of limited value. We expect to rely on third parties for future manufacturing of our product candidates. We also
expect to collaborate with third parties on the development of our product candidates and as a result must, at times, share trade secrets with our collaborators. We also conduct joint research and development programs that may require us to share
trade secrets under the terms of our research and development partnerships or similar agreements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Trade secrets or confidential
<FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to maintain as confidential. To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to
beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees,
consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential
information. The need to share trade secrets and other confidential information, including with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, increases the risk
that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results
of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time consuming and unpredictable. In addition, some courts inside and
outside the United States are less willing or unwilling to protect trade secrets and <FONT STYLE="white-space:nowrap">know-how.</FONT> The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to
our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties,
independent development or publication of information by any of our third-party collaborators and we would have no right to prevent them from using that technology or information to compete with us. A competitor&#146;s discovery of our trade secrets
would impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may need to acquire or license additional intellectual property from
third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A third party may hold intellectual
property, including patent rights that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and
future product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established
companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater
clinical development. If we are unable to acquire such intellectual property outright, or obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize our product
candidates, if approved, would likely be delayed or we may have to abandon development of that product candidate and our business and financial condition could suffer. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates in the future, we might become dependent on proprietary rights from third parties with
respect to those product candidates. Any termination of such licenses could result in the loss of significant rights and would cause material adverse harm to our ability to develop and commercialize any product candidates subject to such licenses.
Even if we are able to <FONT STYLE="white-space:nowrap">in-license</FONT> any such necessary intellectual property, it could be on nonexclusive terms, including with respect to the use, field or territory of the licensed intellectual property,
thereby giving our competitors and other third parties access to the same intellectual property licensed to us. <FONT STYLE="white-space:nowrap">In-licensing</FONT> IP rights could require us to make substantial licensing and royalty payments.
Patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
filed by or against our licensors or another licensee or in administrative proceedings. If any <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents are invalidated or held unenforceable,
we may not be able to prevent competitors or other third parties from developing and commercializing competitive products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not have the right to control the
prosecution, maintenance, enforcement or defense of patents and patent applications that we license from third parties. In such cases, we would be reliant on the licensor to take any necessary actions. We cannot be certain that such licensor would
act with our best interests in mind, or in compliance with applicable laws and regulations, or that their actions would result in valid and enforceable patents. For example, it is possible that a licensor&#146;s actions in enforcing and/or defending
a patent licensed by us may be less vigorous than had we conducted them ourselves. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our present or future licensors may have relied upon or may rely upon third-party consultants or collaborators or on funds from third parties such that our present or
future licensors may not be the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> If other third parties have ownership rights to our present or future <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results
of operations, and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our diligence obligations with respect to the use of licensed technology in relation to our development and
commercialization of our product candidates and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use
of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be
unable to successfully develop and commercialize the affected product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The risks described elsewhere pertaining to our intellectual property rights also
apply to the intellectual property rights that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an adverse
effect on our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense
process with respect to such patents, and potential future licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our trademarks of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not currently own any registered trademarks and we have not
filed any trademark applications to date. While we may have common law protection for certain of our trademarks and trade names, it may be harder for us to rely on any such common law protection to prevent third parties from copying or using our
trademarks or trade names without our permission. Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. As a means to enforce our trademark
rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may not be able to
protect our rights to our trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or
trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered
trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to
compete effectively and our business may be adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such
rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation
proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered
it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an
equivalent administrative body in a foreign jurisdiction) objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under
applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent
infringement claim asserted by the owner of a senior trademark. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property rights do not necessarily address all potential threats to our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may be able to make products that are competitive to our product candidates or any of our future product candidates
that are not covered by the claims of our patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies
without infringing our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we or any of our collaborators might not have been the first to invent the inventions covered by our patent portfolio;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or
patent applications that we or they own or have obtained a license, or will own or will have obtained a license; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that our owned and in-licensed pending patent applications or those that we or our collaborators may file in
the future will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may have access to the same intellectual property rights licensed to us on a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issued patents that we may own or in-license may not provide us with any competitive advantage, or may be held invalid or
unenforceable, including as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights, or in
countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we cannot predict the scope of protection of any patent issuing based on our owned or in-licensed patent applications,
including whether the patent applications that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> will result in issued patents with claims that are directed to our product candidates or uses thereof in the United States or in other
foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the claims of any patent issuing based on our owned or in-licensed patent applications may not provide protection against
competitors or any competitive advantages, or may be challenged by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if enforced, a court may not hold that our owned or in-licensed patents are valid, enforceable and infringed;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be
costly whether we win or lose; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ownership of our patent portfolio may be challenged by third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on
our business; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent enforcement is expensive and time-consuming and difficult to predict; thus, we may not be able to enforce any of our
patents against a competitor; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject
matter similar to or improving that covered by our patents and patent applications; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may choose not to file a patent application for certain inventions, instead choosing to rely on trade secret protection,
and a third party may subsequently file a patent application covering such intellectual property. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Should any of these or similar events occur,
they could significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to the offering, our common stock, and operating as a public
company </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>You will incur immediate and substantial dilution as a result of this offering. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you purchase common stock in this offering, you will incur immediate and substantial dilution of $7.28 per share, representing the difference between the assumed
initial public offering price of $15.00 per share, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
estimated midpoint of the price range set forth on the cover page of this prospectus, and our pro forma as adjusted net tangible book value per share as of June 30, 2024 after giving effect to
this offering. To the extent the underwriters exercise their option to purchase additional shares, you will incur further dilution. For a further description of the dilution you will experience immediately after this offering, see
&#147;Dilution.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in this
offering. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The initial public offering price for our common stock was determined through negotiations with the underwriters. This initial public offering
price may vary from the market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial public offering price. The market price for our common stock may be influenced by those
factors discussed in this &#147;Risk factors&#148; section and many others, some of which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and results of preclinical studies and clinical trials for our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure or discontinuation of any of our development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">results of any preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or
announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">commencement or termination of collaborations for our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary
rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of efforts and level of expenses related to any of our research programs, clinical development programs or
current or future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts, if any, that cover our stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general economic, industry and market conditions, including the ongoing geopolitical conflict in Ukraine and the
Israel-Hamas war, tensions in U.S.-China relations, rising interest rates and inflation; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the other factors described in this &#147;Risk factors&#148; section. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In recent years, the stock market in general and the market for pharmaceutical and biotechnology companies in
particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. In
particular, in relation to uncertainty around inflation and the U.S. Federal Reserve&#146;s measures to slow inflation, the stock market has been exceptionally volatile. Market and industry factors may seriously affect the market price of our common
stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. Following periods of such volatility in the market price of a company&#146;s
securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result
in substantial costs and divert management&#146;s attention and resources from our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have wide discretion in the use of the net proceeds from this
offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our
management will have wide discretion in the application of the net proceeds, including for any of the purposes described in &#147;Use of proceeds.&#148; Accordingly, you will have to rely upon the judgment of our management with respect to the use
of the proceeds, with only limited information concerning management&#146;s specific intentions. Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a
favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that
does not produce income or that loses value. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required
to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a public company, and particularly after we are no longer an
&#147;emerging growth company,&#148; we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act,
the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls
and corporate governance practices. We expect that we will need to hire additional accounting, finance and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company. Our management
and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming
and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us
to attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and
regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could
result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to
SOX Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC
after we become a public company. However, while we remain an emerging growth company, we will not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404
within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources,
potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls
are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or
at all, that our internal control over financial reporting is effective as required by SOX Section&nbsp;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial
statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not know whether a market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may
be difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before this offering, there was no public trading market for our common stock. Although we
have applied to list our common stock on the Nasdaq Global Select Market, an active trading market for our shares may never develop or be sustained following this offering. If a market for our common stock does not develop or is not sustained, it
may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be
below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may
not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our common stock is listed on
Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&#146;s listing requirements, our common stock may be delisted. If we fail to meet any of Nasdaq&#146;s listing standards, our common stock
may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair
our stockholders&#146; ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our
ability to raise capital and the value of your investment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If securities analysts do not publish research or reports about our business or if they publish
negative evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading market for our common stock will rely in part on the research and
reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our
stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover
our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Future sales of our common stock in the
public market could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our stock price could decline as a result of sales of a large number of shares of our common stock after
this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem
appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, 30,153,698 shares of our common stock will be outstanding (or 31,428,698 shares
of common stock will be outstanding assuming exercise in full of the underwriters&#146; option to purchase additional shares), based on our shares outstanding as of June 30, 2024. All shares of common stock expected to be sold in this offering will
be freely tradable without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act, unless held by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The resale
of 21,477,098, or approximately 99.2% of our outstanding shares of common stock, after giving effect to the conversion of convertible preferred stock into shares of common stock, but before giving effect to this offering, is currently prohibited or
otherwise restricted as a result of securities law provisions, market standoff agreements entered into by our stockholders with us, stock option agreements entered into by our employees with us, or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements entered into by our directors, officers and stockholders with the underwriters. However, subject to applicable securities law restrictions and excluding shares of restricted common stock that will remain unvested, these shares will be
able to be sold in the public market beginning 180 days after the date of this prospectus. The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters are subject to certain exceptions and the representatives of the
underwriters may, in their sole discretion, release all or some portion of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time and for any reason. See &#147;Underwriting&#148; for more information on <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters. Shares of unvested restricted common stock that were issued and outstanding as of the date of this prospectus will become available for sale immediately upon the vesting of
such shares, as applicable, and the expiration of any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Shares issued upon the exercise of stock options pursuant to
future awards that may be granted under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules,
any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities Act. For more information see the section entitled &#147;Shares
eligible for future sale&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, the holders of approximately 20,336,599 shares, or
approximately 67.4%, of our common stock, will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for
ourselves or other stockholders. We also intend to register the offer and sale of all shares of common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of registration rights
and shares to be issued under our equity incentive plans, they can be freely sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section entitled
&#147;Underwriting&#148; included elsewhere in this prospectus. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in the future, we may issue additional shares of common stock or other equity or
debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause
our stock price to decline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company,&#148; and the reduced disclosure requirements
applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging
growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We could be an emerging growth company for up to five years following the completion of this offering, although circumstances could cause us to
lose that status earlier, including if we are deemed to be a &#147;large accelerated filer,&#148; which occurs when the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million
as of the prior June&nbsp;30, or if we have total annual gross revenue of $1.235&nbsp;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&nbsp;31, or
if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
year period before that time, in which case we would no longer be an emerging growth company immediately. For so long as we remain an emerging growth company, we are permitted and plan to rely on
exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of SOX
Section&nbsp;404, not being required to comply with any requirement for a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive
compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders
will be different than the information that is available with respect to other public companies. In this prospectus, we have not included all of the executive compensation related information that would be required if we were not an emerging growth
company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption, and,
therefore, while we are an emerging growth company we will not be subject to the new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this
election, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting
standards whenever such early adoption is permitted for private companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our
stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue is less than $100&nbsp;million during
the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth
companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict whether investors will find our
common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions,
including a change of control. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After this offering, our directors and executive officers and their affiliates will beneficially own shares representing
approximately 46.5% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval. For example, these stockholders may be
able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This concentration of ownership may have the effect of delaying or preventing a change
in control of our company and might affect the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not expect to pay any dividends for the foreseeable future. Investors in this offering may never obtain a
return on their investment. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any
dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility may contain terms prohibiting or limiting the amount
of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result,
investors seeking cash dividends should not purchase our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to establish and maintain proper and effective internal control over
financial reporting, our operating results and our ability to operate our business could be harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ensuring that we have adequate internal financial and
accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be <FONT STYLE="white-space:nowrap">re-evaluated</FONT> frequently. Our internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In
connection with this offering, we intend to begin the process of documenting, reviewing and improving our internal controls and procedures for compliance with SOX Section&nbsp;404, which will require annual management assessment of the effectiveness
of our internal control over financial reporting starting with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take
significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy or consequent inability to produce accurate financial statements on a timely
basis could increase our operating costs and harm our business. In addition, investors&#146; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis cause investors to
lose confidence in the accuracy and completeness of our financial reports and could cause the market price of our common stock to decline significantly. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our
disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the closing of this offering, we will become subject to the
periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to
management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how
well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These inherent limitations
include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people
or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our amended and restated bylaws that will become effective upon the effectiveness of our registration statement
designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit stockholders&#146; ability to obtain a favorable judicial forum for disputes with us. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to our amended and restated bylaws that will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, unless
we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf;
(ii)&nbsp;any action asserting a claim of or based on a breach of a fiduciary duty owed by any director, officer or other employee of ours to us or our stockholders; (iii)&nbsp;any action asserting a claim pursuant to any provision of the Delaware
General Corporation Law, or DGCL, our fourth amended and restated certificate of incorporation or our amended and restated bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or (iv)&nbsp;any action
asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Securities Exchange Act of 1934, as amended, or
the Exchange Act. Our amended and restated bylaws further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any
complaint asserting a cause of action arising under the Securities Act, the Exchange Act, the respective rules and regulations promulgated thereunder or the Federal Forum Provision. In addition, our amended and restated bylaws will provide that any
person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and
will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognize that the Delaware Forum
Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware.
Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#146; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which
may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court and other state courts have upheld the
validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum
Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or
invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be
located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provisions in our fourth
amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering and amended and restated bylaws that will become effective upon the effectiveness of the registration statement of which
this prospectus forms a part and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to
replace or remove our current management. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our fourth amended and restated certificate of incorporation that will become effective immediately prior to the
closing of this offering and amended and restated bylaws that will become effective upon the effectiveness of the registration statement of which this prospectus forms a part and Delaware law contain provisions that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you
might otherwise receive a premium for your shares. Our fourth amended and restated certificate of incorporation and our amended and restated bylaws will include provisions that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">authorize &#147;blank check&#148; preferred stock, which could be issued by our board of directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">specify that special meetings of our stockholders can be called only by our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders,
including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though
less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">specify that no stockholder is permitted to cumulate votes at any election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expressly authorized our board of directors to make, alter, amend or repeal our amended and restated bylaws; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated
certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These provisions, alone or together, could delay or prevent hostile takeovers and
changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section&nbsp;203 of the DGCL, which prohibits a person who owns
in excess of 15&nbsp;percent of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15&nbsp;percent of our outstanding voting stock,
unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any provision of our fourth amended and restated certificate of incorporation, amended and
restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some
investors are willing to pay for our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Adverse developments affecting the financial services industry could adversely affect our current and
projected business operations and our financial condition and results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Adverse developments that affect financial institutions, such as events
involving liquidity that are rumored or actual, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&nbsp;10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection
and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts
adequate to finance or capitalize our current and projected future business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
operations could be significantly impaired by factors that us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or
economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or
instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other general risks </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may become involved in securities class action
litigation that could divert management&#146;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other
strategic transaction, or the announcement of negative events, such as negative results from clinical trials. These events may also result in or be concurrent with investigations by the SEC. We may be exposed to such litigation or investigation even
if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#146;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic
transaction or the ultimate value our stockholders receive in any such transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unfavorable global economic conditions could adversely affect our
business, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our results of operations could be adversely affected by general conditions in the global economy,
geopolitical tensions and in the global financial markets. A severe or prolonged economic downturn or additional global financial and political crises could result in a variety of risks to our business, including weakened demand for any product
candidates we develop or our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers or other third parties and create import and export issues, possibly resulting
in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face risks related to health epidemics, pandemics and other widespread outbreaks of contagious diseases, which could significantly disrupt our operations,
impact our financial results or otherwise adversely impact our business.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant outbreaks of
contagious diseases and other adverse public health developments could have a material impact on our business operations and operating results. For example, the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> affected segments of the
global economy and our operations. As a result of similar public health crises that may arise, we may experience disruptions that could adversely impact our operations, research and development, and as we continue developing, any preclinical
studies, clinical trials and manufacturing activities we may conduct, some of which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays or disruptions in research programs, preclinical studies, clinical trials or
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies that we or our collaborators may conduct; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption of, or delays in receiving and distributing, supplies of drug substance and drug product from our contract
development manufacturing organizations, or CDMOs, to preclinical or clinical research sites or delays or disruptions in any preclinical studies or clinical trials performed by CROs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations imposed on our business operations by local, state or federal authorities to address a pandemic or similar
public health crises; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees
working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations, and cybersecurity and data accessibility or security issues. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the trading prices for biopharmaceutical companies have been highly volatile and we may face similar volatility in our stock price after we complete this
public offering. We cannot predict the scope and severity of any economic recovery of health epidemics, pandemics and other widespread outbreaks of contagious diseases, including following any additional &#147;waves&#148; or other intensifying of a
pandemic. If we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively
affected, which could have a material adverse impact on our business, financial condition, our results of operations and prospects. Furthermore, such pandemics could exacerbate the other risks described in this section. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We or the third parties upon whom we depend may be adversely affected by climate change, earthquakes, outbreak of disease, or other natural disasters and our
business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Climate change, earthquakes, outbreak of disease, or
other natural disasters, including extreme weather events and changing weather patterns such as storms, flooding, droughts, fires and temperature changes, which have become more common, could severely disrupt our operations, and have a material
adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, extreme weather risk, power outage, cybersecurity attack or other event occurred that prevented us from using all or a significant
portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party CDMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our
business for a substantial period of time. For example, we may experience delays in the supply of drug product for our clinical trials as a result of disruptions to the operations of the manufacturing facilities of some of our third-party CDMOs. The
disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. In addition, cybersecurity liability insurance is difficult to obtain and
may not cover any damages we would sustain based on any breach or compromise of our computer security protocols or other cybersecurity attack. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business
continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance matters,
including related social expectations and concerns, may impose unexpected costs on us or result in reputational or other harm to us that could have a material adverse effect on our business, financial condition and results of operations.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is an increasing focus and rapid and ongoing developments and changing expectations from certain investors, customers, consumers, employees and other
stakeholders concerning environmental, social and corporate governance, or ESG matters. Additionally, public interest and legislative pressure related to public companies&#146; ESG practices continue to grow, which may result in increased
regulatory, social or other scrutiny on us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are
widely publicized. In addition, investment in funds that specialize in companies that perform </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures to their investment decisions. Topics taken into
account in such assessments include, among others, the company&#146;s efforts and impacts on climate change and human rights, ethics and compliance with law, and the role of the company&#146;s board of directors in supervising various sustainability
issues. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may be required to make investments in matters related to ESG, which could be significant. Our failure or perceived failure to meet the standards set by
various constituencies could damage our reputation and our relationships with investors, governments, customers, employees, third parties and the communities in which we operate and expose us to increased regulatory risk, put us at a commercial
disadvantage relative to our peers and materially adversely affect our business, financial condition, results of operations, ability to participate in debt and equity markets and the value of our shares.<B><I><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_5"></A>Special note regarding forward-looking statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus, including the sections entitled &#147;Prospectus summary,&#148; &#147;Risk factors,&#148; &#147;Management&#146;s discussion and analysis of financial
condition and results of operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in
this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the initiation, timing, progress and results of our current and future research and development programs, preclinical
studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to successfully complete our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to finalize the design or formulation of any product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ability of our platform to optimize pharmacokinetic and/or pharmacologic properties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to advance any product candidates that we may identify and successfully complete any clinical studies,
including the manufacture of any such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to quickly leverage programs within our initial target indications and to progress additional programs to
further develop our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to internalize certain of our discovery capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prevalence of certain diseases and conditions we intend to treat and the size of the market opportunity for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">estimates of the number of patients with certain diseases and conditions we intend to treat and the number of patients that
we will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of our investigational new drug applications submissions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of announcement of interim and final results from clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our projected operating expenses and capital expenditure requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the implementation of our strategic plans for our business, programs and technology; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology and
platform; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to leverage the clinical, regulatory, and manufacturing advancements to accelerate our clinical trials and
approval of product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to meet future regulatory standards with respect to our product candidates, if approved; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to identify and enter into future license agreements and collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our reliance on third parties to conduct clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our reliance on third parties for the manufacture of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments related to our technology and platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our commercialization, marketing and manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act or a
smaller reporting company; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our use of proceeds from this offering, our financial performance, estimates of our expenses, capital requirements, and
needs for additional financing. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148;
&#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms
or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases,
beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk factors&#148; and
elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking
statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement, of which
this prospectus forms a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause
our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus also contains estimates, projections
and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties
and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal
estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not
aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to
change based on various factors, including those discussed under the section entitled &#147;Risk factors&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><A NAME="toc790774_6"></A>Use of proceeds </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the net proceeds to us from the sale of 8,500,000 shares of our common stock in this offering will be approximately $114.8 million, or approximately
$132.6 million if the underwriters exercise in full their option to purchase additional shares, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A $1.00 increase (decrease) in the assumed initial public
offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by $7.9 million, assuming the number of shares offered by us, as
set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares
offered by us, as set forth on the cover page of this prospectus, would increase (decrease) net proceeds to us from this offering by $14.0 million, assuming no change in the assumed initial public offering price per share, the midpoint of the price
range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the offering price or the number of shares by
these amounts would have a material effect on our intended uses of the net proceeds from this offering, although it may impact the amount of time prior to which we may need to seek additional capital. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, we had cash, cash equivalents and marketable securities of $55.3&nbsp;million, exclusive of approximately $63.5 million in gross proceeds from the
Series C Financing received in August 2024. We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents and marketable securities, as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $148.6&nbsp;million to advance development of our two clinical-stage programs, MBX 2109 through Phase 2
topline data and into Phase 3 development, and MBX 1416 through Phase 1 topline data and into Phase 2 development; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $31.2&nbsp;million to advance development of MBX 4291 through preclinical development and into clinical
development; and </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the remainder to fund our discovery research and development activities and additional clinical development, and for
general corporate purposes, working capital and capital expenditures. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also use a portion of the remaining net proceeds and our existing
cash, cash equivalents and marketable securities to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do
so. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our current plans, we believe our existing cash and cash equivalents and marketable securities, including the proceeds from our Series C Financing,
together with the net proceeds from this offering, will be sufficient to fund our operations and capital expenditure requirements into mid-2027. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have
multiple programs in preclinical and clinical development, including one product candidate in a Phase 2 trial and one product candidate in a Phase 1 trial. The expected use of the net proceeds from this offering represents our intentions based upon
our current plans and business conditions, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be
received upon the closing of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our
research and development, the status of and results from preclinical studies or clinical trials, as well as any collaborations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
that we may enter into with third parties for our product candidates or strategic opportunities that become available to us, and any unforeseen cash needs. As a result, our management will retain
broad discretion over the allocation of the net proceeds from this offering. We expect the net proceeds from this offering, together with our existing cash and cash equivalents, and short-term investments, will not be sufficient for us to advance
any of our programs through regulatory approval, and we will need to raise additional capital to complete the development and potential commercialization of any of our programs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending our use of proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation instruments, including short-term,
investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_7"></A>Dividend policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to fund the development and expansion of our
business, and therefore we do not anticipate paying cash dividends on our common stock in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our results of
operations, financial condition, capital requirements and other factors deemed relevant by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_8"></A>Capitalization </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2024: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the Series C Financing, (ii)&nbsp;the filing and effectiveness of our
fourth amended and restated certificate of incorporation immediately prior to the closing of this offering in each case as if such events had occurred on June 30, 2024 and (iii)&nbsp;the conversion of all outstanding shares of our convertible
preferred stock into an aggregate of 20,336,599 shares of common stock immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of 8,500,000&nbsp;shares of our common
stock in this offering at an assumed initial public offering price of $15.00&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The pro forma as adjusted information below is illustrative only, and our capitalization
following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the information in this table together with our financial statements
and the related notes included elsewhere in this prospectus and &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; section of this prospectus. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Pro</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>forma</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Pro&nbsp;forma</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>as&nbsp;adjusted</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">55,262</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">118,762</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$233,587</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible preferred stock (Series A and B), $0.0001 par value; 182,838,619 shares authorized; 182,838,619
shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, $0.0001 par value; no shares authorized, issued or outstanding, actual;
10,000,000&nbsp;shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.0001 par value; 237,000,000 shares authorized, 1,317,099 shares issued and outstanding,
actual; 500,000,000&nbsp;shares authorized, 21,653,698 shares issued and outstanding, pro forma; 500,000,000&nbsp;shares authorized, 30,153,698 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$232,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="12" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00&nbsp;per share, which is the midpoint of
the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents and marketable securities, total stockholders&#146;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
equity and total capitalization by $7.9&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase
(decrease) the pro forma as adjusted amount of each of cash, cash equivalents and marketable securities, total stockholders&#146; equity and total capitalization by $14.0&nbsp;million, assuming no change in the assumed initial public offering price
per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common
stock in the table above is based on 21,653,698 shares of our common stock (which includes 35,703 shares underlying unvested restricted stock awards subject to a repurchase option by us) outstanding as of June 30, 2024, after giving effect to the
Preferred Stock Conversion, and excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,864,410 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2024, with a
weighted-average exercise price of $6.68 per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">357,544 shares of common stock issuable upon the exercise of stock options granted after June 30, 2024, with a
weighted-average exercise price of $10.46 per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">783,287 shares of common stock reserved for issuance under the 2019 Plan, as amended, as of August 15, 2024, which shares
will cease to be available for issuance at the time our 2024 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">3,065,000 shares of common stock reserved for future issuance under our 2024 Plan, which will become effective upon the
date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">289,436 shares of common stock reserved for future issuance under our 2024 ESPP, which will become effective upon the date
immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_9"></A>Dilution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our historical net tangible book value (deficit) as of June 30, 2024 was $(97.9)&nbsp;million, or $(74.32)&nbsp;per share of our common stock. Our historical net
tangible book deficit per share is the amount of our total tangible assets less our total liabilities and the carrying values of our convertible preferred stock, which is not included within stockholders&#146; deficit. Our historical net tangible
book value (deficit) per share represents historical net tangible book value (deficit) divided by the 1,317,099&nbsp;shares of our common stock outstanding as of June 30, 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pro forma net tangible book value as of June 30, 2024 was $118.0&nbsp;million, or $5.45&nbsp;per share of our common stock. Pro forma net tangible book value
represents the amount of our total tangible assets less our total liabilities, after giving effect to (i)&nbsp;the Series C Financing, (ii)&nbsp;the filing and effectiveness of our fourth amended and restated certificate of incorporation immediately
prior to the closing of this offering in each case as if such events had occurred on June 30, 2024 and (iii)&nbsp;the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 20,336,599 shares of common stock
immediately prior to the completion of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares outstanding as of June&nbsp;30, 2024, after giving effect to the pro
forma adjustments described above. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After giving further effect to our issuance and sale of&nbsp;shares of our common stock in this offering at an assumed initial
public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro
forma as adjusted net tangible book value as of June 30, 2024 would have been $232.8 million, or $7.72 per share. This amount represents an immediate increase in pro forma as adjusted net tangible book value per share of $2.27 to our existing
stockholders and immediate dilution of $7.28 in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public
offering price per share paid by new investors. The following table illustrates this dilution on a per share basis (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Historical net tangible book value (deficit) per share as of June 30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase per share attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net tangible book value per share as of June 30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">7.72</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dilution per share to new investors participating in this
offering</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">7.28</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price
and other terms of this offering determined at pricing.&nbsp;Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by $0.26 and dilution per share to new investors
purchasing common stock in this offering by $0.74, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. Each increase of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after
this offering by $0.20 and decrease dilution per share to new investors purchasing common stock in this offering by $0.20, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. Each decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book
value per share after this offering by $0.21 and increase dilution per share to new investors purchasing common stock in this offering by $0.21, assuming no change in the assumed initial public offering price and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their option to purchase additional shares in
full, our pro forma as adjusted net tangible book value per share after this offering would be $250.6, representing an immediate increase in pro forma as adjusted net tangible book value per share of $0.25 to existing stockholders and immediate
dilution in pro forma as adjusted net tangible book value per share of $0.25 to new investors purchasing common stock in this offering, based on the assumed initial public offering price of $15.00 per share and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes on the pro forma as adjusted basis described above, the
total number of shares of common stock purchased from us on an as converted to common stock basis, the total consideration paid or to be paid, and the average price per share paid or to be paid by existing stockholders and by new investors in this
offering at an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, before deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. As the table shows, new investors purchasing common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="6"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="6"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:arial" ALIGN="right"><B>Total&nbsp;Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Average<BR>price<BR>per<BR>share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,653,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.8%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$221,762,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$10.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$127,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">30,153,698</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$349,262,435</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the
underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to 68.9 percent of the total number of shares of our common stock outstanding after
this offering, and the number of shares of common stock held by new investors purchasing common stock in this offering would be increased to 31.1 percent of the total number of shares of our common stock outstanding after this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The discussion and tables above are based on 21,653,698 shares of our common stock (which includes
35,703&nbsp;shares underlying unvested restricted stock awards subject to a repurchase option by us) outstanding as of June 30, 2024, after giving effect to the Preferred Stock Conversion, and excludes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,864,410 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2024, with a
weighted-average exercise price of $6.68&nbsp;per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">357,544 shares of common stock issuable upon the exercise of stock options granted after June 30, 2024, with a
weighted-average exercise price of $10.46 per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">783,287&nbsp;shares of common stock reserved for issuance under the 2019 Plan, as amended, as of August 15, 2024, which
shares will cease to be available for issuance at the time our 2024 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">3,065,000 shares of common stock reserved for future issuance under our 2024 Plan, which will become effective upon the
date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">289,436 shares of common stock reserved for future issuance under our 2024 ESPP, which will become effective upon the date
immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To
the extent that new stock options are issued or any outstanding options are exercised, or we issue additional shares of common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise additional
capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities,
the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_10"></A>Management&#146;s discussion and analysis of financial condition and results of
operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial
statements and the related notes appearing elsewhere in this prospectus. This discussion and other parts of this prospectus contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives,
expectations, intentions and projections. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those
discussed in the &#147;Risk factors&#148; section of this prospectus. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. </I></B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company focused on the
discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this
expertise, we designed our proprietary Precision Endocrine Peptide<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or PEP<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, platform to overcome the key limitations of unmodified
and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent
drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated
targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have
devoted substantially all of our resources to drug discovery and development of our product candidates, MBX 2109, MBX 1416 and MBX 4291, and other preclinical programs, building our intellectual property portfolio, organizing and staffing our
company, business planning, raising capital and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales. We have historically funded our
operations primarily through sales of our convertible preferred stock and convertible notes, which generated approximately $214.1 million in aggregate gross proceeds, including the proceeds received from the Series&nbsp;C Financing in August 2024.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have incurred significant operating losses since inception and we expect to continue to incur substantial losses for the foreseeable future. Our ability to
generate revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $13.6&nbsp;million and $28.2&nbsp;million for the six
months ended June 30, 2023 and 2024, respectively. Our net losses were $26.1 million and $32.6 million for the years ended December 31, 2022 and 2023, respectively. We had an accumulated deficit of $75.6 million and $103.8 million as of December 31,
2023 and June 30, 2024, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that our expenses and operating losses will increase substantially for the foreseeable future as we: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance the development of our lead product candidates, MBX 2109, MBX 1416 and MBX 4291, and future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance our&nbsp;current research activities and further develop our platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue preclinical development and discover and develop future product candidates we may identify; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approval for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish either internally or through contract manufacturing organizations manufacturing capacity capabilities to supply
our clinical trials in our pipeline and eventually for commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">transition from a company with a research focus to a company capable of supporting commercial activities, including
establishing sales, marketing, and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attract, hire and retain additional research and development, clinical, commercial, general and administrative personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain, expand, protect and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">defend against any claims by third parties that we have infringed, misappropriated or otherwise violated any intellectual
property of any such third party; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">confirm, maintain or obtain freedom to operate for any of our owned or licensed technologies and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add operational, financial and management information systems and personnel; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, audit, accounting, compliance, insurance, investor relations and other expenses to operate as a
public company that we did not incur as a private company. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will not generate revenue from product sales unless and until we successfully
complete clinical development and obtain regulatory approval for one or more product candidates. If we obtain regulatory approval for any product candidate and do not enter into a commercialization partnership, we expect to incur significant
expenses related to developing our commercialization capability to support product sales, manufacturing, marketing, and distribution. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth
strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing,
distribution or licensing arrangements with third parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such
agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of our platform or delay our pursuit of potential <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. </P>
 <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We had cash, cash equivalents and marketable securities of $80.7 million and $55.3&nbsp;million as of December&nbsp;31, 2023 and June&nbsp;30, 2024, exclusive of
approximately $63.5 million in gross proceeds from the Series&nbsp;C Financing received in August 2024, respectively. We believe that the anticipated net proceeds from this offering, together with our existing cash, cash equivalents and marketable
securities, including the proceeds from our Series&nbsp;C Financing, will be sufficient to fund our operating expenses and capital expenditure requirements into mid-2027. We have based this estimate on assumptions that may prove to be wrong, and we
could exhaust our available capital resources sooner than we expect. See &#147;Liquidity and capital resources&#148; and &#147;Risk factors&#151;Risks related to financial position and need for capital.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>License agreement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Below is a summary of the key terms for our license
agreement. For a more detailed description of this agreement, see the section titled &#147;Business&#151;License agreement.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Indiana University Research And Technology Corporation Exclusive License Agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2020, we entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation, or IURTC, a non-profit corporation organized
under the laws of the State of Indiana, represented by The Trustees of Indiana University, or IU, pursuant to which we have been granted an exclusive, royalty-bearing license to certain IURTC patent rights, or the Licensed Intellectual Property,
developed by Dr.&nbsp;DiMarchi and other collaborators to further scientific research, for new product development, and for other applications in public interest, such license, the IURTC License Agreement. In particular, we have been granted an
exclusive, royalty-bearing license to make, have made, use, have used, offer to sell, have offered for sale, sell, have sold, import and have imported products that are covered by the Licensed Intellectual Property, or Licensed Products, with the
right to sublicense to third parties. IURTC and IU have retained the right to (i)&nbsp;practice and use the Licensed Intellectual Property for <FONT STYLE="white-space:nowrap">non-commercial</FONT> educational, research, and patient care and
treatment purposes, and (ii)&nbsp;permit other <FONT STYLE="white-space:nowrap">non-profit</FONT> and academic entities to practice and use the Licensed Intellectual Property for the same <FONT STYLE="white-space:nowrap">non-commercial</FONT>
purposes. Under the IURTC License Agreement, we agreed to use commercially reasonable efforts to develop, promote and sell Licensed Products in accordance with the IURTC License Agreement and any applicable laws. The IURTC License Agreement
leverages IURTC&#146;s expertise in peptide therapies as well as our scientific, clinical, and regulatory capabilities to accelerate the development of peptide treatments for people with endocrine and metabolic disorders. MBX 2109, MBX 1416 and MBX
4291 are Licensed Products under the IURTC License Agreement. Any future product candidates developed pursuant to our sponsored research agreement with IU or otherwise covered by the Licensed Intellectual Property may be subject to the IURTC License
Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As initial consideration for the license, we paid IURTC an immaterial issue fee. As additional consideration for the license, we are required to pay
IURTC: (i)&nbsp;royalties with a rate based on net sales per calendar year; (ii)&nbsp;an annual maintenance fee of up to $0.1&nbsp;million beginning in the first year in which the first commercial sale occurs; (iii)&nbsp;a mid-single digits
percentage of any sublicensing revenue; and (iv)&nbsp;milestone payments in the event of successful achievement of specified development milestones up to an aggregate of $0.4&nbsp;million. IURTC is also entitled to receive reimbursement for all
patent prosecution and maintenance related expenses. Our tiered royalties are in the low single-digits on annual net sales of the Licensed Products. In the event that we are required to pay a <FONT STYLE="white-space:nowrap">non-affiliate</FONT>
third party consideration for intellectual property owned or controlled by such <FONT STYLE="white-space:nowrap">non-affiliate</FONT> third party that we or a sublicensee licensed for the development of Licensed Products, we can deduct such amounts
from the royalty payments up to a certain amount of the running royalties owed that year. The royalty term will terminate on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each
Licensed Product, until the expiration or termination of the last valid claim within the patent rights covering such Licensed Product in that country. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On
January&nbsp;5, 2024, we and IURTC entered into a fourth amendment to the IURTC License Agreement, or the Fourth Amendment. The Fourth Amendment specifies IURTC is entitled to the receipt of additional clinical and regulatory milestones, as defined
in the Fourth Amendment, up to an aggregate of $9.0&nbsp;million. Following the execution of the Fourth Amendment, future remaining clinical and regulatory milestone payments in the IURTC License Agreement and all amendments total up to
$9.3&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The IURTC License Agreement will expire at the expiration of the last of the patent rights covered in the IURTC License Agreement, unless
terminated earlier by mutual agreement or by one of the parties. We may terminate the IURTC License Agreement with or without cause upon ninety (90)&nbsp;days prior written notice to IURTC. IURTC may terminate the IURTC License Agreement if we
commit a material breach of the IURTC License Agreement and fail to cure the breach within the respective cure period after receipt of the notice of material breach or upon our failure to undertake certain activities in furtherance of commercial
development goals. Upon termination of the IURTC License Agreement, all rights granted by IURTC will terminate and automatically revert to IURTC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Components of results of operations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our operating expenses consist of (i)&nbsp;research
and development expenses and (ii)&nbsp;general and administrative expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Research and development </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The largest component of our total operating expenses since our inception has been research and development activities. Research and development expenses are expensed as
incurred and consist primarily of: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external research and development expenses incurred under agreements with contract research organizations, or CROs,
consultants and other third parties to conduct our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">costs related to manufacturing our product candidates for preclinical studies and clinical trials, including agreements
with contract development and manufacturing organizations, or CDMOs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">license fees, including any milestone-based payments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">compensation and benefits, including stock-based compensation expense, for research and development personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of acquiring research and development supplies and services; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacturing process development costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">costs associated with regulatory activities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">costs incurred in development of intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other outside services and consulting costs; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an allocated portion of facilities and other infrastructure costs associated with our research and development activities.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and
development activities to advance our programs and conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product
candidates is highly uncertain. As a result, expenses may vary significantly based on factors such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of research and development, preclinical and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our existing or future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our existing or future product candidates by the FDA and
comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or for such authorities to change their requirements
on studies that had previously been agreed to; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our existing or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred to attract, hire and retain skilled research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">per subject clinical trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of sites included in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the countries in which our clinical trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">length of time required to enroll subjects and initiate our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of subjects that participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> and discontinuation rate of subjects; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the duration of subject participation in our clinical trials and <FONT STYLE="white-space:nowrap">follow-up,</FONT>
including the duration of open label extensions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of license agreement milestone payments related to development, regulatory and commercial events;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacturing success with patient materials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">mitigation/responses to potential health authority questions and/or inspections; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the degree to which we obtain, maintain, defend and enforce our intellectual property rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we establish collaboration, licensing or similar arrangements and the performance of any related third
parties. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A change in the outcome of any of these variables with respect to the development of any of our existing or future product candidates
could significantly change the costs and timing associated with the development of that product candidate. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>General and administrative </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses consist primarily of compensation and benefits, including stock-based compensation expense, for general and administrative personnel;
other expenses for outside professional services, including legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, consulting and tax services; insurance costs; administrative travel expenses;
website development costs; marketing and public relations costs; and facilities, information technology and other allocated overhead costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that our
general and administrative expenses will increase in the future as we increase our headcount to support continued growth of our research and development activities. We also anticipate that we will incur increased accounting, audit, legal,
regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company. We also expect our intellectual property expenses to increase as we expand our intellectual
property portfolio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Other income (expense) </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest expense </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest expense related to the issuance of our 2022
convertible notes and subsequent conversion to Series B Convertible Preferred Stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest and other income, net </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Total other income, net, is comprised of interest income earned on our cash and cash equivalents and marketable securities and amortization expense and accretion income
on our marketable securities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in derivative liability and loss on extinguishment debt </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Change in derivative liability and loss on extinguishment of debt related to the issuance of our 2022 convertible notes and subsequent conversion to Series B Convertible
Preferred Stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Results of operations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Comparison of the six
months ended June 30, 2023 and 2024 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our results of operations for the six months ended June 30, 2023 and 2024 (in thousands):
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#8196;11,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#8196;25,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#8196;13,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(13,557</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8202;(28,194</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(14,637</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Research and development expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
following table summarizes our research and development expenses for the periods indicated (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Direct research and development program expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">MBX 2109</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#8201;4,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#8196;8,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">MBX 1416</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preclinical and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Indirect research and development costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel related costs (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facility-related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development
expense</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000" ALIGN="right">$11,734</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000" ALIGN="right">$25,445</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000" ALIGN="right">13,711</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses increased by $13.7&nbsp;million from $11.7&nbsp;million for the six months ended
June&nbsp;30, 2023 to $25.4&nbsp;million for the six months ended June&nbsp;30, 2024, as detailed below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Direct research and development program expenses related to
MBX 2109 increased by $4.3&nbsp;million, primarily due to the initiation of the Phase 2 clinical trial and costs associated with conducting preclinical studies. Direct program expenses related to MBX 1416 increased by $4.5 million, primarily due to
the ongoing Phase 1 clinical trial and costs associated with conducting preclinical studies and manufacturing. Direct program expenses for preclinical and other programs increased by $1.4&nbsp;million primarily due to pipeline candidate development
activities. Personnel-related costs (including stock-based compensation), increased by $2.4&nbsp;million, primarily due to increased headcount and stock-based compensation expense. Facility-related and other, which include allocated overhead,
including rent, repairs and maintenance costs, common facilities and information technology-related expenses allocated to research and development increased by $1.1 million, primarily due to a one-time cash gift to Indiana University to support
research in macromolecular chemistry and peptide therapeutics and related areas in the Department of Chemistry, and other infrastructure costs to support organizational growth. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>General and administrative expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative
expenses increased by $1.9 million, from $2.6 million for the six months ended June&nbsp;30, 2023 to $4.5 million for the six months ended June&nbsp;30, 2024. The increase was primarily due to higher professional fees related to legal and accounting
services and higher personnel-related costs, including compensation, benefits and stock-based compensation, as we expanded our infrastructure to support growth in our operations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Interest and other income, net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest and other income, net, which
includes interest income and amortization of premiums and discounts on our investments in marketable securities, increased by $1.0 million from $0.8 million for the six months ended June 30, 2023 to $1.8 million for the six months ended
June&nbsp;30, 2024, due to increased interest on our cash, cash equivalents and marketable securities, which increased primarily due to the closing for the Series B Convertible Preferred Stock financing in August 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Comparison of the years ended December&nbsp;31, 2022 and 2023 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
following table summarizes our results of operations for the years ended December&nbsp;31, 2022 and 2023 (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8196;21,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8196;28,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8196;&#8199;7,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(26,135</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(32,563</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8199;(6,428</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our research and development expenses for the periods indicated (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Direct research and development program expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">MBX 2109</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">MBX 1416</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preclinical and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Indirect research and development costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel related costs (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facility-related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expense</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">21,397</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">28,534</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">7,137</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses increased by $7.1&nbsp;million from $21.4&nbsp;million for the year ended December&nbsp;31, 2022 to
$28.5&nbsp;million for the year ended December&nbsp;31, 2023, as detailed below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Direct research and development program expenses related to MBX 2109 decreased by
$2.8&nbsp;million, primarily due to the completion of the Phase 1 clinical trial in 2023. Direct program expenses related to MBX 1416 increased by $6.2&nbsp;million, primarily due to the initiation of a Phase 1 clinical trial, costs associated with
conducting preclinical trials and costs associated with manufacturing drug supply. Direct program expenses for preclinical and other programs increased by $0.9&nbsp;million primarily due to pipeline candidate development activities.
Personnel-related costs (including stock-based compensation), increased by $2.5&nbsp;million, primarily due to increased headcount and stock-based compensation expense. Facility-related and other, which include allocated overhead, including rent,
repairs and maintenance costs, common facilities and information technology-related expenses allocated to research and development increased by $0.4&nbsp;million, primarily due to increases in rent expense and other infrastructure costs to support
organizational growth. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses increased by $3.0&nbsp;million, from $3.8&nbsp;million for the year ended December&nbsp;31, 2022 to $6.8&nbsp;million for the year
ended December&nbsp;31, 2023. The increase was primarily due to higher professional fees related to legal and accounting services and higher personnel-related costs, including compensation, benefits and stock-based compensation, as we expanded our
infrastructure to support growth in our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Interest expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest expense decreased by $0.4&nbsp;million, from $0.4&nbsp;million for the year ended December&nbsp;31, 2022 to $0 for the year ended December&nbsp;31, 2023 due to
our convertible notes issuance and subsequent conversion to Series B Convertible Preferred Stock in 2022. There were no similar activities for the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Interest and other income, net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest and other income, net, which
includes interest income and amortization of premiums and discounts on our investments in marketable securities, increased by $2.4&nbsp;million from $0.4&nbsp;million for the year ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
December&nbsp;31, 2022 to $2.8&nbsp;million for the year ended December&nbsp;31, 2023, due to increased interest on our cash, cash equivalents and marketable securities, which increased primarily
due to the closing for the Series B Convertible Preferred Stock financing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Change in derivative liability and loss on extinguishment debt </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Change in derivative liability and loss on extinguishment of debt decreased by $1.0&nbsp;million, from $1.0&nbsp;million for the year ended December&nbsp;31, 2022 to $0
for the year ended December&nbsp;31, 2023 due to our convertible notes issuance and subsequent conversion to Series B Convertible Preferred Stock in 2022. There were no similar activities for the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Liquidity and capital resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sources of liquidity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have incurred significant operating losses. We have historically funded our operations primarily through sales of our convertible preferred stock
and convertible notes, which generated approximately $214.1 million in aggregate gross proceeds, including the proceeds received from the Series&nbsp;C Financing in August 2024. As of December&nbsp;31, 2023 and June&nbsp;30, 2024, we had
$80.7&nbsp;million and $55.3 million in cash, cash equivalents and marketable securities, respectively, exclusive of the proceeds from the Series&nbsp;C Financing. We have not yet generated any revenue from product sales and do not expect to in the
foreseeable future as our product candidates are in various phases of clinical and preclinical development. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Future funding requirements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the development of our product candidates. In
addition, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of research and development, preclinical&nbsp;and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our existing or future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our existing or future product candidates by the FDA and
comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or for such authorities to change their requirements
on studies that had previously been agreed to; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our existing or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our existing or future product candidates for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of filing and prosecuting our patent applications, and maintaining and enforcing our patents and other
intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any product liability or other lawsuits related to our existing or future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of other factors, including inflation, economic uncertainty and geopolitical tensions, which may exacerbate the
magnitude of the factors discussed above. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We had $80.7 million and $55.3 million in cash, cash equivalents and marketable securities as of
December&nbsp;31, 2023 and June&nbsp;30, 2024, respectively. In August 2024, we completed the Series&nbsp;C Financing and received approximately $63.5 million in gross proceeds. We believe that our existing cash, cash equivalents and marketable
securities, including proceeds from our Series&nbsp;C Financing, will be sufficient to fund our current operating plan for at least the next 12 months from the date of this prospectus. Based on our current operating plan, we estimate that our
existing cash, cash equivalents and marketable securities, together with the estimated net proceeds from this offering, will be sufficient to fund our projected operating expenses and capital expenditure requirements into mid-2027. We have based
this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until such time, if ever,
as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third
parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interest for existing investors may be materially diluted, and the terms of such securities could include liquidation or
other preferences that adversely affect existing investors&#146; rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified
actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings
or other arrangements when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and
market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash flows </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
following table summarizes our sources and uses of cash for the periods presented (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&#8195;&#8195;&#8195;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&#8195;&#8195;&#8195;2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&#8195;&#8195;&#8195;2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&#8195;&#8195;&#8195;2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(23,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(31,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(13,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(23,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net increase (decrease) in cash, cash equivalents and restricted
cash</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8196;11,530</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8196;&#8199;6,313</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8194;&#8196;4,230</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(18,020</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash flows from operating activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the six months ended June&nbsp;30, 2024 was $24.0 million. This was primarily due to our net loss of $28.2 million, partially
offset by net cash provided by changes in our operating assets and liabilities of $2.5 million and non-cash charges of $1.8 million. The changes in our net operating assets and liabilities primarily consisted of a $3.3 million increase in accounts
payable and accrued expenses primarily related to balances with CDMOs, partially offset by a $0.8 million increase in our prepaid expenses and other current assets related to prepaid balances with CROs. Non-cash charges primarily consisted of $2.5
million of stock-based compensation expense, partially offset by $0.9&nbsp;million of net amortization and accretion of marketable securities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in
operating activities for the six months ended June&nbsp;30, 2023 was $13.1 million. This was primarily due to our net loss of $13.6 million, partially offset by net cash provided by changes in our operating assets and liabilities of $0.4 million and
non-cash charges of $0.1 million. The changes in our net operating assets and liabilities primarily consisted of a $0.2 million decrease in our prepaid expenses and other current assets and a $0.2 million increase in accounts payable and accrued
expenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the year ended December&nbsp;31, 2023 was $32.0&nbsp;million. This was primarily due to our net loss of
$32.6&nbsp;million and net cash used by changes in our operating assets and liabilities of $0.7&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.3&nbsp;million. The changes in our net operating assets
and liabilities primarily consisted of a $1.1&nbsp;million increase in our prepaid expenses and other current assets and other assets related to prepaid balances with CROs and CDMOs and a $0.1&nbsp;million increase in our operating lease liability,
offset by a $0.5&nbsp;million increase in accounts payable and accrued expenses related to timing. <FONT STYLE="white-space:nowrap">Non-cash</FONT> charges primarily consisted of $2.0&nbsp;million of stock-based compensation expense,
$0.2&nbsp;million of depreciation expense on fixed assets, and $0.1&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense, offset by $1.0&nbsp;million of net amortization and accretion of marketable securities.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the year ended December&nbsp;31, 2022 was $23.1&nbsp;million. This is primarily due to our net loss for the period of
$26.1&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.7&nbsp;million and net cash provided by changes in our operating assets and liabilities of $1.3&nbsp;million.
<FONT STYLE="white-space:nowrap">Non-cash</FONT> charges primarily consisted of $0.9&nbsp;million in loss on extinguishment of convertible notes, $0.4&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense,
$0.3&nbsp;million of stock-based compensation expense, and $0.1&nbsp;million of change in derivative liability. The changes in our net operating assets and liabilities primarily consisted of a $2.1&nbsp;million increase in accounts payable and
accrued expenses related to timing, offset by a $0.8&nbsp;million increase in prepaid expenses and other current assets driven by an increase in our prepaid balances with CROs and CDMOs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash flows from investing activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by investing activities for the six months ended June 30, 2024 was $7.5 million, which consisted of maturities of marketable securities of $32.5
million, partially offset by purchases of marketable securities of $24.2 million and purchases of property and equipment of $0.7 million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by
investing activities for the six months ended June 30, 2023 was $16.6 million, which consisted of maturities of marketable securities of $26.0 million, partially offset by purchases of marketable securities of $9.3 million and purchases of property
and equipment of $0.1 million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in investing activities for the year ended December&nbsp;31, 2023 was $30.9&nbsp;million, which consisted of purchases
of marketable securities of $63.8&nbsp;million and purchases of property and equipment of $0.1&nbsp;million, partially offset by maturities of marketable securities of $33.0&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in investing activities for the year ended December&nbsp;31, 2022 was $11.4&nbsp;million, which consisted of purchases of marketable securities of
$20.2&nbsp;million and purchases of property and equipment of $0.4&nbsp;million, partially offset by maturities of marketable securities of $9.2&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash flows from financing activities </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in financing
activities for the six months ended June 30, 2024 was $1.6 million, which primarily consisted of payments related to initial public offering costs of $1.8 million, partially offset by proceeds from the exercise of common stock options of $0.2
million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the six months ended June 30, 2023 was $0.7 million, which consisted of proceeds from the exercise of common
stock options of $0.7 million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the year ended December&nbsp;31, 2023 was $69.2&nbsp;million, which primarily consisted
of proceeds from the issuance of Series B Convertible Preferred Stock of $68.5&nbsp;million and proceeds from the exercise of common stock options of $0.7&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the year ended December&nbsp;31, 2022 was $46.1&nbsp;million, which primarily consisted of proceeds from the issuance of
Series B Convertible Preferred Stock of $36.5&nbsp;million and proceeds from issuance of convertible notes of $10.0&nbsp;million, partially offset by preferred stock issuance costs of $0.4&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Contractual obligations and commitments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Leases </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into two separate lease agreements for corporate office space and laboratory space, with terms extending through December 2025. As of December&nbsp;31,
2023, our future remaining operating lease payments were $0.4&nbsp;million, with $0.2 million payable within the next twelve months, with respect to leases already commenced as of such date. As of June&nbsp;30, 2024, our future remaining operating
lease payments were $0.3 million, with $0.2&nbsp;million payable within the next twelve months, with respect to leases already commenced as of such date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Refer to
Note 8 in our audited financial statements and Note 9 in our unaudited financial statements included elsewhere in this prospectus for more information on our lease obligations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>License agreement and other agreements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the IURTC License
Agreement, we have payment obligations that are contingent upon future events, such as the achievement of specified development, regulatory and commercial milestones, and in some cases, we are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
required to make royalty payments in connection with the sales of products developed under those agreements. Although we could be required to make milestone payments under the IURTC License
Agreement, we are unable to estimate the timing or likelihood of achieving the milestones or making future product sales. For additional details regarding the IURTC License Agreement, see the section titled &#147;Business&#151;License
Agreement.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for
preclinical studies and clinical trials, research supplies and other services and drugs for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts. In addition, certain
of our supply agreements contain minimum purchase commitments in certain situations, the timing and likelihood of which we cannot estimate at this time. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Recently issued accounting pronouncements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A description of recently issued
accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Critical accounting policies and significant judgments and estimates </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP. The preparation of
these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the
reported expenses incurred during the reporting periods. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On an ongoing basis, we evaluate our estimates and judgments, including but not limited to those related to
accrued research and development costs, the fair value of common stock and stock-based compensation expense and other fair value measurements. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances,
and material changes in these estimates and assumptions could occur in the future. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may
differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While our significant accounting policies are described in more detail in Note&nbsp;2 to our
audited financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Accrued research and development expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development
expenses are recognized as services are performed and as costs occur. As part of our process of preparing our financial statements, we are required to estimate our research and development expenses as of each balance sheet date. Research and
development expense accruals are estimated based on the level of services performed, progress of the work orders, including the phase or completion of events, and contracted costs. This process involves reviewing open contracts and purchase orders
and communicating with our personnel to identify the level of services that have been performed. We then make estimates of levels of service performed when we have not yet been invoiced or otherwise notified of actual costs incurred as of the
balance sheet date. We make significant judgments and estimates in determining the accrual balance at each reporting period based on the facts and circumstances known to us at that time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There may be instances in which vendors will require nonrefundable advance payments for goods or services to be
received in the future. Such advance payments for use in research and development activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the services are
performed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the level of services and timing
of services performed differ from actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular reporting period. To date, there have been no material differences between
estimates of such expenses and the amounts actually incurred. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Stock-based compensation expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (usually
the vesting period) on a straight-line basis. We estimate the fair value of all stock option grants using the Black-Scholes option pricing model and recognize forfeitures as they occur. Estimating the fair value of equity awards as of the grant date
using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the
expected dividend yield and the fair value of the underlying common stock on the date of grant. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are
subjective and generally require significant analysis and judgment to develop. See Note 12 to our audited financial statements and unaudited condensed interim financial statements included elsewhere in this prospectus for information concerning
certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted for the years ended December 31, 2022 and 2023, respectively, and the six months ended
June&nbsp;30, 2023 and 2024, respectively. The majority of our stock option program allows for early exercise of granted options, before vesting requirements have been satisfied. Shares acquired through the early exercise of options which have not
vested at the time of any employee&#146;s termination may be purchased by us at the lower of the original exercise price or the then current fair market value. As of June&nbsp;30, 2024, the unrecognized stock-based compensation expense related to
stock options was $11.2 million and is expected to be recognized as expense over a weighted-average period of approximately 3.1 years. The intrinsic value of all outstanding stock options as of June&nbsp;30, 2024 was approximately
$23.8&nbsp;million, based on the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), of which approximately $7.0&nbsp;million related to vested options and
approximately $16.8&nbsp;million related to unvested options. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Determination of the fair value of common stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are required to estimate the fair value of the common stock underlying our stock-based awards when performing fair value calculations. As there has been no public
market for our common stock to date, we develop an estimate of the fair value of our common stock on each grant date of options to purchase common stock. The fair value of our common stock has been determined by our board of directors on each grant
date of options to purchase common stock, taking into account input from management, results from independent third-party valuations and our board of directors&#146; assessment of additional objective and subjective factors that it believed were
relevant and which may have changed from the date our most recent valuation through the date of the grant. These objective and subjective factors include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prices of our convertible preferred stock sold to investors in arm&#146;s length transactions and the rights,
preferences and privileges of our convertible preferred stock relative to those of our common stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the progress of our research and development programs, including the status of preclinical studies and clinical trials for
our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our results of operations and financial position, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of marketability of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a
sale of our company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">trends and developments in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the economy in general. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our determinations of the fair value of our common stock were made using methodologies, approaches and assumptions consistent with the American Institute of Certified
Public Accountants Accounting and Valuation Guide: Valuation of Privately Held Company Equity Securities Issued as Compensation, or the Practice Aid. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Practice
Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The cost approach
establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present
value of future cash flows that are reasonably reflective of our future operations, discounting to the present value with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the
value of an asset is equal to the value of a substitute asset with the same characteristics. Each valuation methodology was considered in our valuations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock in accordance with the Practice Aid include the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Current value method.</I> Under the current value method, once the fair value of the enterprise is established, the
value is allocated to the various series of preferred and common stock based on their respective seniority, liquidation preferences or conversion values, whichever is greatest. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Option pricing method, or OPM</I>. Under the OPM, shares are valued by creating a series of call options with exercise
prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Probability-weighted expected return method, or PWERM</I>. The PWERM is a scenario-based analysis that estimates the
value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our early stage of development, the complexity of our capital structure, the difficulty in predicting the likelihood and range of specific outcomes, including
uncertainty related to the timing and type of an exit event, and other relevant factors, the OPM was considered most appropriate for valuations prior to August 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For options granted after April&nbsp;19, 2023, a hybrid method between the PWERM and OPM was used, where the equity
value was probability-weighted across multiple scenarios. The value of the shares under an initial public offering event scenario was determined according to the PWERM and the OPM scenario, using an appropriate time to a liquidity event, was used to
estimate the fair value of the share class assuming the initial public offering event does not occur. The resulting share values under each scenario are weighted by their respective probabilities. This method was determined to be the most
appropriate valuation methodology based on our stage of development and other relevant factors. In determining the estimated fair value of our common stock, our board of directors also considered the fact that our stockholders could not freely trade
our common stock in the public markets. Accordingly, discounts were applied to reflect the lack of marketability of our common stock based on the weighted-average expected time to liquidity. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions
regarding our future operating performance, the time to complete an initial public offering or other liquidity event, and the determination of the appropriate valuation methods. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our board
of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options or for any other such awards we may grant, as the fair value of our common stock will be determined based on the closing price of
our common stock as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes information
related to stock options we granted from January&nbsp;1, 2023 through September&nbsp;9, 2024: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Grant date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>shares&nbsp;subject<BR>options&nbsp;granted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;share<BR>exercise&nbsp;price<BR>of&nbsp;options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Fair&nbsp;value&nbsp;per<BR>common&nbsp;share<BR>on grant date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Per share<BR>estimated&nbsp;fair<BR>value&nbsp;of&nbsp;options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">January&nbsp;18, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">April&nbsp;19, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">August&nbsp;15, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,418,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$7.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$7.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">November&nbsp;2, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$7.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$7.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">January&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$9.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$9.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$6.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">April 24, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$10.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$10.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">August 2, 2024</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">357,544</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$10.46</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$10.46</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$8.83</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We utilize a third-party valuation firm to assist in determining the grant date fair market value of our common stock. On
November&nbsp;7, 2022, our board of directors, with the assistance of a third-party valuation firm, determined the fair market value of our common stock to be $3.25, or the Initial Valuation. The fair market value of our common stock was
subsequently reassessed as of November&nbsp;7, 2022, solely for financial reporting purposes, to appropriately bifurcate upside and downside scenarios in accordance with the Practice Aid. As a result, the fair value of common stock as of
November&nbsp;7, 2022 was determined to be $4.09, as compared to the $3.25 determined by the Initial Valuation for tax reporting purposes. This revaluation resulted in recognition of additional stock-based compensation expense. The exercise price
for stock options granted from November&nbsp;7, 2022 through April&nbsp;19, 2023 was derived from the Initial Valuation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Equity Grants in Connection with
this Offering </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, our board of directors has approved the grant of options for the purchase of an aggregate of 487,225 shares
of common stock to our non-employee directors and certain employees, including certain of our executive officers, assuming the number of shares outstanding following this offering will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
equal to 30,153,698 based on an assumed initial public offering price of $15.00, which is the midpoint of the price range set forth on the cover page of this prospectus. The effectiveness of this
grant of stock options is contingent on, and effective immediately following, the effectiveness of the registration statement of which this prospectus forms a part. The stock options will have a per share exercise price equal to initial public
offering price set forth on the cover page of the final prospectus included in the registration statement, which will be the fair market value of a share of our common stock on the grant date of the stock options. The stock options will be subject
to the terms and conditions of the 2024 Stock Option and Incentive Plan, and the applicable stock option agreements thereunder. Based on an assumed exercise price of $15.00 per share, which is the midpoint of the estimated price range set forth on
the cover page of this prospectus, we estimate that the aggregate grant-date fair value of the options granted is $6.2&nbsp;million, which is expected to be recognized as stock-based compensation expense over a period of four years. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet arrangements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the periods presented we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined in the
rules and regulations of the SEC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Quantitative and qualitative disclosures about market risks </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Interest rate risk </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary objectives of our investment activities
are to ensure liquidity and to preserve capital. We are exposed to market risks related to changes in interest rates of our cash equivalents and marketable securities. However, due to the nature of these cash equivalents and marketable securities,
we do not believe that a hypothetical 10% increase or decrease in interest rates during any of the periods presented would have had a material effect on our business, results of operations, or financial condition, or on our audited financial
statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Effects of inflation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Inflation generally affects us by increasing our cost of labor and research and development costs. We do not believe that inflation had a material effect on our
business, results of operations, or financial condition, or on our audited financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Emerging growth company
and smaller reporting company status </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We qualify as an &#147;emerging growth company,&#148; as defined in the JOBS Act. As an emerging growth company, we may
take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: (i)&nbsp;being permitted to present only two years of audited financial statements, in
addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure in this prospectus; (ii)&nbsp;reduced
disclosure about our executive compensation arrangements; (iii)&nbsp;not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden parachute arrangements not previously approved; (iv)&nbsp;an
exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; and (v)&nbsp;an exemption from compliance with the requirements of the Public Company
Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#146;s report on the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging
growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our
fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on
which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the
information contained herein may be different from the information you receive from other public companies in which you hold stock. Additionally, the JOBS Act provides that an emerging growth company can take advantage of an extended transition
period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail
ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth
companies. As a result of this election, our audited financial statements and unaudited condensed financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public
company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
are also a &#147;smaller reporting company,&#148; meaning that the market value of our shares held by nonaffiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual
revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our shares held by nonaffiliates is less than
$250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our shares held by nonaffiliates is less than $700&nbsp;million. If we are a smaller reporting
company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose
to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure
obligations regarding executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_11"></A>Business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company focused on the
discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this
expertise, we designed our proprietary Precision Endocrine Peptide<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or PEP<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, platform to overcome the key limitations of unmodified
and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent
drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel
candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>MBX 2109:</B>&#8195;Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a
potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous,
infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. In a Phase 1 clinical trial, MBX 2109 demonstrated a low ratio between the highest concentration of active drug observed after a dose and the
concentration of active drug observed immediately prior to the next dose, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio, which is consistent with a continuous, infusion-like profile, and an
extended half-life, potentially enabling the first once-weekly PTH dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2
clinical trial in patients with HP and dosed our first patient in this trial in August 2024. We anticipate reporting topline data in the third quarter of 2025. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>MBX 1416:</B>&#8195;We are advancing MBX 1416, which is designed to be a long-acting glucagon-like peptide 1, or <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, or PBH, a chronic complication of bariatric surgery. MBX 1416 is designed as a convenient once-weekly therapy to reduce insulin
secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events. In our ongoing Phase&nbsp;1 clinical trial preliminary data regarding the way the compound is absorbed, distributed, metabolized and excreted, or
pharmacokinetics, from the single ascending dose portion demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional
single ascending dose and multiple ascending dose data from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Obesity portfolio:</B>&#8195;Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly
potent <FONT STYLE="white-space:nowrap">GLP-1</FONT> and glucose-dependent insulinotropic polypeptide, or GIP, receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> prodrug with the goal of reducing dosing frequency of and improving efficacy
and tolerability relative to existing standards of care. In our preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component of MBX 4291 supporting the potential for once-monthly administration. During our preclinical
studies, the concentration of the active component of MBX 4291 was significantly lower than the concentration of tirzepatide during the comparison period. Although we believe MBX 4291 has the potential to be dosed less frequently, less frequent
dosing would necessarily require a higher dose of MBX 4291. The results observed from our preclinical studies may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. In addition, the study supporting
potential duration of MBX 4291 was conducted separately from studies evaluating its effects. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
studies with an anticipated investigational new drug, or IND, submission in the second quarter of 2025. Beyond MBX 4291, we have a robust discovery pipeline including multiple programs in the
lead optimization stage of development. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate
their function and maintain homeostasis, which impact metabolism, growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. In addition to
using peptides as hormone replacement therapies, peptide-based drugs have been developed as pharmacologic agents to treat endocrine and other diseases. However, whether as replacement therapies or novel pharmacological actions, these therapeutic
peptides often have significant drawbacks. Unmodified peptides often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours<B> </B>by<B><I> </I></B>the liver and kidney. This often necessitates
frequent, daily injections of these peptides, which can result in wide fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high levels of the peptide. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens. Although these convenient, patient-friendly therapies
could increase compliance and result in improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios, which can lead to side effects and limit potential
efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent injections and have the potential to provide improved
efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we are designing and developing novel peptide therapeutics with the goal of achieving four key, distinct attributes: 1) high potency, 2) high target
selectivity, 3) half-lives that allow a dosing at weekly or less frequent intervals, and 4) low or flat <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios to improve tolerability, thereby
facilitating higher dosing and greater potential efficacy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our platform </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have built our proprietary PEP platform to develop innovative precision peptide therapies that are designed to overcome key limitations of current peptide therapies.
We were founded by leaders in the field of peptide discovery and development with the goal of transforming the treatment landscape for endocrine and metabolic diseases with novel, efficacious, safe and convenient treatments. Our PEP platform builds
upon the expertise and chemical technologies originally discovered at the Indiana University laboratory of our scientific <FONT STYLE="white-space:nowrap">co-founder,</FONT> Dr.&nbsp;Richard DiMarchi, who is globally recognized for translational
breakthroughs in endocrine pharmacology, including the discovery of the first <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist</FONT> as well as other dual and triple incretin agonists. Our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art,</FONT></FONT></FONT> proprietary PEP platform has enabled us to engineer novel product candidates that are designed to have optimized
pharmaceutical properties, including a longer duration of action, consistent drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios, and less frequent dosing, which support
our goals of improved tolerability, efficacy and potency. We currently rely on the discovery capabilities of Dr. DiMarchi and the Indiana University laboratory, but are continuing to grow and develop our internal discovery and development capacity,
including having hired an experienced cross-functional discovery team and building a peptide synthesis laboratory that will fully launch in the third quarter of 2024. We have developed a proprietary platform of tools that we believe will allow us to
continually design transformative therapies. These proprietary tools and <FONT STYLE="white-space:nowrap">know-how</FONT> include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advanced chemical modifications</B> with a goal to provide enhanced physical properties including stability and
solubility, increased potency, and multiple mechanisms of action in a single peptide </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Programmable prodrug technologies</B> that are designed to precisely time the chemical conversion of the prodrug into an
active form to reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios and improve clinical outcomes </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Fatty acylation</B> aims to increase duration of action for more convenient dosing regimens and compatibility with <FONT
STYLE="white-space:nowrap">non-injectable</FONT> formulations </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our PEP platform is designed to improve clinical outcomes and simplify disease
management for patients. Our PEPs are engineered to potentially optimize pharmaceutical properties yielding peptides with extended time-action profiles, convenient dosing regimens and the potential to enhance compliance and improve treatment
effectiveness in a real-world setting. PEPs may improve efficacy and reduce adverse events by providing a more continuous, infusion-like exposure to the peptide. We believe that our PEP technology, along with our significant <FONT
STYLE="white-space:nowrap">know-how</FONT> in the synergistic application of these tools, provides the opportunity to discover novel, highly selective and efficacious peptides with extended time-action profiles and low
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios that may improve on the shortcomings of existing peptide therapies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our pipeline </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are leveraging our PEP platform to advance a pipeline
of programs to treat both endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet needs and large potential market opportunities. Developing product candidates, including
conducting preclinical studies and clinical trials, is a time consuming, expensive and uncertain process. We have not yet demonstrated an ability to obtain regulatory approvals. We retain exclusive, worldwide development and commercialization rights
to all of our product candidates and discovery programs. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g02s97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyond MBX 4291, we have a robust discovery pipeline including multiple obesity programs in the lead optimization stage of
development. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>MBX 2109: Potential treatment for chronic hypoparathyroidism </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment
of HP. HP is a rare endocrine disease where parathyroid glands fail to produce sufficient amounts of PTH, which is a hormone that regulates calcium levels in the blood through its effects on bone, kidneys and intestines. We estimate that HP affects
approximately 120,000 people in the United States and more than 250,000 in the United States and Europe. HP is caused by damage to or removal of the parathyroid glands during neck surgery in approximately 75% of cases, or, less commonly, from an
autoimmune disease or a genetic disorder. A deficiency of PTH results in lower blood calcium levels, or hypocalcemia, which can result in a variety of acute symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as
depression, confusion and cognitive impairment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To avoid hypocalcemia and its symptoms, patients are treated with high dose calcium supplements and prescription
strength active vitamin D therapy, which can require the daily ingestion of approximately seven or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
more pills taken at multiple times throughout the day. This treatment does not address PTH deficiency and symptom relief can be suboptimal. Once-daily injectable PTH therapies have been shown in
clinical studies to reduce the need for high doses of calcium and active vitamin D supplements, decrease urinary calcium excretion and, by patient-reported-outcome assessments, result in improvements in patients&#146; quality of life. However, these
therapies can have significant fluctuations in drug concentrations that require daily subcutaneous injections, which impacts the potential outcomes for patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP. MBX 2109 is a prodrug, which is a compound engineered to be
biologically inactive at the time of subcutaneous injection that then converts to an active peptide in an intrinsically controlled, time-dependent fashion. The prodrug design is supplemented by fatty acylation, the addition of fatty acids to the
compound, which facilitates binding to proteins and extends the time of the compound in circulation. This combination is meant to provide an extended time-action profile that allows a once-weekly administration and provides a continuous,
infusion-like PTH exposure with lower daily <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios than observed with daily PTH dosing regimens. This continuous, infusion-like exposure to MBX 2109 may
reduce the frequency and severity of events of excessive blood calcium, or hypercalcemia, and insufficient blood calcium, or hypocalcemia. The once-weekly MBX 2109 dosing regimen may improve compliance relative to daily PTH dosing regimens, which we
believe improves effectiveness in a real-world setting. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In a Phase 1 clinical trial in 76 healthy adults, weekly subcutaneous injections of MBX 2109 led to
sustained and dose-dependent elevations of serum calcium and the suppression of endogenous PTH. The half-life of the MBX 2109 active drug across all doses was approximately 7.7 to 8.9 days, supporting a once-weekly dosing regimen. MBX 2109 was
generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating the safety, tolerability and efficacy of three fixed doses of MBX 2109 in a randomized, double-blind, placebo-controlled Phase 2 clinical
trial in approximately 48 patients with HP. The primary endpoint of the Phase 2 clinical trial is the proportion of patients who can discontinue active vitamin D and reduce calcium supplements after 12 weeks of treatment while maintaining normal
serum calcium levels. We expect to report topline data from our Phase 2 clinical trial in the third quarter of 2025. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>MBX 1416: Potential treatment for
post-bariatric hypoglycemia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416, our potential treatment for PBH, is designed to be a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT>
receptor antagonist, which is a molecule that binds to the applicable receptor to prevent the native molecule that would otherwise activate the receptor from binding. PBH is a rare, serious and chronic complication of bariatric surgery typically
occurring six months or later after surgery. We estimate PBH affects more than 90,000 people in the United States. In PBH, pathologic increases in <FONT STYLE="white-space:nowrap">GLP-1</FONT> are released following a meal leading to
hyperinsulinemia, or excessive levels of insulin, that may result in hypoglycemia, or low blood glucose. Hypoglycemic symptoms may include confusion, weakness, dizziness, blurred vision, loss of consciousness and seizures. While <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT><B> </B>therapies have been recently approved to treat obesity and its <FONT STYLE="white-space:nowrap">co-morbidities,</FONT> people with severe obesity, defined
as a BMI <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>40 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, often can require a greater degree of weight loss than these current therapies can achieve. According to the CDC, the
prevalence of severe obesity in the United States in adults over 20 years increased from 4.7% in 2000 to 9.2% in 2018. Bariatric surgery still remains the most efficacious means of treating severe obesity, with bariatric surgeries increasing by
approximately 23% since 2017 to approximately 280,000 in the United States in 2022, according to the American Society for Metabolic and Bariatric Surgery. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are
currently no U.S. Food and Drug Administration, or FDA, approved pharmacologic therapies for PBH. The current treatment options to reduce the frequency and severity of hypoglycemic episodes focus on dietary interventions and, secondarily, on the use
of <FONT STYLE="white-space:nowrap">off-label</FONT> medications with significant side effect profiles and unproven effectiveness in patients with PBH. While glucagon is used as a rescue therapy to treat severe hypoglycemic events, it does not
prevent hypoglycemia from occurring. In certain patients with severe, intractable hypoglycemia, surgical reversal of the bariatric procedure may be considered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416 is designed as a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist to prevent <FONT
STYLE="white-space:nowrap">GLP-1</FONT> from augmenting insulin release to cause hyperinsulinemia following a meal and thereby prevent the occurrence of severe hypoglycemia in patients with PBH. Leveraging our PEP platform, we aim to improve the
pharmaceutical properties of the <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence required to inhibit <FONT STYLE="white-space:nowrap">GLP-1</FONT> action by chemically modifying the amino acid backbone to achieve enhanced potency, stability
and solubility, relative to the corresponding, unmodified <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence. We are evaluating the safety, tolerability, pharmacokinetics and the effects that the drug has on the body, or pharmacodynamics, of MBX
1416 in an ongoing randomized double-blind, placebo-controlled single-and multiple-ascending dose, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 clinical trial in healthy adults. Preliminary
pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting once-weekly
dosing. We anticipate topline results from our Phase 1 clinical trial in the fourth quarter of 2024. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our obesity portfolio </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our PEP platform, we are discovering and developing candidates with optimized pharmacokinetic profiles and pharmacologic attributes to potentially improve on
the current treatments for obesity and related <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We are engineering our candidates to extend the time-action profile and to potentially improve tolerability, thereby providing the potential for
higher doses leading to greater weight loss than can be achieved with existing therapies. We are prioritizing candidates targeting clinically validated mechanisms for weight loss and are focusing on discovering peptides that target multiple unique
receptors. Our obesity portfolio currently includes one product candidate, MBX 4291, in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and a robust discovery pipeline with multiple development programs in lead optimization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MBX 4291: Long-acting and highly potent potential treatment for obesity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist</FONT> prodrug. Obesity is a common and costly chronic condition leading to significant morbidity and mortality. According to the CDC, an estimated 42% of U.S. adults aged 20 and over have obesity, or BMI<FONT
STYLE="font-family:Times New Roman">&#8805;</FONT>30&nbsp;kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, as of 2018, including 9% of adults with severe obesity, and another 31% of adults who are overweight, or BMI between 25.0 and 29.9
kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>. Based on the CDC&#146;s 2018 prevalence rates, we estimate that at least 190&nbsp;million adults in the United States are obese or overweight. While the current, approved <FONT
STYLE="white-space:nowrap">GLP-1-based</FONT> agonists represent significant and clinically meaningful advances in the treatment of obesity, they require weekly injections and can be associated with significant gastrointestinal, or GI, side effects.
These side effects often lead to reduced adherence and increased discontinuation, thereby limiting a patient&#146;s ability to lose weight. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe MBX 4291 has
the potential to be a safe and efficacious therapy that will help people achieve their weight loss goals and improve their overall health. MBX 4291 is designed to achieve the extended time-action profile using two of our proprietary technologies,
programmable prodrug and fatty acylation. In our preclinical studies, MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT
STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component of MBX 4291 supporting the potential for once-monthly administration. We believe that our proprietary PEP platform and <FONT
STYLE="white-space:nowrap">know-how</FONT> also provide significant optionality in devising dosing regimens that could lead to clinically meaningful improvements in tolerability and increase the maximally attained weight loss, relative to existing,
approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an anticipated IND submission in the second
quarter of 2025. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our company and team </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX was founded by pioneers
in the endocrine drug development field and is led by a team of seasoned industry veterans with a common goal to transform the treatment of endocrine and metabolic disorders and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
improve patients&#146; lives. Members of our leadership team have collaborated successfully over several decades on the discovery, development and commercialization of endocrine therapeutics
including Forteo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Humalog<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and Byetta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Our
<FONT STYLE="white-space:nowrap">co-founders,</FONT> Dr.&nbsp;DiMarchi and Kent Hawryluk, were central to the success of MB2 and Marcadia Biotech in advancing multiple
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-and</FONT></FONT> glucagon-based product candidates in clinical development through strategic transactions with Eli Lilly, Merck, Novo Nordisk, and Roche. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our team is led by executives who have deep experience in drug development and company-building in the biopharmaceutical industry. Key members of our executive and
leadership team include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Kent Hawryluk, President, Chief Executive Officer and <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> has spent more
than 20 years as a life sciences entrepreneur, leader and investor, and prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> MBX held biopharma executive leadership roles at Avidity Biosciences, MB2, and Marcadia Biotech.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Salomon (Sam) Azoulay, M.D., Chief Medical Officer, has over 35 years of experience in drug development and operations,
including as the Chief Medical Officer at Sumitovant Biopharma and Pfizer Essential Health. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Richard Bartram, Chief Financial Officer, has over 15 years of financial leadership experience spanning strategic and
operational finance roles, including serving as the Chief Financial Officer of Esperion Therapeutics and as a public accountant at PricewaterhouseCoopers LLP. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Michelle Graham, Chief Human Resources Officer, has over 25 years of experience in human resources, talent management, and
organizational development across various sectors of the healthcare industry, including as the Chief Human Resources Officer at Albireo Pharma, Tesaro, and Parexel. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Steven J. Prestrelski, Ph.D., Chief Scientific Officer, is a seasoned biopharmaceutical executive with over 30 years of
scientific and operational expertise who has led successful endocrine and metabolism product development programs from discovery through regulatory approval, including Byetta, Bydureon<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
Gvoke<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our platform technology includes patent rights and proprietary technology
exclusively licensed from Indiana University and developed in the Indiana University laboratory of our scientific founder, Dr.&nbsp;DiMarchi. Dr.&nbsp;DiMarchi developed the original PEP technology, and is the inventor of the first dual and triple
incretin agonists. Dr.&nbsp;DiMarchi is known as a world class innovator and inventor, a member of the National Inventor Hall of Fame and the National Academy of Medicine, and one of the world&#146;s leading peptide chemists. He is a former
decade-long chairman of the Peptide Therapeutics Foundation and is widely recognized as an international spokesperson for macromolecular medicines. He has an extensive track record of drug development in big pharma, early-stage biotech, and
academia, and is a successful repeat entrepreneur. In particular, he is recognized for his contributions to the discovery and development of rDNA-derived Humalog, rGlucagon, and Forteo, which he shepherded through development and commercialization.
His research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity. A former officer and director, Dr.&nbsp;DiMarchi is not currently an employee of
the Company, but acts as the principal investigator under our research agreement with the Trustees of Indiana University, pursuant to which we have the option to license intellectual property developed on our behalf by Dr.&nbsp;DiMarchi. Dr.
DiMarchi is not required to devote any specified number of hours to the Company. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have raised approximately $214&nbsp;million in funding
from leading healthcare investors, including Deep Track Capital, Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management, and Wellington Management. Prospective investors should not rely on the
investment decisions of our existing investors, as these investors may have different risk tolerances and in certain cases received their shares in prior offerings at prices lower than the price offered to the public in this offering. See the
sections titled &#147;Certain relationships and related person transactions&#148; and &#147;Principal stockholders&#148; for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
building a leading biopharmaceutical company with a focus on endocrine and metabolic disorders. Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative
precision peptide therapies. We are leveraging our propriety PEP platform to significantly improve clinical outcomes by discovering novel treatments that overcome key limitations of current peptide therapies. The key pillars of our business strategy
to achieve this mission include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advance MBX 2109, a potential PTH peptide prodrug therapy, through clinical development to improve outcomes for patients
with HP.</B>&#8195;MBX 2109 leverages our PEP platform and is designed as a long-acting PTH replacement therapy for HP, a rare endocrine disorder that we estimate affects more than 250,000 people throughout the United States and Europe. MBX 2109 is
precisely engineered to treat the underlying pathophysiology of HP by achieving a continuous, infusion-like exposure to PTH with a convenient once-weekly dosing regimen. We believe MBX 2109 has the potential to transform the HP treatment paradigm by
providing dependable control to normalize serum and urinary calcium levels and simplifying treatment through once-weekly dosing that could significantly improve patient outcomes and quality of life. In a Phase 1 clinical trial, MBX 2109 demonstrated
a low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio, which is consistent with a continuous, infusion-like profile, and an extended half-life, potentially enabling the first once-weekly PTH
dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2 clinical trial in patients with HP and dosed our first patient in
this trial in August 2024. We anticipate reporting topline data in the third quarter of 2025. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advance MBX 1416, a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist, through clinical
development to potentially address the unmet medical need in patients with PBH.</B>&#8195;There are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies for patients who suffer from hypoglycemia after bariatric surgery. We
estimate PBH affects more than 90,000 people in the United States, representing a large unmet medical need and significant commercial opportunity. We are developing MBX 1416 to be a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor
antagonist, a clinically validated mechanism, which is designed to reduce the frequency and severity of hypoglycemic events. Preliminary pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial demonstrated
that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional single ascending dose and multiple ascending dose data from our
ongoing Phase 1 clinical trial in the fourth quarter of 2024. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advance our obesity portfolio, including our lead obesity candidate, MBX 4291, with a focus on improving efficacy,
tolerability and dosing frequency compared to existing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies.&#8195;</B>While there have been significant advances in the treatment of obesity, there is
a need for better tolerated, more convenient and efficacious treatment options. Our lead obesity product candidate, MBX 4291, is designed as a long-acting <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor
<FONT STYLE="white-space:nowrap">co-agonist</FONT> prodrug. We also have a robust discovery pipeline with multiple development candidates in lead optimization. In our preclinical studies, the active component of MBX 4291 demonstrated a similar
activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active
component of MBX 4291, supporting the potential for once-monthly administration. In addition to providing a less frequent and more convenient dosing regimen, the extended time-action profile and lower <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio provide the opportunity to identify an optimal dosing regimen to improve tolerability and potentially increase the maximally attained weight loss, relative to existing, approved <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an anticipated IND submission in the second quarter of 2025.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Leverage our proprietary PEP technology platform and the capabilities of our experienced discovery team to expand our
pipeline in endocrine, metabolic and other disease areas.&#8195;</B>Our focus is on diseases with unmet medical need and clinically validated targets with established endpoints for regulatory approval and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
large potential market opportunities to allow us to minimize our risk profile and efficiently advance our programs through development and regulatory approval. We are continuing to build upon our
discovery capabilities to complement the scientific foundation of our <FONT STYLE="white-space:nowrap">co-founder</FONT> Dr.&nbsp;DiMarchi. Our initial focus is building out a robust pipeline in endocrine and metabolic disorders. Our PEP platform is
also widely applicable in discovering and developing peptides in other therapeutic areas. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Build a fully-integrated biopharmaceutical company</B> <B>and selectively evaluate strategic opportunities to maximize
the value of our pipeline.&#8195;</B>We aim to discover, develop, manufacture, and commercialize our endocrine product candidates.&nbsp;We may seek strategic collaborations where we believe the resources and expertise of third-party pharmaceutical
or biotechnology companies could accelerate the clinical development or maximize the market potential of our product candidates, or where such collaborations could expand our internal capabilities and PEP platform. In particular, assets within our
obesity portfolio may also benefit from a partnership to expand the indications under development, such as type 2 diabetes. We may seek additional partnership opportunities which complement our technologies, with the objective of accelerating our
development programs and potentially supplementing our future commercial capabilities. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Maintain an entrepreneurial, scientifically rigorous, and inclusive corporate culture where employees are fully engaged
and strive to bring improved therapeutic options to patients.&#8195;</B>We are driven to make a positive impact for patients worldwide and are guided by our core values of transparency, integrity, teamwork, and innovation to help us achieve our
mission rapidly, responsibly, and efficiently. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our platform </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Peptide background.&#8195;</I>Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate their function and maintain
homeostasis, which impact metabolism, growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. Diseases characterized by hormonal
deficiencies are optimally treated by replacing the deficient hormone. The development of peptides as endocrine replacement therapies has led to significant advances in the treatment of human disease such as in the treatment of diabetes with
insulin. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to using peptides as hormone replacement therapies, peptide-based drugs have been developed as pharmacologic agents to treat endocrine and
other diseases. Due to the selective and highly specific nature of the peptide binding to its cognate receptor, peptide drugs typically carry a lower risk of <FONT STYLE="white-space:nowrap">off-target</FONT> side effects relative to small
molecules. Further, peptide therapeutics are typically associated with lower production complexity compared with protein-based biopharmaceuticals and, therefore, the production costs are also lower, generally closer to those of small molecules. More
than 80 peptide therapies have been approved, and there are currently more than 150 peptides candidates in clinical trials, and another 400 to 600 in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. Global sales of peptide-based
therapies exceeded $50&nbsp;billion in 2019, according to the Global Peptide Therapeutics Sales Market Report<I>. </I> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, whether as replacement therapies or
novel pharmacological actions, these therapeutic peptides often have some significant drawbacks. Unmodified peptides often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours by the liver and
kidney. This often necessitates frequent, daily injections of these peptides, which can result in wide fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high
levels of the peptide. Alternatively, the unmodified peptide can be delivered by a subcutaneous pump infusion to maintain optimal blood levels of the hormone, such as insulin. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens. Although these convenient, patient-friendly therapies
could increase compliance and result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios, which can lead to side effects and limit
potential efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent injections and have the potential to provide
improved efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we believe we are designing and developing novel peptide therapeutics with the goal of achieving four key, distinct attributes: 1) high
potency, 2) high target selectivity, 3) half-lives that allow a dosing at weekly or less frequent intervals, and 4) low or flat <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios to improve
tolerability, thereby facilitating higher dosing and greater potential efficacy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our PEP Platform</I>.&#8195;We have built our proprietary PEP platform to
develop innovative precision peptide therapies that are designed to overcome key limitations of current peptide therapies by extending the half-life and providing a more continuous, infusion-like exposure to the peptide. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>PEPs are designed to overcome limitations of existing peptide therapeutics by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>demonstrating infusion-like exposure </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g790774g14v41.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have developed a deep understanding of the relationship between the chemical structure and the biologic activity and
pharmacokinetic properties to address the current limitations of peptide therapies. We were founded by leaders in the field of peptide discovery and development with the goal of transforming the treatment landscape for endocrine and metabolic
diseases with novel, efficacious, safe and convenient treatments. Dr.&nbsp;DiMarchi and his research team at Indiana University are recognized as global leaders in the peptide field through their groundbreaking approach to peptide drug design and
development, including the discovery of the first <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist</FONT> as well as other dual and triple incretin agonists. Leveraging this expertise and <FONT
STYLE="white-space:nowrap">know-how,</FONT> we have built our PEP platform with chemical technology and tools that we are utilizing in developing PEPs with clinically validated targets, established endpoints for regulatory approval, significant
unmet medical needs and large potential market opportunities. We believe our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art,</FONT></FONT></FONT> proprietary PEP platform has
enabled us to engineer novel product candidates that are designed to have optimized pharmaceutical properties, including a longer duration of action, consistent drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios, and less frequent dosing, which support our goals of improved tolerability, efficacy and potency. We are continuing to grow and develop our internal discovery and development capacity,
including having hired an experienced cross-functional discovery team and building a peptide synthesis laboratory that will fully launch in the third quarter of 2024. We have developed a proprietary platform of tools that we believe will allow us to
continually design transformative therapies. These proprietary tools and <FONT STYLE="white-space:nowrap">know-how</FONT> include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advanced chemical modifications</B> with a goal to provide enhanced physical properties including stability and
solubility, increased potency, and multiple mechanisms of action in a single peptide. Advanced chemical modifications, or ACM, of peptides as part of the PEP platform employs the use of native amino acid
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
substitutions, <FONT STYLE="white-space:nowrap">non-native</FONT> amino acid substitutions, alternative amino acid linkers, and other chemical modifications. The goal of these modifications is to
create peptides with enhanced physical properties relative to the existing peptide therapies, improving their utility as drugs. Some typical properties enhanced with ACM are the solubility and stability of the peptide, the potency at the applicable
receptor, and importantly, the ability to design more than one mechanism of action into a single peptide sequence such as MBX 4291. ACM is utilized in the design of each of MBX 2109, MBX 1416 and MBX 4291. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Programmable prodrug technologies</B> that are designed to precisely time the chemical conversion of prodrug into an
active form to reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios and improve clinical outcomes. This transformative proprietary programmable prodrug technology allows for the insertion of
two amino acids that locks the peptide in an inactive form and is transformed to an active drug at an intrinsically controlled <FONT STYLE="white-space:nowrap">(non-enzymatic)</FONT> rate under physiologic conditions. We can precisely program this
rate of activation from minutes to weeks with established design rules. By using modifications intrinsic to the peptide structure, the programmable prodrug approach can avoid the potential toxicity of other means to achieve an extended time-action
profile. The prodrug approach enables the design of peptides with more convenient weekly or monthly dosing as well as the potential for greater efficacy and tolerability, relative to shorter acting peptide therapies. This programmable prodrug
technology was utilized in designing the MBX 2109 and MBX 4291 peptides. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Fatty acylation</B> that aims to provide increased duration of action for more convenient dosing regimens and
compatibility with <FONT STYLE="white-space:nowrap">non-injectable</FONT> formulations. Fatty acids can improve the pharmacokinetic profiles and biological activities of peptides by increasing their stability, solubility, and interactions. Fatty
acylation of peptides leads to serum albumin binding of the acylated peptide, thereby extending serum half-lives. Fatty acylation has also been utilized to extend the half-life of peptides such as semaglutide and tirzepatide. We apply this fatty
acylation to increase the duration of action of our designed peptides, including in the design of MBX 2109, MBX 1416 and MBX 4291. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our PEP
platform is designed to improve clinical outcomes and simplify disease management for patients. Our PEPs are engineered to optimize pharmaceutical properties yielding peptides with extended time-action profiles, convenient dosing regimens and the
potential to enhance compliance and improve treatment effectiveness in a real-world setting. PEPs may improve efficacy and reduce adverse events by providing a more continuous, infusion-like exposure to the peptide. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have developed significant <FONT STYLE="white-space:nowrap">know-how</FONT> in the synergistic application of these tools to create proprietary PEPs with novel
mechanisms of action and enhanced pharmacokinetic profiles. To date, we have designed and tested numerous novel peptides with the PEP technology in <I>in vitro</I> and <I>in vivo</I> trials. This gives us the ability to uniquely and synergistically
combine these three aspects of PEP technology to meet our designed target product profile of a new peptide to program a longer duration of action and blood levels with low
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios, consistent with an infusion-like profile. Given that MBX 2109 and MBX 1416 displayed extended time-action profiles in Phase 1 trials as those
predicted based on their chemical modifications, we believe we have validated the reproducible nature of the three components of our PEP platform in their ability to yield long-acting peptides. We believe our expertise and nonclinical and clinical
experience with our PEP platform will allow us to develop our future programs efficiently. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our Programs </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are leveraging our proprietary PEP platform to advance a pipeline of programs to treat both endocrine and metabolic disorders with clinically validated targets,
established endpoints for regulatory approval, significant unmet needs and large potential market opportunities. We retain exclusive worldwide development and commercialization rights to all of our product candidates and discovery programs. Our lead
product candidates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and programs include two clinical-stage programs targeting rare endocrine disorders, MBX 2109 for the treatment of HP and MBX 1416 for the treatment of PBH, and an advancing obesity portfolio
with MBX 4291 in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and multiple development programs in lead optimization. We believe these programs have significant benefits over current treatment options and these include: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Potential benefits of our programs over current treatment options </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g00s44.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>MBX 2109 for the treatment of chronic hypoparathyroidism </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment
of HP. HP is a rare endocrine disease where parathyroid glands fail to produce sufficient amounts of PTH, which is a hormone that regulates calcium levels in the blood through its effects on bone, kidneys and intestines. Leveraging our proprietary
PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to PTH with a convenient once-weekly injection. In a Phase 1 clinical trial in healthy adults, MBX 2109 demonstrated a
low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio, which is consistent with a continuous, infusion-like profile, and an extended half-life potentially enabling the first once-weekly PTH dosing
regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. The FDA has granted Orphan Drug Designation to MBX 2109 for the treatment of HP. Orphan Drug Designation does not shorten the
development time or regulatory review time of a product candidate and does not provide any guarantee of approval in the regulatory review or approval process. We are currently evaluating MBX 2109 in a Phase 2 clinical trial in patients with HP and
dosed our first patient in this trial in August 2024. We anticipate reporting topline data in the third quarter of 2025. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Overview of chronic
hypoparathyroidism </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">HP is a rare endocrine disease caused by a deficiency of PTH released by parathyroid glands that results in decreased calcium levels in
the blood leading to hypocalcemia. Hypocalcemia can result in a variety of acute symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as depression, confusion and cognitive impairment. More serious complications can
occur, including seizures and cardiac arrhythmias. As a result, HP can interfere with daily activities, negatively impacting the quality of life for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
patients. We estimate that HP affects approximately 120,000 people in the United States and more than 250,000 in the United States and Europe. The most common cause for HP, in approximately 75%
of cases, is inadvertent removal or damage to the parathyroid glands during neck surgery. It can also be caused by certain autoimmune processes and genetic conditions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Current treatments and limitations </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The current standard of care for HP
does not address the PTH deficiency, which is the underlying cause of the disease. To avoid hypocalcemia and its symptoms due to PTH deficiency, the current standard of care consists primarily of high doses of oral calcium supplements and active
vitamin&nbsp;D. Patients are treated with high dose calcium supplements (approximately 1.8 grams per day, compared to 250 to 500 mg in a multivitamin) and prescription strength active vitamin D therapy, which can require the daily ingestion of
approximately seven or more pills taken at multiple times throughout the day. Despite this therapy, symptom relief can be suboptimal and does not address PTH deficiency. In addition, treatment with large doses of calcium and active vitamin D are
associated with long-term complications such as cardiovascular disease, vascular calcification and increased urinary calcium excretion, which can result in chronic kidney disease and kidney stones. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As the underlying pathophysiology of HP is a deficiency in PTH, clinicians have used Natpara<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a once-daily,
unmodified PTH peptide replacement therapy to treat HP. However, Natpara has a short half-life and does not provide PTH exposure over a full <FONT STYLE="white-space:nowrap">24-hour</FONT> period. The inability to provide continuous blood exposure
to PTH leads to suboptimal efficacy as patients are unable to stop active vitamin D and calcium supplements. After the recall of Natpara in 2019, Takeda announced in 2022 that it decided to discontinue manufacturing of Natpara on a voluntary basis
at the end of 2024 due to unresolved supply issues that are specific to the product and has indicated that it will not <FONT STYLE="white-space:nowrap">re-commercialize</FONT> the product. Palopegteriparatide, manufactured by Ascendis Pharma, is a
once-daily PTH replacement therapy that is approved in the United States and European Union, marketed as Yorvipath<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, for the treatment of HP in adults. In Phase 3 trials, palopegteriparatide
treatment rendered the majority of patients independent of active vitamin D and calcium supplements (which reduced pill burden), reduced urinary calcium excretion and, by patient-reported-outcome assessments, improved quality of life. We believe
there is a need for a more effective therapy, which can ultimately normalize serum and urine calcium levels with a sustained PTH pharmacology, with a more convenient, once-weekly dosing regimen for patients with HP. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our solution: MBX 2109 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 2109 is designed to treat the underlying
pathophysiology of HP by providing a continuous, infusion-like exposure to PTH with a convenient once-weekly injection. Utilizing our PEP platform, we designed MBX 2109 to address the narrow therapeutic window of PTH by delivering a consistent
exposure to the hormone, thereby maintaining normal serum and urinary calcium levels and reducing the need for vitamin D and calcium supplements. The FDA granted Orphan Drug Designation to MBX 2109 for the treatment of HP in July 2022. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 2109 is a fatty acylated prodrug engineered to be biologically inactive at the time of subcutaneous injection and convert to an active PTH peptide in an
intrinsically controlled, time-dependent fashion to enable once-weekly administration with reduced fluctuations in peptide concentration. As shown in &#147;A&#148; in the graphic below, MBX 2109 features fatty acids at both termini which facilitate
binding to plasma proteins like albumin, extending time in circulation. Under physiologic conditions, as depicted in &#147;B&#148;, the prodrug is converted at a precisely controlled rate to the active peptide and an inactive fatty acylated two
amino acid metabolite. This conversion step is essential for achieving the desired pharmacokinetic profile. Finally, in &#147;C,&#148; the fatty acylated active drug slowly diffuses from albumin and engages the PTH receptor, increasing calcium
levels in the blood. MBX 2109 incorporates two independent mechanisms utilizing our PEP technologies &#151; programmable prodrug and fatty acylation &#151; to provide sustained, predictable PTH peptide levels and convenient, once-weekly dosing. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 2109: Prodrug chemically converts to active drug at a precisely controlled rate </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g84m86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The once-weekly MBX 2109 dosing regimen may improve compliance relative to daily PTH dosing regimens, which we believe has the
potential to improve effectiveness in a real-world setting. The prodrug design and the fatty acylation are meant to provide an extended time-action profile that allows a once-weekly administration and provides a continuous, infusion-like PTH
exposure with a lower daily <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios than observed with daily PTH dosing regimens. This continuous, infusion-like exposure to MBX 2109 may reduce the
frequency and severity of events of hypercalcemia and hypocalcemia. Our goal is to simplify and improve the treatment of HP by providing a convenient, once-weekly therapy that addresses the underlying pathophysiology of HP and thereby eliminating
the need for complicated treatment regimens with oral calcium supplements and active vitamin D and their long-term complications. By maintaining normal serum calcium levels, MBX 2109 aims to reduce episodes of hypercalcemia and hypocalcemia and
thereby potentially improve the quality of life of patients living with HP. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 2109 normalized serum calcium levels in a preclinical study of rats with surgically removed parathyroid glands, or PTX rats, that induced a PTH deficiency and
hypocalcemia. In this study, we administered daily subcutaneous injections of MBX 2109 at 7.5 or 15 nmol/kg, for 28 days.&nbsp;As shown in the figure below, MBX 2109 normalized serum calcium levels in PTX rats. The results of this study provided
proof of concept for MBX 2109 to treat HP and served as key data in support of the Orphan Drug Designation for MBX 2109 in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 2109 demonstrated normalized serum calcium level in PTX rats </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g72d51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Phase 1 clinical development and results </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of MBX 2109 in our completed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> randomized double-blind, placebo-controlled, single and multiple ascending dose Phase 1 clinical trial in healthy adults. The primary endpoint of the
Phase 1 clinical trial was safety and tolerability and secondary endpoints were pharmacokinetics and pharmacodynamic activity of MBX 2109. The key pharmacokinetic endpoints for the active drug were half-life, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios and time to reach steady-state. The key pharmacodynamic endpoints for the active drug were changes in albumin-adjusted serum calcium levels and suppression of endogenous PTH secreted by
the parathyroid gland. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Five single ascending dose cohorts of healthy adults received subcutaneous placebo or MBX 2109 doses ranging between 50 &micro;g and 600
&micro;g, while subjects in the four multiple ascending dose cohorts received four weekly subcutaneous placebo or MBX 2109 doses of 200 &micro;g, 400 &micro;g, 600 &micro;g and 900 &micro;g. 36 and 40 adults were randomized into the single- and
multiple-dose portions, respectively, of the Phase 1 clinical trial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects
being observed. No dose-limiting toxicities or <FONT STYLE="white-space:nowrap">off-target</FONT> adverse effects were noted. Adverse events were generally mild in nature. Injection site adverse events were the most common treatment-related adverse
event, with the most common reaction being a <FONT STYLE="white-space:nowrap">non-raised,</FONT> painless and <FONT STYLE="white-space:nowrap">non-pruritic</FONT> red area generally less than 50 mm in diameter, which resolved without intervention.
Similar injection site reactions have been observed in trials with daily PTH agents. As expected for a trial investigating the dose range for PTH replacement, hypercalcemia was observed in three subjects each in the single and multiple ascending
parts of the trial. These events occurred at the higher dose levels, resolved without intervention and were asymptomatic laboratory findings.<B> </B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Single and
multiple weekly doses of MBX 2109 had dose-proportional and time-dependent increases in exposure to the active drug, with low to moderate intersubject variability. We believe these findings support use of a reliable titration regimen across
subjects. The half-life of the MBX 2109 active drug across all doses was approximately 7.7 to 8.9 days, which we believe supports a once-weekly dosing regimen. Mean
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios of the active drug following the last dose ranged from 1.47 to 1.79, indicating a continuous, infusion-like profile over a <FONT
STYLE="white-space:nowrap">seven-day</FONT> period. The graphic below shows the mean concentration of active drug for each dose at each measured time post dose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Plasma concentration-time profile for active drug demonstrated infusion-like profile </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>and supported once-weekly dosing </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g70y95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We observed similar mean serum calcium concentrations in our Phase&nbsp;1 trial as were observed in the TransCon PTH Phase&nbsp;1
trial when both agents were estimated to be at steady state, which was after the fourth weekly dose of MBX 2109 and day 11 for daily dosing of TransCon PTH, according to the Journal of Bone and Mineral Research. The active component of MBX 2109 is
highly bound to albumin and the free, unbound fraction is thought to be the biologically-active form able to bind to and activate the PTH receptor, which increases calcium levels in the blood. Using the total serum concentrations of the active
component of MBX 2109, which measures both albumin bound and unbound peptide, observed in our Phase&nbsp;1 trial, we calculated the peak and trough concentrations of the unbound active component of MBX 2109 using different assumptions (0.01 to 10%)
for the unbound percentage. Based on these calculations, a free, unbound fraction of MBX 2109 active of 0.1% yields PTH exposures comparable to the PTH exposure estimates seen in response to TransCon PTH in their Phase 1 study. The cross-study
comparison is provided for illustrative purposes only as there is no head-to-head comparison available. Comparing the results from different trials may be unreliable due to factors such as protocol design and trial objectives varying between the
trials. Therefore, cross-study comparisons provide limited information about the effectiveness of a product candidate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once-weekly MBX 2109 increased serum calcium
levels assessed by either the maximal increase in serum calcium (E<SUB STYLE="font-size:75%; vertical-align:bottom">max,adj</SUB>) or the total serum calcium levels between injections (AUEC0-<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#116;</FONT></FONT> adj) in a dose- and time-dependent fashion. Maximal increases in albumin-adjusted serum calcium, or <FONT STYLE="white-space:nowrap">adj-Ca,</FONT> were seen approximately 48 hours after injection. At
the higher doses, increases in serum calcium were apparent after the first injection, with the effect being nearly maximal after the third weekly injection. These results have demonstrated a dose- and time-dependent effect of MBX 2109 in increasing
serum calcium levels with an initial effect within days after the first dose and nearly maximal after the third dose. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Maximal increases in serum
calcium levels (E<SUB STYLE="font-size:75%; vertical-align:bottom">max,adj</SUB>) after MBX 2109 weekly injections demonstrated a </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">dose-</FONT> and time-dependent effect </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g80i17.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once-weekly MBX 2109 increased serum calcium levels assessed by the total serum calcium levels between injections
(AUEC0-<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#116;</FONT></FONT> adj) in a dose- and time-dependent fashion, as shown below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Total serum calcium levels between MBX 2109 weekly injections (AUEC0-<FONT STYLE="FONT-FAMILY:SYMBOL">&#116;</FONT>, adj) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>increased in a dose- and time- dependent fashion </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g77b51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Increases in serum calcium create a negative feedback response that reduces the endogenous secretion of PTH from the parathyroid
glands in these normal adults, which is another pharmacodynamic marker of MBX 2109 action. The figure below shows the endogenous PTH at days after the first injection. We observed a dose-dependent reduction in PTH to levels at or below the lower
limit of normal for PTH with the maximal effect seen between one and four days after the initial injection of MBX 2109. Suppression of endogenous PTH secretion further substantiated the PTH agonist activity of MBX 2109 at the doses evaluated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Endogenous PTH in healthy subjects decreased after MBX 2109 weekly injections in a </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>dose- and time-dependent fashion </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g75h77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Ongoing Avail<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Phase 2 clinical trial </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are conducting a randomized double-blind, placebo controlled Phase 2 clinical trial in adult patients with HP, or the Avail trial. The Avail trial evaluates the
safety, tolerability and efficacy of MBX 2109 over a <FONT STYLE="white-space:nowrap">12-week</FONT> period in approximately 48 patients. The primary endpoint of the Phase 2 clinical trial is the proportion of patients who can discontinue active
vitamin D and reduce calcium supplements to less than or equal to 600 mg per day after 12 weeks of treatment while maintaining normal serum calcium levels. Secondary endpoints include safety and tolerability of MBX 2109 and characterization of the
pharmacokinetics and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
pharmacodynamic activity (including urine calcium, serum phosphorus, 1,25 dihydroxyvitamin D and bone biomarkers) and the impact on quality of life using patient-reported outcome tools. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the Avail trial, patients are randomized (1:1:1:1) to weekly subcutaneous injections of placebo or 400 &micro;g, 600 &micro;g, and 800 &micro;g of MBX 2109. The <FONT
STYLE="white-space:nowrap">12-week</FONT> treatment period is comprised of a 4-week fixed dose period and a 8-week titration period. During the titration period, patients who have not been able to discontinue active vitamin D and/or reduce calcium
supplements may <FONT STYLE="white-space:nowrap">up-titrate</FONT> the study drug using a protocol-specified algorithm. Patients completing the <FONT STYLE="white-space:nowrap">12-week</FONT> treatment period will be eligible to participate in a <FONT
STYLE="white-space:nowrap">104-week</FONT> long-term extension study in which all patients will receive MBX 2109. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g43a01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Avail trial began in 2024 and we dosed our first patient in
this trial in August 2024. We anticipate reporting topline results in the third quarter of 2025. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe there is a regulatory pathway for approval of PTH
replacement therapy in HP. The general design and the primary endpoint analysis used in the Phase 3 trial is anticipated to be similar to that used for the Phase 3 trial supporting approval of palopegteriparatide, a daily PTH replacement therapy,
for the treatment of HP in adults in the United States and EU. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>MBX 1416 for the treatment of post-bariatric surgery hypoglycemia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are developing MBX 1416, a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist, that is designed to be a potential treatment for PBH. MBX
1416 is designed to block pathologic increases in <FONT STYLE="white-space:nowrap">GLP-1</FONT> released following a meal, which leads to hyperinsulinemia and may result in hypoglycemia. By inhibiting <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">GLP-1-induced</FONT></FONT> hyperinsulinemia in patients with PBH, MBX 1416 is designed to reduce insulin secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events with convenient
once-weekly administration. Preliminary pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure
and a half-life supporting a once-weekly dosing regimen. We anticipate topline results from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Post-bariatric surgery hypoglycemia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PBH is a rare, serious and chronic
complication of bariatric surgery typically occurring six months or later after surgery. We estimate PBH affects more than 90,000 people in the United States. In PBH, pathologic increases in <FONT STYLE="white-space:nowrap">GLP-1</FONT> are released
following a meal leading to hyperinsulinemia, or excessive levels of insulin, that may result in hypoglycemia, or low blood glucose. Hypoglycemic symptoms may include confusion, weakness, dizziness, blurred vision, loss of consciousness and
seizures. The unpredictable onset of hypoglycemia and anxiety due to fear of hypoglycemia significantly negatively impact the quality of life in patients with PBH. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies have been recently approved to treat obesity and its <FONT
STYLE="white-space:nowrap">co-morbidities,</FONT> people with severe obesity, defined as a BMI <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>40 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, often can require a greater degree
of weight loss than these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
current therapies can achieve. According to the CDC, the prevalence of severe obesity in the United States in adults over 20 years increased from 4.7% in 2000 to 9.2% in 2018. Bariatric surgery
still remains the most efficacious means of treating severe obesity. Bariatric surgeries have increased by approximately 23% since 2017 to approximately 280,000 in the United States in 2022, according to the American Society for Metabolic and
Bariatric Surgery. Further, the use of bariatric surgery to address severe obesity and related comorbidities has increased by more than 50% over the past decade from 2011 to 2022, according to the Journal of the American Heart Association, with
further increases expected due to the use of bariatric surgery to treat severe obesity and its <FONT STYLE="white-space:nowrap">co-morbidity</FONT> of type 2 diabetes. The most commonly employed bariatric procedures are <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Roux-en-Y</FONT></FONT> gastric bypass, or RYGB, and sleeve gastrectomy, or SG, which represent approximately 75% of bariatric surgeries performed annually. We estimate that PBH impacts up
to approximately 13% and approximately 2% of patients who undergo RYGB and SG, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following a meal, nutrients are absorbed from the upper small intestine
causing blood glucose levels to increase. In response to increasing glucose levels, <FONT STYLE="white-space:nowrap">GLP-1</FONT> is released from intestinal <FONT STYLE="white-space:nowrap">L-cells</FONT> which augments insulin release from the
pancreas to maintain euglycemia, or normalized blood glucose levels. Following RYGB and SG, the transit of nutrients from the stomach to the upper small intestine is markedly increased, which requires more rapid
<FONT STYLE="white-space:nowrap">GLP-1</FONT> and insulin secretion to maintain euglycemia. In PBH, <FONT STYLE="white-space:nowrap">GLP-1</FONT> release following a meal is excessive which results in a pathologic increase in insulin release from
the pancreas leading to hyperinsulinemia and hypoglycemia. The figures below show concentrations of blood glucose, insulin, and <FONT STYLE="white-space:nowrap">GLP-1</FONT> after a meal in patients with hypoglycemia resulting from RYGB,
asymptomatic patients following a RYGB, and <FONT STYLE="white-space:nowrap">non-surgical</FONT> controls. Both peak <FONT STYLE="white-space:nowrap">GLP-1</FONT> and peak insulin levels are higher and the lowest blood glucose levels are lower in
patients with PBH than in patients without hypoglycemia following bariatric surgery. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Patients with PBH have higher
<FONT STYLE="white-space:nowrap">GLP-1</FONT> and insulin levels and lower blood glucose </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>relative to normal subjects or post-bariatric surgery
patients without PBH </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g40a82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><I>Source: J Clin Endocrinol Metab 103: 2815-2826, 2018 </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients with PBH can experience symptomatic hypoglycemia sometimes multiple times a day. Hypoglycemia also causes a shortage of glucose in the brain, or
neuroglycopenia. Neuroglycopenic symptoms, such as confusion, weakness, dizziness, blurred vision, loss of consciousness and/or seizures may develop, which can result in emotional and physical trauma to the individual. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The unpredictable nature and severity of hypoglycemic episodes can meaningfully hinder daily activities. As a result, the patient burden is substantial with some
patients unable to drive, work, or live alone, leading to a significant negative impact on a patient&#146;s quality of life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Current treatments and limitations </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> pharmacologic therapies for PBH. The current treatment options to reduce the frequency and
severity of hypoglycemic episodes focus on dietary interventions and secondarily on the use of <FONT STYLE="white-space:nowrap">off-label</FONT> medications with unproven effectiveness for patients with PBH and significant effect profiles. While
glucagon is used as a rescue therapy to treat severe hypoglycemic events, it does not prevent hypoglycemia from occurring. In certain patients with severe, intractable hypoglycemia, surgical reversal of the bariatric procedure may be considered.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">GLP-1</FONT> antagonism as a clinically validated solution for PBH </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Use of a <FONT STYLE="white-space:nowrap">GLP-1</FONT> inhibition-based mechanism has been clinically validated as a potential therapy to reduce the frequency and
severity of hypoglycemic episodes in patients with PBH. When administered to patients with PBH, exendin <FONT STYLE="white-space:nowrap">(9-39),</FONT> a short-acting, unmodified <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist,
prevents hyperinsulinemia and blood glucose levels from decreasing into the hypoglycemic range. In a study in patients with PBH, patients who received treatment with exendin <FONT STYLE="white-space:nowrap">(9-39)</FONT> did not experience
hyperinsulinemia and blood glucose levels remained in the euglycemic range after a meal. On the other hand, without treatment with exendin <FONT STYLE="white-space:nowrap">(9-39),</FONT> blood glucose levels in patients can decrease into the
hypoglycemic range and rescue therapy was needed to avert symptomatic hypoglycemia after a meal. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our solution: MBX 1416 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416 is a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist that is designed to prevent <FONT STYLE="white-space:nowrap">GLP-1</FONT>
from augmenting insulin release to cause hyperinsulinemia following a meal and thereby prevent the occurrence of severe hypoglycemia in patients with PBH. Unlike exendin (9-39), which is derived from a non-human sequence, we have engineered the
amino acid sequence derived from a segment of human GLP-1 to improve immunogenicity. MBX&nbsp;1416 binds to the GLP-1 receptor but lacks the ability to activate the receptor, acting as a competitive antagonist of GLP-1. Leveraging our PEP platform,
we aim to improve the pharmaceutical properties of the <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence required to inhibit <FONT STYLE="white-space:nowrap">GLP-1</FONT> action by chemically modifying the amino acid backbone to achieve
enhanced potency, stability and solubility, relative to the corresponding, unmodified <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence. To achieve sustained exposures able to support once-weekly dosing, fatty acylation has been incorporated to
enhance binding to albumin from which the peptide is slowly released. Leveraging the clinically validated <FONT STYLE="white-space:nowrap">GLP-1</FONT> antagonist approach, MBX 1416 has the potential to be the first pharmacologic therapy to prevent
and reduce the severity of hypoglycemia in patients with PBH with convenient once-weekly administration. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our goal is for MBX 1416 to improve the quality of life in
patients with PBH by reducing the burden of living with the unpredictable nature of hypoglycemia and anxiety from fear of suffering the potentially severe adverse clinical outcomes from hypoglycemia. We aim to do this by reducing the frequency and
decreasing the severity of hypoglycemic episodes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In <I>in vitro</I> studies, MBX 1416 inhibited <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor activation and was approximately a six to nine times more potent
inhibitor than exendin <FONT STYLE="white-space:nowrap">(9-39).</FONT> By blocking <FONT STYLE="white-space:nowrap">GLP-1</FONT> action, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-induced</FONT></FONT> augmentation of
insulin release is blocked. The ability of MBX 1416 and exendin <FONT STYLE="white-space:nowrap">(9-39)</FONT> to block <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor activation were evaluated in an <I>in vitro</I> <FONT
STYLE="white-space:nowrap">GLP-1</FONT> receptor assay. In <I>in vitro</I> receptor assays, the concentration required to inhibit 50% of <FONT STYLE="white-space:nowrap">GLP-1</FONT> action was 54 nM and 503 nM for MBX 1416 and exendin <FONT
STYLE="white-space:nowrap">(9-39),</FONT> respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We established the proof of mechanism for MBX 1416 inhibition of
<FONT STYLE="white-space:nowrap">GLP-1</FONT> action in an <I>in vivo</I> model. In a diet-induced obesity mouse model, we evaluated whether MBX 1416 could block the ability of semaglutide, a <FONT STYLE="white-space:nowrap">GLP-1</FONT> agonist, to
reduce food intake. In this study, on days 0, 1 and 2, rodents were administered semaglutide alone, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
MBX 1416 alone or semaglutide in combination with MBX 1416. In the graph below, semaglutide is shown to inhibit food intake. However, this inhibition was blocked by the administration of MBX 1416
with semaglutide. MBX 1416 administered alone did not affect food intake. These data provide <I>in vivo</I> evidence for the clinical potential of MBX 1416-induced inhibition of <FONT STYLE="white-space:nowrap">GLP-1</FONT> action. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 1416 induces inhibition of <FONT STYLE="white-space:nowrap">GLP-1</FONT> action when administered in combination with </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>semaglutide in an </B><B><I>in vivo</I></B><B> model </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g75q33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In rodent and <FONT STYLE="white-space:nowrap">non-human</FONT> primate toxicology studies of up to four weeks in duration, no
clinical signs of toxicity were observed. In <I>in vitro</I> assessments of interactions with drug transporters, MBX 1416 inhibited hepatic organic anion transporting polypeptide transporters, OATP1B1 and OATP1B3. Inhibition of these transporters
could result in a potential drug-drug interaction by reducing elimination of drugs transported by these transporters that could require an adjustment in dose or avoidance in using the drug when treated with MBX 1416.<B><I> </I></B>The clinical
relevance of this preclinical finding is being evaluated in our Phase 1 clinical trial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Phase 1 clinical development and results </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of MBX 1416 in an ongoing randomized, double-blind, placebo-controlled, single- and
multiple- ascending dose, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 clinical trial in healthy adults. The primary endpoint of the Phase 1 clinical trial is to evaluate the safety and
tolerability of MBX 1416. Secondary endpoints are to evaluate the pharmacokinetic profile of MBX 1416 to establish the time-action profile to support a once-weekly dosing regimen and to utilize pharmacodynamic parameters (e.g., blood glucose,
insulin, <FONT STYLE="white-space:nowrap">c-peptide</FONT> levels) obtained during a mixed meal tolerance test to select a range of MBX 1416 doses to advance into the next phase of development. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The single ascending dose portion of this Phase 1 trial evaluates subcutaneous MBX 1416 doses of 10 mg, 30 mg, 100 mg and 200 mg, in up to eight healthy adults per
cohort randomized 3:1 (six MBX 1416; two placebo in each cohort). The multiple ascending dose portion of the trial evaluates four weekly subcutaneous doses of placebo and 10 mg, 30 mg and 100 mg MBX 1416 in four cohorts in up to eight healthy adults
per cohort (six MBX 1416; two placebo in each cohort). An additional cohort will assess the clinical relevance of preclinical transporter findings. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The single
ascending dose portion of this Phase 1 clinical trial is clinically complete, and the multiple ascending dose portion is ongoing. Preliminary pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial
demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and showed a half-life supporting a once-weekly dosing regimen. In the graph below, preliminary pharmacokinetic data from the single
ascending dose portion of the Phase 1 trial demonstrate dose-proportional increases in MBX 1416 concentration levels. The observed mean half-life of MBX 1416 was approximately 90 hours supporting a once-weekly dosing regimen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Preliminary data demonstrate dose-proportional increases in mean MBX 1416 concentrations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>with increasing doses </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g790774g83a26.jpg" ALT="LOGO">
 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate topline results from our ongoing Phase 1 trial in the fourth quarter of 2024. Following completion of the Phase 1
clinical trial and using the pharmacodynamic results from the mixed meal tolerance test, we plan to select MBX 1416 doses to be administered once-weekly and advance MBX 1416 into a Phase 2 clinical trial in which the primary endpoint will be the
rate of severe hypoglycemic episodes that require the assistance of another person, or Level&nbsp;3 hypoglycemia. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Obesity portfolio </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obesity is widely recognized as a global epidemic which imposes a substantial health care burden and is associated with significant
<FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We believe that we are well positioned to deliver an array of differentiated obesity candidates offering treatment flexibility to improve patient outcomes. Based on the significant unmet need,
we see a potentially large commercial opportunity for our obesity portfolio. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our PEP platform, we are discovering and developing candidates with
optimized pharmacokinetic profiles and pharmacologic attributes to potentially improve on the current treatments for obesity and related <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We are engineering our candidates to extend the
time-action profile and to potentially improve tolerability, thereby providing the potential for higher doses leading to greater weight loss than can be achieved with existing therapies. We are prioritizing candidates targeting clinically validated
mechanisms for weight loss and are focusing on discovering peptides that target multiple unique receptors. Our obesity portfolio currently includes one product candidate, MBX 4291, in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and
a robust discovery pipeline with multiple development programs in lead optimization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>MBX 4291 for the treatment of obesity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist</FONT> prodrug that reduces dosing frequency with a goal of improving tolerability and efficacy relative to existing standards of care. In our preclinical studies, the active component of MBX 4291 demonstrated a
similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component
of MBX 4291, supporting the potential for once-monthly administration. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an IND submission anticipated in the second quarter of 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Obesity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obesity is
a common and costly chronic condition leading to significant morbidity and mortality. According to the CDC, an estimated 42% of U.S. adults aged 20 and over have obesity (BMI<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>30 kg/m<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP>) as of 2018, including 9% of adults with severe obesity (BMI<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>40 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>), and another 31% of
adults who are overweight (BMI between 25.0 and 29.9 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>). Based on the CDC&#146;s 2018 prevalence rates, we estimate that at least 190 million adults in the United States are obese or
overweight. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obesity leads to <FONT STYLE="white-space:nowrap">co-morbidities</FONT> that have a significant impact on the health. Obesity associated <FONT
STYLE="white-space:nowrap">co-morbidities</FONT> include illnesses such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, osteoarthritis, metabolic dysfunction associated steatohepatitis, infertility, heart failure, stroke, coronary
artery disease, venous thromboembolic disease, gall stones, disease, depression and certain types of cancer. These <FONT STYLE="white-space:nowrap">co-morbidities</FONT> have a negative impact on the quality and quantity of life, reduce productivity
and impose a substantial economic cost to society. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Current treatments and limitations </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Initial treatment options for people with obesity focus on a combination of diet, exercise and lifestyle modifications. The American College of Cardiology, or the ACC,
and American Association of Clinical Endocrinologists, or the AACE, recommend people with obesity should initially be prescribed aerobic exercise and resistance training, a reduced calorie diet, and behavioral intervention. Behavioral modification
therapy typically results in only modest weight loss that is often not sustained. Therefore, surgery and pharmacological treatment are often required. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The AACE
guidelines recommend that pharmacotherapy combined with lifestyle modifications be considered in individuals with a BMI of at least 27 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>. <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor
mono-agonists have been approved by the FDA and EMA for obesity, such as Wegovy<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (semaglutide) and Saxenda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (liraglutide). Recently the
first <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist,</FONT> Zepbound<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (tirzepatide), has been approved for obesity. In a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study in overweight and obese subjects with type 2 diabetes, tirzepatide, the <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist,</FONT> provided statistically and clinically meaningful greater weight loss, relative to semaglutide, the <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor mono- agonist. Based on demonstrating reductions
in the risk of heart attack, stroke, or cardiovascular disease-related death, a weight loss drug (Wegovy) has been approved by the FDA to reduce the risk of major cardiovascular events in overweight or obese individuals with cardiovascular disease
and no prior history of type 2 diabetes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While the current GLP-1-based agonists represent significant and clinically meaningful advances in the treatment of
obesity, they require weekly injections and can be associated with significant GI side effects such as nausea, diarrhea, constipation, and vomiting. These side effects often lead to reduced adherence and increased discontinuation, thereby limiting a
patient&#146;s ability to lose weight. The availability of better tolerated agents with weight loss equal to or exceeding the approved <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor mono-agonist therapies or more efficacious <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> therapies would be a clinically meaningful therapeutic advance for people with obesity and its
<FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We believe that our PEP technology can improve on the shortcomings of existing pharmacologic weight loss therapies through the discovery of novel, highly selective and efficacious peptides with
extended time-action profiles and the flexibility to utilize dosing regimens that may improve efficacy and tolerability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our solution: MBX 4291 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our PEP technology, we have engineered MBX 4291, a highly selective and potent <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist</FONT> with an extended time-action profile, and have advanced this product candidate into <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for the treatment of obesity. MBX 4291&#146;s <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist</FONT> approach has been clinically validated in providing a similar activity profile and body weight loss in mice relative to dual agonist
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
approaches in existing therapies, such as tirzepatide. MBX 4291 was designed to achieve an extended time-action profile to reduce dosing frequency and improve GI tolerability. MBX 4291 has
demonstrated the desired pharmacokinetic profile by utilizing two independent mechanisms &#150; programmable prodrug and fatty acylation. When injected subcutaneously, MBX 4291 is an inactive prodrug that at physiological conditions will slowly and
precisely convert in an intrinsically controlled, time-dependent fashion to the active drug. Additionally, we incorporated fatty acylation into the peptide to enhance binding to albumin from which the active peptide is slowly released to interact
with its cognate receptors. The combination of the prodrug and fatty acylation approaches to MBX 4291 provides the potential for a once-monthly dosing regimen. We believe that our proprietary PEP platform and
<FONT STYLE="white-space:nowrap">know-how</FONT> provide significant optionality in devising dosing regimens that could lead to clinically meaningful improvements in tolerability and increase the maximally attained weight loss, relative to existing,
approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While the design of MBX 4291 utilized similar,
clinically validated mechanisms to prolong half-life as those used in designing MBX 2109, including prodrug and fatty acylation, with its extended half-life, additional prodrug modifications were made to extend the time-action profile beyond that
seen with MBX 2109 potentially allowing for a once-monthly dosing regimen. We believe MBX 4291 has the potential to be a safe and efficacious therapy that will help people achieve their weight loss goals and improve their overall health. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preclinical studies </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The active component of MBX 4291 has demonstrated
a similar activity profile and body weight loss in mice as the clinically-validated and approved weight-loss drug, tirzepatide, in <I>in vitro </I>studies. In the <I>in vitro </I>study in cells expressing the human
<FONT STYLE="white-space:nowrap">GLP-1</FONT> or GIP receptors, MBX 4291 active drug binds to <FONT STYLE="white-space:nowrap">GLP-1</FONT> and GIP receptors with the same activity as tirzepatide, as shown in the graphs below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B></B><B><I>In vitro</I></B><B> receptor binding of MBX 4291 active drug has similar activity in binding to the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><FONT STYLE="white-space:nowrap">GLP-1</FONT> and GIP receptors as tirzepatide </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g59i17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The MBX 4291 active drug was compared to tirzepatide in diet-induced obesity, or DIO, rodent models, which are commonly used to assess
weight loss of agents being evaluated as clinical development candidates. In this study, eight mice were subcutaneously dosed daily with the MBX 4291 active drug and eight with tirzepatide for ten days and weight and food intake were assessed each
day. As shown in the graphs below, MBX 4291 active drug produced similar reductions in body weight and food intake as tirzepatide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 4291 active drug produced similar reductions in body weight and food intake as </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>tirzepatide in DIO mouse model </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g790774g80w10.jpg" ALT="LOGO">
 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As metabolism and albumin turnover rates in <FONT STYLE="white-space:nowrap">non-human</FONT> primates more closely resemble
humans than rodents, <FONT STYLE="white-space:nowrap">non-human</FONT> primates were used to assess the conversion of MBX 4291 to the active drug and overall pharmacokinetic profile. The figure below shows the pharmacokinetic profile observed in a
preclinical study of two non-human primates dosed with MBX 4291, and two dosed with tirzepatide. After a single, subcutaneous MBX 4291 injection, peak exposure to the biologically active component of MBX 4291 occurred
<FONT STYLE="white-space:nowrap">4-5</FONT> days later. This reflects the prodrug design, in which the biologically inactive prodrug converts into the active peptide in a time-dependent fashion, allowing an extended duration of action for the
biologically active component of the compound. In contrast, peak exposure to tirzepatide, which is itself the active compound, occurred within 24 hours of injection as shown in the below figure. In addition, the decline in exposure to the active
component of MBX 4291 was flatter than the more rapid reduction in tirzepatide exposures, which requires weekly dosing because of its loss in efficacy after one week. Based on this observed pharmacokinetic profile, which illustrates the prodrug and
fatty acylation mechanisms, we believe MBX 4291 has the potential to be dosed less frequently than the once weekly dosing required for tirzepatide in humans. The mean concentration of tirzepatide ranged from a maximum of 387 nM at 12 hours to 50.0
nM at 168 hours, whereas the mean concentration of the active component of MBX 4291 ranged from a maximum of 5.05 nM at 96 hours to 3.96 nM at 168 hours and 0.615 nM at the final measurable concentration at 456 hours. Based on the findings in the
figure below, it appears that less frequent dosing would necessarily require a higher dose, and possibly an adjustment based on the prodrug conversion and fatty acylation mechanisms. We believe the observed slower flatter decline in mean active drug
concentration may allow us to find a dosage for MBX 4291 that can maintain an appropriate active concentration of MBX 4291 within the therapeutic window for longer, without dosing once a week. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 4291 active drug demonstrated extended time-action profile compared to tirzepatide that </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>may support once-monthly dosing </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g790774g48m48.jpg" ALT="LOGO">
 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently in the process of conducting IND-enabling
studies of MBX&nbsp;4291. IND submission is anticipated in the second quarter of 2025, with the goal of moving to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials in healthy obese adults as soon
as possible. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Manufacturing </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third
parties for the manufacturing of our product candidates for preclinical and clinical testing, as well as for commercial manufacturing if our product candidates receive marketing approval. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">As a key part of our product development approach, we aim to complete formulation work at an early stage of development,
such that our clinical studies are conducted with a formulation that has the potential for eventual <FONT STYLE="white-space:nowrap">scale-up.</FONT> We expect to continue to develop product candidates that can be produced cost-effectively at
contract manufacturing facilities. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Commercial strategy </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We
intend to build a commercial infrastructure to support sales of any of our approved future drugs if and when we believe a regulatory approval of the first of such product candidates in a particular geographic market appears imminent. We expect to
manage sales, marketing and distribution through a combination of internal resources and third-party relationships. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In addition, we will opportunistically explore commercialization partnerships, particularly with entities that have strong
capabilities in geographies outside the United States and depending on the specific development path pursued. For more specialized indications, we would consider commercializing our product candidates independently. For example, we believe the
patient and prescriber populations for HP and PBH are relatively concentrated, with significant overlap, and can be addressed with a focused sales team. We also do not believe any existing pharmaceutical companies have significant expertise in the
commercialization of therapies in the PBH specific area. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We will, however, continuously review our partnering strategy in the light of new clinical data and market understanding.
As our current and future drug candidates progress through clinical development, our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
commercial plans may change. Clinical data, the size of the development programs, the size of our target markets, the size of the requisite commercial infrastructure and manufacturing needs may
all influence our commercialization strategies. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Competition </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding
of disease etiology, intense competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic
research institutions and governmental agencies and public and private research institutions. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new
therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for our product candidates. This may include other peptide companies using similar approaches or other types of
therapies, such as small molecule, antibody, and/or protein therapies. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In addition, many of our current or potential competitors, either alone or with their collaboration partners, have
significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and approved products than we do today. Mergers and acquisitions in the pharmaceutical and
biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. We also compete with these companies in recruiting, hiring, and retaining qualified scientific and management talent, establishing clinical trial sites and patient registration for clinical trials, obtaining
manufacturing slots at contract manufacturing organizations. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, particularly if they represent cures, have
fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for
ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be their potential efficacy, safety,
convenience, and availability of reimbursement. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our most direct competitors with respect to HP include: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Ascendis Pharma currently has Yorvipath (palopegteriparatide) approved in the United States and EU for the treatment of HP
in adults. Yorvipath is currently marketed in Germany, Austria and the United&nbsp;Kingdom. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">AstraZeneca is developing eneboparatide, an investigational once-daily injectable PTH receptor 1 agonist, for the treatment
of HP in adults. Eneboparatide is currently in Phase 3 clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Extend Biosciences has underway a Phase 1 clinical trial investigating injectable EXT608, a long-acting <FONT
STYLE="white-space:nowrap">PTH(1-34)</FONT> using <FONT STYLE="white-space:nowrap">D-VITylation</FONT> technology. Extend announced positive interim results and that they intend to move directly into a Phase 2a clinical trial. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In 2015, Natpara was approved for once-daily subcutaneous injection as an adjunct to vitamin D and calcium in patients with
hypoparathyroidism. Natpara has not demonstrated an ability to reduce incidences of hypercalcemia, hypocalcemia, or hypercalciuria relative to conventional therapy </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
in treated patients, and was recalled in 2019 and will ultimately be discontinued by Takeda at the end of 2024. Natpara is currently only available via a compassionate use program.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our most direct competitors with respect to PBH include: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In May 2020, Xeris Pharmaceuticals announced results from a Phase 2 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> glucagon injector but has not announced any updates on its PBH program since then.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Vogenx is developing mizagliflozin for treatment of PBH, and in June 2023 announced results from a Phase 2 single ascending
dose trial evaluating mizagliflozin in patients with PBH. In February, Vogenx they completed enrollment for its their second Phase 2 clinical trial. Mizagliflozin is designed to inhibit sodium dependent glucose cotransporter 1.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In July 2024, Amylyx Pharmaceuticals Inc., or Amylyx, announced its acquisition of avexitide (exendin <FONT
STYLE="white-space:nowrap">9-39)</FONT> from Eiger BioPharmaceuticals, Inc., or Eiger, as a once or twice daily subcutaneous injection of a&nbsp;selective GLP-1 antagonist, which has received Breakthrough Therapy and Orphan Drug Designation from the
FDA. Eiger previously completed Phase 2 clinical trials for avexitide in 2021. Amylyx announced its plans to initiate a Phase&nbsp;3 trial in PBH in 2025. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our most direct competitors with respect to obesity include: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Eli Lilly and Company has several obesity compounds approved and under development, including: tirzepatide&#151;expanding
indications and labeling of Zepbound (tirzepatide) via the potential addition of long-term usage data, as well as data showing long-term reductions in cardiovascular-related mortality. Orforglipron, an oral
<FONT STYLE="white-space:nowrap">(non-peptide)</FONT> <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist currently in phase 3 trials. Retatrutide, a <FONT STYLE="white-space:nowrap">tri-agnoist</FONT> targeting <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> GIP and glucagon currently in Phase 3 clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Novo Nordisk has several obesity compounds approved and under development, including: semaglutide &#150; expanding
indications and labeling of Wegovy (semaglutide). Novo received FDA approval on March&nbsp;8, 2024 for reducing the risk of heart attacks, strokes and cardiovascular-related death in patients with heart disease and who are overweight or obese.
Amycretin, a fusion peptide, that acts on <FONT STYLE="white-space:nowrap">GLP-1</FONT> as well as amylin receptors expected to enter Phase 2 clinical trials in H2 2024 with both injectable and oral formulations being evaluated. CagriSema, a
combination of semaglutide and cagrilinitide, a dual amylin and calcitonin receptor agonist, administered as a single, once-weekly injection currently in Phase 3 clinical development. NN9541 a potential once-weekly oral <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> has completed Phase 1 clinical development and will be moving into Phase 2 clinical development as an injectable. NNC0480-0389, a potential
once-weekly injectable GIP receptor agonist to be <FONT STYLE="white-space:nowrap">co-administered</FONT> with semaglutide has completed Phase 1 clinical development. <FONT STYLE="white-space:nowrap">INV-202</FONT> (NN9441) and <FONT
STYLE="white-space:nowrap">INV-347</FONT> are two potential once-daily, oral cannabinoid <FONT STYLE="white-space:nowrap">receptor-1</FONT> (CB1R) inverse agonists currently in Phase 2 clinical development. INV 202 (NN9441) and <FONT
STYLE="white-space:nowrap">INV-347</FONT> were acquired by Novo in late 2023 through their acquisition of Inversago Pharma. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Amgen is developing <FONT STYLE="white-space:nowrap">AMG-133</FONT> (maridebart cagraglutide), a fused/conjugated molecule
combining a <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist with a GIP receptor antagonist, as a potential once-monthly injectable currently in Phase 2 clinical development. <FONT STYLE="white-space:nowrap">AMG-786</FONT> is an oral
candidate with an undisclosed target currently in Phase 1 clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Carmot Therapeutics, recently acquired by Roche, is developing <FONT STYLE="white-space:nowrap">CT-868,</FONT> <FONT
STYLE="white-space:nowrap">CT-388,</FONT> and <FONT STYLE="white-space:nowrap">CT-996</FONT> for obesity (with or without type 1 or type 2 diabetes). <FONT STYLE="white-space:nowrap">CT-388</FONT> is a potential weekly, injectable <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist.</FONT> <FONT STYLE="white-space:nowrap">CT-868</FONT> is being targeted for obesity with type 1 diabetes and is a once-daily injectable and <FONT
STYLE="white-space:nowrap">CT-996</FONT> is a potential once-daily oral for type 2 diabetes and obesity. Both <FONT STYLE="white-space:nowrap">CT-388</FONT> and <FONT STYLE="white-space:nowrap">CT-868</FONT> are in Phase 2 clinical development and
CT996 is in Phase 1 clinical development. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Pfizer is developing danuglipron, a potential twice-daily oral <FONT STYLE="white-space:nowrap">(non-peptide)</FONT> <FONT
STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist currently in Phase 3 clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Viking Therapeutics is developing <FONT STYLE="white-space:nowrap">VK-2735,</FONT> a potential once-weekly subcutaneous
injectable <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> currently in Phase 2 clinical development. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Zealand Pharma is developing 3 obesity compounds: petrenlintide, a long-acting, once-weekly amylin analog currently in
Phase 1b clinical development; dapiglutide a long-acting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1/GLP-2R</FONT></FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> in Phase 2 clinical development; and
survodutide, a long-acting once-weekly injectable <FONT STYLE="white-space:nowrap">GLP-1/glucagon</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> currently in Phase 2 clinical development. Survodutide was <FONT
STYLE="white-space:nowrap">co-invented</FONT> by Boehringer Ingelheim who is leading development of the candidate. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>License agreement </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Indiana University Research and Technology Corporation Exclusive License Agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2020, we entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation, or IURTC, a
<FONT STYLE="white-space:nowrap">non-profit</FONT> corporation organized under the laws of the State of Indiana, represented by The Trustees of Indiana University, or IU, pursuant to which we have been granted an exclusive, royalty-bearing license
to certain IURTC patent rights, or the Licensed Intellectual Property, developed by Dr.&nbsp;DiMarchi and other collaborators, to further scientific research, for new product development, and for other applications in public interest, such license,
the IURTC License Agreement. In particular, we have been granted an exclusive, royalty-bearing license to make, have made, use, have used, offer to sell, have offered for sale, sell, have sold, import and have imported products that are covered by
the Licensed Intellectual Property, or Licensed Products, with the right to sublicense to third parties. IURTC and IU have retained the right to (i)&nbsp;practice and use the Licensed Intellectual Property for
<FONT STYLE="white-space:nowrap">non-commercial</FONT> educational, research, and patient care and treatment purposes, and (ii)&nbsp;permit other <FONT STYLE="white-space:nowrap">non-profit</FONT> and academic entities to practice and use the
Licensed Intellectual Property for the same <FONT STYLE="white-space:nowrap">non-commercial</FONT> purposes. Under the IURTC License Agreement, we agreed to&nbsp;use commercially reasonable efforts to develop, promote and sell Licensed Products in
accordance with the IURTC License Agreement and any applicable laws. The IURTC License Agreement leverages IURTC&#146;s expertise in peptide therapies as well as our scientific, clinical, and regulatory capabilities to accelerate the development of
peptide treatments for people with endocrine and metabolic disorders. MBX 2109, MBX 1416 and MBX 4291 are Licensed Products under the IURTC License Agreement. Any future product candidates developed pursuant to our sponsored research agreement with
IU or otherwise covered by the Licensed Intellectual Property may be subject to the IURTC License Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As initial consideration for the license, we paid IURTC
an immaterial issue fee. As additional consideration for the license, we are required to pay IURTC: (i)&nbsp;royalties with a rate based on net sales per calendar year; (ii)&nbsp;an annual maintenance fee of up to $0.1&nbsp;million beginning in the
first year in which the first commercial sale occurs; (iii)&nbsp;a mid-single digits percentage of any sublicensing revenue; and (iv)&nbsp;milestone payments in the event of successful achievement of specified development milestones up to an
aggregate of $0.4&nbsp;million. IURTC is also entitled to receive reimbursement for all patent prosecution and maintenance related expenses. Our tiered royalties are in the low single-digits on annual net sales of the Licensed Products. In the event
that we are required to pay a <FONT STYLE="white-space:nowrap">non-affiliate</FONT> third party consideration for intellectual property owned or controlled by such <FONT STYLE="white-space:nowrap">non-affiliate</FONT> third party that we or a
sublicensee licensed for the development of Licensed Products, we can deduct such amounts from the royalty payments up to a certain amount of the running royalties owed that year. The royalty term will terminate on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each Licensed Product, until the expiration or termination of the last valid claim within the patent rights covering such Licensed Product
in that country. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;5, 2024, we and IURTC entered into a fourth amendment to the IURTC License Agreement, or the Fourth Amendment. The Fourth Amendment
specifies IURTC is entitled to the receipt of additional clinical and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
regulatory milestones, as defined in the Fourth Amendment, up to an aggregate of $9.0&nbsp;million. Following the execution of the Fourth Amendment, future remaining clinical and regulatory
milestone payments in the IURTC License Agreement and all amendments total up to $9.3&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The IURTC License Agreement will expire at the expiration of the
last of the patent rights covered in the IURTC License Agreement, unless terminated earlier by mutual agreement or by one of the parties. We may terminate the IURTC License Agreement with or without cause upon ninety (90)&nbsp;days prior written
notice to IURTC. IURTC may terminate the IURTC License Agreement if we commit a material breach of the IURTC License Agreement and fail to cure the breach within the respective cure period after receipt of the notice of material breach or upon our
failure to undertake certain activities in furtherance of commercial development goals. Upon termination of the IURTC License Agreement, all rights granted by IURTC will terminate and automatically revert to IURTC. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We strive to protect and enhance the proprietary
technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on
trademarks, copyrights and trade secrets relating to our proprietary technology platform and on <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and <FONT STYLE="white-space:nowrap">in-licensing</FONT>
opportunities to develop, strengthen and maintain our proprietary and intellectual property position. We additionally may rely on regulatory and other protections afforded through data exclusivity, market exclusivity and patent term extensions,
where available. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important
technologies, inventions and trade secrets related to our business, defend and enforce our intellectual property rights, particularly our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and
enforceable intellectual property rights of others. A discussion of risks relating to intellectual property is provided under the section titled &#147;Risk factors&#151;Risks related to our intellectual property&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent positions for biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal, scientific, and factual issues. In
addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates
will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide
sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our patent portfolio
includes issued patents and pending patent applications exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> from IURTC relating to our PEP technology and product candidates, and two pending U.S. provisional patent applications that are
owned by us relating to MBX 2109. We do not currently own or <FONT STYLE="white-space:nowrap">in-license</FONT> any issued patents relating to any of our product candidates and we also do not own or <FONT STYLE="white-space:nowrap">in-license</FONT>
any issued U.S. patents relating to our PEP technology or otherwise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to our PEP technology, as of August 15, 2024, we exclusively <FONT
STYLE="white-space:nowrap">in-license</FONT> from IURTC two issued patents, in Japan and Mexico, with claims directed to composition of matter relating to peptide prodrugs with fatty acylation linked via a
<FONT STYLE="white-space:nowrap">non-enzymatic</FONT> self-cleaving dipeptide, each with an expected expiration date of 2029, not including any patent term adjustments or patent term extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to our MBX 2109 product candidate, as of August 15, 2024, we exclusively
<FONT STYLE="white-space:nowrap">in-license</FONT> from IURTC a pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application and 12 foreign patent applications pending in Australia, Brazil, Canada, China, Europe, Israel,
Japan, South Korea, Mexico, New Zealand, Russia, and Singapore, with claims directed to composition of matter, pharmaceutical composition, and method of treatment relating to MBX 2109. Any patents that issue from these applications are expected to
expire in 2041, not including any patent term adjustment or patent term extensions that may be available. We also own two pending U.S. provisional patent applications with claims directed to dosage regimen relating to MBX 2109. Patent applications
claiming priority to these provisional applications, if issued, are expected to expire in 2044, not including any patent term adjustment or patent term extensions that may be available. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With regard to our MBX 1416 product candidate, as of August 15, 2024, we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> from IURTC two&nbsp;pending U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications, 15 foreign patent applications pending in Australia, Brazil, Canada, China, Europe, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Saudi Arabia, Taiwan, Hong&nbsp;Kong,
and Singapore, and an international patent application with claims directed to composition of matter, pharmaceutical composition, and method of treatment relating to MBX 1416. Any patents that issue from these patent applications or claim priority
to the international patent application are expected to expire between 2042 and 2043, not including any patent term adjustment or patent term extensions that may be available. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With regard to our obesity portfolio including our MBX 4291 product candidate, as of August 15, 2024, we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT>
from IURTC three pending U.S. provisional applications, including one with claims directed to composition of matter, pharmaceutical composition, and method of treatment relating to MBX 4291. Patent applications claiming priority to this provisional
application, if issued, are expected to expire in 2045, not including any patent term adjustment or patent term extensions that may be available. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of
individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20&nbsp;years from the earliest date of filing a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the term of a patent covering an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments, as compensation for the loss of patent
term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval.
Only one patent among those eligible for an extension may be extended, and only those claims covering an approved product, a&nbsp;method for using it or a method of manufacturing it may be extended. Moreover, a given patent may only be extended
once. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if
available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities,
including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to
patent protection, we also rely on <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secret protection for our proprietary information to develop and maintain our proprietary position. However, trade secrets can be difficult to protect.
Although we take steps to protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators,
third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our
<FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, and other proprietary information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and
market exclusivities. See &#147;&#151;Government regulation&#148; for additional information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Government regulation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively
regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and
import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations, require the
expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Review and approval of drugs in the united states </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The failure to comply with
applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve
pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the U.S. Department of Justice or other governmental entities. In addition, an applicant may need to recall a
product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">completion of nonclinical, or preclinical, laboratory tests, animal studies and formulation studies in compliance with the
FDA&#146;s good laboratory practice, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission to the FDA of an investigational new drug application, or IND, which must take effect before human clinical
trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approval by an institutional review board, or IRB, representing each clinical site before each clinical trial may be
initiated at that site; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCPs, to
establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparation and submission to the FDA of a new drug application, or NDA, and payment of user fees; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">review of the product by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or
components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the
clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">FDA review and approval of the NDA; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">compliance with any post-approval requirements, including risk evaluation and mitigation strategies, or REMS, and
post-approval studies required by the FDA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before an applicant begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of
the purity and stability of the manufactured drug substance or active pharmaceutical ingredient, or API, and the formulated drug or drug product, as well as <I>in vitro</I> and animal studies to assess the safety and activity of the drug for initial
testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Some long-term preclinical testing, such as animal tests of
reproductive adverse events, or AEs, and carcinogenicity, may continue after the IND is submitted. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>The IND and IRB processes </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for
FDA authorization to administer such investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of the investigational drug. In an IND, applicants must submit a protocol for each clinical trial
and any subsequent protocol amendments. In addition, the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the
FDA as part of an IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. The
FDA also may impose a clinical hold or partial clinical hold after commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing
investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written
explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or full investigation in the case of a partial clinical hold) may only resume after the FDA has notified the sponsor that the
investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND
requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study is conducted in accordance with GCP, including review and approval by an independent ethics committee, or
IEC, and informed consent from subjects. The GCP requirements are intended to help ensure the protection of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trials, as well as the quality and integrity of
the resulting data. FDA must also be able to validate the data from the study through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection if necessary. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing
review of the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can
suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate has been associated with
unexpected serious harm to patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a
data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. The FDA or the
sponsor may suspend or terminate a clinical trial at any time on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving
business objectives and/or competitive climate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of
Health, or NIH, for public dissemination on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Human clinical trials in support of an NDA </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP
requirements, which include, among other things, the requirement that all research subjects, or their legal representative, provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted
under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Phase 1</I>. The drug is initially introduced into healthy human subjects or, in certain indications such as cancer,
patients with the target disease or<I> </I>condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine maximal dosage.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Phase 2</I>. The drug is administered to a limited patient population to identify possible adverse effects and safety
risks, to preliminarily evaluate<I> </I>the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Phase 3</I>. The drug is administered to an expanded patient population, generally at geographically dispersed clinical
trial sites, in well-controlled clinical trials to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the
labeling of the product. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Post-approval studies, often referred to as Phase 4 studies, may be conducted after initial regulatory approval. These
studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Progress reports detailing the results of the
clinical trials must be submitted at least annually to the FDA. In addition, within 15 calendar days after the sponsor determines that the information qualifies for reporting, IND safety reports must be submitted to the FDA for any of the following:
serious and unexpected suspected adverse reactions; findings from other studies or animal or <I>in vitro</I> testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious
suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s
initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and
the integrity of the clinical data submitted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional
information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of
consistently producing quality batches of the drug candidate and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and
tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Review of
an NDA by the FDA </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical
trials, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one
or more indications. Under federal law, the submission of most NDAs is additionally subject to a significant application user fee as well as annual prescription drug product program fees. These fees are typically increased annually. Certain
exceptions and waivers are available for some of these fees. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA conducts a preliminary review of an NDA within 60 days of its receipt, before accepting the NDA
for filing, to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the
additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review.
The FDA has agreed to specified performance goals in the review process of NDAs. Applications for drugs containing new molecular entities are meant to be reviewed within 10 months from the date of filing, and applications for &#147;priority
review&#148; products containing new molecular entities are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the
applicant to address an outstanding deficiency identified by the FDA following the original submission. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During its review of an NDA, the FDA typically will inspect
the facility or facilities where the product is or will be manufactured. These <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with an NDA, including drug component manufacturing (such as APIs),
finished drug product manufacturing, and control testing laboratories. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk
minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product,
seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans
for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and
the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a
panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fast track, breakthrough therapy, and priority review </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA has a number of programs intended to facilitate and expedite development and review of new drugs if they are intended to address an unmet medical need in the
treatment of a serious or life-threatening disease or condition. Three of these programs are referred to as Fast Track Designation, Breakthrough Therapy Designation, and priority review designation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment
of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may
initiate review of sections of a Fast Track product&#146;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a
Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#146;s time period goal for
reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track Designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data
emerging in the clinical trial process. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or
more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process;
providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical
trials in an efficient manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Third, the FDA may designate an NDA review for a priority review if it is for a product that treats a serious or life-threatening
disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the
proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial
reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to
direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a marketing application from 10 months to six months. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Accelerated approval pathway </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may grant accelerated approval
to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely
to predict clinical benefit or on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit,
taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those
granted traditional approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement,
radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An
intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on
intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is
a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accelerated approval pathway is
most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs
rapidly. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accelerated approval pathway is contingent on a sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory
studies to verify and describe the product&#146;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical
trials to confirm the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period
after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post
this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct such studies in a timely
manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the agency, <FONT
STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials for product candidates approved under accelerated regulations, which could adversely impact the timing of the commercial launch of the product. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>The FDA&#146;s decision on an NDA </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On the basis of the FDA&#146;s evaluation
of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes
commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in
order for the FDA to reconsider the application. If a complete response letter is issued, the applicant may resubmit the NDA to address all of the deficiencies identified in the letter, withdraw the application, or request a hearing. If the
applicant resubmits the NDA, the FDA will issue an approval letter only when the deficiencies have been addressed to the FDA&#146;s satisfaction. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of
information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the
product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#146;s safety or effectiveness after approval, require testing and surveillance programs to monitor the product after
commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or
surveillance programs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Post-approval requirements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Drugs manufactured or
distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and
promotion, reporting of adverse experiences with the product and applicable product tracking and tracing requirements. After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to
prior FDA review and approval. There also are annual prescription drug product program fee requirements for certain marketed products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, drug
manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these
state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any
deviations from cGMP and impose reporting and documentation requirements upon the NDA holder and any third-party manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the
area of production and quality control to maintain cGMP compliance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or
imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
voluntary product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fines, warning or untitled letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved
indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be
subject to significant liability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA,
which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription
pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Hatch-Waxman amendments </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A
Section&nbsp;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the
information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.
This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section&nbsp;505(j) establishes an abbreviated
approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application, or ANDA. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form,
strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product, known as a reference listed drug, or RLD. ANDAs are termed &#147;abbreviated&#148; because they are
generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as,
the innovator drug through <I>in vitro</I>, <I>in vivo</I>, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#146;s bloodstream in the same amount of time as the innovator drug and can often be
substituted by pharmacists under prescriptions written for the reference listed drug. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-patent</FONT> exclusivity </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases accept) an ANDA or 505(b)(2) application until any applicable period of <FONT
STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the RLD has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity for a new drug containing a new chemical entity, or
NCE. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological
action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, which states the
proposed generic drug will not infringe one or more of the already approved product&#146;s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following the original
product approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDCA also provides for a period of three years of exclusivity for <FONT STYLE="white-space:nowrap">non-NCE</FONT> drugs if the NDA or a
supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application or supplement.
This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication, but it generally would not protect the original, unmodified product from
generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; it only
prevents FDA from approving such ANDAs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A drug product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six
months to existing exclusivity periods&nbsp;for all formulations, dosage forms, and indications of the active moiety and to patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other
exclusivity protection&nbsp;and patent term,&nbsp;may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a
study,&nbsp;provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Hatch-Waxman patent certification and the <FONT STYLE="white-space:nowrap">30-month</FONT> stay </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In seeking approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#146;s product or
an approved method of using the product. Upon approval, each of the patents listed by the NDA sponsor is published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Upon submission
of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents listed for the RLD in the Orange Book that: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no patent information on the drug product that is the subject of the application has been submitted to the FDA;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">such patent has expired; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the date on which such patent expires; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">such patent is invalid, unenforceable or will not be infringed upon by the manufacture, use, or sale of the drug product
for which the application is submitted. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except
where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking
approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV
certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in
response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application
until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#146;s favor or settled, or
such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT STYLE="white-space:nowrap">30-month</FONT> stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV
certification, the NDA holder or patent owner(s) regularly take action to trigger the <FONT STYLE="white-space:nowrap">30-month</FONT> stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of
an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s decision to initiate patent litigation. If the drug has NCE exclusivity and
the ANDA is submitted four years after approval, the <FONT STYLE="white-space:nowrap">30-month</FONT> stay is extended so that it expires seven and a half years after approval of the innovator drug, unless the patent expires or there is a decision
in the infringement case that is favorable to the ANDA applicant before then. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Patent term restoration and extension </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent term restoration of up
to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the
submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date, provided the sponsor acted with diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of
14 years from the product&#146;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
within 60 days of drug approval. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark
Office, or USPTO, reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rest of the world regulation
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For other countries outside of the United States, such as those in Europe, Latin America or Asia, the requirements governing product development, the conduct of
clinical trials, product marketing, product licensing, pricing and reimbursement can vary from country to country. Failure to comply with applicable foreign regulatory requirements may subject sponsors, manufacturers or marketers of pharmaceutical
products to, among other things, fines, suspension or withdrawal of regulatory authorizations and approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other healthcare laws </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business operations and current and future
arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws that may affect
our ability to operate include, but are not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting,
receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease,
order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment,
and exclusion from government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act, or FCA, which can be enforced through civil
&#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims
for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal
government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to
&#147;cause&#148; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the FCA. The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal
statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property
owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any
materially false </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or
entity can be found guilty of violating these statutes without actual knowledge of the statutes or specific intent to violate them in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, imposes
requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health
information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal
penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs
associated with pursuing federal civil actions. Even when HIPAA does not apply, according to the Federal Trade Commission, or FTC, failing to take appropriate steps to keep consumers&#146; personal information secure constitutes unfair acts or
practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act, 15 U.S.C. &#167; 45(a). The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity
and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that
merits stronger safeguards; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Physician Payments Sunshine Act, created under the ACA and its implementing regulations, which requires
manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to HHS information related to
payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare professionals, and teaching hospitals, as well as ownership and investment
interests held by physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate
and timely manner to government programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements as well as submitting claims involving healthcare items or services
reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing
information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales
representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be
subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Coverage and reimbursement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States and markets in other
countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product
candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care
organizations, provide coverage, and establish adequate reimbursement levels for, the product. Factors payors consider in determining coverage and reimbursement are based on whether the product is: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cost-effective; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug
products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay
for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage
costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order
to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private
health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product
is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a third-party payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be
approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly
from payor to payor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a
focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products,
government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for
substitution of generic products. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from
countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the
level of reimbursement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average
sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare
programs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved
products. Even if we do receive a favorable coverage determination for approved products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the U.S. Centers for Medicare&nbsp;&amp;
Medicaid Services, or CMS, may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial
products, which has resulted in several U.S. Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to
government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to
other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the European Union, pricing and
reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the
cost-effectiveness of a particular product candidate to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU
Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for
a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control
prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to
manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become
intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement
has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no
assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Current and future U.S. healthcare reform </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the U.S., there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. For
example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including
those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the
average manufacturer price; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">required collection of rebates for drugs paid by Medicaid managed care organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer
70&nbsp;percent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers
who sell &#147;branded prescription drugs&#148; to specified federal government programs. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There has been increasing legislative and enforcement
interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to
drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. President Biden has issued multiple
executive orders that have sought to reduce prescription drug costs. In February 2023, HHS also issued a proposal in response to an October 2022 executive order from President Biden that includes a proposed prescription drug pricing model that will
test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#146;s accelerated approval pathway. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, on December&nbsp;2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan
sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The Inflation Reduction Act of 2022, or IRA, delayed implementation of this rule
to January&nbsp;1, 2032. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of
2% per fiscal year, and, due to subsequent legislative amendments to the statute, will remain in effect until 2031. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The U.S. American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of
providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">On May&nbsp;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework
for certain patients to access certain investigational new drug products that have completed a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without
obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a
drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. Due to the Statutory
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Pay-As-You-Go</FONT></FONT></FONT> Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent
legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices
we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our
product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The IRA includes
several provisions that may impact our business to varying degrees, including provisions that create a $2,000 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cap for Medicare Part D beneficiaries, impose
new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, and require
companies to pay rebates to Medicare for drug prices that increase faster than inflation. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which
the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The drug price negotiation provisions of the
IRA are subject to ongoing constitutional challenges. The outcome of these challenges and the effect of IRA on our business and the healthcare industry in general is not yet known. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Individual states have also been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other
health care programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although a number of these and other proposed measures may require authorization through additional
legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Human capital resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of August&nbsp;15, 2024, we had 36 full-time
employees, of which ten have M.D. or Ph.D. degrees. Within our workforce, 23 employees are engaged in research and development and 13 are engaged in general and administrative. We have never had a work stoppage, and none of our employees is
represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and
integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase
shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Facilities
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We lease our office space, which consists of 6,493 square feet located in Carmel, Indiana. Our lease expires on December&nbsp;31, 2025, with the option to renew
for an additional three-year period. We also lease 1,580 square feet of laboratory space in Indianapolis, Indiana, under a lease that expires on December&nbsp;31, 2025. We believe our current facilities are sufficient to meet our needs until the
expiration of our leases. To meet the future needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any
future expansion of our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Legal proceedings </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to
time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a
material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management
resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_12"></A>Management </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth information about our executive officers and directors as of the date of this prospectus. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Position(s)</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">55&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Salomon Azoulay, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">67&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">43&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tiba Aynechi, Ph.D. (2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">48&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James M. Cornelius (2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">80&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Carl L. Gordon, Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">59&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Heron (1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">54&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Edward T. Mathers (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">64&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ora Pescovitz, M.D. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">67&#8196;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="center">73&#8196;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Director</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Nominating and Corporate Governance Committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Compensation Committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Audit Committee. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a biographical summary of the experience of our executive officers and
directors. There are no family relationships among any of our executive officers or directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Kent Hawryluk</I> is one of our <FONT STYLE="white-space:nowrap">co-founders</FONT> and has served as our President and Chief Executive Officer since January 2020 and
as a member of our board of directors since April 2019. Mr.&nbsp;Hawryluk has also served as a partner of Twilight Venture Partners, LLC, a private seed- and early-stage life science venture capital fund, since January 2003. Prior to joining MBX,
Mr.&nbsp;Hawryluk was <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Business Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), an RNA therapeutics company, from January 2013 to December 2019. Previously, he served as <FONT
STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer of MB2 LLC (subsequently acquired by Novo Nordisk Inc.), a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. Mr.&nbsp;Hawryluk <FONT
STYLE="white-space:nowrap">co-founded</FONT> Marcadia Biotech Inc. (subsequently acquired by F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG) and served as its Chief Business Officer and Vice President, Business Development from
January 2006 to April 2011. Mr.&nbsp;Hawryluk served as a director of Gemphire Therapeutics Inc. (Nasdaq: GEMP), a public clinical-stage cardiovascular drug company, from February 2015 to February 2019. Mr.&nbsp;Hawryluk holds a B.A. from Princeton
University, an MBA from Kellogg School of Management at Northwestern University, and an M.S. in Biology from Purdue University. Our board of directors believes that Mr. Hawryluk is qualified to serve as a director because of his experience founding
and developing biopharmaceutical companies and his extensive management experience in the biopharmaceutical industry. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Salomon (Sam) Azoulay, M.D.</I>, has served
as our Chief Medical Officer since June 2024. Prior to joining MBX, Dr.&nbsp;Azoulay served as Consulting Chief Executive Officer of Nervosave Therapeutics from September 2023 to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
June 2024. Prior to that, Dr. Azoulay served as Chief Medical Officer at Sumitovant Biopharma Ltd., following Roivant Sciences Ltd.&#146;s, or Roivant, strategic spin-out of multiple portfolio
companies to create an independent subsidiary of Sumitomo Pharma Co. Ltd., from January&nbsp;2021 to July&nbsp;2023. Dr. Azoulay also previously served as Chief Medical Officer of Roivant from May&nbsp;2018 to December&nbsp;2020. Prior to Roivant,
he served at Pfizer for nearly 20 years in positions of increasing responsibility, culminating in his position as Chief Medical Officer of Pfizer Essential Health from September&nbsp;2013 to May&nbsp;2018. Dr. Azoulay serves as an advisor to the
board of directors of PharmStars. Dr.&nbsp;Azoulay earned his M.D., with a specialty in cardiology, from the University of Paris VI. He also holds a D.E.S.S. in Business Administration and Management from Sorbonne University. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Richard Bartram</I> has served as our Chief Financial Officer since April 2022. Prior to joining MBX, Mr.&nbsp;Bartram served as Chief Financial Officer at Esperion
Therapeutics, Inc., or Esperion, (Nasdaq: ESPR), a publicly-traded pharmaceutical company focused on the development and commercialization of therapies for patients with elevated <FONT STYLE="white-space:nowrap">LDL-C</FONT> cholesterol, from
January 2018 to April 2022. Mr.&nbsp;Bartram also served as Esperion&#146;s Vice President, Finance, from January 2015 to January 2018, and as Esperion&#146;s Controller from February 2013 to January 2015. Previously, Mr.&nbsp;Bartram served as a
public accountant at PricewaterhouseCoopers, LLP in its assurance practice. Mr.&nbsp;Bartram earned both a M.S. in Accounting and a B.A. in Accounting from Michigan State University and is a licensed Certified Public Accountant in the state of
Michigan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Tiba Aynechi, Ph.D.,</I> has served on our board of directors since November 2022. She has served as a General Partner of Norwest Venture Partners&#146; healthcare
team since December 2021 and previously, Dr.&nbsp;Aynechi served in various roles at Novo Holdings A/S, one of the top life sciences investment firms, from March 2010 to December 2021, most recently as senior partner. Dr.&nbsp;Aynechi currently
serves on the boards of directors of Spruce Biosciences Inc. (Nasdaq: SPRB), Rezo Therapeutics Inc., Avalyn Pharma Inc., Engrail Therapeutics, Inc. and Ray Therapeutics, Inc. She previously served on various public and private boards of directors
including iRhythm Technologies, Inc. (Nasdaq: IRTC) from May 2014 to April 2017, Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) from October 2018 to August 2021, Nkarta, Inc. (Nasdaq: NKTX) from August 2015 to June 2022, Aristea Therapeutics, Inc. from
August 2018 to December 2021, Arcellx Inc., from July 2015 to November 2021, and MDLive Inc. from July 2018 to May 2021. Dr.&nbsp;Aynechi attended the University of California Irvine where she received a B.S. in Physics with a biomedical
concentration. She also holds a Ph.D. in Biophysics from the University of California San Francisco, where she also did her Postdoctoral Fellowship. Dr.&nbsp;Aynechi is also a published author of scientific articles and book chapters in rational
drug design. Our board of directors believes Dr. Aynechi is qualified to serve as a director because of her extensive experience in the biotechnology and pharmaceutical industries, including her expertise in handling a wide range of financing
transactions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>James M.</I> <I>Cornelius</I> has served on our board of directors since September 2020. Mr.&nbsp;Cornelius is an accomplished global
biopharmaceutical leader as well as a recognized venture investor and philanthropist. Previously, he served as Chairman of the Board of Bristol Myers Squibb Co., or BMY, (NYSE: BMY) from February 2008 to May 2015, and as Chief Executive Officer from
September 2006 to March 2010. Mr.&nbsp;Cornelius served as Chairman of the Board of Mead Johnson Nutrition (subsequently acquired by Reckitt Benckiser) from December 2009 to June 2017. Mr.&nbsp;Cornelius served as Board Chairman and Chief Executive
Officer of Guidant Corporation (subsequently acquired by Boston Scientific Corporation (NYSE: BSX)), from November 2005 to April 2006. Previously, he was executive Chairman of the Board of Guidant Corporation and its senior executive starting from
September 1994 when the Company was formed within Eli Lilly and Co., or Eli Lilly, (NYSE: LLY). Mr.&nbsp;Cornelius was a member of Eli Lilly&#146;s Board of Directors and its Chief Financial Officer from 1983 until 1995. In addition, he has served
on the Board of Directors of a dozen private and public companies, including The Chubb Corporation, The DIRECTV Group and Given Imaging. Mr.&nbsp;Cornelius is currently Chairman of Cornelius Family Foundation and Cornelius Private Investments. He
earned a B.A. magna cum laude and M.B.A. from Michigan State University. Our board of directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
believes that Mr.&nbsp;Cornelius is qualified to serve as a director because of his extensive experience as a venture capitalist and his experience serving on multiple public boards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Carl L. Gordon, Ph.D.,</I> <I>CFA</I>, has served on our board of directors since July 2020. He has served as a founding member, Managing Partner, and <FONT
STYLE="white-space:nowrap">Co-Head</FONT> of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr.&nbsp;Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc.
(Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr.&nbsp;Gordon previously served on the boards of Alector,
Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics
Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc.
(formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr.&nbsp;Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The
Rockefeller University. Our board of directors believes that Dr.&nbsp;Gordon is qualified to serve as a director because of his venture capital experience, expertise in the scientific field of molecular biology and financial credentials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Patrick Heron</I> has served on our board of directors since July 2020. He has been a Managing Partner of Frazier&#146;s Life Sciences team since August 1999. Prior
to that, Mr.&nbsp;Heron helped develop McKinsey&nbsp;&amp; Company&#146;s west coast biotechnology consulting practice. He currently serves on the boards of directors of HilleVax, Inc. (Nasdaq: HLVX) since September 2021 and Mirum Pharmaceuticals,
Inc. (Nasdaq: MIRM) since November 2018, as well as chairman of the board of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) since January 2017. Mr.&nbsp;Heron previously served as chairman of the board of Scout Bio, Inc. from January 2018 to December
2023, and as a director of SanReno Therapeutics from January 2022 to December 2023, Imago Biosciences, Inc. (acquired by Merck&nbsp;&amp; Co., Inc). from October 2014 to May 2022, Vaxcyte, Inc. (Nasdaq: PCVX) from April 2017 to September 2021,
Passage Bio, Inc. (Nasdaq: PASG) from July 2018 to June 2021 and Iterum Therapeutics plc (Nasdaq: ITRM) from August 2015 to March 2021. He has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage
drug discovery companies to $100M commercial-stage dermatology companies. He received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and
Morehead Scholar. Our board of directors believes that Mr.&nbsp;Heron is qualified to serve as a director because of his investment experience in the biopharmaceutical industry as well as his experience on numerous public and private company boards
of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Edward T. Mathers</I> has served on our board of directors since July 2020. He has been a Partner at New Enterprise Associates, a venture capital
firm, since August 2008. Mr.&nbsp;Mathers currently serves on the boards of directors of Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), Inozyme Pharma, Inc. (Nasdaq: INZY), Synlogic, Inc. (Nasdaq: SYBX), Trevi Therapeutics, Inc. (Nasdaq: TRVI), Reneo
Pharmaceuticals, Inc. (Nasdaq: PHM), and Senti Biosciences, Inc. (Nasdaq: XBIO), as well as a number of private life sciences companies. Mr.&nbsp;Mathers previously served on the board of directors of Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) from
November 2019 to September 2022, Akouos, Inc. (Nasdaq: Formerly AKUS, acquired by Eli Lilly) from October 2017 to December 2022, Ra Pharmaceuticals, Inc. until its acquisition by UCB S.A. in April 2020 and Liquidia Corporation (Nasdaq: LQDA) until
May 2019. Prior to joining New Enterprise Associates, Mr.&nbsp;Mathers served in various corporate development roles at MedImmune, Inc., a biotechnology company that was acquired by AstraZeneca PLC in 2007, culminating in the position of Executive
Vice President, Corporate Development and Venture. In this role, he also led the company&#146;s venture capital subsidiary, MedImmune Ventures, Inc. Prior to that, Mr.&nbsp;Mathers was Vice President, Marketing and Corporate Licensing and
Acquisitions at Inhale Therapeutic Systems, Inc., a biopharmaceutical company, which is now known as Nektar Therapeutics, Inc. (Nasdaq: NKTR). Previously, for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
15 years, Mr.&nbsp;Mathers was at Glaxo Wellcome, Inc., where he held sales and marketing positions of increasing responsibility. Mr.&nbsp;Mathers received a B.S. in chemistry from North Carolina
State University. Our board of directors believes that Mr.&nbsp;Mathers is qualified to serve as a director because of his senior executive roles in publicly traded life sciences companies, his extensive experience as a venture capitalist, and his
service on the boards of directors of numerous biotechnology companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Ora Pescovitz, M.D.</I><B>,</B><I></I> has served on our board of directors since April
2022. She has served as President of Oakland University since July 2017 and currently serves on the board of directors of Priority Health and Transformative AI Limited. Previously, Dr.&nbsp;Pescovitz served as Senior Vice President and U.S. Medical
Leader for Lilly Biomedicines at Eli Lilly from October 2014 to June 2017. From April 2012 to February 2014, she served on the board of directors of Life Technologies Corporation (Nasdaq: Formerly LIFE, acquired by Thermo Fisher Scientific Inc.
(NYSE: TMO)). From May 2009 to October 2014, she was the University of Michigan&#146;s first female Executive Vice President for Medical Affairs and Health System Chief Executive Officer. Dr.&nbsp;Pescovitz is a nationally recognized pediatric
endocrinologist and researcher who has published 180 papers and books, and received numerous awards for her research and teaching. Dr Pescovitz received her B.M.Sc. in the Honors Program in Medical Education at Northwestern University and earned her
M.D. from the Northwestern University Feinberg School of Medicine, where she earned Distinguished Alumni Awards from both the Feinberg School of Medicine and Northwestern University. Dr.&nbsp;Pescovitz was elected to the National Academy of
Medicine.&nbsp;Our board of directors believes that Dr.&nbsp;Pescovitz is qualified to serve as a director because of her extensive academic, business and medical experience in the health care fields and her service on
<FONT STYLE="white-space:nowrap">non-profit</FONT> boards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Steven Ryder, M.D.,</I><B> </B>has served on our board of directors since January 2024. Dr.&nbsp;Ryder
has served as the Chief Medical Officer of Rallybio Corporation (Nasdaq: RLYB) since January 2019. Previously, Dr.&nbsp;Ryder was the Chief Development Officer at Alexion Pharmaceuticals, Inc. (Nasdaq: Formerly ALXN, acquired by AstraZeneca PLC)
from July 2013 to December 2018 and was the founding President of Astellas Pharma Global Development, Inc. from April 2008 to April 2013. Dr.&nbsp;Ryder also worked at Pfizer Inc. (Nasdaq: PFE) for 21 years where he held positions of increasing
responsibility, including senior vice president of Global Research and Development. He has also held board positions at Reata Pharmaceuticals, Inc. (Nasdaq: Formerly RETA, acquired by Biogen Inc. (Nasdaq: BIIB)) and Levo Therapeutics, Inc.
Dr.&nbsp;Ryder earned his Doctor of Medicine from the Icahn School of Medicine at Mount Sinai. Our board of directors believes that Dr.&nbsp;Ryder is qualified to serve as a director because of his extensive drug development experience at
biopharmaceutical companies. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Board composition </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of
directors currently consists of eight directors, each of whom is a member pursuant to the board composition provisions of our current third amended and restated certificate of incorporation and agreements with our stockholders, which agreements are
described in the section of this prospectus entitled &#147;Certain relationships and related person transactions.&#148; These board composition provisions will terminate upon the closing of this offering. Upon the termination of these provisions,
there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and
background of nominees. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is identification of persons who will further the interests of our stockholders through their
established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences
and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until their earlier resignation or removal. Our fourth amended and restated certificate of incorporation and amended
and restated bylaws </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
that will become effective immediately prior to the closing of this offering and upon the effectiveness of the registration statement of which this prospectus forms a part, respectively, also
provide that our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all our stockholders would be entitled to cast in an annual election of
directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Staggered board </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In accordance with the terms of our fourth amended and
restated certificate of incorporation and our amended and restated bylaws that will become effective immediately prior to the closing of this offering and upon the effectiveness of the registration statement of which this prospectus forms a part,
respectively, our board of directors will be divided into three staggered classes of directors and each director will be assigned to one of the three classes. At each annual meeting of the stockholders, one class of directors will be elected for a
three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the
years 2025 for Class&nbsp;I directors, 2026 for Class&nbsp;II directors and 2027 for Class&nbsp;III directors. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;I directors will be Tiba Aynechi, Carl L. Gordon and P. Kent Hawryluk; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;II directors will be James M. Cornelius, Patrick Heron and Edward T. Mathers; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;III directors will be Ora Pescovitz and Steven Ryder. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our fourth amended and restated certificate of incorporation and amended and restated bylaws will provide that the number of our directors shall be fixed from time to
time by a resolution of the majority of our board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The division of our board of directors into three classes with staggered three-year terms may delay
or prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Director independence </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; Under the Nasdaq listing rules, independent directors must
comprise a majority of a listed company&#146;s board of directors within twelve months from the date of listing. In addition, the Nasdaq listing rules require that, subject to specified exceptions, each member of a listed company&#146;s audit,
compensation and nominating and governance committees be independent within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule
<FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not
have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the
Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (i)&nbsp;accept, directly or indirectly, any
consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be
considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining
whether a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the
director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2024, our board of directors undertook a
review of the composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations, including
family relationships, our board of directors has determined that all members of our board of directors, except P. Kent Hawryluk, are independent directors, including for purposes of Nasdaq and the SEC rules. In making that determination, our board
of directors considered the relationships that each director has with us and all other facts and circumstances the board of directors deemed relevant in determining independence, including the potential deemed beneficial ownership of our capital
stock by each director, including <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that are affiliated with certain of our major stockholders. Upon the completion of this offering, we expect that the composition and functioning of our
board of directors and each of our committees will comply with all applicable requirements of Nasdaq and the rules and regulations of the SEC. There are no family relationships among any of our executive officers and directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have adopted a policy, subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a part, that outlines a process
for our securityholders to send communications to the board of directors. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Board committees </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate
pursuant to a charter adopted by our board of directors, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part. We believe that the composition and functioning of all of our committees
will comply with the applicable requirements of Nasdaq, the Sarbanes-Oxley Act of 2002 and SEC rules and regulations that will be applicable to us. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following the consummation of this offering, the full text of our audit committee charter, compensation committee charter and nominating and corporate governance
committee charter will be posted on the investor relations portion of our website at https://www.mbxbio.com. We do not incorporate the information contained on, or accessible through, our corporate website into this prospectus, and you should not
consider it a part of this prospectus. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Audit committee </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the effectiveness of the registration statement of which this prospectus forms a part, our audit committee will consist of James M. Cornelius, Tiba Aynechi and Carl
L. Gordon and will be chaired by James M. Cornelius. The functions of the audit committee will include: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All members of our audit committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq listing rules.
Our board of directors has determined that James&nbsp;M.&nbsp;Cornelius qualifies as an &#147;audit committee financial expert&#148; within the meaning of applicable SEC regulations. In making this determination, our board of directors considered
the nature and scope of experience that James M. Cornelius has previously had with public reporting companies, including service as a principal financial officer, principal executive officer and principal accounting officer. Our board of directors
has determined that all of the directors that will become members of our audit committee upon the effectiveness of the registration statement of which this prospectus forms a part satisfy the relevant independence requirements for service on the
audit committee set forth in the rules of the SEC and the Nasdaq listing rules. Both our independent registered public accounting firm and management will periodically meet privately with our audit committee. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Compensation committee </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the effectiveness of the registration
statement of which this prospectus forms a part, our compensation committee will consist of Patrick Heron, Tiba Aynechi and James M. Cornelius, and will be chaired by Patrick&nbsp;Heron. The functions of the compensation committee will include: </P>
 <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the
compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such
evaluation (i)&nbsp;reviewing and determining the cash compensation of our Chief Executive Officer and (ii)&nbsp;reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards
identified in the applicable Nasdaq listing rules; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving our policies and procedures for the grant of equity-based awards; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and recommending to the board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparing our compensation committee report if and when required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; if and when
required, to be included in our annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation
of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each member of our compensation committee will be a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as
defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Nominating and corporate governance committee </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the
effectiveness of the registration statement of which this prospectus forms a part, our nominating and corporate governance committee will consist of Ora Pescovitz, Patrick Heron and Edward T. Mathers and will be chaired by Ora Pescovitz. The
functions of the nominating and corporate governance committee will include: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate
skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate
governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Compensation committee interlocks and insider participation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of the
members of our compensation committee is, or has at any time during the prior three years been, one of our officers or employees. None of our executive officers currently serve, or have in the past fiscal year served, as a member of the board of
directors or compensation committee of any entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Code of business conduct and ethics </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has adopted a
written Code of Business Conduct and Ethics in connection with this offering. The Code of Business Conduct and Ethics will apply to all of our employees, officers (including our principal executive officer, principal financial officer, principal
accounting officer or controller, or persons performing similar functions), agents and representatives, including directors and consultants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics and our Code
of Ethics on our website identified below. Upon the completion of this offering, the full text of our Code of Business Conduct and Ethics and our Code of Ethics will be posted on our website at https://www.mbxbio.com. The inclusion of our website
address in this prospectus does not include or incorporate by reference the information on our website into this prospectus, and you should not consider that information a part of this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Limitations on liability and indemnification agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by
Delaware law, provisions in our fourth amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to the closing of this offering and upon the effectiveness of the registration
statement of which this prospectus forms a part, respectively, limit or eliminate the personal liability of directors and officers for a breach of their fiduciary duty of care as a director or officer. The duty of care generally requires that, when
acting on behalf of the corporation, a director and or officer exercise an informed business judgment based on all material information reasonably available to him or her. Consequently, a director or officer will not be personally liable to us or
our stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director or officer&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief,
such as injunctive relief or rescission. These provisions will not alter a director or officer&#146;s liability under other laws, such as the federal securities laws or other state or federal laws. Our fourth amended and restated certificate of
incorporation that will become effective upon the closing of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by Delaware law, our amended and restated bylaws to be effective upon the effectiveness of the registration statement will provide that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other agents, in
connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then the liability of our
directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director, employee or other
agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained such insurance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the indemnification that will be provided for in our fourth amended and restated certificate of
incorporation and amended and restated bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the Delaware
General Corporation Law. These indemnification agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts
incurred by a director or executive officer in any action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that
these provisions and agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This description of the
indemnification provisions of our fourth amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as
an exhibit to the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the Securities Act may be
permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act,
and is, therefore, unenforceable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought,
nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_13"></A>Executive compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding our future
compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As an emerging growth company, we have opted to comply with the executive compensation disclosure rules applicable to &#147;smaller reporting companies,&#148; as such
term is defined in the rules promulgated under the Securities Act. The compensation provided to our named executive officers for the fiscal year ended December&nbsp;31, 2023 is detailed in the 2023 Summary Compensation Table, and accompanying
footnotes and narrative that follow. Our named executive officers, or NEOs, for the fiscal year ended December&nbsp;31, 2023 are: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Peter Kent Hawryluk, our President and Chief Executive Officer and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Richard Bartram, our Chief Financial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, the compensation of our named executive officers has consisted of a combination of base salary, cash bonuses, and equity interests in the form of stock awards
and option awards. Our named executive officers, like all of our full-time employees, are eligible to participate in our health and welfare benefit plans and 401(k) plan. As we transition from a private company to a publicly traded company, we
intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2023 Summary compensation table
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table shows the total compensation earned by, or paid to, our named executive officers for services rendered to us in all capacities during the
fiscal year ended December&nbsp;31, 2023. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name and principal position</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>awards(1)&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>incentive plan<BR>compensation(2)&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peter Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,290,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,862,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">425,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">473,106</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">153,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,051,106</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant date fair value of stock options granted to the named executive officers during 2023, as calculated in accordance with Financial Accounting Standards
Board, or FASB, Accounting Standards Codification, or ASC, Topic 718. Such grant date value does not take into account any estimated forfeitures related to service-based vesting conditions. The assumptions used in the grant date fair value of the
awards in this column are described in Note 12&#151;Stock-Based Compensation to our financial statements included elsewhere in this prospectus. These awards are described in more detail under &#147;Narrative Disclosure to Summary Compensation
Table&#151;Equity-Based Compensation&#148; below. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported represent annual bonuses under our annual cash bonus program based on achievement of company performance and individual performance during the year ended December&nbsp;31, 2023. For more information
on these bonuses, see description of the annual performance bonuses under the section titled &#147;Narrative disclosure to summary compensation table&#151;Annual cash bonuses&#148; below. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Narrative disclosure to summary compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2023 base salaries
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our named executive officers each receive a base salary to compensate them for services rendered to our Company. The base salary payable to each named
executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role, and responsibilities. Base salaries may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, the annual base salary for Mr.&nbsp;Hawryluk and Mr.&nbsp;Bartram were $420,000 and $425,000, respectively. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2023 cash bonuses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the fiscal year ended December&nbsp;31, 2023,
each of the named executive officers was eligible to earn an annual cash bonus determined by our board of directors in its reasonable and sole discretion, based on the individual performance and achievement of certain corporate performance
milestones, including clinical milestones, research and development goals, and business development and organizational goals.. The target annual bonus for each of our named executive officers for the fiscal year ended December&nbsp;31, 2023 was
equal to the percentage of the executive&#146;s respective annual base salary specified below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Target&nbsp;bonus<BR>percentage</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peter Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Equity-based compensation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we
do not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and
help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. During
the fiscal year ended December&nbsp;31, 2023, we granted stock options to our named executed officers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For additional information regarding outstanding equity
awards held by our named executive officers as of December&nbsp;31, 2023, see the &#147;Outstanding equity awards at 2023 fiscal year end&#148; table below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Perquisites or personal benefits </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not provide perquisites or
personal benefits to our employees with an aggregate equal to or greater than $10,000. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>401(k) plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain a retirement savings plan for our employees, or 401(k) plan, that is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code,
and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. U.S. employees are generally eligible to participate in the 401(k) plan, subject to certain criteria. Participants may make <FONT
STYLE="white-space:nowrap">pre-tax</FONT> and certain <FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code.
Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for <FONT STYLE="white-space:nowrap">catch-up</FONT> contributions. Participant contributions are held in trust as required by law. We do
not provide matching or discretionary contributions under the 401(k) Plan at this time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Outstanding equity awards at fiscal 2023&nbsp;year end </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table lists all outstanding equity awards held by our named executive officers as of December&nbsp;31, 2023 </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option&nbsp;awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock&nbsp;awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Vesting<BR>commencement<BR>date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options (#)<BR>exercisable</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options (#)<BR>unexercisable</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Option</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>exercise<BR>price&nbsp;($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>expiration<BR>date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of<BR>shares or<BR>units of<BR>stock that<BR>have not<BR>vested&nbsp;(#)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Market<BR>value of<BR>shares or<BR>units of<BR>stock&nbsp;that<BR>have not<BR>vested<BR>($)(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peter Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/15/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718,391</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$7.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/14/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/7/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,567</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,650</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/12/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,946</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/8/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,256</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/15/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,209</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$7.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/14/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/7/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,806</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4/11/2022</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">93,577</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">(8)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$3.01</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4/19/2032</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each stock option award is subject to the terms of our 2019 Stock Option and Grant Plan, as amended, or the 2019 Plan. Each stock option is subject to acceleration in the event of a sale event (as defined in the 2019
Plan), subject to the named executive officer&#146;s service relationship with the Company at the time of the sale event, as described below under &#147;Executive compensation arrangements&#151;Employment arrangements in place prior to the offering
for named executive officers.&#148; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents the fair market value of a share of our common stock as of December&nbsp;31, 2023. The fair market value is based on the assumed initial public offering price of $15.00, per share, which is the midpoint of
the price range set forth on the cover page of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares subject to this stock option are early exercisable, subject to a right of repurchase that lapses as the shares vest. All the shares subject to this option vest in 48 equal monthly installments following the
vesting commencement date, in each case, subject to Mr.&nbsp;Hawryluk&#146;s continuous service relationship with the Company through each applicable vesting date. As of December&nbsp;31, 2023, 59,866 shares of common stock underlying this option
had vested, with an unvested balance of 658,525 shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the 478,927 shares originally subject to this option were exercisable as of the date of grant, subject to a right of repurchase that lapses as the shares vest, and Mr.&nbsp;Hawryluk exercised 166,360 shares. All
the shares subject to this option vest in 48 equal monthly installments following the vesting commencement date, in each case, subject to Mr.&nbsp;Hawryluk&#146;s continuous service relationship with the Company through each applicable vesting date.
As of December&nbsp;31, 2023, (i) Mr.&nbsp;Hawryluk has exercised 166,360 shares subject to the option, of which 36,650 shares remain unvested and (ii)&nbsp;all 312,567 unexercised were unvested. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents shares of restricted stock acquired upon the early exercise of a stock option, subject to a right of repurchase that lapses as the shares vest. Such shares vest in 48 equal monthly installments following the
vesting commencement date, in each case, subject to Mr.&nbsp;Hawryluk&#146;s continuous service relationship with the Company through each applicable vesting date. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares subject to this stock option are early exercisable, subject to a right of repurchase that lapses as the shares vest. All the shares subject to this option vest in 48 equal monthly installments following the
vesting commencement date, in each case, subject to Mr.&nbsp;Bartram&#146;s continuous service relationship with the Company through each applicable vesting date. As of December&nbsp;31, 2023, 6,601 shares of common stock underlying this option had
vested, with an unvested balance of 72,608 shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares subject to this stock option are early exercisable, subject to a right of repurchase that lapses as the shares vest. 25% of the shares subject to the stock option vested on the first anniversary following the
vesting commencement date, and the remaining 75% of the shares subject to the stock option vest in 36 equal monthly installments thereafter, subject to Mr.&nbsp;Bartram&#146;s continuous service relationship with the Company through each applicable
vesting date. As of December&nbsp;31, 2023, 14,302 shares of common stock underlying this option had vested, with an unvested balance of 38,504 shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares subject to this stock option are early exercisable, subject to a right of repurchase that lapses as the shares vest. 25% of the shares subject to the stock option vested on the first anniversary following the
vesting commencement date, and the remaining 75% of the shares subject to the stock option vest in 36 equal monthly installments thereafter, subject to Mr.&nbsp;Bartram&#146;s continuous service relationship with the Company through each applicable
vesting date. As of December&nbsp;31, 2023, 38,991 shares of common stock underlying this option had vested, with an unvested balance of 54,586 shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive compensation arrangements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into executive employment agreements with each of our named executive officers. Each employment agreement provides for
<FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employment and the compensation and benefits described below. In connection with this offering, we intend to enter into a new employment agreement with our named executive officers that
will be effective as of the closing of this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Employment arrangements in place prior to the offering for named executive officers </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Peter Kent Hawryluk </I></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On July&nbsp;8, 2020, we entered into an executive
employment agreement with Mr.&nbsp;Hawryluk, or the Hawryluk Employment Agreement, for the position of President and Chief Executive Officer. The Hawryluk Employment Agreement provides for Mr.&nbsp;Hawryluk&#146;s
<FONT STYLE="white-space:nowrap">at-will</FONT> employment. Prior to the closing of our initial public offering, Mr.&nbsp;Hawryluk&#146;s annual base salary was $460,000, and he was eligible to receive an annual discretionary bonus with an annual
target amount of 40% of his annual base salary. Mr.&nbsp;Hawryluk is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a termination of Mr.&nbsp;Hawryluk&#146;s employment by us without Cause (other than due to death or in connection with a bankruptcy, assignment for the benefit of
creditors or winding up of the Company) or by Mr.&nbsp;Hawryluk for Good Reason, each, as such terms are defined in the Hawryluk Employment Agreement and collectively, a Qualifying Termination, at any time, subject to (i)&nbsp;signing a general
release of claims in favor of the Company and (ii)&nbsp;not breaching any of the post-employment covenants and contractual obligations to the Company, collectively, the Severance Conditions, Mr.&nbsp;Hawryluk shall be entitled to receive
(A)&nbsp;continued payment of his then-current base salary for a period of twelve (12)&nbsp;months following termination, (B)&nbsp;accelerated vesting of the unvested portion of any outstanding time-based equity award in an amount equal to the
amount that would have vested had Mr.&nbsp;Hawryluk remained employed with us through the twelve (12)&nbsp;month anniversary following the date of termination, and (C)&nbsp;if Mr.&nbsp;Hawryluk was participating in the Company&#146;s group health
plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to Mr.&nbsp;Hawryluk had
Mr.&nbsp;Hawryluk remained employed by us, or the Hawryluk COBRA Premium, until the earliest of (a)&nbsp;the twelve (12)&nbsp;month anniversary following the date of termination; (b)&nbsp;Mr.&nbsp;Hawryluk&#146;s eligibility for group health plan
benefits under any other employer&#146;s group health plan; or (c)&nbsp;the cessation of Mr.&nbsp;Hawryluk&#146;s continuation rights under COBRA; provided, however, if the Company determines that the Hawryluk COBRA Premium would result in a
violation of applicable law, then the Hawryluk COBRA Premium shall be converted into a taxable cash payment and will be paid on a monthly basis to Mr.&nbsp;Hawryluk during the same period set forth in (a)-(b), provided that such cash payment will be
grossed up by the Company in an amount that results in Mr.&nbsp;Hawryluk receiving, after reductions for tax withholdings, the full Hawryluk COBRA Premium for such period before any reductions for tax withholding. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Hawryluk Employment Agreement also provides that, upon a sale event (as defined in the 2019 Plan), provided Mr.&nbsp;Hawryluk remains employed by the Company as of
the closing date of the sale event, 100% of all outstanding equity awards held by Mr.&nbsp;Hawryluk will be fully accelerated and vested on such date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Hawryluk
Employment Agreement further provides that, in the event the amount of any compensation by the Company to or for the benefit of Mr.&nbsp;Hawryluk under the Hawryluk Employment Agreement would be subject to the excise tax imposed by Section&nbsp;4999
of the Code, then such compensation shall be reduced (but not below zero) so that the sum of the compensation shall be $1.00 less than the amount at which the NEO becomes subject to the excise tax imposed under Section&nbsp;4999 of the Code;
provided that such reduction shall only occur if such reduction would result in a higher net <FONT STYLE="white-space:nowrap">after-tax</FONT> benefit to Mr.&nbsp;Hawryluk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Mr.&nbsp;Hawryluk has entered into an Employee Confidentiality, Assignment, and Noncompetition Agreement that contains
various restrictive covenants, including confidentiality and nonsolicitation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Richard Bartram </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On March&nbsp;16, 2022, we entered into an executive employment agreement with Mr.&nbsp;Bartram, or the Bartram Employment Agreement, for the position of Chief Financial
Officer. The Bartram Employment Agreement provides for Mr.&nbsp;Bartram&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment. Mr.&nbsp;Bartram&#146;s current annual base salary is $442,000, and he is eligible to receive an annual
discretionary bonus with an annual target amount of 40% of his current annual base salary. Mr.&nbsp;Bartram is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a Qualifying Termination (which, in the case of Mr.&nbsp;Bartram, shall not include a termination due to disability) not in connection with a sale event, and
subject to the Severance Conditions, Mr.&nbsp;Bartram shall be entitled to receive the following severance benefits, collectively, the Bartram Severance Benefits: (A) continued payment of his then-current base salary for a period of twelve
(12)&nbsp;months following termination, (B)&nbsp;accelerated vesting of the unvested portion of any outstanding time-based equity award in an amount equal to the amount that would have vested had Mr.&nbsp;Bartram remained employed with us through
the twelve (12)&nbsp;month anniversary following the date of termination, and (C)&nbsp;if Mr.&nbsp;Bartram was participating in the Company&#146;s group health plan immediately prior to the termination date and timely elects continuation coverage
under COBRA, a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to Mr.&nbsp;Bartram had Mr.&nbsp;Bartram remained employed by us, or the Bartram COBRA Premium, until the earliest
of (i)&nbsp;the twelve (12)&nbsp;month anniversary following the date of termination; (ii)&nbsp;Mr.&nbsp;Bartram&#146;s eligibility for group health plan benefits under any other employer&#146;s group health plan; or (iii)&nbsp;the cessation of
Mr.&nbsp;Bartram&#146;s continuation rights under COBRA; provided, however, if the Company determines that the Bartram COBRA Premium would result in a violation of applicable law, then the Bartram COBRA Premium shall be converted into a taxable cash
payment and will be paid on a monthly basis to Mr.&nbsp;Bartram during the same period set forth in (i)-(ii), provided that such cash payment will be grossed up by the Company in an amount that results in Mr.&nbsp;Bartram receiving, after reductions
for tax withholdings, the full Bartram COBRA Premium for such period before any reductions for tax withholding. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the Bartram Severance Benefits, upon
a Qualifying Termination (which, in the case of Mr.&nbsp;Bartram, shall not include a termination due to disability) on, or within six (6)&nbsp;months following, a sale event, subject to the Severance Conditions, Mr.&nbsp;Bartram shall be entitled
to receive a payment equal to 100% of the annual performance bonus for the year in which the termination occurs, payable in twelve (12)&nbsp;monthly installments following the date of termination. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary set forth above, the Bartram Employment Agreement also provides that, upon a sale event, provided Mr.&nbsp;Bartram remains
employed by the Company as of the closing date of the sale event, 100% of all outstanding equity awards held by Mr.&nbsp;Bartram will be fully accelerated and vested on such date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Bartram Employment Agreement further provides that, in the event the amount of any compensation by the Company to or for the benefit of Mr.&nbsp;Bartram under the
Bartram Employment Agreement would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then such compensation shall be reduced (but not below zero) so that the sum of the compensation shall be $1.00 less than the amount at which
the NEO becomes subject to the excise tax imposed under Section&nbsp;4999 of the Code; provided that such reduction shall only occur if such reduction would result in a higher net <FONT STYLE="white-space:nowrap">after-tax</FONT> benefit to
Mr.&nbsp;Bartram. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Mr.&nbsp;Bartram has entered into an Employee Confidentiality, Assignment, and Noncompetition Agreement that contains various restrictive
covenants, including confidentiality and nonsolicitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Employment Arrangements in Place as of the Offering For Named Executive Officers </I></B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective as of the closing of our initial public offering, each of our named executive officers
entered into an employment agreement with the Company, or an Executive Agreement. The Executive Agreements provide for each named executive officer&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment and set forth, among other things,
the applicable named executive officer&#146;s annual base salary and annual target cash bonus. Pursuant to his Executive Agreement, Mr.&nbsp;Hawryluk&#146;s base salary was increased to $540,000, and he is eligible to receive an annual discretionary
bonus with an annual target amount of 50% of his base salary. Mr.&nbsp;Bartram&#146;s base salary and annual target cash bonus under his Executive Agreement are as described above. In addition, each named executive officer is&nbsp;eligible to
participate in the benefit plans and programs of the Company, subject to the terms of such plans. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each of the named executive officers will also be eligible to
receive severance payments and benefits in connection with a termination without &#147;cause&#148; or for &#147;good reason&#148;. In connection with such a termination, a named executive officer would be eligible to receive the following payments
and benefits subject to the name executive officer&#146;s execution of a release and subject to not breaching any of the named executive officer&#146;s post-employment contractual obligations to the Company: (i)&nbsp;continued payment of the named
executive officer&#146;s then-current base salary for a period of twelve (12)&nbsp;months following termination, (ii)&nbsp;if the named executive officer was participating in the Company&#146;s group health plan immediately prior to the termination
date and timely elects continuation coverage under COBRA, company-paid COBRA premiums for the named executive officer and such named executive officer&#146;s eligible dependents for a period of 12 months following termination, and
(iii)&nbsp;accelerated vesting of the unvested portion of any outstanding time-based equity award in an amount equal to the amount that would have vested had the named executive officer remained employed with us through the twelve (12)&nbsp;month
anniversary following the date of termination. Each of the named executive officers will also be eligible to receive enhanced severance payments and benefits (in lieu of the payments and benefits described in the immediately preceding sentence) if
such a qualifying termination of employment occurs within three months prior to or 12 months following a sale event. In connection with such a termination, a named executive officer would be eligible to receive the following payments and benefits
subject to the named executive officer&#146;s execution of a release and subject to not breaching any of the named executive officer&#146;s post-employment contractual obligations to the Company: (i)&nbsp;a lump sum payment equal to 1.5 (or 1.25 in
the case of Mr.&nbsp;Bartram) multiplied by the sum of the named executive officer&#146;s (A)&nbsp;then-current base salary, plus (B)&nbsp;the target bonus for the year of termination at target level, (ii)&nbsp;if the named executive officer was
participating in the Company&#146;s group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, company-paid COBRA premiums for the named executive officer and the named executive officer&#146;s
eligible dependents for a period of 18 months (or 15 months in the case of Mr.&nbsp;Bartram) following termination, and (iii) 100% of all unvested and outstanding time-based equity awards shall accelerate and become fully vested and exercisable or
nonforfeitable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary set forth above, the Executive Agreements also provide that, upon a sale event, provided the named
executive officer remains employed by the Company as of the closing date of the sale event, 100% of all equity awards held by the named executive officer immediately prior to the closing of our initial public offering (other than any awards granted
in connection with this offering under the 2024 Plan (as defined below)) will be fully accelerated and vested no later than the date of the sale event. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Executive Agreements further provide that, in the event the amount of any compensation by the Company to or for the benefit of the named executive officers under the Executive Agreements would be subject to the excise tax imposed by
Section&nbsp;4999 of the Code, then such compensation shall be reduced (but not below zero) so that the sum of the compensation shall be $1.00 less than the amount at which the named executive officer becomes subject to the excise tax imposed under
Section&nbsp;4999 of the Code; provided that such reduction shall only occur if such reduction would result in a higher net <FONT STYLE="white-space:nowrap">after-tax</FONT> benefit to the named executive officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employee benefit and equity compensation plans </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019 Stock option and grant plan </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2019 Plan was adopted by our
board of directors and approved by our stockholders on April&nbsp;9, 2019. The 2019 Plan will continue to govern outstanding equity awards granted thereunder. As of June&nbsp;30, 2024, options to purchase 2,864,410 shares of our common stock at a
weighted-average exercise price of $6.68 per share and 253,615 shares of our common stock remained available for future issuance under the 2019 Plan. On August 2, 2024, our board of directors authorized the increase of the number of shares that may
be issued under the 2019 Plan to 4,476,790 shares. Following this offering, we will not grant any further awards under our 2019 Plan, but all outstanding awards under the 2019 Plan will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock underlying any awards under the 2019 Plan that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the
issuance of stock or otherwise terminated (other than by exercise) and shares withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, are currently added back to the shares of common stock
available for issuance under the 2019 Plan. Following this offering, such shares will be added to the shares of common stock available for issuance under the 2024 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors and our compensation committee have acted as administrators of the 2019 Plan. The administrator has the full power to select, from among the
individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to determine the time or times of grant, and the amount, any award, to accelerate at any time the exercisability or
vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2019 Plan. Persons eligible to participate in the 2019 Plan are officers, employees,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, consultants and key persons as selected from time to time by the administrator in its discretion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2019 Plan permits the granting of nonqualified stock options and options intended to qualify as incentive stock options under Section&nbsp;422 of the Code. The per
share exercise price of each option is determined by our board of directors but may not be less than 100% of the fair market value of the common stock on the date of grant. The term of each option is fixed by the administrator but may not exceed 10
years from the date of grant. The administrator determines at what time or times each option may be exercised. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the 2019 Plan permits the granting of
restricted shares of common stock, unrestricted stock awards and restricted stock units. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2019 Plan provides that in the case of and subject to the consummation
of a sale event, the 2019 Plan and all outstanding stock options issued thereunder shall terminate upon the effective time of any such sale event unless assumed, substituted, or continued by the successor entity. In the event of a termination of the
2019 Plan and all stock options issued thereunder, each holder of stock options shall be permitted, within a period of time prior to the consummation of the sale event, to exercise all such stock options which are then exercisable or will become
exercisable as of the effective time of the sale event. In addition, the administrator may provide for a cash payment to the holders of stock options for each stock option award canceled in the sale event. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to restricted stock awards or restricted stock units, in the case of and subject to the consummation of a sale event, all such awards shall be forfeited
immediately prior to the effective time of the sale event unless assumed, substituted, or continued by the successor entity. In the event of a forfeiture of restricted stock awards, all such awards shall be repurchased from the holder at a price per
share equal to the original purchase price paid by the holder. Notwithstanding anything to the contrary, the Company may provide for a cash payment to the holders of restricted stock or restricted stock units, without the consent of such holders, in
exchange for the cancellation of such awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the occurrence of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse
stock split or other similar change in common stock, the administrator will equitably adjust the outstanding awards, which may include adjustments to the number and type of securities subject to such outstanding award and/or the exercise price or
grant price, thereof. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise determined by the administrator, awards may generally not be sold, assigned, transferred, pledged or otherwise encumbered by
the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The board of directors may
amend, suspend or terminate the 2019 Plan at any time, subject to stockholder approval where such approval is required by applicable law. The administrator of the 2019 Plan may also amend, modify or cancel any outstanding award, provided that no
amendment to an award may materially and adversely affect a participant&#146;s rights without his or her consent. In addition, the administrator may exercise its discretion to reduce the exercise price of outstanding stock options or effect
repricing through cancellation of outstanding stock options and by granting such holders new awards in replacement of the cancelled Stock Options. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No awards may be
granted under the 2019 Plan upon the earlier of 10 years from the date on which the 2019 Plan was initially adopted by our board of directors or 10 years from the date the 2019 Plan was initially approved by our stockholders. Our board of directors
has determined not to make any further awards under the 2019 Plan following the closing of this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2024 Stock option and incentive plan </I></B></P>
 <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2024 Plan was adopted by our board of directors on August&nbsp;26, 2024, approved by our stockholders on August&nbsp;30, 2024 and will become effective upon the
date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The 2024 Plan will replace the 2019 Plan as our board of directors has determined not to make additional
awards under the 2019 Plan following the closing of our initial public offering. However, the 2019 Plan will continue to govern outstanding equity awards granted thereunder. The 2024 Plan allows us to make equity-based and cash-based incentive
awards to our officers, employees, directors and consultants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have initially reserved 3,065,000 shares of our common stock for the issuance of awards under the
2024 Plan, or the Initial Limit. The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January&nbsp;1, 2025 and each January&nbsp;1 thereafter, by five percent of the
sum of the outstanding number of shares of our common stock and the numbers of shares of common stock issuable pursuant to the exercise of any outstanding pre-funded warrants to acquire common stock for a nominal exercise price on the immediately
preceding December&nbsp;31 or such lesser number of shares as determined by our compensation committee, or the Annual Increase. The number of shares reserved under the 2024 Plan is subject to adjustment in the event of a stock split, stock dividend
or other change in our capitalization. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares we issue under the 2024 Plan will be authorized but unissued shares or shares that we reacquire. The shares
of common stock underlying any awards under the 2024 Plan and the 2019 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting,
satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2024 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The maximum number of shares of common stock that may be issued in the form of incentive stock options shall not exceed the Initial Limit, cumulatively increased on
January&nbsp;1, 2025 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 3,065,000 shares of common stock. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The grant
date fair value of all awards made under our 2024 Plan and all other cash compensation paid by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director shall not exceed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
$750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected
or appointed to the board of directors. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024 Plan will be administered by our compensation committee. Our compensation committee has the full power to
select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the exercisability
or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2024 Plan. Persons eligible to participate in the 2024 Plan will be those full or part-time officers, employees, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024
Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be determined by
our compensation committee but generally may not be less than 100&nbsp;percent of the fair market value of our common stock on the date of grant unless the option (i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent
with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax or (iii)&nbsp;complies with Section&nbsp;409A of the Code. The term of each option will be fixed by our compensation committee and may
not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee
may award stock appreciation rights under the 2024 Plan subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in
our stock price over the exercise price. The exercise price of each stock appreciation right will be determined by our compensation committee but generally may not be less than 100&nbsp;percent of the fair market value of our common stock on the
date of grant unless the stock appreciation right (i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income
tax or (iii)&nbsp;complies with Section&nbsp;409A of the Code. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at
what time or times each stock appreciation right may be exercised. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may award restricted shares of common stock and restricted stock units
to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. Our
compensation committee may also grant shares of common stock that are free from any restrictions under the 2024 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be
issued in lieu of cash compensation due to such participant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may grant dividend equivalent rights to participants that entitle the
recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may
grant cash bonuses under the 2024 Plan to participants, subject to the achievement of certain performance goals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024 Plan provides that upon the effectiveness
of a &#147;sale event,&#148; as defined in the 2024 Plan, an acquirer or successor entity may assume, continue or substitute outstanding awards under the 2024 Plan. To the extent that awards granted under the 2024 Plan are not assumed or continued
or substituted by the successor entity, upon the effective time of the sale event, such awards shall terminate. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise such
options and stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind, to participants
holding vested and exercisable options and stock appreciation rights equal&nbsp;(A) the difference between the per share cash consideration payable to stockholders in the sale event and the per share exercise price of the options or stock
appreciation rights, multiplied by (B)&nbsp;the number of shares subject to such outstanding vested and exercisable options and stock appreciation rights (to the extent exercisable at prices not in excess of the per share cash consideration), and we
may make or provide for a payment, in cash or in kind, to participants holding other vested awards equal to the per share cash consideration multiplied by the number of vested shares underlying such awards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may amend or discontinue the 2024 Plan and our compensation committee may amend or cancel outstanding awards for purposes of satisfying changes in
law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2024 Plan require the approval of our stockholders. The administrator of the 2024 Plan is
specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation and
<FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. No awards may be granted under the 2024 Plan after the date that is 10 years from the effective date of the 2024 Plan. No awards under the 2024 Plan have been made prior
to the date of this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2024 Employee stock purchase plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ESPP was adopted by our board of directors on August&nbsp;26, 2024, approved by our stockholders on August&nbsp;30, 2024 and will become effective on the date
immediately preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of
Section&nbsp;423 of the Code. The ESPP initially reserves and authorizes the issuance of up to a total of 289,436 shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance
will automatically increase on January&nbsp;1, 2025 and each January&nbsp;1 thereafter through January&nbsp;1, 2034, by the least of (i)&nbsp;578,872 shares of common stock, (ii)&nbsp;one percent of the outstanding number of shares of common stock
on the immediately preceding December&nbsp;31, or (iii)&nbsp;such lesser number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock
split, stock dividend or other change in our capitalization. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All employees employed by us or any designated subsidiary as of the first day of an offering are
eligible to participate; provided that the administrator of the ESPP may determine that employees must satisfy one or more of the following service requirements before participating in the ESPP: (1)&nbsp;customary employment with us for more than 20
hours per week and 5 or more months per calendar year, (2)&nbsp;continuous employment with us for a minimum period of time, not to exceed two years, prior to the first date of an offering or (3)&nbsp;such other criteria as the administrator of the
ESPP may determine consistent with the requirements of section 423 of the Code.&nbsp;However, any employee who owns&nbsp;5&nbsp;percent or more of the total combined voting power or value of all classes of our stock will not be eligible to purchase
shares of common stock under the ESPP. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may make one or more offerings each year to our employees to purchase shares under the ESPP, consisting of one or more
purchase periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least&nbsp;15&nbsp;business days before the applicable offering date </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up to 15 percent of his or her eligible
compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the last business day of the
offering period at a price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
equal to&nbsp;85&nbsp;percent of the fair market value of the shares of our common stock on the first business day of the offering period or the last business day of the purchase period,
whichever is lower, provided that no more than a number of shares of common stock determined by dividing $25,000 by the fair market value of our common stock on the offering date of the offering (or such other number as established by the
administrator in advance of the offering period) may be purchased by any one employee during each offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of our common stock, valued at the start of
the purchase period, under the ESPP in any calendar year. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering
period will be refunded. An employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of our common stock authorized under the
ESPP and certain other amendments require the approval of our stockholders. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Senior executive cash incentive bonus plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26, 2024 our board of directors adopted the Senior Executive Cash Incentive Bonus Plan, or the Bonus Plan. The Bonus Plan provides for annual cash bonus
payments based upon the attainment of Company and individual performance targets established by our compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our Company, or the
Corporate Performance Goals, as well as individual performance objectives. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may select Corporate Performance Goals from among the
following: research, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> <FONT STYLE="white-space:nowrap">non-clinical,</FONT> developmental, publication, clinical or regulatory milestones; scientific or technological advances; R&amp;D
capabilities; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation, and amortization; net income (loss) (either before or after interest, taxes,
depreciation, and/or amortization); changes in the market price of our common stock; economic value-added; acquisitions or strategic transactions, including collaborations, joint ventures, or promotion arrangements; operating income (loss); return
on capital assets, equity, or investment; stockholder returns; sales; net sales; return on sales; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss)
per share of our common stock; bookings, new bookings, or renewals; sales or market shares; number of customers, number of new customers, or customer references; operating income and/or net annual recurring revenue; or any other performance goal as
selected by the compensation committee, any of which may be measured in absolute terms, as compared to any incremental increase, in terms of growth, as compared to results of a peer group, against the market as a whole, compared to applicable market
indices, and/or measured on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each executive officer who
is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The
Corporate Performance Goals will be measured at the end of each performance period after our financial reports have been published or such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and
individual performance objectives are met, payments will be made as soon as practicable following the end of each performance period, but no later than 74 days after the end of the fiscal year in which such performance period ends. Subject to the
rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the bonus payment date to be eligible to receive a bonus payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its sole discretion. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Equity Grants in Connection with this Offering </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with
this offering, our board of directors has approved the grant of options for the purchase of an aggregate of 487,225 shares of common stock to our non-employee directors and certain employees, including certain of our executive officers, based on the
number of shares outstanding following this offering, which will be equal to $7.3 million based on an assumed initial public offering price of $15.00, which is the midpoint of the price range set forth on the cover page of this prospectus. The
effectiveness of this grant of stock options is contingent on, and effective immediately following, the effectiveness of the registration statement of which this prospectus forms a part. The stock options will have a per share exercise price equal
to initial public offering price set forth on the cover page of the final prospectus included in the registration statement, which will be the fair market value of a share of our common stock on the grant date of the stock options. The stock options
will be granted under and subject to the terms and conditions of the 2024 Plan, and the applicable stock option agreements thereunder. The stock options will vest and become exercisable as follows: 25% of the shares subject to the stock option
vested on the one-year anniversary of the vesting commencement date, and the remaining 75% of the shares subject to the stock option vest on a monthly basis thereafter, in each case, subject to the individual&#146;s continuous service relationship
with us through each applicable vesting date. Our board of directors has approved such option grants for Messrs. Hawryluk and Bartram to purchase 120,436 and 42,578 shares of our common stock, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Director compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2023 director compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents the total
compensation paid by the Company to <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors during the fiscal year ended December&nbsp;31, 2023. We did not pay any compensation or issue any equity awards or <FONT
STYLE="white-space:nowrap">non-equity</FONT> awards to any of the members of our board of directors in 2023 for their services as members of the board of directors. In addition, Mr.&nbsp;Hawryluk, our President and Chief Executive Officer, does not
receive any compensation from the Company for his service on our board of directors. See the section titled &#147;Executive compensation&#148;, above, for more information on the compensation paid to or earned by Mr.&nbsp;Hawryluk as an employee for
year ended December&nbsp;31, 2023. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name (1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>Awards($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tiba Aynechi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James M. Cornelius (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard DiMarchi (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Carl L. Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Edward T. Mathers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ora Pescovitz (4)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No grants of equity awards or any other compensation were made to any directors in 2023. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, Mr.&nbsp;Cornelius held outstanding options to purchase an aggregate of 16,636 shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, Mr.&nbsp;DiMarchi held (i)&nbsp;outstanding options to purchase 141,976 shares of our common stock, and (ii) 9,648 shares of restricted stock. Effective January&nbsp;1, 2023, we entered
into a consulting agreement with Mr.&nbsp;DiMarchi, or the DiMarchi Consulting Agreement, pursuant to which Mr.&nbsp;DiMarchi is entitled to continue to vest in the outstanding equity awards held by him as of January&nbsp;1, 2023, subject to the
terms and conditions of the existing equity award agreements (including the condition the Mr.&nbsp;DiMarchi continues to be in a service relationship with us on each vesting date). In addition, the DiMarchi Consulting Agreement provides that, upon
the achievement of specified milestones, subject to and contingent upon approval by our board of directors, Mr.&nbsp;DiMarchi will be granted an option to purchase 74,862 shares of our common stock. The DiMarchi Consulting Agreement was subsequently
amended on January&nbsp;17, 2024 to provide that such milestones were successfully achieved, and on January&nbsp;31, 2024 our board of directors approved an option to Mr.&nbsp;DiMarchi to purchase 74,862 shares of our common stock, which was fully
vested as of the grant date. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, Ms.&nbsp;Pescovitz held 4,852 shares of restricted stock. </TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we have
reimbursed and will continue to reimburse all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred
in attending board of directors and committee meetings. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> director compensation policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we adopted a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that will become effective as of the
completion of this offering and will be designed to enable us to attract and retain, on a long term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the policy, <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors</FONT> will be eligible to receive cash retainers (which will be payable
quarterly in arrears and prorated for partial years of service) and equity awards as set forth below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Annual Retainer for Board Membership</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$ 40,000 for general availability and participation in meetings and conference calls of our Board of
Directors</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional Annual Retainer for Committee Membership</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Audit Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Audit Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nominating and Corporate Governance Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nominating and Corporate Governance Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Science&nbsp;&amp; Technology Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Science&nbsp;&amp; Technology Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional Annual Retainer for Non-Executive Chairperson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional Annual Retainer for Lead Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our policy will provide that, upon initial election or appointment to our board of directors, each <FONT
STYLE="white-space:nowrap">new&nbsp;non-employee&nbsp;director</FONT> will be granted <FONT STYLE="white-space:nowrap">a&nbsp;one-time&nbsp;grant</FONT> of <FONT STYLE="white-space:nowrap">a&nbsp;non-statutory&nbsp;stock</FONT> option to purchase
32,000 shares of common stock on the date of such director&#146;s election or appointment to the board of directors, or the Director Initial Grant. The Director Initial Grant will vest over three years, with 1/3 of the Director Initial Grant vesting
upon the first anniversary of the vesting commencement date and the remaining 2/3 of the Director Initial Grant vesting in 24 monthly installments thereafter, subject to
<FONT STYLE="white-space:nowrap">the&nbsp;non-employee&nbsp;director&#146;s</FONT> continued services to the us. On the date of each annual meeting of stockholders of our company following the completion of this offering, <FONT
STYLE="white-space:nowrap">each&nbsp;non-employee&nbsp;director</FONT> who will continue as <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> following such meeting will be granted an annual award of <FONT
STYLE="white-space:nowrap">a&nbsp;non-statutory&nbsp;stock</FONT> option to purchase 16,000 shares of common stock. The Director Annual Grant will vest in full on the earlier of
<FONT STYLE="white-space:nowrap">the&nbsp;one-year&nbsp;anniversary</FONT> of the grant date or on the date of our next annual meeting of stockholders, subject to <FONT STYLE="white-space:nowrap">the&nbsp;non-employee&nbsp;director&#146;s</FONT>
continued services to the us. If a <FONT STYLE="white-space:nowrap">new&nbsp;non-employee&nbsp;director</FONT> joins our Board on a date other than the date of the Company&#146;s annual meeting of stockholders, then
<FONT STYLE="white-space:nowrap">such&nbsp;non-employee&nbsp;director</FONT> will be granted <FONT STYLE="white-space:nowrap">a&nbsp;pro-rata&nbsp;portion</FONT> of the Director Annual Grant based on the time between
<FONT STYLE="white-space:nowrap">such&nbsp;non-employee&nbsp;director&#146;s</FONT> appointment and such next annual meeting of stockholders on the first eligible grant date following such <FONT STYLE="white-space:nowrap">non-employee</FONT>
director&#146;s appointment to our board of directors. Such awards are subject to full acceleration vesting upon the sale of our company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate amount of
compensation, including both equity compensation and cash compensation, paid to <FONT STYLE="white-space:nowrap">any&nbsp;non-employee&nbsp;director</FONT> for service as <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> in a
calendar year period will not exceed $1,000,000 in the first calendar year such individual becomes <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> and $750,000 in any other calendar year. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will reimburse all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reasonable&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> incurred by directors
for their attendance at meetings of our board of directors or any committee thereof. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Employee directors will receive no additional compensation for their service as
a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_14"></A>Certain relationships and related person transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a description of transactions or series of transactions since January&nbsp;1, 2021, to which we were or will be a party, in which: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the amount involved in the transaction exceeds, or will exceed, the lesser of (i) $120,000 or (ii)&nbsp;one percent of the
average of our total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in which any of our executive officers, directors or holder of five percent or more of any class of our capital stock,
including their immediate family members or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Compensation
arrangements for our named executive officers and our directors are described elsewhere in this prospectus under &#147;Executive compensation&#148; and &#147;Director compensation.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series A convertible preferred stock milestone financing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2021,
we issued an aggregate of 16,011,641 shares of our Series A convertible preferred stock in connection with the achievement of a certain development milestone for gross proceeds of $11.0 million. The following table summarizes purchases of our Series
A convertible preferred stock by related persons: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;A<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;purchase&nbsp;and/or<BR>conversion price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences X, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,307,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$4,333,332.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James Cornelius (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8201;&#8202;499,999.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard DiMarchi (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8201;&#8202;237,499.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New Enterprise Associates 17, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,124,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2,833,332.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VII, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,124,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2,833,332.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk(6)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">345,705</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8196;&#8199;237,499.34</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frazier is a holder of five percent or more of our capital stock. Mr. Heron is a Managing Partner of Frazier and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Cornelius is a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr. DiMarchi was a former member of our board of directors until January 2024. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with NEA are holders of five percent or more of our capital stock. Mr. Mathers is a General Partner of NEA and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">OrbiMed Private Investments VII, LP, or OrbiMed, is a holder of five percent or more of our capital stock. Dr. Gordon is founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed and a member of
our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr. Hawryluk is our President and Chief Executive Officer and a member of our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Convertible
promissory notes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, we entered into certain convertible promissory notes with certain shareholders, or the 2022 Notes. In connection with the
Series B convertible preferred stock financing, the 2022 Notes were converted into 12,573,381 shares of Series B convertible preferred stock. The following table summarizes purchases of the original 2022 Notes by related persons: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Stockholder</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Original&nbsp;Note&nbsp;Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences X, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3,552,606.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James Cornelius (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8201;&#8202;185,465.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard DiMarchi (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8201;&#8202;440,300.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New Enterprise Associates 17, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2,322,857.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VII, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2,322,857.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk(6)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8199;&#8201;&#8202;440,568.70</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frazier is a holder of five percent or more of our capital stock. Mr.&nbsp;Heron is a Managing Partner of Frazier and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Cornelius is a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Richard DiMarchi was a former member of our board of directors until January 2024. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with NEA are holders of five percent or more of our capital stock. Mr.&nbsp;Mathers is a General Partner of NEA and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">OrbiMed is a holder of five percent or more of our capital stock. Dr.&nbsp;Gordon is founding member, Managing Partner, and <FONT STYLE="white-space:nowrap">Co-Head</FONT> of Global Private Equity at OrbiMed and a
member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hawryluk is our President and Chief Executive Officer and a member of our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series B
convertible preferred stock financing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2022 and August 2023, we issued an aggregate of 129,240,032 shares of our Series B convertible preferred stock
as follows: (a) 40,545,552 shares of Series B convertible preferred stock sold at a purchase price of $0.90 per share at the initial closing for gross proceeds of $36.5&nbsp;million, (b) 12,573,381 shares of Series B convertible preferred stock
which were converted pursuant to the conversion of the 2022 Notes and (c) 76,121,099 shares of Series B convertible preferred stock sold at a purchase price of $0.90 per share pursuant to the achievement of certain development milestones for gross
proceeds of $68.5&nbsp;million. The following table summarizes purchases of our Series B convertible preferred stock by related persons: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;purchase&nbsp;and/or<BR>conversion price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences X, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,297,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$25,065,524.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James Cornelius (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8199;&#8201;&#8202;188,886.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard DiMarchi (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">553,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8199;&#8201;&#8202;448,421.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New Enterprise Associates 17, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,142,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$22,365,700.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Norwest Venture Partners XVI, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$14,999,999.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VII, LP(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,587,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$17,365,700.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,396,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;1,207,230.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliates with RA Capital (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$14,999,999.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Wellington Biomedical Innovation Master Investors (Cayman) II
L.P.(9)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$14,999,999.40</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frazier is a holder of five percent or more of our capital stock. Mr.&nbsp;Heron is a Managing Partner of Frazier and a member of our board of directors. 4,466,829 shares were issued pursuant to conversion of a
convertible note in the amount of $3,618,132.07 of principal and interest then outstanding. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Cornelius is a member of our board of directors. All shares were issued pursuant to conversion of a convertible note in the amount of $188,886.33 of principal and interest then outstanding. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;DiMarchi was a former member of our board of directors until January 2024. All of the shares were issued pursuant to conversion of a convertible note. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with NEA are holders of five percent or more of our capital stock. Mr.&nbsp;Mathers is a General Partner of NEA and a member of our board of directors. 2,920,619 shares were issued pursuant to
conversion of a convertible note in the amount of $2,365,701.74 of principal and interest then outstanding. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Norwest Venture Partners XVI, LP, or Norwest, is a holder of five percent or more of our capital stock. Dr.&nbsp;Aynechi is a General Partner at Norwest and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">OrbiMed is a holder of five percent or more of our capital stock. Dr.&nbsp;Gordon is founding member, Managing Partner, and <FONT STYLE="white-space:nowrap">Co-Head</FONT> of Global Private Equity at OrbiMed and a
member of our board of directors. 2,920,619 shares were issued pursuant to conversion of a convertible note in the amount of $2,365,701.73 of principal and interest then outstanding. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hawryluk is our President and Chief Executive Officer and a member of our board of directors. 553,944 shares were issued pursuant to conversion of a convertible note in the amount of $448,694.74 of principal
and interest then outstanding. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliates with RA Capital, or RA Capital, are holders of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Wellington Biomedical Innovation Master Investors (Cayman) II L.P., or Wellington, is a holder of five percent or more of our capital stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series C convertible preferred stock financing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2024, we issued an aggregate of 61,650,480 shares of our Series C convertible preferred stock at a purchase price of $1.03 for gross proceeds of $63.5 million.
The following table summarizes purchases of our Series C convertible preferred stock by related persons: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;C<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;purchase<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences Public Fund, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,497,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,721,999.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences Public Overage Fund, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,211,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,277,999.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Genesis Master Fund, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,854,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,999,999.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk Revocable Trust dated January 25, 2011(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">970,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">999,999.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Wellington Biomedical Innovation Master Investors (Cayman) II
L.P.(4)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,854,368</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,999,999.04</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frazier is a holder of five percent or more of our capital stock. Mr. Heron is a Managing Partner of Frazier and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">OrbiMed is a holder of five percent or more of our capital stock. Dr. Gordon is founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed and a member of our board of directors.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr. Hawryluk is our President and Chief Executive Officer and a member of our board of directors. He is also a holder of five percent or more of our capital stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Wellington Biomedical Innovation Master Investors (Cayman) II L.P., or Wellington, is a holder of five percent or more of our capital stock. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Agreements with stockholders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with our Series A, Series B and
Series C convertible preferred stock financings, we entered into investors&#146; rights, voting and right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights, information rights, voting
rights and rights of first refusal, among other things, with certain holders of our preferred stock and certain holders of our common stock. These agreements will terminate upon the closing of this offering, except for the registration rights
granted under our amended and restated investors&#146; rights agreement, as more fully described in &#147;Description of capital stock&#151;Registration rights.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Management&nbsp;rights&nbsp;and side letters </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the initial
issuance and sale of our convertible preferred stock, we entered into management rights and side letters with certain purchasers of our convertible preferred stock, including holders of more than 5% of our capital stock and entities with which
certain of our directors or officers are affiliated, pursuant to which such entities were granted certain&nbsp;management&nbsp;rights, among other things, including the right to consult with and advise our management on significant business issues,
review our operating plans, examine our books and records and inspect our facilities. These management rights letters will terminate upon completion of this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Research and consulting agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2019, we entered into the IU
Research Agreement, pursuant to which we agreed to fund certain research of Dr.&nbsp;DiMarchi. The term of the agreement was originally June&nbsp;1, 2019 through May&nbsp;30, 2022 with a total contract cost of $2.8&nbsp;million, and was subsequently
extended through April&nbsp;1, 2026 and amended to increase the total contract costs by $3.3&nbsp;million. We paid $0.7&nbsp;million, $1.2&nbsp;million and $1.1&nbsp;million pursuant to this agreement during the years ended December&nbsp;31, 2023,
2022 and 2021, respectively. We paid $0.6 million pursuant to this agreement during the six months ended June 30, 2024. The IU Research Agreement also provided us an option to license the technology arising under the agreement, which option was
exercised and pursuant to which we <FONT STYLE="white-space:nowrap">in-license</FONT> technology pursuant to our IURTC License Agreement. For additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
information on our IURTC License Agreement, please see &#147;Business &#150; Indiana University Research and Technology Corporation Exclusive License Agreement.&#148; Dr.&nbsp;DiMarchi was our
former Chief Scientific Officer and a former member of our board of directors until January 2024 and currently serves as a consultant. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;1, 2023,
we entered into a consulting agreement with Dr.&nbsp;DiMarchi, or the Consulting Agreement. Pursuant to the Consulting Agreement, Dr.&nbsp;DiMarchi&#146;s outstanding equity continued to vest, and we granted him an additional 74,862 in options in
January 2024. All of Dr. DiMarchi&#146;s outstanding options were accelerated to vest on January 31, 2024. We did not pay any consulting fees during the year ended December&nbsp;31, 2023 nor during the six months ended June 30, 2024. This agreement
can be terminated by either party at any time. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stock option grants to directors and executive officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted stock options to our directors and named executive officers as more fully described in the section entitled &#147;Executive compensation.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Indemnification agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we intend to
enter into new agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement
amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s status as a member of our board of
directors to the maximum extent allowed under Delaware law. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Certain relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Timothy Knickerbocker, son-in-law of our co-founder and former director and chief scientific officer, Richard DiMarchi, served as the Company&#146;s Chief Operating
Officer from August 1, 2020 to December 31, 2022. In fiscal 2021, Mr. Knickerbocker received cash compensation of $209,615, and a cash bonus in the amount of $44,000. In fiscal 2022, Mr. Knickerbocker received cash compensation of $210,000, a cash
bonus in the amount of $60,000 and the option to purchase up to 16,636 shares of common stock under our 2019 Plan, with an aggregate grant date fair value of $34,468. As part of his Separation Agreement, Mr. Knickerbocker&#146;s 2019, 2020 and 2022
stock option grants fully accelerated. In fiscal 2023, Mr. Knickerbocker received cash compensation of $178,412 as part of his severance package. While at the Company, Mr. Knickerbocker was also eligible to participate in our employee benefit plans.
</P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Directed share program </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At our request, the underwriters have
reserved for sale, at the initial public offering price, up to approximately 425,000 shares of our common stock being offered hereby (approximately 5%) for directors, executive officers, employees and business associates. The directed share program
will not limit the ability of our directors, officers and their family members, or holders of more than 5% of our capital stock, to purchase more than $120,000 in value of our common stock. We do not currently know the extent to which these related
persons will participate in our directed share program, if at all, or the extent to which they will purchase more than $120,000 in value of our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Policies for approval of related party transactions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors
reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party. Prior to this offering, the material facts
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
as to the relationship or interest in the transaction were disclosed to our board of directors prior to their consideration of such transaction, and the transaction was not considered approved by
our board of directors unless a majority of the directors who are not interested in the transaction approved the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related
party&#146;s relationship or interest in the transaction were disclosed to the stockholders, who must approve the transaction in good faith. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with
this offering, we adopted a written related party transactions policy that will provide that such transactions must be approved by our audit committee. This policy will become effective on the date on which the registration statement of which this
prospectus forms a part is declared effective by the SEC. Pursuant to this policy, the audit committee has the primary responsibility for reviewing and approving or disapproving &#147;related party transactions,&#148; which are transactions between
us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person will be
defined as a director, executive officer, nominee for director, or greater than 5&nbsp;percent beneficial owner of our common stock, in each case since the beginning of the most recently completed year, and their immediate family members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><A NAME="toc790774_15"></A>Principal stockholders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth, as of August&nbsp;15, 2024, information regarding the beneficial ownership of our common stock by: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each person, or group of affiliated persons, who is known by us to be the beneficial owner of five percent or more of our
outstanding common stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">all of our current directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The information in the following table is calculated based on 21,646,058 shares of common stock deemed to be outstanding before this offering and 30,146,058&nbsp;shares
of common stock outstanding after this offering, assuming no exercise by the underwriters of their option to purchase additional shares of common stock. The number of shares outstanding is based on the number of shares of common stock outstanding as
of August&nbsp;15, 2024 as adjusted to give effect to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 20,336,599 shares of
common stock upon the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the sale of 8,500,000 shares of common stock in this offering (assuming no exercise of the underwriters&#146; option to
purchase additional shares). </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each individual or entity shown on the table has furnished information with respect to beneficial ownership.
Except as otherwise indicated below, the address of each officer, director and five percent stockholder listed below is c/o MBX Biosciences, Inc., 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other
purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities as well as any shares of common stock that the person has the right
to acquire within 60&nbsp;days of August&nbsp;15, 2024 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the
percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and
investment power with respect to all shares shown as beneficially owned by them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table does not reflect any shares of common stock that may be purchased pursuant to our directed share
program described under &#147;Underwriting&#151;Directed share program.&#148; If any shares are purchased by our existing principal stockholders, directors or their affiliated entities, the number and percentage of shares of our common stock
beneficially owned by them after this offering will differ from those set forth in the following table. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Shares of</B><br><B>common&nbsp;stock</B><br><B>beneficially<BR>owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage&nbsp;of&nbsp;shares<BR>beneficially&nbsp;owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name of Beneficial Owner</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Before&nbsp;offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>After<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Frazier Life Sciences(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,735,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.88%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.71%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with New Enterprise Associates(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,120,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.42%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with OrbiMed Advisors LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,062,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.15%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.16%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deep Track Biotechnology Master Fund, Ltd.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,018,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.33%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.70%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Wellington Biomedical Innovation Master Investors (Cayman) II L.P.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,790,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.27%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.94%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Norwest Venture Partners XVI, LP(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.60%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliates with RA Capital(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.60%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Directors, Named Executive Officers and Other Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,910,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.43%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.13%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.03%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tiba Aynechi, Ph.D.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.60%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James M. Cornelius(11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Carl Gordon, Ph.D.(12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,062,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.15%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.16%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Heron(13)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,735,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.88%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.71%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Edward T. Mathers(14)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,114,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.39%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.33%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ora Pescovitz, M.D.(15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Steven Ryder, M.D.(16)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">All executive officers and directors as a group
(10&nbsp;persons)(17)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">14,654,520</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">63.70%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">46.52%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;1,574,005 shares of common stock issuable upon conversion of Series A preferred stock and 2,353,769 shares of common stock issuable upon conversion of Series B preferred stock held directly by
Frazier Life Sciences X, L.P., or FLS X, (ii)&nbsp;623,608&nbsp;shares of common stock issuable upon conversion of Series C preferred stock held by Frazier Life Sciences Public Fund, L.P., or FLS Public Fund, and (ii) 183,965 shares of common stock
issuable upon conversion of Series C preferred stock held by Frazier Life Sciences Public Overage Fund, L.P., or FLS Overage Fund. FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James
Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Mr. Heron is a member of our board of directors. Dr. Topper and Mr. Heron disclaim
beneficial ownership of such securities except to the extent of their pecuniary interest therein. FHMLSP, L.P. is the general partner of FLS Public Fund and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Albert Cha, James N. Topper, Patrick
J. Heron and James Brush are the managing directors of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by FLS Public Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares
held by FLS Public Fund except to the extent of their pecuniary interests in such shares, if any. FHMLSP Overage, L.P., is the general partner of FLS Overage Fund and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Dr. Cha, Dr.
Topper, Mr. Heron and Dr. Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by FLS Overage Fund. Dr. Cha, Dr. Topper, Mr.&nbsp;Heron and Dr. Brush disclaim beneficial ownership of
the shares held by FLS Overage Fund except to the extent of their pecuniary interests in such shares, if any. The address for above referenced entities and persons is 1001 Page Mill Rd., Building 4, Ste. B, Palo Alto, CA 94304. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,023,103 shares of common stock issuable upon conversion of Series A preferred stock and 2,091,383 shares of common stock issuable upon conversion of Series B preferred stock held by New Enterprise
Associates 17, L.P., or NEA 17, and (ii) 6,053 shares of common stock issuable upon conversion of Series A preferred stock held by NEA Ventures 2020, L.P., or NEA Ven 2020. NEA Partners 17, L.P., or NEA Partners 17, is the sole general partner of
NEA 17. NEA 17 GP, LLC, or NEA 17 LLC, is the sole general partner of NEA Partners 17. The securities directly held by NEA Ven 2020 are indirectly held by Karen Welsh, the general partner of NEA Ven 2020. Forest Baskett, Ali Behbahani, Carmen Chang,
Anthony Florence, Jr., Mohamad Makhzoumi, Edward Mathers, Scott D. Sandell, Paul Walker, and Rick Yang are the managers of NEA 17 LLC. NEA 17, NEA Partners 17, NEA 17 LLC and the managers of NEA 17 LLC share voting and dispositive power with regard
to the securities held by NEA 17. Mr. Mathers is a partner at New Enterprise Associates and member of our board of directors. Each of NEA 17, NEA Partners 17 and NEA 17 LLC as well as each of the managers of NEA 17 LLC disclaims beneficial ownership
of all shares held by NEA 17 except to the extent of their actual pecuniary interest therein. NEA 17&#146;s and NEA Ventures 2020, L.P.&#146;s mailing address is 1954 Greenspring Drive, Suite 600, Timonium, MD 21093-4135. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">Consists of (i) 1,029,157&nbsp;shares of common stock issuable upon conversion of Series A preferred stock and
1,629,271&nbsp;shares of common stock issuable upon conversion of Series&nbsp;B preferred stock held by OrbiMed Private Investments VII, LP, or OPI VII, and (ii) 403,787&nbsp;shares of common stock issuable upon conversion of Series&nbsp;C preferred
stock held by OrbiMed Genesis Master Fund, L.P, or Genesis Master Fund. OrbiMed Capital GP VII LLC, or OrbiMed GP VII, is the general partner of OPI VII. OrbiMed Genesis GP LLC, or Genesis GP, is the general partner of Genesis Master Fund. OrbiMed
Advisors LLC, or OrbiMed Advisors, is the managing member of OrbiMed GP VII and Genesis GP. By virtue of such relationships, OrbiMed GP VII and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">
OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII, and Genesis GP and OrbiMed Advisors may be deemed to have voting and investment
power with respect to shares held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild. Dr.&nbsp;Gordon is a member of OrbiMed
Advisors and a member of our board of directors. Each of OrbiMed GP VII, Genesis GP, OrbiMed Advisors, Mr.&nbsp;Borho, Mr.&nbsp;Neild, and Dr.&nbsp;Gordon disclaims beneficial ownership of the shares held by OPI VII and Genesis Master Fund, except
to the extent of its or his pecuniary interest therein if any. The address for each of the entities and individuals identified in this footnote is c/o OrbiMed Advisors LLC, 601 Lexington Avenue 54th Floor, New York, NY 10022. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,018,935&nbsp;shares of common stock issuable upon conversion of Series C preferred stock held by Deep Track Biotechnology Master Fund, Ltd., or Deep Track Fund. Deep Track Capital, LP, or Deep Track
Manager, is the investment manager of Deep Track Fund. Deep Track Capital GP, LLC, or Deep Track Partner, is the general partner of Deep Track Manager and David Kroin is the managing member of Deep Track Partner. The address of each of Deep Track
Fund, Deep Track Manager, Deep Track Partner and Mr. Kroin is 200 Greenwich Ave, 3rd Floor, Greenwich, Connecticut 06830. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,386,335 shares of common stock issuable upon conversion of Series B preferred stock and 403,787 shares of common stock issuable upon conversion of Series C preferred stock held by Wellington Biomedical
Innovation Master Investors (Cayman) II L.P., or Wellington Biomedical Fund. Wellington Management Company LLP, a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the investment adviser to Wellington Biomedical
Fund, and Wellington Alternative Investments LLC is its general partner. Wellington Management Investment, Inc. is the managing member of Wellington Alternative Investments LLC. Wellington Management Company LLP is an indirect subsidiary of
Wellington Management Group LLP. Wellington Management Group LLP and Wellington Management Company LLP may be deemed beneficial owners with shared voting and investment power over the shares held by Wellington Biomedical Fund. Additional information
about Wellington Management Company LLP is available in its Form ADV filed with the SEC. The address of all entities referenced in this footnote is 280 Congress Street, Boston, MA 02210. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,386,335 shares of common stock issuable upon conversion of Series B preferred stock held by Norwest Venture Partners XVI, LP, or NVP XVI. Genesis VC Partners XVI, LLC, or Genesis XVI, is the general
partner of NVP XVI and NVP Associates, LLC, or NVP Associates, is the managing member of Genesis XVI. Genesis XVI, NVP Associates and Jeffrey Crowe and Jon E. Kossow, as co-chief executive officers of NVP Associates, and Tiba Aynechi, Ph.D., as an
officer of NVP Associates and director of MBX Biosciences, may be deemed to share voting and dispositive power over the shares held by NVP XVI. Each of Genesis XVI, NVP Associates, Messrs. Crowe and Kossow and Dr. Aynechi disclaims beneficial
ownership of the securities held by NVP XVI, except to the extent of its, his or her respective pecuniary interest therein. The address for each of these entities and individuals is 1300 El Camino Real, Suite 200, Menlo Park CA 94025.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 415,900 shares of common stock issuable upon conversion of Series B preferred stock held by RA Capital Healthcare Fund, L.P., or RA Healthcare, and (ii) 970,434 shares of common stock issuable upon
conversion of Series B preferred stock held by RA Capital Nexus Fund III, L.P., or Nexus III. RA Capital Management, L.P. is the investment manager for RA Healthcare and Nexus III. The general partner of RA Capital Management, L.P. is RA Capital
Management GP, LLC, of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky, Ph.D. and Rajeev Shah may be deemed to have voting and investment power over
the shares held of record by RA Healthcare and Nexus III. RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky, Ph.D. and Rajeev Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary
interest therein. The address of the entities listed above is 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 205,177 shares of common stock outstanding held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, or the Hawryluk Trust, 187,804 and 77,186&nbsp;shares of common stock outstanding issued
pursuant to early exercise of stock options held by Mr. Hawryluk and the Hawryluk Trust, respectively, 9,747&nbsp;shares of restricted stock outstanding issued pursuant to early exercise of stock options subject to continued vesting for Mr.
Hawryluk, 167,664 and 28,755 shares of common stock issuable upon conversion of Series A preferred stock held by Mr. Hawryluk and the Hawryluk Trust, respectively, 116,182 and 6,402 shares of common stock issuable upon conversion of Series B
preferred stock held by Mr. Hawryluk and the Hawryluk Trust, respectively, 80,757 shares of common stock issuable upon conversion of Series C preferred stock held by the Hawryluk Trust and 1,030,958 shares of common stock underlying outstanding
early exercise stock options that are immediately exercisable within 60 days of August&nbsp;15, 2024. Mr.&nbsp;Hawryluk exercises voting and dispositive power over the shares beneficially owned by the Hawryluk Trust. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 225,592 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60&nbsp;days of August&nbsp;15, 2024. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of the shares described in footnote (6) above. Dr. Aynechi disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 82,686 shares of common stock issuable upon conversion of Series A preferred stock held by Mr. Cornelius, 19,396 shares of common stock issuable upon conversion of Series B preferred stock held by Mr.
Cornelius and 39,277 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of August&nbsp;15, 2024. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of the shares described in footnote (3) above. Dr. Gordon disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of the shares described in footnote (1) above. Mr. Heron disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(14)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares held by NEA 17 described under footnote (2) above, over which Mr. Mathers shares voting and dispositive power. Mr. Mathers, a member of our board of directors and a General Partner at New Enterprise
Associates, Inc. has no voting or dispositive power with regard to any shares held by NEA Ventures. In addition, Mr. Mathers disclaims beneficial ownership of above-referenced shares held by entities affiliated with New Enterprise Associates, Inc.
described in footnote (2) except to the extent of his actual pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(15)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 8,723 shares of common stock outstanding issued pursuant to early exercise of stock options, 7,913&nbsp;shares of restricted stock outstanding issued pursuant to early exercise of stock options subject to
continued vesting, and 22,641 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of August&nbsp;15, 2024. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(16)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 39,277 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of August&nbsp;15, 2024. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(17)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 496,550&nbsp;shares of common stock, of which a certain number are restricted stock subject to vesting as noted above, (ii) 3,905,370 shares of common stock issuable upon conversion of Series A preferred
stock, (iii) 7,602,738 shares of common stock issuable upon conversion of Series B preferred stock (iv)&nbsp;1,292,117 shares of common stock issuable upon conversion of Series&nbsp;C preferred stock and (v)&nbsp;1,357,745&nbsp;shares of common
stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of August&nbsp;15, 2024. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_16"></A>Description of capital stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following descriptions are summaries of the material terms of our fourth amended and restated certificate of incorporation and amended and restated bylaws, which
will be effective immediately prior to the closing of this offering and upon the effectiveness of the registration statement of which this prospectus forms a part, respectively. The descriptions of the common stock and preferred stock give effect to
changes to our capital structure, that will occur immediately upon the closing of this offering. We refer in this section to our fourth amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our
amended and restated bylaws as our bylaws. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>General </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion
of this offering, our authorized capital stock will consist of 500,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock will be
undesignated. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, 1,317,099&nbsp;shares of our common stock were outstanding and held of record by 39 stockholders, and 53,598,587 shares of Series
A preferred stock and 129,240,032 shares of Series&nbsp;B preferred stock were outstanding and held of record by 31 stockholders. This amount does not take into account the conversion of all outstanding shares of our preferred stock into common
stock upon the closing of this offering. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders
of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the common stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to
receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion
rights or other subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of our liquidation, dissolution or winding up, holders of our common
stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued
and paid for, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preferred stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock. Upon the closing of this offering,
our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These
rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or
all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon
our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately after consummation of this offering, no shares of
preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Options </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30,
2024, options to purchase 2,864,410 shares of common stock at a weighted-average exercise price of $6.68 per share were outstanding under the 2019 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration rights </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, the holders of
20,336,599&nbsp;shares of our common stock, including those issuable upon the conversion of preferred stock upon closing of this offering, will be entitled to rights with respect to the registration of these securities under the Securities Act.
These rights are provided under the terms of a second amended and restated investors&#146; rights agreement between us, certain holders of our common stock and holders of our preferred stock. The second amended and restated investors&#146; rights
agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including
underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Demand registration rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beginning 180 days after the effective date of this registration statement, the holders of 20,336,599 shares of our common stock, including those issuable upon the
conversion of shares of our preferred stock upon closing of this offering, are entitled to demand registration rights. Under the terms of the second amended and restated investors&#146; rights agreement, upon the written request of holders of at
least 40% of the securities eligible for registration then outstanding to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> with respect to the securities eligible for registration having an anticipated aggregate
offering price of not less than $10&nbsp;million, net of selling expenses, we will be required to file a registration statement within 60 days of such request covering all securities eligible for registration that our holders request to be included
in such registration. We are required to effect only one registration pursuant to this provision of the second amended and restated investors&#146; rights agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Short-form registration rights </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the second amended and
restated investors&#146; rights agreement, if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written request of holders of at least 20% of the securities eligible for registration then
outstanding to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with respect to securities eligible for registration having an aggregate offering price of at least $5&nbsp;million, net of selling expenses, we will be
required to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within 45 days of such request covering all outstanding securities eligible for registration that our holders request to be included in such registration.
We are required to effect only two registrations in any twelve month period pursuant to the second amended and restated investors&#146; rights agreement. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is
further subject to other specified conditions and limitations. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Piggyback registration rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the second amended and restated investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other
security holders, certain holders of our common stock, including those issuable upon the conversion of our preferred stock, are entitled to include their shares in the registration. Subject to certain exceptions contained in the second amended and
restated investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the
success of the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our second amended and restated investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders
of securities eligible for registration in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
 <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Expiration of registration rights </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The demand registration
rights, short form registration rights and piggyback registration rights granted under the second amended and restated investors&#146; rights agreement will terminate on the earliest to occur of (a)&nbsp;the closing of certain liquidation events,
(b)&nbsp;the fifth anniversary of the completion of this offering or (c)&nbsp;at such time after this offering when the holder&#146;s shares may be sold without limitation pursuant to Rule 144 or another similar exemption under the Securities Act
during a three-month period without registration and such holder holds less than one percent of the outstanding capital stock of the company. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Expenses
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ordinarily, other than underwriting discounts and commissions, we are generally required to pay all expenses incurred by us related to any registration
effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling
security holders and <FONT STYLE="white-space:nowrap">blue-sky</FONT> fees and expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Anti-takeover effects of delaware law and certain provisions of our
certificate of incorporation and bylaws </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some provisions of Delaware law include, and our fourth amended and restated certificate of incorporation and amended
and restated bylaws will include, a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral
takeover proposals to negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Board composition and filling vacancies </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of
incorporation will provide for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also will provide that directors may be removed
only for cause and then only by the affirmative vote of the holders of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting power of the outstanding shares of capital stock of the voting power of the outstanding shares of
capital stock then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative
vote a majority of the remaining directors then in office even if less than a quorum or by sole remaining director. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of
making it more difficult for stockholders to change the composition of our board of directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>No written consent of stockholders </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation will provide that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and
that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our
stockholders without holding a meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Meetings of stockholders </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation and bylaws will provide that only our board of directors may call special meetings of stockholders and only those matters set forth in
the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws will limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the
meeting. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Advance notice requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our bylaws will establish
advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures will provide that notice of
stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor
more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws will specify the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from
bringing matters before the stockholders at an annual or special meeting. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Amendment to certificate of incorporation and bylaws </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of
incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the
provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the
outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote
of our board of directors, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the
amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Preferred stock </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation will
provide for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer,
proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause
shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this
regard, our certificate of incorporation will grant our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount
of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or
preventing a change in control of us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Delaware anti-takeover statute </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203
prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless
the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85&nbsp;percent of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of
10&nbsp;percent or more of the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, Section&nbsp;203 defines an interested stockholder as any entity or person
beneficially owning 15&nbsp;percent or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Choice of forum </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our bylaws will provide that, unless we consent in writing
to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action
asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, and employees to us or our stockholders, (3)&nbsp;any action asserting a claim arising pursuant to the Delaware General Corporation Law, our certificate of
incorporation or our bylaws (including the interpretation, validity or enforceability thereof), or (4)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine; provided, however, that the this provision shall not apply to
any causes of action arising under the Securities Act or Exchange Act. In addition, our bylaws will provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the
sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
shall be deemed to have notice of and consented to these forum provisions. These forum provisions may impose additional costs on stockholders, may limit our stockholders&#146; ability to bring a
claim in a forum they find favorable, and the designated courts may reach different judgments or results than other courts.&nbsp;In addition, there is uncertainty as to whether the federal forum provision for Securities Act claims will be enforced,
which may impose additional costs on us and our stockholders. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stock exchange listing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; The closing of this offering is contingent upon such
listing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Transfer agent and registrar </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Transfer Agent and Registrar
for our common stock will be Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_17"></A>Shares eligible for future sale </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the availability of such shares for
sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on
resale. Nevertheless, sales of shares of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise
equity capital in the future. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the number of shares outstanding as of June 30, 2024, upon the completion of this offering, 30,153,698 shares of our
common stock will be outstanding, assuming the issuance of 8,500,000 shares offered by us in this offering, no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares,
all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in compliance with the limitations described below,
and&nbsp;restricted shares of common stock are subject to time-based vesting terms. All remaining shares of common stock held by existing stockholders immediately prior to the completion of this offering will be &#147;restricted securities&#148; as
such term is defined in Rule 144 under the Securities Act. These restricted securities were issued and sold by us in private transactions and are eligible for public sale only if registered under the Securities Act or if they qualify for an
exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, summarized below. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, a person who has beneficially owned restricted stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is
not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii)&nbsp;we are subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Persons
who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to
sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">1&nbsp;percent of the number of shares then outstanding, which will equal approximately 301,537 shares immediately after
this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the number of shares outstanding as of June 30, 2024; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Select Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided, in each case, that we are subject to the periodic reporting
requirements of the Exchange Act for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice
provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rule&nbsp;701 under the
Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees,
executive officers or directors who purchased shares under a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
written compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90 days after the date
of this prospectus before selling their shares. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, substantially all Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements as described below and under &#147;Underwriting&#148; included elsewhere in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> agreements </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, all of
our directors and officers and holders of approximately 95.9% of our common stock have agreed not to sell or otherwise transfer or dispose of any of our securities for a period of 180 days from the date of this prospectus, subject to certain
exceptions. The representatives of the underwriters may, in their sole discretion, permit early release of shares subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. The holders of approximately an additional 3.3% of our
common stock, after giving effect to the reverse stock-split, but before giving effect to this offering, have agreed with the Company not to transfer any of such shares during the 180 day restricted period, and, for the duration of the restricted
period, the Company has agreed (A) to enforce all existing agreements between the Company and any of its stockholders that prohibit the sale, transfer, assignment, pledge or hypothecation of any of the Company&#146;s securities until the expiration
of the restricted period; (B) to direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such existing &#147;lock-up,&#148; &#147;market stand off,&#148; &#147;holdback&#148; or similar
provisions of such agreements for the duration of the restricted period; and (C) not to release or otherwise grant any waiver of such provisions in such agreements during the restricted period without the prior written consent of J.P. Morgan
Securities LLC and Jefferies LLC. See the section entitled &#147;Underwriting,&#148; included elsewhere in this prospectus for more information. As a result, holders of approximately 99.2% of our common stock, after giving effect to the reverse
stock-split, but before giving effect to this offering, are currently prohibited or otherwise restricted as a result of securities law provisions, market standoff agreements entered into by our stockholders with us, or lock-up agreements entered
into by our stockholders with the underwriters. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration rights </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities
Act.&nbsp;Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration.&nbsp;See the section entitled
&#147;Description of capital stock&#151;Registration rights&#148; included elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Equity incentive plans </B></P>
 <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register our shares issued
or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC. Accordingly, shares
registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. As of the
date of this prospectus, we estimate that such registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> will cover approximately 6,440,596 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><A NAME="toc790774_18"></A>Material U.S. federal income tax considerations for
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion is a summary of certain material U.S. federal income tax considerations
applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering, referred to below as &#147;our common
stock&#148;. For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a foreign corporation or other foreign organization taxable as a corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a foreign trust or estate the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion does not address the tax treatment of partnerships or other entities or arrangements that are treated as pass-through entities for
U.S. federal income tax purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax
advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is based on current provisions of the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and
judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax
consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences
described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, generally property held for
investment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it address any aspects of U.S. state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, the Medicare contribution tax on net investment income, the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code, or
any other aspect of any U.S. federal tax other than income taxes. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special
tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;regulated investment companies&#148; and &#147;real estate investment trusts&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension fund&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and partners
and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who have elected to mark securities to market for U.S. federal income tax purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that hold our common stock as part of a straddle, conversion transaction, synthetic security or other integrated
investment; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our
common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Distributions on our common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid any cash
distributions on our capital stock and we do not anticipate paying cash distributions on our common stock for the foreseeable future. Distributions, if any, on our common stock will generally constitute dividends for U.S. federal income tax purposes
to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT
STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject
to the tax treatment described below in &#147;Gain on sale and other taxable disposition of our common stock.&#148; Any such distributions will also be subject to the discussions below under the sections entitled &#147;Backup withholding and
information reporting&#148; and &#147;Withholding and information reporting requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussion in the following two paragraphs
in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30&nbsp;percent rate or a reduced rate specified by an applicable income tax treaty
between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30&nbsp;percent withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification
requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected
income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30&nbsp;percent rate or a reduced rate
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a
properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable or successor form) to the applicable withholding agent and
satisfy applicable certification and other requirements. Any documentation provided to an applicable withholding agent may need to be updated in certain circumstances. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult
their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S.
withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Gain
on sale or other taxable disposition of our common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions below under &#147;Backup withholding and information reporting&#148; and
&#147;Withholding and information reporting requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income or withholding tax on any gain realized upon such
holder&#146;s sale or other taxable disposition of shares of our common stock unless: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a U.S.
trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on our common stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30&nbsp;percent
tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital
losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed
U.S. federal income tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; as described below, unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5&nbsp;percent of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period
ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a U.S. real property holding corporation if the fair market value of its U.S.
real property interests, as defined in the Code and applicable Treasury regulations, equals or exceeds 50&nbsp;percent of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade
or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be
regularly traded on an established securities market for purposes of the rules described above. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Backup withholding and information reporting
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We (or the applicable paying agent) must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the
distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may have to comply with specific certification procedures to establish
that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders subject to withholding of U.S. federal income tax, as described above in &#147;Distributions on our common stock,&#148; generally will be exempt from U.S. backup withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock
by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies
certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the
transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and backup withholding
rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or
agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Withholding and information reporting requirements&#151;FATCA </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Provisions of
the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding tax at a rate of 30&nbsp;percent on payments of dividends on, or, subject to the discussion of certain proposed U.S.
Treasury regulations below, gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain
due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign
entity is otherwise exempt under FATCA. However, the U.S. Treasury released proposed regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30&nbsp;percent applicable to the gross proceeds of a sale or
other disposition of our common stock. In the preamble to such proposed regulations, the U.S. Treasury stated that taxpayers (including withholding agents) may generally rely on the proposed regulations until final regulations are issued. Under
certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United&nbsp;States and an applicable foreign country may
modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the
entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30&nbsp;percent withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_19"></A>Underwriting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC and Jefferies LLC are acting as
joint book-running managers of the offering, and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell
to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next
to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting
agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters propose to offer the shares of common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus
and to certain dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195; per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to $&#8195;&#8195;&#8195;&#8195; per share
from the initial public offering price. After the initial offering of the shares to the public, if all of the shares of common stock are not sold at the initial public offering price, the underwriters may change the offering price and the other
selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have an option to buy up to
1,275,000 additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this
option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of
common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $&#8195;&#8195;&#8195;&#8195; per share. The following table shows the
per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Without<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>With full<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing
fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $3.75 million. We have agreed to reimburse the underwriters for expenses relating to the clearance of this offering with the
Financial Industry Regulatory Authority of up to $40,000. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At our request, the underwriters have reserved up to 5% of the shares of common stock being offered by
this prospectus for sale at the initial public offering price to our directors, officers, certain employees and certain other persons associated with us. The sales will be made by J.P. Morgan Securities LLC, an underwriter of this offering, through
a directed share program. We do not know if these persons will choose to purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public. Except
for reserved shares purchased by our executive officers and directors, these reserved shares will not be subject to the lock-up restrictions described below. Any reserved shares not so purchased will be offered by the underwriters to the general
public on the same terms as the other shares of common stock. We have agreed to indemnify J.P. Morgan Securities LLC against certain liabilities and expenses, including liabilities under the Securities Act of 1933, as amended, or the Securities Act,
in connection with the sales of the directed shares. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A prospectus in electronic format may be made available on the web sites maintained by one or more
underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We<I> </I>have agreed that we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any
shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii)&nbsp;enter into any
swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the
delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Jefferies LLC for a period of 180 days after the date of this prospectus, other than
the shares of our common stock to be sold in this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions on our actions, as described above, do not apply to certain transactions, including
(i)&nbsp;the issuance of shares of common stock or securities convertible into or exercisable for shares of our common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options
(including net exercise) or the settlement of RSUs (including net settlement), in each case outstanding on the date of the underwriting agreement and described in this prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock,
RSUs, or other equity awards and the issuance of shares of our common stock or securities convertible into or exercisable or exchangeable for shares of our common stock (whether upon the exercise of stock options or otherwise) to our employees,
officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the closing of this offering and described in this prospectus; (iii)&nbsp;the issuance of up to 5% of the outstanding shares of our
common stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, our common stock, immediately following the closing of this offering, in connection with any bona fide licensing, commercialization, joint
venture, technology transfer, acquisition, development collaboration or other strategic transaction, provided that for (i)-(iii) such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; or
(iv)&nbsp;our filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
on the date of the underwriting agreement and described in this prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors and executive officers, and holders of approximately 95.9% of our common stock, or such persons, the <FONT STYLE="white-space:nowrap">lock-up</FONT>
parties, have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited
exceptions, for a period of 180&nbsp;days after the date of this prospectus or such period, the restricted period, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities
LLC and Jefferies LLC, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of,
directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be
beneficially owned by such <FONT STYLE="white-space:nowrap">lock-up</FONT> parties in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant,
or collectively with the common stock, the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, (2)&nbsp;enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of
ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in
cash or otherwise, (3)&nbsp;make any demand for, or exercise any right with respect to, the registration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (4)&nbsp;publicly disclose the intention to do any of the foregoing. Such
persons or entities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put
or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or
transfer (by any person or entity, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any
such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the
underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a)&nbsp;transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT>
securities: (i) as bona fide gifts, as a charitable contribution, or for bona fide estate planning purposes, (ii)&nbsp;by will or intestacy or any other testamentary document, (iii)&nbsp;to any trust for the direct or indirect benefit of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or its immediate family, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor, trustee (or co-trustee) or beneficiary of the trust or to the estate of a beneficiary
of such trust (for purposes hereof, &#147;immediate family&#148; shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin), (iv) to a corporation, partnership, limited
liability company, investment fund or other entity (A)&nbsp;of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and/or its immediate family are the legal and beneficial owner of all of the outstanding equity securities or similar
interests or (B)&nbsp;controlled by, or under common control with, the lock-up party or the immediate family of the lock-up party, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under
clauses (i)&nbsp;through (iv), (vi) if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited
liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling,
controlled by, managing or managed by or under common control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates (including, for the avoidance of doubt, where the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is
a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a distribution to limited partners, members or shareholders of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party, (vii)&nbsp;by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement, (viii)&nbsp;to us from an employee upon death,
disability or termination of employment, in each case, of such employee, (ix)&nbsp;as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
part of a transaction related to <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in this offering (if not a director or officer) or in open market transactions following this
offering, (x)&nbsp;to us in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of our common stock (including, in each case, by way of &#147;net&#148; or
&#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such
shares of our common stock received upon such exercise, vesting or settlement shall be subject to the restrictions similar to those in the immediately preceding paragraph, and provided further that any such restricted stock units, options, warrants
or rights are held by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in this
prospectus, (xi)&nbsp;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by our board of directors and made to all shareholders involving a change in control, provided that if such
transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the restrictions in the immediately preceding paragraph (xii)&nbsp;to an immediate family member of the lock-up party, or
(xiii)&nbsp;to us in connection with the transfer of shares pursuant to option agreements relating to the early exercise by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party of unvested options issued pursuant to our equity incentive plans,
which plans are in each case described in this Registration Statement, under which we have the right to repurchase such shares and only to the extent we elect to exercise such right.; provided that (A)&nbsp;in the case of any transfer or
distribution pursuant to clauses&nbsp;(i), (ii), (iii), (iv), (v), (vi), (vii) and (xii)&nbsp;of this paragraph, such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to
the representatives of the underwriters a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (B)&nbsp;in the case of any transfer or distribution pursuant to
clauses&nbsp;(iii), (iv), (v), (vi), (ix) and (xii)&nbsp;of this paragraph, no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or
shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 or a filing required pursuant to Section 13 of the Exchange Act and the rules and regulations promulgated thereunder made after the
expiration of the restricted period) and (C)&nbsp;in the case of any transfer or distribution pursuant to clauses (i), (ii), (vii), (viii), (x) and (xiii)&nbsp;of this paragraph it shall be a condition to such transfer that no public filing, report
or announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of our common stock in connection with
such transfer or distribution shall be legally required during the restricted period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; (b)&nbsp;exercise of the options,
settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to plans described in in this prospectus, provided that any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or
settlement would be subject to restrictions similar to those in the immediately preceding paragraph; (c)&nbsp;the conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible securities into shares of our common
stock or warrants to acquire shares of our common stock, provided that any common stock or warrant received upon such conversion would be subject to restrictions similar to those in the immediately preceding paragraph; (d)&nbsp;the establishment or
modification by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities,
provided that (1)&nbsp;such plans do not provide for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period and (2)&nbsp;no filing by any party under the Exchange Act or other public announcement
shall be required or made voluntarily in connection with such trading plan; and (e)&nbsp;the sale of our common stock pursuant to the terms of the underwriting agreement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of approximately an additional 3.3% of our common stock, after giving effect to the reverse stock-split, but before giving effect to this offering, have
agreed with the Company not to transfer any of such shares during the 180 day restricted period, and, for the duration of the restricted period, the Company has agreed (A) to enforce all existing agreements between the Company and any of its
stockholders that prohibit the sale, transfer, assignment, pledge or hypothecation of any of the Company&#146;s securities until the expiration of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
restricted period; (B) to direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such existing &#147;lock-up,&#148; &#147;market
stand off,&#148; &#147;holdback&#148; or similar provisions of such agreements for the duration of the restricted period; and (C) not to release or otherwise grant any waiver of such provisions in such agreements during the restricted period without
the prior written consent of J.P. Morgan Securities LLC and Jefferies LLC. As a result, holders of approximately&nbsp;99.2% of our common stock, after giving effect to the reverse stock-split, but before giving effect to this offering, are currently
prohibited or otherwise restricted as a result of securities law provisions, market standoff agreements entered into by our stockholders with us, or lock-up agreements entered into by our stockholders with the underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC and Jefferies LLC, in their sole discretion, may release the securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements with the underwriters described above, in whole or in part at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed to indemnify the underwriters against certain liabilities,
including liabilities under the Securities Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the
Nasdaq Global Select Market under the symbol &#147;MBX.&#148; The closing of this offering is contingent upon such listing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, the
underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while
this offering is in progress. These stabilizing transactions may include making short sales of common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this
offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to
purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional
shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which
the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the
open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P>
<P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize, maintain or
otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the
representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>  <P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These
activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price
that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on the Nasdaq Global Select Market, in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>  <P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no
public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the
underwriters expect to consider a number of factors including: </P> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we nor the underwriters can assure investors that an active trading market will develop for our shares of common stock, or that the shares will trade in the
public market at or above the initial public offering price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than in the United States, no action has been taken by us or the underwriters that would permit a
public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any
other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and
regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not
constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial
banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time
to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or
loans, and may do so in the future. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Selling restrictions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to
prospective investors in the european economic area </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to each Member State of the European Economic Area, or each, a Relevant State, no shares of our
common stock have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares of our common stock which has been approved by the competent authority
in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of shares of common stock may be
made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of shares of common stock shall require the Issuer or any underwriter to publish a
prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each person in a
Relevant State who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning
of the Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the case of any shares of common stock being offered to a financial intermediary as that term is used in Article 5(1) of the
Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock acquired by it in the offer have not been acquired on a
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or
resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of common stock in any Relevant State means the
communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of common stock, and the
expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the united kingdom </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to the United Kingdom, or the UK, no shares of our common stock have been offered or will be offered pursuant to the offering to the public in the UK prior
to the publication of a prospectus in relation to the shares of common stock which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of shares of common
stock may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at any time in other circumstances falling within section 86 of the FSMA, </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of shares of
common stock shall require the Issuer or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each person in the UK who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to
and with the Company and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the case of any shares of common
stock being offered to a financial intermediary as that term is used in Article 5(1) of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock
acquired by it in the offer have not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances
which may give rise to an offer to the public other than their offer or resale in the UK to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of our common stock in the UK means the communication in
any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of our common stock, the expression &#147;UK
Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, and the expression &#147;FSMA&#148; means the Financial Services and Markets Act 2000. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document is for distribution only to persons who (i)&nbsp;have professional experience in matters relating to investments and who qualify as investment
professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, or as amended, the Financial Promotion Order, (ii) are persons falling within Article 49(2)(a) to (d) (&#147;high net
worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii)&nbsp;are outside the United Kingdom, or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment activity (within the meaning
of Section&nbsp;21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#147;relevant persons&#148;). This document
is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in
only with relevant persons. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Canada </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National
Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT>
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable
securities laws. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts, or NI 33-105, the underwriters are not required to
comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Switzerland </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock
may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or six or on any other stock exchange or regulated trading facility in Switzerland. This document does </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering
or marketing material relating to the shares of common stock, or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares of common stock have been or will be filed with or
approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares of common stock will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of
shares of common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not
extend to acquirers of shares of common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Hong Kong </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document
being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong), or CO, or which do not constitute an offer to the public within the meaning of the CO. No advertisement,
invitation or document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of
which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common stock which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in
Singapore </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each joint book-running manager has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of
Singapore. Accordingly, each joint book-running manager has represented and agreed that it has not offered or sold any shares of common stock or caused the shares of common stock to be made the subject of an invitation for subscription or purchase
and will not offer or sell any shares of common stock or cause the shares of common stock to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this
prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock, whether directly or indirectly, to any person in Singapore other than: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time, or the SFA,) pursuant to Section&nbsp;274 of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified
in Section&nbsp;275 of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where the shares of common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person
which is: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based
derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or
that trust has acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of
shares of common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares of common stock are &#145;&#145;prescribed capital markets products&#146;&#146; (as defined in the
CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on
Recommendations on Investment Products). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Japan </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none
of the shares of common stock nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including
any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to
an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the United Arab Emirates </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of
common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and
the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial
Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Israel </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law,
5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#150;1968, including, inter alia, if:
(i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First
Addendum of the Israeli Securities Law, 5728&#151;1968, subject to certain conditions, or the Qualified Investors. The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase
securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#151;1968. We have not and will not
distribute this prospectus or make, distribute or direct an offer to subscribe for our shares of common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#151;1968. In
particular, we may request, as a condition to be offered shares of common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of the
categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968 regarding Qualified Investors is applicable to it;
(iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be issued shares of common stock; (iv)&nbsp;that the shares of common
stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#151;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of
Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence
in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number.</P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Australia </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the Corporations Act; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, a as a disclosure document for the purposes of the Corporations Act and does not purport to include the
information required of a disclosure document for the purposes of the Corporations Act; and </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act, or Exempt
Investors. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe
for or buy the shares of common stock may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares of common stock may be distributed in Australia, except where disclosure to
investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares of common stock, you represent and warrant to us that
you are an Exempt Investor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As any offer of shares of common stock under this document will be made without disclosure in Australia under Chapter
6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies
to that resale. By applying for the shares of common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer, transfer, assign or otherwise alienate those shares of common
stock to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in China </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus will not be
circulated or distributed in the PRC and the shares of common stock will not be offered or sold, and will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents
of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in
compliance with applicable laws and regulations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Korea </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and
regulations thereunder, or FSCMA, and the shares of common stock have been and will be offered in Korea as a private placement under the FSCMA. None of the shares of common stock may be offered, sold or delivered directly or indirectly, or offered
or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the
Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or FETL. Furthermore, the purchaser of the shares of common stock shall comply with all applicable regulatory requirements (including but not limited to
requirements under the FETL) in connection with the purchase of the shares of common stock. By the purchase of the shares of common stock, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of
Korea, it purchased the shares of common stock pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Saudi Arabia
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued
by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution number <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended, or the CMA Regulations. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any
liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the shares of common stock offered hereby should conduct their own due diligence on the accuracy of the information
relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective
investors in the Dubai International Financial Centre, or DIFC </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai
Financial Services Authority, or DFSA. This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth
herein and has no responsibility for this document. The shares of common stock to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares of common stock offered should conduct
their own due diligence on the securities. If you do not understand the contents of this document, you should consult an authorized financial advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation
to its use in the DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any
other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in
Bermuda </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Shares of common stock may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which
regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so
under applicable Bermuda legislation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the British Virgin Islands </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock are not being and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf
of us. The shares of common stock may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (BVI Companies), but only where the offer will be made to, and received by, the relevant BVI Company
entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Taiwan </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and
regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the
Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares of common stock in Taiwan.</P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in South Africa </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to restrictions under
the securities laws of South Africa, no &#147;offer to the public&#148; (as such term is defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the South African Companies
Act), is being made in connection with the issue of the shares of common stock in South Africa. Accordingly, this document does not, nor is it intended to, constitute a &#147;registered prospectus&#148; (as that term is defined in the South African
Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The
shares of common stock are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96
(1) applies: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;96 (1) (a) the offer, transfer, sale, renunciation or delivery is to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the South African Public Investment Corporation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons or entities regulated by the Reserve Bank of South Africa; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorized financial service providers under South African law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions recognized as such under South African law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a wholly-owned subsidiary of any person or entity contemplated in (iii), (iv) or (v), acting as agent in the capacity of an authorized portfolio manager for a pension fund, or as manager for a collective investment
scheme (in each case duly registered as such under South African law); or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any combination of the person in (i)&nbsp;to (vi); or </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;96 (1) (b) the total contemplated acquisition cost of
the shares of common stock, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the
South African Companies Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information made available in this prospectus should not be considered as &#147;advice&#148; as defined in the South African Financial
Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Malaysia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No prospectus or other offering material or document in connection with the offer and sale of the shares of common stock has been or will be registered with the
Securities Commission of Malaysia, or the Commission, for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or
invitation for subscription or purchase, of the shares of common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether
directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services License; (iii)&nbsp;a person who acquires the shares of common stock, as principal, if
the offer is on terms that the shares of common stock may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total
net joint assets with his or her spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or
its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with&nbsp;his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the
preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding
RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan
Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares of common stock is made by a
holder of a Capital Markets Services License who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose
of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Qatar </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock described in this prospectus have not been, and will not be, offered, sold or delivered, at any time, directly or indirectly in the State of
Qatar in a manner that would constitute a public offering. This prospectus has not been, and will not be, registered with or approved by the Qatar Financial Markets Authority or Qatar Central Bank and may not be publicly distributed. This prospectus
is intended for the original recipient only and must not be provided to any other person. It is not for general circulation in the State of Qatar and may not be reproduced or used for any other purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_20"></A>Legal matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain legal matters
relating to this offering will be passed upon for the underwriters by Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_21"></A>Experts
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The financial statements as of December&nbsp;31, 2023 and December&nbsp;31, 2022, and for the years then ended, included in this Prospectus have been audited
by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting
and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_22"></A>Where you can find more information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File Number
<FONT STYLE="white-space:nowrap">333-281764)</FONT> under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the
information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our
contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy
statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at https://www.mbxbio.com and upon completion of the offering,
you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and
any amendments to those reports, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not
incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_23"></A>Index to financial statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:12pt"><B>Index to Annual Financial Statements</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_3">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_4">Statements of Stockholders&#146; Deficit (Equity) and Convertible Preferred
Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:12pt"><B>Index to Unaudited Interim Condensed Financial Statements</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_7">Condensed Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-28</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_8">Condensed Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-29</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_9">Condensed Statements of Stockholders&#146; Deficit (Equity) and Convertible Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-30</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_10">Condensed Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-31</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_11">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-32</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_1"></A>Report of independent registered public accounting firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the Stockholders and the Board of Directors of MBX Biosciences, Inc. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Opinion
on the financial statements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have audited the accompanying balance sheets of MBX Biosciences, Inc. (the Company) as of December&nbsp;31, 2023 and 2022, the
related statements of operations and comprehensive loss, stockholders&#146; equity (deficit) and convertible preferred stock, and cash flows for the years then ended, and the related notes (collectively referred to as the &#147;financial
statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2023 and 2022, and the results of its operations and its cash flows for the years then
ended, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Basis for opinion </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an
opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our audits included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">/s/ Ernst&nbsp;&amp; Young LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">We have served as the Company&#146;s auditor since 2023.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Indianapolis, Indiana</P></TD></TR>
</TABLE>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">March&nbsp;22, 2024, except for Note&nbsp;17 as to which the date is September&nbsp;9, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_2"></A>Balance sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Share repurchase liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Convertible Preferred Stock, $0.0001 par value, 53,598,587 shares authorized, issued and
outstanding (liquidation preference of $36,822,229) as of December&nbsp;31, 2023 and 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Convertible Preferred Stock, $0.0001 par value, 129,240,032 shares authorized and 129,240,032
issued and outstanding (liquidation preference of $116,316,029) as of December&nbsp;31, 2023 and 129,240,032 shares authorized and 53,118,933 issued and outstanding (liquidation preference of $47,807,040) as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.0001 par value, 237,000,000 shares authorized and 1,257,080 issued and outstanding as of
December&nbsp;31, 2023 and 237,000,000 shares authorized and 1,007,995 issued and outstanding as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, convertible preferred stock and
stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">45,095</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">84,180</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_3"></A>Statements of operations and comprehensive loss </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(in thousands, except share and per share amounts) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000;border-bottom:1.00px solid #000000"><B>Years ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized gain (loss) on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reclassification of net (gains) losses included in net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in
computation of net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">667,018</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,018,757</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:220pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_4"></A>Statements of stockholders&#146; equity (deficit) and convertible preferred stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(in thousands, except share amounts) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series A<BR>convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series B<BR>convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Common&nbsp;stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income (Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>973,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$&#8199;&#8199;&#8198;48</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$(16,885</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>$&#8196;&#8202;&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$(16,836</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of Series B Convertible Preferred Stock, net of $429 issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,118,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="37" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance&nbsp;at&nbsp;December&nbsp;31,&nbsp;2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,118,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,007,995</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$&#8199;&#8198;411</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$(43,020</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$&#8199;3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>$(42,605</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of Series B Convertible Preferred Stock, net of $30 issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,121,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="37" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>129,240,032</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>115,856</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>1,257,080</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>$1</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>$3,054</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>$(75,583</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>$60</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>$(72,468</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>)&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_5"></A>Statements of cash flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(in thousands) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000;border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Non cash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accretion and amortization of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Non cash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from the issuance of Series B Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible notes issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vesting of early exercised stock options and founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> property and
equipment disposal</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_6"></A>Notes to financial statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>for the years ended December&nbsp;31, 2023 and 2022 </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. Nature of business and liquidity </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX Biosciences, Inc. (&#147;MBX&#148;
or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of
novel candidates for endocrine and metabolic disorders. The Company was organized in August 2018 in Indiana as a Limited Liability Company and converted to a C corporation in the state of Delaware in April 2019. The Company maintains its corporate
offices in Carmel, Indiana. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since inception, the Company has devoted substantially all of its resources to drug discovery and development of its product candidates
MBX 2109, MBX 1416 and MBX 4291, and other preclinical programs, building an intellectual property portfolio, organizing and staffing the Company, business planning, raising capital and providing general and administrative support for these
operations. The Company does not have any products approved for sale and have not generated any revenue from product sales. The Company has historically funded its operations primarily through sales of convertible preferred stock and convertible
notes, which generated approximately $150.6 million in aggregate gross proceeds. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From inception and through December&nbsp;31, 2023, the Company has devoted substantially all of its efforts to drug discovery and development. The Company has a limited
operating history, has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December&nbsp;31, 2023, the Company has an accumulated deficit of $75.6&nbsp;million and
cash, cash equivalents and marketable securities of $80.7&nbsp;million. Based on the Company&#146;s current business plan, management believes that existing cash and cash equivalents and marketable securities will be sufficient to fund the
Company&#146;s obligations for at least 12 months from the date of issuance of these financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. Summary of significant accounting policies
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The financial statements have been
prepared in accordance with generally accepted accounting principles in the United States of America (US GAAP). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Use of estimates </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preparation of financial statements in conformity with US&nbsp;GAAP requires management to make judgments, assumptions, and estimates that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the
determination of the fair value of stock option grants and estimates related to the amount of prepaid and accrued research and development expenses as of the balance sheet date. Management evaluates its estimates and assumptions on an ongoing basis
using historical experience and other factors, including the current economic environment, and makes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
adjustments when the facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from
those estimates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash and cash equivalents </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company considers
all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&nbsp;31, 2023 and 2022, cash and cash equivalents consisted primarily of checking and savings deposits,
money market fund holdings, and commercial paper. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Concentration of credit risk </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company&#146;s
investment policy includes guidelines regarding the quality of the financial institutions and financial instruments and defines allowable marketable securities that it believes minimizes the exposure to concentration of credit risk. The Company may
invest in money market funds (minimum of $1&nbsp;billion in assets), U.S. Treasury securities, corporate debt, bank debt, U.S. government-related agency securities, other sovereign debt, municipal debt and commercial paper. These deposits may exceed
federally insured limits. The Company has not experienced any losses historically in these accounts. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Property and equipment </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life
of each asset, generally three to seven years. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the asset. Upon retirement or sale, the cost of assets disposed of, and the related accumulated
depreciation, are removed from the accounts and any resulting gain or loss is included in loss from operations in the period realized. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operating
expenses as incurred. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment losses have been recognized during the years ended December&nbsp;31, 2023 and 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Fair value of financial instruments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Fair value is defined as the
price that the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most
advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest
priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 investments) and the lowest priority to unobservable inputs (Level 3 investments). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The three levels of the fair value hierarchy are as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level&nbsp;1 inputs: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical,
unrestricted assets or liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level&nbsp;2 inputs: Quoted prices in markets that are not considered to be active or financial instrument valuations for
which all significant inputs are observable, either directly or indirectly; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level&nbsp;3 inputs: Prices or valuations that require inputs that are both significant to the fair value measurement and
unobservable. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value
measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s money market funds and marketable securities are carried at fair value determined according to the fair value hierarchy described above (Level 1 and
Level&nbsp;2, respectively). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses include employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; external research and
development expenses incurred under arrangements with third parties, such as contract research organization agreements, contract manufacturing organization agreements, clinical sites and consultants; costs associated with preclinical and clinical
activities; costs associated with required regulatory filings, licenses and fees; costs incurred in development of intellectual property; and an allocated portion of facilities and other infrastructure costs associated with our research and
development activities. Costs incurred in connection with research and development activities, both internal and external, are expensed as incurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Costs are
considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided to the Company by its clinical sites and vendors. These costs consist of direct and indirect costs
associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued
expenses related to these costs. These accrued or prepaid expenses are based on management&#146;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of
these factors and adjusts estimates accordingly. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Deferred financing costs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Direct costs incurred in connection with the issuance of the convertible notes are capitalized as incurred, presented as a direct reduction of the carrying amount of the
notes, and amortized over the period of indebtedness using the effective interest method. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Patent costs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in
general and administrative expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company measures all stock options and other stock-based awards granted to employees, nonemployees, and directors based on the fair value on the date of the grant
and recognizes compensation expense of those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
awards over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues stock option awards with only service-based vesting
conditions and records the expense for these awards using the straight-line method. The Company&#146;s policy is to account for forfeitures when they occur. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company classifies stock-based compensation expense in its statement of operations in the same manner in which the award recipient&#146;s payroll costs are classified or in which the award recipients&#146; service payments are classified. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks company-specific historical
and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until it has adequate historical data regarding
the volatility of its own traded stock price. The expected term of the Company&#146;s stock options has been determined utilizing the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options. The expected term of
stock options granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the US Treasury yield curve in effect at the time of grant
of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero because the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable
future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In determining the exercise prices for options granted, the Company has considered the estimated fair value of the common stock as of the measurement date.
The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> sales of the
Company&#146;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. Among other factors are the Company&#146;s financial position and
historical financial performance, forecasted future operations of the Company, an evaluation or benchmark of the Company&#146;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying
the factors used could result in different fair values of common stock at each valuation date. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income taxes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a
determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies,
and results of recent operations. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded
amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records
uncertain tax positions on the basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process whereby (1)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical
merits of the position and (2)&nbsp;for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent
likely to be realized upon ultimate settlement with the related tax authority. The Company&#146;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. Any accrued interest and penalties are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
included within the related tax liability. The Company had no significant uncertain tax positions as of December&nbsp;31, 2023 and December&nbsp;31, 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) asset and lease liability for substantially all leases for which it is a lessee, in accordance with ASC 842. Leases with an initial term of 12 months or less are not recorded on
the balance sheet. The Company recognizes lease expense for leases on a straight-line basis over the lease term. At inception of a contract, the Company considers all relevant facts and circumstances to assess whether or not the contract represents
a lease by determining whether or not the contract conveys the right to control the use of an identified asset, either explicit or implicit, for a period of time in exchange for consideration. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Basic and diluted net loss per share </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company calculates basic and
diluted net loss per share using the <FONT STYLE="white-space:nowrap">two-class</FONT> method. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income available to common stockholders for the period to be allocated between
common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&#146;s Series A Convertible Preferred Stock and Series B Convertible Preferred Stock
are participating securities. These participating securities do not contractually require the holders of such shares to participate in the Company&#146;s losses. As such, net losses for the years presented were not allocated to the Company&#146;s
participating securities. Accordingly, basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net
loss per share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially
dilutive securities include vested and unexercised stock options, restricted stock issued upon early exercise of stock options, restricted stock related to unvested founder shares and convertible preferred shares. The dilutive effect of stock
options are computed using the treasury stock method and the dilutive effect of convertible preferred shares is calculated using the <FONT STYLE="white-space:nowrap">if-converted</FONT> method. The Company has generated a net loss for all periods
presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Segments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Operating segments are defined as components of an entity
for which separate financial information is made available and is regularly evaluated by the chief operating decision maker (&#147;CODM&#148;) in making decisions regarding resource allocation and assessing performance. The Company&#146;s CODM is
the chief executive officer and operations are managed as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#146;s assets are located in the United States. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comprehensive income (loss) </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Comprehensive income (loss) represents
net income (loss) for the period plus the results of certain other changes in stockholders&#146; equity (deficit). The Company&#146;s comprehensive loss included unrealized gains related to marketable securities for the years ended December&nbsp;31,
2023 and 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently issued accounting pronouncements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to enhance the transparency, decision usefulness and effectiveness of income tax
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
disclosures. The amendments in this ASU require an entity to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. An entity is also required
to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes
and also disaggregated by individual jurisdictions. The amendments also remove certain disclosures that are no longer considered cost beneficial. The amendments are effective prospectively for public entities for annual periods beginning after
December&nbsp;15, 2024 and for entities other than public entities for annual periods beginning after December&nbsp;15, 2025. Early adoption and retrospective application are permitted. Although the ASU only modifies the Company&#146;s required
income tax disclosures, the Company is currently evaluating the impact of adopting this guidance on its financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2023, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2023-07,</FONT> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional and more detailed
information about a reportable segment&#146;s expenses. The amendments expand a public entity&#146;s segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker
(&#147;CODM&#148;), clarifying when an entity may report one or more additional measures to assess segment performance, requiring enhanced interim disclosures, providing new disclosure requirements for entities with a single reportable segment, and
requiring other new disclosures. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> is effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods within fiscal years beginning after December&nbsp;15, 2024, with early
adoption permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. The Company does not anticipate the adoption to have a material impact on the Company&#146;s financial disclosures. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. Fair value measurements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents information about
the Company&#146;s financial instruments as of December&nbsp;31, 2023 and 2022, that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the inputs the Company utilized to determine such fair value (<I>in
thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">39,630</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">29,850</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9,780</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">80,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">70,590</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9,922</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. Marketable securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of
the Company&#146;s marketable securities as of December&nbsp;31, 2023 and 2022 is based on Level&nbsp;1 and Level&nbsp;2 inputs. The Company&#146;s investments consist mainly of U.S. government and agency securities, government-sponsored bond
obligations and certain other corporate debt securities. Fair value is determined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs
are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
There were no transfers between levels within the fair value hierarchy during the years ended December&nbsp;31, 2023 and 2022. The Company has assessed U.S. government treasuries as Level&nbsp;1 and all other marketable securities as Level&nbsp;2
within the fair value hierarchy of ASC 820. The Company classifies its entire investment portfolio as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> as defined in ASC 320, Debt Securities, and
views all investments as available for use in its current operations. We have therefore classified all securities as current, even if we do not necessarily intend to dispose of the securities in the following year. Securities are carried at fair
value with the unrealized gains (losses) reported in other comprehensive income (loss). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023 and 2022, none of the Company&#146;s
investments were determined to be other than temporarily impaired. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the Company&#146;s investments (<I>in thousands</I>): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>(Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Fair<BR>Value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government and agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$28,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$28,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$28,028</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$3</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$28,031</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>(Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Fair<BR>Value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government and agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$50,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$50,093</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$62</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$50,153</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair values of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities as
of December&nbsp;31, 2023, by contractual maturity, are summarized as follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due in one year or less</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$47,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due after one year through two years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$50,153</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. Prepaid expenses and other current assets </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prepaid and other current assets consisted of the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total prepaid and other current assets</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,750</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. Property and equipment, net </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment, net consisted of the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depreciation expense was $0.2&nbsp;million for the year ended December&nbsp;31, 2023 and $0.1&nbsp;million for the year ended
December&nbsp;31, 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. Accrued expenses </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses consisted
of the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>2022</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>2023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,318</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,382</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. Commitments and contingencies </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2022, the Company entered into an operating lease
agreement for principal executive office in Carmel, Indiana (the &#147;Carmel Lease&#148;). The Carmel Lease commenced in October 2022 and has an initial term of 39 months, terminating in December 2025, with an option to extend for 36 additional
months at the Company&#146;s discretion. The option to extend is not considered reasonably certain as of the lease inception. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, The Company entered
into an operating lease agreement for laboratory space in Indianapolis, Indiana (the &#147;Laboratory Lease&#148;). The Laboratory Lease commenced in December 2023 and has a term of 12 months, terminating in December 2024. The lease does not contain
an option to extend the term. Due to the lease term being only one year, we have elected to account for it as a short-term lease with no corresponding lease liability or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset recorded, and lease payments recognized as expense on a straight-line basis over the lease term. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has no other operating or finance leases as of December&nbsp;31, 2023 or 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The future minimum rent payments relating to the Carmel Lease under the terms and conditions existing as of
December&nbsp;31, 2023, are summarized as follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Years ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company incurred rent expense of $0.2&nbsp;million and $0.1&nbsp;million for the years ended December&nbsp;31, 2023 and 2022,
respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the operating lease term and discount rate for the Carmel Lease as of December&nbsp;31, 2023 and 2022: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">8.0%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">8.0%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash paid for amounts included in the measurement of the Company&#146;s operating lease liability was $0.2&nbsp;million for the year
ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the amount of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities included on the Company&#146;s balance sheet as of December&nbsp;31, 2023 and 2022 (<I>in thousands</I>): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Right-of</FONT> use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>License agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2020, the
Company entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation (&#147;IURTC&#148;) (the &#147;License Agreement&#148;), to license certain intellectual property arising under the Research Agreement.
Pursuant to the License Agreement, IURTC is also entitled to receive reimbursement for all patent prosecution and maintenance related expenses and an annual maintenance fee of up to $0.1&nbsp;million beginning in the first year in which the first
commercial sale occurs. In addition, IURTC is entitled to the receipt of specified clinical and regulatory milestones, as defined in the License Agreement, up to an aggregate of $0.4&nbsp;million, plus certain royalties on net sales. The parties may
terminate the License Agreement at any time by mutual agreement. In addition, the Company may terminate the License Agreement by giving 90 days&#146; notice to IURTC and IURTC may terminate the License Agreement immediately in the event of certain
breaches of the agreement by the Company or upon the Company&#146;s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the License Agreement will
continue until the final expiration of all patent rights under the License Agreement. In consideration for the license, during the years ended December&nbsp;31, 2023 and 2022, the Company paid immaterial licensing fees to IURTC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether a potential loss amount or a potential
range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to its legal proceedings. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. Convertible notes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, the Company received gross cash
proceeds of $10.0&nbsp;million from the issuance of convertible notes (the &#147;2022 Notes&#148;). The Company incurred immaterial issuance costs in relation to the issuance of the 2022 Notes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2022 Notes accrued interest at a rate of 8% per annum and were not payable until converted or paid in connection with repayment in full of the principal amount of
the 2022 Notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2022 Notes a) automatically convert into shares of convertible preferred stock from the next qualified financing, as defined in the 2022 Notes
agreement, at 90% of the per share price of the convertible preferred stock sold in the qualified financing consummated on or prior to March&nbsp;31, 2023, or 80% of the per share price of the convertible preferred stock sold in the qualified
financing consummated after March&nbsp;31, 2023; b) note holders had the right, but not the obligation to convert into shares of convertible preferred stock from the next <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing at 90% of the
per share price of the convertible preferred stock sold in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing consummated on or prior to March&nbsp;31, 2023, or 80% of the per share price of the convertible preferred stock sold in
the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing consummated after March&nbsp;31, 2023; or c) redeem in the event of a change in control. The number of shares of convertible preferred stock to be issued upon such conversion would
be equal to the quotient obtained by dividing the amount due on the date of conversion by 90% of the per share price of the convertible preferred stock sold in the qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing, if
consummated prior to March&nbsp;31, 2023, or 80% of the per share price, if consummated after March&nbsp;31, 2023. In the event of a change in control, the holders would receive an amount equal to 2.5 times the principal then outstanding plus the
amount of accrued interest outstanding immediately prior to the closing of such change in control. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company evaluated the provisions of the Notes and determined
an embedded derivative liability existed which was recorded upon issuance and remeasured periodically through the conversion date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the Series B
Convertible Preferred Stock issuance (&#147;Series B Issuance&#148;), the 2022 Notes were converted into 12,573,381 shares of Series B Convertible Preferred Stock at a price of $0.90, on November&nbsp;7, 2022. As the Series B Issuance was a
qualified financing event and was consummated prior to March&nbsp;31, 2023, the shares were converted using a 90% discount rate as follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Principal balance of convertible notes</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total converted to Series B convertible preferred stock</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">11,316</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. Convertible preferred stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On
November&nbsp;7, 2022, the Company amended and restated its certificate of incorporation increasing the total number of shares authorized to issue 237,000,000 shares of common stock, $0.0001 par value per share, and 182,838,619 shares of convertible
preferred stock, $0.0001 par value per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Issuances of convertible preferred stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In July 2020, the Company entered into a Series A convertible preferred stock purchase agreement (&#147;Series A SPA&#148;) under which it issued 29,112,081 shares of
Series A convertible preferred stock, for cash, at a price of $0.687 per share, for gross proceeds of $20.0&nbsp;million (the &#147;Initial Series A Closing&#148;). The Company incurred issuance costs of $0.3&nbsp;million in relation to the issuance
of Series A Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series A Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. The Series A SPA contained provisions that potentially
obligated the Company to sell an additional 14,556,039 shares of Series A Convertible Preferred Stock at $0.687 per share in an additional closing contingent upon either the achievement of a regulatory milestone defined in the Series A SPA or upon
the agreement of the Company&#146;s board of directors and lead investor to waive the requirement to achieve the milestone. In the event that an Initial Series A Closing purchaser failed to purchase all of their required shares in the subsequent
Series A closing, each of the Series A Convertible Preferred Stock held by such purchaser automatically converted into <FONT STYLE="white-space:nowrap">one-half</FONT> of a share of common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with the Initial Series A Closing, convertible notes issued by the Company in 2019 and 2020, including accrued interest and accrued deferred compensation,
plus interest, were converted into 8,474,865 shares of Series A convertible preferred stock at a conversion price equal to 90% of the Series A financing, or $0.6183, representing a total of $5.4&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;12, 2021, the Company sold 16,011,641 additional shares of Series A convertible preferred stock at the same terms and conditions as those contained in
the initial Agreement. The gross proceeds from the sale of Series A Convertible Preferred Stock upon achieving the milestone event was $11.0&nbsp;million at $0.687 per share. The Company incurred immaterial issuance costs in relation to the issuance
of Series A Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series A Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;7, 2022 (the &#147;Initial Series B Closing&#148;), the Company entered into a Series B Preferred Stock Purchase Agreement (the &#147;Series B
SPA&#148;) to issue certain investors Series B Convertible Preferred Stock at a purchase price of $0.90 per share ($0.0001 par value). The Company amended the Certificate of Incorporation (&#147;Charter&#148;) on November&nbsp;7, 2022, which
authorized the issuance of 129,240,032 shares of Series B Convertible Preferred Stock, in addition to 53,598,587 shares of Series A Convertible Preferred Stock issued and outstanding. The Company also executed the Amended and Restated Right of First
Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement (the &#147;ROFR and CS&#148;) and the Amended and Restated Investors&#146; Rights Agreement (the &#147;A&amp;R Investors&#146; Rights&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Initial Series B Closing resulted in the issuance of 40,545,552 shares of Series B Convertible Preferred Stock, at a price of $0.90 per share, for gross cash
proceeds of $36.5&nbsp;million. The Company incurred issuance costs of $0.4&nbsp;million in relation to the issuance of Series B Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series B Convertible Preferred
Stock in mezzanine equity in the accompanying balance sheets. Concurrently with the Initial Series B Closing, the 2022 Notes, including accrued interest, were converted into 12,573,381 shares of Series B Convertible Preferred Stock at a conversion
price equal to 90% of the Series B financing. After the Initial Closing, the Company agreed to sell on the same terms and conditions as the first sale, an additional 76,121,099 shares of Series B Preferred Stock (the &#147;Series B Milestone
Issuance&#148;) upon achieving certain development milestones. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;15, 2023, the Company issued 76,121,099 shares of Series B Convertible Preferred
Stock, at a price of $0.90 per share, for gross cash proceeds of $68.5&nbsp;million in the Series B Milestone Issuance. The Company incurred immaterial issuance costs in relation to this issuance of Series B Convertible Preferred Stock, which have
been recorded as a reduction to the value of the Series B Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the Series A and Series B Convertible Preferred Stock have the following rights and preferences: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Voting rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Series A and Series B Convertible Preferred Stock are
entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A and Series B Convertible Preferred Stock held by such holder are convertible as of the record date for determining
stockholders entitled to vote on such matter. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Election of directors </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of record of shares of Series A Convertible Preferred Stock, exclusively and as a separate class, shall be entitled to elect three directors of the Company.
The holders of record of shares of Series B Convertible Preferred Stock, exclusively and as a separate class, shall be entitled to elect one director of the Company. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Non-cumulative</FONT> dividend </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Holders of Series A and Series B Convertible Preferred Stock, in preference to the holders of common stock, are entitled to receive, when, as and if declared by the
board of directors of the Company, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the Series A and Series B original issue price per annum on each outstanding share of Series A and
Series B Convertible Preferred Stock (the &#147;Preferred Dividends&#148;). All such Preferred Dividends shall be payable only when, as and if declared by the board of directors of the Company and shall be
<FONT STYLE="white-space:nowrap">non-cumulative.</FONT> No dividends have been declared <FONT STYLE="white-space:nowrap">to-date</FONT> as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion right </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each share of Series A and Series B Convertible
Preferred Stock is automatically converted into common stock upon either (a)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $2.061 or $2.25, respectively, per share (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act
of 1933, as amended, resulting in at least $50,000,000 of gross proceeds to the Corporation and in connection with such offering the common stock is listed for trading on the Nasdaq Stock Market&#146;s National Market, the New York Stock Exchange or
another exchange or marketplace approved the Board of Directors or (b)&nbsp;the affirmative vote or written consent of the majority preferred stockholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidation preference </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Corporation, the holders of shares of Series A and Series B Convertible Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its
stockholders, and in the event of a Deemed Liquidation Event (as defined in the Company&#146;s amended and restated certificate of incorporation), the holders of shares of Series A and Series B Convertible Preferred Stock then outstanding shall be
entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the available proceeds, as applicable, before any payment shall be made to the holders of common stock by reason of their ownership
thereof, an amount per share equal to the greater of (i)&nbsp;the Series A and Series B Convertible Preferred Stock original issue prices, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable
had all shares of Series A and Series B Convertible Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. Common stock </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company&#146;s certificate of incorporation, as amended and restated, authorized the Company to issue 237,000,000 shares of common stock, $0.0001 par value. As of December&nbsp;31, 2023 and 2022, there were 1,257,080 and 1,007,995 shares of common
stock issued and outstanding, respectively. Shares of common stock issued and outstanding as of December&nbsp;31, 2023, include 90,324 shares of restricted stock related to the unvested portion of early exercised common stock options. Shares of
common stock issued and outstanding as of December&nbsp;31, 2022, include 94,866 shares of restricted stock related to the unvested portion of early exercised common stock options and 89,764 shares of restricted stock related to unvested founder
shares. These are included in shares of common stock as they are considered to be legally outstanding as of December&nbsp;31, 2023 and 2022, respectively. These shares are subject to the Company&#146;s option to repurchase and are not transferrable
until such time as they are fully vested. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock reserved </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of common stock that have been reserved for the potential conversion of Preferred Stock, and outstanding stock options granted and stock options
available for grant under the Company&#146;s 2019 Stock Option and Grant Plan (the &#147;2019 Plan&#148;) as of December&nbsp;31, 2023 and 2022, are as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion of Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,418,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,750,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,203,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,493,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock options available for grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10,540,503</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">18,386,568</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. Stock-based compensation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019
Stock option and grant plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s 2019 Plan, as amended, provides for the Company to sell or issue common stock or restricted common stock or
to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors, and consultants of the Company. The 2019 Plan is administered by the board of directors or at the
discretion of the board of directors by a committee of the board. The exercise prices, vesting periods, and other restrictions are determined at the discretion of the board of directors or a committee of the board, except that the exercise price per
share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the contractual term of stock option may not be greater than 10 years. Stock options granted to date typically vest and
become exercisable over four years from the date of grant. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total number of shares of common stock that may be authorized under the 2019 Plan is 3,728,169
shares, of which 684,284 remained available for future grant as of December&nbsp;31, 2023. The shares available for issuance under the 2019 Plan may be authorized but unissued shares or shares reacquired by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock option valuation </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.01&#151;$4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.09&#151;$7.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80%&#151;90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.62%&#151;4.40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.42%&#151;4.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (years)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">6.02&#151;6.08</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">6.02&#151;6.08</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The determination of the grant date fair value of stock-based awards granted to employees, directors and nonemployees during the
years ended December&nbsp;31, 2023 and 2022, is estimated using the Black-Scholes option-pricing model, which is affected by a number of assumptions, presented as follows: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value of common stock: </I></B>As there has been no public market for the Company&#146;s common stock to date, the Company develops an estimate of the fair
value of our common stock on each grant date of options to purchase common stock. The fair value of the common stock underlying stock option awards was determined on each grant date by the Company&#146;s board of directors, taking into account input
from management and independent third-party valuation specialists, as well as other objective and subjective factors. These objective and subjective factors include, but are not limited to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prices of our convertible preferred stock sold to investors in arm&#146;s length transactions and the rights,
preferences and privileges of our convertible preferred stock relative to those of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the progress of our research and development programs, including the status of preclinical studies and clinical trials for
our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our results of operations and financial position, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of marketability of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a
sale of our company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">trends and developments in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the economy in general. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Dividends: </I></B>Expected dividend yield is zero because the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends
in the foreseeable future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expected volatility: </I></B>The Company lacks company-specific historical and implied volatility information. Therefore, it
estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until it has adequate historical data regarding the volatility of its own traded stock price. To
identify these peer companies, the Company considered the industry, stage of development, size, and financial leverage of potential comparable companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Risk-free interest rate: </I></B>The risk-free interest rate is determined by reference to the US Treasury yield
curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expected term: </I></B>The expected
term of the Company&#146;s stock options has been determined utilizing the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options. The expected term of stock options granted to
<FONT STYLE="white-space:nowrap">non-employees</FONT> is equal to the contractual term of the option award. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Summary of option activity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s stock option activity regarding employees, directors, and nonemployees for the years ended December&nbsp;31, 2023 and 2022, is summarized as follows
(<I>in thousands except share and per share amounts</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>average<BR>remaining<BR>contractual<BR>life (years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>intrinsic<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding&#151;January 1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8201;384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding&#151;December 31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,203,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,752,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250,347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(212,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding and exercisable&#151;December 31, 2023</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,493,777</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$6.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9.26</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$4,543</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additional information with regard to stock option activity involving employees and directors for the years ended December&nbsp;31,
2023 and 2022, is as follows (<I>in thousands except per share amounts</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>&#8195;As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average grant date fair value per option of total options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$7.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aggregate intrinsic value of stock options exercised</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, total unrecognized compensation cost related to the unvested awards to employees, directors, and
nonemployees is $10.2&nbsp;million, which is expected to be recognized over a weighted-average period of 3.4 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the years ended December&nbsp;31, 2023 and 2022, the Company recorded stock-based compensation expense regarding its employees, directors, and nonemployees as
follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>&#8195;For&nbsp;the&nbsp;year&nbsp;ended<BR>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8201;904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$306</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$2,043</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. Income taxes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recorded no
income tax benefit for the net loss incurred for the years ended December&nbsp;31, 2023 and 2022, due to the uncertainty of realizing a benefit from such losses. All of the Company&#146;s operating losses since inception have been generated in the
United States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A reconciliation of the U.S. federal statutory income tax rate to the Company&#146;s effective tax rate is as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>&#8195;As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State tax rate, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal research tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Debt financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Permanent differences and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">%&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant components of the Company&#146;s deferred tax assets as of December&nbsp;31, 2023 and 2022, are included
in the table below (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Capitalized research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net deferred tax assets</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets,
which are composed primarily of net operating loss (&#147;NOL&#148;) carryforwards, capitalized research and development costs and research and development credit carryforwards. Management has considered the Company&#146;s history of net losses
incurred since inception and probability of future losses to conclude it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. As a result, the Company has established a valuation
allowance for the full amount of the net deferred tax assets as of December&nbsp;31, 2023 and 2022. At such time as it is determined that it is more likely than not that the deferred tax assets will be realizable, the valuation allowance will be
reduced. The valuation allowance increased by $9.2&nbsp;million during the year ended December&nbsp;31, 2023, due to the increase in the deferred tax assets by the same amounts. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, the Company had $30.1&nbsp;million and $71.3&nbsp;million of US federal NOLs and state NOL carryforwards, respectively. The federal NOLs
have no expiration and the state NOLs begin to expire in 2039. In addition, the Company had US federal research and development tax credit carryforwards of $4.7&nbsp;million, which may be available to reduce future tax liabilities which start to
expire in 2039. The Company had Indiana state research and development tax credits of $1.2&nbsp;million as of December&nbsp;31, 2023, which begin to expire in 2029. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective January&nbsp;1, 2022, the 2017 Tax Cuts and Jobs Act (&#147;TCJA&#148;) requires research and experimental (&#147;R&amp;E&#148;) expenses under Internal
Revenue Code Section&nbsp;174 to be capitalized. R&amp;E expenses are required to be amortized over a five-year period for domestic expenses and over a fifteen-year period for foreign expenses. Prior to the TCJA being effective, businesses had the
option of deducting Section&nbsp;174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The Company has reflected this change in treatment of R&amp;E expenses in the current tax provision and resulted in the
capitalization of $27.3&nbsp;million and $21.0&nbsp;million of R&amp;E expenses for tax years ended December&nbsp;31, 2023 and 2022, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Realization of
the future tax benefits is dependent on many factors, including the Company&#146;s ability to generate taxable income within the NOL carryforward period. Under the provisions of Sections 382 and 383 of the Internal Revenue Code, and corresponding
provisions of state law, certain substantial changes in the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of NOL carryforwards, which could
be used annually to offset future taxable income. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to the existence of the valuation allowance, future recognition of previously unrecognized tax benefits will
not impact the Company&#146;s effective tax rate. The Company is subject to taxation in the U.S and various state jurisdictions. All tax years since incorporation remain open to examination by the major taxing jurisdictions (state and federal) to
which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (IRS) or other authorities if they have or will be used in a future period. The Company is not
currently under examination by the IRS or any other jurisdictions for any tax year. The Company&#146;s practice is to recognize interest and penalties related to income tax matters in income tax expense. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company had no accrued interest or penalties related to income tax matters in the Company&#146;s balance sheets as of December&nbsp;31, 2023, and 2022. Further, the
Company is not currently under examination by any federal, state or local tax authority. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Inflation Reduction Act 2022 (&#147;IRA 2022&#148;) which incorporates
a Corporate Alternative Minimum Tax (CAMT) was signed on August&nbsp;16, 2022 and became applicable to the Company on January&nbsp;1, 2023. The new tax will require companies to compute two separate calculations for federal income tax purposes and
pay the greater of the new minimum tax or their regular tax liability. As of December&nbsp;31, 2023, IRA 2022 has not had a material impact to the Company&#146;s financial results. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the changes to the Company&#146;s gross unrecognized tax benefits for the years ended December&nbsp;31, 2023 and 2022, respectively (in
thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at January&nbsp;1,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Decrease related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at December&nbsp;31,</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,179</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,114</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The unrecognized tax benefit amounts are reflected in the determination of the Company&#146;s deferred tax assets. If recognized, none of
these amounts would affect the Company&#146;s effective tax rate, since it would be offset by an equal corresponding adjustment in the valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits
within the next twelve months. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is subject to taxation in the U.S. federal and various state jurisdictions. All tax years since incorporation remain open
to examination by the major taxing jurisdictions (state and federal) to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (IRS) or other
authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax year. The Company&#146;s practice is to recognize interest and penalties related to income
tax matters in income tax expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company had no accrued interest or penalties related to income tax matters in the Company&#146;s balance sheets as of
December&nbsp;31, 2023, and 2022. Further, the Company is not currently under examination by any federal, state or local tax authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. Defined contribution plan </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company established a defined contribution savings plan under Section&nbsp;401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet
minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. As of December&nbsp;31, 2023 and 2022, the Company did not make any contributions to the plan on behalf of our employees.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15. Net loss per share attributable to common stockholders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net
loss per share </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company.
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For the year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in
computation of net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">667,018</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,018,757</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s potential dilutive securities, which include convertible preferred stock, restricted stock related to early
exercise of common stock options, restricted stock related to unvested founder shares and outstanding common stock options, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the
weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The potential dilutive securities included in the table below, presented on an as
converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For the year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Convertible Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Convertible Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,418,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,750,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,203,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,493,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock related to early exercise of options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock related to unvested founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10,264,594</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">17,792,608</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>16. Related party transactions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April
2019, the Company executed a Master Research Agreement with The Trustees of Indiana University (the &#147;Research Agreement&#148;) pursuant to which the Company agreed to fund certain research of a director and former officer of the Company. The
period of performance for this agreement is June&nbsp;1, 2019 through April&nbsp;30, 2022 and the contract totals approximately $2.8&nbsp;million. On February&nbsp;14, 2022, the Research Agreement was amended to extend the period of performance from
April&nbsp;30, 2022 to April&nbsp;30, 2025 and increase the total contract costs by $3.0&nbsp;million. The Company paid $0.7&nbsp;million and $1.2&nbsp;million pursuant to this agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
during the years ended December&nbsp;31, 2023 and 2022, respectively. The Research Agreement also provides the Company an option to license the technology arising under the agreement (see Note 8
and 16). </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, two of the officers of the Company, who are also directors, participated in the 2022 Notes financing totaling $0.9&nbsp;million. The
2022 Notes were converted to Series B Convertible Preferred Stock (see Note 9 and 10) in November 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2023, one of the officers of the Company, who is
also a director, participated in the Series&nbsp;B Milestone Issuance financing totaling $0.7 million.<B> </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>17. Subsequent events </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has evaluated subsequent events through March&nbsp;22, 2024, the date the financial statements were issued, to ensure these financial statements include
appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. The Company has further evaluated subsequent events through September&nbsp;9, 2024. The
Company has concluded no subsequent events have occurred that require disclosure, except for those referenced below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Series C Convertible Preferred Stock
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;2, 2024, the Company entered into a Series C convertible preferred stock purchase agreement (&#147;Series C SPA&#148;) under which it issued
61,650,480&nbsp;shares of Series C Convertible Preferred Stock, for cash, at a price of $1.03 per share, for gross proceeds of $63.5&nbsp;million (the &#147;Series C Closing&#148;). The Series C SPA entitles holders of Series C Convertible Preferred
Stock substantially the same rights and preferences as the holders of Series A and Series B Convertible Preferred Stock with respect to voting rights, dividends, conversion rights and liquidation preference described in Note&nbsp;10. None of the
holders of the Series C Convertible Preferred Stock are entitled to the election of a director for the Company&#146;s board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">One of the officers of the
Company, who is also a director, participated in the Series C Closing totaling $1.0&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26, 2024, the Company&#146;s board of directors approved a one-for 12.0221 reverse stock split, to be effected on September&nbsp;6, 2024, of its issued
and outstanding shares of common stock and a proportional adjustment to the existing conversion prices for the Company&#146;s convertible preferred stock (see Note 10). Accordingly, all issued and outstanding share and per share amounts of common
stock and stock option awards for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split. The par value of the common stock and
preferred stock was not adjusted as a result of the reverse stock split. The number of authorized shares has not changed as the Company plans to file an amended and restated certificate of incorporation upon the closing of the offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2024 Stock Option and Incentive Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26, 2024, the
Company&#146;s board directors adopted, and on August&nbsp;30, 2024, its stockholders approved, the 2024 Stock Option and Incentive Plan (the &#147;2024 Plan&#148;), which will become effective immediately preceding the date on which the
registration statement of which this prospectus forms a part is declared effective by the SEC. The 2024 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The 2024 Plan
provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares of common stock, restricted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stock units, dividend equivalent rights and cash bonuses. The number of shares initially reserved for issuance under the 2024 Plan is 3,065,000 shares. In addition, the number of shares reserved
and available for issuance under the 2024 Plan will automatically increase on January 1, 2025 and each January 1 thereafter, by five percent of the sum of the outstanding number of shares of common stock and the numbers of shares of common stock
issuable pursuant to the exercise of any outstanding pre-funded warrants to acquire common stock for a nominal exercise price on the immediately preceding December 31 or such lesser number of shares as determined by the compensation committee. The
number of shares reserved under the 2024 Plan is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
shares of common stock underlying any awards under the 2024 Plan and the 2019 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to
vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2024 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2024 Employee Stock Purchase Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26, 2024, the
Company&#146;s board directors adopted, and on August&nbsp;30, 2024, its stockholders approved, the 2024 Employee Stock Purchase Plan (the &#147;2024 ESPP&#148;), which will become effective immediately preceding the date on which the registration
statement of which this prospectus forms a part is declared effective by the SEC. A total of 289,346 shares of common stock were initially reserved for issuance under this plan. The 2024 ESPP provides that the number of shares reserved and available
for issuance will automatically increase on January 1, 2025 and each January 1 thereafter, by the least of (i)&nbsp;578,872&nbsp;shares of common stock, (ii)&nbsp;one percent of the number of shares of common stock issued and outstanding on the
immediately preceding December&nbsp;31, or (iii)&nbsp;such lesser number of shares of common stock as determined by the administrator of the 2024 ESPP. The number of shares reserved under the 2024 ESPP is subject to adjustment in the event of a
stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Amended Certificate of Incorporation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26, 2024, the Company&#146;s board of directors adopted, and on August 30, 2024, its stockholders approved, the Fourth Amended and Restated Certificate of
Incorporation, which will become effective immediately preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. The Fourth Amended and Restated Certificate of Incorporation
increases the number of shares of common stock authorized for issuance from 237,000,000 to 500,000,000 and authorizes the issuance of 10,000,000&nbsp;shares of undesignated preferred stock, par value of $0.0001. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_7"></A>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>CONDENSED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>(in thousands, except share and per share
amounts) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8196;12,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;84,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8196;62,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8199;&#8196;3,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Share repurchase liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Convertible Preferred Stock, $0.0001 par value, 53,598,587 shares authorized, issued and
outstanding (liquidation preference of $36,822,229) as of June&nbsp;30, 2024 and December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Convertible Preferred Stock, $0.0001 par value, 129,240,032 shares authorized and 129,240,032
issued and outstanding (liquidation preference of $116,316,029) as of June&nbsp;30, 2024 and December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.0001 par value, 237,000,000 shares authorized and 1,317,099 issued and outstanding as of
June&nbsp;30, 2024 and 237,000,000 shares authorized and 1,257,080 issued and outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, convertible preferred stock and
stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">84,180</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8199;&#8196;62,882</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_8"></A>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(Unaudited&#151;in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in
computation of net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">923,696</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,229,473</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:230pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_9"></A>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>CONDENSED STATEMENTS OF STOCKHOLDERS&#146; EQUITY (DEFICIT) AND CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(Unaudited&#151;in thousands, except share amounts) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series A<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series B<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at January&nbsp;1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8199;53,118,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8199;47,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,007,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8198;411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(43,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8196;3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(42,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="37" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">53,118,933</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">47,378</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,234,145</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$1,186</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(56,577</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8197;&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(55,390</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series A<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series B<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at January&nbsp;1, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,240,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,257,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;(75,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8196;60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(72,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="37" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at June&nbsp;30, 2024</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">129,240,032</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,317,099</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$5,905</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(103,777</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(15</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(97,885</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_10"></A>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>CONDENSED STATEMENTS OF CASH FLOWS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(Unaudited&#151;in thousands) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000;border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Non cash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accretion and amortization of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Payments related to offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vesting of early exercised stock options and founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred initial public offering costs included in accounts payable
and accrued expenses</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">934</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_11"></A>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. NATURE OF BUSINESS AND LIQUIDITY </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX Biosciences, Inc. (&#147;MBX&#148; or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel
precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders. The Company was organized in August 2018 in Indiana as a Limited
Liability Company and converted to a C corporation in the state of Delaware in April 2019. The Company maintains its corporate offices in Carmel, Indiana. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since
inception, the Company has devoted substantially all of its resources to drug discovery and development of its product candidates MBX 2109, MBX 1416 and MBX 4291, and other preclinical programs, building an intellectual property portfolio,
organizing and staffing the Company, business planning, raising capital and providing general and administrative support for these operations. The Company does not have any products approved for sale and have not generated any revenue from product
sales. The Company has historically funded its operations primarily through sales of convertible preferred stock and convertible notes, which generated approximately $214.1&nbsp;million in aggregate gross proceeds, including the proceeds received
from the issuance of Series C convertible preferred stock discussed in Note 16. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From inception and through June&nbsp;30, 2024, the Company has devoted substantially all of its efforts to drug discovery and development. The Company has a limited
operating history, has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of June&nbsp;30, 2024, the Company has an accumulated deficit of $103.8&nbsp;million and
cash, cash equivalents and marketable securities of $55.3&nbsp;million. Based on the Company&#146;s current business plan, management believes that existing cash and cash equivalents and marketable securities, along with proceeds received from the
issuance of Series C convertible preferred stock discussed in Note 16, will be sufficient to fund the Company&#146;s obligations for at least 12 months from the date of issuance of these financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accompanying unaudited condensed financial
statements as of June&nbsp;30, 2024 and for the six months ended June&nbsp;30, 2023 and 2024 have been prepared in accordance with U.S. generally accepted accounting principle (U.S. GAAP) for interim financial information and pursuant to Article 10
of Regulation of the Securities Act of 1933, as amended. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal
and recurring adjustments that the Company believes are necessary to fairly state the Company&#146;s financial position and the results of its operations and cash flows. The results for the six months ended June&nbsp;30, 2024 are not necessarily
indicative of the results expected for the full fiscal year or any subsequent interim period. The condensed balance sheet at December&nbsp;31, 2023 has been derived from the audited financial statements at that date but does not include all
disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed financial statements and the notes
accompanying them should be read in conjunction with the Company&#146;s audited consolidated financial statements for the year ended December&nbsp;31, 2023 included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s significant accounting policies are disclosed in the audited financial statements appearing elsewhere in this prospectus. Since the date of such
audited financial statements, there have been no changes to the Company&#146;s significant accounting policies, except as noted below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Deferred offering
costs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company capitalizes as deferred offering costs all direct and incremental legal, professional, accounting and other third-party fees incurred in
connection with the Company&#146;s initial public offering (&#147;IPO&#148;). The deferred offering costs will be offset against the IPO proceeds upon the consummation of an offering. As of June&nbsp;30, 2024, $0.7&nbsp;million of deferred offering
costs were included in accounts payable and $0.2&nbsp;million deferred offering costs were included in accrued expenses in the accompanying balance sheets. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Recently issued accounting pronouncements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, new
accounting pronouncements are issued by the FASB or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are
not yet effective will not have a material impact on the accompanying financial statements and disclosures. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. FAIR VALUE MEASUREMENTS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents information about the Company&#146;s financial instruments as of June&nbsp;30, 2024 and December&nbsp;31, 2023, that are measured at fair
value on a recurring basis and indicates the fair value hierarchy of the inputs the Company utilized to determine such fair value (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">80,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">70,590</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9,922</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">54,689</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">51,701</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,988</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. MARKETABLE SECURITIES </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of
the Company&#146;s marketable securities as of June&nbsp;30, 2024 and December&nbsp;31, 2023 is based on Level&nbsp;1 and Level&nbsp;2 inputs. The Company&#146;s investments consist mainly of U.S. government and agency securities,
government-sponsored bond obligations and certain other corporate debt securities. Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry
standard valuation models, for which all significant inputs are observable, either </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities;
and other observable inputs. There were no transfers between levels within the fair value hierarchy during the six months ended June&nbsp;30, 2024 and year ended December&nbsp;31, 2023. The Company has assessed U.S. government treasuries as
Level&nbsp;1 and all other marketable securities as Level&nbsp;2 within the fair value hierarchy of ASC 820. The Company classifies its entire investment portfolio as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> as defined in ASC 320, Debt Securities, and views all investments as available for use in its current operations. We have therefore classified all
securities as current, even if we do not necessarily intend to dispose of the securities in the following year. Securities are carried at fair value with the unrealized gains (losses) reported in other comprehensive income (loss). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2024 and December&nbsp;31, 2023, none of the Company&#146;s investments were determined to be other than temporarily impaired. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the Company&#146;s investments (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>(Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Fair<BR>Value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government and agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$50,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$50,093</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$62</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$50,153</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>(Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Fair<BR>Value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government and agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$42,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$42,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$42,774</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$(15</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$42,759</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair values of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities as
of June&nbsp;30, 2024, by contractual maturity, are summarized as follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due in one year or less</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due after one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">42,759</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. PREPAID EXPENSES AND OTHER CURRENT ASSETS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prepaid and other current assets consisted of the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#8201;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:9pt; font-family:arial; " ALIGN="right"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="7" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total prepaid and other current assets</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$2,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$3,539</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. PROPERTY AND EQUIPMENT, NET </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment, net consisted of the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:9pt; font-family:arial; " ALIGN="right"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8196;162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;&#8201;181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$&#8196;439</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$1,105</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depreciation expense was $0.1&nbsp;million for the six months ended June&nbsp;30, 2024 and 2023, respectively. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. ACCRUED EXPENSES </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses consisted of the following (<I>in
thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:9pt; font-family:arial; " ALIGN="right"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$2,382</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$4,815</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. OTHER ASSETS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other assets consisted of
the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8201;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Security deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other assets</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$50</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$2,802</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2022, the Company entered into an operating lease
agreement for a principal executive office in Carmel, Indiana (the &#147;Carmel Lease&#148;). The Carmel Lease commenced in October 2022 and has an initial term of 39 months, terminating in December 2025, with an option to extend for 36 additional
months at the Company&#146;s discretion. The option to extend is not considered reasonably certain as of the lease inception. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, The Company entered into an operating lease agreement for laboratory space in Indianapolis, Indiana
(the &#147;Laboratory Lease&#148;). The Laboratory Lease commenced in December 2023 and has a term of 12 months, terminating in December 2024. The lease does not contain an option to extend the term. Due to the lease term being only one year, we
have elected to account for it as a short-term lease with no corresponding lease liability or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset recorded, and lease payments recognized as expense on a
straight-line basis over the lease term. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has no other operating or finance leases as of June&nbsp;30, 2024 or December&nbsp;31, 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The future minimum rent payments relating to the Carmel Lease under the terms and conditions existing as of June&nbsp;30, 2024, are summarized as follows (<I>in
thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024 (remaining six months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$249</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company incurred $0.1&nbsp;million and $0.1&nbsp;million of rent expense for the six months ended June&nbsp;30, 2024 and 2023,
respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the operating lease term and discount rate for the Carmel Lease as of June&nbsp;30, 2024 and December&nbsp;31, 2023:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B><br><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">8.0%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">8.0%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash paid for amounts included in the measurement of the Company&#146;s operating lease liability was immaterial for the six months ended
June&nbsp;30, 2024. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the amount of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets
and lease liabilities included on the Company&#146;s balance sheet as of June&nbsp;30, 2024 and December&nbsp;31, 2023 (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Right-of</FONT> use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>License agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In January 2024,
the Company entered into an amendment (the &#147;Amendment&#148;) for the Exclusive License Agreement with Indiana University Research and Technology Corporation (&#147;IURTC&#148;) (the &#147;License Agreement&#148;), to license certain
intellectual property arising under the Research Agreement. The Amendment specifies IURTC is entitled to the receipt of additional clinical and regulatory milestones, as defined in the Amendment, up to an aggregate of $9.0&nbsp;million. Following
the execution of the Amendment, future remaining clinical and regulatory milestone payments in the License Agreement and all amendments total up to $9.3&nbsp;million. In consideration for the license, during the six months ended June&nbsp;30, 2024
and year ended December&nbsp;31, 2023, the Company paid immaterial licensing fees to IURTC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Legal proceedings </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether a potential loss amount or a potential
range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to its legal proceedings. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;7, 2022, the Company
amended and restated its certificate of incorporation increasing the total number of shares authorized to issue 237,000,000 shares of common stock, $0.0001 par value per share, and 182,838,619 shares of convertible preferred stock, $0.0001 par value
per share. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Issuances of convertible preferred stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In July
2020, the Company entered into a Series A convertible preferred stock purchase agreement (&#147;Series A SPA&#148;) under which it issued 29,112,081 shares of Series A convertible preferred stock, for cash, at a price of $0.687 per share, for gross
proceeds of $20.0&nbsp;million (the &#147;Initial Series A Closing&#148;). The Company incurred issuance costs of $0.3&nbsp;million in relation to the issuance of Series A Convertible Preferred Stock, which have been recorded as a reduction to the
value of the Series A Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. The Series A SPA contained provisions that potentially obligated the Company to sell an additional 14,556,039 shares of Series A Convertible
Preferred Stock at $0.687 per share in an additional closing contingent upon either the achievement of a regulatory milestone defined in the Series A SPA or upon the agreement of the Company&#146;s board of directors and lead investor to waive the
requirement to achieve the milestone. In the event that an Initial Series A Closing purchaser failed to purchase all of their required shares in the subsequent Series A closing, each of the Series A Convertible Preferred Stock held by such purchaser
automatically converted into <FONT STYLE="white-space:nowrap">one-half</FONT> of a share of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with the Initial Series A Closing,
convertible notes issued by the Company in 2019 and 2020, including accrued interest and accrued deferred compensation, plus interest, were converted into 8,474,865 shares of Series A convertible preferred stock at a conversion price equal to 90% of
the Series A financing, or $0.6183, representing a total of $5.4&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;12, 2021, the Company sold 16,011,641 additional shares of Series A
convertible preferred stock at the same terms and conditions as those contained in the initial Agreement. The gross proceeds from the sale of Series A Convertible Preferred Stock upon achieving the milestone event was $11.0&nbsp;million at $0.687
per share. The Company incurred immaterial issuance costs in relation to the issuance of Series A Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series A Convertible Preferred Stock in mezzanine equity in
the accompanying balance sheets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;7, 2022 (the &#147;Initial Series B Closing&#148;), the Company entered into a Series B Preferred Stock Purchase
Agreement (the &#147;Series B SPA&#148;) to issue certain investors Series B Convertible Preferred Stock at a purchase price of $0.90 per share ($0.0001 par value). The Company amended the Certificate of Incorporation (&#147;Charter&#148;) on
November&nbsp;7, 2022, which authorized the issuance of 129,240,032 shares of Series B Convertible Preferred Stock, in addition to 53,598,587 shares of Series A Convertible Preferred Stock issued and outstanding. The Company also executed the
Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement (the &#147;ROFR and CS&#148;) and the Amended and Restated Investors&#146; Rights Agreement (the &#147;A&amp;R Investors&#146; Rights&#148;).
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Initial Series B Closing resulted in the issuance of 40,545,552 shares of Series B Convertible Preferred Stock, at a price of $0.90 per share, for gross cash
proceeds of $36.5&nbsp;million. The Company incurred issuance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
costs of $0.4&nbsp;million in relation to the issuance of Series B Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series B Convertible Preferred Stock in
mezzanine equity in the accompanying balance sheets. Concurrently with the Initial Series B Closing, the 2022 Notes, including accrued interest, were converted into 12,573,381 shares of Series B Convertible Preferred Stock at a conversion price
equal to 90% of the Series B financing. After the Initial Closing, the Company agreed to sell on the same terms and conditions as the first sale, an additional 76,121,099 shares of Series B Preferred Stock (the &#147;Series B Milestone
Issuance&#148;) upon achieving certain development milestones. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;15, 2023, the Company issued 76,121,099 shares of Series B Convertible Preferred
Stock, at a price of $0.90 per share, for gross cash proceeds of $68.5&nbsp;million in the Series B Milestone Issuance. The Company incurred immaterial issuance costs in relation to this issuance of Series B Convertible Preferred Stock, which have
been recorded as a reduction to the value of the Series B Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the
Series A and Series B Convertible Preferred Stock have the following rights and preferences: </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Voting rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Series A and Series B Convertible Preferred Stock are entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of
Series A and Series B Convertible Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Election of directors </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of record of shares of Series A
Convertible Preferred Stock, exclusively and as a separate class, shall be entitled to elect three directors of the Company. The holders of record of shares of Series B Convertible Preferred Stock, exclusively and as a separate class, shall be
entitled to elect one director of the Company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Non-cumulative</FONT> dividend </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Holders of Series A and Series B Convertible Preferred Stock, in preference to the holders of common stock, are entitled to receive, when, as and if declared by the
board of directors of the Company, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the Series A and Series B original issue price per annum on each outstanding share of Series A and
Series B Convertible Preferred Stock (the &#147;Preferred Dividends&#148;). All such Preferred Dividends shall be payable only when, as and if declared by the board of directors of the Company and shall be
<FONT STYLE="white-space:nowrap">non-cumulative.</FONT> No dividends have been declared <FONT STYLE="white-space:nowrap">to-date</FONT> as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion right </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each share of Series A and Series B Convertible
Preferred Stock is automatically converted into common stock upon either (a)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $2.061 or $2.25, respectively, per share (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act
of 1933, as amended, resulting in at least $50,000,000 of gross proceeds to the Corporation and in connection with such offering the common stock is listed for trading on the Nasdaq Stock Market&#146;s National Market, the New York Stock Exchange or
another exchange or marketplace approved the Board of Directors or (b)&nbsp;the affirmative vote or written consent of the majority preferred stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidation preference </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Series A and Series B Convertible
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, and in the event of a Deemed Liquidation Event (as defined in the Company&#146;s amended and restated
certificate of incorporation), the holders of shares of Series A and Series B Convertible Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the
available proceeds, as applicable, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;the Series A and Series B Convertible Preferred Stock
original issue prices, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable had all shares of Series A and Series B Convertible Preferred Stock been converted into common stock immediately
prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. COMMON STOCK </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s certificate of incorporation, as amended and restated, authorized the Company to issue 237,000,000 shares of common stock, $0.0001 par value. As of
June&nbsp;30, 2024 and December&nbsp;31, 2023, there were 1,317,099 and 1,257,080 shares of common stock issued and outstanding, respectively. Shares of common stock issued and outstanding as of June&nbsp;30, 2024, include 35,703 shares of
restricted stock related to the unvested portion of early exercised common stock options. Shares of common stock issued and outstanding as of December&nbsp;31, 2023, include 90,324 shares of restricted stock related to the unvested portion of early
exercised common stock options. These are included in shares of common stock as they are considered to be legally outstanding as of June&nbsp;30, 2024 and December&nbsp;31, 2023, respectively. These shares are subject to the Company&#146;s option to
repurchase and are not transferrable until such time as they are fully vested. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock reserved </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of common stock that have been reserved for the potential conversion of Preferred Stock, and outstanding stock options granted and stock options
available for grant under the Company&#146;s 2019 Stock Option and Grant Plan (the &#147;2019 Plan&#148;) as of June&nbsp;30, 2024 and December&nbsp;31, 2023, are as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion of Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,750,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,750,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,493,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,864,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock options available for grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">18,386,568</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">18,326,532</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. STOCK-BASED COMPENSATION </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019
Stock Option and Grant Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s 2019 Plan, as amended, provides for the Company to sell or issue common stock or restricted common stock or
to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors, and consultants of the Company. The 2019 Plan is administered by the board of directors or at the
discretion of the board of directors by a committee of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
board. The exercise prices, vesting periods, and other restrictions are determined at the discretion of the board of directors or a committee of the board, except that the exercise price per
share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the contractual term of stock option may not be greater than 10 years. Stock options granted to date typically vest and
become exercisable over four years from the date of grant. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total number of shares of common stock that may be authorized under the 2019 Plan is 3,728,169
shares, of which 253,615 remained available for future grant as of June&nbsp;30, 2024. The shares available for issuance under the 2019 Plan may be authorized but unissued shares or shares reacquired by the Company. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock option valuation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The determination of the grant date fair value
of stock-based awards granted to employees, directors and nonemployees during the six months ended June&nbsp;30, 2024 and 2023, is estimated using the Black-Scholes option-pricing model and was calculated based on the following assumptions. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.14&#151;$10.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90%&#151;100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.42%&#151;3.69</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.93%&#151;5.18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (years)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">0.50&#151;6.08</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Summary of option activity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company&#146;s stock option activity regarding employees, directors, and nonemployees for the six months ended June&nbsp;30, 2024, is summarized as follows (<I>in thousands except share and per share amounts</I>): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Life&nbsp;(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>intrinsic<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding&#151;December 31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,493,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&#8199;4,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,032</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding and exercisable&#151;June 30, 2024</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,864,410</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$6.68</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9.06</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$10,828</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additional information with regard to stock option activity involving employees and directors for the six months ended June&nbsp;30,
2024 and 2023, is as follows (<I>in thousands except per share amounts</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>&#8199;&#8199;As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average grant date fair value per option of total options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$9.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aggregate intrinsic value of stock options exercised</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2024, total unrecognized compensation cost related to the unvested awards to employees, directors, and
nonemployees is $11.2&nbsp;million, which is expected to be recognized over a weighted-average period of 3.1 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June&nbsp;30, 2024 and 2023, the Company recorded stock-based compensation expense regarding its employees, directors, and nonemployees as
follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>&#8199;&#8199;For&nbsp;the&nbsp;six&nbsp;months&nbsp;ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">$2,542</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. DEFINED CONTRIBUTION PLAN </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company
established a defined contribution savings plan under Section&nbsp;401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their
annual compensation on a pretax basis. As of June&nbsp;30, 2024, the Company did not make any contributions to the plan on behalf of our employees. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. NET LOSS
PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net loss per share </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands except share and
per share amounts). </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;six&nbsp;months&nbsp;ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#8201;&#8196;&#8199;&#8196;(13,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#8201;&#8196;&#8199;&#8199;&#8199;&#8196;(14.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in
computation of net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">923,696</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,229,473</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s potential dilutive securities, which include convertible preferred stock, restricted stock related to early
exercise of common stock options, restricted stock related to unvested founder shares and outstanding common stock options, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the
weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The potential dilutive securities included in the table below, presented on an as
converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For the six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Convertible Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Convertible Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,418,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,750,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,864,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock related to early exercise of options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock related to unvested founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10,164,502</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">18,108,620</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15. RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2019, the Company executed a Master Research Agreement with The Trustees of Indiana University (the &#147;Research Agreement&#148;) pursuant to which the
Company agreed to fund certain research of a director and former officer of the Company. The period of performance for this agreement is June&nbsp;1, 2019 through April&nbsp;30, 2022 and the contract totals approximately $2.8&nbsp;million. On
February&nbsp;14, 2022, the Research Agreement was amended to extend the period of performance from April&nbsp;30, 2022 to April&nbsp;30, 2025 and increase the total contract costs by $3.0&nbsp;million. The Company paid $0.6&nbsp;million and
$0.5&nbsp;million pursuant to this agreement during the six months ended June&nbsp;30, 2024 and 2023, respectively. The Research Agreement also provides the Company an option to license the technology arising under the agreement (see Note 9). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>16. SUBSEQUENT EVENTS </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has evaluated subsequent events
through September 9, 2024, the date the unaudited condensed financial statements were available to be issued, to ensure these financial statements include appropriate disclosure of events both recognized in the financial statements and events which
occurred but were not recognized in the financial statements. The Company has concluded no subsequent events have occurred that require disclosure, except for those referenced below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B></B><B><I>Series C Convertible Preferred Stock</I></B><B> </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;2,
2024, the Company entered into a Series C convertible preferred stock purchase agreement (&#147;Series C SPA&#148;) under which it issued 61,650,480 shares of Series C Convertible Preferred Stock, for cash, at a price of $1.03 per share, for gross
proceeds of $63.5&nbsp;million (the &#147;Series C Closing&#148;). The Series C SPA entitles holders of Series C Convertible Preferred Stock substantially the same rights and preferences as the holders of Series A and Series B Convertible Preferred
Stock with respect to voting rights, dividends, conversion rights and liquidation preference described in Note 10. None of the holders of the Series C Convertible Preferred Stock are entitled to the election of a director for the Company&#146;s
board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">One of the officers of the Company, who is also a director, participated in the Series C Closing totaling $1.0&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B></B><B><I>Reverse Stock Split</I></B><B> </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26, 2024, the
Company&#146;s board of directors approved a <FONT STYLE="white-space:nowrap">one-for</FONT> 12.0221 reverse stock split, to be effected on September&nbsp;6, 2024, of its issued and outstanding shares of common stock and a proportional adjustment to
the existing conversion prices for the Company&#146;s convertible preferred stock (see Note 10). Accordingly, all issued and outstanding share and per share amounts of common stock and stock option awards for all periods presented in the
accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split. The par value of the common stock and preferred stock was not adjusted as a result of
the reverse stock split. The number of authorized shares has not changed as the Company plans to file an amended and restated certificate of incorporation upon the closing of the offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B></B><B><I>2024 Stock Option and Incentive Plan</I></B><B> </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26,
2024, the Company&#146;s board directors adopted, and on August&nbsp;30, 2024, its stockholders approved, the 2024 Stock Option and Incentive Plan (the &#147;2024 Plan&#148;), which will become effective immediately preceding the date on which the
registration statement of which this prospectus forms a part is declared </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
effective by the SEC. The 2024 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The 2024 Plan provides for the
grant of incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, stock appreciation rights, restricted shares of common stock, restricted stock units, dividend equivalent rights and cash bonuses. The number of
shares initially reserved for issuance under the 2024 Plan is 3,065,000 shares. In addition, the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January&nbsp;1, 2025 and each January&nbsp;1
thereafter, by five percent of the sum of the outstanding number of shares of common stock and the numbers of shares of common stock issuable pursuant to the exercise of any outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to
acquire common stock for a nominal exercise price on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by the compensation committee. The number of shares reserved under the 2024 Plan is subject to adjustment
in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock underlying any awards under the 2024 Plan and the
2019 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise
terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2024 Plan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2024 Employee Stock Purchase
Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26, 2024, the Company&#146;s board directors adopted, and on August&nbsp;30, 2024, its stockholders approved, the 2024 Employee Stock
Purchase Plan (the &#147;2024 ESPP&#148;), which will become effective immediately preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. A total of 289,346 shares of common
stock were initially reserved for issuance under this plan. The 2024 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January&nbsp;1, 2025 and each January&nbsp;1 thereafter, by the least of
(i) 578,872 shares of common stock, (ii)&nbsp;one percent of the number of shares of common stock issued and outstanding on the immediately preceding December&nbsp;31, or (iii)&nbsp;such lesser number of shares of common stock as determined by the
administrator of the 2024 ESPP. The number of shares reserved under the 2024 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Amended Certificate of Incorporation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;26, 2024, the
Company&#146;s board of directors adopted, and on August 30, 2024, its stockholders approved, the Fourth Amended and Restated Certificate of Incorporation, which will become effective immediately preceding the date on which the registration
statement of which this prospectus forms a part is declared effective by the SEC. The Fourth Amended and Restated Certificate of Incorporation increases the number of shares of common stock authorized for issuance from 237,000,000 to 500,000,000 and
authorizes the issuance of 10,000,000 shares of undesignated preferred stock, par value of $0.0001. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">****** </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B></B><B><I>8,500,000</I></B><B> </B><B><I>Shares</I></B><B> </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g790774g00a06.jpg" ALT="LOGO" STYLE="width:2.27777in;height:0.664165in;">
 </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:14pt">
<TD VALIGN="top" ALIGN="center"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Stifel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Guggenheim&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:110pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8195;&#8195;&#8195;&#8195;, 2024 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Through and including
&#8195;&#8195;&#8195;&#8195;, 2024 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in
addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Part II </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Information not
required in prospectus </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;13. Other expenses of issuance and distribution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, to be paid by us in connection with the sale of the shares of
common stock being registered hereby. All amounts shown are estimates except for the SEC registration fee, the FINRA filing fee and the Nasdaq Global Select Market initial listing fee. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.50pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">SEC registration fee</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.50pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.50pt solid #000000" ALIGN="right">23,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">3,750,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;14. Indemnification of directors and officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out
of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including
attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145 permits corporations to pay expenses
(including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain insurance on
behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to
indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will adopt provisions in our fourth amended and restated certificate of
incorporation and our amended and restated bylaws, which will be effective immediately prior to the closing of this offering and upon the effectiveness of this registration statement, respectively, that limit or eliminate the personal liability of
our directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director or officer will not be personally liable to us or our stockholders for monetary damages or breach of
fiduciary duty as a director or officer, except for liability for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director or officer&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These limitations of liability do not alter director and officer liability under the federal securities laws and do
not affect the availability of equitable remedies such as an injunction or rescission. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our bylaws, which will be effective upon the effectiveness of
this registration statement will provide that: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to enter into indemnification agreements with each of our directors and executive officers. These agreements provide that we will indemnify each of our
directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146; fees (but excluding judgments, fines and settlement amounts), to each
indemnified director or executive officer in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person&#146;s services as a director
or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third
parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our
obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in
their capacities as directors or officers, including liabilities under the Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting agreement filed as Exhibit 1.1 to this registration
statement provides for indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;15. Recent sales of unregistered securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the three years
preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Convertible
note issuances </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, we issued the 2022 Notes to certain accredited investors for gross in the aggregate principle amount of $10.0&nbsp;million
which included two options for conversion: (1)&nbsp;automatic conversion into shares of convertible preferred stock from the next qualified financing at 90% of the per share price of the convertible preferred stock sold in the qualified financing
consummated on or prior to March&nbsp;31, 2023, or 80% of the per share price of the convertible preferred stock sold in the qualified financing consummated after March&nbsp;31, 2023 and (2)&nbsp;optional conversion into shares of convertible
preferred stock from the next <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing at 90% of the per share price of the convertible preferred stock sold in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing consummated on
or prior to March&nbsp;31, 2023, or 80% of the per share price of the convertible preferred stock sold in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing consummated after March&nbsp;31, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preferred stock issuances </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2021, we issued an aggregate of 16,011,641 shares of our Series A preferred stock at a purchase price of $0.687 per share in connection with the achievement
of a certain development milestone for gross proceeds of $11.0 million. In November 2022 and August 2023, we issued an aggregate of 129,240,032 shares of our Series B preferred stock as follows: (a) 40,545,552 shares of Series B preferred stock sold
at a purchase price of $0.90 per share at the initial closing for gross proceeds of $36.5&nbsp;million, (b) 12,573,381 shares of Series B preferred stock which were converted pursuant to the conversion of the 2022 Notes and (c) 76,121,099 shares of
Series B preferred stock sold at a purchase price of $0.90 per share pursuant to the achievement of certain development milestones for gross proceeds of $68.5&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2024, we issued an aggregate of 61,650,480 shares of our Series C preferred stock at a purchase price of $1.03 for gross proceeds of $63.5 million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Option issuances </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since January&nbsp;1, 2021, we have granted to
our directors, officers, employees, consultants, and other key persons options to purchase an aggregate of 3,842,304 shares of common stock pursuant to the 2019 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock issuances </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since January 1, 2021, we have sold to our
directors, officers, employees, consultants, and other key persons an aggregate of 413,312&nbsp;shares of common stock at a weighted-average exercise price of $2.56 per share pursuant to the 2019 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock repurchases </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since January 1, 2021, we have
repurchased 25,267 shares of our common stock from former employees at a weighted-average cash purchase price of $1.60 per share for an immaterial total fair value. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, the
Registrant believes these transactions were exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2) of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule 701 promulgated under
Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these
transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these
transactions. All recipients had adequate access, through their relationships with the Registrant, to information about the Registrant. The sales of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;16. Exhibits and financial statement schedules </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(a) Exhibits. </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Exhibit<BR>number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Exhibit table</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d790774dex11.htm">Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d790774dex31.htm">Third Amended and Restated Certificate of Incorporation of the Registrant, as amended, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex32.htm">Form of Fourth Amended and Restated Certificate of Incorporation of the Registrant (to be effective immediately prior to the closing of
 this offering) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1776111/000119312524206227/d790774dex33.htm">Bylaws of the Registrant, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex34.htm">Form of Amended and Restated Bylaws (to be effective upon the effectiveness of this registration statement) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;4.1*&#043;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1776111/000119312524206227/d790774dex41.htm">Second Amended and Restated Investors&#146; Rights Agreement among the Registrant and certain of its stockholders, dated August 2, 2024</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1776111/000119312524206227/d790774dex42.htm">Form of Common Stock Certificate </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d790774dex51.htm">Opinion of Goodwin Procter LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.1*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1776111/000119312524206227/d790774dex101.htm">2019 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.2*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex102.htm">2024 Stock Option and Incentive Plan and forms of award agreements thereunder </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.3*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex103.htm">2024 Employee Stock Purchase Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.4*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex104.htm">Form of Officer Indemnification Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.5*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex105.htm">Form of Director Indemnification Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.6*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex106.htm">Senior Cash Incentive Bonus Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.7#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d790774dex107.htm">Non-Employee Director Compensation Policy </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.8*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1776111/000119312524206227/d790774dex108.htm">Exclusive License Agreement, dated as of June&nbsp;
10, 2020, between Indiana University Research and Technology Corporation and MBX Biosciences, Inc., as amended. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.9*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1776111/000119312524206227/d790774dex109.htm">Office Lease between Zeller-Carmel Property, L.L.C. and MBX Biosciences, Inc., dated April&nbsp;28, 2022. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.10*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex1010.htm">Employment Agreement between the Registrant and P. Kent Hawryluk, President and Chief Executive Officer, to be in effect upon the closing
 of this offering. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.11*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex1011.htm">Employment Agreement between the Registrant and Richard Bartram, Chief Financial Officer, to be in effect upon the closing of this offering.
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.12*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001776111/000119312524211217/d790774dex1012.htm">Employment Agreement between the Registrant and Salomon Azoulay, Chief Medical Officer, to be in effect upon the closing of this offering.
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1776111/000119312524206227/d790774dex211.htm">Subsidiaries of the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d790774dex231.htm">Consent of Ernst&nbsp;&amp; Young LLP, Independent Registered Public Accounting Firm </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d790774dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1776111/000119312524206227/d790774ds1.htm#sig">Power of Attorney (included on signature page) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">107</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><A HREF="d790774dexfilingfees.htm">Filing Fees Exhibit </A></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">#</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates a management contract or any compensatory plan, contract or arrangement. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) will be omitted in accordance with the rules of the SEC because the Registrant has determined that information is both not material and is the type that the registrant
treats as private or confidential. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#043;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Certain exhibits and schedules to these agreements have been omitted pursuant to Item&nbsp;601(a)(5) and (6) of Regulation&nbsp;S-K. The registrant will furnish copies of any of the exhibits and schedules to the SEC
upon request. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(b) Financial statement schedules. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;17. Undertakings </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the Underwriting Agreement certificates in such denominations and
registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Signatures </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to
the requirements of the Securities Act, MBX Biosciences, Inc. has duly caused this Amendment No.&nbsp;2 to the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Carmel, Indiana, on the 9th day of September, 2024. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MBX Biosciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">/s/ P. Kent Hawryluk</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">P. Kent Hawryluk</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the requirements of the Securities Act, this Amendment No.&nbsp;2 to the registration statement has been signed by
the following persons in the capacities indicated on the 9th day of September, 2024. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Signature</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Title</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">/s/ P. Kent Hawryluk</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">P. Kent
Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">/s/ Richard Bartram</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">Richard
Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">(Principal Financial Officer and Principal Accounting Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tiba Aynechi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James M. Cornelius</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Carl L. Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Edward T. Mathers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ora Pescovitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">*</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Steven Ryder</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">*&nbsp;By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ P. Kent Hawryluk</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Attorney-in-Fact</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d790774dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MBX BIOSCIENCES, INC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;]
Shares of Common Stock </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Underwriting Agreement </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">September, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">in
Schedule 1 hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383
Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MBX Biosciences, Inc., a
Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &#147;Underwriters&#148;), for whom you are acting as representatives (the &#147;Representatives&#148;), an
aggregate of [&#149;] shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), of the Company (the &#147;Underwritten Shares&#148;). In addition, the Company proposes to issue and sell, at the option of the Underwriters,
up to an additional [&#149;] shares of Common Stock of the Company (the &#147;Option Shares&#148;). The Underwritten Shares and the Option Shares are herein referred to as the &#147;Shares&#148;. The shares of Common Stock of the Company to be
outstanding after giving effect to the sale of the Shares are referred to herein as the &#147;Stock&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC
(the &#147;Directed Share Underwriter&#148;) has agreed to reserve a portion of the Shares to be purchased by it under this Agreement, up to [&#149;] Shares, for sale to the Company&#146;s directors, officers, and certain employees and other parties
related to the Company (collectively, &#147;Participants&#148;), as set forth in the Prospectus (as hereinafter defined) under the heading &#147;Underwriting&#148; (the &#147;Directed Share Program&#148;). The Shares to be sold by the Directed Share
Underwriter and its affiliates pursuant to the Directed Share Program are referred to hereinafter as the &#147;Directed Shares&#148;. Any Directed Shares not orally confirmed for purchase by any Participant by [&#149;] [A/P].M., New York City time
on the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the
purchase and sale of the Shares, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities and
Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (File No.&nbsp;333-281764), including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule
430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration Statement&#148;; and as used herein, the term
&#147;Preliminary Prospectus&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the
prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the prospectus in the form first used (or made available upon request of purchasers
pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &#147;Rule 462 Registration
Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Capitalized terms used but not defined herein shall have the meanings given to such terms in
the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company had prepared the
following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): a Preliminary Prospectus dated [&#149;], 2024 and each &#147;free-writing prospectus&#148; (as defined pursuant to
Rule 405 under the Securities Act) listed on Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means [&#149;] P.M., New York City time, on
[&#149;], 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this underwriting agreement (this
&#147;Agreement&#148;), and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of
$[&#149;] (the &#147;Purchase Price&#148;) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the
Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares at the Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares.
If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of
Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the
several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representatives in their sole discretion shall make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to purchase Option Shares at any time in whole, or from time to time in part, on or before the
thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is being exercised and the date and time when the
Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after
the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public offering of the Shares, and initially to offer the Shares on the
terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the accounts specified by the Company to the
Representatives, in the case of the Underwritten Shares, at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 450 Lexington Avenue, New York, New York 10017, at 10:00 A.M. New York City time on [&#149;], 2024, or at such other time or place on the
same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the Representatives
in the written notice of the Underwriters&#146; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the &#147;Closing Date&#148;, and the time and date for such payment for
the Option Shares, if other than the Closing Date, is herein referred to as the &#147;Additional Closing Date&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the
Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date
with any transfer taxes payable in connection with the sale of such Shares duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#147;DTC&#148;) unless the Representatives shall
otherwise instruct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges and agrees that the Representatives and the other Underwriters
are acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial
advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person in connection with the offering as to any legal, tax,
investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions
contemplated hereby, and neither the Representatives nor any other Underwriter shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the
transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Representatives and the other Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission,
and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue
statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no
representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly
for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of
the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in
writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in
the Prospectus has been omitted therefrom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer Free Writing Prospectus. </I>Other than the Registration Statement, the
Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make,
use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company or
its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of
the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representatives. Each such Issuer Free
Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433 under the Securities Act) filed in accordance with the Securities Act (to the extent required thereby)
and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing
Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or
Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or
Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Emerging Growth Company</I>. From the time of initial confidential submission of the Registration Statement to the Commission (or, if
earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication undertaken in
reliance on Section&nbsp;5(d) of the Securities Act) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;Emerging Growth Company&#148;). <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with potential investors undertaken in reliance on either Section&nbsp;5(d) of, or Rule
163B under, the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Materials. </I>The Company (i)&nbsp;has not alone engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representatives (x)&nbsp;with entities that are qualified institutional buyers (&#147;QIBs&#148;) within the meaning of Rule 144A under the Securities
Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act (&#147;IAIs&#148;) and otherwise in compliance with the requirements of Section&nbsp;5(d) of the
Securities Act or (y)&nbsp;with entities that the Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B under the Securities Act and (ii)&nbsp;has not authorized anyone other than the
Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications by virtue of a writing substantially in the form of Exhibit A hereto. The Company has not distributed or approved for distribution any
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than those listed on Annex B hereto. &#147;Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is
a written communication within the meaning of Rule 405 under the Securities Act. Any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict with the
information contained in the Registration Statement or the Pricing Disclosure Package, complied in all material respects with the Securities Act, and when taken together with the Pricing Disclosure Package as of the Applicable Time, did not, and as
of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Registration Statement and Prospectus.</I> The Registration Statement
has been declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the
Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the
Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the
case may be, the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only
such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Financial
Statements.</I> The financial statements (including the related notes thereto) of the Company included in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements
of the Securities Act and present fairly in all material respects the financial position of the Company as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial
statements have been prepared in conformity with generally accepted accounting principles (&#147;GAAP&#148;) in the United States applied on a consistent basis throughout the periods covered thereby, except in the case of any unaudited financial
statements, which are subject to normal year end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Registration Statement present fairly in all material respects the information required to be stated therein; the other financial information included in the Registration Statement, the
Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and presents fairly in all material respects the information shown thereby; and the <I>pro forma</I> financial information and the related
notes thereto included in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been prepared in accordance with the applicable requirements of the Securities Act and the assumptions underlying such pro forma financial
information are reasonable and are set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>No
Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock
(other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the
Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material
adverse change, or any development involving a prospective material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company; (ii)&nbsp;the
Company has not entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company or incurred any liability or obligation, direct or contingent, that is material to the Company; and
(iii)&nbsp;the Company has not sustained any loss or interference with its business that is material to the Company and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance
or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Organization and Good Standing.</I> The Company has been duly organized and is validly existing and in good standing under the laws of
its jurisdiction of organization, is duly qualified to do business and is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of its business requires such qualification, and has all power and authority
necessary to own or hold its properties and to conduct the business in which it is engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material
adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company or on the performance by the Company of its obligations under this Agreement (a &#147;Material
Adverse Effect&#148;). The Company does not have any direct or indirect subsidiaries and does not own or control, directly or indirectly, any corporation, association or other entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Capitalization.</I> The Company has an authorized capitalization as set forth in the
Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Capitalization&#148;; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated
by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or
instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of
the Company, any such convertible or exchangeable securities or any such rights, warrants or options; and the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the
Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Stock Options. </I>With respect to the stock options (the &#147;Stock
Options&#148;) granted pursuant to the stock-based compensation plans of the Company (the &#147;Company Stock Plans&#148;), (i) each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal
Revenue Code of 1986, as amended (the &#147;Code&#148;) so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary
corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and
the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in all material respects in accordance with the terms of the Company Stock Plans and all applicable laws and
regulatory rules or requirements, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company. The Company has not knowingly granted, and there is no and
has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or its results of
operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this
Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been
duly and validly taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and delivered by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>The Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and,
when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the
Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Descriptions of the Underwriting Agreement.</I> This Agreement conforms in all
material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>No Violation or Default.</I> The Company is not (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT>
or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in
any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any property or asset of the Company is subject; or (iii)&nbsp;in violation of any
law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or
in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No Conflicts. </I>The execution, delivery and performance by the Company of this
Agreement, the issuance and sale of the Shares by the Company and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a
breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right
or asset of the Company pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any property, right or asset of the Company is
subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or (iii)&nbsp;result in the violation of any law or statute or any
judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that
would not, individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>No Consents Required.</I> No consent, approval,
authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement and the consummation of the
transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry
Regulatory Authority, Inc. (&#147;FINRA&#148;) and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>Legal Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are
no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company is or may be a party or to which any property of the Company is or may be
the subject that, individually or in the aggregate, if determined adversely to the Company, could reasonably be expected to have a Material Adverse Effect; to the knowledge of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are
required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and
(ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package
or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Independent Accountants</I>. Ernst&nbsp;&amp; Young LLP, who has certified certain financial statements of the Company, is an
independent registered public accounting firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Title to Real and Personal Property.</I> The Company has good and marketable title in fee simple to, or has valid rights to lease
or otherwise use, all items of real and personal property that are material to the business of the Company, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not
materially interfere with the use made and proposed to be made of such property by the Company or (ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Intellectual Property.</I> (i)&nbsp;The Company owns or has a valid and enforceable right to use all patents, trademarks, service
marks, trade names, domain names and other source indicators, copyrights, copyrightable works, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, systems, procedures, proprietary or confidential information and all other intellectual
property, industrial property and proprietary rights, and all registrations and applications for registration of, and all goodwill associated with, any of the foregoing (collectively, &#147;Intellectual Property&#148;), in each case used or held for
use in the conduct of its business as conducted or proposed to be conducted in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii)&nbsp;to the knowledge of the Company, the Company&#146;s conduct of its business as
currently conducted or as proposed to be conducted in the Registration Statement, the Pricing Disclosure Package or the Prospectus does not infringe, misappropriate or otherwise violate, and has not infringed, misappropriated or otherwise violated,
any Intellectual Property of any third party; (iii)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, or proceeding by any third party (A)&nbsp;alleging that the Company has infringed, misappropriated or
otherwise violated the Intellectual Property rights of any third party, or (B)&nbsp;challenging the inventorship, ownership, validity, scope or enforceability of, or any rights of the Company in, any Intellectual Property owned by or licensed to the
Company; (iv)&nbsp;no Intellectual Property owned by or exclusively licensed to the Company has been adjudged by a court of competent jurisdiction to be invalid or unenforceable; (v)&nbsp;the Intellectual Property owned by the Company is exclusively
owned by the Company free and clear of all liens, encumbrances, and security interests; (vi)&nbsp;to the knowledge of the Company, no third party has infringed, misappropriated or otherwise violated any Intellectual Property owned by or exclusively
licensed to the Company; (vii)&nbsp;the Company has at all times taken reasonable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
steps in accordance with normal industry practice to appropriately protect, maintain and safeguard the confidentiality of all Intellectual Property, the value of which to the Company is
contingent upon maintaining the confidentiality thereof, including requiring employees, contractors, consultants and other third parties who receive such Intellectual Property to execute appropriate confidentiality agreements; and (viii)&nbsp;all
current and former employees and consultants and other parties involved in the development of Intellectual Property for the Company have signed agreements with the Company or, to the knowledge of the Company, a contractor of the Company, such that
the Company either (A)&nbsp;has obtained, or has the right or option to obtain, exclusive ownership of such Intellectual Property, or (B)&nbsp;has obtained a right to exploit such Intellectual Property, sufficient for the conduct of its business as
currently conducted or as proposed to be conducted in the Registration Statement, the Pricing Disclosure Package or the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)
<I>No Undisclosed Relationships.</I> No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company, on the other, that is
required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Investment Company Act.</I> The Company is not and, after giving effect to the offering and sale of the Shares and the application of
the proceeds thereof received by the Company as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by
an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Investment Company Act&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>Taxes.</I> The Company has filed all tax returns required to be filed through the date hereof and paid all taxes required to be paid
(except insofar as the failure to file or pay could not reasonably be expected to result in a Material Adverse Effect, or except taxes that are being contested in good faith and for which adequate reserves have been established by the Company).
Except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its
properties or assets and that could reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>Licenses and Permits.</I> The
Company possesses all licenses, <FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and has made all declarations and filings with, the appropriate federal, state, local or foreign
governmental or regulatory authorities that are necessary for the ownership or lease of its properties or the conduct of its business as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, including,
without limitation, from the U.S. Food and Drug Administration (the &#147;FDA&#148;), except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in each
of the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not received written notice of any revocation or modification of any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate,
permit or authorization or has any reason to believe that any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation,
modification or nonrenewal would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the
Company exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its principal suppliers, contractors or
customers, except as would not have a Material Adverse Effect. The Company has not received any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>Certain Environmental Matters</I>. (i)&nbsp;The Company (x)&nbsp;is in compliance with all, and have not violated any, applicable
federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety, the
environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental Laws&#148;); (y) has received and is in compliance with all, and has not violated any, permits, licenses,
certificates or other authorizations or approvals required of it under any Environmental Laws to conduct its business; and (z)&nbsp;has not received notice of any actual or potential liability or obligation under or relating to, or any actual or
potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and has no knowledge of any event or condition that
would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except as described in each of the Pricing Disclosure Package and the Prospectus, (x)&nbsp;there is no proceeding that is pending,
or that is known to be contemplated, against the Company under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will
be imposed, (y)&nbsp;the Company is not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or
contaminants, that could reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company, and (z)&nbsp;the Company does not anticipate material capital expenditures relating to any
Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3) of
the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under common control with the
Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Code) would have any liability (each, a &#147;Plan&#148;)
has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a
statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to
satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning
of Section&nbsp;303(i) of ERISA) and no Plan that is a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and
305 of ERISA)&nbsp;(v) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#147;reportable event&#148; (within
the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified,
and nothing has occurred, to the knowledge of the Company, whether by action or by failure to act, which would cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably
expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer
plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made
to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group
affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company&#146;s &#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT
STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the Company&#146;s most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof,
as would not, individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Disclosure Controls</I>. The Company maintains an
effective system of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)) that complies with the
requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions
regarding required disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Accounting Controls.</I> The Company maintains systems of &#147;internal control over financial
reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that are designed to comply with the applicable requirements of the Exchange Act and have been designed by, or under the supervision of, its
principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company maintains internal accounting controls sufficient to provide reasonable
assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to
maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at
reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the Company&#146;s
internal controls. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal controls over
financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves
management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)
<I>Insurance. </I>The Company has insurance covering its properties, operations, personnel and business, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained
by similarly situated companies and which the Company reasonably believes are adequate to protect the Company and its business; and the Company has not (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or
other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Cybersecurity; Data Protection.
</I>The Company&#146;s information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;IT Systems&#148;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of its business as currently conducted, in each case, to the knowledge of the Company, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants. The Company has implemented, maintained and complied with commercially reasonable information technology, information security, cybersecurity and data protection controls, policies, procedures, and safeguards designed to maintain and
protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential information or trade secrets
(collectively, &#147;Sensitive Data&#148;)) collected, used, stored or processed by, or to the knowledge of the Company, on behalf of the Company in connection with its business, and, to the Company&#146;s knowledge, there have been no breaches,
violations, outages or unauthorized uses of or accesses to any IT Systems and Sensitive Data, except for those that have been remedied without material cost or liability. The Company is presently in compliance with all applicable laws or statutes
and all other applicable judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal and external policies, and contractual obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to the privacy and security of IT Systems and the collection, use, transfer, import, export, storage, disposal and disclosure of Sensitive Data and to the protection of such IT Systems
and Sensitive Data from unauthorized use, access, misappropriation or modification (&#147;Data Security Obligations&#148;) except where the failure to comply would not, individually or in the aggregate, have a Material Adverse Effect. The Company
(i)&nbsp;has not received any notification of or complaint regarding any actual or potential liability under or relating to, or actual or potential violation of any Data Security Obligation and has no knowledge of any event or condition that would
reasonably be expected to result in any such notice, (ii)&nbsp;is not currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any Data Security Obligation, (iii)&nbsp;is not a
party to any order, decree, or agreement that imposed any obligation or liability under any Data Security Obligation and (iv)&nbsp;is not subject to any pending or, to the knowledge of the Company, threatened action, suit, investigation or
proceeding by or before any court or government agency, or body alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>No Unlawful Payments.</I> Neither the Company nor any director or officer of the Company nor, to the knowledge of the Company, any
employee, agent, affiliate or other person associated with or acting on behalf of the Company has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity;
(ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled
entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in
violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or
committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful
benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company has instituted, maintained and enforced, and will continue to maintain and enforce, policies and
procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Compliance with
Anti-Money Laundering Laws</I>. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued,
administered or enforced by any governmental agency (collectively, the &#147;Anti-Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its directors
or officers, nor, to the knowledge of the Company, any employees, agent, affiliate or other person associated with or acting on behalf of the Company is currently the subject or the target of any sanctions administered or enforced by the U.S.
government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;OFAC&#148;) or the U.S. Department of State and including, without limitation, the designation as a &#147;specially
designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council (&#147;UNSC&#148;), the European Union, His Majesty&#146;s Treasury (&#147;HMT&#148;) or other relevant sanctions authority (collectively,
&#147;Sanctions&#148;), nor is the Company located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the Crimea Region of Ukraine, the
<FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, Cuba, Iran, North Korea and Syria (each, a &#147;Sanctioned Country&#148;); and
the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund
or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or
(iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past ten years, the Company has not
knowingly engaged in and is not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>No Broker&#146;s Fees.</I> The Company is not a party to any contract, agreement or understanding with any person (other than this
Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>No Registration Rights</I>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no
person has the right to require the Company to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission, the issuance and sale of the Shares by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>No Stabilization.</I> Neither the Company nor, to the Company&#146;s knowledge, any of its affiliates has taken, directly or
indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>Margin Rules</I>. Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as
described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and
Section&nbsp;21E of the Exchange Act) included in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>Statistical and Market Data.</I> Nothing has come to the attention of the Company
that has caused the Company to believe that the statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and
accurate in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Regulatory Matters; Products and Product Candidates</I>. The Company: (i)&nbsp;has operated
and currently operates its business in compliance in all material respects with applicable provisions of the Health Care Laws (as defined below) of the FDA, the Department of Health and Human Services and any applicable comparable foreign or other
regulatory authority (collectively, the &#147;Applicable Regulatory Authorities&#148;) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of any of the
Company&#146;s product candidates manufactured or distributed by the Company; (ii)&nbsp;has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other written notice from any court or arbitrator or
governmental or regulatory authority alleging or asserting <FONT STYLE="white-space:nowrap">non-compliance</FONT> with (A)&nbsp;any Health Care Laws or (B)&nbsp;any licenses, certificates, approvals, clearances, exemptions, authorizations, permits
and supplements or amendments thereto required by any such Health Care Laws (&#147;Regulatory Authorizations&#148;); (iii) possesses all material Regulatory Authorizations required to conduct its business as currently conducted, and such Regulatory
Authorizations are valid and in full force and effect in all material respects and, to the knowledge of the Company, the Company is not in material violation of any term of any such Regulatory Authorizations; (iv)&nbsp;has not received written
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the Applicable Regulatory Authorities or any other third party alleging that any product candidate of the Company is in violation of
any Health Care Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities or any other third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding;
(v)&nbsp;has not received written notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take action to limit, suspend, materially modify or revoke any material Regulatory Authorizations and has no knowledge that
any of the Applicable Regulatory Authorities is considering such action; (vi)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
as required by any Health Care Laws or Regulatory Authorizations and that all such material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material
respects on the date filed (or were corrected or supplemented by a subsequent submission); (vii) is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements,
monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Applicable Regulatory Authority; and (viii)&nbsp;along with its employees, officers and directors, has not, to the knowledge
of the Company, been excluded, suspended or debarred from participation in any government health care program or human clinical research and, to the knowledge of the Company, is not subject to a governmental inquiry, investigation, proceeding, or
other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Health Care Laws&#148; means Title XVIII of the Social Security Act, 42
U.S.C. &#167;&#167; 1395-1395hhh (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396-1396v (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(b);</FONT> the civil False Claims Act, 31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act, 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(a);</FONT> any criminal laws relating to health
care fraud and abuse; the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7a</FONT> and <FONT STYLE="white-space:nowrap">1320a-7b;;</FONT> the Exclusion Statute, 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7;;</FONT> the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq.; the Public Health Service Act, 42 U.S.C. &#167;&#167; 201 et seq.; the regulations promulgated pursuant to such laws; and any
similar federal, state and local laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>Clinical Trials. </I>The clinical, preclinical and nonclinical trials and
studies conducted by or on behalf of or sponsored by the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or the results of which are referred to in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, as applicable, were, and if still pending are, being conducted in all material respects in accordance with their protocols and procedures and in material compliance with all applicable statutes and all rules
and regulations of the FDA and other applicable regulatory authorities (including, without limitation, any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA)
(collectively, the &#147;Regulatory Authorities&#148;) and current Good Clinical Practices and Good Laboratory Practices (as defined by the FDA), as applicable; the descriptions in the Registration Statement, the Pricing Disclosure Package and the
Prospectus of the results of such studies and tests are accurate and complete and materially present the data derived from such trials or studies; the Company has no knowledge of any other trials, the results of which call into question the results
described or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; the Company has not received any written notices, correspondence or other written communications from the Regulatory Authorities or any other
governmental agency requiring the termination, material modification or suspension of any preclinical, clinical or nonclinical trials that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results
of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and, to the knowledge of the Company, there are no reasonable grounds for the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or any of the Company&#146;s directors or
officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;), including Section&nbsp;402
related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>Status under the Securities Act</I>. At the time of filing
the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the
Shares and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt
securities, convertible securities or preferred stock issued or guaranteed by the Company that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>Directed Share Program</I>. The Company represents and warrants that (i)&nbsp;the Registration Statement, the Pricing Disclosure
Package and the Prospectus, any Preliminary Prospectus and any Issuer Free Writing Prospectuses comply in all material respects, and any further amendments or supplements thereto will comply in all material respects, with any applicable laws or
regulations of foreign jurisdictions in which the Pricing Disclosure Package, the Prospectus, any Preliminary Prospectus and any Issuer Free Writing Prospectus, as amended or supplemented, if applicable, are distributed in connection with the
Directed Share Program, and that (ii)&nbsp;no authorization, approval, consent, license, order, registration or qualification of or with any government, governmental instrumentality or court, other than such as have been obtained, is necessary under
the securities laws and regulations of foreign jurisdictions in which the Directed Shares are offered outside the United States. The Company has not offered, or caused the Underwriters to offer, Shares to any person pursuant to the Directed Share
Program with the specific intent to unlawfully influence (i)&nbsp;a customer or supplier of the Company to alter the customer or supplier&#146;s level or type of business with the Company, or (ii)&nbsp;a trade journalist or publication to write or
publish favorable information about the Company or its products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company</U>. The Company covenants and
agrees with each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the
Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act and will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will
furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this
Agreement in such quantities as the Representatives may reasonably request. The Company will pay the registration fee for this offering within the time period required by Rule 456(b)(1) under the Securities Act (without giving effect to the proviso
therein) and in any event prior to the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, without
charge, (i)&nbsp;to the Representatives, two signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith; and (ii)&nbsp;to each Underwriter (A)&nbsp;a
conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and
supplements thereto and each Issuer Free Writing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such period of time after the first date of the public offering of
the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any
Underwriter or dealer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I> Before making, preparing,
using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the
Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus
or file any such proposed amendment or supplement to which the Representatives reasonably objects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the
Representatives.</I> The Company will advise the Representatives promptly, and confirm such advice in writing (which may be by email), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration
Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the
Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but
not limited to, any request for information concerning any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission or any other governmental or
regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the initiation or, to the knowledge of the Company, threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the
Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of any notice with respect to any suspension
of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the
issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending any such qualification of the Shares and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus Delivery
Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will,
as soon as practicable, notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments
or supplements to the Prospectus as may be necessary so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so
that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented
would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser,
not misleading or (ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will immediately notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file
with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to the Pricing Disclosure Package as may be necessary so that the statements in the
Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with
law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> If required by the law, the Company will use commercially reasonable efforts, with
the Underwriters&#146; cooperation, if necessary, to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will use commercially reasonable efforts, with
the Underwriters&#146; cooperation, if necessary, to continue such qualifications in effect so long as required for distribution of the Shares; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or
other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in
any such jurisdiction if it is not otherwise so subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earning Statement. </I>The Company will make generally available to
its security holders and the Representatives as soon as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least
twelve months beginning with the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement; provided that the Company will be deemed to have furnished such statements to
its security holders and the Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system (&#147;EDGAR&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 180 days after the date of the Prospectus (the &#147;Lock-Up Period&#148;), the
Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or
indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention
to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction
described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representatives, other than the Shares to be sold hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described above do not apply to (i)&nbsp;the issuance of shares of Stock or securities convertible into or
exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of restricted stock units (&#147;RSUs&#148;)
(including net settlement), in each case outstanding on the date of this Agreement and described in the Prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of Stock
or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company&#146;s employees, officers, directors, advisors, or consultants pursuant to the terms of an
equity compensation plan in effect as of the Closing Date and described in the Prospectus; (iii)&nbsp;the issuance of up to 5% of the outstanding shares of Stock, or securities convertible into, exercisable for, or which are otherwise exchangeable
for, Stock, immediately following the Closing Date, in connection with any bona fide licensing, commercialization, joint venture, technology transfer, acquisition, development collaboration or other strategic transaction, provided that for (i)-(iii)
such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters; or (iv)&nbsp;the filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or
to be granted pursuant to any plan in effect on the date of this Agreement and described in the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Representatives, in their sole discretion, agree to release or waive the restrictions set forth in a <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter described in Section 6(l) hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver substantially in the form of Exhibit B hereto at least
three business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver substantially in the form of Exhibit D hereto through a major news service at least two business days before the
effective date of the release or waiver. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the
sale of the Shares as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of proceeds&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Stabilization.</I> Neither the Company nor its affiliates will take, directly or indirectly, any action designed to
or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Company will use its reasonable best efforts to list, subject to notice of issuance, the
Shares on the Nasdaq Global Select Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Reports.</I> For a period of three years from the date of this
Agreement, the Company will furnish to the Representatives, as soon as they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements
furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <I>provided</I> the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they
are filed on EDGAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good
faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Filings.</I> The Company will file with the Commission such reports as may be required by Rule 463 under the Securities
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Directed Share Program.</I> The Company will comply with all applicable securities and other laws, rules and
regulations in each jurisdiction in which the Directed Shares are offered in connection with the Directed Share Program. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Agreements with Securityholders. </I>Until the expiration of the Lock-Up Period, the Company will (A) enforce all
existing agreements between the Company and any of its securityholders that prohibit the sale, transfer, assignment, pledge or hypothecation of any of the Company&#146;s securities; (B) direct the transfer agent to place stop transfer restrictions
upon any such securities of the Company that are bound by such existing &#147;lock-up&#148;, &#147;market stand-off&#148;, &#147;holdback&#148; or similar provisions of such agreements for the duration of the Lock-Up Period; and (C) not release or
otherwise grant any waiver of such provisions in such agreements without the prior written consent of the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Emerging Growth Company</I>. The Company will promptly notify the Representatives if the Company ceases to be an
Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of Shares within the meaning of the Securities Act and (ii)&nbsp;completion of the <FONT STYLE="white-space:nowrap">180-day</FONT> restricted period
referred to in Section&nbsp;4(h) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements of the Underwriters</U>. Each Underwriter hereby severally represents
and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not and will not use, authorize use of, refer to or participate in the planning for use of,
any &#147;free writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the
Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared
pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such underwriter and approved by the Company in advance in writing (each such free writing
prospectus referred to in clauses (i)&nbsp;or (iii), an &#147;Underwriter Free Writing Prospectus&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not
and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission;
<U>provided</U> that Underwriters may use a term sheet substantially in the form of Annex C hereto without the consent of the Company; <U>provided further</U> that any Underwriter using such term sheet shall notify the Company, and provide a copy of
such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is
not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Underwritten Shares on the Closing
Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be
in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with
the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for
additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Representations and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the
statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change.</I> No event or condition of a type
described in Section&nbsp;3(h) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or
supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may
be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<I>Officer&#146;s Certificate.</I> The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and
one additional senior executive officer of the Company who is satisfactory to the Representatives (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to
the knowledge of such officers, the representations of the Company set forth in Sections 3(b) and 3(d) hereof are true and correct, and (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and
correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the
effect set forth in paragraphs (a)&nbsp;and (c) above . </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Comfort Letters.</I> On the date of this Agreement and on
the Closing Date or the Additional Closing Date, as the case may be, Ernst&nbsp;&amp; Young LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the
Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial
statements and certain financial information contained in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may
be, shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Opinion of Intellectual Property Counsel for the Company</I>. Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional
Corporation, intellectual property counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed
to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement
of Counsel for the Company.</I> Goodwin Procter LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the
Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The
Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Davis Polk&nbsp;&amp;
Wardwell LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon
such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Legal Impediment to Issuance and/or Sale.</I> No action shall have been taken and no statute,
rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or
sale of the Shares by the Company; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the
Shares by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date or
the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company in its jurisdiction of organization and its good standing in such other jurisdictions as the Representatives may reasonably request, in each
case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be,
shall have been approved for listing on the Nasdaq Global Select Market, subject to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit D hereto, between the Representatives and certain shareholders, officers
and directors of the Company, relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to the Representatives on or before the date hereof, shall be full force and effect on the Closing Date or the
Additional Closing Date, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Additional Documents.</I> On or prior to the Closing Date or the
Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Indemnification and Contribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters by the Company.</I> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and
liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that
arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be
stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any
Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any Pricing Disclosure Package that
has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case
except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in paragraph (b)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Underwriter agrees, severally and not
jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration
Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each
Underwriter: the concession and reallowance figures appearing in the third paragraph under the caption &#147;Underwriting&#148;, the information contained in the seventeenth, eighteenth and nineteenth paragraphs under the caption
&#147;Underwriting&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory
investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#147;Indemnified Person&#148;) shall
promptly notify the person against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have
under the preceding paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided, further,</U> that the failure to notify
the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an
Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel
to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section&nbsp;7 that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees
and expenses in such proceeding including the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a
reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those
available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for
the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter,
its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by J.P. Morgan Securities LLC and any such separate firm for the Company, its directors, its officers who signed the Registration
Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent,
the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an
Indemnifying Person </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without
its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such
request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could
have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such
Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is unavailable to an Indemnified Person
or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or
payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other,
from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the
relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the
Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative
fault of the Company, on the one hand, and the Underwriters, as the case may be, on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to
paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose)or by any other method of allocation that does not take account of the equitable considerations
referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (e)&nbsp;above shall be deemed to include, subject to the limitations
set forth above, any reasonable and documented legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter
be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds
the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several
in proportion to their respective purchase obligations hereunder and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or
in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Directed Share Program Indemnification.</I> The Company agrees to indemnify and hold harmless the Directed Share
Underwriter, its affiliates, directors and officers and each person, if any, who controls the Directed Share Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (each a &#147;Directed
Share Underwriter Entity&#148;) from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal fees and other expenses incurred in connection with defending or investigating any suit, action or
proceeding or any claim asserted, as such fees and expenses are incurred)&nbsp;(i) caused by any untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for
distribution to Participants in connection with the Directed Share Program or caused by any omission or alleged omission to state therein a material fact necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading; (ii)&nbsp;caused by the failure of any Participant to pay for and accept delivery of Directed Shares that the Participant agreed to purchase; or (iii)&nbsp;related to, arising out of, or in connection with the Directed Share
Program, other than losses, claims, damages or liabilities (or expenses relating thereto) that are finally judicially determined to have resulted from the bad faith or gross negligence of the Directed Share Underwriter Entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) In case any proceeding (including any governmental investigation) shall be instituted involving any Directed Share Underwriter Entity in
respect of which indemnity may be sought pursuant to paragraph (g)&nbsp;above, the Directed Share Underwriter Entity seeking indemnity shall promptly notify the Company in writing and the Company, upon request of the Directed Share Underwriter
Entity, shall retain counsel reasonably satisfactory to the Directed Share Underwriter Entity to represent the Directed Share Underwriter Entity and any others the Company may designate in such proceeding and shall pay the reasonable fees and
disbursements of such counsel related to such proceeding. In any such proceeding, any Directed Share Underwriter Entity shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such
Directed Share Underwriter Entity unless (i)&nbsp;the Company and such Directed Share Underwriter Entity shall have mutually agreed to the retention of such counsel, (ii)&nbsp;the Company has failed within a reasonable time to retain counsel
reasonably satisfactory to such Directed Share Underwriter Entity, (iii)&nbsp;the Directed Share Underwriter Entity shall have reasonably concluded that there may be legal defenses available to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it that are different from or in addition to those available to the Company or (iv)&nbsp;the named parties to any such proceeding (including any impleaded parties) include both the Company and
the Directed Share Underwriter Entity and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. The Company shall not, in respect of the legal expenses of the Directed
Share Underwriter Entities in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Directed Share Underwriter
Entities. The Company shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Company agrees to indemnify the Directed Share Underwriter Entities from and against any loss
or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time any Directed Share Underwriter Entity shall have requested the Company to reimburse such Directed Share Underwriter Entity for fees and expenses of
counsel as contemplated by the second and third sentences of this paragraph, the Company agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than
30 days after receipt by the Company of the aforesaid request and (ii)&nbsp;the Company shall not have reimbursed such Directed Share Underwriter Entity in accordance with such request prior to the date of such settlement. The Company shall not,
without the prior written consent of the Directed Share Underwriter, effect any settlement of any pending or threatened proceeding in respect of which any Directed Share Underwriter Entity is or could have been a party and indemnity could have been
sought hereunder by such Directed Share Underwriter Entity, unless (x)&nbsp;such settlement includes an unconditional release of the Directed Share Underwriter Entities from all liability on claims that are the subject matter of such proceeding and
(y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of the Directed Share Underwriter Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To the extent the indemnification provided for in paragraph (g)&nbsp;above is unavailable to a Directed Share Underwriter Entity or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then the Company in lieu of indemnifying the Directed Share Underwriter Entity thereunder, shall contribute to the amount paid or payable by the Directed
Share Underwriter Entity as a result of such losses, claims, damages or liabilities (1)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Directed Share Underwriter Entities on
the other hand from the offering of the Directed Shares or (2)&nbsp;if the allocation provided by clause 7(i)(1) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in
clause 7(i)(1) above but also the relative fault of the Company on the one hand and of the Directed Share Underwriter Entities on the other hand in connection with any statements or omissions that resulted in such losses, claims, damages or
liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Directed Share Underwriter Entities on the other hand in connection with the offering of the Directed Shares
shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Directed Shares (before deducting expenses) and the total underwriting discounts and commissions received by the Directed Share Underwriter
Entities for the Directed Shares, bear to the aggregate public offering price of the Directed Shares. If the loss, claim, damage or liability is caused by an untrue or alleged untrue statement of material fact or the omission or alleged omission to
state a material fact, the relative fault of the Company on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the one hand and the Directed Share Underwriter Entities on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement or the omission
or alleged omission relates to information supplied by the Company or by the Directed Share Underwriter Entities and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company and the Directed Share Underwriter Entities agree that it would be not just or equitable if contribution
pursuant to paragraph (i)&nbsp;above were determined by pro rata allocation (even if the Directed Share Underwriter Entities were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in paragraph (i)&nbsp;above. The amount paid or payable by the Directed Share Underwriter Entities as a result of the losses, claims, damages and liabilities referred to in the immediately preceding paragraph
shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by the Directed Share Underwriter Entities in connection with investigating or defending such any action or claim.
Notwithstanding the provisions of paragraph (i)&nbsp;above, no Directed Share Underwriter Entity shall be required to contribute any amount in excess of the amount by which the total price at which the Directed Shares distributed to the public were
offered to the public exceeds the amount of any damages that such Directed Share Underwriter Entity has otherwise been required to pay. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in paragraphs (g)&nbsp;through (j) are not exclusive and shall not limit any rights or remedies which may otherwise
be available to any indemnified party at law or in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The indemnity and contribution provisions contained in paragraphs
(g)&nbsp;through (j) shall remain operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Directed Share Underwriter Entity or the Company, its officers
or directors or any person controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Directed Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This
Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the
Additional Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any
exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State
authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is
material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this
Agreement, the Pricing Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the
Shares that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the
terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Shares, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other persons become obligated or agree
to purchase the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full
business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company
agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless
the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be,
does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the
Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any
arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of
Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company
shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall
terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that
the Company and the Underwriters will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may
have to the Company or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<U>Payment of Expenses</U><I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement
is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and
delivery of the Shares and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing
Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants;
(iv)&nbsp;the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the laws of such jurisdictions as the Representatives may designate and the
preparation, printing and distribution of a Blue Sky Memorandum (including the related reasonable and documented fees and expenses of counsel for the Underwriters);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges
of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA (in an amount not to exceed, when taken together with costs, fees and expenses
incurred pursuant to clause (iv), $40,000 (exclusive of filing fees)) without the prior written consent of the Company; (viii)&nbsp;all reasonable and documented expenses incurred by the Company in connection with any &#147;road show&#148;
presentation to potential investors, provided, however, the Company and the Underwriters shall each pay 50% of the total costs of chartering any aircraft to be used in connection with any such &#147;road shows&#148;; (ix) all expenses and
application fees related to the listing of the Shares on the Nasdaq Global Select Market; and (x)&nbsp;all of the reasonably incurred fees and disbursements of counsel incurred by the Underwriters in connection with the Directed Share Program and
stamp duties, similar taxes or duties or other taxes, if any, incurred by the Underwriters in connection with the Directed Share Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender the Shares for
delivery to the Underwriters (other than by reason of a default by any Underwriter) or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all
reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the reasonable and documented fees and expenses of their counsel) incurred by the Underwriters in
connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, the Company will not be required to pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to
purchase the Shares, as described in Section&nbsp;10 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in
this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be
deemed to be a successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution,
representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall
survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers,
controlling persons or affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement,
(a)&nbsp;except where otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act, (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted
or required to be closed in New York City; and (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT
STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include
the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. Miscellaneous. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be
given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) <FONT STYLE="white-space:nowrap">622-8358),</FONT> Attention: Equity Syndicate Desk; c/o Jefferies LLC, 520 Madison Avenue, New
York, New York 10022, Attention: General Counsel. Notices to the Company shall be given to it at MBX Biosciences, Inc., 11711 N. Meridian Street, Suite 300 Carmel, Indiana 46032, Attention: Richard Bartram. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by
and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission to Jurisdiction</I>. The Company hereby submits to
the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company
waives any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and
binding upon the Company and may be enforced in any court to the jurisdiction of which Company is subject by a suit upon such judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)<I> Waiver of Jury Trial.</I> Each of the parties hereto hereby waives any right to trial
by jury in any suit or proceeding arising out of or relating to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)<I> Recognition of the U.S. Special Resolution
Regimes</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S.
Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution
Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As used in
this Section&nbsp;16(e): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81,
47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Counterparts.</I> This Agreement may be signed in counterparts (which may include
counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature,&#148;
and words of like import in this Agreement or in any other certificate, agreement or document related to this Agreement, if any, shall include images of manually executed signatures transmitted by facsimile or other electronic format (including,
without limitation, &#147;pdf,&#148; &#147;tif&#148; or &#147;jpg&#148;) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation,
any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping
system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without
limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Amendments or
Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">MBX BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and on behalf of the</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#149;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch. 1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">[&#149;] </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information Provided Orally by Underwriters </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Initial public offering price per share: $[&#149;] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of Underwritten Shares to be sold by the Company: [&#149;] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of Option Shares to be sold by the Company: [&#149;] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[None.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MBX Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term Sheet </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[None.]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Testing the Waters Authorization </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In reliance on
Section&nbsp;5(d) of the Securities Act of 1933, as amended (the &#147;Act&#148;), MBX Biosciences, Inc. (the &#147;Issuer&#148;) hereby authorizes J.P. Morgan Securities LLC (&#147;J.P. Morgan&#148;), Jefferies LLC (&#147;Jefferies&#148;), Stifel,
Nicolaus&nbsp;&amp; Company, Incorporated (&#147;Stifel&#148;), and Guggenheim Securities, LLC (&#147;Guggenheim Securities&#148;) and their respective affiliates and employees, to engage on behalf of the Issuer in oral and written communications
with potential investors that are &#147;qualified institutional buyers&#148;, as defined in Rule 144A under the Act, or institutions that are &#147;accredited investors&#148;, within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8),
(a)(9), (a)(12) or (a)(13) under the Act, to determine whether such investors might have an interest in the Issuer&#146;s contemplated initial public offering
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(&#147;Testing-the-Waters</FONT></FONT> Communications&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a
written communication within the meaning of Rule 405 under the Act. Each of J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities, individually and not jointly, agrees that it shall not distribute any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that has not been approved by the Issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer represents that it is an
&#147;emerging growth company&#148; as defined in Section&nbsp;2(a)(19) of the Act (&#147;Emerging Growth Company&#148;) and agrees to promptly notify J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities in writing if the Issuer hereafter
ceases to be an Emerging Growth Company while this authorization is in effect. If at any time following the distribution of any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication
there occurs an event or development as a result of which such Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact
or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Issuer will promptly notify J.P. Morgan, Jefferies, Stifel,
and Guggenheim Securities and will promptly amend or supplement, at its own expense, such Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue
statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this authorization is intended to limit or otherwise affect the ability of J.P. Morgan, Jefferies, Stifel, and
Guggenheim Securities and their respective affiliates and employees, to engage in communications in which they could otherwise lawfully engage in the absence of this authorization, including, without limitation, any written communication containing
only one or more of the statements specified under Rule 134(a) under the Act. This authorization shall remain in effect until the Issuer has provided to J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities a written notice revoking this
authorization. All notices as described herein shall be sent by email to the attention of David Ke at david.ke@jpmorgan.com, Peter Castoro at peter.j.castoro@jpmorgan.com, Charlie Glazer at cglazer@jefferies.com, Ken Clausman at
clausmank@stifel.com, and James Lee at james.lee@guggenheimpartners.com with copies to Richard D. Truesdell, Jr. at richard.truesdell@davispolk.com, Arisa Akashi Sin at arisa.sin@davispolk.com, and Jenny Li at jenny.li@davispolk.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Waiver of <FONT STYLE="white-space:nowrap">Lock-up</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>J.P. MORGAN SECURITIES LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JEFFERIES LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MBX
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Public Offering of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and Address of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Officer or Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Requesting Waiver] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr./Ms.&nbsp;[Name]: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This letter is being
delivered to you in connection with the offering by MBX Biosciences, Inc. (the &#147;Company&#148;) of [] shares of common stock, $0.0001 par value (the &#147;Common Stock&#148;), of the Company and the
<FONT STYLE="white-space:nowrap">lock-up</FONT> letter dated __________________, 2024 (the <FONT STYLE="white-space:nowrap">&#147;Lock-up</FONT> Letter&#148;), executed by you in connection with such offering, and your request for a [waiver]
[release] dated&#8195;__________________, 20__, with respect to ______shares of Common Stock (the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J.P. Morgan
Securities LLC and Jefferies LLC hereby agree to [waive] [release] the transfer restrictions set forth in the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Letter, but only with respect to the Shares, effective __________________, 20__ ;
<U>provided</U>, <U>however</U>, that such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release] by press release through a major news service at least two business days before effectiveness of such [waiver]
[release]. This letter will serve as notice to the Company of the impending [waiver] [release]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly [waived] [released]
hereby, the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Letter shall remain in full force and effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Yours very truly,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[Signature of J.P. Morgan Securities LLC Representative]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[Name of J.P. Morgan Securities LLC Representative]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[Signature of Jefferies LLC Representative]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[Name of Jefferies LLC Representative]</B></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cc: Company<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Press Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MBX
Biosciences, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[Date] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MBX Biosciences, Inc.
(the &#147;Company&#148;) announced today that J.P. Morgan Securities LLC and Jefferies LLC, the representatives of the several underwriters in the Company&#146;s recent public sale of [ ]&#8195;shares of common stock, is [waiving] [releasing] a <FONT
STYLE="white-space:nowrap">lock-up</FONT> restriction with respect to&#8195;shares of the Company&#146;s common stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on
____________________, 20__, and the shares may be sold on or after such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release is not an offer for sale of the securities in the
United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as
amended. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit D </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">____ __, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;several Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;in Schedule 1 hereto
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MBX Biosciences, Inc. &#151; Public Offering </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, as representatives (the &#147;Representatives&#148;) of the several Underwriters (as defined below), propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with MBX Biosciences, Inc., a
Delaware corporation (the &#147;Company&#148;), providing for the public offering (the &#147;Public Offering&#148;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of common stock of the
Company (the &#147;Securities&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public Offering of the Securities, and for other good and
valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, the undersigned will not, and will not cause any direct or
indirect affiliate to, during the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and ending at the close of business 180 days after the date of the final prospectus relating to the Public Offering (the
&#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase,
lend, or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transfer or dispose of, directly or indirectly, any shares of common stock, $0.0001 per share par value, of the Company (the &#147;Common Stock&#148;) or any securities convertible into or
exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and
Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Stock, the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), (2) enter into any hedging, swap or
other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction described in clause (1)&nbsp;or (2)
above is to be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise, (3)&nbsp;make any demand for, or exercise any right with respect to, the registration of any
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or (4)&nbsp;publicly disclose the intention to do any of the foregoing. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or
other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however
described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in
part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise. The undersigned further confirms that it has furnished the Representatives with the details of any transaction the undersigned, or any of its affiliates, is a party to
as of the date hereof, which transaction would have been restricted by this Letter Agreement if it had been entered into by the undersigned during the Restricted Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;transfer or dispose of the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) as a bona fide gift or gifts, as a charitable contribution, or for bona fide estate planning purposes, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) by will or intestacy or any other testamentary document, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is
a trust, to a trustor, trustee (or <FONT STYLE="white-space:nowrap">co-trustee)</FONT> or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#147;immediate family&#148; shall mean any
relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) to a
corporation, partnership, limited liability company, investment fund, or other entity (A)&nbsp;of which the undersigned and/or the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or
similar interests or (B)&nbsp;controlled by, or under common control with, the undersigned or the immediate family of the undersigned, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would
be permissible under clauses (i)&nbsp;through (iv) above, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;if the undersigned is a corporation, partnership, limited liability
company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended)
of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the
undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a distribution to limited partners, members or shareholders of the undersigned, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) to the Company from an employee of the Company upon death, disability or termination of employment, in each case, of such employee,
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) as part of a transaction related to the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities acquired in
the Public Offering (if the undersigned is not an officer or director of the Company) or in open market transactions following the Public Offering, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to
purchase shares of Common Stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or
exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further that
any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) pursuant to a bona fide third-party tender offer, merger,
consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company&#146;s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof,
&#147;Change of Control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of
capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving entity)); <U>provided</U> that in the event that such tender
offer, merger, consolidation or other similar transaction is not completed, the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of this Letter Agreement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) to an immediate family member of the undersigned, or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) to the Company in connection with the transfer of shares of Common Stock pursuant to option agreements relating to the early exercise
by the undersigned of unvested options issued pursuant to the Company&#146;s equity incentive plans, which plans are in each case described in the Registration Statement, under which the Company has the right to repurchase such shares and only to
the extent the Company elects to exercise such right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that (A)&nbsp;in the case of any transfer or distribution pursuant to clauses
(a)(i), (ii), (iii), (iv), (v), (vi), (vii) and (xii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representatives a
<FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement, (B)&nbsp;in the case of any transfer or distribution pursuant to clauses (a) (iii), (iv), (v), (vi), (ix) and (xii)&nbsp;no filing by any party (donor,
donee, devisee, transferor, transferee, distributer or distributee) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or other public announcement shall be required or shall be made voluntarily in connection with
such transfer or distribution (other than a filing on a Form 5 or a filing required pursuant to Section&nbsp;13 of the Exchange Act and the rules and regulations promulgated thereunder made after the expiration of the Restricted Period referred to
above) and (C)&nbsp;in the case of any transfer or distribution pursuant to clauses (a) (i), (ii), (vii), (viii), (x) and (xiii)&nbsp;it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made
and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally
required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) exercise outstanding options, settle restricted stock units or other equity awards or exercise warrants pursuant to plans described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities received upon such exercise, vesting or settlement shall be subject to the terms of this Letter
Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) convert outstanding preferred stock, warrants to acquire preferred stock or convertible securities into shares of Common
Stock or warrants to acquire shares of Common Stock; provided that any such shares of Common Stock or warrants received upon such conversion shall be subject to the terms of this Letter Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) establish or modify trading plans pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer
of shares of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities; <U>provided</U> that (1)&nbsp;such plans do not provide for the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the Restricted Period and
(2)&nbsp;no filing under the Exchange Act or other public announcement shall be voluntarily made during the Restricted Period by or on behalf of the undersigned or the Company regarding the establishment or modification of any such trading plan
pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1,</FONT> provided that if a filing under the Exchange Act or other public announcement is required, such announcement or filing shall include a statement to the effect that no transfer of <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities may be made under such Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan during the Restricted Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the undersigned represents and warrants that no
single natural person, entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)) beneficially owns, directly or indirectly, 50% or more of the common
equity interests, or 50% or more of the voting power, in the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company,
the undersigned further agrees that the foregoing provisions shall be equally applicable to any Company-directed Securities the undersigned may purchase in the Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, (i)&nbsp;the Representatives, on behalf of the Underwriters, agree that, at least
three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, the Representatives, on behalf of the
Underwriters, will notify the Company of the impending release or waiver, and (ii)&nbsp;the Company has agreed in the Underwriting Agreement to announce the impending release or waiver through a major news service at least two business days before
the effective date of the release or waiver. Any release or waiver granted by the Representatives on behalf of the Underwriters hereunder to any such officer or director shall only be effective two business days after the publication date of such
announcement. The provisions of this paragraph will not apply if (a)&nbsp;the release or waiver is effected solely to permit a transfer not for consideration or that is to an immediate family member as defined in FINRA Rule 5130(i)(5) and
(b)&nbsp;the transferee has agreed in writing to be bound by the same terms described in this Letter Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities
described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The
undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to the undersigned in connection with the Public Offering, the
Representatives and the other Underwriters are not making a recommendation to the undersigned to participate in the Public Offering, enter into this Letter Agreement, or sell any Shares at the price determined in the Public Offering, and nothing set
forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if the Underwriting Agreement does not become effective by
September&nbsp;30, 2024, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, the undersigned
shall be released from all obligations under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and
construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement may be delivered via facsimile, electronic mail
(including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any
Letter Agreement so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NAME OF STOCKHOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d790774dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THIRD AMENDED AND RESTATED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF INCORPORATION<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MBX BIOSCIENCES, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections 242 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MBX Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State
of Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> That the name of this corporation is MBX Biosciences, Inc., and that this corporation was originally incorporated pursuant to the
General Corporation Law on April&nbsp;9, 2019 under the name MBX Biosciences, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> That an Amended and Restated Certificate of
Incorporation of this corporation was filed with the Secretary of State of Delaware on July&nbsp;15, 2020 and a Second Amended and Restated Certificate of Incorporation of this corporation was filed with the Secretary of State of Delaware on
November&nbsp;7, 2022 (the &#147;<B>Existing Certificate</B>&#148;).<I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> That the Board of Directors of this Corporation (the &#147;<B>Board of Directors</B>&#148;) duly adopted resolutions proposing to
amend and restate the Existing Certificate, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the
consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Existing Certificate be amended and restated in its entirety to read as follows (the &#147;<B>Certificate of
Incorporation</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST</B><B>:</B> The name of this corporation is MBX Biosciences, Inc. (the
&#147;<B>Corporation</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND</B><B>:</B> The address of the registered office of the Corporation in the State of Delaware
is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD</B><B>:</B> The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH</B><B>:</B> The total number of shares of all classes of stock
which the Corporation shall have the authority to issue is 558,968,899. The Corporation has two classes of stock, referred to as Common Stock and Preferred Stock. There are 314,479,800 shares of authorized Common Stock, $0.0001 par value per share
(&#147;<B>Common Stock</B>&#148;), and 244,489,099 shares of authorized Preferred Stock, $0.0001 par value per share (&#147;<B>Preferred Stock</B>&#148;).<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, preferences and special
rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.
COMMON STOCK </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and
qualified by the powers, preferences and special rights of the holders of the Preferred Stock set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. Except
as otherwise provided herein or by applicable law, the holders of the Common Stock shall be entitled to one vote for each share of Common Stock held as of the applicable record date for each meeting of stockholders (and written actions in lieu of
meetings); <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate of Incorporation that relates solely to the terms of one or
more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation or
pursuant to the General Corporation Law. There shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of
the holders of one or more series of Preferred Stock that may be required by the terms of this Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes
represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">53,598,587
shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>Series A Preferred Stock</B>&#148;, 129,240,032 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>Series B Preferred
Stock</B>&#148; and 61,650,480 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>Series C Preferred Stock</B>&#148;, in each case with the following powers, preferences, and special rights. Unless otherwise
indicated, references to &#147;sections&#148; or &#147;Sections&#148; in this Part B of this Article Fourth refer to sections of Part B of this Article Fourth. References to &#147;<B>Preferred Stock</B>&#148; mean the Series A Preferred Stock,
Series B Preferred Stock and Series C Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Preferred Stock, in preference to the holders of Common Stock, shall be entitled to receive, when, as and if declared by the Board
of Directors of the Corporation, but only out of funds that are legally available therefor, cash dividends at the rate of (i)&nbsp;in the case of the Series A Preferred Stock, eight percent (8%) of the Series A Original Issue Price (as defined
below) per annum on each outstanding share of Series A Preferred Stock (the &#147;<B>Series A Preferred Dividends</B>&#148;), (ii) in the case of the Series B Preferred Stock, eight percent (8%) of the Series B Original Issue Price (as defined
below) per annum on each outstanding share of Series B Preferred Stock (the &#147;<B>Series B Preferred Dividends</B>&#148;) and (iii)&nbsp;in the case of the Series C Preferred Stock, eight percent (8%) of the Series C Original Issue Price (as
defined below) per annum on each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding share of Series C Preferred Stock (the &#147;<B>Series C Preferred Dividends</B>&#148; and, together with the Series A Preferred Dividends and the Series B Preferred Dividends, the
&#147;<B>Preferred Dividends</B>&#148;). All such Preferred Dividends shall be payable only when, as and if declared by the Board of Directors of the Corporation and shall be <FONT STYLE="white-space:nowrap">non-cumulative,</FONT> and, if and when
declared, shall be declared on each series of Preferred Stock and not an individual series of Preferred Stock. The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the
Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Certificate of Incorporation) the holders of the Preferred Stock then
outstanding shall first receive, or simultaneously receive a dividend on each outstanding share of Preferred Stock in an amount at least equal to (A)&nbsp;in the case of a dividend on Common Stock or any class or series that is convertible into
Common Stock, that dividend per share of the Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted
into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of such Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in
the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock
by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and
(2)&nbsp;multiplying such fraction by an amount equal to the applicable Original Issue Price (as defined below); <U>provided</U> that if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or
series of capital stock of the Corporation, the dividend payable to the holders of a series of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock
that would result in the highest dividend for such series of Preferred Stock. The &#147;<B>Series A Original Issue Price</B>&#148; shall mean $0.687 per share, subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A Preferred Stock. The &#147;<B>Series B Original Issue Price</B>&#148; shall mean $0.90 per share, subject to appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to the Series B Preferred Stock. The &#147;<B>Series C Original Issue Price</B>&#148; shall mean $1.03 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series C Preferred Stock. The term &#147;<B>Original Issue Price</B>&#148; shall refer to the Series A Original Issue Price, the Series B Original Issue Price or the
Series C Original Issue Price, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset
Sales</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of Preferred Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.1 <U>Series C and B Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the
Corporation, the holders of shares of Series C Preferred Stock and Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, or in the event of a
Deemed Liquidation Event (as defined below), the holders of shares of Series C Preferred Stock and Series B Preferred Stock then outstanding, on a <I>pari passu</I> basis based on their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respective Series C Liquidation Amount (as defined below) and Series B Liquidation Amount (as defined below), shall be entitled to be paid out of the consideration payable to stockholders in such
Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of the Series A Preferred Stock and Common Stock by reason of their ownership thereof, an amount per share
equal to the greater of (i)&nbsp;with respect to the Series C Preferred Stock, the Series C Original Issue Price and with respect to the Series B Preferred Stock, the Series B Original Issue Price, in each case, plus any dividends declared but
unpaid thereon and (ii)&nbsp;such amount per share as would have been payable had all shares of such series of Preferred Stock (and all shares of all other series of Preferred Stock that would receive a larger distribution per share if such series
of Preferred Stock were converted into Common Stock) been converted into Common Stock pursuant to Section&nbsp;4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event regardless of whether such conversion is
permitted (the amount payable to holders of Series C Preferred Stock pursuant to this sentence is hereinafter referred to as the &#147;<B>Series C Liquidation Amount</B>&#148; and the amount payable to holders of Series B Preferred Stock pursuant to
this sentence is hereinafter referred to as the &#147;<B>Series B Liquidation Amount</B>&#148; ). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for
distribution to its stockholders shall be insufficient to pay the holders of shares of Series C Preferred Stock and Series B Preferred Stock the full amount to which they shall be entitled under this Subsection&nbsp;2.1.1, the holders of shares of
the Series C Preferred Stock and the Series B Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by
them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.2 <U>Series A Preferred
Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, and after payment of the Series C Liquidation Amount and Series B Liquidation Amount to the holders of Series C Preferred Stock and
Series B Preferred Stock, respectively, the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, or in the event of a Deemed
Liquidation Event, out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds, as applicable, before any payment shall be made to the holders of Common Stock by reason of their ownership
thereof, an amount per share equal to the greater of (i)&nbsp;the Series A Original Issue Price plus any dividends declared but unpaid thereon and (ii)&nbsp;such amount per share as would have been payable had all shares of Series A Preferred Stock
(and all shares of all other series of Preferred Stock that would receive a larger distribution per share if such series of Preferred Stock were converted into Common Stock) been converted into Common Stock pursuant to Section&nbsp;4 immediately
prior to such liquidation, dissolution, winding up or Deemed Liquidation Event regardless of whether such conversion is permitted (the amount payable pursuant to this sentence with respect to the Series A Preferred Stock is hereinafter referred to
as the &#147;<B>Series A Liquidation Amount</B>&#148;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be
insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled under this Subsection&nbsp;2.1.2 after payment of the Series C Liquidation Amount and the Series B Liquidation Amount to the
holders of shares of Series C Preferred Stock and Series B Preferred Stock, respectively, the holders of shares of Series&nbsp;A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the
respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Payments to Holders of Common Stock</U>. In the event of any voluntary or
involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, after the payment in full of the Series C Liquidation Amount and Series B Liquidation Amount required to be paid to the holders of shares of Series C
Preferred Stock and Series B Preferred Stock, respectively, and after the payment in full of the Series A Liquidation Amount required to be paid to the holders of shares of Series A Preferred Stock, the remaining assets of the Corporation available
for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Series A Preferred Stock, the holders of shares of Series B Preferred Stock or the holders of shares of
Series C Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or the remaining Available Proceeds, as the case may be, shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares of Common
Stock held by each such holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Deemed Liquidation Events</U>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Definition</U>. Each of the following events shall be considered a &#147;<B>Deemed Liquidation Event</B>&#148; unless the holders of
a majority of the shares of Preferred Stock (voting together on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), which such majority must include at least one Series B New Investor (as defined in the Company&#146;s
Series C Preferred Stock Purchase Agreement, dated on or about the Original Issue Date) (the &#147;<B>Requisite Holders</B>&#148;) elect otherwise by written notice sent to the Corporation at least ten (10)&nbsp;days prior to the effective date of
any such event: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) a merger, consolidation,<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>statutory conversion, transfer,
domestication or continuance in which </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger, consolidation, statutory conversion, transfer, domestication or continuance, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger,
consolidation, statutory conversion, transfer, domestication or continuance involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger, consolidation, statutory
conversion, transfer, domestication or continuance continue to represent, or are converted into or exchanged for shares of capital stock or other equity interests that represent, immediately following such merger, consolidation, statutory
conversion, transfer, domestication or continuance, a majority, by voting power, of the capital stock or other equity interests of (1)&nbsp;the surviving or resulting corporation or entity; or (2)&nbsp;if the surviving or resulting corporation or
entity is a wholly owned subsidiary of another corporation or entity immediately following such merger, consolidation statutory conversion, transfer, domestication or continuance, the parent corporation or entity of such surviving or resulting
corporation or entity; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) (1) the sale, lease, transfer, exclusive license or other disposition, in a single
transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole or (2)&nbsp;the sale, lease, transfer exclusive
license or other disposition (whether by merger, consolidation, statutory conversion, domestication, continuance, or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Corporation
if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary
of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Subsection 2.3.1(a)(i)</U> unless the
agreement or plan with respect to such transaction, or terms of such transaction (any such agreement, plan or terms, the &#147;<B>Transaction Document</B>&#148;), provide that the consideration payable to the stockholders of the Corporation in such
Deemed Liquidation Event shall be allocated to the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a Deemed Liquidation Event referred to in <U>Subsection 2.3.1(a)(ii)</U> or <U>2.3.1(b)</U>, if the Corporation does not
effect a dissolution of the Corporation under the General Corporation Law within ninety (90)&nbsp;days after such Deemed Liquidation Event, then (i)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later than the
ninetieth (90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause to
require the redemption of such shares of Preferred Stock, and (ii)&nbsp;if the Requisite Holders so request in a written instrument delivered to the Corporation not later than one hundred twenty (120)&nbsp;days after such Deemed Liquidation Event,
the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors
of the Corporation)<B>, </B>together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the &#147;<B>Available</B><B>
Proceeds</B>&#148;), on the one hundred fiftieth (150<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day after such Deemed Liquidation Event (the &#147;<B>DLE Redemption Date</B>&#148;), to redeem all outstanding shares of Preferred Stock
at a price per share equal to the Series C Liquidation Amount in the case of Series C Preferred Stock, Series B Liquidation Amount in the case of the Series B Preferred Stock and the Series A Liquidation Amount in the case of the Series A Preferred
Stock (the &#147;<B>Redemption Price</B>&#148;); provided, that if the definitive agreements governing such Deemed Liquidation Event contain contingent indemnification obligations on the part of the Corporation and prohibit the Corporation from
distributing all or a portion of the Available Proceeds while such indemnification obligations remain outstanding, then the DLE Redemption Date shall automatically be extended to the date that is ten business days following the date on which such
prohibition expires. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Series C Preferred Stock and Series B Preferred Stock, the Corporation shall redeem a pro rata portion of each holder&#146;s shares of Series C Preferred Stock and Series B Preferred Stock to
the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem the
remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. After redemption in full of the Series C Preferred Stock and Series B Preferred Stock, if the Available Proceeds are not sufficient to
redeem all outstanding shares of Series A Preferred Stock, the Corporation shall redeem a pro rata portion of each holder&#146;s shares of Series A Preferred Stock to the fullest extent of such Available Proceeds, based on the respective amounts
which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing
distributions to stockholders. The Corporation shall send written notice of the mandatory redemption (the &#147;<B>Redemption Notice</B>&#148;) to each holder of record of Preferred Stock not less than forty (40)&nbsp;days prior to the date of any
such redemption (the &#147;<B>Redemption Date</B>&#148;). The Redemption Notice shall state: (1)&nbsp;the number of shares of each series of Preferred Stock held by the holder that the Corporation shall redeem on the Redemption Date specified in the
Redemption Notice; (2)&nbsp;the Redemption Date, the Series A Liquidation Amount, the Series B Liquidation Amount and Series C Liquidation Amount; (3)&nbsp;the date upon which the holder&#146;s right to convert such shares terminates (as determined
in accordance with <U>Subsection 4.1</U>); and (4)&nbsp;for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place designated, his, her or its certificate or certificates
representing the shares of Preferred Stock to be redeemed. On or before the Redemption Date, each holder of shares of Preferred Stock to be redeemed on the Redemption Date, unless such holder has exercised his, her or its right to convert such
shares as provided in <U>Section</U><U></U><U>&nbsp;4</U>, shall, if a holder of shares in certificated form, surrender the certificate or certificates representing such shares (or, if such registered holder alleges that such certificate has been
lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or
destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the Series A Liquidation Amount, the Series B Liquidation Amount and Series C Liquidation Amount for such shares,
as applicable, shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. In the event less than all of the shares of Preferred Stock represented by a certificate are redeemed, a new
certificate, instrument or book entry representing the unredeemed shares of Preferred Stock shall promptly be issued to such holder. If the Redemption Notice shall have been duly given, and if on the Redemption Date the Series A Liquidation Amount,
the Series B Liquidation Amount and Series C Liquidation Amount payable upon redemption of the Preferred Stock to be redeemed on the Redemption Date, as applicable, is paid or tendered for payment or deposited with an independent payment agent so as
to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, all rights with respect to such shares of Preferred
Stock shall forthwith after the Redemption Date terminate, except only the right of the holders to receive the Series A Liquidation Amount, Series B Liquidation Amount and Series C Liquidation Amount, as the case may be, without interest upon
surrender of any such certificate or certificates therefor. Prior to the distribution or redemption provided for in this <U>Subsection 2.3.2(b)</U>, the Corporation shall not expend or dissipate the Available Proceeds for any purpose, except to
discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>Amount Deemed Paid or Distributed</U>.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall
be the cash or the value of the property, rights or securities to be paid or distributed to such holders pursuant to such Deemed Liquidation Event. The value of such property, rights or securities shall be determined in good faith by the Board of
Directors of the Corporation, including the approval of a majority of the Preferred Directors (as defined herein). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.4 <U>Allocation of
Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to <U>Subsection 2.3.1(a)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of
contingencies (the &#147;<B>Additional Consideration</B>&#148;), the Transaction Document shall provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B>Initial Consideration</B>&#148;)
shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event;
and (b)&nbsp;any Additional Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections
2.1</U> and <U>2.2</U> after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Subsection 2.3.4</U>, consideration placed into escrow or retained as a holdback to be
available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Voting</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1
<U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of a meeting), each holder of
outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible (as provided in Section&nbsp;4
below) as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of
Common Stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of
Directors</U>. The holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, and by the vote or written consent of the Requisite Series B Holders (as defined below), shall be entitled to elect one
(1)&nbsp;director of the Corporation (the &#147;<B>S</B><B>eries B Director</B>&#148;), the holders of record of the shares of Series A Preferred Stock, exclusively and as a separate class, shall be entitled to elect three (3)&nbsp;directors of the
Corporation (the &#147;<B>S</B><B>eries A Directors</B>&#148; and, together with the Series B Director, the &#147;<B>Preferred Directors</B>&#148;) and the holders of record of the shares of Common Stock, exclusively and as a separate class, shall
be entitled to elect two (2)&nbsp;directors of the Corporation; <U>provided</U>, <U>however</U>, for administrative convenience, the initial Series B Preferred Director may also be appointed by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board of Directors in connection with the approval of the initial issuance of Series B Preferred Stock without a separate action by the holders of the Series B Preferred Stock. Any director
elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a
special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>If the holders of shares of Series B Preferred Stock, Series A Preferred Stock
or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this
<U>Subsection</U><U></U><U>&nbsp;3.2</U>, then any directorship not so filled shall remain vacant until such time as the holders of the Series B Preferred Stock, Series A Preferred Stock or Common Stock, as the case may be, elect a person to fill
such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such
directorship, voting exclusively and as a separate<B> </B>class. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class,
shall be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the
class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director. Except as otherwise provided in this <U>Subsection</U><U></U><U>&nbsp;3.2</U>,<B> </B>a vacancy in any directorship filled by the
holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this
<U>Subsection</U><U></U><U>&nbsp;3.2</U>. The rights of the holders of the Series A Preferred Stock under the first sentence of this <U>Subsection 3.2</U> shall terminate on the first date following the Original Issue Date (as defined below) on
which there are issued and outstanding less than 4,500,000 shares of Series A Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization with respect to the
Series A Preferred Stock). The rights of the holders of the Series B Preferred Stock under the first sentence of this <U>Subsection 3.2</U> shall terminate on the first date following the Original Issue Date on which there are issued and outstanding
less than 12,924,003 shares of Series B Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization with respect to the Series B Preferred Stock). The rights of
the holders of Common Stock under the first sentence of this <U>Subsection</U><U></U><U>&nbsp;3.2</U> shall terminate on the first date on which the rights of the holders of both the Series A Preferred Stock and Series B Preferred Stock under the
first sentence of this <U>Subsection 3.2</U> have terminated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when at least
19,089,051 shares of Series C Preferred Stock and Series B Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series C Preferred Stock
and Series B Preferred Stock) are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance, recapitalization, reclassification, waiver, statutory conversion, or
otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the Requisite Holders given in writing or by vote at
a meeting, consenting or voting (as the case may be) together as a single class,<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>and any such&nbsp;act or transaction that has not been approved by such consent or vote prior to such act or
transaction being effected shall be null and void <I>ab initio</I>, and of no force or effect.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business
and affairs of the Corporation or effect any Deemed Liquidation Event, or any other merger, consolidation, statutory conversion, transfer, domestication or continuance, or consent to any of the foregoing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 amend, alter or repeal any provision of this Certificate of Incorporation or Bylaws of the Corporation in a manner that adversely
affects the special rights, powers and preferences of the Series C Preferred Stock and Series B Preferred Stock;<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 create or issue or obligate itself to issue shares of or reclassify any capital stock unless the same ranks junior to the Series C
Preferred Stock and Series B Preferred Stock with respect to its special rights, powers and preferences including the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of
redemption, or increase the authorized number of shares of Series C Preferred Stock and Series B Preferred Stock or any additional class or series of capital stock of the Corporation unless the same ranks junior to the Series C Preferred Stock and
Series B Preferred Stock with respect to its special rights, powers and preferences; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 purchase or redeem (or permit any subsidiary
to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein,
(ii)&nbsp;dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock and (iii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed
services for the Corporation or any subsidiary in connection with the cessation of such employment or service at no greater than the original purchase price thereof;<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 create or issue any debt security or create any lien or security interest (except for purchase money liens or statutory liens of
landlords, mechanics, materialmen, workmen, warehousemen and other similar persons arising or incurred in the ordinary course of business) or incur other indebtedness for borrowed money, including but not limited to obligations and contingent
obligations under guarantees, or permit any subsidiary to take any such action with respect to any debt security lien, security interest or other indebtedness for borrowed money, if the aggregate indebtedness of the Corporation and its subsidiaries
for borrowed money following such action would exceed $500,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6 create, or hold capital stock in, any subsidiary that is not wholly
owned (either directly or through one or more other subsidiaries) by the Corporation, or permit any subsidiary to create or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose
of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions)
of all or substantially all of the assets of such subsidiary; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7 increase or decrease the authorized number of directors constituting the Board of
Directors, change the number of votes entitled to be cast by any director or directors on any matter, or adopt any provision inconsistent with Article Sixth; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 adopt any new or amend any existing stock plan to increase the aggregate number of shares of Common Stock reserved thereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 enter into any material joint development, licensing or collaboration agreement or any acquisition of all or substantially all of the
stock or assets of another entity; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 make any change in the Corporation&#146;s line of business; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.11 enter into any agreements or commitments to do any of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Series C Preferred Stock Protective Provisions</U>. At any time when at least 6,165,048 of the shares of Series C Preferred Stock
(subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization) are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation,
statutory conversion, transfer, domestication or continuance, or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the holders
of a majority of outstanding shares of Series C Preferred Stock (the &#147;<B>Requisite Series C Holders</B>&#148;), given in writing or by vote at a meeting, consenting or voting (as the case may be) as a single and separate class,<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>and any such&nbsp;act or transaction that has not been approved by such consent or vote prior to such act or transaction being effected shall be null and void <I>ab initio</I>, and of no force or
effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.1 increase the authorized number of shares of Series C Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.2 amend, alter or repeal (whether by merger, consolidation, operation of law, or otherwise) any provision of the Corporation&#146;s
amended and restated certificate of incorporation or bylaws in a manner that would adversely alter or change the special rights, powers or preferences of the Series C Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.3 reclassify any other class or series of stock, if it would render such class or series senior to or on parity with the Series C
Preferred Stock; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.4 amend, waive or modify the original issue price of the Series C Preferred Stock, the applicable conversion
price of the Series C Preferred Stock (including any anti-dilution rights with respect thereto) or the Series C Preferred Stock liquidation preference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Subsection 3.4.2 above, for the avoidance of doubt, an amendment, alteration or repeal of any provision of this Certificate
of Incorporation or Bylaws of the Corporation shall not be deemed to affect the Series C Preferred Stock adversely or in a manner differently than any other series of Preferred Stock if the effect is solely due to proportional differences in the
amounts of respective issue prices, liquidation preferences or redemption prices that arise out of differences between the original issue price of the Series C Preferred Stock and any other series of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5 <U>Series B Preferred Stock Protective Provisions</U>. At any time when at least 10% of
the shares of the Series B Preferred Stock originally issued are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, statutory conversion, transfer, domestication or continuance, or otherwise,
do any of the following without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the holders of a majority of outstanding shares of Series B Preferred Stock, which such
majority must include at least one Series B New Investor (the &#147;<B>Requisite Series B Holders</B>&#148;), given in writing or by vote at a meeting, consenting or voting (as the case may be) as a single and separate class,<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>and any such&nbsp;act or transaction that has not been approved by such consent or vote prior to such act or transaction being effected shall be null and void <I>ab initio</I>, and of no force or
effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.1 increase the authorized number of shares of Series B Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.2 amend, alter or repeal (whether by merger, consolidation, operation of law, or otherwise) any provision of the Corporation&#146;s
amended and restated certificate of incorporation or bylaws in a manner that would adversely alter or change the special rights, powers or preferences of the Series B Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.3 reclassify any other class or series of stock, if it would render such class or series senior to or on parity with the Series B
Preferred Stock; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.4 amend, waive or modify the original issue price of the Series B Preferred Stock, the applicable conversion
price of the Series B Preferred Stock (including any anti-dilution rights with respect thereto) or the Series B Preferred Stock liquidation preference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Subsection&nbsp;3.5.2 above, for the avoidance of doubt, an amendment, alteration or repeal of any provision of this
Certificate of Incorporation or Bylaws of the Corporation shall not be deemed to affect the Series B Preferred Stock adversely or in a manner differently than any other series of Preferred Stock if the effect is solely due to proportional
differences in the amounts of respective issue prices, liquidation preferences or redemption prices that arise out of differences between the original issue price of the Series B Preferred Stock and any other series of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.6 <U>Series A Preferred Stock Protective Provisions</U>. At any time when at least 10% of the shares of the Series A Preferred Stock
originally issued are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate of
Incorporation) the written consent or affirmative vote of the holders of a majority of outstanding shares of Series A Preferred Stock (the &#147;<B>Requisite Series A Holders</B>&#148;), given in writing or by vote at a meeting, consenting or voting
(as the case may be) as a single and separate class,<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>and any such&nbsp;act or transaction that has not been approved by such consent or vote prior to such act or transaction being effected shall
be null and void <I>ab initio</I>, and of no force or effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.6.1 increase the authorized number of shares of Series A Preferred Stock;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.6.2 amend, alter or repeal (whether by merger, consolidation, operation of law, or
otherwise) any provision of the Corporation&#146;s amended and restated certificate of incorporation or bylaws in a manner that would adversely alter or change the rights, preferences or privileges of the Series A Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.6.3 reclassify any other class or series of stock, if it would render such class or series senior to or on parity with the Series A
Preferred Stock; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.6.4 amend, waive or modify the original issue price of the Series A Preferred Stock, the applicable conversion
price of the Series A Preferred Stock (including any anti-dilution rights with respect thereto) or the Series A Preferred Stock liquidation preference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Subsection&nbsp;3.6.2 above, for the avoidance of doubt, an amendment, alteration or repeal of any provision of this
Certificate of Incorporation or Bylaws of the Corporation shall not be deemed to affect the Series A Preferred Stock adversely or in a manner different than any other series of Preferred Stock if the effect is solely due to proportional differences
in the amounts of respective issue prices, liquidation preferences or redemption prices that arise out of differences between the original issue of the Series A Preferred Stock and any other series of Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<B>Conversion Rights</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) Each share of Series A Preferred Stock shall be convertible, at the option of the holder thereof, at any time, and without the payment of
additional consideration by the holder thereof, into such whole number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by dividing the Series A Original Issue Price by the Series A
Conversion Price (as defined below) in effect at the time of conversion. The &#147;<B>Series A Conversion Price</B>&#148; shall initially be equal to $0.687. Such initial Series A Conversion Price, and the rate at which shares of Series A Preferred
Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) Each share of Series B
Preferred Stock shall be convertible, at the option of the holder thereof, at any time, and without the payment of additional consideration by the holder thereof, into such whole number of fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by dividing the Series B Original Issue Price by the Series B Conversion Price (as defined below) in effect at the time of conversion. The &#147;<B>Series
B Conversion Price</B>&#148; shall initially be equal to $0.90. Such initial Series B Conversion Price, and the rate at which shares of Series B Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided
below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) Each share of Series C Preferred Stock shall be convertible, at the option of the
holder thereof, at any time, and without the payment of additional consideration by the holder thereof, into such whole number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by
dividing the Series C Original Issue Price by the Series C Conversion Price (as defined below) in effect at the time of conversion. The &#147;<B>Series C Conversion Price</B>&#148; shall initially be equal to $1.03. Such initial Series C Conversion
Price, and the rate at which shares of Series C Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a notice of redemption of any shares of Preferred Stock pursuant to
<U>Section</U><U></U><U>&nbsp;2.3.2</U>, the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding the date fixed for redemption, unless the redemption price is not fully
paid on such redemption date, in which case the Conversion Rights for such shares shall continue until such price is paid in full.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>In the event of a liquidation, dissolution or winding up of the
Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred
Stock; <U>provided</U> that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with <U>Subsection</U><U></U><U>&nbsp;2.1</U> to holders of Preferred Stock pursuant to such
liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 <U>Number of Shares Issuable Upon
Conversion</U>. The number of shares of Common Stock issuable to a holder of Preferred Stock upon conversion of such Preferred Stock shall be the nearest whole share, after aggregating all fractional interests in shares of Common Stock that would
otherwise be issuable upon conversion of all shares of that same series of Preferred Stock being converted by such holder (with any fractional interests after such aggregation representing 0.5 or greater of a whole share being entitled to a whole
share). For the avoidance of doubt, no fractional interests in shares of Common Stock shall be created or issuable as a result of the conversion of the Preferred Stock pursuant to Section&nbsp;4.1.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of
Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation&#146;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own
transfer agent) that such holder elects to convert all or any number of such holder&#146;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder&#146;s shares are certificated,
surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the
Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the
principal office of the Corporation if the Corporation serves as its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
own transfer agent). Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the
Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney
duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit
and agreement) shall be the time of conversion (the &#147;<B>Conversion Time</B>&#148;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation
shall, as soon as practicable after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such
conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash in lieu of any
fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep
available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the
conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation
shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain
the requisite stockholder approval of any necessary amendment to this Certificate of Incorporation. Before taking any action which would cause an adjustment reducing the Series A Conversion Price, the Series B Conversion Price and/or the Series C
Conversion Price below the then par value of the shares of Common Stock issuable upon conversion of the Series A Preferred Stock, the Series B Preferred Stock or the Series C Preferred Stock, as applicable, the Corporation will take any corporate
action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at such adjusted Series A
Conversion Price, Series B Conversion Price or Series C Conversion Price, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3 <U>Effect of Conversion</U>. All shares of
Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the
right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion and to receive payment of any dividends declared but unpaid thereon.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the
need for stockholder action) as may be necessary to reduce the authorized number of shares of such series of Preferred Stock accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the
applicable Conversion Price shall be made for any declared but unpaid dividends on the Series A Preferred Stock, the Series B Preferred Stock or the Series C Preferred Stock surrendered for conversion or on the Common Stock delivered upon
conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5 <U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any
issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any
transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or
entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments</U><U> to Conversion Price for Diluting Issues</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Option</B>&#148; means rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Original Issue Date</B>&#148; means the date on which the first share of Series C Preferred Stock was issued.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Convertible Securities</B>&#148; means any evidences of indebtedness, shares or other securities directly or indirectly
convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Additional Shares of Common Stock</B>&#148; means
all shares of Common Stock issued (or, pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> below, deemed to be issued) by the Corporation after the Original Issue Date, other than (1)&nbsp;the following shares of Common Stock and (2)&nbsp;shares
of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#147;<B>Exempted Securities</B>&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to any series of Preferred Stock, shares of Common Stock, Options or Convertible Securities issued as a
dividend or distribution on such series of Preferred Stock (including dividends payable in connection with dividends on other classes or series of stock); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Subsection 4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Corporation, including the approval of a majority of the Preferred Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial
institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board of Directors, including the approval of a majority of the Preferred Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to suppliers or third party service providers
in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors, including the approval of a majority of the Preferred Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the
acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, <U>provided</U> that such issuances are approved by the Board of Directors of the
Corporation, including the approval of a majority of the Preferred Directors; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors of the Corporation, including the approval of a majority of the Preferred Directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of Conversion Price</U>. No adjustment in the Series A Conversion Price shall be made as the
result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Series&nbsp;A Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed
issuance of such Additional Shares of Common Stock. No adjustment in the Series B Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from
the Requisite Series B Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series C Conversion Price shall be made as the result of
the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Series C Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of
such Additional Shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the
maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a
subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of
Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Series A Conversion Price, the
Series B Conversion Price or the Series C Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible
Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock
issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Series A Conversion Price, the Series B Conversion Price or the Series C Conversion Price, as
the case may be, computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Series A Conversion Price, Series B Conversion Price or the Series C
Conversion Price, as the case may be, as would have been obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this
<U>clause (b)</U>&nbsp;shall have the effect of increasing the Series A Conversion Price, the Series B Conversion Price or the Series C Conversion Price to an amount which exceeds the lower of (i)&nbsp;the Series A Conversion Price, the Series B
Conversion Price or the Series C Conversion Price, as the case may be, in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the Series A Conversion Price, the
Series B Conversion Price or the Series C Conversion Price, as the case may be, that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the
issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any
Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Series A Conversion Price, the Series B Conversion Price or the
Series C Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U> (either because the consideration per share (determined pursuant to <U>Subsection 4.4.5</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater
than the Series A Conversion Price, the Series B Conversion Price or the Series C Conversion Price, as the case may be, then in effect, or because such Option or Convertible Security was issued before the Original Issue Date), are revised after the
Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar
provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2)&nbsp;any
decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the
manner provided in <U>Subsection</U><U></U><U>&nbsp;4.4.3(a)</U>) shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which
resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Series A Conversion Price, the Series B Conversion Price or the Series C Conversion Price pursuant to the terms of
<U>Subsection</U><U></U><U>&nbsp;4.4.4</U>, the Series A Conversion Price, the Series B Conversion Price or the Series C Conversion Price, as the case may be, shall be readjusted to such Series A Conversion Price, Series B Conversion Price or the
Series C Conversion Price, as the case may be, as would have been obtained had such Option or Convertible Security (or portion thereof) never been issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or
exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is potentially
subject to adjustment based upon subsequent events, any adjustment to the Series A Conversion Price, the Series B Conversion Price or the Series C Conversion Price provided for in this <U>Subsection 4.4.3</U> shall be effected at the time of such
issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses&nbsp;(b) and (c)&nbsp;of this
<U>Subsection 4.4.3</U>). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or
exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Series A Conversion Price, the Series B Conversion Price or the Series C Conversion Price, as the case may be, that
would result under the terms of this <U>Subsection 4.4.3</U> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent
adjustments), assuming for purposes of calculating such adjustment to the Series A Conversion Price, the Series B Conversion Price or the Series C Conversion Price, as the case may be, that such issuance or amendment took place at the time such
calculation can first be made. In the event an Option or Convertible Security contains alternative conversion terms, such as a cap on the valuation of the Corporation at which such conversion will be effected, or circumstances where the Option or
Convertible Security may be repaid in lieu of conversion, then the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of such Option or Convertible Security shall be deemed not calculable until such time as the
applicable conversion terms are determined. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4 <U>Adjustment of Conversion Price Upon Issuance of Additional Shares of Common
Stock</U>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>In the event the Corporation at any time after the Original Issue Date issues Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant
to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>), without consideration or for a consideration per share less than the Series A Conversion Price in effect immediately prior to such issuance or deemed issuance and/or the Series B Conversion Price in
effect immediately prior to such issuance or deemed issuance and/or the Series C Conversion Price in effect immediately prior to such issuance or deemed issuance, as the case may be, then the Series A Conversion Price, the Series B Conversion Price
and/or the Series C Conversion Price, as the case may be, shall be reduced, concurrently with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the
following formula: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> =
CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB>* (A + B) &divide; (A + C). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions
shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;CP<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>&#148; shall mean (1)&nbsp;in the case of an adjustment
to the Series A Conversion Price, the Series A Conversion Price in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock, (2)&nbsp;in the case of an adjustment to the Series B Conversion Price, the Series B
Conversion Price in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock and (3)&nbsp;in the case of an adjustment to the Series C Conversion Price, the Series C Conversion Price in effect immediately after
such issuance or deemed issuance of Additional Shares of Common Stock; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB>&#148; shall mean
(1)&nbsp;in the case of an adjustment to the Series A Conversion Price, the Series A Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock, (2)&nbsp;in the case of an adjustment to the
Series B Conversion Price, the Series B Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock and (3)&nbsp;in the case of an adjustment to the Series C Conversion Price, the Series C
Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;A&#148;
shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of
Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior
to such issue); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares
of Common Stock had been issued or deemed issued at a price per share equal to CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB>); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#147;C&#148; shall mean the number of such Additional Shares of Common
Stock issued in such transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of this <U>Subsection 4.4</U>, the
consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and Property.</U> Such consideration shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issue, as determined in good faith by the Board of Directors of the Corporation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i)&nbsp;and (ii) above, as determined in good faith by the Board of Directors of the Corporation.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration)
payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the
conversion or exchange of such Convertible Securities, by </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are
a part of one transaction or a series of related transactions and that would result in an adjustment to the Series A Conversion Price, the Series B Conversion Price and/or the Series C Conversion Price pursuant to the terms of
<U>Subsection</U><U></U><U>&nbsp;4.4.4</U>, and such issuance dates occur within a period of no more than ninety (90)&nbsp;days from the first such issuance to the final such issuance, then, upon the final such issuance, the Series A Conversion
Price, the Series B Conversion Price and/or the Series C Conversion Price, as the case may be, shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any
additional adjustments as a result of any such subsequent issuances within such period). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U>.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>If the Corporation shall at any time or from time to time after the Original Issue Date effect a subdivision of the outstanding Common Stock, the Series A Conversion Price in effect immediately before
such subdivision, the Series B Conversion Price in effect immediately before such subdivision and the Series C Conversion Price in effect immediately before such subdivision shall be proportionately decreased so that the number of shares of Common
Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Original
Issue Date combine the outstanding shares of Common Stock, the Series A Conversion Price in effect immediately before such combination, the Series B Conversion Price in effect immediately before such combination and the Series C Conversion Price in
effect immediately before such combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number
of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of business on the date the subdivision or combination becomes effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the
Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each
such event the Series A Conversion Price in effect immediately before such event, the Series B Conversion Price in effect immediately before such event and the Series C Conversion Price in effect immediately before such event shall be decreased as
of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Series A Conversion Price then in effect, the Series B Conversion Price then in effect or the
Series C Conversion Price then in effect, as the case may be, by a fraction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the numerator of which shall be the total number of
shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully
made on the date fixed therefor, the Series A Conversion Price, the Series B Conversion Price and the Series C Conversion Price, as the case may be, shall be recomputed accordingly as of the close of business on such record date and thereafter the
Series A Conversion Price, the Series B Conversion Price and the Series C Conversion Price, as the case may be, shall be adjusted pursuant to this subsection as of the time of actual payment of such dividends or distributions; and (b)&nbsp;no such
adjustment shall be made with respect to the Series A Conversion Price, the Series B Conversion Price and/or the Series C Conversion Price, as the case may be, if the holders of the Series A Preferred Stock, the Series B Preferred Stock and/or the
Series C Preferred Stock, as the case may be, simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of Series
A Preferred Stock, Series B Preferred Stock and/or Series C Preferred Stock, as the case may be, had been converted into shares of Common Stock on the date of such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation
at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation
(other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or distribution, then and in each
such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities
or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Subsection 2.3</U>, if there shall occur any
reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a
transaction covered by <U>Subsections 4.5</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of
the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of
Series A Preferred Stock, one share of Series B Preferred Stock or one share of Series C Preferred Stock, as the case may be, immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been
entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors) shall be made in the application of the provisions in this <U>Section</U><U></U><U>&nbsp;4</U> with
respect to the rights and interests thereafter of the holders of Preferred Stock, to the end that the provisions set forth in this <U>Section</U><U></U><U>&nbsp;4</U> (including provisions with respect to changes in and other adjustments of the
Series A Conversion Price, the Series B Conversion Price and/or the Series C Conversion Price, as the case may be) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable
upon the conversion of the Preferred Stock.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to
Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Series A Conversion Price, the Series B Conversion Price and/or the Series C Conversion Price pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation at its
expense shall, as promptly as reasonably practicable, but in any event not later than ten (10)&nbsp;days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Series A Preferred Stock,
Series B Preferred Stock and/or the Series C Conversion Price, as the case may be, a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which the Series A Preferred
Stock, the Series B Preferred Stock and/or the Series C Preferred Stock, as the case may be, is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably
practicable after the written request at any time of any holder of Series A Preferred Stock, Series B Preferred Stock and/or Series C Preferred Stock, as the case may be (but in any event not later than ten (10)&nbsp;days thereafter), furnish or
cause to be furnished </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to such holder a certificate setting forth (i)&nbsp;the Series A Conversion Price then in effect, the Series B Conversion Price then in effect and/or the Series C Conversion Price then in effect,
as the case may be, and (ii)&nbsp;the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of the Series A Preferred Stock, the Series B Preferred Stock
and/or the Series C Preferred Stock, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or series or any other
securities, or to receive any other security; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the Common
Stock of the Corporation, or any Deemed Liquidation Event; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) of the voluntary or involuntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the
holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which
such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or
other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange
applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10)&nbsp;days prior to the record date or effective date for the event specified in such notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. Immediately prior to (a)&nbsp;the closing of the sale of shares of Common Stock to the public at a price of at
least $2.25 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to
an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50,000,000 of gross proceeds to the Corporation and in connection with such offering the Common Stock is listed for trading on the Nasdaq Global
Market, Nasdaq Global Select Market, the New York Stock Exchange or another exchange or marketplace approved the Board of Directors or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the Requisite
Holders<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>(the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the &#147;<B>Mandatory Conversion
Time</B>&#148;), then (i)&nbsp;all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to <U>Subsection 4.1.1.</U> and (ii)&nbsp;such shares
may not be reissued by the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Procedural Requirements</U>. All holders of record of shares of Preferred Stock (or
the applicable series thereof) shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such notice
need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock being converted that holds such shares of Preferred Stock in certificated form shall surrender his,
her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the
Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any
certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized
in writing. All rights with respect to the Preferred Stock converted pursuant to <U>Subsection 5.1</U>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion
Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost
certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Subsection 5.2</U>. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or
certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common
Stock issuable on such conversion in accordance with the provisions hereof or issue and deliver to such holder, or to his, her or its nominees, a notice of issuance of uncertificated shares and may, upon written request, issue and deliver a
certificate for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof; and (b)&nbsp;pay cash in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and
for the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Redeemed or Otherwise Acquired
Shares</U>. Any shares of Preferred Stock that are redeemed, converted or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred.
Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption, conversion or acquisition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Waiver</U>. Except as otherwise set forth herein, any of the rights, powers, preferences and other terms of the Series A Preferred Stock
set forth herein may be waived on behalf of all holders of Series A Preferred Stock solely by the affirmative written consent or vote of the Requisite Series A Holders, any of the rights, powers, preferences and other terms of the Series B Preferred
Stock set forth herein may be waived on behalf of all holders of Series B Preferred Stock solely by the affirmative written consent or vote of the Requisite Series B Holders and any of the rights, powers, preferences and other terms of the Series C
Preferred Stock set forth herein may be waived on behalf of all holders of Series C Preferred Stock solely by the affirmative written consent or vote of the Requisite Series C Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Any notice required or permitted by the provisions of this Article Fourth
to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission in compliance with the provisions of the General
Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH</B><B>:</B> Subject to any additional
vote required by this Certificate of Incorporation or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws
of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH</B><B>:</B> Subject to any additional vote required by this Certificate of Incorporation, the number of
directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one vote on each matter presented to the Board of Directors; <U>provided</U>, <U>however</U>, that, so long
as the holders of Series B Preferred Stock are entitled to elect a Series B Director and/or the holders of Series A Preferred Stock are entitled to elect a Series A Director, the affirmative vote of a majority of the Preferred Directors shall be
required for the authorization by the Board of Directors of any of the matters set forth in Section&nbsp;5.5 of the Second Amended and Restated Investors&#146; Rights Agreement, dated on or about the Original Issue Date, by and among the Corporation
and the other parties thereto, as such agreement may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH</B><B>:</B> Elections of directors need not
be by written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH</B><B>:</B> Meetings of stockholders may be held
within or outside of the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such
manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH</B><B>:</B> To the fullest extent permitted by law, a director or officer of the Corporation shall not be personally liable to the
Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article Ninth
to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the
General Corporation Law as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or elimination of the foregoing provisions of this Article Ninth by the
stockholders of the Corporation shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of, or increase the liability of any director or officer of the Corporation with respect to any acts
or omissions of such director or officer occurring prior to, such amendment, repeal or elimination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH</B><B>:</B><SUP STYLE="font-size:75%; vertical-align:top"> </SUP><B></B>To the
fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which the General Corporation Law
permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise
permitted by <U>Section</U><U></U><U>&nbsp;145</U> of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal, modification or elimination of
the foregoing provisions of this Article Tenth shall not (a)&nbsp;adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal, modification or elimination or
(b)&nbsp;increase the liability of any director, officer or agent of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to such amendment, repeal, modification or elimination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH</B><B>:</B> The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in,
or in being offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B>Excluded Opportunity</B>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes
into the possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or
agent of any such holder, other than someone who is an officer or employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in clauses (i)&nbsp;and (ii) are &#147;<B>Covered Persons</B>&#148;), unless such matter,
transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation while such
Covered Person is performing services in such capacity. Any repeal or modification of this Article Eleventh will only be prospective and will not affect the rights under this Article Eleventh in effect at the time of the occurrence of any actions or
omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Certificate of Incorporation, in addition to any other vote required by law or this Certificate of Incorporation, the affirmative vote of
the Requisite Holders, will be required to amend or repeal, or to adopt any provisions inconsistent with this Article Eleventh.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH</B><B>:</B> Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State
of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of
fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees
arising pursuant to any provision of the General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees governed by the
internal affairs doctrine or that otherwise relates to the internal affairs of the Corporation, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not
subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of
a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article Twelfth shall be held
to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other
circumstance and of the remaining provisions of this Article Twelfth (including, without limitation, each portion of any sentence of this Article Twelfth containing any such provision held to be invalid, illegal or unenforceable that is not itself
held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* &#8195;*&#8195; * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B>
That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.</B> That this Third Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of
the Corporation&#146;s Second Amended and Restated Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Third Amended and Restated Certificate of Incorporation has
been executed by a duly authorized officer of this corporation on this 2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> day of August, 2024.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ P. Kent Hawryluk</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">P. Kent Hawryluk, President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MBX BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MBX
Biosciences, Inc. (the &#147;<U>Corporation</U>&#148;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#147;<U>General Corporation Law</U>&#148;), </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&#8195;That the name of the Corporation is MBX Biosciences, Inc., and that this corporation was originally incorporated pursuant to
the General Corporation Law on April&nbsp;9, 2019 under the name MBX Biosciences, Inc. (the &#147;<U>Original Certificate</U>&#148;). The Original Certificate was amended by that certain Amended and Restated Certificate of Incorporation dated
July&nbsp;15, 2020, as amended by a certain certificate of amendment dated as of November&nbsp;12, 2021 (the &#147;<U>Amended and Restated Certificate of Incorporation</U>&#148;). The Corporation&#146;s Amended and Restated Certificate of
Incorporation was amended and restated by that certain Second Amended and Restated Certificate of Incorporation dated as of November 7, 2022 (the &#147;<U>Second Amended and Restated Certificate of Incorporation</U>&#148;). The Corporation&#146;s
Second Amended and Restated Certificate of Incorporation was amended and restated by that certain Third Amended and Restated Certificate of Incorporation dated as of August&nbsp;2, 2024 (the &#147;<U>Third Amended and Restated Certificate of
Incorporation</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&#8195;That the Board of Directors of the Corporation duly adopted resolutions proposing to amend the
Third Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to
solicit the consent of the stockholders therefor, which resolutions setting forth the proposed amendments are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the following is hereby inserted into Article FOURTH immediately before the first sentence therein: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Effective upon the filing of this Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation
with the Secretary of State of the State of Delaware (the &#147;<U>Effective Time</U>&#148;), every 12.0221 shares of Common Stock then issued and outstanding or held in the treasury of the Corporation immediately prior to the Effective Time shall
automatically be combined into one (1)&nbsp;share of Common Stock, without any further action by the holders of such shares (the &#147;<U>Reverse Stock Split</U>&#148;). The Reverse Stock Split will be effected on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis, and any fractional shares resulting from such combination shall be rounded down to the nearest whole share on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis. No fractional shares shall be issued in connection with the Reverse Stock Split. In lieu of any fractional shares to which a holder would otherwise be entitled, the
Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Corporation&#146;s Board of Directors. The Reverse Stock Split shall occur
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
automatically without any further action by the holders of the shares of Common Stock and Preferred Stock affected thereby. All rights, preferences and privileges of the Common Stock and the
Preferred Stock shall be appropriately adjusted to reflect the Reverse Stock Split in accordance with this Third Amended and Restated Certificate of Incorporation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&#8195;That the foregoing amendment was approved by the holders of the requisite number of shares of the Corporation in accordance
with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&#8195;That said amendment has been duly adopted in accordance with
Section&nbsp;242 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&#8195;All other provisions of the Third Amended and Restated Certificate of
Incorporation shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Follow] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Certificate of Amendment has been executed by a duly
authorized officer of the Corporation on this 6<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of September, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ P. Kent Hawryluk</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: P. Kent Hawryluk</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> A<SMALL>MENDMENT</SMALL>
</B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d790774dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g790774dsp01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Northern Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02210</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 617 570 1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">September&nbsp;9, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MBX Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11711 N. Meridian Street, Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carmel, IN 46032 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-281764)</FONT> (as amended or supplemented, the &#147;Registration Statement&#148;) pursuant to the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), relating to the registration of the offering by MBX Biosciences, Inc., a Delaware corporation (the &#147;Company&#148;), of up to 9,775,000&nbsp;shares (the &#147;Shares&#148;) of the Company&#146;s Common Stock, $0.0001
par value per share, including Shares purchasable by the underwriters upon their exercise of an over-allotment option granted to the underwriters by the Company. The Shares are being sold to the several underwriters named in, and pursuant to, an
underwriting agreement among the Company and such underwriters (the &#147;Underwriting Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such
examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on
certificates of officers of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Company Shares have been duly authorized and, when delivered and paid for in accordance with the terms
of the Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter and the
opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to the inclusion of this opinion as Exhibit&nbsp;5.1 to the Registration Statement and to the references to our firm under the caption &#147;Legal Matters&#148; in the Registration Statement. In giving our consent, we do not admit
that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Goodwin Procter LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>5
<FILENAME>d790774dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy (the &#147;Policy&#148;) of MBX Biosciences, Inc., a
Delaware corporation (the &#147;Company&#148;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its
subsidiaries (&#147;Outside Directors&#148;). This Policy will become effective as of the effective time of the registration statement for the Company&#146;s initial public offering of its equity securities (the &#147;Effective Date&#148;). In
furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as Outside Directors as set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cash Retainers</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Annual Retainer for
Board Membership</U>: $40,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the number of actual
days served by the director during such calendar quarter. No additional compensation will be paid for attending individual meetings of the Board of Directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Additional Annual Retainer for <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Chairperson</U>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Additional Annual Retainer for Lead Director (if any)</U>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Additional Annual Retainers for Committee Membership</U>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Science and Medicine Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Science and Medicine Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Equity Retainers</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with
the following provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Initial Award</U>: Upon his or her initial election to the Board of Directors, each Outside Director will
receive an initial, <FONT STYLE="white-space:nowrap">one-time</FONT> stock option award (the &#147;Initial Award&#148;) to purchase 32,000&nbsp;shares, which shall vest and become exercisable as follows: 1/3<SUP
STYLE="font-size:75%; vertical-align:top">rd</SUP> of the Initial Award shall vest and become exercisable on the first anniversary following the date of grant, and the remaining 2/3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> of the
Initial Award shall vest and become exercisable in equal monthly installments over two years following the first anniversary of the date of grant, such that the Initial Award is fully vested on the third anniversary of the date of grant, provided,
however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as on the Board of Directors of the Company, unless the Board of Directors determines that the circumstances warrant continuation
or acceleration of vesting. Any vested and outstanding shares subject to the Initial Award as of the date the Outside Director resigns from the Board of Directors or otherwise ceases to serve on the Board of Directors of the Company shall be
exercisable until the earlier of (i)&nbsp;the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary following the date of such termination, and (ii)&nbsp;the original expiration date of the Initial Award. The Initial Award shall expire ten
years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#146;s 2024 Stock Option and Incentive Plan, as amended from time to time) of the Company&#146;s common stock on the
date of grant. This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent to the Effective Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Annual Award</U>: On each date of each Annual Meeting of Stockholders of the Company following the Effective Date (the &#147;Annual
Meeting&#148;), each continuing Outside Director, other than a director receiving an Initial Award, will receive an annual stock option award (the &#147;Annual Award&#148;) to purchase 16,000&nbsp;shares, which shall vest and become exercisable in
full upon the earlier of (i)&nbsp;the first anniversary of the date of grant or (ii)&nbsp;the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to
serve on the Board of Directors of the Company, unless the Board of Directors determines that the circumstances warrant continuation or acceleration of vesting. Any vested and outstanding shares subject to an Annual Award as of the date the Outside
Director resigns from the Board of Directors or otherwise ceases to serve on the Board of Directors of the Company shall be exercisable until the earlier of (i)&nbsp;the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary following the date
of such termination, and (ii)&nbsp;the original expiration date of the Annual Award. Such Annual Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value of the Company&#146;s
common stock on the date of grant. If a new Outside Director joins the Board of Directors on a date other than the date of the Annual Meeting, then the Annual Award granted to such Outside Director at the next Annual Meeting following the Outside
Director&#146;s appointment shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the quotient of (A)&nbsp;the total number of days between (1)&nbsp;the date of the Outside Director&#146;s appointment and (2)&nbsp;the date of the
Annual Meeting following the date of the Outside Director&#146;s appointment divided by (B) 365. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Sale Event Acceleration</U>: All outstanding Initial Awards and Annual Awards held by an
Outside Director shall become fully vested, exercisable (if applicable) and nonforfeitable upon a Sale Event (as defined in the Company&#146;s 2024 Stock Option and Incentive Plan, as amended from time to time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Expenses</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company will reimburse all
reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maximum Annual
Compensation </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The aggregate amount of compensation, including both equity compensation and cash compensation, paid by the Company to any
Outside Director in a calendar year for services as an Outside Director shall not exceed $750,000 (or such other limit as may be set forth in Section&nbsp;3(b) of the Company&#146;s 2024 Stock Option and Incentive Plan, as amended from time to time,
or any similar provision of a successor plan); provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable Outside Director is initially elected or appointed to the Board of Directors (or such other limit as
may be set forth in Section&nbsp;3(b) of the Company&#146;s 2024 Stock Option and Incentive Plan, as amended from time to time, or any similar provision of a successor plan). For this purpose, the &#147;amount&#148; of equity compensation paid in a
calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with FASB ASC Topic 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted August&nbsp;26, 2024, subject to effectiveness of the Company&#146;s Registration Statement on Form&nbsp;S-1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>d790774dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;22, 2024 (except for Note&nbsp;17
as to which the date is September&nbsp;9, 2024) in Amendment No.&nbsp;2 to the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-1</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-281764)</FONT> and related Prospectus of MBX
Biosciences, Inc. for the registration of shares of its common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Ernst&nbsp;&amp; Young LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indianapolis, Indiana</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">September 9, 2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>d790774dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Calculation of Filing Fee Table </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MBX Biosciences, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered Securities and Carry Forward Securities </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Class&nbsp;Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount<BR>Registered</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>Maximum<BR>Offering<BR>Price<BR>Per Unit</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>Maximum<BR>Aggregate<BR>Offering<BR>Price(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Rate</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">Amount of<BR>Registration<BR>Fee</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="17" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="17" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees to</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common&nbsp;Stock,<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$0.0001 par<BR>value&nbsp;per<BR>share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(a)&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">9,775,000(1)&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$16.00(2)&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$156,400,000&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">0.00014760&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$23,084.64&#8201;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Previously</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common&nbsp;Stock,<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$0.0001 par<BR>value&nbsp;per<BR>share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(a)&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$100,000,000&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">0.00014760&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$14,760.00&#8201;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="17" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="17" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Carry Forward Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Securities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="padding-bottom:1pt ;">Total Offering Amounts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$23,084.64</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$14,760.00</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="padding-bottom:1pt ;">Total Fees Offsets</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$8,324.64</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,275,000 shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g790774dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774dsp01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M(*D9!!X->\CP'H.IB"@"JVHV4<_D->0+-TV&10WY9I 6J &NZ1H7=@JCJ6.
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MJ$L.G)(8XH(CQG^ZH/  R.<$DT 6?$WPYG\%6;>(?"NIW43VGSRQLPSM[D$
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M5HH\6K7J5G>;N7@,5J8BTP"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
("@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g790774g00a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g00a06.jpg
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M ?<  /IQ^?Y1CG9_6OW?_KU+_P#&Z/Y-= _T1P7\!#_PX/QZUC_23+_QDO\
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MI<'\';37H\+D]46(]ILO/Z"BS#R*%!SZB1&_9L7BT3C]J@I_>M'.S.^IRE#
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MRTI8;\=8R16)V@E@EK58:I4;QNDD;I CJP<,&9D9 %5WH-_(,<\__+:=Q_\
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=LXE-31?%+BIF1C46-:9O*HF:$1Q]+LQ*(25'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g790774g00m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g00m01.jpg
M_]C_X1$ 17AI9@  34T *@    @ # $   ,    ! WH   $!  ,    ! 2H
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-#HQ.2 P,#HS-CHQ-0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   %:H , !     $   !G          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M4L<&,;D5%SG$ #]5:-7.4F*(AGS"@>&,I1!']V45DY<6+%J?5*(E^U@[H?\
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M@@Z.:YI^DUR\VZOT[-^J'6:L[ITC$>2,9Q)+2T^ZWIN2[7V[6;J7/_,9ZO\
M/XJCQ"&7'[1J.2-G'+][^K)?D,L<N/4P.DQ^[_6?1,W,QL#%MS,NP544MW/>
M?#P'[SW.]K&?GO7$=#ZMU_KWUI;DU764X5'NNQP?T3*"'MJIL8/T=N7>_P!_
MJ?\ &>G^AI5/KG6\SZU]0QNG=/J+*)!IJ?H76Q^ER,G9NV4XK=W_ )]_G+<=
M=WT3H^/T;I[,*@[R/?=:1!LL/T[7?=[/]'7LK1,1@QGB .7(*$3^A!0D<LQP
MFL<#O^_)_]#IO\8O4O2P<?IC#[LM_J6C3^:I+70?^,R#3_VW:N"6G]9^I?M'
MKV7?/Z.IWV:D'LRDNK=_GW^O8LOW.(;6-]CB&UL'+G..VM@_KO.U;'+X^#%$
M=3ZI><G-SSX\A/;TCZ.]]6\;;7=F.&MA]*K^JT[K7#^M;MK_ .M*EUS)]?J#
MV@RS&'HM^(]USO\ MWV?];79=6Z?7T+ZN8UC(<>G5['GL]]A_G/^N9K]W_75
MYZ#XF3W/B3R4W#(9)2R#:^$?R_NIRQX (?4J)@$\QV764,;TKI@%@UQ:R^T>
M-A]SV?\ ;SO165]4^G?M'K^-4=:L<_:KOA41Z3?[>2ZG^QZBT_KTX8N5]B:=
M,IWVEW]4'Z/]K)W6)9)"62.+PXBJ$:@<G^"&A]3NIOPOK!2ZUTMSIQ[SKJ^P
M^I2__P!B?T?_ *$+U%>)&8]KMKN6N!U#AJUP_JN7K_1.I-ZITG%SQ -S ; .
M!8W]'>S^Q<Q[%7Y['K&8Z^D_]RS\I/0P[:AR_KYD"KZMW5]\FRJD?-[;'_\
M@5=BP^E]&=E_4'+<UNZZRZS,HTD[J"*FM;_QK,9]7_75:_QEY.S%P,?\UUEE
M[OA4ST__ '971?5O%^R= Z?1$.;0PO'\MP]2S_P1[DP2./EH$;RR<?\ B?\
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M _\ *S$_[8K_ /(*Y113CU-IQZVTU,$,K8 UK1X-8WVM1$DC*1W)/F5"(&P
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M,#$X0DE-!"4      ! BK:EPRE^=C2MMG9\S?IYQ.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !
M+     $  @$L     0 ".$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -!    !@              9P   5H    &
M &< ,  P &T ,  Q     0                         !
M  %:    9P                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    9P    !29VAT;&]N9P   5H    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   &<     4F=H
M=&QO;F<   %:     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
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M?+I!N^Z6>R;7?[ON#Z;.VB:1R,FBBM /,G@!YD@=:U=5_P *2<Q+55$F+^'
MBQCS.V.CS/=,,&76C)_8_BD%!U_6T-/7LEC+'#--'&Q*K(X&HY6)]U6!443<
M]5FIW:;6JU\]),P)'H2 3QH.'6/;_>"E+L8N4QX5<5N,T\J@1$ ^H!-/4]8/
M^@D7<_\ WAYC/_1W2?\ VMO=_P#@5K/_ *;A_P#LD'_6_JG_  05S_TR:_\
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MD%QE8(V\X822 <>))JDI32!@U[@<[W7.^]&[&I-G@)6VC.**>,KC_?D@H3_
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MGQ=^7/0G=\E5)28';>^J' ;\:-0YDZWWV/[H[TUHS*C1X['Y1<CZN ]"I%B
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M9&V9'7U+@=NS)6;@JXK@%/O\_)'#J'#I2$>X=]SMT\6\V_9(SV0IXLG^G?"
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M0AV/E]1%2.;Y L/#D^9<GK+3V,W_ />'*\^QS25N=NETKZ^#)5X_]Y.M/D%
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MY0W=W/?W=U?74A>ZFD:1V/%F=BS$_:23UT.MK>&TMX+2W0+!$BHH]%4 */R
M'3[[3]/=::/_  H6ZS3:OS#ZQ[+I:5XZ7MSI&&AKZO0!%-N'K#<];CY4\@0!
MI?X!NRA%B2VF/\ #WGA]V'=OK>1MWVEW[['<"5'HEQ&&_9KC?]O6(WOUMPMN
M:]NW%4[;JS )_I0N1_QUU_9TB?Y!'97]R?GI7[(E8"D[IZ3WCMX!G*J<UL/)
M8G?&)95N%>88J'*J/SI9O]@8_>5VG]X>V\>X =]AN$3_ .TF5HF_+48_Y=(O
M8S<?H^>)+,GMO+.1?]M$5D7_ (SKZMJ_X44_]D;]5_\ BRFS?_>)[#]PI]UO
M_E>]Y_Z5,O\ U=@ZE/W^_P"51VW_ *6,?_5N7K5D^*.Y=O[*^5?QBWINW+T.
MWMI[/[_ZHW/NC<&4G6EQ>"V_A=X8RNRV8R54_HIJ#'T<+2RR'A$4D^\Q>=+2
MYW#DSF_;[*!I;V?;+F.-%%6=VB8*JCS9C@#S/6,O*]Q;V?,_+=Y=S+':PWT#
MN[&BJJR*68GR &2>M[H_S)_@&#;_ &<+X^'_ !'9FVF!_P 0RUI!!_P]\Y?]
M:?W+_P"F&W/_ )P2?YNLVO\ 7$Y%_P"FLL/^<R?Y^NO^')_@%_WF#\??_1E[
M;_\ JWW[_6G]R_\ IAMS_P"<#_YNO?ZXG(O_ $UEA_SF3_/TS9_^:-_+RVUC
M9LMD_E_TA)2P WBPV[Z;<F3F8*6$5'A=N1Y7,5\[ >F.""1V/ !/M1;>SWNA
M=S+##R/N <^;1%%'VN^E0/F6 Z:G]R^0;>,RR<V66D?PR!S^2KJ8_D#UJV_S
M7?YH4'SJRNW.KNI,5GMN?'+K[.G<L5;N6E?$[E[8WO!2RT..W'DMOM)))M[:
M.V:>JJ/X525-J^IJ)S55,<!2&%,PO9CV@;VZANMXWN:.7FJZC\.D9U1VT1(+
M(K\'ED(7Q&7L4#0A:K,<:O=#W)7G62WVS:HWCY?@?75QI>>0 @.R_@1*G0I[
MB3J8+0* "_E7_&[+_)KYP=.8*/&/6;(ZHSN+[N[2KI(6DQU#M[8^03(;7Q%;
M(&334[OWO2T=+!&#JD@AJ7 TQ.0)?>3FN#E+V]WVY,P7<+V-K2W%>XO,M)&'
MRCA+,3Y$H.+#HB]L>7I>8^<]I@$9-G:NMQ,:8"1FJ*?G)(% 'H&/D>M]G?.^
M=H=9[-W/V%O_ '#C-I[*V9A,CN3=.Y,S4+2XS"X3$TTE77U]9,02(X((R0JA
MG=K*BLQ /-S;MNOMWO[/:]LM7GW"XD6..-!5G=C0*!\S^0XG'6<%[>VFW6ES
M?WTZQ6<*%W=C0*JBI)_+\SP&>M!/^8I\\=V_/?O"3>;_ ,4P/2NQ)<GA^BM@
M5Y>GFQ^$JF$-?O\ W-0*[0IOO?,,"/*AU'&8\142L6%0\O2GVM]N++VVY>%@
M-$F_W(5KN89#.,B&,\?!A)(!_P!$?5(132!@W[@<[W7/&\_5]R;/ 2MM$<44
M\97'^_),$_P+1 ?B)5_\LC^7MGOGMW'-#N&+(8?XY=8U]!5=R[II_/2S;FJY
M%BK<?T_M2NCT$9W<=*1)EJJ-@<3B6+7%34TH*'W<]SK;VVV)6M2LG-5XI%K&
M:$1C@US(O\"'$:G^TDQ\"/TK]M^0Y^=]V9;@,G+]LP-PXJ"YXB!#_$PRY'P(
M?XF7K?.VWMS [/V]@]I[5P^.V]MG;.(QV V]@<12Q4.*PV%Q%)#08S%XZC@5
M(:6BH**!(HHT 5$4 ?3WS?N[JYOKJXO;R=I;N9V=W8U9G8EF9B<DDDDGS/6;
MMO;P6D$-K;1+';1H%55%%55%  !@  4 Z>O:?I[JF[^;U_+@@^975T?:?5F,
MIH?D[U!A:Q]HA!'3KVGLV.23(Y;J?-5)*!:JHE:2JP%5)J6BRI,;:8*NH83O
M['^ZK<A[P=FWF8GE"^D'B>?T\N%6Y0>@%%F4?%'D59%'42>ZWMZ.;MM&Y;9&
M!S':(='EXT?%H&/J<M$3\+X^%VZT@0:J"<,IRV$RN+R0((^ZPNXMN;@P60N#
M_NJOPFY-N9JA_P!IGI*R#\,GOH1V,OX)(73Y.CHZ_F'C=#\PRGT/6&7>K?C2
M56^:NC*?VJZ,/M5AZCK>"_E$?S'X/F9U=)UAVED::#Y.=08:BCWEJ,-,G:6T
M$D3'8GMG!TBA D]5+XZ;/4L8*465.M0M/5TZCGK[W^U3<A;P-WV>(GE&^D)B
MXGZ>7XFMG/H,M"Q^./!JR.>LSO:KW!7F_;3MNY2 <QVB#Q/+QH^"SJ/4X$JC
MX7R.UE'5QON"NI:Z_]<P7\S7X#_-VJ^;G??86&Z.[3[LV7VOO!=[[&WUUQ@:
MG>M!#MF?"8C&8_9^8@QKR9+;F5V<N,-"(*F&.*:"*.:!Y%D-N@WM'[E>WR>W
MW+>UW',-GM]_90>%-#.XB)D#LS2J6[7675KU*20258"G6&WN/R-SD_..][A#
MLUS>6EU+XD<D2F0!-*@(P&59*::$ $ $$UZ(7_LBGSD_[PU^3'_HI=R__4WN
M2?\ 7%]O/^F\VG_LIC_S] 7^I7.G_3([E_S@?_-U[_9%/G)_WAK\F/\ T4NY
M?_J;W[_7%]O/^F\VG_LIC_S]>_J5SI_TR.Y?\X'_ ,W4FC^ OSSRM928K%?#
M/Y$/E,E4146/&6Z\R>W\2*NI<10/E<]F318G#8V.1@9ZFHE2*&,,Q)M8TD]R
MO;>"-YI^?-K$* DZ9U=J#CI1*L[>BJ"2:#J\?(O.\KK'%RC?^(QH-43(M3PU
M,U%4>I)H!GK>X^$GQOH?B5\6>FNA:=J2IRFR=I4QWCE*14\>=W]G)IL_OG->
M98H7JDKMT9.J,,DBA_MQ&IL% '.7W!YKDYVYQW[F1PPAN)CX2G\$* )"E*FE
M(U6H&-53Y]9M<F\O1\K<L[1L:T,D,0\0C\4K5:1J^=7)H3Y4Z'/LG9E/V)U_
MO/8U3*E,FZMM9C"15CQ^88^KKJ*:&@R:1W&J;%UQCJ(_R'C'L.[3?MM>YV&X
MJM3#*KD<-0!!*_8PJI^1Z.=QLUW"PO+%C02QLM?0D8/Y&A'S'7S]=V?R[/GW
ML;<V>VGN'XH]X;FS&%RM?25VZ-E[-KMY;3W1,*J5WW)M_<F#-719#'9QG^Y3
M48ZB/RZ)HXY%91TML_=#VVW&TM[VUYTVZ*"1%(CEE$4D8I\#QO0JR?">(-*J
M2*'K!>XY!YYLKB:TN.5[V29&(+QQF1'S\:NM00W$>8K0@''2>_V1?YP_]X;_
M "7_ /12[F_^IO:C_7$]O?\ IN]I_P"RF/\ S],_U+YS_P"F2W'_ )P/_FZ]
M_LB_SA_[PW^2_P#Z*7<W_P!3>_?ZXGM[_P!-WM/_ &4Q_P"?KW]2^<_^F2W'
M_G _^;H7>A?Y8/S([L[@Z_ZWW9\;NY.M=AY_<N)3L??N_MGU>T-O;:Z^@K89
M]WU K\T])]_F:W"1S4M!24PEJ):J=#I5%=U)>8_=WD3E_8]SW6SYJL;O<HH6
M\"&&42/),01&*)6BAZ,[-10H/$T!--D]M^;=YW:QV^ZY?N[:Q>1?&DEC**L5
M1XF6I5BM0JBI)(\JGK?RPV'Q>W</BMOX2AI\9A<'C:'#XC&TJ>.EQ^+QE+%1
M8^AIH[G13TE) D:#\*H]\V9YYKJ>>YN)"]Q(Y9F/%F8U)/S)))ZSCAACMX8H
M(4"PHH50. 4"@ ^0 IU7S_-3^-O8/RA^&79>P.HZ6+(=I4!Q&YMI89ZFDQ\F
MZX\/E*2HW'LJ'*5TD5+CYMU[<6IIH6E=87JO"LC(A,B2;[-\U[9R?S[M.Y[V
MY79VU1R/0GP]2D)*5%2PC?2QH"0NH@$X(#]S>7K_ )EY1W"QVI0VYKI>-:@:
M])!>/4<#6E0*XK0&@R-+8_!;YQJ65_AK\F$=&*.AZGW#)H=39E\D$4T$EB/U
M([HWU5B+'WGG_KB>WN".>]II_P ]*?Y<_M /J.L1/ZE\Y^?*.X@_\T&_R8_9
M4=>_V1?YP_\ >&_R7_\ 12[F_P#J;W[_ %Q/;W_IN]I_[*8_\_7OZE\Y_P#3
M);C_ ,X'_P W7O\ 9%_G#_WAO\E__12[F_\ J;W[_7$]O?\ IN]I_P"RF/\
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M@=%OZI^??PV[NW=3["ZP^0O7VYMXUKM%C-N_?5N%R69G0F]-@H=PT.)&=J[
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MZUZB7[K/)</)7+'.%G#S;M.[^/O,DFNPN$N(T'A1J%D9"0DK4+&,Y52I)JQ
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M)B*>>GB*@D8(B+F/VL]]>;HK"U]^O=[:=N]O;6>,R/#)%!XT@8:*DP6T3.Y
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>&,1^)' \]7%OXDC>+,]%33602#8S]@>ORZS]Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g790774g00s44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g00s44.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!E@,4 P$1  (1 0,1 ?_$ .,  0 " @,! 0$!
M       '" 8)! 4* P(!"P$!  (" P$!              4&! <" P@!"1
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MW\<_FD]H?C'J-_\ LO.)^8HU@^9&^O@J]^.G'LM<P^D,;^.?S2>T/QCU&_\
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M8W\<_FD]H?C'J-_^R\XGYBC6#YD;Z^"KWXZ<>RUS#Z0QOXY_-)[0_&/4;_\
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M.'_&;C[.<I\?;_G_ **>WOX<?0V;_%:_.$_C,T5\UMM?!P_XS<?9SE/C[?\
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MB&#<)48>^!7 ./:BW!*6:+"@1H@&",!H(>$'.#Q/,8R:TWY"&S@L<>#-!6:
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MKG<B]J'KIU?[(B>G]1OK7$\RR0K#I3:[ZRR*0-F+1NB3B4EN(ELQ>T";)Y!
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M;CJ1=^&.X?,]VXR4:""RC7%KNZ=.P*I_5[*NQL\4D=;H-CCC&YFK&R%Y-=U
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MUCC'&9"0P2/ +6%Y!#-Q&X@@5*ZOG-8:['#0[":AOH6MQ$R%K<-HWC")3EJ
MXY)"HPWC<,%>4"MRG'@?A9'XG<S@79V9[><.I'U.EN'5I6E16GNT[:>^LH6-
MZ;,Y$0RG'B3IF78[IA]-VPOIMWT(.VM:&M*+KN<UBKL2&AV5-Z]W2M;BI:FH
M28#FYD(E)S>VB6&X(2!7K2RA)D8E1V< +P8(.1BSV![<\X&2-KQ&YP$CNP5%
M33MH.TT65'8WLUK)?0PROLH2T22!CBQA<:-WO VMW'1NXBIT&JZ[G-8J<(G"
M)PB<(G")PB<(G")PB<(G")PB^MD_LC[&?]8I+_O-QYG8'^J;/_=S_P"H%^E'
M_;0_S*SW\IC_ 'RU#\W OVD3A$X1.$3A$X1.$3A$X1.$3A$X1.$7>)HS)%K"
MZ2E''WM7&&-8WM[U(TS4O/86A>[>/EJ0NCN4G&WMZQSPE-\N4:8 9WAB[F,]
MW/9U.N(&3-MGO8+AX):TD!S@WM(;6I J*D#2NJX&2,/$9<!(02!45(';0=II
MY5T?.U<TX1.$3A$X1.$3A$X1.$7:M#$]R \]*PL[J]JDJ)4Y*4S0WJW(].W(
M@>(L7GDHR3C"420O/>--%C "P^Z+.,<ZY9H80'3.:QI( +B!4GL&OE/D'E7%
MSV,%7D $TU--?<75<[%R3A$X1.$3A$X1.$3A%_J8<_.Q>=EY\O\ 44?LP4C_
M .>BOU>S3GIW[K7]89#^6G]_$O/WWA_Z8L?^?_X4B\?_ #W*O(BF*@7J 1^W
MX*Y6?6I-N0P+VG2N<!52AVAZ)[,<.U"A$N>V,DYU D;UJ@M2,@K(/,X*\(8\
M &+M@N36^3N<'<Q8B[-C?],ELPC;*6;=31CR&U< 6@FNVNX"H"E\#/86^7@E
MR=L+NSW@.B+W1AU=!5S>]0$@D"E:4)H2MKF[.O&MQ_5G,UZ> H=?*:E2.JXN
MA75?&8TRM$3D4DKYAPRKU+$!(C9\-[S)U!1;BI%DH9?FAJS1B\,>!Z7\/N4<
MK;X*#E$&[)YZ%UQ(1<22/=(R.9^]H?4NW-C!,;=0=H8 *BFUN:\>XX[Q8/'I
MMN/PTH@8# QC6QO?"S:2V@;1SR \Z$;B\DT-:B;0Z3)=1ZI:%UHS)6.]);<U
MGQ&*5\W(DY+0;4-6O2Z(*[6=3E><O*4N8RU +#*1DL!*MOSE0$T>0# &\</\
M07\WS3X\/ WZN06%O+).XDN])N&"46S0.Z>E$[]::DM?W2T5!51Y/PIG$L4Q
M^4F/\<EO)HXX@ &^CP.,9G=7O#J2#]6*4<SO5-"%BE1:KL=NZ>[); ,<E?3;
M*UZEE9)EM>HV]&J;GF%64\)8\B>"S0Y]*X<TCJ4M%D!81@$4GQ[G;G/,W.<R
MN,'SK$\9N(8QB<I!<$3EQ#FRP-+RVGP=I;LU-#5RQ<1Q:#+<0R6?@E><ECY8
M08@ 0Z.9P8'?^K<';NS2@5]YOTBHI!-AZDK=SMJ3*ZJD5%W+:-I6 C86T*^(
MR*A"WEOLAD9B5 BFU4UM<HRUI G'BQG(5(Q=[.,E"SK7'^.%[DN+WV6ALH6Y
MF+(VMO;PE[MLK+S:Z![B.\'.CZCJ#_T@4[0KY?>$EI8<AM,;+=RG%26-Q//*
M&MK&^UW"9K:]TM:_8VI]TGW%%]8Z!:\(HMJ>V;'VY;D1M_>/*$^D66M(5&9#
M$8*T2EX:&"OWBU%DB>&EX<B):N?4IH -)8/!*&+!@P!#D[DQF/$SE$EYFIN*
M6-C/@^.U%V^XED9+,Z-KGS-MPQKFM,08X$R$U(T!)VJ+QG >/,M<3%R.[NX<
MOG*&V;#&Q\<37N:R)TY>YKCU"YI C&@[2!JL.B.A%?5K"]AKBW"G-A1RKZ(O
MYTUF1M%*1U@>)]8MF-)I@G%<Q#G#BT1QMBR%L$2L":<,8E90C AR6,K&#<^^
M\2LGELAB\%P6WM9<QDL8V_+KM[VPP6[AW0_HM<]TA=5M !M-":AVF':<#Q^-
MLLAF.83W$>,L;]UF&VS&.EFF;VEO5+6!@;1U23N%1H1K=#3G6]IU(ZC &-IF
M*N95E-M,9W>=;S!V91,+POK6;PE8L;C'UF*.5A3.K6H:U:8_PA=T[*?Q,%E9
M'DDN@<[Y7/S?PK](G@;!E[?/PVD\37[VMGBE =L=05:X.:X5[-U*NIN-SX=Q
MR+B?B)T(9C-C)\-+<PR.;M<898R1N;K1S2UP-.VE:"NT4%>=8(QK.[:BII[+
M7@W:"R+!KR=2>H4B-&0TU#6[K)&@Z)%3A:=@QS^4&3$B"IPVA"3E$G$+Q\!S
M@K*C9<'+[SET&<?C8(QP^TM9X8[DDEUS.V-PD,('=Z,9[O4UWN^#7O;*'-QB
MUXU+B&W\KSR>YN(I7VX #;>%SVF/JGX75>-=FFT?"\FZYFZFKT9V,VVZIDA1
MRUY;+<U^BT,N.)0E(WHUK7.(2QP:( L8Y4:,1:](JC2#*?)6"LB\4U:7CNY[
MN<"H7 .87?%>$<-M9((WX/)S2VLLI<0Z&5\TO0 _LD2.W5KV!AUUTN/,^,6W
M(N6<IN&2O;E\?%'<1Q@ MEC;%'UJ^4%@I2G:7#31:T=@M:F&B*/U0FR^3/"V
MT=B(#(+7?H6H0I$K1#Z_4/N$%:.*)8$0UKD=-6D!JL0AX+ 3X60XP+&<"SMO
MC'++GDG(LUCXH8VX?%W++9DH)+I9@S=<-([&B)U&Z5)K73L6M>0<;M\%@\5>
MR2O=E,C;OG=&0 V.(NI"0>UQD;5VM*4I[ZV(:_26OZ%Z49FQ =9M7[LLY1MN
MOK8+E?U,LED"!&7&&('/",A9@]GD <HUB'M3E^=RG+\8W]%D0^W&K>3VF3Y+
MXT#BQR^8Q^(&$$^VRNGP?K&RN;4BCF:@]X[-QH-=%L+C]SC\#X5'D(QF+O<F
M<N8:W5NV;N&,.H#5K]"-!NH*G35=UN4]55J5)-4=EX%J7K)ZV;0ZM%OEH:ZV
MW6ADTJ>$21P5P*0ES.)UP<^M X8]JAC4-J40!EEE(R5)8B/,&*!YZ.!V^9YM
M:9KB62S>7]"P^9V6]];3]*YFC:)F=*2<,=U6#NR.J"2XL.[:&A=_,9L5Q.YQ
M7);#$XSTO*8O=/:3P]2"-Y,3^I'#N;TW'5C=0 T.&W<7%<[J[V=7M-RPK7"M
M=1M-8<Q6)2%<SI78D<H-DC]N1IZ?GIR6.&(?+F!P:T;,E&&/%D8[R$\W*<\X
M C!=_&0]7@?B,IGK(\KRV<ST]S:Y&>$0/O'OMI&,8T-ZL3VN+CWR?A@;@T@"
MFO/Q<R>/P]V..8W$8:&"XL893,RU:R=CG.)/3D:6AH[@'P2:%P)UTG+:_IK6
M-+]T]:9I0^K44QKHECFO9]C!B+'6<8A"L]'+U"^P3I!$<*VC#T:ICAI?GA#0
MGY6$=A>?$[.[BN\+\6<58\ RV/Y)F9_K4Z6]$'5?<22@&(" ,EH[91]=E'C:
M==.U3G*_#;(WG,\;>X+%Q?5T1VAFZ;861DB0F7?'5NZK*;NZ=PTU[%J+ZH,.
MB-?[Y;$P^!Q6.0F),DCC9#+%HBQMD;CC00? 8DL/):V1F2HFQ 4<L4F&C"44
M# C#!"S[X6<YW?X/W]]D_#?%WV2FEN+Z2*0ODE>Z1[B)I "Y[B7.H  *DZ #
MR+4GB=9VF/YWD;.PBC@M&2,#61M:QC08HR=K6@-&I)T':25+<[TXU2I2B*OM
M.X;YLDB:7QK DMBI*ZBD%3JBS++.;W-2-JE4H.(5MJ&#J'$;:C3Y+#Y_(C5)
MIHBBR2O'A,;SSFG(.27F&P6-M#C\;F#;7,\DQ'Z@.:-T<8(<9@WJ.=7N:,:T
M.+CME[[AW%<+@K7*9B_N1>W^,$\$+(@?UU'':]Y! C)V-%.]JXD@ ;I?BO3-
MH4J6T?K'9]TVE'-Q=A:E36I%4C!!H\Z4C !O#+)7Y@AE@."MX33=:^J$L7/*
M4G-Z?"<@\6/Y2\!&9!WOBWR1UCD>7X?'V<O!,7>FWD+YGMNYMKXV/EA:&F(,
M!D!:'NW.'OU E[7PTP(N['C.3O;J/F&0M!.P,B8ZVBW->YD<I+A(7$,()8*
M^]0F *;TVH\>L4@VAV7LJS8)'X'M _:[R^%UQ$6*229>>@KYDDB$3$J>G)"V
MM[L!^=#2E0U?B)@I$^>YC)H@X%9L]SSD(Y?%P_B5I9W-S<X=E]%+/*^.,!TS
MXSO#&ESF[&@M#:.W.U[M:0&'X=A#QF3D_);FY@MX,HZTDCAC:]Y(B:\;2X@!
MVYQ#MU1M&FM%L1U!U48-5NHI%D,!G"FR*BN+2^<W74DR<$)3:\.,*F<34^23
MOB(G "2W-,8B$/OE@+ <G.)'W"QY&47JWG/,[GF7A9-)D[<6F<L,_#:7,327
M-;+%(*EA.NTUI0DD.#A4BA.P^(\5M^+>(<3+"<W.(O,++<P2$4<8Y(S0. _M
M"G:  00: U U>:H5!HY9:&+,5[W)?;-:\ZF(HJT0VIJT:71FC*92J1(VA_D4
MC>CEYCNA5Y4&''%($F#TI10N\'/9@0MP\TSGB)B9)KGC=AC9,+;0=1TMS.YK
MI" 2YC(V ;2*  O=1Q(I[@UAQ3$<(R3(H,[>7[,K/-L;'!"US6 D!KWO<3N!
MJ20QM6@&ONF7(;TUD!>S^V%4VO::J,4SIQ%WNP;.LR/1P+L_O,13HTKS&&]@
MCIBT126429@5".R 8U)*4Q,:7CQA>'WX._\ %F0\/PN:PMFV;/9Z9D-O;ODV
ML;*26R.>^E3'&\4J TN#FGNBM):S\-F#D^6Q65NC%AL/$Z6:9C-SW1@!S UE
M='O8:_V@T@CO:5ZJM-/=8=FKUS&=<+@MQ#2$$J"8W+>DPMN#,1$QA,<@R@@I
MP2QU#&UX661KGK"Y-Y; A$>  PP8L&Y)$6+ORW.N7\1XYZ7RNQL7<AN;Z*UL
MXK:9YBE?,"6EYD&^,,H[=VUH -NZHZL;Q#C')LYZ-QR\NVX2"SDN+F2>)HDC
M9$14,##M>75%.RE236E%U%HZ>4<YUI0VPNM<^M=XI2V+[*UTE#7<,8C#-8<(
MG0O <4RLM3$71RC#RV/D=R>I3@!W1)_ #@P8QF&%I^[#\ZY%#ELEQ?EEM91\
M@LL;Z=&ZUDD=!-#JTBDK6R-<Q^UKB?A5-   7=.4X?@Y<;8<@XW<7;\+=W_H
MCQ<,8V6.70@UC<6.:YE7#W*:DDD-ML'I9ZM*IQM91*/9&URKIUHB#[:3X\+J
MS90UFWU\VDMKP0D4%)'A1)Y1)R8Z[)S%0DOH]/Y@S("0&8+SD5)/C'S%F.PO
M(Y,39' 9>=ENQHN'^D.G<7-)%6B..,O:X-W;SM%7$5TMOV7<6=?97!,R5V,U
MC(73N<86]$1-VNH:.+WO#' NV[14T -%72W=!*R?:NU/N#4*>6+,8SL]<)]"
M(&:YF*/QZ0M$]R]J&)N<C,Q)2Y(R(ZL5MBP9N.Q0-*G* 8(T>1B 7:L'XEY>
MVS&:P7.+:U@N\/8B\+K5[WL=#L#W-_6!I+P'- ^"'.)  H":[E^!8R?%XG+\
M1GN)K;)WAM0VX:QCVR[BT._5DC82UQ/:6@ U-2!EUF=/G70AIVGKZE;EMN6;
M$:70=QG]MIY?!(RTU/.66)G$$6&172UH?ETH9E40PH$(>70!@5 R<@*P, Q*
M",'$>)W*73X;)\@L+&'BV?N&PVQBFD=<POD!,!G#F"-XEIITR-H-74(#79>3
M\/\ CK8LIC\+>7<O(<- 99Q)$QL$K8R!*(2UQ>TQU_M@U(H*@ES>_KOIW:L"
M6:>LMO7K<#9*MT:NA#_7<?@T#CBU)'9O)U!R5:.52-W<?!#$25*M"2E*3)#5
MIIF3Q'&$EA (>-E/%+F73SMQ@\;8OL\!>3,G?-,\%\48!'38UM>J0'EQ<X,
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M,-G[J<JAIZT)C )K6Z6.!MJ -<U;4R61OL;CSBF[#\I'0E/Y5Y--  A62'S
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MV$U+KZJG(K2^U[";:&D5+EQN,5E(TSA49#$_PZO)VTG*HBJ$B6'*4:DLL!H
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M7,Z$C&1-82!)N<.\[:YPV-!(J=3HK!(MW-8"=T.IG;)EF]VO]@]:)97U0/\
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M\9BG<QI<PD.+'$ EA<TEI+3H2TD&E0:+2$[(XYWQPO$D+7D-> 0' &@< ZA
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M6K]4@IF1.Q-?V)),S&+-#?AH:9)"9'7J]N4-Z]<UB4^;2B4D&&F.2@CP\$
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M@@]H7SY]7%.$3A$X1.$3A$X1.$3A$X1.$7:*61Z1-C8]K&AT2,ST-:6S.ZE
MK(;'8QM- 0X@;%YI0$J\;><8$!^"ACR4(6,"[,YQS@V6-SW1-<TR-I4 BHKV
M5':*^2O:LR;'W]O9PY">"9EA<%XBE<QPCD,9 >(WD!KRPD!^TG:2 :%=7SFL
M-.$65KIS,7*)LD#<)*\K(9&UR]S8(PH7GFLC.X.@S#'%8WMXAY3IE"TPT63!
M!QC(\BSV\Z&VMNRX==,8T7+P YU.\0.P$^6GD4U<<BSMWA+?C=S=W$F M)'R
M0V[GDQ1/D)+W,97:USR27$#6NJYS0[6'4,M;WQH42>O)LU$!6M;@ I?'Y @3
M/38,!:Q&,XM.L3DN;0O%W#0=F#4YWO<Y"+W>$D=ID+<Q2!DULXT(T<TD'L/D
MT([/(0LBQO>4<&S<61LG7F+Y#"W?&\!\$S&RQD![20U[1)$\T</A,=H2"L+.
M..4G&J%!IJA0H-,.//.,&:<<<:/(S3331Y$,PTP8LY$+.<YSG/;GF2 &B@T
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M.6KW!>M.&I6+ERQ2,Q0K6*U!@C#33!"&8,61"SG.<YY9V,9$P1Q@-C:   *
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MP:!HH*4V1SGPBS?/_'&7!\NY!<W./Q_&8<A>9":"+JQ6<40<8XX81'&YVZ0
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MQMO>7L,;,;<O#6EKB7MW5VE]10@@5T[![^AU<.^O=Y16&,=H36E[AB-3OY;
ML;K.>ZOF+="'%JDQ1*MC<F:3.;6W1UW)>F\X)Z')2S %H!!R6/(18%S8D6;P
M]S=OQUI=VLN29N!B;,PR LT<',!+F[3HZK>[Y0K"V^LY)3;Q2Q.N6UJP/:7
MCM! )(H>W31;($.DFEMSTOL3(M5;\O.:V7K75;_;\@7V16#5#JOGT4AH,K92
M&*8(.42%B<0M6/%3$.)XE AB+#DH01&&$T-_+>5XK+6,'([*SAQ]_<M@:(I2
M^6-[]&;^QKA70EHIVZZ &"=ELM:7<#,C#"RWN) P!KRY[2[LKY"*]I&G_P!^
M/5&B&M3=4^I,KV9M.[&:<;R2-]8*6:Z9B$+?HK"BVZ4L$,0NMFN<F>DJ]Q+5
M.DI0J3DS06)40G,$4(.#0][GW)<RS[\ED[;C]M:/L\/&UTYG?(U\E6.D(B#&
MD"@8X O-"16M%]N<S?NN;F/'QPF&S:#(9'.!=4%U& "@T!%7:5U61._3LH.#
M2/:R<6G.[LB&NNGSC#:WFREJ:H)*;5LRYI*L1H3&NNBBSVJ(-<7R!T1JRQN0
MQ*2"%183\ASXHRNB+G.:O(,;9XZ&TESN4:^6,$R,AB@8":R]KR_1P.W0D&GD
M!ZVYR]FCMH;9D+KZZ#G-J7!C&#RN[7$Z$::::>_U..F;!GW9;3>'PBU98ZZV
M[N1B02NLK!=HRWMEAQ[$6C2UWD<7DK#A28QJ7Q@6^1 <<G,"G.+6>\QCN8$/
MM^T"\AP&5NKRVB;GL1(UDL0>3$[>\-:]CJ;@UPW4!%06Z]NG+^/S,L+J6:-H
MO[1P#V@DM-30$'MH=>W718_.M$=>U6J6P=R47<UFS:RM2)7$(M=K3,8,S16$
MR,^32?$25K*T"G<U[Z2W-+A@X\)KD;XRA,E'G)!(S"P\[[/F.;;R2RQ68M+>
M&PR<;WVY9(Y\C=C-X$M0&U<*"C!0$CO$ E=D.8OADH+6\BC9;W+7&,M<2X4&
M[OZ 5(]SL)[2K*2?3.>;47%TYZ@LO8N9R6.370B$7$4M60^.*'NO(0EC2I^.
MK>!M,=2-694XC,3DHT[@YC4N @9P8<)3X!:<<!;\JLN.8O.Y3'V,4<\.9D@H
M'N#99"\-ZLA<3L':XM91OD&W<7# CRL..M;ZZMX&-D9>N9\(T<ZM-SB:T'E(
M%![E*U548W26@4AV[UGI^&27;);%YW:C;7EHQJTX#!HS,6:0/DBBS' T!8$;
MRW%%QR2NKP<4\FB %Q:T).32"5)Q@"L62?+\T@XQD,I=1XT7$-L987PR2/8Y
MK6O=(=6GO,#06#X+W&A+0"5(R7>:9C+BZE;;"1D9<PL<XM( )<>PZ@#N^0G0
MD#51SU/&6D8_N-=K53F9PG5([,GJ:P&62QB(QJ+,$G(D2@OT56A<6?'4Q=#T
MY.,X*,6IV]1C& X\#&/Y,[P]ER\_%K23*=$M-O&8W->][W,VC67>T4>?*&EP
M]]9''WW;\7"ZZV4,;=I!<213M?4#O?@)'OJ2:RT]U2:-9=?MIMG;HMR(P^Y9
M79T$5QJL(0QR!Y;W^(R4#6RNI#FZJ1$)8XG9T:Q4YXRD5K!F>"6E*%VC[,'(
M<HY)+R"]X[QZTM9;JUCBD#Y9'-:6O95S: :N+BT,U:VE2X]BQ[C*9)V0GQV/
MBB=+$UCJO<0"'"I%!Y:T U [:J0R>E4SHMOMG]:)/=66:+4OK/)ME85:J6.^
MF$;]%F\^"*&H4B86Q0J7>63M<K5 6^C\FG&GH>^F ,!@ YP3XCRNXQC\_;VF
M^XN\@RUDA+MI:\]0':X@"I+!MW4 #J.((*Z#R-QQ=O?QQ5DEN!$YE:4)W5H3
M[X%*^0ZK#:\TRU,N><6U-JQNRW\ZAZW4BTV5=E@R&#M!-G+IBXN,A1(X+!HU
M_P"G,Z<R0$-&#49ZPP\LK)9H#!#[<"!E7W*N2XJSMK3(6EK]9[^[=%;QMD=T
M@P!I,DC]7';NHX- )J"*>7MGRN2M(8H;B&+^)SS%D;0X[-H [SCJ=*ZT7[E/
M3BC5B*M0)OJ7/YA*J4V_GKE6+2NMB,MS//JIF$<=%B>3IYL@C"U4PO*%&R-+
M@Y$FMQW8:4W'@_D\(TWY;<[N+%N4M.2P11Y;%PB5PA>71S,< 6&,O <TESFM
M(<-"YI]T!'G9(!=0Y-C6W=JP/.PDM>TC3:3J-2!K[H]]7RJ"HM2:8J/JL5]K
MW;%N6%.:^UDL*O[2+L.%L+#&U;I&G%Z;%K] G9E7F*3&D#TA.393K2/%$'(3
M2S1@]W--RF3Y-E<GQN]S=M:P6<^0BDAZ4CG/ >&D-D:X4W;2#5IIY" 5#75U
MD[NZQL]]%$R%]PUS-KB30@&C@1VTUJ/Q*@B/3+4VO-:]>=BMBK\LN-8V,KNU
M'"%P*"P1.\.)D^KR4A9,^9D!R=<V((<4D7(,* G%87&J%?:3GPRC,XNCN5\E
MOL_?8+!V5O)Z!/"))))"T=.5F[1NA+ZAU*': W74A31RN2GOY[&QAC=T'L#G
M.=0;7"O9VEW;3R4&JZJ7: Q"-N73%0D6!)%(-\_4'UM&:V-8!0+UPE==1Y3Z
MN8 +L<O)DS4TP'F>SO"(#C/N9SSLM>:W4\?('F",?P;J;-3^LV,E<-WN5Z8&
MGNE<HLU+(W($L;_[+=MU/>VAQU]SX/D69M'3UIN(ON]<ZNVS;-3Z]Z4V8U5>
MIS64<BSO;D^>I+,PQ!C/3(Y Z-\68$:0Y0G,4FJ18*.R?W"A8$6+&<67F^5N
MH</9XBWMSF\M;NE'5<]L,;6,WNJ6@O<30@ :BE3VKJ=F[J5EG#:1Q^G7<9?W
MR0QH#=Q[ 2?+2GN:J'-XM7:(UTAM!R:HY%<,M(V$AJ.XHB\6&EA30@25D]H2
M!-T>=&-@RH="+ 9W(_ %JC!XFM03D(D^,YR+NRG$.19G.W5[;Y..UB-C*8'M
MB,CB96DU<'.H.FX?!%-X/PEE8C(WE]+-'<MB:8'['!NXG>.T@G3:1V#M'E6N
MCEZ4ZO\ 4PY^=B\[+SY?ZBC]F"D?_/17ZO9IST[]UK^L,A_+3^_B7G[[P_\
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MK>BV]>M++%@EYRZ?PJS2X1()9%+'K:9+'IS7Q1SQ'FU6[,CP@?G@Q9@2DLL
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M6HT<*^\O9?B#]Y',X_AG$..^%.?GMVV7&;2VR+(H71EEW%#%&YHDG@#B6[7
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MI4:-*28H5*E2@P)*=,F3DA&:>H/-'@( !QD0A9QC&,YSSXYS6M+G$!H%23V
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MED5RYT8>YU!%4GNUU: SO  #04HIWQ#\(.*/Y9X:^'N>@BP%YDN/0P7LMM!
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MB-<>O<51CJ<=W2T1) 0) !SDW)HL@Q#2<NR;,<W+BWA] ;*8W]\[R=Q'<%*
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M.,2MI(L$)U2TSR'-2\CX#RK*7G);:^PHR65OYI'V%_)-#TX+>E8X6"1V^)[
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M")PB^MD_LC[&?]8I+_O-QYG8'^J;/_=S_P"H%^E'_;0_S*SW\IC_ 'RU#\W
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MPFM I@Y%+$3A%5YJW&H1ZTZ-WR;Y0Y&ZTDT"\[-&3 49?RG;%0,$)76$YO\
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MT _R"E\LD1MQ\@DPZT%F:R)&Z*2YY>XPTLDHA=5394FCJ]:[-*9H/((.&O1
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MK!KD"@G.%;VTW/HN^S1S*"JP,S*0.#1@PI"4,)%<NW6%+=M>6_:TF5/2R*[
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M$@48"+./<SG'N<(N\X1.$3A$X1.$3A$X18'#K*AT^>K,8(LZ>DW*H9X16L[
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MQP2.J'-U!,9"CAQ"I&F5'X])X0C$1:Y&6R9Y"M+^N%7$5C]SZ],^LU@$_(3
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MA2]33^5M+[+FF,4-02"S[8LY8ZW+3=1J&N-O\_94Y3M-WL)H'1[P6V9$J5*
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M)I:%.LYG4@3UQ))QII&9;)R8TY/\E<WE)&7.6D'.@V;*@35YY>L,\O\ SHW
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MAG2HNZ0M5O985 SS3EY2U3DL\LBQ]\T/J&0:S$:J+)'9!5>$7O'MA0/*9WC
M)GF:1K<%LW70M@G$V'G,>8N;:C46WG$X;L*Q1\0B J0K,X78(I?/UYA9^SC9
MM<-SE&+$:J'?->4[,%:TXA8X6_V#'K(6.9S=EDR^"E!3Y&B"BC@N(4@4@S B
M3",R$T)%5HOIQQJ&0[45GH2_;JHN=:9:VIM2*WMAF15!.)/+Z%PQ50T.42M"
M/6)5\CKU^7.SE24;=\N+:T-"M*YH1^6$2D4J4AI%-NJ.I[/J8U6JRQ^T[0LY
M#;-L2&ZGM1:9D$5O"2PIRF0*+(>T[C"8/""S?7R5ICWE0F&3Y%O4*A)VTA$A
M+*3 (HJL?0-',[1N^=1'8V\:@B&THHR=L[4L$1T^NB]MK8S7+%3V7)-)9S5L
MNL6N'*45-%6J.NQT=>&\8T+:0>B\BXX,7&$6?4WI?#JA1ZEX'8=D3MYTZI2<
MT'7+Y)Q09"=(H+-T]9MN1SA!$X3'6Y<^1QBJ1G1(%#>6V@$ )YBHM2<;X@"+
MI7W0"DY%#]J8>Y/-C9)VQV*C.U<C?TC^RH9-5MY0.(4+&:WF=-.:2,DEQY57
M3QK?&)"UA=2GO'IPD_*K*E";A" BR2IM2\P.V6B_+#OBY;]N=IK&;4\5+;#^
M3..,8:_FDKKN9&M"*OJFKJO(2UKFE]KDDXIR(1A<UGI%46O4*TY+40V$5O>$
M3A$X1.$3A$X1.$3A%K_V(_;LZ=/][K]3K)PBV <(G")PB<(G"+AN+<WN[>N:
M79"C=&MT1J6YR;7%,2M;W%O6DC3+$*Y&I :G5HU:<T19I1@1 , +(18SC.<<
M(M>%>]..,0I;2T<?-@[\LW7[6F01R5:]ZUSU15BF 5X_01*K1U:<[3!BK%CN
M.S&^F4RD&(FDD<D<24!Z1&K5X7KT*%6F(NPL30#UM6WBEA6T^Q=.039V4/TJ
MV!@$#Q3"I',5\GA45K=_'%)A,*ADMB5:H=H!#D+48<QNZ89!9>523RSD(:X1
M%F5DZ21A[D%73VB[/L+52RZ?JD=$1"65"@KM\:UM)>:8EJ*KI? [9A%APV11
MV.+8\G5,J@*5,[-"K)OEU@4ZI:F5$672/7^X5]9PB&1?=?8.*3B).#TM>[B,
MAVKTEE=F$OJY<N,:YW&'G7P=:I&]ERL 6V9C;+'5"4I(268:>7E0!011+CIU
M5D54,.@2*S;A;K2@E^R;:R.;0H7.#E7@GV0G!TQ+G-F*2!P,VIEJ68QFP'F-
MKXZ;%Q1H487B;BT!999 RB*S-)U?/JR:7I/8VPUH;$/KVX)EH7ZR(_3D5*CJ
M9*C C"S19BIJL*T:TK6H& 2DX;@%S7F*C1]BD)&"4Y)%UZS72#+]ET.TZI?)
M#9ZAH-_UT#'QJF<R#*8-(Y_'[%<%ZMJ,8QO)TDP\QPD@!OI'"/R8S "3",R$
MT)%5B&=-F'1(54097?-YRW5NA)I$Y_2FHTDS5 JH@K[6SR*1T\TGRMHJ]JNJ
M7P.CI$0A7P]B=Y.L1MBEG;<G^;+;T99)%G%CZ62"XIP2JM7:Z]YO1B2V(1<J
M76I='M?6B">LU:3]BM*OHXOFT:I5EM]WKN)S^,M[B2V*G\U2KRB*3K5BI'XJ
M8TB^<ETC=4]F6E8M$;5W_K"1>\D;IM<T+J]IH*5Q:33]OB;-!CK%C*:\*4MA
M37LTD$4C36D=C&PP#<O$V$*A(@KA*E:DBO2G*RG3D$"..49))**RH4" )0?D
ML 09./$6 L CC<A[PLA"'&19SV8Q_)PBH$T]-J@V*J-R*B9GJQVYEW6LRT+8
MG+\0Z0\<HK:66DYJ)6K'3JE1!SF9C;XA9;FXRUC*>4+\)+(754:>)2F&6E+(
MLVG6D%:22J-<*UA,JGU,O6H(8EG6NTZX51<,ZK3,0KE=4A:'*.6163P65QF4
M5JZ*V9[:'5F5MRY(IR8640K(1JDQ%R7'4E?/:&G]%WOL9=EY$V.\,;L[3J0M
MM(PR2L">/.D8>F^/0QLK*GX;#VR/^E(N \SS[:Z.)@U:CO*\AR0$@BUX["TT
M,6Z5_P!K7IKWO7.6671BF(9KS/\ 0"\+OI,EPK*'Q-6X26(7B9K;L?04K?)^
MUW/*I$H1*I:6N9DL>6-P&Q20;AV!PBM/J/K+9*^M-;9GLZXVPUV?K_=FR%GU
M)#YY:C3;L[BM9VL=<< JBM+UL\\4S669,(#1%CI$JU<FD#B?AX2 ":\O!9)B
MI8125973_H^V&?>Y@F+G82IIZA<-8X1=B1$_,R#U>:X]4!5+MJNLSR(UA2QN
M0(ZG L&)S&\$C<@]_)?E\Y39(K-U5#9; X4V1N<6W,KNDJ41YKC84Z8ZVC;\
MZF'BP/!.6:J(/7L/1(4G_"0$MO\ 'P#_ .J<<+WW"+7=9G2MCEC16_JA3[2;
M%P?6[8J:6O:<SH&)):,RPM=IW)(W&P9C)XY/9%3;]:R)G4V\Z'3'#*<]'H!O
M1@TYN#&4PQI$17BBE"LD;N!9?"^5RZ4V4\456U"R)P>,QE&SO;)6LHGDR12L
MQEC\:9RD$N?W^QG :_RQA39@H)):9&GP 61D5<P=.JJ6BCX'3T)L&VH2_5!L
M3<>U%+W8UN,&7VI5]QWC9]TV5.5S0%X@:ZO7V*N"78&4Q<QH=V%>F515Q$F4
M9-6A"X8(IDHO6%JI:;V/:KC:%HV]:]PQ6L8Q9DXLI=$@>G0U*NL=3$US-%(+
M$(7#82$A#9:A 8B:$"1O-3H$R@PD;F:Y.#@16=X1.$3A$X1>8'_:/_Y0/]B7
M"+;_ "/_ !3:;^P!LK^\5J?PBO\ \(G")PB<(G")PB<(JXH=ABV6)R>8W174
MNHMK:]CFS7F)XEZN./IMAF3FZXM1-,6+'PPQW?\ R$1N"83=JRW%./E')$0J
M[5J<CNYX1=\ON]J0;)1/6X;&X&/<KH^P;O3R4*A-AJ2-5?3RLH&L8SDF<>;&
MX."NS2%!1@<^&$M*8$7OA!X13APB<(G")PB<(G")PB<(HM)GDM,NMQK$=32X
MF"(ZM99XEO4;G%<P-REKG+'^/KJF3LP7K,W+ES*SM*=X.4C;L-0T;@4 "G*@
M(RL$4I<(G"+ UME0YOLZ,T\I=.[8$M@<XLIE90)SS?%AU=R"O8O)W12J+ ),
MA\!ZM!H*(+-$ Q5XAV2L#PG.R BSSA$X1.$3A$X1.$3A$X1.$3A$X14 Z=G]
M76QOV_\ ??\ >FLOA%?_ (1.$3A$X1.$3A$X1.$3A$X11;)IY+6.U*M@354T
MNE41GC38KA+;;:7.*IHC4JR&I(THC+3+VQU>D4J<U5EG/:HAL$THEQ:<QL.R
MKR0 90Q$4I<(L#8K+ATDGD^K5G=/-R^LD<.73-M"G/"!H)GB-V<(R 2L1>$Q
MRA<B93C1%@%D91>0"'C&# 9$19YPBP>SIPEK*MK"LE<A4.B&O8/+)PL;4AA9
M*IQ2Q-A7ORA"F-.[22E"LE!DL A^]"(6,Y]SA$K&<);-K:O;)0H5#6AL*#Q.
M<(VU686<J;DLL84#\G0J32>PDU0D)7X+&('O1"#G./<X19$_N"UI8GIU;65=
M)'%L:7%P01UL.;TSD_+42,Y2E96]0[+&]J(7.AY82"AJ5!"<)AF,F& !C(L$
M6,U;+)!/*TKZ;RROY!5$IE\+C,FD=82M8RN,GKQ\?&9&Y.L+D"^.+W1A6O$9
M6J1HU!J-0:G,-)$( N[G'"+"Y;=[5$K\I:@U#&X*W>Z(/=4W;'\E0F VLJ6E
M5-6)G1"O3#QYI0H>Q6FGRG$7GNEX2F=__B#PBG#A$X1.$3A$X1.$3A$X1.$3
MA$X1.$6O_8C]NSIT_P![K]3K)PBV <(G")PB<(G"+BKCSTR)8I2HCG)2G2J#
MT[<G-3$J%YY10S"D1!RT],C*.5&!P (CC"R@B%C(A!#VYP18#3\UDUCU; IY
M,ZRE%,RR61=I?)#5,U71YSE< =EZ8!RV,/KA%'1ZCJUP:SA9 ,Q(I-*%V8S[
MW/:$)%)'")PB<(G")PB<(G"+ [&LJ'51'V^43ET]#LKI/*LK5$K\N>I\:8W/
M9T0IZNVOPTX## ^G+ G38B\3./#)\QWQY" (A8(L+7W>U(-DHGK<-C<#'N5T
M?8-WIY*%0FPU)&JOIY64#6,9R3./-C<'!79I"@HP.?#"6E,"+WP@\(IPX187
M9$F?877<]F,7@[Y9LEB<+E,FCM;1A8S-\DL)]86-<Z-,'CR^1+VN/H7R6+TI
M:!(<O4ID92A0 1QI9>!#P1=M%G9P?HQ''UWCSE$75Z86AV<XF\GMRIWC#@XM
MZ=8MCSJI9UCBT*')E4G"3'C2J#TPS2A9*,&#(19(N^X1.$3A$X1.$3A%7.T=
MBV6KKVU?HE?''1T=MGWRV61A?D:M(2W1<VIJP=;/<3W=,=C*E86[(&L24G!.
M<9 </ A>]QGA$UQV+9=CD%RKV6..D;!3>QERZZ.9;HK2*Q/+U3<D]6W.1H<I
M,8PG:WD_]*049^E+![@_=X16,X1.$3A$X1.$7F!_VC_^4#_8EPBV_P C_P 4
MVF_L ;*_O%:G\(K_ /")PB<(G")PBU![OWLKTQVD:MBE2ER71&?:!;<QPR-&
M*E1K2Z7/JH4R;&4NPMC.68+"R136#/MD$8"F!A8I$WIR0!.R(."B*GNH9-MQ
M93K'TVK FTHD%BZS;UV++[=DZN6/[K(9C2->:]1W;N-/*]_7.)[E(V,Z]=L:
M^8CLF&G(<$(CT(L!$2$D)%A>SM?1>ZM36(BT4SI+RD'^H2A$%1X7263)A)X?
M*NKG$H*\QT!C:\(C/18XH=E&G+SG.$( @&F\$PLL82*]]I:MTI.M^-;J/D4<
M?#*FA73\V#(9X2U3^PH\WJ4C+?.JS:T-\B71^4MCW*VMN*4>,6E<U2M/E842
MI$ 2A.0:612=TL5[DGJ+8JMS7A^=HI16]NX5*U>1)9"^RQUC=6PRW'0V&0SU
MCD[B[R)S:8BA=A-[;A6J/&D;2$Z4 L$D%A"11C&Z=@^ZVZ^_R+8U%-)A%]6;
M H2B*.AR>R[+AD,BS-)-8:GV(F<[:H_!91%6X^?RR9W4:WJWH\*IP+01Y G(
M/)+*&7DB_353T*VXW0V\JB]0V%)*IU&B.KU:4I7N+6M6-,*%;/:T=[(F=O+5
M<8F+&]R^QGPQX0L13XZJEZUM3Q\S"(X@Y<YB4$5;H/)YM=U0]-ZGK0L&TY,R
MD]5O?/36?S(JPY=')3?M1:HT?U9Z]A"N:3J)OC1)I:7*DM"QY3(%!BK G=X0
MJ##\CR+(A$74O]/S".J.L+K)J\OE+"70<1TSVFU:@Y\VGDC31K8!AC<EN-.Q
M1]Q?7U^D#)%K.G%#LB-T;$AF4!P%R[.4IGG519Y%(5T[>.]B+=EMWJ$=E#S7
M.D?2 F>P-4(#<#4,DPO3:FM5VQ,3&\,Q CD3H\5Y3=#1DPLL_(L%H[&-"6$6
M#A""18#K_&[.C5B:,36C-0M[8E-5DV94&XUWWU8<'70N[*BGU23@%A32R4).
MSMFJW^5)[B71^4L8TK$4J;!I#$",:-L4*41I%%^S<#;1].KJ:[EGR*SC]D-9
M[FZB,IH*QOEAM=(HJ9;2NQ5ER"O&^&,3=,T49:V%I<FDOQD.$>4ZY,(292$U
M-W20D5Y]N;SGM 77U%[=A2I4N>J)Z.3?><(CBH9Z]C%/8%+-T9.UJLL0Q&(C
MU3BKBR(@_."\C/)* 6+.0A#C!%6C7^-V=&K$T8FM&:A;VQ*:K)LRH-QKOOJP
MX.NA=V5%/JDG +"FEDH2=G;-5O\ *D]Q+H_*6,:5B*5-@TAB!&-&V*%*(TBB
M_9N!MH^G5U-=RSY%9Q^R&L]S=1&4T%8WRPVND45,MI78JRY!7C?#&)NF:*,M
M;"TN327XR'"/*=<F$),I":F[I(2*Y,\UUIV;]<BO9C*(B8Z2)IT$>[8;EV9+
M+4926P8)LQ3K)%I$!N0/R5K$8VM:$DH2<1.4BK!8<GE&BQV\(MU?")PB<(G"
M)PB<(G")PB<(G")PBH!T[/ZNMC?M_P"^_P"]-9?"*_\ PB<(G")PB<(O-3=5
MBTXBENN>U>HM';5@]>.I'K'5KAN7(K=>#*DL2,W%MI%-?;CC 8E9^RZFX)I6
M$E:)T[(8V$F!*(B28C0JFL9")&A/ 13W)8_$:)VVLBTM\*;N]Y8IIM)")!K;
MNS&[1ELFHJKHX_BK2%4Y3L\B$,L-AE6OB=JL;(6U6-7$U$&?5+H)8Y/!@URT
MHLB26/Q&B=MK(M+?"F[O>6*:;20B0:V[LQNT9;)J*JZ./XJTA5.4[/(A#+#8
M95KXG:K&R%M5C5Q-1!GU2Z"6.3P8-<M*+(LLK.A8SO>Z;SV?=LKMAEL&![5W
MIK[0TFC%O6978M:(C2C+&XA$)/5C9$)7'F-DDCM)TZF9KG=0E/6.BAP)(5&J
M&U&A3DD4+:X3MZZF$NT29-GTDN50!]Z25,[F2ZOF65R^O(A8=_WK(X_&%\ME
M3?!'J.F21IA;/%ERF.-ZI0<W)PRD:L:7"HE$<017Q>(@T4YNIH!45>J)(T5V
MV4!O7A-''*9S"5EF!12'5=<V 7N,N?7UX=2V,Q\5%MP52@X+<E-\NEP4G" H
M)%K0NJQ:<12W7/:O46CMJP>O'4CUCJUPW+D5NO!E26)&;BVTBFOMQQ@,2L_9
M=3<$TK"2M$Z=D,;"3 E$1),1H536,A$C0G@(K(ZL494$)ZE/5LNML@BI;.J[
MF-&R:.J"I-+CS@++'U<0S6?)$38H>EC.(4JD#XM-" :0TM*8ISA, H. AP14
M<UCD=Z6AKMHUM76NH^\+[NG:LBU&ONW-DY!.((TTI9]?7G,JND&T;(N:3MGW
MPXNA0T-)GX,'8Q1'N,)C<S'I6U(K(SC!%:E;4L5VSJOJE[ 7@=8[M8=8W'N%
M3=.F-EN6M"6^HZYU_KH$'C#/ &>$RZ+M36CFB]O7O[\,:<TQ_/?#TRX:M 6F
M3ED6W_4W]EC6C[/]-?JZCG"+79HK3D-7:?->TK\IF\LO]WJ>]8V?9$OLRQ),
MX)(PV2V=LK'&69E>).JBK QQYECZ),A(1($^"<$B-[<J#U)QQ%6[->S^94=T
MV+EM:BKUW&U<;NG=5;+/:XI:RU9,_AESR>&U$]EWE(*E/L&M%][$K8LB5-P3
M6]Q>Y,R&C/&@:3\."LX!%V&U^T;17*SI^[ :0PB3;'MAVB^[R[7"/-A$VE2I
MV94+%J2XMS[.%$K5ESL:& 1)B5N+RA=E9$G=53:)D38.D2Y$C/(LSL6@USE1
MFDD_K1%<W48U;$39-V[$-U>6^CA5J[-RZ]H^PRN"[(D,#Y.JJB-AQF,.J]X4
M)J_$_M2!F0NC>!G;U!C&W(0$6T33F84/-M>82Y:VYD2:J&M=-(DWQV99GA4T
M@<HATYDD9L.MIBU6<J5SJ-2:NY\UN3,K:5X^QK&B\LG"%(4GQ@BL[PB<(G")
MPB<(G")PB<(G")PBU_[$?MV=.G^]U^IUDX1; .$3A$X1.$3A$X1>>2@&0=Y:
MT] *N[*DT_>(?<&A; LMQK;;'G<546AZ,TZI*:ITD\?(G(620R1O/EK>0O5D
M*%8BUYI>0*L'$&GE&D409UNKI?K[ULG-6[6^8JTDN38Z/:B]R_[R3I]=T$;T
M8H+9IB'621-81*5F<&JZK6>'8E4,!R@!0TZ' _((TJ4DBNPQ1=NVYV4HN-WN
MME4JA4NZ:-373**_:IW.87!Y'9BFQTWEY/(8[#)&P)) <U D:["0A=YA*2(_
M!GA9.)(,*(J\L;[+W.ID>O)]@6JEA5-=:DS4>+/R2SIP@L9=KNX-1LE35PX6
M>A>$D^5-+/&K*415.KRY"=0LJ!/CS?FB\'X(K1W32]?,6Q.BF@$3;)=#=7+'
MBNYE_69#8O8-B-0+ >:83TBPQ*NI;,4\G!-5,*<GW899(U#26Z%)URJ-)"CB
MS4(#TXR*M5IQ2?5FU=3C7>@7:P%K1IE&]+.H-K#'G6:2^7K(S+VEUG]FS/6^
M)O\ (GUYD1L(GIVJ1I/H!8H-;TQ%@*4Q82T!Q9))%WFU>V<L5I.H7O!0,C,=
MHIHOTO'4JBE8 #<(\LV#V0KM/M(]3!YCQQ9K6X>H-1Q:I7)-A0$2CR$C<"?Y
MN0H$-01<RDX38%=[%:>N&ONG6]=9)QS"20C<VS]CK%A;M&+2I]VI:U7,$_GQ
M)&S]Q.,GN!!L8DB:] XA:1K26]:Z(BU)"-0(&"*;^L_5$"M*C=744Z8S'M*#
MJ1]."-^"!Y?F@(V2?[KT9$Y:@-RR.;:(\MU85AA.!#R(Q./(32!%G  8$B6E
MJW2DZWXUNH^11Q\,J:%=/S8,AGA+5/["CS>I2,M\ZK-K0WR)='Y2V/<K:VXI
M1XQ:5S5*T^5A1*D0!*$Y!I9%KZ<;@L* :PQ_7%@0WS9%9R'K<["Z1GPNK)DY
M.%WG:K04.P]XIJ=B5C3.QHA(4#*H(J]-%AJ3I0A6(XDI-0I5(>X07PBF9:1:
MU=U?U1 5UK;LOJUJJZ=.B=S2%-%WS&+J3(GLY&(?>B&;.51-T5NJWW&)-<P@
M*Z,*EI9*MO0%.K#YI.G K5KCU)%:VSH$T7OM;H%3-E.LV<ZIDW3VW2L*9P-E
ML";0YAGDIA5H],%GB2V;E0]^8E,G)CQ%A.QJ8E4:84 ]4(>0YSVXR17 VHFZ
MS4G1+8^QZC9 F.&LNI5OS>L8XH&N>PC64Q3LA?H6R'F.)KBYNX1'QM,0+)YA
MYZC';WQ#&+.<D6M^8TFQ:>0;0W9"K9A;K[=,RV-TVJ"]9E);;L:9*MF(UL_(
MH[35E.=J1F1RYRB#PJ;'&?8FJ$U(A3^KZID"!MPF08-2&$6"3N43:.5)MGTW
M$<L?DMA6;U 637RHWPIV=RY$AU;WS7"VFG#Y&WP1XGT J>I%9<3(RY)&$:(4
M!**+,)3$@/+(L?F#^3L5M-U V&V-5=W;U:*&N:&ZTZ_OFM,MC$*BM#1UJUBU
MYN=QD,0&NV3I-P:+N>;'MQ4\#?B&DU06R%,J(M<:0G,( 13%%(C;>Q5C=+.I
M=Y&^<,<TE/3 VSGFTM0-%C/\48I5?]?V%TNXVN638NL)(UMLA3M#[.WY6D1X
M5*424Y=G !&X#WAD7;[=1#527/\ 8M,1+7+:O86U=<=>XE''$5(73)(1&-:X
MZX1A].JQ6ED=I[/T=7S99^&8CTP<?'#'2:&-Z9"J7^('#;WB*.JRLZ6W:[_Z
M;.YI^X"=IW;E S>SIJZC[>^YRV?=.0J521P%VYSGO+7EV.,S_P#$7"*WO2Z_
M^W=YO_R?[S?K2X1;/^$3A$X1.$3A%Y@?]H__ )0/]B7"+;_(_P#%-IO[ &RO
M[Q6I_"*__")PB<(G")PBJYM+J)5>WC;337::B4)"*.O>%[ 1,R*K65"<X22(
M-$HC"V*2/+TP2 M; YW"YL[LCZD3A2K%+8X&A(5IC>X<$BY#1J;5[+MO+-ST
M9\DS:TOI=LI!<UFJ63U,0Q]))&Z1N\C;4)3 5(PS"78C4?0.9Y[HH1&((TV@
M(2D&%J#5!%%\^T#K*:4C+J90SJS(D8^[3XW/C%AM2N&N$NKV_D&QB':2-/<?
M0/L,<86\1>-V@V$@*:7EK<BU+3@2=08::+S."*:(YKRU-5K5]=TBL"P)]9T!
MH^943ZPR;$#;D\KC\ZF=?3I]DDC9(1!8BSDRS#Q6R$M.)L);FXI,:>$2,8Q
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M3*)4K(\Q@8DIZ0BM?PB<(G")PB<(G")PB<(G")PB<(J =.S^KK8W[?\ OO\
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M:%9L<ES"WJQ(*SS'#*JDF8FZ2Y@;Y+B.H4RQ8M?\L2MP)=,,J-&W*#357A>
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M6[QYO2"BJ.MW9^DBM&BRF//$$!:0T:D1B@:8DBNY$;(KNP#7LB!SV%S8^-+
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MRXHU;G KOK1IKN8.*6$$*I7"8Y%KZ=_!/,$2_J5J=(<I<C@@.*/(I"ANG#-
M;<V5L2+V_:C="MJI JGUGTAY:KUD"S:CI4L I)YL-CD3A6ZRV&Q8N@=6,6 -
MN)$)G(7D'GX3""H\$LBY"W2JK%]7:=5*<_V &.:1S"F)M5*TMUCF'N0.M&5R
M]UC$D]A*114:!U;W%A?CCG$#:F:3#E@0#),3EX$4(BM_PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(O,#_M'_P#*!_L2X1;?Y'_BFTW]@#97
M]XK4_A%?_A$X1.$72,<ECDG(7*8T_LDA3-CLXL+DH8W5"[$-[XT'Y2NS,N-0
M'J"TCLUJ<9+4)S,A.('[T80Y]SF1<6EU9N:R[BDB>]C7M#VEI<QPJUP#@*M<
M-6N&A&H*Z8+FWN6N=;2,D:UY:2UP< YIHYIH31S3H0=0>U=WS'7<L%L2T*TJ
M"-&S.V;$@M7P\A4G0GRNQ):P0F-$K5??\HC-?9*X-C66J5>$+PR\FX&/NY[,
M9[,\(N9!K @=GQI!,ZUFT1L.'NH1#:Y7!I(S2V-.00]G>$@?6!:X-:P(>W';
MDLT6,=O"++N$3A%UK.\L\A;$;TP.K:^,SB3A0WNS.N2N;8O3BSD.#T:]$:>E
M5$Y$'.," ,0>W'\O"+K9E+H_ (A*IY+%IC;%H3&WR725Q*0.+J:WQ^-MBIY>
M5I36SI'!W<C$K<B,,"0E(/4G9#W"BQCR$.2+BP"=1:T8'";,@KF)[A-BQ&-S
MJ'/(V]S:1N\6ES,BD$><Q-3VB;7EL$O:7 DW*=6G(5$Y'W#2P#P(."++N$3A
M%'\RM*"5_(JGB<N??1$@O&P'*K:M;_1CPO\ 6B=M%667=;@Q>:;&]:B9/+UE
M3\C<_-.)B1&/T=Y<)N5:A*0<19)))/&H:R.$FE\A8XI&VDLLYTD$D=D#$R-I
M1QY24HUP=G10E0(RS5)X"PB,,#@1@PAQ[N<8X18C%[GIZ;MK\\PNUZUE[/%D
MHUTG=HO.HN_ML<1%ISU9BQ^7-3HK2M"4"5,89DQ0,L&"RQ"SGL#G."+$4FTV
ML2]4F0H=C:'6KEJ@E(C1I+>KY2J5JE)@24Z9,G)D(SCU!YP\   &,B$+.,8Q
MG.>$4R-SXRO!SNF:'AK=%$?=,L;\G;G!(N.9'H+>WNV6=W*3'&F-KIAK=DJG
M*<[ #?+J2C.[W# 9R1&=\99$A])Q]X:WUM\XYMWI!G<$CFA](,KFK97E#YM$
M<>G\XTO#>>D5%=[OD*2#"AX", @X(NTX1.$3A$X1.$3A$X1.$3A$X1.$3A%0
M#IV?U=;&_;_WW_>FLOA%?_A%CZN*1APD+3+5T?9UDG84;@WLC^I;TI[NTHG7
M)&7%.WKS"Q*$A:SRP<#[@L=H>W'\@A8SWMN;AD#K5CWBW>07-!.UQ%:$CL-*
MJ*GP>&NLM!G;FUMY,U:QOCAG<QIEB9+MZC6/(W-#MHK0C2H[":Y!SH4JG")P
MBK@3J/KTGBDHA!-?=R+S/9!@VXDK9ZUS<7I+86+W1#=A6*P?.BDHG!'Y&X*_
M:'?T2G-*9#?*>5,1C1&G)C"+/RZ9K4FZ%FPQ<;[MP.%7ME,JY?Z8?\^-6K/*
MW:;MT;] "=,Q<OR\H?%2KS@405X_%\,1XB0@+"14BN?IX5I*4.EE8UY#&UGH
MRC=V;HVGLJ-*)W/T3\%7<5"[R%OLH@TK+>5<T038>S^SB"1(Q)'5NRR P::W
M&I@HDB;!%/#'HUK&PTS>-"%P-^?J_P!EHS*H??RR=VO<-DV?;L>F<(.K=\13
MJ];!GTGO!^.Q!% FM"I-D6534D[H4)B?NAS@BG6U*LKZ[:]E=4VI%V^9U_-F
ML31)8XY"5%$+DGC$JDYI"Q H1N;4Z-J],4J1+D9Y"U L(*4)S2CRBS D424A
MJ-3U!RF33^+#LR8V-+&-MB;I9%VW-;%]3Y-"69Q7O#5!(_*[@F$S=HM"TSLY
MG+#6YM,2IUJT6%*L*A0 !H2+.(-K_4%:VE=%U0B&)V&S=A5$$57!)R75_5BE
MYU:,*R-PK.6EQ=5C$PELS4XJ<9 V)40%2A2<I48-4FF&B(H3)T(U\;K'<K(C
M)MUP,;[8BBW))7E;;*["5Q2TEM!>])9(]35]IF#V6PUPO<)3($>%SXERW8;)
M"M-4*'-,L/5*C#B+)+&TNH2T+2.N&0-4\:)B\L[''+ )K^X+9K&)W+&XOZ5]
M68]>,&KR:1J(7$SL1;VK3DDR%$OP8W*3FX[Q6TXY(813K6E<PJGJY@%25JP)
M8G7-6PF*US (LA-5GHHU"H0Q((S%6!&>X*%B\Y*S,380F+&>::<(!>,C&(7:
M+)%K!ZB72UK'9W6S<N.U'&%3->FQ%4V"WLS2Z79=D6U[=;DD,;]&,EF32BF2
M8*Z*43HIR2I5)TH-B"M^PI( IR>-0 (\$5S[LTZI:^IS'K,EH[6BE@Q^,JH+
MF9TM>]U4%)9#7JUQ$]*(!+WFEYY!E\GBI;V/*U*4K,,.;58S341J82A1DXBQ
MV2Z$ZQ/U9UW5+1#)!6L?IZ>3&RZ@>*=L>Q:HGE5S*PUTU6SM? ;!@TH99A'6
MN7 L5[2+VHI9Z(/;EXD>4OEBB"BB+%VOILZE-\%V-K5;$; E4+VXAZ"';(-<
MVO:\I@MMHI)&SX:LE$CDC]8:V4E6 _1'*5K7/R-:F=#F]L0D!. 6D)"$BM>F
MJV")+3>;K3L7AV;(*_C56N\E])O _-P2'R.62R.L7H8;@*/D>CI!.'11YHI(
M!8=YKN&FC++) 615TANIL-UAUSM2IM5XXZ*25=?RYMJRJK7MVS9Q5#"X C3V
ME@];1YKL!]G;55]3DKUQ2(QO96\M&0W9P'*<X)!182+,-+]=6_4K4_7S6Y L
M]*FU!5<3B+\_B&(TZ5S1.VE*Y[,UAHP%B-<)I-E;@ZJ1Y"'O'K!Y[H>WLP1?
M6\]3:AV!?8Q,9;FQHE84-:7F.1VSJ7MZT*+LA)$Y&L:W"0PU9-*EED0>WR&O
M"]E2*3&MP-5(2UB<I4466J++."1=BTZIT Q556M),]>)6^L:BFT+LB!1M,^R
MHLQLG\!G9-GQZ8NC]Z=S))9(CK$)R].BIW6+S7UR.//<\JQJ#\F$5A>$5<*^
MU'UZJN):U06!U]Z"BNH#>8U:ZM?K7-W3Y/$!M>/M4F$>>>9*XN,M[T!DJU!W
MGTYS'CQ_'QGS("S@D64I->J72P^WZ^,KYE=8-?C]/9)<42D8U\JC\_<[0;BV
MB?!?&J2K'9)EID[85A.H;R@E-_A9$$!(<"%VD4>4CIW5- 2$N10B4["O1C?'
M38A'&&TMIMC;BA<1BYN6KNM,;@]H6?*XFD.3%LJ8HAQ-1GNQ"<(R2U02C3@&
M$5J>$3A$X1:_]B/V[.G3_>Z_4ZR<(M@'")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB\P/^T?_P H'^Q+
MA%M_D?\ BFTW]@#97]XK4_A%?_A%!FP6R-/:N0A+8UW2@Z(Q!9(FF+$NQ+!(
MI  +N]"-\H!43'&MU/0I E)S##%!X2R 8!W>]DP98!V+C/%,[S#(.Q7'X1/?
M-B=(6E[&=UE*T+W-!-2 &BI-:TH"1!Y_D>(XQ9#(YJ4PVAD:S=M>_O.[*[&N
M(&A))H/?J0#1RU+JF&X]^+]/M:IHMCE2U\E0.^X&P,-5@RN(:7DK!C+1M32A
M$:<2BF<R3A/PY.I&<#:TI9N23,GIS4YNP\-@+'@G&F\YY9;MES=TYS<992C0
MN8>_=W,9H3%$:=.,Z2.+=PVN:X4G*9F\YAGG<1XW,Z/$VX#K^ZC.H:[X-M \
M5I)(*[WC5C0:'<TM.RJ"02'UC#X[ (!'6R)PV)MA#/'H\SD83H&U GQG(2RP
MYR(PXXXP0C3CC1#/4'C&::,9@Q"SJ?(Y&^R]]+D\G*^:_F>7/>XU<YQ_\@.P
M 4#0     MCV-C9XRSCL+"-L5G$T-8QHH !_]_*2:DDDDDDE99S"66M4F\=>
MV9'MI-8=OF[6]\W(IZDZCV+K.;47""Z]=+3@<MM^04:^1G8>KH5:;_%HG/GR
M/1NKGN,KT:5S12(ALD9OHX"T)ZM+DBP.R-Q*[3ZOTW9.C!B.HDD@ZE>E6N5T
M0<ZFFRM)K"W:U=NJ1K/82J;4J>;P]&Z0.R'6!S4Q,M./0D.I:9>G<$"K 3$:
MS)%8>[KPOV*[)V]7=2$)YDICG3OG]X5E52MI:3$LKOUGGKLQPLA2ZEEMTD,3
MOAB=,VC2!<R$F0FY'C #?TN"*'=')R;L5")HG9NJ'L!:]N&5>W,%K5K)ZLT[
MJJU]5+1D2="L.D[32:C4:*6%7KHR.1:] W-UC))FU'%%8"9Y\Y.<H.(H#Z:H
MI5$^BWK9:]M=06Q*J2V'0%&3]==EF-NI38VT$BD2!C&ZQ2NUKY13#$%2.1+7
M+*-"IG94T=,+U178<I%V$&$66Z_;@3E>=U,ZHC>SLVV@1:M:ZUC>U1;!656U
M4Q"<D.EMPO8Y&IB3@FK"GZ9JF>,L*F6NXW%N<DT2(*/(=\HU!J[RV3<D4M+;
M,V-N2?Z 4M&MA))2:38+0"_=B[>L> 5]3S_9JZ<U7)NGNT1U5"16I +!K")&
M+#=BG_SP546=T)J-0(HI(0H"D6(R*K4@Z@MMTCK#:\;L^^VDF>Q'J>J.G>Q[
M=VG%J];5K# W?$;L%9=DXAD)B$,J)98T'J9W=4;>20S-L=7OK>A4*T0B#5"(
MTBZ\GJC-E$(=XU,-VL%U#H'06A4OW(@T[D+-43?*([8=;+'^-R.F9Q(==ZRI
MFNE\9F"I7&7!IR%A3/2'!KN(]4K3Y1@2$4Z6%3FPU;;'=)9WNW;J=;#N#WNC
M/2Y9%I+6M$P^%1BP1=+?J,JECC3JJJ:KK>9M,%*'EP2EMLL<)>Y&)AHQY<0'
M)U(UQ%*O6M,:RNFO?)KV06J92Y7K48[IC4)CH4H:P;54D)>0:VE$*C7$LU)@
M81$!*,$=C/<P$6<]F2*#E<,HFW-\-*I#I]0V8TR5V'8@.WU@M&M,WH^NY%KK
M-Z$F\/C5*S"32>M83$K772:_GB)OJ2,!-<E" B/JG PM,7V>;(LAH/737TKJ
MQ]05M+HJFRVZ,ZJ=,]\C: %8PD"*//3G-^H'ER=V-*%CP0TNCAED19/4$!+-
M-RD([PL^$7W2+!-5MC974.R/5DC3%J=L_>R1=U'U#X9+J4:*77Q5N4J=%]&T
M XXX'6+=M;/89 D*; *C0E(34N$RPC(3Q&9-+*(K#]%EU.?= H\^*65XC2AY
MVGZCKJHCDA WE/[ <X]1[;!6:ROA;2X.[66\-0SLD*0IE:I/@XL6"S3 =@\D
M58KDWU8Y=LKN)5CIU)H[H9C5N91*FJOA)<?H-[4VK.EM,59=\DLZW2;OJBQ)
M(LK4#Q9J>)(VR*K(PK&0T.JGTB-0J1&MQ%G3OU$K8A.O.DG42EK"\+M>]CM<
M(FS6_KJSL;&WR&NMFK/A:.<4N\PUZ>$!<N5HYS9Q*BJU3<XN!R,M?((^YX"C
M)2NZ@\BE^6NNY+*YZ):[R[9 R'VEL!']A%&PMI5_7%3NSQ'9"P1EIL]"TTBG
MF<&>8&U)ZW7KAQEC<)!'9 !?'BO'=D2]V-PO)(H8F.Z%]ZQP??\ J206$7?5
MMZW3C4.'4'<MH1"(1]P>#.H!*(?4E.XNR-4W&ZXA$B453<D@6G.!T>:(T4[1
MDI&0(M.M"I7G$4WKY1LAJ5LEKE6DPV3L#;:(;<I[Q@$>:KA@VO4)DD$ONLJ@
MD=^0\$)D%"U72;=BLY5!ZVE"%<@D*)]<DZP#>>!X  )Y2DBPSIHW>^WB%@=;
M0WVM2P]EFVJV9QV6T6L>K-=J4-H>RGHM&7)RV:K4.OL!V@88?#IBF<&=H<'F
M62=K<TI(3,+UX\A4C(L7JC;C862]*C3S9)[L'SMU6GLAH5 9Y,_52$)O3L3N
MGJ54;0%EM/JZDC1$3:_66HYBY-/CHT"=2C\SYI*80M+*4 (K#HENPMW[A;*U
MJU[/3BEJNUT?-=9!&XU5U=46Y/DW^4" !D,NAEC2JWZRM4Q37:]0QY$04PI(
M])4QZ]4(+X(GRB9&1:KK-ZK 3J[VQV:8NH)&:[L?7VUMF6FF^GTFCM'.<>MN
M):D6+8E;IH19)DFJIXV)565M(=7:M>V&QV6QXIGP\,Q)*0[RZW+D1>F9F=4K
MZSM3VAP=A$\MJ%U1X4%"(482N"4I6GP>0/WY)V"CL=X&?="+MQGA%V7")PBH
M!T[/ZNMC?M_[[_O367PBO_PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PBU_[$?MV=.G^]U^IUDX1; .$3A%
M_!"" (A"%@(0XR(0A9Q@(0XQVY$+.>S&,8QCW<\(JBT]M)]8FSI"W4I%02.@
MH"H>8_*]@G%Q.11V86 W&C1&1"EVTI"=Z^-3"K +TM(<J$[668#"='YT0QFD
M6C*\<_@..CDR\O3S<X:YEL!5T<1UWW!K^K<X? BH7D'<_90!TK=XWT"V:Z\=
MMOGT+8@-6M/]J0U[I/\ 9;0N\IIV&W?*NHI.$58-*=D?KA:CZY;3^IGR=_6
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M=TZ'C9N,)VEL85+5*']RNRLF2&6"V2833B4B;U\ E9@24P5@$!I:G!HR,G!
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M@1B)R2X)7(S#D2I.>813=PB<(G"*#Y;=[5$K\I:@U#&X*W>Z(/=4W;'\E0F
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M#>$3A$X1.$3A$X1.$3A%Y@?]H_\ Y0/]B7"+;_(_\4VF_L ;*_O%:G\(K_\
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MH"217&3;1T2KA.P=BIYSXD-U7D%BQ:^7CU9F(/41^J>(ML[GZ'T>./!=9/Z
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M[T6;V]E0/K,X2TC8>0%N0SG!44(DM'A,4E$4<(\BPFL-$C8=,Z1G%E;3;&[
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MO:U"V9R)H0/*UZ9UAC\A8S!"&@)7>8*0&#$-.$L0Q9R13[ZIQ7UJ]>O5F/\
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MY"(8RQ!3+O!!<O$_)X7C-A'X7\,E$F)MW]6]G!!==75:AKW-T+(   T$M#Z
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M!)PH3-9ZAN3F#3@$$H0R"Q9#G( YP18G+ZGJRP7N'R6>UI7\WD=>.@GR /\
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M4>13@%Y9Q-AST%U;1,R8E6H4.P5R7+80G;\G!7GG+\&^5*)1"3F8.$(> E9
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MVR%CP_,*-0:A6%G)% DX<&EC!VAR1297.DVGLEV2ZQ\%D6KU"/T"@0Z;45[
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M!M81NP@95%MA*U>,P18!!P<()7B=_P $GP\UV1OWV#,6Z:0XYDCI&QU.P/<
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MJ^,U\9-%R%QF#HUDJEDAE2EI(/2LV)%)WE4Y2-Z2L296<6WIU*HPA 6>8%.
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$?"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g790774g02s97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g02s97.jpg
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MM8.5%7!N&1LQ6(% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M!J+A_6-#LU*BCXSC#-[1"C+2VXLJRR%-;-C!.&%'.:1[&IDY<G6W) !<T'D
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MV1V$Z+Y SYB2:1Q0<0I.9)1$)2]M@E245QI55D;C#E!(%28=[W+-#:PP7O\
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MFNGQGM1\N*.E-9A1S<3U6+DP8X5XMTE:G6Z48_A*_!.2$DMRJB=G#'<?/81
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'>Q_P#U\O\
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MVI?X,- 8V@% * 4 H!0"@% 9)![!OYX?WU;&8R*9"M@% * 4 H!0"@% * 4
MH!0"@% 2'^K/_'?ZVM?[S]-P>@GM:RB@% * 4 H!0"@% * 4 H!0$(E/OI+_
M #<?X2MDOTD4C%; * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MS,V?,<YC9,+:.8YKFQ2*1:J1PIB5$6)/<IZT\(8G;\8'N0\AS1^S%%E4\Q]
M<2XKR!E;([S VQ RN+Y.#X/!F!Z?VB*,">1H JUJPD@H"E82G#<:@P!5^-1W
M#>%8Z<C>:ERY#[#WS)C);$>JJB,MO<B*YUET$15P(JXDB;9]Y4TA&*ZVYTQM
MIK6M<YRMP1=9:BJB)%(JN[#&8&5:_--;!%L/RF.2&7Y?MGN+NLZQ-&<&8UGN
M79Q+8+'P-@I/,P0R&1]SD#-'(L<])$SB>XD)+I5Z@",0>%BWBMLGNW>LR=/D
MS6LD=&>C)CILQDMC7K&RVTYR-5SH*K4:JQ1+7[.$Q?>M&R7+F,5TSG6JYJ,:
MY[E:D(K!$BB)%$6,(+@QX#8W$^5\>YRQS$,M8IDZ*8X]G;06]QB1H"U:<E>A
M&::G- <C<$Z-R;7! M3FIE:1422K1JB3"#RRS2Q@#U=;1U-WU3Z*L8LNIEN@
MYJ^A?UI%%14PHJ*J*BHJ*J*<N1/DU4EM1(<CI+DBB_IA3?1<*+@4L.N*;A0"
M@% 0B4^^DO\ -Q_A*V2_212,5L!K%EG6AI5P/D1JQ1F3.$/QQ/GAA8)2G99*
M3("$:&,2J1.41C4BD<G3,BJ)0]C?90S*T"94[KT)!BI.,%A=RHJP!"E'6*:*
M$>1<@XE6Y^8D&1,4,\RD62HRX1')J$V$1S'[7*7J72*0N:N#DL:&/-C7"'<X
MM==5=(OLW'!2&*!AL&\M88 V39,J8YD<S(QVQ3%G=)PIQK&\QIXPE,47=#<6
M3%W<&"+SH !IP$\A/CTTJ4Q MWOMS21;H ;;+WL4!3V.-:FE++F37K#..LYP
MV2918'">-*V'6+?V9<K<L6/)\=R:ACBZ1,C0RS%3CU[2F)WH+.J7W;1 $(_<
M M<5D4C &R=G)LN(H%G1KN,]Q,9B V<D5Q*'DFP[G,Y ;'[3G8FQ8MVE#M/#
MN;[0VV7J@K><YIQUCB<8?QS*WLQ),,ZS-V@6.VI(C-<!*Y RXZF^55O+9B:X
MO-QIO#,=.QQ2U58"<Y00$@(KF&!M458 LH#@W&"/ 6Y-I@T@C@*P%N",P242
M<!1JD*H(#Q73B3%'EC,L/<[V$P-Q;+"#>]!Z&NC40I+1'NK60M.))4DHCG)"
M4M.3*5%D:922D,/"H-3J5@K$EC"&X3#;V &]Q7V4!SJ 4 H#V  1@PE@#<0Q
MB"  ;>R(0KV"$-O\M[WH"E&'4;@F4)L8+(_E2)NB3-,@R)%,4JB%*H!$ZDF(
MRI4?DUG9#5",D%U4))@SP)=<^Y)8 MQUPB%L#NI$%OJ%R%& XU8O0(RDQ%U*
MDQ8M2I2TR:P3!W4J!J#BPD)MP2,6^"O8&Y *^W8&^R@]QJDA1J).:K1E*'*Y
MMFP@Q6G+/<[D)[*S[-I(S F.%R4HK&CWFP]R5>P[[ ]V@/ %:,P\U*6M1&*R
M$X%9Z0M8F&J(2#-,3@5'I@&W/)2B4$C+L8(-@7, (.W=!O:P'' [LYB"SJ6\
MLXVFY9QUG4#LWC:[E)S!%*#;.(5-T5RTYH+A,%N]A8K7L+9>UZ Q$DFT.AS!
M+93*93'V*/0)@7RF:NK@ZHRDT5CK8W*79:\/H0FC.;D13:C-."(P%KF !?<6
M%?N4!!(IGO%4VRA+L/1J3%N$XA4%Q3DAV373F)VE;$\U7GWT>K(Z\GW CD2Q
MR!C-X&H2I;C/1ED $:$-C0U(I& +;"I2CL1<*M((*J][)A!5)[A4W"((!63B
ML9L/N$8K!ON-NP5[6OW;VJ@^:5P;%IB I(ZM2@QU*/4-@27-"==Q2I;A"K5H
M+%'C$M2([CMOQI5A@*V_;7M0%!3+5%BG'&GE[U/9%O-8%C&.,3W(WE%+H0\L
M>1$C;'WA2RN%OHZ5A#(SUUS4W""2"RQ&&H3"U%K;V,-ZD4!:4?G['(!R@ TK
M_%[Q7(+OC4X4[95$-+D$@9TZ!2-="QO8DX9;&70#A:R!P2;LE:,DX)>VY0J(
ML02<YU:4PC@*7=H3#3EIS5 %+HWIQIB5:JZ%*:H <H (@I4N#<@L0[6",^UR
MPWN.VYJ@R%[7M>]KVO:]KWM>U[;+VO;N7M>U^[:]KT!XH#\S_P#B'_?6DO\
MFV9?PV.Z^POE1Q7[^ND_X@^7?F2_Y-_O/^Q/S65]?GRZ* 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * _1I_A\L[2-+D3,>FIP7
MJ%4.>H>++\5;SC1F$,4I87=GC\I$@+$*X4Q,C:7M*8H"&U@B.0!'LW0A7O\
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M"@% * 4 H!0"@% * _2[_A^M-\F3.^5=5T@;5+?%W".#Q%C50J)&3:2*CWI
M\SM\;MW8._M30-D1MX3P[2S%1AX WO<D>SX^^:7O=1OD47<BE>U]:R;TJH1%
MCS:(Q626.W'.MO?#&C4:O]Y#Z?\ EW[M53)U7WMJ&JVE=*Z/)54_;]I'37)N
MM:K6LCB5UI/[JGZ=*^-SZF% * B+M[^,_:E_@PT!C: 4 H!0"@% * 4!DD'L
M&_GA_?5L9C(IU*:^=9V;8.ORCB[3S'&QE%@Z6]7X=FG-#G-0-DC84>J_5-$H
M:@AN-,='8_E;7.KN6/FEQ3OREP=&3@B9[+X#<Y22/<57 B&IGK2,@8W)UFQ#
M&T#P3(YQA73[FS-F))5%,V23(,4&##&7H+B"6Q_+9 L-L+1'I\SJ,CH7,ME9
MG"1IBU*12UN*M&>7OH['T V7G&N"1XLU+X"T[SN&X66K,NR['^+):7CO.TCF
M&2L9Y(R%CZ8S5J<'6 *L+,#*5C"ZV'#0IEKH^M+ZY)U92].U;P$9=%= $9SU
MK)D&"=3.08(S1239)<%C)U>T&B<+>\BL41Q@@ENK_4!G?##7)4ETN-GR5Q]<
MVN412GR%6<M=RES:4G+1($IZ<P2PJP!QY]KYFS-U=N:]6C9C*.1S+^,9YD7
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MDROLCU=_!/23S/\ -: ?%J;5O>;5%W_B3LHV<;@UE6\F5]D>KOX)Z2>9_FM
M/BU-JWO-JB[_ ,2=E&SC<&LJWDROLCU=_!/23S/\UH!\6IM6]YM47?\ B3LH
MV<;@UE6\F5]D^1_^'CP422<;;4EF>]RRQ#M:\6@&R][?8OL36IM6]YM47?\
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M$- .1FGP:C]Q#0#D9I\&H_<0T Y&:?!J/W$- .1FGP:C]Q#0#D9I\&H_<0T
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MQ#0#D9I\&H_<0T Y&:?!J/W$- .1FGP:C]Q#0#D9I\&H_<0T Y&:?!J/W$-
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M^0L,Y.5Y*QP)Z;,SM^(E<2A+XIC;".21T0EHE@7(T"8\!I8DXT^VUS*B.BL
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MMS;9:_V:V ^(1@':]P# .UA" *Y8PCL$8+[D8!7!>]@F %W!!OW;7[EZ ]J
M4!YW(MS86YON;WO:PME]S>]ME[VM?V+WM:]OT: 7M>VS;:]MU;;;;:]MMMM[
M;;?FVVVH#Q0'SL<1<82['I[FCN;8!5CRKFCNGN&RBP"[#N,5T]QVL9:UOX.]
M[;K9MM0'TH!0"@% * 4!(?ZL_P#'?ZVM?[S]-P>@GM:RB@% * 4 H!0"@% *
M 4 H!0$(E/OI+_-Q_A*V2_212,5L H!0&KNI#31;.[KAB>QC(CAB/,>GV6RN
M48NR$EB,?R$T%HLB09VQODF$3: 28U&V2^%3>).VY/("K0*TRU&D4D*0")N
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M[OX>G_"9]D=.K_OY_P"(_P"T//*9_+.8_.N0>4:=GW=_#T_X3/LCIU?]_/\
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M:^ M"U^).<C&/?D)8EKD-,IM8J0[I--4DRC,-/&$97FY-$4F89#C"(.N32H
M\,\@@YDS5-) WI;$WN/.+O'W%A=%'^U)QH5:I&$!VX)-,+"$5\DC#""[:H%
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MIB>DB31D66'T:.583QX_2J08T:9 H$GNO623&YLV=$K0[@.*7 0J=Z4"4B
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ME]:G:R93)$EDB7@EL:C4_4B03U$UKCFP4 H!0$(E/OI+_-Q_A*V2_212,5L
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M)-XW$E8E3 BAH"TPA+!A%;2P!7$<ZRK58_XP:<E.V4H@P2W'&'M(,SA6*TL
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M@V#81@Q#O8-O8#:XKWO8-MOL4!Z4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MFU)_Q!QMR^(4MH(+O#S:D_X@XVY?$*6T$%WAYM2?\0<;<OB%+:""[P\VI/\
MB#C;E\0I;007>'FU)_Q!QMR^(4MH(+O#S:D_X@XVY?$*6T$%WAYM2?\ $'&W
M+XA2V@@N\/-J3_B#C;E\0I;007>'FU)_Q!QMR^(4MH(+O#S:D_X@XVY?$*6T
M$%WAYM2?\0<;<OB%+:""[P\VI/\ B#C;E\0I;007>'FU)_Q!QMR^(4MH(+O#
MS:D_X@XVY?$*6T$%WAYM2?\ $'&W+XA2V@@N\/-J3_B#C;E\0I;007>'FU)_
MQ!QMR^(4MH(+O#S:D_X@XVY?$*6T$%WAYM2?\0<;<OB%+:""[P\VI/\ B#C;
ME\0I;007>'FU)_Q!QMR^(4MH(+O#S:D_X@XVY?$*6T$%WAYM2?\ $'&W+XA2
MV@@N\/-J3_B#C;E\0I;007>'FU)_Q!QMR^(4MH(+O'&/B,G/%86[8 [ [-G"
M7*_V;W^ V_-K%RHXN$^'F7)_;6#C#E\2K'V=\81YER?VU@XPY?$J>SOC"/,N
M3^VL'&'+XE3V=\81YER?VU@XPY?$J>SOC"/,N3^VL'&'+XE3V=\81YER?VU@
MXPY?$J>SOC"/,N3^VL'&'+XE3V=\81YER?VU@XPY?$J>SOC"<M'%90C-N984
M?,V@N#<W5.0?9N&^W;P&_L;*8-\83)\CRGVN/<=<_)]/9WQA'(\I]KCW'7/R
M?3V=\81R/*?:X]QUS\GT]G?&$<CRGVN/<=<_)]/9WQA'(\I]KCW'7/R?3V=\
M81R/*?:X]QUS\GT]G?&$<CRGVN/<=<_)]/9WQA'(\I]KCW'7/R?3V=\83YG,
M<I.)-*W$>#OH+@W7#'.^S;]G9P"VVF#?&$POF7)_;6#C#E\2I[.^,(\RY/[:
MP<8<OB5/9WQA'F7)_;6#C#E\2I[.^,(\RY/[:P<8<OB5/9WQA'F7)_;6#C#E
M\2I[.^,(\RY/[:P<8<OB5/9WQA'F7)_;6#C#E\2I[.^,(\RY/[:P<8<OB5/9
MWQA'F7)_;6#C#C\2I[.^,)G0LTIL$(=[CU]R$(=O#'/N[D-K;?Z/^SLI[.^,
M)YY'E/M<>XZY^3Z>SOC".1Y3[7'N.N?D^GL[XPCD>4^UQ[CKGY/I[.^,(Y'E
M/M<>XZY^3Z>SOC".1Y3[7'N.N?D^GL[XPCD>4^UQ[CKGY/I[.^,(Y'E/M<>X
MZY^3Z>SOC".1Y3[7'N.N?D^GL[XPF)51.4*CA'7%'P7%8-MS92Y7V;D-@^SP
M*WL[*>SOC"<?S+D_MK!QAR^)4]G?&$>9<G]M8.,.7Q*GL[XPCS+D_MK!QAR^
M)4]G?&$>9<G]M8.,.7Q*GL[XPCS+D_MK!QAR^)4]G?&$>9<G]M8.,.7Q*GL[
MXPCS+D_MK!QAR^)4]G?&$>9<G]M8.,.7Q*GL[XPG)(B<G(L*VZ8!;K9_[TY6
MV;-O^XW_ #:R:Y&C"??S:D_X@XVY?$*RMH2"[P\VI/\ B#C;E\0I;007>'FU
M)_Q!QMR^(4MH(+O#S:D_X@XVY?$*6T$%WAYM2?\ $'&W+XA2V@@N\/-J3_B#
MC;E\0I;007>'FU)_Q!QMR^(4MH(+O#S:D_X@XVY?$*6T$%WAYM2?\0<;<OB%
M+:""[P\VI/\ B#C;E\0I;007>'FU)_Q!QMR^(4MH(+O#S:D_X@XVY?$*6T$%
MWAYM2?\ $'&W+XA2V@@N\/-J3_B#C;E\0I;007>,YR.\\@< V-?*'"]]_CUG
M MZWS=;=]X-O^^[G[&XV;?LUA:]JT7##?.J/.76WMV%<P9$Q,;@=QD1D D9\
M>&^E9"1MA;K<E,E4\+ WCB2T:2PN$[-Q<TR]MSMV]VNPDW:Z=*;,1Z(BIN'P
MIXB?.Y1=P._-Z=RIG=N=5/NRK60LY*UDM)D&M=:1BTSU;^U""N7%C*J[;YJZ
M-SKZ4$/,BMO9+^.G N4\9]0N@^$ZCW@SJ@[;YJZ-SKZ4$/,BG9+^.G N4?4+
MH/A.H]X,ZH.V^:NC<Z^E!#S(IV2_CIP+E'U"Z#X3J/>#.J#MOFKHW.OI00\R
M*=DOXZ<"Y1]0N@^$ZCW@SJ@[;YJZ-SKZ4$/,BG9+^.G N4?4+H/A.H]X,ZH.
MV^:NC<Z^E!#S(IV2_CIP+E'U"Z#X3J/>#.J#MOFKHW.OI00\R*=DOXZ<"Y1]
M0N@^$ZCW@SJ@[;YJZ-SKZ4$/,BG9+^.G N4?4+H/A.H]X,ZH.V^:NC<Z^E!#
MS(IV2_CIP+E'U"Z#X3J/>#.J#MOFKHW.OI00\R*=DOXZ<"Y1]0N@^$ZCW@SJ
M@[;YJZ-SKZ4$/,BG9+^.G N4?4+H/A.H]X,ZH.V^:NC<Z^E!#S(IV2_CIP+E
M'U"Z#X3J/>#.J#MOFKHW.OI00\R*=DOXZ<"Y1]0N@^$ZCW@SJ@[;YJZ-SKZ4
M$/,BG9+^.G N4?4+H/A.H]X,ZH.V^:NC<Z^E!#S(IV2_CIP+E'U"Z#X3J/>#
M.J#MOFKHW.OI00\R*=DOXZ<"Y1]0N@^$ZCW@SJ@[;YJZ-SKZ4$/,BG9+^.G
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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ME'S\GW..G3ZOC^I,@V/_ )>=0NTRMZP.S1T6_5$H^?D^YQTZ?5\?U)D&Q_\
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MS&'R9G/X4T2.*RAJ2/D>?FM3L#O[>[M"XE02*]K7N69;;:U^Y60)#0"@% *
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MTX9K^N/*WI$F'EBG,R>(W@0>9GB5\17][PJ\\/IPS7]<>5O2),/+%.9D\1O
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M;<BS&P_9Q(JK%8(9)>]5-=)93RY5J;2I.6V]6HF%$LHJ-6./&L#,WZU)MCT
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M(Y6QH7M"I2+6%Y?4:MC<TBX!Z PTTI8-(,%U*9,=<9 ,DP@V&H!0"@% * 4
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MP-F(WH=U<:(M;>V53>YB2Q0^[5@@,"NTQZ<'.2Q69..!L1KI7!I(^3*'2!5
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M8\9<!.+?B<S(K\JU/Q.=2S <A2/"+*BC&B".3D.-WEO5#6OJ90Q.;>H*7E%
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M%!B& 'Z9$@UAB-$:X)R4;B:B1FN*-.HX8G1N!B8H:Y&G5_\ O9"54(98#?\
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M>@/G0"@% * 4 H!0"@% 2'^K/_'?ZVM?[S]-P>@GM:RB@% * 4 H!0"@% *
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MYX%$HO"RF?&&(H0"T5QY'1M423J5A1!BA0Y.QZE:I.,-.V!J) &UE4"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0&+7?Q@/VG[Z]:WXPAP:UE% * 4 H!0"@%
M 9AE]]#_ )$7[H% 2B@% * 4 H!0"@% <9;[S5?R _\ -0$(H!0"@% * 4 H
M!0"@)\#]87_)E_N T![4 H!0"@% * 4 H"(NWOXS]J7^##0&-H!0"@% * 4
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M\;+!V7W7)EN[MO?PG6#EB4XW)+_\G7;]%L\I5B!R2_\ R==OT6SRE0#DE_\
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M3CU]RV>4Z6D WAX^3CU]RV>4Z6D WAX^3CU]RV>4Z6D WAX^3CU]RV>4Z6D
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M,DM[NZP@Y0M5(2&M;9^;V%68"R4\\15B;V-L7<0;" L>@% * 4 H!0"@% *
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M?)"DD\3#BYD9W(ITU03+,;6KR"N;,<N^3,%1%V12AH6#=EDE,%9N&->HO:X
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MS?,N5&34/DB4.+LI3NDKC9#8U.K4%L'<L&]D)DH'>]0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!UZ]
M87^1V+__ -O3^T /_P"X7^1WO&_]E_\ _P! _,_[B@-_F[^CT/O/WFF_H[^C
M_P")![Q_W/VK_L;* YE :QZQ_P#IRR/_ -,7O)J_ZQ_^G+^G6S^T?_<O@O\
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MZ*2_D'_Y1\'_ .Z[B@)U0%=8G_(1J_LZ]^R3^R?\A/RG>?Z*_P!]\)?C3A%
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g790774g14v41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g14v41.jpg
M_]C_X0MZ17AI9@  34T *@    @ # $   ,    !!V(   $!  ,    ! JL
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   ?    M $R  (    4    TX=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P
M,C0Z,#@Z,S @,34Z,#@Z,C8    $D   !P    0P,C,QH $  P    '__P
MH ( !     $   ,@H , !     $   $A          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MK_T/K+V9)(\R2"*JU#$ ;LO_T/1L[,NISL"BLMV9#WBUI&NT-T<UT_FV;/\
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MT59224I))))2DDDDE/\ _]G_[1,,4&AO=&]S:&]P(#,N,  X0DE-! 0
M !(< @   @  ' (%  9G,31V-#$X0DE-!"4      !##CNX4QR*$^@,N(MWO
MN>0I.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! !+     $  0$L     0 !.$))300F       .
M             #^    X0DE-! T       0    >.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M           !(0   R     & &< ,0 T '8 -  Q     0
M           !              ,@   !(0                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !(0    !29VAT;&]N9P   R     &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   2$     4F=H=&QO;F<   ,@     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    !.$))300,      H0     0
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M^'.P*27.'2>JL!)VUBNQVT3HX/=7[OT?[_\ A?\ P2-N"=31TCJ)+@X1;7<
MTD>Q]?IUN<[8[_!V[]_^D7N:27W@]OQ5[0? ?V9U;_N#E_\ L/=_Z36Q]4OJ
MUG=2Z_BU9>+?5AT.^T9+KJGL:YM9#F4_IF-:_P!:[TV/K_T/K+V9)(\R2"*J
MU#$ ;LO_T/1L[,NISL"BLMV9#WBUI&NT-T<UT_FV;/\ 7^<AT^Q_V_+K+CZ<
MS6WL'!]OK?\ GVA0ZKM_:G20X,(-MFTN:20X5DM]-P/L=MWIL5VW)MN[#,LJ
M<?Y-C*P/_!VTIT=;'@MET\VR;+!U<,+CZ3J/H]M^XEO_ (&VQ/D66,ZCB .(
MJ>VUMC>TGTW5N_Z.W^VA9!C,=?VH=0#\'>K4_P#S&9.]+/W>K8\?]IZF6QX[
M;/5V_P!MN/M3P-1_=K[?_1EI.A\[^S_T5+GVV5W8182&F^+ .[7,MK$_]>LJ
M<FZI;9536]CBTBZLN(_<:?5O'_;++$V>QUSVUU07NIM<P_RAZ8K=_GO3Y!KR
MF89YKO<3'\E]-W_DD!7I/:[4;]0[TRZJZYF!:Z@D6C;LCQW-AO\ :^BK37->
MT/:9:X @^(*H^JZW!Q]^MALJ;9_7KL;ZO_3J>C8'MQA2>:'.JCO##MKG^M5Z
M;T"*CY2*0?5Y@-E))),7J617EWY+,L6D.;3G55U$"/8+*/;R?HOWK76%AQ_E
M$[6M=^TJPXM!!/Z3'VN?_*VI*=:[(>VUM%-?J6D;C)VM:WB7OA[O?^9[$V_J
M'^AI_P"W7?\ O.FQO?D9-O\ *;4T_P E@W?^?;;E93C0TI:+.MM?U,__ $%7
MRM=_&@)O6S!SC _"P?\ ?FM5E)"QV'XIH]S^#7^T9/?%?\G5_P 7M2^U7#4X
MMP'<S6?^INW*PDE8[#\54>Y85V-L8'M#@#V<TM.FGT7AKE-))!+_ /_1]%ZC
M1D69W3[*FES*K'&V(B"V!O\ [7O_ *[/])Z2'A5&_'SV-.USLJW8[]US2WTW
M_P!BQFY:BS\-UF*+F/HM+G7VV2T @A[W/800[]Q$&K01=+X;J\ZO+WC:+7>E
M8R=6GTJVVUG^6Q[GM2P+779%WJ0;:ZZJKQX6--Q?[?W7M>RVO_@K&(PRXDC'
MN$ZGV#_R27VN"2,>Z3R=@_\ )(F6^F]5X($=M=KOQ:^'+<IF,X^_$J>R._IN
M=7]FL_E;ZZ?I?Z6NY-3^CS:\,F/1-MM8[FMT;2T?NU.N=1_89_I%8&:PN,4V
M;AH[1LC\Z'>]/]KUG[/=(T!V#O\ VD>/?3<?BK@VUZ_@UG_HL^O&.C;KO7J\
M_P!'9ZS&_P!6UOK?]?5@'T,X@Z,RQ+?^-8(</ZUE#6[?_"]B?[7_ -U[M./:
M/_))',\<>XQK] ?^20,KZ=**A'\[;*28&0#Q/8ITU<I8]=-](S77-+6OSJK*
MW._<]2CZ/\C\[_U)ZBV%3ZM3=?@OJI!<]SF:" =H>PV[=Q:W=Z>](**3 !^R
M5N=HZP&UP\#83<YO^<]6%7^TV#08ML?];_\ 2J7VJW_N+=_X'_Z51)LD]T 4
M .S8256S.-3#9;196QO+G&L ?,W*-?4F6G;54ZQPG1CZG'31VC;OS4$MQ)5_
MM5O_ '%N_P# _P#TJE]JM_[BW?\ @?\ Z524V$D*JY]A(=2^J!,OVP?\Q[T5
M)3__TO55#UJ0_87MW@@%LB9.H$*:YGJO_+#_ /D;Z5/]*_I7YOT_^$_[B)*>
MA;E8KWEC+JW/;.YH<"1MT?(G\S\Y2]:G]]OCR..%S&1]++_Y$^C=]+G^;N_I
M/\G_ +E?\%ZR%=]"G_Q/_0/\YQ_.V_S'_!_^[/K)*=S*Z3T#-L?9DU4W/O\
MI.+N8 '[W[K?S5?%U,:/; TY'9<8WZ63_P")_EO\Y]'BOZ'_  '_ *.5E_\
M,,_Y!_GLCZ?\W^;_ #?_  __ '-24]7ZM?&]O$\CC_5R8WT@%QL: W5Q)$ >
M:Y-_\Q?_ ,A?T:KC^IA?2_[J?]Q?_:>@U_S+/_$[W^EQ]-WT4E/9BZDF ]I.
MXMT(^D.6?UE-<F/^6<7_ )(_I%O\W_._SG_MS_[N+K$E*22224I))))3"VJJ
MZMU5K0^MWTFN$@H./T[ Q;#;C8U5-A;L+JV-:2T&=OM'T59224I))))2DDDD
ME/\ _]DX0DE-!"$      %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\
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MQ &B    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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MO+49K,U%3-))/4U#Y;(ZZBIGD::IJ' JK!YYW9C;BYX]O]-]>^^R/_.UR_\
MY]LE_P#57OW7NO??9'_G:Y?_ ,^V2_\ JKW[KW7OOLC_ ,[7+_\ GVR7_P!5
M>_=>Z]]]D?\ G:Y?_P ^V2_^JO?NO=>^^R/_ #M<O_Y]LE_]5>_=>Z]]]D?^
M=KE__/MDO_JKW[KW7OOLC_SM<O\ ^?;)?_57OW7NO??9'_G:Y?\ \^V2_P#J
MKW[KW7OOLC_SM<O_ .?;)?\ U5[]U[KWWV1_YVN7_P#/MDO_ *J]^Z]U[[[(
M_P#.UR__ )]LE_\ 57OW7NO??9'_ )VN7_\ /MDO_JKW[KW7OOLC_P [7+_^
M?;)?_57OW7NO??9'_G:Y?_S[9+_ZJ]^Z]U[[[(_\[7+_ /GVR7_U5[]U[KWW
MV1_YVN7_ //MDO\ ZJ]^Z]U[[[(_\[7+_P#GVR7_ -5>_=>Z]]]D?^=KE_\
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M+?\ Y1X_]X7_ #=>\23_ 'Z_^]'_ #]>_O1O#_GN-^_^AUN[_P"O7OW@6_\
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MW?\ UZ]^\"W_ .4>/_>%_P W7O$D_P!^O_O1_P _7O[T;P_Y[C?O_H=;N_\
MKU[]X%O_ ,H\?^\+_FZ]XDG^_7_WH_Y^O?WHWA_SW&_?_0ZW=_\ 7KW[P+?_
M )1X_P#>%_S=>\23_?K_ .]'_/U[^]&\/^>XW[_Z'6[O_KU[]X%O_P H\?\
MO"_YNO>))_OU_P#>C_GZ]_>C>'_/<;]_]#K=W_UZ]^\"W_Y1X_\ >%_S=>\2
M3_?K_P"]'_/U[^]&\/\ GN-^_P#H=;N_^O7OW@6__*/'_O"_YNO>))_OU_\
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M_O1_S]>_O1O#_GN-^_\ H=;N_P#KU[]X%O\ \H\?^\+_ )NO>))_OU_]Z/\
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M3-9+9^P]M?Z0:?9NU:"@[8J-Q[DR=?0IF-C4-#4U..VFE6FU*;)T=!4-3Q3
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MSXS9\.:Q69S.(VYLO+460R.X\X,)5Y"@Q-+55,OV].LDPDE87TZ0=.\%@0>
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M=*"I '2)HWW:RN+7:3_C4=V691\7P*OB4'E4,M1PKF@)/1KOF#V'L#?77_\
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M<33312233(T?<H\NS[KRSM\6Y[K/^YC/(QM!'&JDI<.P#2Z?%*EAJ(KFM!0
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MP="M1FX 'XC@5Z)Q!?;QLT!LRD4IED! ?2" L0H/4&FHU[1YD8Z/%WS4;?\
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MB+Z'KVEO4=>_X;W[3_Y[_8'_ )P[B_Z]>_>(OH>O:6]1U[_AO?M/_GO]@?\
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M_P#H-=M?_47OW^O'L/\ T:+S_>H_\_7OZ@[C_P IT/[&_P W7O\ H$_^;/\
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MY_O4?^?KW]0=Q_Y3H?V-_FZ]_P! G_S9_P"\J/BS_P"@UVU_]1>_?Z\>P_\
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M;/\ WE1\6?\ T&NVO_J+W[_7CV'_ *-%Y_O4?^?KW]0=Q_Y3H?V-_FZ]_P!
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M05RT?_">#XR1L;'(_!#X08M.1RU9LOII-/*M?4JD6X/^(]RM[(QF3W/Y8(_
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MV9"?Y#I5_P KO>*;Q^#W29-0U15[3QV?V'D'9BS+/M#<V7Q-,A)_IBXJ<BW
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M[/E-T/@)8#?_ "FFFS]9554!7Z.CQ4MF4_4'W./L$&3F[>[M>,&QWK@^A"
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M>E[WZ;G5T+KXNSME.2@-BVD9O4 #_A[1/R?S9&2'Y7W$?;;3?] =+4YMY5D
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MS?MC(:MR;:5KY:Q_@<=,=3_*B_E^U(LOQRVW1^EUO0[AWQ3&[?1_3N<^N/\
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M64?[,$=-#V$Y)7^ROMV3[+R3]N0>NG_E$='Q _PGO;Y?88@C1]GWQDB(U/\
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M]3/_ )ND7\-@W57SZ_F!=$RHD%#N[,;+^1.V(%(2%:3=M(8,^*6,$J1_$,M
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MF48_\A&MO_L?9G[M7 NO<OG68&H.X2#_ 'DZ?\G1;[56YM?;GDV$BA^AC/\
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M;^JI/YOK&L^/O4>V8_5-NOY5=&X@0_\ ':$9?)54R_XV,"?CW.GL!^GS9O\
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M/"YHYBW!AVVVQ7C_ &'2H'^$]0E[['Q>6N7]O7X[C>[1*>H#,3_@'5K8
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M>\6Q/CVMQ'*OS*,&I^=*'Y'HMWG;(-ZVG<]IN0/ N8'B/V.I6OY5J/F.J_\
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MF%_EG?RYML(][E&3H79D\L7]NWJIKVNOTY7W./-%(?8KVJA\Y+N]D_XT0/\
M#\_MZA7EFLOO=[H2^4=I9Q_\9!_R?['6QO[@[J:NO>_=>ZKW_F;])Y7N'XK;
MIRNT(Y!V5TODL9W7UW5TL:FOBS>PW?(9"EI)>)D:MP)J0$0WDF2,6) M+'LO
MS)!R_P \V,&X$?N;<4:SN ?A*3]JDCAA].3P!/SZBSWBY=GW_DJ]FL ?WOM[
MK=P$?%KA[F /'*:L#B0.C&_%_N[$?(SH/J[N3$20L-Z;5H*S+TT10?PW<M*I
MQ^YL6\:,QB-!G:6>-5:Q,85K68>PASKRU<<H<U;WR[< _P"+3L$)_%&>Z-O]
MLA4GYU'ET+.3>8X.;.6-FY@@84N(%+ ?AD';(ORHX8?90^?1'?GDR97Y@?RP
M]L@DR1]Z[UW8Z!OK'M_;6*G1](^NA@WN2_:X&#V_]Z;WR.UPQ?\ .21A_FZC
MGW,(GY\]G+/S_>4TO^\1J>K7?<%]3;U[W[KW73 ,I5@&5@592-093P00>""/
M?A4&HX]>I7!X=5 _!Z4_&;Y<?*;X2Y1GH]JYW--\B^@HIY2*>3:N["B[KP./
MUQKYY,34F%2JFR_9SM;\C(#W,4<Y\@\D>Y4(U7T4?T%\0,B6+^R=O0,*G/\
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M ,[T=50/LJCS+_S'&^7\ORQ3;\+T<'=-'O7'I\76Q/\ ?Q%7>:3 ;6_@8K1
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MO+W[KW7O^'3\S_WK!_FO_P#I,>PO_MY>_=>Z]_PZ?F?^]8/\U_\ ])CV%_\
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6]U[KWOW7NO>_=>Z][]U[KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g790774g40a82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g40a82.jpg
M_]C_X1&317AI9@  34T *@    @ # $   ,    !.6@   $!  ,    !%A\
M  $"  ,    $    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q  (
M   >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @ "  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#(T.C U.C$P(#$P.C$U.C,S   $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,"H , !     $   $I          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M.2P64Y=M%#V$D:674U[FN;^=7N]1J+T?(M#;.FY/]*P-K"X"!92[=]DRF?\
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MG__9_^T9'E!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @   #A"24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ $L     0 ! 2P    !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      ST    &              $I   # @
M  0 4  Q #, -P    $                          0             #
M @   2D                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   2D     4F=H=&QO;F<   ,"    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   # @    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M   $     3A"24T$#      0*0    $   "@    /@   >   '1    0#0 8
M  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(
M# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,
M# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ /@"@ P$B
M  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*
M"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4#
M##,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q
M8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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MVCZ?^%K_ )Q6?JQ7A8QS<7"'Z!]HSJ3+G;F98WETV>_^ETY=>S_@_P!];8
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M&[7[/MV;H'^B]N[:DI__V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P ( 0$  0$
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M(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ A061O8F4
M9$     " P 0 P($"                /_; (0  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,#
M P,# P$! 0$! 0$! 0$! @(! @(# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,#_\( % @!*0,"! $1  (1 0,1 001
M /_$ 1@  0 " @,! 0$!           ("08'! 4* P(!"P$!  (# 0$
M          4& @,$ 0<0   & @$# @('" (" P #  ,$!08'" $""0 0(#!
M$Q01$C05-A@X4"$D-187-PHQ(V E(B<H,R89$0 !!0$  0($ @8#" P*!@L#
M 0($!08'"!$2 "$3%" 5$# Q(A8)0$$C43)VEK87=SAA0K,D=-1UM3;6M[A0
M<8'2E"4WE]>8D5)B,T/3)AA@H;%R<R?P-#D2  ("  4!!0,( PP)! (# 0$"
M$0, (3$2!$%182(3!1!Q@2 P0)&A,D(4L2-SP>%28G*"LL(SLS054/#1DM)#
M)#4&\:)3DV"#1!8V)?_:  X$ 0$"$0,1!     #_ #_SW\
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M,NIX&6/+KUEHB9<3.^/D.                  $OTCK^(".V
M         !W++C],QY     !WF.74]'ECVP;RY>K5&GNCGV5UV6/-
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MQ 1VP   E]'2,;^VQRZZ%<G&2AD!R=>GLQU[<:T)U\>W-C:-^%Z#Z^3;P
M        $N$A@,1T?GP                 $O4A@$0D?GX    ;=Y^C7&I>
MCGV+^#]             '<8Y=9U>6/8=ACEPNKRQ["7Z1U_$!';   #UM_/O
MH/G4W=R]>J_%M]+^9^G\               EPD,!B.C\^
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MPE=L=;'P]\^V<:MN*TVV.MV8SGSD\ KU1.V0    _1_/R?W:NC?K_56_1L
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M  /J?.[NL6BJ^C^SU>U0+9("P5X^X;Y=]1\J7^8K]P^'>[L
MEPD,!B.C\^    [W'/J;EZW9*RJ2[-6+2Y7<'?'K?7)UZDK7FH6<
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M^SU>U3]>>_GX^^?4 F/'24:-O<W1KBMJ:A9O            2X2& Q'1^?
M '(\]^-X-8M%5=&UHJUK0!LW1OP2[FLV>K#S\VVHW%         $O4A@$0D?
MGX  >KFA7[SW>4:^T'T(@ !LW1OP3W_?)?KGCX\"OUCY)Z^=/=//LD
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M?GX 'JMH5]\^\1)&/D=0;;*E;T   !Z=*1>*(MA:=V&^6N]42_7'<\.Z
M    N^K%HJNK=FH6;4F^'NT5.6,E(HP&E8F7M=$S#39GJE=75_(G:H!:O S]
M?<*Y.,E!.*+E(J5-3]?L/RW7LQW;G/OUS';LY-T!]O'S_P!)_P"+?:_#YX=?
MJ/RWU85R3,--<      +?Z]8JW8@2,=)"'\A'22_I_/X?W^G\END,"B.C\^
M  +T*M:JGZ0[/5[4?6Y\_P#H/G3H1M=3MW@5+1,NI2</;H*)W?PR'O7JUJJ9
MHHM-5MF      N_K%HJKA/)QDI(,2D5+ )>I# (A(_/P /3K2+Q1%HGJY=LT
M 6VHW"  6[\UBU_5KT0.<2NUR'0RUB9"(?HTX;KI'PFVCY1:;UON/[
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M.>@)%ONX-^Q9[N#?P $N$A@,1T?GP!]_/?E[F:9]3I-K[LD3:-Y8Y"@[Q
M #*M>S'[,X6:@M-F,E8P506R N!M1YY_!]K8]'!CKGQ=O"C;%Y+7%OA<Q"W.
MOV&N:-W;Q;M@[)Q<K+^:E;:?;NZU:*O8 RL1+K"-VK+JFKA 75XQ[K^\#-T3
ME0      67PDW!GVO_,_IWEP_P W'[/\6]NH6U5^P5V2&Y.S3,D>+LTAC6>/
M>Y#CGT^M-VC.?.;<:;=4     !+](Z_SN)VZ!])],NE'M:$U"SHKQF(>9M><
MO#S+      ^I^/690/H'G>Y?GO'ICLE:LYL2AYF%T6._@W_2I9:S:*
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M-LOJLL>PX?OG)"7J0P"(2/S\           "0')UZ>DCQ=VD:[IB&F>
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MFSKL-:^QS)LZ_#6OL,U;>MPIJ[+-&SKL18<_)&?#XKS]\!C]>N>?8
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MF7"Z;/#LL#V:LOY1Q\^T[L/K;F8:;U:\U"3A
M              S#7LQO</-TZUZ7/'L_X\_NX.?IUOI7IYMH;KY>G5L*9.,E
M'_#^@                '9>9<+K?<>:':8Y<#J\L>>
M                                                      !__]H
M" $"  $% /<%U(@;%ZVWTTZUVUWQU_QT&)H,'VTWU$UW,%PQ/C@9U^>)?4\=
MU)/#,]M-]!->WTX^GMD4/&VVVNFH9DN+U\T6^N$8 '\=M]=.L9QG'6!@LY\
M]]1=-A0]1.V,XVQL*'IO^S5%..'1!F^JB I;<6,G?N)5Z$3C?RP10R"(6*FA
M2^F@@9S0J<USDB-L+]V'/KA%!]31M-."BC)HVW1HJH&NBVFP9?LHE#!P$DE*
M!4R81E'HDDJ!4R9R-@O]WG0 ,%C HN21DJ%LFF_IV3S(@)HB<QCY YIT*3$$
M3MDPS\+!8T7-HY(T6$[9_?CX0G0H(GTA@B8UU#WQME..ZF@$XQMJ.3-[$!"B
MCON*'H">#*G0\$"9H,?8F/\ 4"('L;%4PUH &0,9PFZ#!E/_  ?;?33N,=*E
M]M=L;Z^S,+9,L9#5"N=!#A0+)I4+%C!Q3!)B:*(.3 ITF"'\X4^+J?);= C!
M& _?*8@@JDF&MC*BFB* IHR9,BC^]6=<[;@_-?23-;!A Y.8+#Y-[&/9GDM1
M%4,IQX$SLB* 17*:=P;429WYX9+4MP,)R@&*(FGMS6R4H[ )1;8L![M15226
M$FJY%5TZ-$"9W.Z6G""A A :F"),WO\ MD8V5+[>VVWTT[:[:[>@\R1C8=F@
M[94_V\(FJBL::0HHJ-[5<W+;!#ZZ@G$SY7Y_S=FV?NE=)BE<E#0)TM^TM!0A
M-O15U+1*)(XB\4Z;!@0D-[7;77;KZNN,ZZZZ^@N?2,J?\]%,Y;ZO[/8^H; 8
M/&C.<JIPP"'O@4/TPS187?UML?3JF%=PSWH&3Y(GDKH(OJ20FZ)1%PIXI@ -
M<7#@! X$H$_>[_Q#MZ5DT)5(H*B*=+^R#3MP=?N<'305'+[XQC&,>AMG.-1S
MALV.,IN T@E<BAF?<+V!L++-,'Q!.A/_ .,FOJ!,@V?J_<7O4C_O7>RV *GF
MBBREGA?? ))!57]=---%8H51CGN%#!U;5FSL7^3[.!N$]2J.I$E$K[S.?HPU
M?I$)=G.$9%1B&@Q@[[W??4/1JZ;;)W2H2U44]O'=CR3[?4VH:.)(3<IA?MMK
MKOJV"QD@L^SSMKKUG?3&^@P(F_DICX+)S= R70^[B ^3T#$T%#]XY3.Q5$3R
MVI,CV3O_ %Z_[;;;&FK6) B%O!:'RB*X P9D#V2UN#H( *.&HIN \C^3L$^H
MA@AX!![C!:#A-D40('WB_P#Q1[NX]<E1 Q Q=?:KQC)9'9P8FB1X.$ED\DMU
M?3R9#W;B_P"X?Q5/_5K?O ?XQU]WJ*8T!:8@X:Q[5T?2.$7+@% ? _KG<CHN
MIVK:3-?J)WNC?_>ZO^.L9QG'=6(:J:<@']E!+]UG.,8:V,C ]S!8N;"1@ DU
M<]JY-MS2]XF0-31<T@J)(8F7U*%?=)__ 'N9:QJ=6DH/1/7? '_U3D]TX7'\
MH(U#A<=*[ *:<9&Z6/X-9]JF!!G7!Y.(IL<2"*V*.>]<PHG?CDAQ3!?T6S]
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M;XWU\U<,;XJ/\/Y'I:/' -L*I]&,J"L8$%+K1A/-'58V*::X6Y$X*/G78/\
M[]_16OX-6Z=>^VJ>."D$53P'!VVV "VT]9S+P9G"4;**!7SST0/:(A-LGP"Q
M;I9;@"L)H4,-(0$8(P%YK>^^O22'J&4]%:SHI.8BG")"MH%KKC_CRW#TWZ3P
M5,L>#=0(0:8.9,IN,YUSC/TX\577.3229"W"Z.;A:[?]>11?J:F#IE,*] @
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M<)853A%0*X(Y%P;&(#+8H(9@+?7.F_BD[8U*JQ88,7IKY_\ FHBA $D84J*
M,5-'0@4_71/4=$TLG%G$4#PK*>%$7T6\<P26%4GD@HZ;[A;FU52/ZI*)A6+G
MT+Y4H6+&#@IP@<(" %QS(@P Q<3TAOY9TG)II4,;'R"< [=QMUCT2"F=3=P
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M["+!\07YTU\(-8/AB^\QMMC7MMMMOM_Y;__:  @! 0 !!0#VX88@HDN4SMC
M;)Z26^O+P:RAK3=/=!!"#"O%GN>/G7V=337F2LH$2RHZVAO%4G!JN:OV4PY=
MM=M-O!NTKMP[H4[.)LN-H*W;":H[)W8O'CR,H",BK#C5W3#,OL83:"9LT;3\
MB65(LV\(LA&79N4W$W' T%SHU'K^(EO!W-->8KF3&.[EEI=E!.4$DXBL5WN-
MN>^4H_=J0Q_6I[<>N=<6#&O++1=L2+=OF!X[B5;_ /\ U)HUTU;C5Z-S8][
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M(S:9R1W$U;O:T?\ U!>;7;BJ\7-SSN1+2[B]49LBI5$MYRY5N3*P7Y]A>_\
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M@]J70]=;'3AJS&ER%6K:KUSG.V?=@+*N52^RTMK3D4__ "W_V@ ( 00  04
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M^+VZ<@VL9?HWS2'N6>%7E)2S7BH4QO91=RX=5R!&*\[[,3P,(Z18GEE!!!+
M]UE3(I2>&VU_?4)EJ)=-^6,ZC&&RUD!NU]Y*82F [3"S<C2ZP$YVKA(Z<>Z
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M,5XA&O"/Z,V$W8=M1 ,;2OHN"AY%"3HV/@N/^B#W7]$'NEJ/U#0R P1RP/\
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MLZ#3&5+UT;F@;@76:2K%3N.;/F,_XQB3A$NI5&!, 993D2)8*3J0&(!Z]/\
M\(7>X&XP),2>P=I[O:Z77 .M1L(S)V*0"T &0"1IGA64^$B1]$MX]JV@5L@=
MPA**7C;N8:3($Q G/'+LO<55U7&LER "0 9&?6<AKEBE;.36IL^Y+ ;OY.>?
M33M':,<?B[PW(LL5-H(W+N!(8B9C+[1BNCR;;>0REME:[F"C(L= !)@9R3D
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M=(Q51PN562*/,-A0PQW%0FR04S5M^>X$ :SBWE<8HE=/&2UE(W;RZ%RNZ1M
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MP])$DQ&>)X*[:ZX0K$;8 ( '9!R/TV3ICF<QAXK^5:T]HW0/T>WE+Q@2WA+
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MB7^:9((Z_0+[%Y/!L8MFEHK5@>H#J)_WU8]IQ6R\<5)H%!5ECH5*$J5/33O
MQ6MEBJS&%!(!)[!VGN&+8N7]7][,>'*?%V99Y],"WCVJ]?:I!'V?*Y%Y/W$9
MOJ!.. 2/$ZES[V8G]W'&Y[[C?4K!<\O%J8[8R_U$8XG(LJ#>D-X;&$[JV)\+
M'^)T.4_8"KHP*$2",P0="#V>T@C+'J'IES,_$2]C6R#<%5LV4Y@^%I&0/7%=
M]+AJ7 ((T(.A^<:GB\>G:L>*VS;,]%50S9=K1W ZX8\CCBNP&,F#HW>K"#'0
M@@$'IU^<0?@XG%G^=8?^'V/QK.02RF&8*S*I[&8"!W]G7'&;D5BVI6%BYF"8
MR.1AAGH9!QR?4/3>%2>4D,?" 2H/C (@SMG%'*I::K%##W$3AD82I$'W'',]
M,<_K.)R'3^:3N7["?F[FJX'-3DR)LI  ;(=K;6'3Q*=(P'Y+,6),;D".!I#
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M*#G% 6KF&!CQ".L=TY>T0888W!P&&F"+$(?[#@B(;Y=/$IOK3G-8F^4)E<_
M7"[0["=@8@]FHP$K0*@Z#(=OS/\ Y;ZP6\(N8*?V:[0/K..!7>[-<4W,223+
M>+4YY3'RK_R>W\UM.V=-W2<5\@KMO!*V+_!=<F'UYCN/MX?K_'4FSC&+ /Q4
ML8;_ '=1V9G"6UM-; $'M!$@_5\TG)YM[47/EN1W1GCH0A\4#J08$"<;_3LZ
M68DMXB689$L6\1.42?AE\TU_*N6ND=28'N[SW#/'KWJ*V!MUBHG;Y:KD8U 8
MZ2.G;.+^:E0'*M"AFSDA=!V".Z)Z^R"PG$G3&T-GB6,# 5E5P"#!$P1H8/4'
M0X)K<, 2#!!@C49=1U'3'HGJXR5+?*<_Q+,A]3?-4[[;:^0:V"E-A-GCKBH!
MP069MI$00 23$X6%<6;WW[B"V_>=Y)4!3+3!4 1H!I\OT/TD3MMOWM_)3_U)
M^'M(4P!@VN98?4/E\KB.,K*V7XD9?4<\ 5AFOK 2U1]XBI@' [RHGOQZ75Z0
MU:\U;Z]I V&L2)WM C+(R3)S[_DJRYQTPKV @'_7/Y?(+^NM0SLC,@>H0RA=
MK0RE@?"IUZ#'%O5W8,NK%2QS(DE0%SUR$>Q#=8%W,%$]6.@ U)]W23H#A.+;
MR%%[1 ]^0GH).0DB3D)^39:WW54GZA.*UY-0>KD.]A!$@[G)$_4,  9?+YO,
MH#"V\@N)\,CJ!T)ZGK[;*K%FM@01V@B"/JQS/0.0Q-G&,UD_BI8RI_FGPGX#
MYI-E=RVUL0#792I*LH))\PGPDY1 ,K.D'">:;"\G[[(S:G4U^#W1F!KG\UP+
M@">*I8&-%8Q!/O$@'H<NN';A$[[5-,CML@ 2/Q#4=1KCCT-:3L0+),DP(DSF
M9QNW",$G7 S\,:=<!0/%A2[2)^K"L3X<>H<$*?R?)'GH1H&TL'8),'ZNW'-X
MH^^R$K_*&:Q\0,<+E'^T* -_*7)I^(/S/&2KS6HAB5I9%MG(!I<CP $@[2#)
M$R,5_F7FT%AF5+ !C <KX2X&3D9;@?EV.C35P^.5RS'F.V8]X (/L+-I@NQ"
MDG3&T?,>M^G'^SL*WIT'BR<#^<!B_CW<9#78/%  )[Y&<C4'H<?E>7RQ<$8A
M&B#Y?X0QZD=O9&&\FY'C6"#'OCY!5AD<&L^(=/W\$1##Y/+JY1JIN+H4=J/,
M+5[1N@[2&;=*P?NB,CECBFZK99MTVA<NAVC[I(@E?PDQT]AO479<<BHUC=%N
MXD@B#&X!!)A2 P)&/4^-9Q6/+Y/E$,H)2=B*TMHNQE8YD91MDGV#V^IW#44L
M/][P_NXX](D5<#A5H<\O,L$M/PZ=ON^8OXY=E#H5D&")$2,?Y?ZQ8WYNAS6S
MA6=2!DKLP!B1K.<B<);6X:M@"",P0="/92>)-?*IJ@N-2'SVP9$ "=-3W8Y/
M%YA#75@,&@"5,B"!E((U S![1G\Q5<U50M<P6/%/(+0,@=N:QT)UT&%!I" .
MT17Y((W&&%>JSKGF=>OS7#],K/ZSEWJG\T'<_P!0&*D%%9%32H@>%HU'88/O
MSPTX+LL]F-Q03\@K C#5@G8.F"'DK]<8Y%7'L+5/<U@!'W=QG:(Z=<^N PZ_
M,<:[C+:+PK#<CU*0IVDJ1:"&!(!R$@C7/"; P.]]VYE=M^]MY9E\)):2=N70
M>SA<'TY5_.\AB S"515$LY'=( ]^*D];YB7>G6@Q<$*E&&>U@)R(TZ_;C@<+
MT;RVOY%9L\QYV)4/Q1E)), ?NX;A?^07T@%-]=RRJ-G!4@Z,/T?">/P/1*Z[
M+GJ%IL8G8M9R4Y?>+=(Z?9ZMZ?S%CU$L+"9E61I@@_RMQ,]O=@JHS&"[_AT'
M3W_->A^JZ)O-+GIML^[]3#V4*SLG":]%N9=163GIT)@']_'H9]!9%Y5EL,*V
MD-5!+%X)TU!.?U?)WIF<%FU/SW(])HJ)K5U#O.1*L"54==()/68!C YO$J"[
MSXA #;ER(8C4B(!DY1&7S/*](YWIMS<LN\;4++=N)(.[3.8,Z?9BGT3EEJO4
M:Y\#B)!)(V'J "!&OL3D"XU<D""0)##H")&8Z$'K&?3\XI-_IC@"X[8=""8<
M :H)S'3[<5WT6!J6$@C,$'YCCI5RGKL=76$2RQBIV[F45Z,F6UFE06[8QMK-
MGD[VVAU=659R6'\4#H3KTRCYK@>F/R&KJ1""5,'<P+$*>A*A1/0'#5>GV,_I
M]E)+ACN*V PA#:DMG(.BB3TP=P!8ZXR^4-RYC'J5%[&S@L=]3DB5G(UD:P.G
M2.\X>KU#B6+SJR58+$%AEUS6>P@]TC%'-M 1W!;:- I)V_';!)[>S 93G@'Y
M2)RFX[H9*!N,;=@\()9@_A62)8@"-=,-Q4 #U&/#7Y:$20&K66\$@B9S()@2
M/90'=0[$A9(!)B8$ZY"2!BOCV,@L:2%:"3&I"G6)UPM1=#R37H,FV ]FI4$_
M XJ_S5J0A)VBP YZ$@$&/?$8'JW%M J\@5H$R4J"22V6<9! ( @GNQRO4:["
M;K:U4@Z*%/X>X]5[<YQ.^6ZS@R98_-<VE!^M";E_E)XA^B,<+F _VE8)]\0?
MMG#5V(&0B"")!'80=<._#X5=;MJ5 !^OL[L<>NS@V656@A64@DV=*]NN8SG[
M#G@<#F<&WB\QE+*KP0X&NTC*1U&&OY5RUTC4L8&#;PN2EM8,$J9CW]GQP;>1
M<J5]K$ ?;@6T6J]9ZJ01]8^=/(Y3P-% S9CT51U)_P#7'.NXGI[;18Q99'@)
M.[9)C<PG,#/W8K-5FYF=B^4;7F"L?Q8 []>OS0KY=,D&589,I[5;4?H/48:^
MXMY%2B3FS0($]I[S\3A.:O-K_*MHQ8 3V9QGW:]V-];K92PU!# C0]Q[#AN1
MQU9__'[&ET&9H)_$O\0]1T^K%=U-@:IA((S!!^74M/!+UH)#+R&I8$R"/"I)
M$1UCNRPB7U,EDG(V&TZF/&P!/NZ:=/F22<L<_P!2>/-Y-[LLQ(K0[ 1U@Z2/
M=@0,H/S-CI7N<*2%TD@9">DZ8J]1?@U_F<U8,H9E89%22,XZ2-(.6%X=S$^A
M<A_U;'_DN?P,>B-^$G3_ 'C@PHP!6Y"GICQL2OUXBO3MP0P\0]JT\QK//KG)
M5N$@P2"4$.OW21)68G/'YC@[C78-6+3 )R ?-?$6)$"6)/7V<6[B(7LI8RHU
M(8#-?XP(&6I!,9XW\^JZKC*#))*N3T"G[P'4G(1EUQ3=Z,[F]29#V'<0="K$
MY$9R) (/:,W]0]5 -@7:JEMYSB6)S B(4 G4G+ (,-@F98_.<CD<;^VE5!UV
M[B!N^$Y=)C'';CW-Y>\ I)*L"8(C0$SD1!GV^G^H<! _)XMA;83 =6$, = P
M&F.#SN9P#Q>)Q@Q4,P+N[".FB@?7^C@<SU>TV^C%F@%?!4\ +N U!S,GK\9/
M)]%4?DEXY%S((1F)\ &0!89Z8I'KQ0^G^430#]S=(G?.6[7/2-O7'JP])C_*
MO+2=OW/-DSM_FZQD3\/G$WJ;.588KK7-G;H .@[3T[SE@<FVC\]Z\#X:T/ZC
MC#L+YKO'4YP>LB<<Q/3N)5?Q+K#8-S[36[YL&_A">HSCOQY5]@;DO8UCD:;G
M,D#N&0^WYN#IBW_,:*Z^%94&JW"*S9,.8^Z&C0:1WD8]5N]%X%O(]'+((KC:
MMD>-E!U&D[<I[HPW"6NQ>05)*6(5D#(ZB",^W/!OIE_0+6S2?%4Y_@2<U;LZ
M?:4X=W%MHN<>#>(#]P/;V=#VSE] Y0XZD\JP>6@&I9_"/JF2>@!.*^(M?]A4
ME9:,F:"Q )U +22,I/4C$*L?,D@9XYOJG-Y;)SS986*ML\I@QCP@C/*9.NF'
MY'*5;+S5G(G+= <CH=OC]^>F*N3Q[F%ZL(S/B_BG/,'2#A=X@_H.)F6QN4P<
M;JV!;J.F,E$8##'#2AF3F%7AO-%0V^'<I+*X8D[2%VR(F0-:FJ##Q-.YMY+!
MB&;>,G!:2&$ C0#3Z'9Q^16'I<00="/]?JP>5Z18_P"?J8.@<AE)7/;F.O0D
MG/Z\)R:QML!VNAU1QJI_<[1\AA<%\J,]T1'?.6&N2RI.(N9(VA1]66&]1XE-
MS^GJHK#[3M)!).WK!G4CW],<OF/6R\9JPHD$;C,R >BC*>_+K\U?S.08IK4L
M?AT'>=!WX/J-WH]:\$K(\9+KN^Z;!&FDQ'PPWK'JB,WJULYM'@3H% R61J-1
MIVR:^+0E:$DPH S.<Y?("H1."+#\<9 _5@[%(/>, [B<9DCX8_M!@[5&W 8'
M7&HQY/(XZ6KK# $?;.>!536M:+^$  #W1B=PG'IUAL6:+P\:@@#-8TS,9GI.
M.&%Y IMJNW!P)(RCP]AT(Z$C/3"'A<]>77U#(@8=G43/<1&+1R/0P16A9CFF
M0Z@G<K>X&8P?7D]0.8+JH<@[!)E:_N;8!\)S(US..'S&4!K*PQC22,X[NSYC
M;!)Q*X=J/3^3;PU)!M1)3+(E<Y8#M SZ3A.1Q[ U;@%2-"#U& 6,B9S_ ->S
M&6GS;<J_B VL9:"0&/:P! /^LXY7KGI]K5<A5 =  :[%R2&0Y0!&<1 TZXJ]
M1_,>:1MW*8VN'(!"1F" ?"9.DX6CF3RO3F!\BP$;\O\ EN9@P-&[!UT!XKT-
M5R""5!(8,!K!$9C6"-,Q,'VG:1MP%&.,C5.W#S+%*EM<-EM&U@T*1NE@I,P#
M .= Y*;;!( @*=H)VRJ^%6*P2HR!RRT^BCUWBC_H[2%Y"#K)A;%'\($YC4_$
MG'Y:BQEN.@92NZ-=O0]L:QG'MXW!IY"M4@)=09\<Y!NV!,#IF2-,)Q;ZB_#5
M2[+)"R("E@,C)R[_ '#"HBA4 @ " !W#YFKB-:!R74LJYR0NI[,L&FJV7SC(
M@-M,-M8B&VG([28Q=1?6'J8"0>L$']S%E%R!JG7:1T(.4?[.SIA46GP@ #/L
MQ_8?;@EIG]&!M< #KUQ^LL8_9@;,C@DF6]A4C(X#9F/9FHP=L;< ,LMVX^YB
M:QEV8)M7X8_LQ@A0 V/UA$=V/"2/<</6UFZM@001,@B"/B,*JJ H$ = !E$=
MVF*JJZPB*,@,@/F.5PJWW<FL!F !R#:9Z3VB9TQR:VOSJ<H1N=&D"6R!4D=\
M&8,8I\@CR=HV;=-L>&(Z1B_D\"[AMZ?&U0 /,K),$QHT,3EH-8UQPK>5P%KX
MS6)GMC?F/"<SLW#.($_9\[91<@:IP00="#J,5,]EUE%9E*W<M6O\WKW3./2R
M2Z>EVVD.-QV(8E0.J!SD<]!CAK_XZX'+6IW8)XPNT>$Q)$O)6)SD'74\1^3^
M6\E 7@,DDG+< 0TF-)"@"8DXYGIWK)MN-+"'12\*1/B.L1!!;,9@G+%WJ7 Y
MR4<8.PKK@'<%R\1(.9/;E/0#,\?EV(%M,A@--RDJ8[B1.+TLHXHL(238S!BS
MY!X! \M /$,B>A'7CM4B!)8>"=AAV!99D[6(W"<P#'T51Q4+V5V!BHU8008'
M4B9 ZQEG&*CQ:6KLK;=O=2%4C29 DDY;1\<L5\7FV5*EC$"RK<&:!)4S]V=<
MLS$=N*O2TY]Z<>\D-M8DP%),$R1,02.ASG#<)>"AH.9D26/:6.<]\Y=,-7P^
M,M:DR8&9]YU/Q/S7I;)18:E%FY@!"[E@3GW= 8QZ1Q[.,R?E X=C&UI0HNPZ
MMNG=H( @YY>S<$$^W<PS[LL *('T/<4&[Y)8Z 8IY5;,Z6DA JL68B9A8G*"
M3($ 9XIM5F<6 D!59FA<F)4"0%.32)!RB<L);4P:M@""-"#F"/?CF\STWACD
M\;D[2R;@K*ZB)!.14CZOTW^J>K4H?4K+"P )(K$0%!T)C4Y]VDXL],X'+H_R
M\R$=P?,K1IE1&1B2 ?T=/*X=2KZ@JC;:9DLL9L-(:(.60.6F./P.;P$X_'6Q
M6LL#AMVPS" :21UT^?>GD5*]+#,,)!^!PZ\'B)4&UVB"?>=<?YEZ9SCQ^:4"
MO*AE<#25/4=#[L<EKKVNY=[38["-T"  - H&0&.15Z7ZNU' M8DIL#;2WWMA
MD1/V8HX7'!\JL0)U/4D]Y.9Q+("?=B%$#Z.>-RZ@]1,]A!&A!&8([1^C#6\6
MHFXB-S$L8[!.@[8UZ_0O+:NQW"%VV"=J QN;,9:P!+&# ,'"6(P*, 01H0<P
M?951;38%=PH>!L+,,A,SGI.V)RG"5(KA7+!&(\#E/O;3,Y02) D E9 ]E0<,
MUCMM55$LQU,#L DL3  $DX9'KL;8H9RHD5J9AFSTR)@28!,1@$&0</R+B=BQ
MH)))(  '4DD #M.'W56B];%3RR!O+,)4  E2"),[H !DB#@V5@@ABK B&5AJ
M".T>\@B""0<>?<&\O<!D)C<0 3V"3F>F*^/;38%=PH>!L+$2!,SGI.V)RG%=
M2(X#[MC$0MFW7:9GO$@2,Q(SQ1YJL198J" 3!8P)[!.4G%U*TV;*V8,Y " J
M).<SW:1.%K2NQ2R;T++ =) W+F<LQD8:&!B#CC5V*TVOM! ) ,$^(Z#3*=<?
MEU1XWL@<CP%T!+*#,R &S( .TP3A:U2Q=ZED++ L41+)G,9@P0#!!B/DDP3
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M]X8@J9S76")!],WW%6"N+& ,@[&KJ<]IK0B(S@=N&K7D+NBDL3YI4M6[%BI
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M_$9_0Q^SL_NV^7R*^4I6KB+)?659LA&NX$F.T>[.D<=".-4" 3JQ)S8@:#(
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M=G\(]->A^1S>%;42S4DJ\?<9=-W8I)$D09 $P2#7?>$?CL8#HP=9["1H??\
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MLB([C!^&.0[<9SP0Y"V:J1.1GI\8S]KLU>ZEQ##0Y:$=X^V<?EWXCMQ6$-)
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MY@_5CF/>JOPPR2OE&T[O%M8!60J -P+%H,Q!)RM6UE/A6-J[ %*@JNPYH0L
MJ9(.I.OMN]R_T%^@5\CCV%+D,@C4'_7Z^N!Q/5ZJ_P#+[5*.4!5@&RW:G3J
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MD!B)S^Z5SD>I<FJUCR.6J IMC9#*SDMH<UA8Z&3$1[+^.>4>/:;4<.%W2%#
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M85A%%])['N^-E#X3V/<\P@]!K@UFRK\O<$BUU\*(R4RMFRZ\K3PF7M*V<?\
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MXAI\UR+C%=PNFRHKSMU$*PR-%<$T.=M)=[4]7#?1M;4W$^>YTL!QAE1K$P#
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MCFG*^: Y+0YN!1?DUAB,OH8/0JX]5&;,U6XD7%7.-M['>!*MA)E32'^JDO\
ML58)!M;6YR/Y!39/;*?M\L^!\+-#RV7-Y#C^DV$(]MD^<W_7;LLN@N 9*]G
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MH-Q4641_TY5?:5DH4VOG1B>B^R1$E@81B_U.:B_'@AY*SY$B%U_J%C)U>&'
MHI=M E#F9R)1>3.0N=7&1E1G3Y;J5%728<$KED26&>X8O8A'L_H=F>HI[2U#
M2UY+>Y-6U\N<*IJ0E$ UG9DC!*R!7B-(&QQBJP;7/:BN]53UGZN/074C+U=C
M!I[/2!JIQ:"NM[,,J16U<^X8!U=$L;"/!,0 "$:4K O<QJHQRIEM=JL%M,SD
M]S&/,Q.GT&6O*;/;&)%^E]U*RUU8P8U;H8T;Z[/J/B%,UGO;ZJGJGZ/%W_3/
MY1_\T\!_#XP\P@Q4FEVW>.641HR_-'U\G9T[K553T7U:.K&9RI_6C?CS4U]:
M?[BK3N&DRU4J/]XQ5^"'#PT:.'YJU@@,SOM1K?DBHOX.]?RT>];2VO\  ^:_
M&9^)Y#,VEM/TD3FOD+SB/,UW&[;,1[L\N)0K+FQ317?0^BA"MBL^?HU$U6$U
MM<:GU6*T=YDM+4R/3Z]7?YRSE4]Q7F]JJU2PK&&0;O153U;_ $6)_HD\D?\
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MO#W_ (H=GKYA7I6CA]-"M;B=(8#6/:^;GMH2*T17*U(X99G^Y/3X[%X\[L!
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MD#SCR2%GL9$P]-*P%E5?_J\=!1)-ONB;&/=54M0%F.40Z4[$> +?J>A7*/\
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MP3,?E]-I[6XIZ)(T+\LA.BQ)LDK'EK*GTA1'D][X<%$C!48$0?Z-[_@]R/\
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MI"CC@BL0?O57.E#]&^X>Z\?^];T',*@C9'2>2:'.!'U;'&M R74%77:.0QU
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MFXQV*L[ZSP&:L-1IN3Y/I<B7T#-\8U5_)D6.0AVQ7R@YZ3$3T8/Z8F?HWO\
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MK6YV68\8%Q232!C'5@YD0T>0 X@R8TD+QD&U4174MYM.W^.7'NN:NCK;_,\
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M)*^H8(Q^3G$.+^3M5JNHTO(.O0+BLQNF67<\P8W,6U79:V@^M3UL#<5N6L9
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M_1WC(;?MI-:/LO*]G6?_ *M=)Q>SJ]E"[@0T>%RC9F[Y[J\</ 8FQJ8%_90
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M+PGV<&9]YD]K4GH]+5HV=&DMCK8UDEXOK#1AQ>[W#>UWHOZ-U19RT2!5])S
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M<X7N&4)PO0@BB(U4<P@R-16JB^J*GK\?RLL=WWN+>H<_N_#/NF^ZS1= Z_\
M7S[^T5(?,^#D]-T24FHKRUW3(U<*FBPGV,@5B:(D(#4>(S&%Q[XW'_"V_OLK
MQ#^5;N06&TJL;J+V\Z#W'1KD/)%-@EAJ_JZ119Y[BW%0<:1J$WMF$!&DM20O
MDM,YOQC%=,K\]M/-/)Z+58K2\@L-)Q[IM!Y&V%'XRW3NCZSI<+J8.>TW*:NG
M?75&7JK>HVD.RGE,8LH1%B?RT*385.2O/'^N\MO,J%Y3U&VL1T_.R=@MN08R
MWXP?I\Z5:4T./^<<YH" SIBR0>]]?:"BD0J2$6KD$Y5XB9;2W/AOX;][L;C"
MT^5R&N@=WD^>&;XKL*JJDUFG9*H!S. 'D$T.:CB$AF_^O) 1F8LKXZ-BF8+Q
M:M:+I75_YVM9>:VWM*"_V%!F>(9$6S\4GX3<S-A*G9)T?7B:F<L@N))TH%+"
M86<(KF?'@32:MI&=EH? KD<+JX9:^EU!C3-ATBZXG5Z<3_26"]@>/-IE$&.0
MB&%4.@#5$:QK4_\ #6-Z=SN_G93>\]U%%M,7IZQ0I8Y[4YFSC7%#=0%D".!)
ME99PQ&'[V/;[V)ZHJ?+X&7"=?U6:(+L!>_#=7NKD5G8SYO09 N_3Z\ W_KQ^
M:U5A#5?_ +GZ4I_[GKZ*C<B_J&D_AQG(\]P8=6TD-@1<BR?3Q]IS>'"1D1L@
M-72]4"R\CO:]) YS$<A/:B-^*6\[7KX^TNZ$-D.-=?PGBLY<6$BYDAF7-QI[
M3)YVAG[+27$R.TLNUMR3K*27U>4[G.<JU'0X_1BY'7UN\X[V"9;8^!%JG:+N
MG#,/+YYA>Z7T>0V?&D]17-SY'YA-$P(+"9*/*,!3F(]R<];T>_3%IS"[XPF>
M]87V'^:[2=AC]_O,7Z?:?6_*++LD0>@(GO\ J_?,3T>@_P!SXLNA2.C$V&JG
M=(Z7W")/VE;"N14??^IX9>>WW>*F$,<*(/I]70M$2KEF8:+ GQ8\EL=2A8J*
MYRJYSE555555557U555?FJJO],L:.-:V4:EMY-=,MJ<$Z4&KM)E.DUM3+L:\
M96Q)LFK;9R4C$*QS@)()[%;]1WK^B7=Z*WM+ZYGO82=;W5A+M+.:08A@&^7/
MG%/*DO& 36-5[U5&-1$^2)_^UW__V@ ( 00!!C\ _H[B$<UC&-<][WN1K&,:
MBN<YSG*B-:U$]55?DB?%YB.7]HYOO-=G$.^WSV7UE1;6@ 13)'E2X\:+)>ZQ
M@13JC"R(WU@#<YJ.>BN;Z_%:.UM:VL)<60::H983HL)]K;R 2)(*JM;)*)9U
MD>-#*1@!>XKF">Y&JC7*GWU/90+:#]S-A_>5LR//B_=UDV16V47[B*0H?N:^
MQB%CG9Z^X1A/8Y$<U43X>4CD8,;'/>]WR1K&(KG.5?ZD:U/7XI=7E[2)>9S1
MU<*ZHKB 3ZL*TJK&.R5!GQ"^B?4CRHY&O8OI\VK^EEQ1R2RZY\RT@-,6%.KW
MK*I;2936(_MK&-$E(T%C7E8UZL]A6M1XU<-S7+3XZ^W./I-=H6@?09:WTM-6
MZ*[9*E$@Q75-+,FALK%LF:)X1J$;_J%8YC?5R*GQ&MF;3*.JYE;?W$6R;H:E
M8!ZC*/:+4VHI:2_MW5N:*]K+ _N^E">Y&F<QRHGQ4:=>Q<N'G+^?.JJ.\-O<
ML"IM[2L]OYE6UL\UH.--GU_O;]<(W.(%'(KT1%3X1S51S7(CFN:J*US53U14
M5/DJ*GX8'$[[MW,JCK-FZ.*%@;#84L;2$E2T:L* 2"64UT:TG(]BQXI59)/]
M1GTV.][/=^@=OG;BJOJDQYL8-G2V$2TKBR:R=)K+*..;!,>,0]?90S1SL1RN
M$<3QN1'M<B?H96K,BI8DBDG#@+($DU\()11RS&15?]=T41SL8XB-]C7O:BKZ
MJGZ::A6V">TOK&XJ*V/"%*L!K9T%>2TN(,Z7 !)A5,F#"$KG-ED KG>C&^KU
M1JS[BYL8-1454.186=K9RX\"NKH$,3SRYT^=*(*-#AQ0#<\A2.:QC&JKE1$^
M*HF7Z!B=&.]-:QZ5]%JJ.W;;R:*."5=QJUT"=(2=(IXLH9)0Q^Y\<9&N(C45
M%^,SF6]'PKM%M*X=QD*)NKHW6VHJ3-D/CV>?KVSEE6]?*'#,X)H[2#,T)%8K
MD8Y4L783<X_:-ISLC6ZY/2TNB2KD%4R"!8K439B0C%6.3VM)[5=['>G]ZOI^
M!A+"9'B,(Y6C4Y&L][D3U5&(O[SO:B_/T3Y?##@*,P2M1XRB>T@WM7]CF/:J
MM<B_['Z#1HNJS<F3'TA<:>/'O*LQP:\%?^;'RIA#E.(/2!JO]\O@N1)38_\
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MD;&PSQ7T\VH96\OC5MQ.!JAW[3K%*0HQ5[*U[WD12?2"[_\ ZE^3'^)?-_\
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MMYS[E.SZ+%I.90**JT3;@6$%?NN[O1I&FLAR)#Y((:2SJ1@VB0;%Q^%X=UK
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MU.S/7+9Q\H*9(KKZ5%%'9*EI @6T: 2SD5P'*Z4*+]8D9&/^HC48[T_HI/\
ME['_ .5U'^I\UY^FP,%W(N-VW.\S)R=!/LLS3ZSM%Y5'O^AWVC#0S(2V@Y[?
M0,V,CA@.3^T,QQ7D<Z#G:JJKJW/UE;'IJZD@PHT6I@U$.*R%%JXE<$;(D>OC
M0QM$P+&(-HT1J)Z)Z?'BIYD<@YYD><9BC[>O.N_0\I11*VML,;VN&_,AU#J>
M,)E57R\Q:O<K9 & <QDM6>OL7T1'-5'-<B.:YJHJ.14]45%3Y*BI_0:O_A=_
M_E%;?CGKX[<VY-?Y/P-N='B[FQ[T-9.%Z/UW355=*NLR:A@P#V-S6Y2+&$R,
MA2LBQ[!?NG*BJ%KNB97+\WM^3=)QG<NATWD%B+W2%V,ZNZZ^7'E6YZW2G" T
M['EK21ATH'-3[" %D7U)]+ZY?T=P\E>*9N\I^FT03=0N>?UEO(7G.OBP;8-W
MT</\,>Q7T$K047WT@Q:XT=B'5SVB1SU=\,/PJLD9C/\ ,BU//IV)DTC<^W*$
M@YVIFUL&H@#>\1<RZMEL9 DL]K3,$[]UJM5/Z1M_\'<1_N^J_"0QB,$$(WE*
M4CD:P8QM5[R/<OHC6,:BJJK\D3X[)V.>-S[7N7E1W3>%L'JKB6%2'3KGJ,BO
M7U^H,<6H=[7?UHOZ>H5W,(UO8SHLO*7.NI: ,J3=7G.J;15]CM:V!#@L?,L$
M6H XTB,)%?)B!*)&O]_L=QZBXN^19]&3IV+LLS)SQ_?+SYZ6\AVMMH94J-]1
M:BLH:")+//,3VL;$80;_ %]_L=_12?\ +V/_ ,KJ/]1=:.V-]O54%38W=F?T
M1?H5]5#-/FF]%5J+].,!SOVI^SXU'=;T'KHO)_MW5>URIY%]94VCN--*J,PV
M0JJJHT%94*HT7Y^TGK^Q4_1V/BDUOJ3?8:YJZ@R/&)T/2@#^8Y:>PQ$5H'0=
M%"BE]_R5$:OS3]OQR;3:!R-W>3K9/*^E1%0B&@[[F<EV3O@R?JJKUDROR\4I
MR_U_<>O]!J_^%W_^45M^/RCXCX5VV,S1.R=3OI5]6]0KI6CQ<+:8O#03;KHX
MRPW,MZ:0MI'E!< "'!)*H!/"Y6L<R^J=+M)'3.K]-W%]U7LG1I$-*]NJZ!J'
M!=8OK8'O*2'1U@ #CQ6$>XCFL<1WL4BC9^BPI[6*&?5VT&7664&0WWQYD"?'
M)%F13L]4]P9$<KF.3^MJK\>6W#H@02>;X*$#/:ITNUCUTL#XUW(M^%Z2KSQU
M?8W0;_ V\T$F6QJ!"X36O)[O8QW]#@"LK*!7EM)K*VL'-F1XA+&P*,A1P(##
MD&Z9-((+W-$-'/5K55$]$7XB9XUO5AOY\*59P:,MA$';S:Z"4 )UA$K7E2;)
MA0S2A,*5C'#&XC4<J*Y/6_SF?UV7O-#E#BC:FAI[^JL[G-2)'U/H1[^KA2SS
MJ8YOI.]C)#!N=[5]$7T7]&W_ ,'<1_N^J_#WC>2SK&'EN2;^V&9/DK)@,S9-
MKT1?5/17SWC;Z_U>OQXO9N<'Z-@O*J2_L$5OM>2;KGR=6<Q%]$<\A777K[E^
M:IZ?@Y%YS<CS%=3Z_P 6^FP]3T>-EZZ)22=QQO;&BYSI==>FJQ1I%ND>*<1T
M^K]7V#<=_P O5WKG];G9H[+/ZBDJM%1V(?7Z4^GNH(+*LF"]41?IRH4ECT]?
MGZ._HI/^7L?_ )74?ZCO5E43%B:;6Y@/,<FC%5#2]!TFQB9"/$![?5RE?#M#
MN1$^?HQ?CCO*H41L(>!YOD,R>,W]C;"MI(8;5Z__ &SV:&([_P"TY?T^6'C9
M)7['&>0=74>6W(8Y')'AI<SG_P -]=I::$S^P1R786S'HWV_V0O<J?U?T&K_
M .%W_P#E%;?BL[FQ*@*^HKYEG/,OIZ!AP(Q)<HJ^JHGH, G+^U/V?!O-'59.
M%,[3V3H7<]%0[N06Q6RC<VV>_.2)41XSIB5;@224GU4DK'62HR*Q"?356K^#
MF_FI796VUN+ZYR+5<-ZMDLX^%&M]%I\?]/7\WE FVI8]5$F_:#D"0A2-58T)
M[$^:HBXSHV4D_>9K=9>CUM%(51J1]7?UL:SAH=!$*,<D89*-*Q'+["-<U?FG
M]#\-[G4#K1W-'Y6XRWIK613R;*?1TK,]IJS46469$@334U>]UM!CRSJX0E0X
MVO=Z+\:&>&\2W[?TWR3Z+R[HO-;?G32ZS(>/57!T).4[W,= /&2PJN99/-55
M/=1FM]**RGWLX+QOM3_49X-4G/<Z>GZ7RKEG7:GRV://3J70T5Q.S=15WE/U
M>QDPXIK*_P!3W"+^9PVRRR#6#XTBPCJ0*N.XJ <-IE&] N*USQ-+[5^FXC&.
M8YPT?Z>J(J*J?UI\;1NADU4NR_(<6KC4T.7 A?1^MIT&S[>;,GG^LCT<JN^J
MK5:K4]$5%_#U;-QU?^9=6M<#R.J0:JA'S=WMJ.N>-B)\W*2",R*G]Q5^,?D(
MZ-0&5RV?S849Z>Q T=3$K!HST]$]J,BIZ?['X-3A=5!99YG99^XS%_7D1OMF
M4][ D5M@#U<UZ-<2+)<C7>BJUWHJ?-/CK/A?T*:^1T+PVZ'88&#(E>YDC0\B
MOCR[SENF DAR2),4U20D=KT;[!A$%O[51/Z*3_E['_Y74?ZCP \7!*V;!W'?
MW=BW=4/YG7%\1J27[#F3T7VQ)%G+5GJOJGN'\T^2?@\6_-_/0YA97C9UZNH>
MF.JXSB2YG#NN$CX_9LF&8USFP*J;(C%:CD5K7G<OPVXR>BHM/4O(X+;3/6T"
MZKG&8P9'";-K9$F,I&C*URM]WJB.1?V*G] J_P#A=_\ Y16WXO(C3Q"M%9&Y
MU:Y6I57M8]UKNG@Q4! JY452MD7Z/3T_>1&JJ?L^'V]S;WTNGT72M>N'I+*R
ME3*?-Y#-?8Y$$/,PI#WBJ*V?=TDZ4\(/:%Q2J]&HYSE7\'4\]50OO==CX >H
MX835=]4FFP"DND@@1B*]Q;VD9-KD:G]]]YZ?',>%]EZD^%9,N;4&:U#,9L4Y
MUBJ/66I;K*\_V70C4[,_7:FL-9D$1OU%AQ D"QQO:QQ/AA1/801&-(,@W(\9
M!O1',>Q[55KV/:OJBI\E3^C;?_!W$?[OJOP_R_>%.:I(73/+W,::Y$U/<Y:;
MDU1,U,M[A^GHX;"2AJOK\O=Z?B\;O,*&BU_.NW-#XI>1$AB**!'/<'^^Y)LK
M@WJ5/=76X?M7O]C?;&C(Q%]7K_12?\O8_P#RNH_U'8-8]C9F?\3O'/)<QII@
MOW@Q=SUBQ)JKX3E]OHDL-&A /_VR)\OV?@X%D8$RTK>5ZW1ZXNM6 8X*_1;"
MC@5,S&9O0O#[6&ACADL;&+$*[Z4F5#0GM<^,STR>7P19D?+[3);<G5<[ ^H/
M/RLW1TQ9E/J+>"%CH4>UI]:2%%AS%:PS_OB1_>K".:GZ^K_X7?\ ^45M^+Q<
M\;H)",F^17E5S/.36C5R^_)9$Y];J_JL8GO^W9$AB<1R*GL8BKZI^U,YS;FN
M:KLAALE!6MSF;JD,D"KAND'ED$%9!3R".-*DD*]Y'O>0CW.<Y555_#VVJB:6
M/C9-CR7HD,.LF'?%AYM\C)6PTNYDH37EBPZSW?6*5B*\8V*YO[R)\&\53\:M
M)73G<AF8=<W_  [&+@;+4RX!!)U@FM<;WI+=)(EPK7B_-?S!J!:WV^AD\?Z8
M^GC;0E9QOF\-=7".^5"OT!DJEC+*%)(B%D0CL1%"]Z->\?HKD155$_HNW_P=
MQ'^[ZK\/BEE$<V95<8\=>O\ 5[*+ZJYL"ZV%@+$4\@C4^3#J,2.8J_M3X(4I
M&"$)CB%*1S6#&-C5<\A'N5&L8QJ*JJJ^B)\#/'*(X"M1XC!(PHB,=\VO&1BN
M8]JI^Q454_!U?BTM&"L=5F9),G8K])I:7;TSF7&/MX\@J+]H2)?P@>\C5:Y
MN>GJB*OQ@=+JD(#IF*6?R?KE=(0K9D#I'.BLH;Y9B'<XWW%H(()SE7T3UE*B
M?L_HA/\ E['_ .5U'^,\N448(T8)9$@Y7(P00!8XA2D>OR:,8VJJJO[$3X\D
M?)RQCE#9>37D[TK702$:OL-B\I/=DL?]L]55711BB249Z?NHG[/P6>!ZCCJ#
M=XVY07YCGM)7@L:XY(Y$+&DL&9JOC38AD1X3B<PP7I[F.:OS^/,SQFH<_75%
M#H,IS'M_))"@]9T'!38Q,]?XBNM)SY%K/H\]IW?4&)QB(,A"/7]YZK_0*O\
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MU#&JYJ#KJWR"P 'AW%.$Y?8(,K54)%GN$/YE.4+?FJ)Z?T,G_+V/_P KJ/\
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MM7H6:Z\&JE='Y18T"2-;1UPZ:!LLUK 69:>PF4D97PJJ_KIE-*C2VQO9&,Q
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M])49NAK!.!6TE#6PJ>HKPO*\S@P:VO#'A1!.,5SU:-C45SE7]JK\$_Y>Q_\
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MD:_H&YW<_H>NTNLI3KEK5EU>2SOB0I&>)1_EGY;!!!A5RQ% .,)S7HOZ*O\
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MWD<=[U1C$7V_$2Q$QPFR1JY1/5%<(C'N$4:N3T1WL*Q4]?Z_3U^%:CFJYO\
M?-1R*YO_ (T1?5/Q\MW/,*GK,#>U-!N,R_>\DZCX^X6P@9:[F92QGY/0Y[R$
MB6F?UM1=6=-&EB)#C))KY,%KOJM:56$HUH8FBAS':[IO\:MV.SR_0MC)Z0WH
MVH'T*QUNQQ#!XNZT-GK&2I$EU2B5PG$^D!&C8C4^.(\(\::ZC7M_D/I=!7UN
MUU=9(N,AR?"8FNAVFVZ+HJT"*R2&M9910 :;U I3>BM(]1B?D<QYL==Q_5O&
M7I=7I/X?\AZ?!6&2F\OZ'3?^N39':U=-'L7SH&J'-*L!RB=(]6M4;_I",QO
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M3<)F.KY+HV-V.#QQ[DC*C$RJ[J\F7N9L*G41'1YLHCA21F1T?VQD$UOX"?\
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MHUHD;.G9.GT5BGL8%'"CR"J[VI\W)DO_ -;>QX[7U5E/G_P92=FJH5O]6PE
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M][_N2S!H9>QTGC9Q_F/>^0=NZ+?]HS@MAT@&2TG).A="&"9M*+32);8IM?G
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M^;9E)8QY4UR)]_ D"0<.8QBJHQA(JJ43QHY417.3U]5^:?L^&OBPH0 L1$<
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M_P#3(I$5/]CXO<]97#M'07]/9TEWGKZ&*7"N:>TA&@653)<UXR+'L81WA?\
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M%G0I0_5KO88)%1'-5KV.]'-<UR(J9JRN=1V[IN&PLXUC@.,].Z98:OE&3E2
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M%;?T*K#RFHL]==\[Z)2[^RP5.U#6NLI(E3>T<Y*6"JM_-;ZA_/&SXT1%0DA
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M()HUK_R9@$=!0ZC,CY/U/8BI^ZWW*GR]?^G71/\ &1G_ !#XOAV.RW@ZD,B
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M4B7$.8#C(,CD^$1$1$1$1$1/1$1/DB(B?)$1/Z9"M3U\$UI6@FQJZR+$ 2?
MC62Q5L8\*8\;I$4$]8(%,QCFM*H6>Y%]C?3]$>KIJV!45D1KF1*ZLAQX$"*Q
;Y'E>V/$B#%'"UY2.<J-:B*YRK^U?_P!KO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g790774g43a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g43a01.jpg
M_]C_X0[.17AI9@  34T *@    @ # $   ,    !/:P   $!  ,    !$>(
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HQ,SHR-      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,6H , !     $   #I          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MW;V[M[-KOW?3>KF]W[CO^C_Y)+[U/]V'^(%?=X]Y_P",7BO^;7U]_P#+AO\
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M/VF8<.6E<_\ 7B_&J^K=PRL>K(J?D55EN0YU=32ZYH%UMM!;<QE7TO8C$7(
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M-< 6N&H(/=.O.>K?XSLZJAV/C=-.%F>Q]5EMC+:]K7C>U[*OI5VLKLI_1O\
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 2P    !  $!+     $  3A"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #/0    8
M     .D   ,6    ! !0 #$ ,P V     0                         !
M              ,6    Z0                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    Z0    !29VAT;&]N9P   Q8    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M .D     4F=H=&QO;F<   ,6     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1"  O * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$
M 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T
M<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$
M P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#
M4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#I
MNNT]7KZO<_\ :=>/BWAMF/2_)MH<VNMC*\G:*Z+:OYUWJ*A6[.<YH?UNET[B
M37U"V2T;K#Z;?LWO?72W_H+M<W$OR/3]'*LQ"PRXU!AW \M=ZS+/[*JNZ3E.
M@.ZED. ((EM!(C]UWV?<W^O_ #O_  BF&>0 %1T%;=F,X8DDV=?%X[)Q_K%5
M-O\ S@IJI<UKV-.5:^&/+*JSO^S[O=98S_/1,/I?UNSP]V'U^K(%9#7FO(L<
M 2-W(H78#I>5[2>I9)<-P>0*&[@Z/I!N.&[F;?98W](CXM%N+4X79%N8]SMV
M^P,#A(:P,:VAE-;6>W]U.^]3_=A_BA;]WAWE_C/(?\VOK[_Y<-_[?M_]YTO^
M;7U]_P#+AO\ V_;_ .\Z[7>[]QW_ $?_ "2A=E5T-#[OT;7.:P%Q&KGN%=;/
MI?GV.VI?>I_NP_Q K[O#O/\ QB\;_P VOK[_ .7#?^W[?_>=+_FU]??_ "X;
M_P!OV_\ O.NIKZWTNVX8]60Q][GNK%0(W;V[M[-KOW?3>KF]W[CO^C_Y)+[U
M/]V'^(%?=X]Y_P",7BO^;7U]_P#+AO\ V_;_ .\ZI9&+]9\5[V9'UAIJ=6]M
M;P[(M$.>'6,:[]7_ #F,<]=WET79 ;Z=MV,YDPZHUZR-OO;;ZK';?I?154].
MZ@6D#J66"9GVXPY_=_5W?12^]3_=A_B!7W>'[T_\8O*8?2/KCG5NMP^NU7UM
M<6%[,BUPW !T;A1^ZY'_ .;7U]_\N&_]OV_^\ZZ6WIV8\6!F?F5A[G.&WT#M
M#RXEC-]3G;&[OT6_WUJ[;D,HI?=<"RJII?8\Q :T;GN,._-:E]ZG^[#_ ! K
M[O#]Z7^,7C?^;7U]_P#+AO\ V_;_ .\Z7_-KZ^_^7#?^W[?_ 'G74#KW23;Z
M(R:_5WMK%>X;B]^WTV!OYV_>Q7=[OW'?]'_R27WJ?[L/\0*^[Q[S_P 8O%?\
MVOK[_P"7#?\ M^W_ -YTO^;7U]_\N&_]OV_^\Z[7>[]QW_1_\DEO,B6.$Z3H
M?^I)2^]3_=A_B!7W>'>?^,7BO^;7U]_\N&_]OV_^\ZJ9>#]:L)Y9E_6"JEP#
M"0[(M&EA>RH_T?\ /=3:N]R\=^15LKOLQW APLJVSIV_2-L;L5-O2\YE;V,Z
MKDR1#"]M#MIG=NUQ][_W?<]+[U/]V'^(%?=X?O3_ ,8O)8?2?KAG,=9A]>JR
M&,=L<ZO(L< Z&OV[A1^Z]JU>B=#^MV)U2G(ZCU)N1ALW^K2+;'[I:YK/8^EC
M?;9M?]);+^EY;M^SJ>4S>9; I.TGZ6W=CGV_UOH*_6W8QK"XNV@#<[DQ^<Y"
M7,S((,8:BOE"1@B"#<M-?F?_T/54DDDE*6=UGK6/TC#^U6,?D$V5TLHIVE[G
MVO;36QOJ/K9]-W[ZMX^7C90><>UMHK<6/VF8<.6E<_\ 7B_&J^K=PRL>K(J?
MD55EN0YU=32ZYH%UMM!;<QE7TO8C$7( ]T6"+!MSLKZZ,^T$'&ZMC.N!BIGV
M,CVM8'!GJVV.8[WM_.]3U+$S?KDUS[&#'ZNX$$FL?8H:+C8VO;:VWU6['LL]
M#]+_ (-<4_*Z'6\,&#TA^X&7,R\K:(V^UQ-S?I;O:F&5T$O(^P=(T EYRLH?
M2+V[?YWW?S?Z3;_I%8]F/8_R_P )9QR\'M!]=A8X;*.M'>7-8&U81!+-^_9S
MOV?^BTUWUU92T66T=:K:0&DEN'J2X['EN[V^^QK/;['_ *+>N.&7TA];0>G]
M)])[G !V;E0"T.][V>L[T][1^C4;,OHE3"]O3^DV3 <VO,RB8)#==UK=VV=S
MT?9AV/\ +_"5Q2\'T3H_UUQ\C,QNF/P\]EF18ZIN1E"@2\-MO][<>W]VE^WT
MJ?36>W_&WT5S0X8&;!U&E/'_ +$+!^J69TG_ )R]/91@=/98^ZQC'XV1?8]I
M]*_=<VJ^ST_S-N]]7^%]BYFOK72RQI_9'31(XWY6G_LZE'# DCA.P49RKH^@
MY/\ C4Z/=2ZL8O4*"8(MJ&/O$$.]OJ7O9V_.8IGZYBZM@KJZP=TO8]C<$R"*
MW!I].S;L9'_@UE=G^C7GG[:Z7_Y4]-_S\G_WM5MF7T5X:6X_1VAPDA[\UI!A
MOM(;EO\ SG(G##L0@3EX/<6?73;C.R'5=993#B7[,#AH>'NB=WZ/TW_YBCD_
M7>BJNVZROJ]-1=RW[$X,W'9MKW6/=LW>W\_8N).7T5M!N&/T=SQ)]%K\S<2W
M?'N=EL9[]GL_XQ1R,_HU3'/&)TFYP,"MK\LN,G:7;OMKF?RT/9AV/\OJGCEX
M/=C_ !L=&  ^P9IC22*9_P#;A6^E?XRND]3ZEC].KP\JJS*?Z;'V"K:##G^[
MT[WN_,_=7F'[9Z7_ .5/3?\ /R?_ 'M6Q]4.JX%OUGZ;55TS!J>^TAMM+KR]
MDUV?I&"[)NJ]O\NI*6& B3PG0=T"<B1L^RH63E8V)4;LJUE%3>7V.#6C^TY<
M5D?XSVT]2NZ=7TM]ME.19C-=ZS&ASJWNIW>YOLW;$K/\8USPUEG0GN#X+6F^
MDC4.>S^K_-O4'M3[?BOXAW>Y:YKVA["'-< 6N&H(/=.O.>K?XSLZJAV/C=-.
M%F>Q]5EMC+:]K7C>U[*OI5VLKLI_1O\ 4_<77?5GZS8'UBP?M.-^COJAN5BN
M,OJ>?_/E5G^ O_PO_&>K56I8Y1%D:)$@30+_ /_1]2-;"9,R?,H637BC&N.0
M=M'IN]9Q<YH#(/J'<'>WV*PF,1KPDK?1P^AX?2L?*L91G#,R/2:UC6N V8[=
MII:YE)VO=[V?IE#ZUW=3HZ#8[IS7FSUZVN-58R;!4;FB]]>+:RRNU[:_WEO#
MT]VD;H^<+)^LF%7E=)LJ=DUX[38QV^\@5R'AVUSOZWT/^$1!H@K(8XPCPP%!
MX"SJ/UK#VBO]H%D'<YW2J 9]NS:UN([^7N_\^)#J/UKW.G]H!H VG]ET$DR_
MU/\ M)^:ST=G]M:U?0Z*G%W[2Z6^1$/>".0?'Z6BF>D8CFEHS>CMDR"'ZCX>
M]2^Z/W0KA/=Q1G?6Z&N<_-!<YP<UO2*G.:W4U_2QZFV;_9O36]0^MP9^B=G.
ML!&C^DTM!$^_;MQW^[9]%;G[*PS,9G1@.X#^WAK8Y0'1<8-+!U#I4[=N[?[O
MZQ.[Z>O[J7O#]T?8%<'B4'U;S_K0_KV$S(&4_'?:]MQNZ?5C-%7IW%KW754!
MU?Z3T?\ M0LIO_CK;1N_:&[O'H\KINB=$IQ^KXMXZC@W&MSB*JGAUCI98V*V
M_P!I9C/J]C!C1^T^EF!$^L/_ "*'NB[X8_8GATW+G?\ KU/_ #8?^ JTS_GZ
M0WU!UIICWAAQ7#= ^CNV^W=O5G_F_C?^672_^WA_Y%$9T?#8UK79G1[-O=UP
M!.I=[BT#]Y$YOZL?L4(^):3O^?WH'8.M?:(=!)Q?3GW>GH/?_HM__7%&[_QP
MO3=]G;U?U9&TV''V@3KN:WW?06A^R<'4'+Z+!U ];4& WVN_Z6U1MZ+A6P&Y
MO1ZB.[+N1X'=*7N_U8_8KA\7)_\ 7J?^;#_P%:'U=_\ '%'7,(]2^V?8?4/V
MGUO2]/9L?._;_*4_^;^-_P"672_^WA_Y%7.B]$HIZOB7,ZAT^QU=A<*Z;0ZQ
MWL>-M;(]R1S6".&/V*$?$N=F?XO^NVY^7>,/!OKOR<BZM]E]C'%EMAMK:\54
M^US&_P M5W?XN>OFLM;@]/:X_G#(N.L_NNIV_P">O4TZ S3'57!'L^2=4^H_
M6L/!NR#TW%Y8&C&NMMNW/>RFMM%+JF,_PGO^@S_"_P"#78_4GZF,Z!4<W+(L
MZKD,V6%IEE59(?\ 9JOW_>UKK;?SW_R%U22$LLI"B5" !L!__]DX0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M="!E;F0](G<B/S[_[@ A061O8F4 9$     ! P 0 P(#!@
M /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M_\( $0@ Z0,6 P$1  (1 0,1 ?_$ 1X  0 !! ,! 0$            '! 4&
M" ,)"@(!"P$!  $% 0$!              $" P0%!@<("1    ,&! 4"!0,#
M @8" P    0& 0(#!0<($106"1(3%1<8(1D0,#$B"D!0&B R-C,U8'!!-#@Y
M0B6 (S<1   '  $! P@& PL(" 8" P$" P0%!@<( !$2$R'3%);6ES@),9$5
M-94W(M06$#!!T3(C-)35-A= TI-WM]<8"B!046$D)B<Y<4(S);9X<'921AD2
M  ( ! ,""@8&!@<$"04! 0$" !$#!"$Q$M$%05&1(I+2$Y,T-F$R,Y0U!A#P
M<8&A%" PL<%"(T!04F)S%0?A<B1T8'#QLD-38[,6@L*#PR6B)O_:  P# 0$"
M$0,1    ]_!JMV?+1#O=.
M       !MQP_72?I]F/Y^7Z=?GWE^#FXKEX]ZQ\K7OJN:W^\Q] UAZ_GIMYW
M=0OT&DIJZ- _3_.0                                         !ZL
M/BWZO],7R/\ 2P_GW?IW^?FM76\QEF%F;7<1VF@OIWG.Y' ]I'6TPYET&XF'
M0;W2KT/A-)_1."                                          'K.^
M)/K?TN?)/TH(XVNM@_/Q,_0!\$:$G$2)E%%46$X3F+\1V2(
M"WF*)R-%M3E2([)$                 +$6Q-\1="/"0P  2QI-MD&-D >2
MY<LR+"FTDIHTC5Y4=@BC=M$H'1<KSA3I JF:)XIH]L2C[             //
MLJUQ32)ZXB6$V%'LS6Y2                -0T^?55J>JX3]1M0CUIJ
M!B9&B<V(_)K1$"=/T[1HDI$;)R\E9$/)S!&)$SGV           ""$SJCZ,"
M3<T7T_2/$XR32B,26B,R3             "-TY6B C9HHSY+,8FFI)*1$ID9
MDI<@  =3:KH23'T3M],X00$G:Y3$,3"DSV_J.OY5%*=ZD=9">\)1Z!E
M       'G@7-+4\J(N(559H;!J=YCI8528IV,3%D.W::.[92
M!YP5S1TKS"DX.GN'4=2Z=J416JF93 "=.CW(*)80  !!1+15G.4)P%0?I7'T
M6PN10GT7(            X@8Z51<BB(RF)3B:TM1=2R%\.0
MXBA*DIRH.(ADG XCB*<YBX'Z          #$)1U,<@   + 7XQ%-Z11GR9&
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M                $/U1C1%U4>";Z?\ )MWM+G9/A;B ]EA=7O:<IL#J-UV
M\]FZP;3&UHVVO[(^6V<,YU%LC(Q+.U4O:[/U?VVO[->7V7-B;".LS%A#.OS#
M:PNE_O>6[A^$ZKKNZOGIMUFP@+98_IV\JZGIT[CGO/;Z7R0   %)4]$OEO=[
M%:C.UJV&+SUW+_;QJ2_9W.YS>Z';[%TQZ?F\[P\[>[G]CJ+M\;!\G%ZC^[Y
M   "RW*?ZWGP]]"[<8MT   =-ZOI,BOU:3:V/0           (1JB;J9'\Z7
MZ<\L\]'IO(UU%5!73\(R.U=H:H^XBPW;?-$W&BY]HS_&NW2W>O5JJ ]I@72B
MO\+971*6)?PR_;L%RBCKHR6Q?X9I][/SIZ;TT]SSWF>]7XX   #\E6T5W"FK
MB*RFKCF+971]I^H4M5-]M7*6J/N)M5RBGF@   "[47/Z\GP_[WL#8N@  #4M
M-$3LB2P           0C5$W4R,;NT1[E60          /PF#!R8.V&+I/O\
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MK,S7798]@NV\@M7,$R;$KX=Z;-=F<-4:V;7"G#79=LN6[O:NVRY;UBV^O
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MFQ\L>Q[JX=X     #S,JY,3 ) L/8E-L0C5$W4R.C;I]7TP=/IP
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M:>H:]2    /@_3@E\PY <AP2_(?1^@J     7^'N2P+UW
M
M                                 !__V@ ( 0(  04 "?IVN543[*U7
M'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[
M*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96
MJX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7
M'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[
M*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96
MJX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7
M'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[
M*U7$\3\[3,P^%%/2DRLG%02"[FBZ/QB\WJ5%2DG2DQF,P6D&H*Y)R9RJLJB*
MLW4^/.Z=SJIAF73DC4MX[.<6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C
M%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:
M,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%
MHQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HNS8SJ_P *&LS5)9LC
M(DV5+R B/2V=T-BS>!(DP:DL\*4?F,-Z7TQ,RA6&Z*FIJ7F:37T"HY:F#";V
M5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#
M*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FA
ME30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30
MRIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH
M94T,J:&5-#*FAE30RIH94T,J:&5-#*FA=I$ALGOPE\]GDIAZR5XUDKQK)7C6
M2O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5X
MUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE
M>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK
M)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\
M:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62
MO&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>#ATY,#'_X
MM-=:QG_ C&-:W[&#[!]@^P?8/L'V#[!]@^P?8/L'V#[!]@^P?8/L'V#[!]@^
MP?8/L'V#[!]@^P8NL#'FC[1]@^P?8/L'V#[!]@^P?8/L'V#[!]@^P?8/L'V#
M[!]@^P?8/L'V#[!]@^P?8.%C?VAC<&?O3&X-;ZM_YV%RIDV_T:<#HTX'1IP.
MC3@=&G Z+.!T:<#HTX'1IP.BS@=&G Z+.!T:<#HLX'1IP.BS@=%G Z+.!T6<
M#HTX'1IP.BS@=&G Z+. \Z\X] +&#3_1IP.C3@=&G Z-.!T:<#HTX'1IP.C3
M@=&G Z+.!T:<#HLX'1IP.BS@=%G Z+.!T:<#HTX'1IP.BS@=&G Z+.!T6<#H
MTX'19P.C3@=&G Z-.!T:<#HTX'1IP.C3@1I;,2T/]GI- A0$G!F4 R:B*F2P
MB,&?RPQ"@'7#,0DIY-,3+L[E[TO+J&5FI=+9T2G$ U-"Y)\ZHI5+CDR44KD\
M5D2*UK'XS0\]'=#7XS QZ.T,?CM81F+LQB2^9PYF4;$BL:QZ.\SFQ1UDB)9/
MI?.H58BL"#/Z0EX,%,\V*.;%'-BCFQ1S8HYL4<V*.;%'-BB838K*2I952L^[
M#-<Y_$PUK3KC##7H[K&3* T_$4<J@P8*FDY@FZ><?-0U+*(LS@38F9ARY12N
M;098H99.6<V*.;%'-BCFQ1S8HYL4<V*.;%'-BA^&X<<,N.PS'[&ZQC1]@=Y>
M-*_\,FD<S+%'!@PY5+2\0L9DB0?=?E$JFLJ4L]*F"KT@BE(:@F27>,S":*9L
MZ9.)D:(E(!<P6DYJ:.'"=+YW,H)J,A()%R)&/'I/'F,O..1II"F!U22N)RU(
M6,FI-(I-EI9 4Y9PR9/.J5Z;DYK*):IDU$@GS=9_]YI+_B/R76M8"$6+"04:
M 3E\D6I*3D(9/*&5*A(,9X\H#39,LLE%E$E@G):QJ/=CEX42:2Y0* ]$*F91
M,BY%6S^1Q#TU4?R87^J:9B;_ &-WZ?"DQJ 82O(:UKQ1U]UA=KK&0'F/.D(#
MCSA-R$ZX3<AP.5$8QL%]X/E'(D2*4<CMF<KAS8@>DI<^2EDB=ED5I=K1&)PS
M B$X<:(TNUK#LJA3"#DG<XTNUHY<4,(PF/0R<. *P'"QB?TA-EXR;Y40<J(.
M5$'*B#E1!RH@Y40<J(.5$'+B#+M8ZTFXV)$*NQGF$83 Z3APXK2[7@\6XV.E
MF..<A[BR,)D2$4<@/02;A=QV V&YRH@Y40<J(.5$'*B#E1!RH@Y40<J((L:$
M1AQWW8IG]C=^GP@QXY=_JDS'5)F.J3,=4F8ZI,QU29CJDS'5)F.J3,=4F8ZI
M,QU29CJDS'5)F.J3,=4F8ZI,QU29CJDS'5)F.J3,=4F8ZI,QU69AK6O-EA6:
MFS'1EX.C+P=&7@Z,O!T9>#HR\'1EX.C+P=&7@Z,O!T9>#HR\'1EX.C+P=&7@
MZ,O!T9>#HR\'1EX.C+P=&7@Z,O!T9>#HR\'1EX.C+P=&7@Z,O!T9>#HR\'1E
MX.C+P3"5JR 5=^OS4O+(4ZGD]D4Q3LQ_2._3X4HE$N<3CKA-]]Z-*W(3K9>^
MZ[#*//08TK,QN$FUV _+3, N_+CD%]TE#;$?EL&/&B2TL_R(&/)+CD%QR"XY
M!<<@N"[\O-M*Q)<>@<DN.07')+AYTDX"T26G(56)20ED^I#"APDKQ/#B>'$\
M.)X<3PXGAQ/#B>'$\#\R*RLL54\MF,* ;A&7^)H:<@L-\3P9,RCTR?4\DAP7
M%1(XA-P[ B''5'*7YB7G<L-0"2BE!^%+9_+)N]Q/#B>'$\.)X<3PXGAQ/#B>
M'$\&.NQ@8<=AFI)(IDH3G:Q9CM8LQVL68[6+,=K%F.UBS':Q9CM8LQVL68[6
M+,=K%F.UBS"2I\J)0HU*FI<J9=/9%,4[,?G,8UK6L:QOQ<P&#@==AM;2O_##
M\P,2)5PI?$A2.' )P9,D&LB2N72\A.)^Y!<@)T_*'C,Q2V$:=G#Q\N>F14G'
ME\0L3/F9D?F)6G4^FDP@'DDZ<>;J*;RV)%BK$T8,F58?GTA.1V*:6S0[(4[*
MF12Y%1G9LY&.3"?0IV3<E4NG*:EL0N8K/_O-)?\ $?DL!)C7$$;+D"TE6Y25
M$@0:2,*! PVO3!1&(DH5SY%^32B6GR3A='PXI%QZ<2Z?*,[&@S26G8,O64]3
ML29SB??)A?ZIK#-T?_R;XG%"Z5F4:;RDL8@J&41SQ69RP]%,S&$Y+(TYE!5^
M!/)69FI&9RR:._%2IJ7*F73V13%.S'YCKK7FERD$JZ8*P3CL2&_#>^#OT^%*
M8D-]'Q);+HSYB32<W!@2J5E8<(O @12Z<3Y..7D4D*%B4IEDN)ERY<I ,223
MFSQJ2R@\=/R:432/.I:[.I6=2TLCRR0)YR1Q(LLEL=DQDLHF\0S)).=.MELO
M:P[)"AHGT\MU6++I?'9BUC6)^0L?(2B52IM98L-^>4@/%(J>X'AP/#@>' \.
M!X<#PX'AP/#@>' \.%_'@>8W@>'+:.![%CK[!POC"(.!X<+XX7QRVX<#XX'A
MP/#@>' \.!X<#PX'AP/#@>!@T7ET&-$=BF*/_P"3?&;0'X"KGLJ/FR\U+''G
MU7#BRZ63>4/E43,I0?BP3A$_&.R9D4[/_P"A2IJ7*F73V13%.S'XX.C!T8.C
M!T8.C!T8.C!T2XO!9#F/^F1=QB'B\*+#P=&#H8QF'PEDYFTFB:[6 UVL!KM8
M#7:P&NU@-=K :[6 UVL!KM8#7:P&NU@-=K :[6 UVL!KM8#7:P&NU@-=K :[
M6 UVL!KM8#7:P&NU@-=K &3)@Y'E<IFTVC:,6XT8MQHQ;C1BW&C%N-&+<:,6
MXT8MQHQ;C1BW&C%N-&+<:,6XT8MQHQ;C1BW&C%N-&+<:,6XT8MQHQ;C1BW&C
M%N-&+<:,6XT8MQHQ;C1BW&C%N-&+<:,6XT8MP?2RK)%G?K1_#4Q@P7*02,QE
MTS<?>=AMP>X6NO,8<,PR!6*5@&7>%[ V=)R\N6/D3D'!YH-'2Q$-=>8WXU4/
MI^%)OEEC+Y9]R)!..O\ )+/&C;YEOP=^GPIDDI$<D6D4JQFD$MCI!+,:U))1
M@:CTLZS2"5Q:CTLQK4@EG0Q'I9K&(]+-8ZD$L\S224&DDH-))0:22@TDE!I)
M*!Q*I&((:62$5S224&DDH-))0:02H:D$LZVIB>ER?G=(X4-Q*?).GH,O+DU&
M2FA<K,2)V(TV38X_,23DQ<BPHC[)H1>FSZJD3D%BHDK2L,Z6C'-02UDQ+3Z3
MFRQ51RDU#EL]E\UB_)<==B/&'77#5'_\FJ!_AATQ%=D'+*3)I(S.3ZFE3\=U
M^(=C2V6* V\[&G,2.X\I2&=&=@*&8/S.,QK['#<>2/S!Z=?!9K,FDR9\^<FA
MSYD&,_ ?,&7S#_Q=]1PL#KC'FTK_ ,,,SDQ(E@[!-L3<" V#($H^\8ETNE9)
M]5PHD>$GSDO,R^(D6EX<WGS?_NY@5Z@4-E(,^-'IU,8"$G$\FI4\EX\U-O0U
M?,RKYA2*Q^(;42CB3U-S VU1R.=F9 GY6P\V5SZ>S\I'-J:.5GI&"79-T@08
M6%9_]YI+_B/R6-:P%(,9U"'2Q2%*%K#EY2(0>*1)VA($+J"B>-2U51)5&D\H
M(GH;(20@1I9#ZR0G2H-179Q+H[DO6TZD+9G-IW\F%_JFL&&Z/,:\IXI9TQ"+
MR>7%!%E9(PX_*B,0XZ2@N,@266%H<66E(YEXE!?8<EQ68PWY61B%GI83>,],
M)YDM*X90Z%FLR:3)GSYR:'/T3OT^%*VL:C3:>DYZ)'3<G,08"<DQ=A0B5(QB
M";E<K?@)F3P"4ODY.60R! G+"QE+R<V8/)N4S$Y,D]*YJ94$J>G,DFB2@&)8
MF)$;DKIA.24TP_(R,Q-1I$0C3!D@E#(AU-E8LK9+877#,BE1QSF/B(EI-%:1
MEA>7/5F:SK5))M+^A<\N.>7'/+CGEQSRXYY<<\N.>7'/+CGEQF8&.:@X.F8+
MHS4$--07F,,P&!AF QK34%K<P7P::@M8TU!:'C,%X-,0&MYY<<\N.>7'/+CG
MEQSRXYY<<\N.>7!F:RV60(T1D4P5-F2474D_&I)^-23\:DGXU)/QJ2?C4D_&
MI)^-23\:DGXU)/QJ2?A#3R<&E:LUF429,^?.30Y^C=^GP3RI4"=9W/6P[GK8
M=SUL.YZV'<];#N>MAW/6P[GK8=SUL.YZV'<];#N>MAW/6P[GK8=SUL.YZV'<
M];#N>MAW/6P[GK8=SUL.YZV'<];#N>MA-IG,9N>==>>'*B#E1!RH@Y40<J(.
M5$'*B#E1!RH@Y40<J(.5$'*B#E1!RH@Y40<J(.5$'*B#E1!RH@Y40<J(.5$'
M*B#E1!RH@Y40<J(.5$'*B#E1 V%$8QWZ_-D4UB22:'SYR:'/TCOT^$'_ $_Z
M&/XAD1WA:\ZZ.)WB<B,>#'G6M:UC UYU@XG6,XF8\3,<68M>8Z&-8UC7L'N)
MK'OZ(_\ = _L^4\^QT,>#'G6LQ9BQYUH8UC0R(S%CS,&M8QF+ QYC6XLQ^6S
MZ_L;&X#B#K_"V$W%SX_]'','<'^%WB=:ZZUCSK'L'6/!]UKSS'7V.\+6!KC0
MUC7FNO-8ZW^[EM:ZUC6-9CQ?T1_[H']GRHC,7'F8O,]0]_=AZ.8!UUKS/5C'
M<&,:S%KP:SYF+/V>#$=8[S(8YD,<R&.9#',ACF0QS(8YD,<R&.9#',ACF0QS
M(8YD,<R&.9#',ACF0QS(8YD,<R&.9#',ACF0Q&?8^]!>=8[Q.CB='$Z.)T<3
MHXG1Q.CB='$Z.)T<3!Q,'$P<3!Q,'$P<3!Q,'$P<3!Q,'$P<3HXG1Q.CB='$
MZ.)T<3HXG1Q.CB=#7W6?\W/_V@ ( 0,  04 $Z6Z13IKNM3@=UJ<#NM3@=UJ
M<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@
M=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#N
MM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ
M<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@
M=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#N
MM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ
M<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@2F<RJ?$_A
M5CUJ2FI<BCB.((XI!CRRGKBD/J8@2()6*B4@;F46F,T@I6#3AV2K.44ZAS"1
MG:=ODY)_PM;:\\V5_"KS&EJD2U50Y:GM;0V'Y369DK?G*B+SB4FJI$GX1VI+
MDR2D&K\$B8E<_23]/S%1VFX&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R
M7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9
M+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,
MEQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF
M2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQ;;"B
M,D_P.R:43)_2J9&E4P-*I@:53 TJF!I5,#2J8#$JF&C2J8&E4P-*I@:53 TJ
MF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-
M*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,
M#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:5
M3 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&
ME4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF
M!I5,#2J8&E4P-*I@%2A4C ^+K6X8MP8UF.#.%K?M:QWBPP8[ZM;]7F,Q;AP.
M\(;PL:QC&M9@QGZQUC6C_P"+.'%[A:/M:W!F/[$S#%K&!WAP9PXLP#<,/E8M
M#<6!F..#6,#6-8WB;@S$8AKS7A@W 8-PQ;^KP;\?48M^/J&L;\,/3]:QC6_U
M8M'J/5GPPP^2[@Q[U:SU=:WZ-8QH:QO%A]KWJUC ]]7L&.X.C!C68,#W]OZE
MUK>#!W%OU:W /8,?P=#68!_#B?:[B\QC&NL8UGKB]CC^K<P8QGJ'0W!@:Z[A
MZ-;@WB=8QKS&L:UOHUF(_P"K?K_7C^VL;C^T8_K?H/4>H]1ZCU'J/4>H]1ZC
MU'W#U'J/4>H]1ZCU'J/4>H]1ZCU'J/4>H]1@/4>H]1ZCU'J/4>H]1ZC[F#[A
MZCU'J/4>H]1ZCU'J/4>H]1ZCU'J/48M9^Y.L8UC>'#[1Z-=]&!_Z_J'?[FX!
MC7<&,8T8,X(GU^;]?VOA;@UC6-^&#</@S%H:QK/Z\&X##'Y^#</Z&,:T?7^I
MK&L^&#</W1K6,=:SUP9PO?V.C!G#ABU[T>^KS,&NL8/_ )8,:WT8'F8.LP8Y
MZ<#6,XFL8'\>'YC/1F'VX>K68O-8[C]6-8/7%OHQK&8L9Z/_ %>PXFL]6,9A
M@(G]_P"WQ8T&"[GR(SY$9\B,^1'4"(SY$9\B,^1'4"(SY$9\B.H$1GR(SY$9
M\B,^1&?(C/D1U B,^1&?(C/D1GR(SY ,:QYD2+"@NY\B,^1&?(C/D1GR(SY$
M9\B,^1&?(C/D1U B,^1&?(CJ!$9\B.H$1GR(SY$9\B,^1&?(C/D1GR(Z@1&?
M(C/D1GR(SY$9\B,^1&?(C/D1#-E8KW[.LX\7J<6"9@P'9/-7S$27S&$]&A&2
M[(\JFI>$TF?8:BR^8P31PF>(/P"YLQ#+RZ9&BY.7S$^YQ1,>*(T<;^'%$'%$
M'&^#)8R5!N 8)Q>-]@XHC1QOC*'@=)'Y<^B3,8Q+UJ:,,FG&^.-\<;XXWQQO
MCC?'&^.-\<;X)EC9Z-&E1\J]%@FX#.*(.2<; XHC V"985ARR91'GY5-8<>)
M",PH+97-&%(I8[!>-R^8D8AV7S"7CC?'&^.-\<;XXWQQOCC?'&^.-\0S4<NV
M$\U^%^QM'J&\6"S_ -X(LAF94[%?-/QX9AA^?N/.'3A0[*I:_#BL.O&(A""H
MGW'($I;+WI:6AFS#T=TP<80RYA6$R;T%U3F'WV.EBYUV"8+M<*\DO)SK&M+M
M<)G#LR=BFHLH>9"@%F2IA Z1/'97/N; @H/_ +%:_P"]_);B#KKL6=Q^?%FL
M@BFSD=YTU"ERD?A.E96XTU)'##AT&H)Z)&4+'6M<)F9;)X3D:&<89,28C.^6
M7E?R7_[(.#('R&>CO#@UOU_4-^*S*Q^I<)AC'<TX\UTP\UL..\QZ(=?=?>.1
M'HC3<6,V%'>:R''=#CQR'#AM-P6$XQL@8@'#\$U,#QV8NL=,L$%XX7$-XY"A
ML=,,!>,<+1&M--@,<,.CDQ1QG<(F;C!$E8Q>7+4F8;-.3%')BCDQ1R8HY,4<
MF*.3%')BCDQ1R8HX3#7L3;'(>:A.M?.M8^TY$ANNF70ZPRXUYAIY[@CM<XCG
M+B--QG8S39A]]TQ$>Y,4<F*.3%')BCDQ1R8HY,4<F*.3%$,F9,/..M<@_(8W
M 8M_5-^+\.'%=R909,H,F4&3*#)E!DR@R909,H,F4&3*#)E!DR@R909,H,F4
M&3*#)E!DR@R909,H,F4&3*#)E!DR@8QC&&XQ*##SR<&>3@SR<&>3@SR<&>3@
MSR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&
M>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@+&Y+$C-^GS9B9:2(R^8%9H5_2-^*R
M/&6'GGC+D-D&8/17G3KKST0PX[$</08;7C3'XCIV#%C9PN^XTV^XXZ>B0H3I
MV.[SXPY\8<^,.?&'/C#GQA%8;@@PPT6B\^,.?&'/C!CQIHC,.EGT?,#!Z7K:
M-%>FV#!@P8,&#!@P8,&#!@P8,!8I&.1(LG-EGHL")!& R\3D<(:4,,*.269O
MAZ2S%V)$+184%DH/O%XDN.0HL:3GX#3<L-DG<&#!@P8,&#!@P8,&#!@P8'8C
M\%L-YKT$\>+2XOK"0#6$@&L) -82 :PD UA(!K"0#6$@&L) -82 :PD UA(!
M-E1)34KE,V-28U+Y@5FA7YQHT6(E9-.92H97\6C%H:UX+/'K!"! /R?GL:=C
MOF(I]1Q(CQ\Z<,2V4/OOQ#4(V\[#4+6.E"Y*%')P(AIPU"?,0(!0L6BJHI+R
MT-R?M),=?E90TYR9)!AERLH+R@X7+,*QR1.8S$_P13,F+$(A: 1)Q9:88?.$
M)\<<C,0?_8K7_>_DNOON/&W^.=OOQGILGX\6/$?:;<EZG?@ND)2[F9/",,.M
MF<(S&-J'ABO0R)LC)H,-XJ8?-FY.0GSQ<M+ODO\ ]D'_ $%E_L7Q+R:,8*PR
M)V-"BRDY!+121R ["*/O&W9<??9%E)^"5,DS9-OQE,V-28U+Y@5FA7YDYG,J
M3TJK?7RH%QDVH_6FI%LRD1JS32_3OP;\5I"?=F;AXW"<AS,_!?B3 [%>B1XL
M9R+-YE&AQ9I,(T8T>,G#$:/%,1(4S.P"L&9G2Y8M,CI.&0.-('"T]-0CLVF[
MTT8X?.0F%)D=(N0IH>@EF3 \R(7F4:#&:<C/$X9PU"'IAU68<)H^;.L0T&)#
MEZW*QW)CQ,'$P<3!Q,'$P<3!Q,'$P<3!Q,'$Z.)@9$X1QCC8T<3HXG1Q,'$P
M<3 Q]C!S,1QL'$P<3!Q,'$P<3!Q,'$P<3!Q,!>!%.17'6N0EE_L7Q(1BD632
MZ8%8#I8R5X)*889-DSSL50.30F[%<-$&0)M$@PI5_1*9L:DQJ7S K-"OQQ:,
M6C%HQ:,6C%HQ:'&,>?NVJ]4-7+>VF' C1ZYF.AHFWJK:_IBN(;[S\+$8_$T2
M*'6=!DXZ#)QT&3CH,G'09..@R<=!DXZ#)QT&3CH,G'09..@R<=!DXZ#)QT&3
MCH,G'09..@R<=!DXZ#)QT&3CH,G'09..@R<0H4*!#-&RA1WK4C'6I&.M2,=:
MD8ZU(QUJ1CK4C'6I&.M2,=:D8ZU(QUJ1CK4C'6I&.M2,=:D8ZU(QUJ1CK4C'
M6I&.M2,=:D8ZU(QUJ1CK4C'6I&.M2,=:D8ZU(QUJ1CK4C'6I&($UE,:(WZ+/
M'H<.%%C1#!0T3:XX]$^'U$""^9BPXT6#\(!>.:B12AJ _P"C! *F#+N+/Z$8
M6F;Y_P"77"A*2K@G5%(ZC4 GTEB+RIY.WNVU-T2EOP;\5;.3Y8XV=3IC.L3S
M%LZG3&MG<Y8.MSI@ZU.L63N<M'6YSAUN<CKDY'6YRT=<G(ZY.1UR<CKDY'7)
MR.N3D/3F=N!^<SN&]UR<CKDY'7)R.M3H=<G."6FL>:$5M%B-F^#!@P8,&#!@
MP8,&#!@P8,!8J^:B1Y5&)Q#! T5=RAAK["!EXD_!B0W6D3.2=D4R>#)),'GX
MI2-!@.2@W$*Q96>@QH\E/P7SLK,D7,&#!@P8,&#!@P8,&#!@P8&1'X+8;6O0
M5E_L29_WYL!ULX8Z^7==@2^#*S,,N]"<)P#,25E7'RY6'"><DT?+&HI*)*R+
MA&$_"@-=@N3%A-DL^$AD$>=QRY> 4@?,JO25(UA2]#:#)2B$@^+1B&O!9-_^
MX*$"\QDL-D!Z:F<'IHH.%PX<-Q($A>APGS4(Q#.L4CC6EY7#9TAR,Z4.%7VD
M2Q<@5C*,I*2+84\+R\LR)))?%<=D4G<=+267.RN8DB,,H=EA6:3$\PLZ<E,K
ME9DM#DY>)+HST1\BI##L5]!_]BM?][^3BU@-1X3\ZB1HCTTD,2+%$3-.DU&_
MPDI4V&8E,(["/ [ _P#WJ%^$9>80CE)&Z[E3,8R8D9*;O%2DO^2__9"_T%FU
MC)$Y'Y3[\P-16N'H\-YR8FH<)IE]X/S(Y$:X=C0H3#+[H@'(I5YAZ.[%SL=D
M+/1VPHTP?,%A()!'G<<N7@%('Z)OQ6;&LFT";'RT/K<RYCTYF+[#!LP:=,S8
MX<=B3H_$CG)D9.QS1N.<BP9V>@%RTZ/%"I2<'B<&6G<E,2D^>=/3J9%YD]#G
M4RA.EIJ:*P7)J9=).SN9NM+3>-#-/'7WI? FAXNQC[['7)U,(;IDW%-,0C&L
MEZTEQIX_R(PY$8<B,.1&'(C#D1AR(PY$8<B,.1&'),8\DPP<B,.1'PY$<,@F
M&!D(RP-A&6MY)C#EF<&PC+PY$<-@1VCD1AR(PY$8<B,.1&'(C#D1AR(PY$8%
MY<;.1''6N0GG'7V9> ,O &7@#+P!EX R\ 9> ,O &7@#+P!EX R\ 3XL7;))
M#((\ZCER\ I ^:SU=;PM:S#@;_;\&_&92F7S-W2$A&D)"-(2$:0D(TA(1I"0
MC2$A&D)"-(2$:0D(TA(1I"0C2$A&D)"-(2$:0D(TA(1I"0C2$A&D)"-(2$:0
MD(TA(0Q(2%C2I8N3@-:Q@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8.)
M@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8,6!OT^:=+.'2I<
MO *0/T.+?BWXO_W?T-8,&XX-:,&X-9@,&L^&#1@T8>F'P^H^@P],/3^ASZ/_
M %^4QF(P&#1@T8-^& P;\<!A\QOT_9, U@>]&_T-:,68_4-;Z-:S%N 8W!F+
M,<1B/H&L]6888L'H/^G]#GT?^ORF?5F& 9] T-;@/J&_5GT^;A^SO.MQX7AP
MO#A>'"\.%X<+PX7APO#A>'"\.%X<+PX7APO#!X8/#A>'"\.%X<+PX7APO#A>
M'"\'68,>8W'!HP:,&C!HP:,&C!HP:,&C!HP:,&C!HP:,&C!HP:,&C!HP:,&C
M!HP:,&C!HP:,&C!HP:,&C!HP:,&_\W/_V@ ( 0$  04 %:KX;0K<U5[KNW /
M==VX![KNW /==VX![KNW /==VX![KNW /==VX![KNW /==VX![KNW /==VX!
M[KNW /==VX![KNW /==VX![KNW /==VX![KNW /==VX![KNW /==VX![KNW
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M@* -V>5HE];%O8M<%3BN-=[1JHVO+*G]N:PJQ+Z5V(7#UTI;0.Q.X*ZE-Q)
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M])C5Z3&KTF-7I,2&4S.KT\4\H/)^B'R+C[+**W/3U.V"V@I*+1JDJ+H+2?\
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M2FJ-^2K:2&=*H<&FQ13J$XO=U[O^5#=6EOO2VW8]=KRE0/YZZ"FFHMS3>JU
M!N=6$M1!*H%!(W9N]_E:M2W1=;WN-UK=FYI-_P 90+B0MPO:&BZI/M"RZ"=.
MEI:FSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XS
MC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XS
MC.,XSC.,XSC.,XSC.,XSC.,XSC./D4R&K\A6$^&7;F0GQ"9D."9X_I^2VM?Y
M@2C61M/.TN+FL2K2R8 @R.,B#D1'R;\T/4JTZNYOS6FF*9(J_FJ0I'4\P4T
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M4U"F%U-($(S:-3$&7ZFG]HB[U>MVC_\ >,OP_J1OL_>/I%G1J!KJC<5-:_Q
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MXDDQ1WG=;LHU-X4Y::C+,\WU21ZK%/X"P)7@(BAO*\W;1JW]*6FHRS82Q6?
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M9A5IM2)J]HK+356 U"BJM-EF@+25B#^B;"_&FHLS2J@3:DYX1EJ1I#M*9(#
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MV5(/J;M$NB2 BLR+VLB"1%3>E1RV\+NN[U5,_P"541C3%OI.(%!5"9#49O\
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M?:;VHHC5Z#:E#@E21P$*0>,C$"8$YB8-Q?W]PU6\JMJ9FS)_8 !@ )!0
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M,N:94K"D7U-41P&8DJJJ2-6H JS%SS0!( '2H83_ %+?9%'BT+^P1<?[]/\
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M^'T^2/A]/DCX?3Y(^'T^2/A]/DCX?3Y(^'T^2/A]/DCX?3Y(2C0IJE)1(
M >@#"%-W71%8R&HC&6. X99F64>-H_7[H\;1^OW1XVC]?NCQM'Z_='C:/U^Z
M/&T?K]T>-H_7[H\;1^OW1XVC]?NCQM'Z_='C:/U^Z/&T?K]T>-H_7[H\;1^O
MW1XVC]?NCQM'Z_='C:/U^Z/&T?K]T>-H_7[H\;1^OW1XVC]?NCQM'Z_='C:/
MU^Z/&T?K]T>-H_7[H\;1^OW1XVC]?NCQM'Z_='C:/U^Z/&T?K]T>-H_7[H\;
M1^OW0M*A>4C58R ! )/$.,^C/Z*TC_&D_2-:X>C&1GZ)<,+2HTV>JV2J)D_8
M!G"+=VSTF;+6I6?V3SAM"DZ1,RQD)@3/WD#[2/HPA*-+3VK93(4<I($5.RJ,
MNI2K2,I@X$'T'+TQA HVU%JE4\"B9^V0X!PQ46O;.CH,0P(D,,3Z.<O*../O
M_&*S4*19::%F.0"K*>>9$QAGZ(&.?Z#W5H^BP'-JDB:O+) ,)NIQU?P# SU%
M3^K&[=\K^5^8;<$V=_34&M;N?X2)CMK=SA5H,P5QBI2H%J+\[?)>^K&G;W6]
M]U5+"K4*FI1NK&I45C6LZATX.4'.(UTCJIU::U%('R3_ *2[DW8-XW%C<5VL
M0J#MZ5.X(:M2>N2%2R1YUCV@"TFFQ>0E!WC=-3WA_J#=4P+B\T\VFIQ-M9AA
MJIT ?6<@5;AAKJZ1V=*E] ^E;2UN&ITPHGIF#/ SU \1E*4N'$RD&.\Z^D_W
MC&G_ #&XU2GZS99S^R"#O*XF,^<8!.\Z\C_>,'_^G7PE_$>'$<O! '^95YF4
MN<<9Y<O! EO.OC_?, _YG7E_OF/B=?IG@SY(^)U^F>#.,-YU^D?M_8)Q\4K]
M,Q\4K],Q\4K],Q\4K],Q\4K],Q\4K],PI?>5P 1,38X@Y$>@\<%*F\;A7' 6
M(..(_#&/BE?IF/BE?IF/BE?IF%__ *5QCESCCP80#_F=>1_OF*S7'M*=33/C
M$@?PG(3F92F29DK1+GLA10RGA.;XRRGGCG(F,HRC*,HRC*,HRC*.RIM3#2_C
M94'*Q$-2OJM*FX1C(.'(91/2P345)F):I#TQ0>O1D*BDKB#,#["<)8@Y$8B<
M/3%!M:IJ(EDI$P3]T-O 4Q^5!E.8^S*<Y^B4Y8REC%)ZE,A7!*DC,# P-X=E
M_P )VFB>'K2GEG+TY10E;J.T0.)LH&DAF!,SAS4)QRECP3I(M)&[124*NC*\
MISTD&1((D1P$@'%EG1N:B#L:A(4S!GIP)PGA.8GPD$<!D+FD$? $JKJ7"F0#
M%0=0Q(!PPGC*+6@]L>VKJ"@!!)!,@<)RQX\N&4446B*@<@ H0XU'3@2LP/67
M.4P01@8IU*NAJ3&6I65@'EJT$J3(R((GF,1A&491E&491E&491E':4V*N <0
M2#E(XC'$8'T8138G$J/V"+C_ 'Z?_N+&[?\ >?\ ]MX6G4H.UFU*HKE]) 7$
MNZ%44 (!J4R#3 D3/2=\4[:V1:/8TU1M*'6FJD V(*XJ^MC(@,TV/- 6W_X,
M5-5NCZ0M,SJ9DY]J><=# 34 : LYQ>VK4::44MZ=34$68:5O-IR!)YSS&J1G
M+#,[NKBA2_)]II--J=,E)LI"'2&R&;,TY2!0%YG==-[.G^7KHQJDA 3)BL^<
M"_,0*X-,K(G6TPT6-M5LZ:]M1JZQH4&:_F"!,@LI4HNF3 B4C/@NZ9H%[:HA
M1R "44L.=BK@@$9,I!C>YM:NMJE)-(=49E752DK'G D"H0<2HD&$I"7YBI;T
M@AW5,D*@DX2IJ;2,0098R F )S$HNJ?Y.F=WKN\/,! 7U+39IR&N3'4)ST8:
M0.;A5WA2H4]=T*:J5DH!4#M=*D"4G48@:B*A'- P^C424W>AY[\)/]A/[W&<
ME'ID(I6UM2"4$$E49 ?7,YDXG'];7^6OFJTYPU-;W" "O:UB)"K1<C#(:T,T
MJ*-+@R!#66ZY7GS+<*/S=^Z!:M=IST(LV[&W0^SH*S 2#.U1YN?I$9&,H82_
M@7\5'XCAC=-K4.FKJ+3 QT-4=#]P<),\"DPMQ2HJH:PFN$OXJ07@PP,IRYLS
M%NRV:5+6XI,E2H, 5U/J.0$Z8&#2UL*6L'3.:4J=)%MJ:<S2)*0W/+#,$-/4
M /5#!23**=+>01[AY=D-*\U0 292TKS, 0)MKU2("NU.]-!.U3=G:J H"=HM
M)2.;+3(%BP$I"4;LWIO(4J=7757G R8Z$[)L=1;2SZL9\W$S"B+>M=E3>&JZ
MAE$IHH42;G/.3!])+GAD0.:+:T_+*:U2B["E(_SE.KGZIZ9@E9%IZ)* 1VB1
MNC=5I;TSN^Z56J#%O7JNK<[#4  JAF!E(%=),XW32MK<:+BHPJ3$]8%1E ,Y
MS!5/5]4!F*@'25J[N93^4%>LL@2#) Y7&<\"HX8W14N VNH*Q<$R#:%4J)D@
M()F1.'-,R1+4+-;1%5RK%M,V4@,RB1+L.">G46!;2S#2 *HM*;BK52FU(%N
MA6J$<845 .=,S4Y1KK*O8U*K!&UD:4D"I$W&I^?,X.I"@:)DL:52\,KEZ=1M
M9;201KT@+J'!3Q!5B9M)DTQ:WC(:ZTK>C363'%9F3G0.:" P5B=+3)Q*JK[P
MI=IHO%%"1F22II(IFN0&IDQX@Q) $7*V8_X4.0N)/-!D#,XXYG.1PC=8N:3F
MYNA4$P3)2KLH(DP ($C(A@>('&#>#MY]F[#V4N:6E_X@;@QDOV Q\K5K2DJW
M1[0 A5,V6H #+3(DRGD6/]XXFQHU)-?TTG48<3!=*S_BE(M.94:M*LP$XO\
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MSE,'+T14N%O'%=Q)F#D,PX02#,SX9YP+<7C]@)R76=(GGA.6/#QSQ@4#>/V
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M#?BC'S_7+*?2:N%("5V>F,HF=(D<\/*O(?.8\LPUC9$H"T?+Q)WJ)7)4S&%
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MMYBJ!IM^QJXO8QO)-DX+3<OG5JU?:DZ+*,6"JCZN3C<[=51(JC=0P=Y)0Y!
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MBFT,11J14H)>$G_E/R=WE\XXX9=G^Q?_ /0+_%E]:\<H=G7T[_#GC!3EL_\
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MU7+#1;0D6H@K&$;1XSPM$"QRK9,R $( (F3*).P2AV>3DSQ\]\V<?P^4?_\
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MG)MSCU!7W4M06AW%?#35:XP/:A9K5M5>KJKFDS'%R,2H>(%T*GH!C-/!$?\
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M6R2SQRNN*210.<PAV_Y3@/\ KJ1_V7Z?^Z$+=JK6[A#E<I/"Q-I@XNP1A7B
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M?4A#_M#4]#]INO+I&I!VCV!_ZIZ%]/9V]G]YOI[.@ -&U,1'R  :EH?:(_\
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MHYM&1A066$ZSAP<X9F_J>UZ76'^)UZX5#%GD':'+!QDE1T3[0#0:MGYTR_\
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M%_I8G[2&$Q>\H(>(H':/E PB _0/:'1FPOW0M3.%'96?I$B#)%VN8AW+MLS
MP-6CIV9,OC*)$(=;L#OB;IV4KYPB218'B9-)LL_:HRT0HL#A2(F$&PI(RT09
MR4%!:N2JH>( &[G> !Z57&6D3K.4$6SU91]+**R;=N<%&R$NH=4QY=%JH4#)
M%="J"1@ 2]@ATR:@_=&91A'"43'JN)%:-ATGBGBO$H6.6.=C#I.U?TE2MDTB
MJF\I@$>C^(N(]\$^WL]*+V>$)A().X!?#-^D(")>P3 /8/:'2A1<' JATSF[
M@NTQ*9( *3PA3 HHE "A^B3NE'^$.G7<,4IGQT3OU.XY%9^+82B@#]82BJ^(
MCW [I53'*'8'D\@=*J Y$!7,F=8.QSX:BJ1!3(L9+N^$*Y4Q[O?[.^)?)V]G
MDZ*;TQP/=,8Y4S+R)D0$XB8P W,84.X8P]HE[O=_[NG*+ERJ[0=@8'2#X[U\
MW7 Y/"/XB#OQDC=Y(.X/Z/E('=^CR=>FKR3UX_!NS:%D'[N3D9%-G'%[L:R2
M?OCN'B3*,+Y&R)3@DW#R)E+TX4!P(JNW*SUXNH5RJX>/7 @9P\>.%2G6=.UQ
M .^JH8QS=@=HCV=?T@/]&MYOK^D!_HUO-]?T@/\ 1K>;Z_I ?Z-;S?7](#_1
MK>;Z_I ?Z-;S?7](#_1K>;Z_I ?Z-;S?7](#_1K>;Z@\=QZH6/1M-TB0;U&G
M4^JP[^5E)*7FC@R057*W0,E&PS#Q17?/W)DF;%HFHLLH0A!'JCUV0.@H_@)'
M#(5ZHU,<[8[N+O%%8N3MSJ$34,@99 PD$Q2B)>SM !\G7RY/];'(G_9'$?\
M0P'%L\T+Y4+'1:[R+YDR>EUGYD%EQZ,ME'JFHDI#&A7'&0TLCF4J+J93:OEE
M)1BF3M5:-5>U3P>P/D#,;;NM3@JQQDK'S*H+D0M)Z$D2LYS)Z+?-N94AWHJA
MWJ,4U)I\#*,E(QT]2(,U'.VYB@9)0A>O^7AUB=V?(J_5.(6GZ!FO)"OVG5Z[
M!7[)IRS<GK?I<'9+1FLW(-9]KFZ5$?MGAK0")H9FDJ5(S@A@[G7*WBMN5EG9
M_%^5$/:=FM$]/3,C8D8^:X5;B;EC5[@^EII:379P]BRJ$ML"N^$Y2BA/ID$_
M8MV&PSFAL=FB*16;]SE'>[O:K;*MX:NT.E6*7L+V#)/S,FLDQA82G51Q&QGB
M+*$102:D*)@ .OD7C+[15ZK'X1SQ^8MHF]D<7A."B\TINF[!&O<YN>F(_:#1
MA"PESJRSLT:^D !-U'J*E(<43G ?DN;/:M#SQ_2."O.#E,_Y+Y8:ZQJVNU>"
MU?E35M+R^_0.%^,>WWNB1%2:_M%]JQ;-RT9$CC)@(+=TAKUQVN_(7'N1^R;#
M\S:V<Q,^EL7V2*W^(K6&KY7;*;.:G9KG%/'Y:-.\@K+8&"J5>>F0FW*+([I^
MV2.@ !_T*+O&#WJ2S38<TDCR5-N4:3TE---SW"3-7M$,<Y&EMSZVM">BS,,Z
M[6[QN/>+X:Y$E2.NQK&YIRAS2-C2;OA!Y(SI2)4=#Z(ST;.7COPW=MR"VNTQ
M%B^ #.(YP86#\".2%,O^ZJ4N".CD(LL1-3_$RF%\5(BIR)+=T1[Q 63 #]T?
M*7M[!\H=?D$Z]YM+_CZ_()U[S:7_ !]?D$Z]YM+_ (^OR"=>\VE_Q]?D$Z]Y
MM+_CZ_()U[S:7_'T0IL%<IE,<I3*&TRFB5,HB &.8" 8X@0/+V  B/\ !U.8
M[H-7G,BH6=22:L+E#YRFJM9U"G-]FZ3:)*/44B;8A(F3,>)*T4<1L>0! IE'
M8*JAS1;R-U+G+%?AG=$WE[4:V%\2J(&MM=!6<.SJ2+BS.BL2]IQ(Q3.Y-V=A
M"F'R#QDP*4N\OL<_66%IVQAM#QM-EJTYGVO$;*5.K9K*VA\\LD]78XK0QWYU
MRH$9OT0;^&!RB4D$SR&(E=#::-.,8>QXBS.NHCH2QP*GZ?"D33<$@+A$,2"H
M25[G@$;IB5]WFP")!!/C=?5"=A1*<;SC9!'M* B E'01[!*(]@^40[0\@B'E
MZ^&N^>O>-?[P.L$863(;/08\NMJ.BSDS9L_F6:CI',M(*A&E:56TS<F#AX54
MYBG,B")03'O' 1* _N0M?Y,8+EFX15:>K2%;1T>G0]D7KSQT1--XO!2#YL>1
MAQ?)HD*X!LJF5P4A04 P%+V? )QI]W<;_'U\ G&GW=QO\?7P"<:?=W&_Q]?
M)QI]W<;_ !]? )QI]W<;_'U\ G&GW=QO\?7P"<:?=W&_Q]? )QI]W<;_ !]?
M )QI]W<;_'U\ G&GW=QO\?7P"<:?=W&_Q]? )QI]W<;_ !]? )QI]W<;_'U\
M G&GW=QO\?7P"<:?=W&_Q]? )QI]W<;_ !]? )QI]W<;_'U\ G&GW=QO\?7P
M"<:?=W&_Q]? )QI]W<;_ !]? )QI]W<;_'U\ G&GW=QO\?7P"<:?=W&_Q]=@
M\ ^-(AY/)_AW&]@]@]OE\OE#_N_AZKN=9C3:OGM!J,<E$5:ETN"C:U5Z]%HF
M.=-A#0<.V:1L<U!10QQ(DF4#',8P]IC"(Q]DY2[-E./5&R2(PT,XU.S0D&UL
MDFB5-RK'PT?++ XG7+-,Q%52-TEA0)V'/W2^7KXT.(?K/6?U3KXT.(?K/6?U
M3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U
M3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U
M3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U
M3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U
M3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U
M3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U3KXT.(?K/6?U
M3J#S3#^6O&*T:;;E!CJW5*M=*LTL=F=?_5"(A&YA9+3,BKW.\FS0%1=3NB)2
M#V#V+HQ3MNPDU;?F:<>^=LSR+5F\-I52!NY<QZ;M@=Z@BIV&,D"Z(G .SOE^
MGKY>9+?/0UC=*Z[R$-&.82MNJLDQ2#)(GTE%XV=66S?:(JE /#,4S<4A[>WO
M]H=D'0<UIEIT6_6ATJQJ]&I$(^LENLKY!FYD5V4# QB2\A*.D(YFLX.1(AC%
M11.<?T2B/5>A^0>)ZK@\Q;D'CJHQ6OTB<H$C:FL:LV;R3JO,["U9K2R$>Y>(
MIK&1 WAG5( _R@[;$YB&3F4;4Z#=6>X.6!"KMZG6&,G$P;RQ6)4I@)%0[:<G
MV#(ZRO8'I3Y!( $RA0Z"/.LT-(F1\8&)E$1>F0#R>*#81\<40_\ \N[W>BLT
MW;-5TLB9P5J1= [A5ND<4C+E0*<5%$4U""43=@E 0[.WM#JLY1G!JM*Z#=);
M]FH1G/6ZLT^&"2!F^D0:V&W6:0CX"KLQ;QZW8J_712,L!4P$5#D*-A;4^\2]
M(EKI4[?E=H+7YDD5(6[/K*)(R^T%VLB85I.HVI*.(A()-S>$];I@'?,D8>\D
MS4=LTUW"IVJ#0RZ!%5EDB%.HV1;B8#**)IG*(D* B4!#R=G47FF+YG>-=T:?
M0>N8FBYU6G]ILS]C%)$7DY$S"/2.#.'BD5"F<O')T6C<#E[ZA1,4!NU)U'*+
M[G%]S"OL;/I54N]9>5RRY[495_#QL19K6RD2)*Q=8FI.Q1R#)[VF:O5GZ ('
M4\0O2G<5:(E].%HKW#HIE^TCF HME.P0#TXYA .X/\X(_P '6I(9S#MK&XQ/
M';AR!U-M]MPT8YJF.T%>%:VZXG;R;UJM)_9:]B9%(Q:E5?.?&[44C@0_8U53
M<MU$GINZS4(LF8CLW=.;NMC 82KF[J9A["]H]A1_[!_Z&2,.!<Y)9_MV82L3
M=+5NG@+K4/"LKDI!)O97>MMBF39W.MZ+&M5X]I1U3@M:E@$Q1:HM59!LB5RH
MDJX*DF"ZJ")VZ*BP$ %5$4%%W)T$CG[1*0RB@E >P3&[.T?WHD':B?LY>H%)
MRMGVFQ;-%>P5%^L &.V63.=$L[5I(Y"E?Q:RA4G!/TB&1<%273UK(+?$1L!,
M:9G,KG%@D5&*TO7[SE\O)MG2MASF7459@5-XZ8I@*IR'=1YQ.W<H$6#K(>,U
M/KR%]D:I,6=;+H]I&D2M4-&6IPF^LL3)VU5R#2-RZ+?!Z><'*2:$>K^EXIOY
MM+HT_*JL+QN=A8$;VS01:"5I#M%>XJI3J @Z)Z3#U5LL4/%6,!7DJJ4%G/=
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MZ*RJ?I!EE%*K%24@Z?1=2XG9J%7CG"@G90 V>^ZDYLBL8W'^;;.)Y:):"Z5
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M.T.D>9;FIM"<:5M;>84;0@G8H[MEJ#&.6E%H:3JH*?;C"(5;(&(C)G)Z(JY
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M+KDJ2@N-JF)2P:8>90?-5$[T$]+S;I1$)/Q08E4 B/=*4H='7/#1PNSF%09
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MLT/Z!#L$/[L_0(=-F)<JT@K)FHBLT9ADE^!JU5;*&6;JMT JWA(J(+&$Q!*
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C4BHB-C5%R%$A%CL6:+4ZI""(B0JADNT $1$ '_\ EO\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g790774g48m48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g48m48.jpg
M_]C_X1!617AI9@  34T *@    @ # $   ,    !!1\   $!  ,    ! JP
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HR.3HR,0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   **H , !     $   &1          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M?G;E(_6'#! ./G2Z8_4LGMKSZ&UO]I)3J)++_P"<.'.W[/F[@ 2/L63P>/\
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MV?_M%^I0:&]T;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (
M   X0DE-!"4      !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !
M+     $  0$L     0 !.$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -'    !@             !D0   HH    )
M %  ,0 T #0 +@!J '  90!G     0                         !
M          **   !D0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !D0    !29VAT;&]N9P   HH    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   9$
M    4F=H=&QO;F<   **     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    ".$))300,      [L     0   *    !C   !X
MN:    [0 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MJA;Z%@MJG\U[?HO$):7J*\E"Q$4>+3>7Z7^*V$D/TB-6/<WR)W#_ *<H6/\
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MV*QF=1P<3)Q,?)=MNS'NKQAM)ES6NM=[F@[/8Q"NZQ13F68KJ;"ZL;B]H!!
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300&       '  @
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M"DTU)2U-6':)?#+(J'2OX]R;N'L5NFV[?N.YKS%;7"Q0O*4(( 1 6:E2. X
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M6S0'7);21C)SK4CUZYS\B_=4]UMGYNY=W>?998[2SOX99C++5'1) S:5UMQ
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MU!/XY)(/U)/U_I_3_#V4&E>T8ZD(%V +J ],TX=<[C^H_P!O[UPZ]YT\^O7
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M?NO=>]^Z]UU?_7_VQ]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZO\
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M%'RKU0(=?BL[&;S-3_@Z[6'3JY'J8G@?0&W'^/OS*QII8#&:BM3Z]6"HIJJ
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M#?\ UO>NM@@\#U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UP;]2\?@\V/\
MO?X]U)3 89/7NWB?BZC-"&YT+<!M).H7+?4D @$G_'W:D1&0:=49YVJ,>&?R
M/Y5_EUQ\(4 V"2<@2>JX!_4+@DV-AQ]/>P%TD18'S_V>JHC+3PHAJ_I$'_!3
MH-]R]0=;[UK4R&Z-E8#)Y15D\><CH$QN?I23ZFH]Q8O['.4DKWN6CJ%;C@^[
MB[N+?L08*FI%*^6,_P"3HKO]EL-REL_WA91,\9+576/2G!O7R\_3K2P^5G3'
M:$'R7^0$.W>J.U:O;\?;^\QALE_<??\ F(*_#OG*PT\L.X/X=4OF*&2)[QSR
MR3>06/D;@^\V>3N8MDM^4]A63<[9;WZ  JTL0 :C5# M4'Y&AZXS>\7MOS==
M>['N&;#E/=Y.79G.B58)G%0U5T:8R6!-,K7&3CK9;_D_X'.[=^$6TL5N/!9S
M;F57?W9,\F+S^'R>#R*Q5&YZN6">2@RU+25B05,9#1N4".I!4D>\:O=&ZBO.
M;[F>*6-XC;P91E9<1K4 J2*@X(X@]=&?NE;+N>T>R'+NU[S;W$-U#<W!*3H\
M<FDRL5JDBJX!K45&1D=6C17\:7^MA^+?[Q]0/<<&A)IPZR75E90R*0OD#Y=9
M/>NK=?_6W^/?NO=0:E$EEA1G4"S%T/)9'!4@W]*QN 03:Y( !'OW7NM;;IOY
MI_SW?F!@-Q]U_&KX]_RT^N^CY>V.U>N]J[(^1O9GR!H^^]NQ=4=K;NZLRY[.
MQ>TMO/@\/N6MR&TY9UI=-/((9(I!&RR*6]U[K8^Q#U+P4QK? *UJ&G^Z^U\I
MIC4HJK5/3&11JI&J"WB;@LEB;_7W[KW3S[]U[KWOW7NO>_=>Z KY _)GH?XJ
M]>U?:_R)[/VQU)UW19O;^VI-T[NK'I*.HW!NG*4^&P.%QE+!%4Y/,93(5]4H
M$%)!-(D(>=PL$4LB>Z]T-0J(Y^$)U)-XW4V!1UU7#"Y(X%_]8^_=>ZUH>@1_
MVU6_.W_'^6ITV?\ UZ.H1_Q'OW7NMFGW[KW7K^_=:)IUQ+"QX)X^@')_P%[#
MGW[K6H=(C>6\<-M3!R9K)K430^>GH:*BH*;[_*YG+U\@I,7@L)C8CY<GE,K6
MR"*)%L@]3NRQ([K=(E<AC_J]>F998U5@"/$_R^0_/_5PZ26RMG9Q\C5;_P!Y
M-2R[TRE&V,HJ&&<5N-V)MORI/'M3$SHBQUU5/-$LF6KU"-7U:J% IX88PZQ5
M:(H[./\ J_U?[#%M TLAN9S^O\/V*/(?;YGSX#'$8T)*W/\ 7B_UM:W-K"]_
M:<@5Z,&%#0=<_?NM=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7K#^GOW7NO>_=>ZZ/OW6B#Y'I
MOK:&*LI:BFJ(:>JAG%I8*N*.>EJ$)4Z:BGDBDBD50H N+FPY]U8,581R%'\F
M'$'U^T=-21&6-XV17!%-+?"?D10X_+H(<ST#U;EZALA#M.DVMF&EGJ%SVP:O
M(=?YU:R5>*]\GLZIPTM96QMRLE2)RI^GYN^EQ=Q@&:<S'^D*_+@:]%K;/:D,
M/!2 >L/813T*Z?YUZ9/]''9^V@@V?W/E:VE@#:<7VCM[%;XCJX](\=+-N7&_
MW6W5&NL<S335KA3^DD>[M-:,/'GL2KZQ\$CC@*?V==(^T9/$YZ2366Z6D;S0
M;NLEO\*"5 6[C5M<@!<Y^'B. H!PJNKNI]Q=V_,OY18[N+#=L[J38NW>B(XL
M-\=OD%OKKG [;_O%M:MJ*FOH]M5.[MER9J/,S4*23A&>6&:F8!9?*2),_>D.
MS\H<N?N8VQ,LEPS^/;0LVI0I'?H=\YTFOI4>76.USL<_._NCS[:<TBZ^CVJR
MMQ;)87]W":S:QE$:)=6*\30G%1TJOCY)@OC[\S^UMA[7VQ\K<GLNOZ$ZWRR;
M6WG5[Z[<R6W]S93>.Z(\IN+1FMR;CFQ6(KZ6@C@%3 YAFGAE1?T\H-XG3=N4
MMLW6[DM?WF;YP0D:I11$:$E5!KY4\P1Y]&O)%D.4_=C>.3=JAW9]GCV-+A&N
M9GNF$K7"5TM-*Y\S7AFM,9ZLJD^0_6V*I7GW!'V%MGPQEI8LYU-V/32)XQ^Y
MJ2BVQ7(OCXN 3]1:_L I9/+&DB*6!%:AR*U^513[*=3S)O-M;M_CFX2(Y.=2
M\#Q((%<_94?/K/0_);H^K5)!V!CJ)7"D',XS<6 MJ_XZ#.8;'&(K_:U6*_FW
MNPVRX&1;D_:U?\)/33\S[$ -.ZBM?Q*P'Y=O3[2]]](5LK0TW;G6E3.I :&+
M?.V7D0M^G5%_$U=&;_4D:O\ #W5K*]7X;/IV#F389\#=(3^W_*O2LI]\[(KP
MIH]Y;5K!JL&IMRX:H!;ZJ!X:]N6'/M/X4PX[?-_+_/T:M-:@T\>/_G(>D?W/
MV9!U9U-V3VQ'CQN6BZXV#NK>\N*HJZ-)<P-LXFHS#8RGK$6H@IGKH:5D$K B
M(D,01?VJVNPN;_<[.T),-M(X5JJ"37S\\ <>B3FO>8=AY9W3?4*.;9=0&H]S
M#@E?0U^SHD=-\O/F%7[*I]^T?\OG(KM"JVE_?.')3_)+JJFE.WI,1_&DK)*.
M>B2IBF?'D,T14NI-B+^QG)RSRW;W$UJ_,JF]27PPG@GN:M--0: 5]>HJC]R?
M<&ZV%>8;/V_3Z0VK3Z#)35&%UU4F.A)&0/,4Z.;\>NU*7O;I/JSN>EP<VVX.
MS-D8/>-)@JFN7(RXB/,TXK(:":N6& 5D]/"P!E")J!^@X]A"^MVV^_GLUKH4
MT/\ G]/V=2IRQO<O,7+^V\QR6HM[V]@JT8\B*U'E_#_JIT-].;Q_6YN;\6 )
MY(_V!]I&4*Q %!T(TKX<1*T)13_(=9_=>K=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW77]?]]_MO?J=>\NHY24"RN0 0?R6('-KL6L/]OQ[
MV)%U4(ZKX8X:S^WK+&&%V8W)M_7@#\<DWY_UO?CUL+I)S7K)[UUOKWOW7NO_
MU]_CW[KW3?5%ONJ=41?(P8)(P!5!<&0V U\67\V!(^GOW7NOFX;BQWPWWGGN
M[>X.D_Y'?9.XNO*W%]R_)^'O/=_\W'NOKV/=_6/7GR.W3T%V7\B=V]7;4RT^
M=%!M3MO#UCYG$T%7496AQC1U<;RTTT,C^Z]U]'S;$?AQ.+A66BG2+#XF/S4$
M[55'.4H*<)-154A\M71M'81RO9G0*3R2??NO=*/W[KW7O?NO=>]^Z]UK8?\
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M65@"%  "A;>_=>Z>/?NO=>]^Z]U[W[KW75A>]A<\$VY/^Q^OOW7NL4JJ%0
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M@^IEDT%@>??NO=/WOW7NO>_=>Z][]U[KWOW7NL4OT7_@X_WH^_=>ZUFN@?\
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M5#,\DFE%4%@+DVN0/K[]U[KMIHY%&APVETO8'^TNH?4"_I/OW7NM9WH(A?\
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M^_=>Z,2?YE__  I,U%1_(>V)Q:__ #D_L(C_ &#_ -_ K?3\>_=>Z]_PY?\
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M\-52Q''U58H2%M97B_NO=&)_X<N_X4F_]Z'MA_\ I3^P?_L]]^Z]U[_AR_\
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MDSL>!C%,@>/5'/OF.2.32>48!U^C 'W[KW6?_AR__A2;_P!Z'MA_^E/[!_\
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M_P YL_?6V<#O':F:A^3.RZ>++[;W-BZ7-8/*14U=O6EKJ>/(8RMBE6.:**5
M]G16! ]U[I2_\.7_ /"DW_O0]L/_ -*?V#_]GOOW7NO?\.7_ /"DS\_R'MB<
M\"WR?V#]3_7_ '_AX]^Z]T7?X[?SW_YY7RQQ78^;^/?\F3K?LG%=1=J;KZ1[
M&K,?\A,3ATVSVILB.@EW5L^=-S;@PLM;78:/)TYDEI5GI6\JZ)6O[]U[HQ'_
M  Y?_P *3?\ O0]L/_TI_8/_ -GOOW7NO?\ #E__  I-_P"]#VP__2G]@_\
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M4U*1GW7NBS9G^:I\,\'\ J#^9KD>P-W0_$#*4V/FI-[_ .C[>4VY6BR_:/\
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MAYHXTIX<>QNLGNO="O\ R M[=N;@^34%51?-CXU=R]:;\^$^VNR.Z/CSU/\
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M#F?BC\@^DNF/E ^YE^%GR/[-BV(FQ?DM_<_;&8WM7Q/M/ ;LRO8?2M9O'8V
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MV_UOV=-NB#K?L;KWL2796=FVSNZ/8>\=N[N?:FY8%5I-L;H7;V4R;;=W##J
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M8Z["[BQ3UE-D]LUD%5$34&2%/=>ZHM^,'3G\S7H[^9%\+ZKY&]#?&RMHL/\
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MKK\OLWI/;.<AS%5(TQ"K,DK.92Q]U[K:KI762-G1]:M([+PRJ$U$(%5U5@-
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MA]("Z.?(YL"=(=C)>4*ATC7<C^OOW6^NQ32)_FI1%Z46X4L3H4JH;6Q&A >
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M%^/]A[]U[KVH?U'Y_(_L\'_;'Z^_=>Z\&4BX92/Z@BWUM_O9]^Z]UXLH(!8
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M%F!04K9+(U%ZU*[W7NBQ_P L+^7Y\GMT_'?X+9CY8=^[WDZC^..XLGWAUO\
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H]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g790774g59i17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g59i17.jpg
M_]C_X0U$17AI9@  34T *@    @ # $   ,    !.;@   $!  ,    !&6L
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   ?    M $R  (    4    TX=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P
M,C0Z,#@Z,C,@,3,Z,#0Z,S4    $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,,H , !     $   $F          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          3A"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              28   ,,
M!@!G #4 .0!I #$ -P    $                          0
M   ##    28                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   28     4F=H=&QO;F<   ,,    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $F     %)G
M:'1L;VYG   ##     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #(
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M_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
M       &!00#!P(( 0D "@L0  (! P0! P," P,# @8)=0$" P01!1(&(0<3
M(@ (,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$
M5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI
M:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8
MV=KDY>;GZ.GJ]/7V]_CY^A$  @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B
M$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V
M160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=7
M9CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI
M^2HZ2EIJ>HJ:JKK*VNKZ_]H # ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]UU?W[KW7K_X>_=:K\NO7_P!]_P :]^ZWUZX]
M^Z]U#I,ECZ]JQ:"NHZYL?628[(+254%2U#D(8X9IJ&L6%W--6115$;-$^EPK
MJ2+,#[]U[J;[]U[KWOW7NO>_=>ZAQ9"@FK:O'0UM'+D*"*DGKJ&*IADK**&O
M\XH9:NE1S-315GVLOB9U D\;Z;Z3;W7NLL%33U2&6FGAJ(A)+$9()$EC$L$K
MPSQEXRRAX9HV1Q>ZL"#S[]U[K/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_
M_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]TV5F;PV/KL7BZ_+8RBR><DJ8<+CZROI::NR\U%!]U618NDFE2HR$
MM)2_NR+$KE(_4UAS[]U[IS]^Z]UU?_??[?\ XI[]U[KU[^_=>Z[]^Z]UU?\
MWW^^_I[]U[KU_?NO=>N/]]_OOZ^_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U4;_-<["_F4;(ZVR47P=Z;Z [#ZTKNF.[*C
MOO>';/9&Z-A;WZ_AHMM1_P &R'64>VJZGER67&%ER=0A:-F6LIJ<"2+46/NM
MK2N>OF@_"KY-?+F?Y4?$).J.\^[^R>R*SOSI2/K+8O:/?/=$'7'86]9-VX9]
MJ;5[&0[KFQU%LS<F56*GRNE#"M)+(MC&2#[/2DJ@6M3^WKZN/PFW5\UMX=.5
MF6^>W5O3/4/>";YW)146U.BMVY?>FR)>OZ>+%G;&7DS&:JZRL&<KJB6K2>+4
MJA(HW\<9<HONDQIY#H@_\X'I'K3?^ZOY?.;W4^\Z+);_ /G3TI\;-U2;5[=[
M5ZX@W7TWV/ANS,[O'KK+X_8.]]KT&3H-Q9/;E)++(\35H^U54E5 5/NK(::O
MLZ+_ +'[T[FG^8.+^+_5/9.U.B]I]G_S)/FCL/?^X>N.K>LZGL?=VUOCO\0N
M@.Q]LP9[<&\<)NF'<O8>8R#K19[=.7I<EG:_"A(#-'-#35,&^MT%*GTZ##/_
M ,PCY&2X/MKM#K+Y83]F?&S=7S.Z"^*^Q-W1TWQ&H>U^L.L,SV7V7M[O;Y-T
M=3%M' =;;#V%N_?N$INLNL:OLDR4L[XJ7-5K5<N2H%?W7J#&/+ID[7_F ?.3
M86S\8^X_DKU=MCM'8/PKV7\AMC;)V;C.DNRL/\LNV,C\S^Q>F]F==Y?<> AS
MU'NMNV>I<-@<=E\?US4XJ:@W?E348^JCIXDHY?=>HN21BO2B^2WSL[8SVZ/G
M%UWUE\DNQX-D[@^&/\URLV=3;AIOC=A]Y]7=Y_"++;4VU'0=-[3V5MA^X]LX
MFBBS6;HZK_2$:K-9ZGIH,SBEH(HUEFUUL*#IK\OY].5=\HNP>L-VXO =>]O[
M(H<5V'MK^2[U9O\ ^;-+L'IK)]F4O5W>2?*FIW!VON?L9MJU?6^Z/[P5FT,?
MMK:=3GL9D-M;?K=QS5$-)43U4HFWUJB^GK_+HN_6/RM^5/5>P>F>C_C_ -K[
M6Q\N2Q7SH[KV+V!O3,?'_KW87R4[OH/YI?9_7F0VYV?NCMR?&8J3K@;(R#Y#
M(XOK/[3<WW^X:.>G:"E%-%)[K9 J3Y];>OO7377O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U__]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]UKM_S?\ '=G9+^91_(II.DLSL+:_;M5V[\XJ#9.[.SMK
MYO>NQML25GQAIOX[FL[M#;6Y=E9[=8Q^!BJ)J3&09K#I69".G2:L@AUN/=6'
M _ZO7HA/87\QKYF_*WXW_%?XN[P[,BZ4[3[O_G*=E_RQ_D?\A?C32Y7KG/;C
MZEZ,RN1J-T[@ZE.0S6X,OU#N_LRA-%2M54]?4S4@IZEH-,=088_=; %?R/\
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MI 5I,UMNFR..J(L'EJ921'4THBF0?1O?NO5/&N>E_?\ WW^^_P ??NM=>O\
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MZ:NW'08O.!&J9*V&DFC]U[&#04Z00_G$?/+^7[MCYW8'*_$KL+^8+\1?Y?\
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M=8RTE?CJZG9DD5N4=&TRPRJT<BI(C*/=;&"?L/5RGQS_ .R>^B/_ !#75_\
M[Q&#]^ZT>)Z&7W[K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW6G-_PHB^-F\S\J.J_F3G]BTV3ZSPO1V.Z"V]OZ*5\SCM
MGYR?>6[MVY>@W9A:BA%-M[)[J&XQ2XZN)J(:J"*2G5XYW\;SS[*6W+#7-Y=3
M@2<T*"$24*46(@!FB4U#.02LC'(3M HQ)P@^^+>^Y;;3M.T[9KB]N7D1YFMB
MZS37*$M&ES(I5DAB(66*-:(TB^*[,4TQGX_E95777\H[^5=F.P?F?EMM?%?I
M^H[5W]W!M^'>N4K3GZ# ]I2X_,8;;AV538J;/)NS+Y&GJI,5MO'KD\NU$\2/
M"DZ2PQQMSY;<N6W,E[%RNY.W@]RC^SCDR&2$UJ8E_#6M#4*64 ]9$>RFX^X6
MZ>WNR7'N5$HWW0 LC:A<3P@ I-=J<+<R'4SD4U+I9D1RPZ+MD_FM_,V_G"X3
M<4OPFZEH_@C_ "RZG ;D3?/S ^4NS9=P=T_(SK@8VN@W-0]#],435IQ6T]RX
M-JBG_B8\TLD+&:CS%%D(7H/89LI(+6[M;B\M1-;HX9HB:"1002C$"JAA45'K
MCAU(NZP7-_M>Y6.U[BUKN$L+I'<H-302,K!944D*S1M1M)-*X8=:W/P=VO\
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M_.O(7*ON5RSN'*?-]@9MLGH5=&\.XMY4KHGMI@"T,R5(# %2K,CJRL1T;_\
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M=H]=],97XW]@MOS>G8=?NFGP&^.YMMST^]:$X?\ B&,2O9\-33)"I]UO3J(
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M]U7I/X+:6U=KR9:;;.VMO[=FS^1DR^=EP>&QV)DS66E 67*99\?34[9'(RJ
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MNX6G\-/"FHRU-95SN9*O)Y?)U3O45E;4O+55E3(\TTCR.S&/MPW&]W6\GO\
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M012RUK)![K>G)J<?Y^J]OYR_\PCXR_*[^0;\G=T;6W]@=@[][=ZYBH<3\?\
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MX]C=6UE'UQUWC,ONS/[QQ.,R%<M4E74BBQ\?V[1QQSAO=:/IUL<>_=:ZZO\
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MY??.#N7X0[A[:^&_0/8?\O+XP?%; ]XP=!;HZ=S6,^3/6O8':V;%;M3K'LS
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M3[IKI;^_=>ZZM_K^_=>Z[]^Z]UU;W[KW7K?[[_#^A]^Z]UW[]U[K7C_E+_\
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MK-HY=Z[;U6L"^6C8W)]UX$BO1'_^%$6"PFV/Y&7S@VWMO#XO;VW-O=3]9X/
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MU_\ ??6W^M]?>L^G7OSZ[][Z]UU?_ CWX_RZ]UUJ]ZR.O?+HC'SK_F0_#_\
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M_=>UO_$?V]>_Z!:?Y//_ #Z+N?\ ]*@[Z_\ LY]^Z]K?^(_MZ]_T"T_R>?\
MGT7<_P#Z5!WU_P#9S[]U[6_\1_;U[_H%I_D\_P#/HNY__2H.^O\ [.??NO:W
M_B/[>B;?'C_A+/\ %A?D+\T)_DKUGG*OXWU>_M@2_!_&;.^37<L>Z=O=?C;6
M1_TBT6^YJ'.XW*U=9+ND4CT;Y.MR=0(_(JNB*I?W6S(Q &H_MZ.3_P! M/\
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M?7_V<^_=:UO_ !']O7O^@6G^3S_SZ+N?_P!*@[Z_^SGW[KVM_P"(_MZ]_P!
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MI),]!0N6OSJB(_P]J9-V9A2+;[2/[(E;_JYKZ+H.55C;5<\P;K./1KID'_5
M0G^?1P^LN[O^$D_3U3%7=?Y+^6OBJZ$*(J_)[#QFZZZ/20RLM9N_;&>J1*"+
MZ]>J_P"?;7[UOU5DCE5%/'0B)_-%4_SZ5-ROLTLD<MQ;O,RFH\6::8 _Z661
MU_ET?;:7\[7^1QL''_PG8OS8^*&RL5Z?]QFTD&W,?Z!I0?98?;-'3>A>!Z>!
M]/:*2:::GBS,U/4D_P"$]&T%C:6I8VMI%&3QTJJU^V@%>E5_P_A_)O\ ^]A7
MQZ_\_P!EO_K+[;Z4Z>N_^'\?Y.'_ 'L*^/7_ )_\M_\ 67W[KU.O?\/X_P G
M#\?S"OCU_P"?_+?_ %E]^Z]3KO\ X?R_DX?]["OCU_Y_\M_]9??NO4Z]_P /
MY?R</^]A7QZ_\_\ EO\ ZR^_=>IU[_A_+^3A_P!["OCU_P"?_+?_ %E]^Z]3
MKW_#^7\G#_O85\>O_/\ Y;_ZR^_=>IU[_A_+^3A_WL*^/7_G_P M_P#67W[K
MU.O?\/X_R<+7_P"'"OCW_P"?_+?\3A??NO4/7O\ A_+^3A_WL*^/7_G_ ,M_
M]9??NO4Z]_P_E_)P_P"]A7QZ_P#/_EO_ *R^_=>IU[_A_+^3A_WL*^/7_G_R
MW_UE]^Z]3KW_  _E_)P_[V%?'K_S_P"6_P#K+[]UZG7O^'\OY.'_ 'L*^/7_
M )_\M_\ 67W[KU.NO^'\OY.'_>PGX]_^?_*__6;W[KU/LZ[_ .'\?Y.'_>PK
MX]?^?_*__67W[KU.O?\ #^7\G#_O85\>O_/_ );_ .LOOW7J=>_X?R_DX?\
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MV=\RTB8"GI:+:]70-5TSU%'EHRU1*!#'(5F7W6PQ (Z.Q_LC?PH_[P^^+?\
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MJ'I?=>ZL'O\ [[_>/?NO==^_=>Z][]U[KWOW7NNK_3_&_P#O'OW7NJ=_E?\
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M@<!@\53TF,P^'Q./IHX*:FIXHX8(45$55  ]UZM<]*'W[KW7O?NO=>]^Z]T
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M8JGQN2::21#B*FKC\4C2 >_=;% <CJJK8.Y>M/YK66R/Q%^;O2W9WQ\_F5?
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M0TDJTU-%$&T1HH]U[I[]^Z]U[W[KW7O?NO=>]^Z]U3W\^/Y>^XLWF]N?,O\
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M@K-D9+;?S2V5TAG<=+NC:>1P.7R?4VU91CLC@<9-)+)EI)JZ/,B2%XXA[K3
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M3\I^FH]O4& [RPVUJW;>6=-VY_;>V:;$YFFJJFJPU;1 NM%%5K'51^Z\#04
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..^Z]U[W[KW7O?NO=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g790774g70y95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g70y95.jpg
M_]C_X1'\17AI9@  34T *@    @ # $   ,    !.=<   $!  ,    !%^T
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HP-3HU-0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,,H , !     $   %#          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MDI^JDE\JI)*?JI)?*J22G__9_^T9J%!H;W1O<VAO<" S+C  .$))300$
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $  3A"24T$
M)@      #@             _@   .$))30/R       *  #_______\  #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      T$    &              %#   ##
M  8 9P W #  >0 Y #4    !                          $
M     PP   %#                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   %#     %)G:'1L;VYG   ##     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !0P    !2
M9VAT;&]N9P   PP    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     $X0DE-! P     $)(    !    H    $(   '@  ![P
M$'8 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $(
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MONP?^Y7_ (,?_)JACC%=FW.NQ64^K]/*-M+B\5?H\</VG[0_<U]CZO4_FO\
M@UK^A1_HV_YH2]"C_1L_S0DIJ>ETK_25_P">U.*^ECBVL?VVJUZ%'^C;_FA+
MT*/]&W_-"2FM'3N/69'AO']ZI8;J6=6+Z\%E9>/1.6+*3NK:7V5>VL_:';W_
M .#=]#_/6MZ%'^C;_FA.*:0016T$<$ )*?_3]527RJDDI^JDE\JI)*?JI)?*
MJ22GZJ27RJDDI^IW_29]'Z7YW/T7?0_E?]\3N^B[C@\\<?G+Y7224_5/;MPG
M7RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_]DX0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$!@      !P (     0$ _^$-ZVAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U
M-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/B \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN
M<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL
M;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E
M;&5M96YT<R\Q+C$O(B!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(@>&UP34TZ1&]C=6UE;G1)1#TB-3@Q1C%&,#8V
M1D4V034U,#A#-SDV-#5#1D(Y03)",T,B('AM<$U-.DEN<W1A;F-E240](GAM
M<"YI:60Z,40W,30V,44X-3!%148Q,4%$1D9%.$8Q0D,P03)"0S,B('AM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#TB-3@Q1C%&,#8V1D4V034U,#A#-SDV-#5#
M1D(Y03)",T,B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.DQE
M9V%C>4E05$-$:6=E<W0](D-$0T9&03=$03A#-T)%,#DP-3<P-S9!14%&,#5#
M,S1%(B!P:&]T;W-H;W Z0V]L;W)-;V1E/2(S(B!X;7 Z0W)E871E1&%T93TB
M,C R-"TP-2TQ,%0P.3HS-CHR,RLP-3HS,"(@>&UP.DUO9&EF>41A=&4](C(P
M,C0M,#4M,3!4,3 Z,#4Z-34K,#4Z,S B('AM<#I-971A9&%T841A=&4](C(P
M,C0M,#4M,3!4,3 Z,#4Z-34K,#4Z,S B('AM<#I#<F5A=&]R5&]O;#TB061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RDB/B \>&UP34TZ2&ES=&]R>3X@
M/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z
M:6YS=&%N8V5)1#TB>&UP+FEI9#HQ0C<Q-#8Q13@U,$5%1C$Q041&1D4X1C%"
M0S!!,D)#,R(@<W1%=G0Z=VAE;CTB,C R-"TP-2TQ,%0Q,#HP-3HQ."LP-3HS
M,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RDB('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V=#IA
M8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C%$-S$T
M-C%%.#4P145&,3%!1$9&13A&,4)#,$$R0D,S(B!S=$5V=#IW:&5N/2(R,#(T
M+3 U+3$P5#$P.C U.C4U*S U.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB
M+R(O/B \+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/#]X<&%C:V5T(&5N9#TB=R(_/O_N  Y!9&]B90!D0     '_
MVP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! 0$! 0(" 0(" P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __
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M6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@ , P$
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MR9B>IJ%FC6/Q\"WE>XVG<[JPV)^5(9(W0B20/)XVH(:R!]6E!JH=.DBO;4U
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MBN#K0]ND,(@ /)?Q&H).?3HZ'PV^:'66WG_EL_$?;/4O9&R=@_)S^7AM[O\
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M1EJ&FP]9]EE*<)'3F.6<!1CO'+D6Z;GR7LNW7D1,^V5$H5PCE/%*DJ0&74$
M-0-+$L034DFM-TDM;+<[Z[M73P[BA5F7@TE"=5=-%+$5)_#C%.K .QOYEO=7
M1O3>_>]/D)\!^Q^F-FTOR(Z#Z8Z6Q>?[KZEW!O3MO:'??8V*Z\Q/96?VYLVH
MSR=0Y+;,^<I:BOVUE*FIKT:7P^9721D#4?+5E=7=K9;9OT=S.87>73&ZK&R
M$J&?3XB\3K6E0I(4D@$U7<;A8I9KG;VB0'MJRDL*,<@5TFBC!."U*X/1GMW_
M #3VULOYR;2^%.8V;DX:C<WQ1[#^5E5VM)FL?%MS![>ZZ[ V_L3*;:J\']N^
M5EK9?X\*W[I76%(H]&EF)*ED&R33[')O<<E56[6#13)9EU UKYY %#P-2,54
MM>*EX;1EI2,/7Y$L/Y:<_:*>?5;=?_.H[DJ>I-E?)W9_\NO>>5^*'>V\L+UW
M\9>Z-X?);J+KJM["W/OW<LNSNGLUVAL/,XRMR/1767:^Z(HZ2AS=;5Y2HHS6
MT3UE!"E2"@E3DS;1<2;=<<T1IND*ZIHQ#(X50 6$;@TF< @A %U9 -01T5OO
M%ZH:1=H8VY-%;Q%!+#B&%.P+1M3$E>TT+56M]6'GR-3B<94YB@CQ66J,=13Y
M3&05@R,.-R,U-%)6T$->L,"UT5'4EHUF"()0NK2+V]@%PH=Q&U4!-#2E1Y&G
ME7TZ/U)*J6%&ID>G3G[UUOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7N@N[GZO3NCK'=G64F_^T.K4W924=(V_>F-XU'7_ &=MS[/*T.4^
MYVIO"EI:RHPM74FA^WF=8G\E+-+']'N/=;!H:] /AOAQ3X;XY[J^.@^3WS(R
MD6ZL_-GV[PS/?>3R'R,V\9LUA\U_!MJ]K-ATKL+@(CB/M4I5IF5:*IJ(KVE)
M'NO5S6@Z[Q?PXI\7\<MP_',?)WYCY"+<&?ESY[ORG?>3K/D=A3+GL;GOX/M[
MM=L.M;B\!&<;]FE**9E6@GFAO:0D>Z]7-:#KA2?#:"D^.63^.?\ LS_S*J8<
MGN5MRGO"K[]RDWR-H&;<=)N+^!8SM<X=:ZCVTII/L12"F*C'2207LU_?NO5S
M6@ZYT_PYIZ?XX5GQQ_V9WYCS0UFX6W">\:COO*2_(^E+;HAW/_!:/MC^$"MI
M]O*T/\/%**8J,6S4]['5[]UZN:T'71^'%.?CA_LN/^S/?,CPC<?]XO\ 3B.^
M\G_LR%_[T_WI_@9[9_@_WW]W-7^X_P"T^VT_PK_)[V]7OW7JYK0==2_#:GE^
M.--\<?\ 9G_F3'#3;E&Y/].$7?F43Y'3D;GEW/\ P*I[8&'^^EVUJE_A_P!I
M]L%_A:K3WL-7OW7JYK0=/F&^*D&&Z6V1TN/D1\K,I'L??V&WZO:>9[JR-?W3
MNML-O&7>(V=O?L%L4E5N+8.4:7^&5N,>%$J,,JTI8*-7OW7B:FM.C7>_=:ZU
M<NKOCG\T-W?RBNY_Y4V=^)?<O4/;F=ZR^76-P'=^YMV]%57Q\W/E]V=\]B]I
M;)V;+G-G]RYSL>CQ7;6V]U4^*GEGVVD-)%4U(J@JH!+[JY8%Z^72\[BZ ^7W
MRZR7S+^5FP/B[O?XS[PPGQ@^%6 ^-O0_;N7ZDHM\=L_*OX(?)C?/S#VMF93L
MK>>ZMD;=VIC=S5E!L7;N6R62@7(15M?4%:;&&*2;W7@0"!@YX_;CH-=G?RHO
MD_DLC\@^L\SMK%[>V/V!\ ^\=^]:;WW%NG"55'@OYEGSMZ.FZ,^2PW NV:RL
MW4F/P$6"EKFR%- ].:;<<OVM3--YE]^ZMK&,>8_8.D;GO@+W1W)\1NXDI_CW
M\VH_E=0=&? SXM5NR?DWN_XBT_3=;L7HOY;=<=P;UV3T4>FJG;^#WCLKK>'%
M9ZKH\YG::%,CAZF.GH@\L\],F^O:@",C3G_!U?!_,]ZE[&[Y_EX?-#I?J';$
MF\^T>T/CGVCLK8.TXLEB<-+N+=.>VQ74&'Q*97.UN-PV/:MK)E02U51# E[N
MZCGWKJBFC*?GU53V[\'OE/N;Y&?*3>>(Z>DRFTNP?GI_(_[=VGDY-S[%%/G^
MM_BB_5[_ ""W,U!69U*FGAZV;;]47I:F)*K(F#_(8JC4E_=6!6F?0_['3KF_
MA'\G*O/[OKX>G?)%E?\ A1;U3\VZ:H7<>QXWJOC'MGK3J+;N2[B:^<64#'UV
MUZJF_AKVSCI3>FF:-DU>Z\&7_C-/SZ8>D_C#\J_C]NK^6'V'N3XZ[[W/C.E?
ME/\ S9:;M[;O7N<ZXSFZ-C[5^:'??8^<Z-[.R./R&]\)C,IL*?;M?39',O0U
ME3E,1!5Q!Z*242QQ^Z\S5#CUI_+H[7S!VEW7U5\Z.B/FQLGX[=A_+?KO ?$[
MY$_%O/\ 4W5=;UVN_=A[Z[3[$Z2[&VAV#C,3V?N_9>W*S:6]*?K"JVSN&L@K
M5JL7'+15$L<U"*HP[ZJ*$$<#T7;^6;\$ODM\3^\_B\.U\%3UNUNK/Y0?7WQO
MW9O7%;EPV5P&'[QH_DAGNQ\CU-A*4UZY_(8C8^T<M%1T626CCQTU'1QK&ZL1
M$ONML00:>O\ DZ*K_-_ZJ[9Z2V#_ #M>SLQT[D^QNFOFQ\5/CI-@>XL/GNO:
M; =-5/Q^P.?V%O#9?;.-WAN;%[MAQ5$<]%N?;K8+&9A,C597(4P6EJU#S:ZL
MA6JYI3H:^_\ XT?)W<_R ^7_ %KMSXV=@[KV9\@OYA?\MSYL[7[TQ&Y^J,;U
M?1],?'?_ &3/ ]P8/)?Q[?6/WQ%V]MV;HG-S46#3#NF3HI*:H@JKEX1OK084
M!KP%.I]'U_\ .S?'\Q#XN=L]U]3=^;BP'QQ^;?RW@RM704WQZPOQIV%\=.Y^
MI_D+U?\ &?L#I>CP&<A[;[+S5?MG=6WINP<KFIFRN$R5?D8&QPIXZ3Q^ZT*:
M6R,CH,.C/Y?7RTV_TM_*=V)E>GJ7:FX.@/Y</\QGH?M]9]U[)2@ZU[<[\VCT
MCBNM<!D*K!Y>M.8BW9EMKU[SUN*2OIH&I#+4.K/&7]U8LM7/SZ$SI/X[?*/<
MV'_E%9/+_'/L+K2L^)/\O#Y??%CNO'[]S?6=%EML=M5/2GQ9ZQV7)AAMO?FY
M:?<6T^R-R]7YF3"Y2CE=314R3UD='YHU;76BP[_F?\_01UG\N7Y@;[^,_P :
MNE9^O(]H[OI/^$YOR;_E_P"\,_G=X;2?$]=?)GLG;OQ,Q6T.NMP5>)RF:KJO
M#Y,];9FCJLGBJ>OH(**GE(EN\"R^ZT6K7/GT=#?_ '9\U]Z=&?'J'JSX@_*?
MXO[9V#V;L_KWY3;7VKM_XO;A^0V-ZTING=VXLO\ $ZAR?8N\.M<YLK!]P_P#
M#97//!2Y1-L3U5=A*)Q$TT/NM4H>(/1/OAY\9?EG\?JO^4IE][?&#MEZ7XR]
MM_S/.H.[\=B=P]3[FW+M3'_+ON>'=W3?=62JJ'>^(P>\.KZK DU6X\KAR:ZA
MK"WCQ.D^-/=69@=8!XT_ETKNGOCY\J?A_N/XB?(3</Q/W_WC2]+;C_G$];[R
MZIZCSO4V<[1VG#\S?G71]\]$=W;%QF[-Z;5VSF\)O+9&R8<3FPF:I,KAZ/.T
MTM1!X(<BD'NMLP.K/&G\AT!_3G\L+Y@]3=1=D=>9[J_%[DSF4_X3Z=H?$'#3
M8C=FS:S#TOR-[$[@^0G8V.^-.!J\EEJ6;^";)PG8>(PU/E7BI]O3T]'$5F5(
MPL?NO:E[?+N_S=6$_,'I?L_;7\LCX=YN+86YMQ]@_ S>'\OOY-;^ZAVBE/N#
M=VY,)\4=R=<9KNS9NVH,;4U4&Y-TX;8F.SE9C*6C:I?*9+'04],)))XK^ZJ"
M-3>AKT6GY"=.?)]\;_-=ZEZ%^/.Z._-C_P XK:&WMQ_'3OG;NZ=DX+K'JNJ[
M9^)FROC+V>?D;)N_/8+>VQL)UYA=ITV\,/+B\+G)-QT.0_A=/''DJ=XW]UX4
M!!)R.C<?(#?/S[V%TIOCXX_&+XP=GXV'J;/_ !8Z+V1\G=N;OZ'W;O;?/1.>
MV/">^^]>FNI]\[PV]A*'M'J"#"?P/%XS=M6E#49S*4^3\5=0T=31R^ZJ*'B>
MA;Z'Z9H\!_+E[*Z5ZF^-_<G0N7R?7??NWL=U]W]NK8FY^[.P^Q]Z8O=,V6[1
M[(["VKV3V3A=U[R[DWIFY<K6YFOSC5=14U;/4)3*%B3W6_Q?GU45VC_+R^7N
M;^.&R-BX#HAYMS8;_A,]OGX'U6'I=U]=TAH_E7FHOCT*+I9)Y=RTM [U+;)R
M5LHLAP*?:&]6OD37[JP9?3&JOY="Y\V/@Q\I>U-K?S:L;L'I5-QS_(GX(_R]
M.G.D:6+<6P<8-\;ZZ:W;WID^SMGTS9+-T*;>AVE2;NQ\AFKS2450:D?;/(T;
M:/=;5@"F>!/6?L#XJ_*8=A?(/XM8WH#>>[*#Y$?S=/CW_,2VK\S8LWUW!U;U
M=TGU]OGXO=C;K@S%3E-UR=F4O>6P*3H&NV1@<)1X1XLCCZ['5$=;%0+7+3;Z
MJ".)IPIT^[!Z/[DKM]=>?"SL3KW<.VMM]K_S3?G?_,9[<E63#9W;=?\ %KJC
MY4;A[E^/&*W)7T)RVWXY>Z^[]Z=?5T>%GJ$R3X?$919J8"&<1ZZ\2./R Z'S
M8]+\D?C7_,X_F =EO\..\NX.G_EUEOA+#UWVOU3N+H63;6 I^LNHY>MNP:[?
M.(W]W'L7>F*IMKYG)FIE^TQE=)444+M3I+(%C?W6B05&<CH6/Y:N%R^]>QOY
MAWS#FPF>VULCY<?+F"LZ:QNX,768.MW'U)\<NE>L/C+A^U1A<I#1YC&X_M7=
MO5^;RF*^[IX)*S;[8ZM4&*JC/OW6VX*OH.K6/?NJ=?_1W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]T5[Y<_(B7XW=40;AV[MMM^]M]C;UVGTO\?^LHI&AE[&[N['
MK9,;L[!U4Z/')CMIX&FIZS<.Z,B"%PVTL)E,D_[=(_OW6P*GH*?Y<OR<[#^4
M?P0Z9^2?<-)LQ.Q-V8#?U3O-.L<;G<7L>OR6Q.P=[;+ER&SL5N/)9K<-'A\U
M3;42JIXJNIFJ%$X#&_ ]UMA1B.BK?RIOG)V?\PXY*_MWY.?%;>N]\ATEU_VI
ME_C+T_TKV?U9V?TU)O\ JFK(I\]N3LSM7= [/VM@ 6V_5Y/#X6GQRYVEE7[J
M[) ?=;< $T!IT+?\R[N;IF7I&NZ@_P!+/6C=KO\ (?X3PQ]7KO[;"]BR5)^7
MW0&>AIHME+EAN:2HFPL9JTC6F+R4H\@!CY][ZTH-0?+JT7WKJO7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]UHZ8OX4_,7!?%3X;X39GQ_[VPV^_F9\5OF!_+&^2U#
M_<'.T.8Z1V;V7\WY>S>L.U^VJ.5(Y]I[-Q'4^:WRD.4KU6"&ER].BDK5H/<]
MW&^;)/O>^/<;G;FTLKNWO8:./UG2T".D;#BVM8^U34L">*]1W:V6XP;;MW@6
M$OU4L;PN6K2-3/4%XS@A@V3QTKZ$]661?'SN^BVY_P *5L)A.CNQ<13=Q[<Q
M^VOC/CL?LC-X^D[5QNW?@GC>LMOT/4:_:(F[8J/,8J'%H<=YE6L AOY 5 2A
MW*Q-S[:/+?1_H3:IB74Z-5PKLSY[>)/=0X)X4)/KNVF-IO\ %' U6MBJ  YI
MXH 7U-"O#U'1)MN=7Y+>G3/\OCJWX+?RQ/DM\3?Y@W5FZ?BI_I8^9&>^(_\
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MB1RQ,*'PY&(4N'S2H!3N!)QTY)(]K?I=?3.;69,D EE8A?B% %4*@%2:EF
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M9*ZCGC1*@R(!(B,/=;'V=$<_V4;YX_\ >V?N7_TE#X8?_:>][ZWC^'^?7O\
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M_]??X]^Z]UJ+[GVET1D?D]\V-U_S$?Y-WSU^>G<.=^4G:.%ZM[BIOB31=_\
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M-!5TM1+5P4]53SS4$Z4U=##-'++15,E-3UJ4]6B,STT[T=7%,$<*QBE1@-+
MGW7NI/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZPP
MSPU"F2GFBGC66>!GAD25!/33R4U3"S(6"RT]3$\<B_5'0J;$$>_=>ZS>_=>Z
M][]U[K!/44]-%YJF>&GBUQ1^6>5(8_)/,D$$>N1E77--*J(+W9V ')'OW7NL
M_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z__T=_<@$6/(/!!_/OW7NJC\Q_*8H=K9G+3_$[YS_.?X5;%SN3R&7K.C^FN
MRM@[UZ.P5?F:^IRV<GZUV#\@.LNWQU)#E\Q6U%7)C]N5>.PL4\[F"AB!M[]U
M[HS_ ,5/@KU-\4<KO#?.+W=W/WEWCV-CL3A.P_D9\E>S,IVUW1NS;F K,CD,
M!M),U54^*VSLO8V$KLM434V!VUB<)ADGE:8TK3?N>_=;))Z 7^;"FW=S],]/
M=.9;XD+\O=R]V?(;:&T>M-KUW=^6^+^%ZS[!VWM+?79F-[:JODUMK&Y;>/2F
M=V_B=CUM%A:W!0MF<KELC!B:>ZU\H/NMJ*USCH'_ .6;\6.Q>B.X>RMW]B_!
MO;O2.:W9UKC<!4?(C='\R3N'^83W7NBGPVYXJ[%=4)DN[NMMN;@V#UU N0J<
MG)%C,E'0U%?30F>DFF\<\/NO-3@&J.KK/?NJ]>]^Z]U[W[KW1"/YEO\ V2?7
M?^+!?"O_ .#1^/\ []U9?B'1]_?NJ]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TV9E,M)B,K'@)Z"FS
MKXZN3"U.5IYZO%T^6:EE7'39*EI9Z6IJ:"*L*--''+'(\8(5E)!'NO=5"R=F
M_P TBG^2V(^,#]C?!N7<.3Z SO?+;R'2_=Z8Z&FP/86WNO7VY_ AW)Y7-74;
MB2J%3]V"JPM'X^0_MS]/CI-.M9Z)=N?J;(5?P-^=W?\ DNWN^MF=S=7]Z?-U
MH<AT5WMVQU1L$[QQ/>NXIJW<>)Z]PFZ8MO2+/E@[Q'(0554:=A'+*S>H7#$L
MB4[>O=#=LC$?/;XJ]U=<=*==1_&[<]?\H<)V1N?%[D[?^0'S/[@I\!0]%X?;
M58D9H=_Y/,G#5NYJ??\ %]Q_"33PO+"SR+($B058HW"M!UX5I\^KM^MCV3_<
M3;![?&QQV;_"XO[Z+ULV>;8@S>N3S_W7;="IN XO1IT?=@2WO?BWMLT\N'6^
MES[UU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H'?D#G.V]L=*=F[EZ)QG
M76:[=V]M'+9S8F&[9S66VYUSELSB8?O_ .&;LW#@X:C)8+&UM)3RQ?>)&Z4T
MC+)(IC5Q[V*5SPZ]UHY_\.W?*O'[Q^2^U^E5Z_\ F+E?YDNYJZ@APN-VKDMN
MT?4>XX/C7M'9.Z\'UAM7;>Y-Q=B;OPVQ:27'X.G>OIJFAW+5XB6MILC TM7"
MCV@  UX'\NMBG$FE!^?5NOQT^6.Y_D-TS_+5V/N7K;%;7I?CI\Q?BKTI7]Q;
M8W[M[='4O;/:&U/C5W!C-W;3ZWC+8O>=#GMCI D6X*')XZG_ (7F!48Z*6L>
MFDF]ZTA=9KDK_EZJ.'5O^WO^WH/;/_BB?0W_ +_KY">V_P 'Y];Z8/Y6IK%^
M O4[8Y*:6O7*]\F@CJY)(J22L'?_ &P:9*J6&.66.G:?2'949E6Y )X][D_M
M&^WKW029#Y%_S.\=WCMKX\R=)_!V3?.[.I=\=QXW,)WAW6NUZ7 ;$W;LK9N0
MQ%<K].IFI,S79+?U%-"T4#0""&?40RK?U$I6IZUU:CM&3=<VU=N2[[I,!1;U
MDPF,DW91;5KLADMM4FXFHX6S%-@,AE:+&Y.MP\%>9%II:BGAFDB"LZ*Q(%32
MN.'6^E'[UU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUX]K7_X:/^)(((/^SD]+
M"Q'/_;P>8 6M^?;H^-_]*?\ !U[HUW>/7?1/>G\T#9_2/>&W^O\ LC#YS^7[
MO7=L/5N]X\7EURLNV/DQUH]%N2/;=<6EJ4PE54-XYPA$;LUOH;4!(%0?/KW5
M=]?\-?BA@_A__-N["PWQ\ZMQ^]NH.ZOE[@.K]T4VVH!F=A8K;W6FT9L#C]JU
MS.]1A:+"U61GEIJ> I3PR2,50!F!M4@I0^G52!0XZV4-@$G8>R23<G:.VR3_
M %)PU%<_['W0\3]O5NB1_%W_ ++5_F9_^),^,W_P+NP?=F^%.M#B>K"O=.M]
M>]^Z]U[W[KW7O?NO=>]^Z]T%W=&Z>S-E=8[LW1T[U7#W=V7B:2CFVKU9/OW#
M=8P[OJYLI04M71OOO<./RF'V\*+%SSU?DGIY%E-/X@ T@(]UL4KGAT0O_9IO
MYFO_ 'JFP_\ Z7MTS_\ :^]^ZW1?XNO?[--_,U_[U38?_P!+VZ9_^U][]UZB
M_P 716?FG\X_YN'6/QD[7WQUY_+/I-@9W 8."HKNRL9\F.L_D!F^K=J39&BI
MMY]F[?Z0V_L[&9'M//["VM-5Y.CQ/G^WDGIEEJ(:N"*2CJ-]>HN.[JJVAW'W
M_P#$'<WQ*[F^$?Q>K\O\@?E)NS&;9I,K5_S%^J_E W\V[:&=RD&\>Q>SN^X=
MN[2I%K<CUAM;,5NZZ#MW"IC,9UI1U28MH&VS6Q;?DUU;M/%L?9U?Q_LTW\S7
M_O5-A_\ TO;IG_[7WOW5:+_%U[_9IOYFO_>J;#_^E[=,_P#VOO?NO47^+IVV
M_P#)O^9!D-P[<QV>_E>XG;NW\EN'!8[<.Y%^<O4&8?;6WZ_*TE)F]R)A:78<
M-7FWP&+FEJQ11/'+5F'Q(RLX(]UZB_Q=643S+3035$@=D@BDF=8D>61DC1G8
M1Q("\CD+PH!)/ ]^ZKUK%_##YP_(/,5?5GS4[SZ=WONT_P R[$=R8[XE;DH?
MD-1YWJ?II=F]?=O][]"_&NG^,^+I,/3[3?L3J/IJKJ<_OM*G.;DRV](Y:*NC
MQ^._AD%-[JQ P*])_P"-^=[!Z.VS_)O^7NW^Y^\.S^Y?YC/4?96ZOF+@NQ.V
M-Y[]V=WEGL__ "_>UOF5MVOPW6F;S%7L;JJ3IGLSK:BP6V$V9C,&E!M2OJ,7
M,E2KQ,F^K/0DC%*]/OQ(J-\]5/\ R./E%B^[^\^Q>VOYGV+F@^:V/[![;WAO
MO:'<,O:'PK["^4]+NG$=:[@RE?L3JD_'S?FQ:7&[979^+P4&.VG4U&+J141R
M(Z:ZJQ&104Z/E\QOFQWYTEW;\ZMB[!FV0NV_C[_)UW;\U^N1F]JUF5KX>_,/
MNWY"X?'3;BKH<[0QY?9#4'6F,U8I(J:9W2=A5 2 1^ZVJZ@OJ6IT2#N'Y\_S
M'-R=G9[9?1U=2XS=6'V-\&(NG>K-A_%S-=WTOR,F^3VVME97O[M?>W;*;CIM
MB_&Z3X]TNX<MD\=M_<5?BD_AN"BR%>]?0Y>B1-];TJ*5^?0Z?SR.U>^^C]L_
M"#L3I7?.]:/<?4/>VZ^_-];9VGG\KM>C[LZ^^./1^^.VNU.O=X8K!5,$&X-N
M9_KK;.:JCBYA)3-54\)"W12-=>0 U!X=5\]_?*SO+?/R$_G$=O[,[M['VUTP
MW\H;YH5'Q9IMO[^W#%M';=;\4-PX?K;)?(7KZAP=>N-I,[N?MK*;B-#G*&$5
MSTN*B6.=U5;>Z]0 #UJ.A0^+>Q=W9OLCN#XX]I]I_,3X4]/]W_RJE[*I=N=S
M?++<W=6\\KV#B-T;=IMX?.CH;OA.S^QZ3H:NZ(IMQXV#<& K,YB7RM3FL56R
MX=:*BJ))M]>/K@FOV=';_DQ=T]G?+6C[A^1_R [>RVZ.[=H;?Z7^,]=U%229
MS:VR=H[1VEUWA^S\+\D<=UM64NWZ6+*?.RD[+I>PZ3*RXUVIMK38?"4U2_\
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M?8/:6Q?C/\R,'\@.NL;\ROY?':--O;#]Y=V]A]V["_FHYO)UG7%5G_EIU/\
MWBW7EYOBGV)L385?4YC*;$JL?M7=>%HM_P!!2I1&#;J5$?NMG4/RZNR_D_\
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M3<5+N_9F>VGME!O[9.XL%O:JVY1XG<.%K-B25&Y,-DB:1E.*G-(M@0<FE>M
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MYL>HDJ_X7D>M<QM:?962VI/*E0M=]C5[7J'I&82B7QL2'U<^_=>J:U\^B?\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKOK_\ M[)M7_QG?O\
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MCT3OYY?%GX?]H[5Z8^3VW-AT.X\[\BOE!\+(<OV/AM[=CXM=_P#67:/9_7N
MK85AQ&[<90I@MX=>5ZTLL<4$2RTL]R/)9AM2>X$\ >O?,=6L]%?'7ICXS[4R
M.Q^CMCTVP]K97<%;NFOQ%)EMP9B*HSV1@I*:LKS4;CRV9K(FF@H8E\:2+$H3
MTJ"3>A)/'KW0V^]=>Z][]U[KWOW7ND3V)V3UWU!LS.]C]L;\V;UCU[MB"GJM
MR[[[!W/A=F[.V]35==38REJ,YN;<5;CL+BH*G(UL-/&\\T:O-*B EF4'W6P"
M>'17_P#ARC^77_WGK\,?_2G^D_\ [-_?NMZ'_A/[.O?\.4?RZ_\ O/7X8_\
MI3_2?_V;^_=>T/\ PG]G02]X_P XG^6;T'UCN3M?='S.Z!W?@-JICY<E@^GN
MS]E]Q[^GBR&1I,7'-B>O^NLYN#=N7AIIZU'J7IZ61::G#S2E8D=A[K?AO_">
MJV^KO^%#G2V&[9WE4_*=\3UA\?.YNP-HX7X<YS;5=MC?V^]H8IDCV)FMN?,3
M;6Q-V[FR_1V\=][RQ4F[=N')4D-!%M'-015\]-64-2K;Z]H/EQZM^_X<H_EU
M_P#>>OPQ_P#2G^D__LW]ZZUH?^$_LZ]_PY1_+K_[SU^&/_I3_2?_ -F_OW7M
M#_PG]G4[%?S$_P"7]G,MB,!A/G+\/\OG=PY;&8' X;%_)3IK(97-9S-5T&,P
M^&Q..I-YRU>1RN6R55%3TU/"CS3SR*B*S, ?=>*L.*GHWF0GJ*6@K:JDHWR%
M534E3/38^*2.&2NJ(87DAI(YIK11/4R*$#-Z5+7/'OW5>M8GXF?S,>_\CN+X
M,]L=M?*[8G;@^853\I<+\FOA/0]6[*V/NGX1[LZ9Z([>^0@VWM,8Z.@[AP>4
MZ?JNH3L?<M)V'596?.39>+)TGV6E(I/=6(\M/0L?'[YD?-+9U+_+=^3GR [P
MP';W4G\S/KSLG?>Y^@L5U1LW9&)^,=9-\2^Q?FQU5C>E-X8"D;?N\,=@=C=:
MU.T,]_?#)9B7*UU5%E::3'A)*-_=;(%2M*$=._Q?^6'S7QV7_E8=]]\=[;=[
M7ZM_FPTV27-]#X[J;9VRL)\7,_V%\;]Z?*[I6EZ;W?@*7^_V[L+MC;.QY=I;
MD.[\GF9LI4529:E>@\;T4GNO$**BF1T>WY+_ ,PJ/XZ]C?+7K]NH*S>)^+7\
MN+*_S!&R\.]J+!1[[3&;A[LP'^B*"BFV]D7V]5SGITS?QJ22JA49(+]H3 3)
M[KP2H!KQ-.B;=]_SG]U=7;JWUB]H_'G8V8QW5]/\-<)GL'V!WU)LKM;LW?OS
MDI]E)UQ_LNW6N$ZPWKE^UNM^N,IOJDI-QYI&I9ZRJI<K38RCGGP]2C[IUX)Z
M]"?_ #<_FYWI\(:?X5[\Z[KL;2[*RGR 7(?*O#1;:Q^Z*C-_'+9>TZG/=N0[
M=J\K3K78.JV[A7ES"5].(JE(,:VJ\9DC;77D74>B@]Z?S/?E-CODG_-PP/56
MYMMT/3OQ0_ET_(?L?XYTV4V5@*B>7Y-?&E,-BNR-W9;,9&(5&<VYB>P=SG!_
M8U$S8]WQ,I,<;"0R>ZWHPOJ3U)^'_P H_G1\F-S=[=#=1?-.B[<R60^!^UNZ
M=B]^]Q_%';WQ[W=T?\KMS;C3&[3V+B^JLOM#:D7>?0FX\5!5U&<SM)M[(Q;?
MD@@I4RTU7D(8H-]>8 >5,]'K_E<_+_O+Y^8G??R:W:=I]?=-8_#[)Z,P70^
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MU%3D)O=7+DU^?5N/^ACI[_GU'6O_ * NU_\ ZU^_=5J?7KW^ACI[_GU'6O\
MZ NU_P#ZU^_=>J?7K)!U!U+2U%/5TO5W7=-54E1!5TM3!LG;4-1355-*D]-4
MT\T>,62&>GF171U(9& (((]^ZUT(WOW7NB0[9^#NQS\GNROECVWN?)]U]B;G
MVQG>L>K<!N; [:PO7O0?3^ZZ?$Q[ZVGL7:>"H((\[O/M"7!T4>Z-WYZ;)9_)
M8S'4.*@EHL73&CE]UNII3RZ+C\>OY5-!TSOGH.?>_P D^R^\NCOAIMOL#:'P
MNZ&WEMC9F&Q?3>WNQ=D9+JBJAWWO3 4D.?[QK]D]-9BMV?MF?*I2+C\%75/W
M4=?72+6Q^Z]7%.I'QQ_E9P]&=A_';*;K^37:'='3/PDQ>\\+\(.C]U[;V=@Z
M'I&AWEM"OZSIZC>F]]O4L&X>[<QUWU)E:O:FU*K*)2?PO#5M0U2E=7NE='[K
MU<4Z0GRP_EZ]T?*CYJ]S;DA[6S/2OQF[L_EPXKX>=K9O9^.Z^W3O+LB#<787
MR)J-X[)Q-'O+&9.NZSK]M;;[+H,A1;CI8:I*MZV:F:$24\4T?NMAJ 8S6O11
M>Z_A?\\=F_(_M#>_QGVOV2.T$H?CMLKXI]Z-O#X?;F^,NV-G]?=5[,ZZW5N#
MO[9G>FP=W_);KG*1U<>>;.8/JO[;&;BQ<E)+CVH\S/DJWWOK>H$4/5R'RI^%
MVPOEUF.I:OL;<6X:' ]9T7?6(R>T\-#B3BM^X+Y!_'_?_P >]UX?<$V1HJRL
MI:;&[?[ J*^D:E>-_OJ>+R%XM2'76@U*]$@P'\E7JW$=:[FZWKN_NY-PTN]?
MY=7=/\O?=V?R]/L^?/;@H._>R]Q=J]C]^9"M?#22U':^8W/N>J9Q*TF/D4JT
MD3R N?=>+$BAZET?\I/>.9QO8.2[6^>G?W87;.Y/BCE_A'UWVMB=B=+=99#I
M+X[;WW'L[.=J4.P]N[(V=1XFI[0[!I-D45(=UY(UE;B!3P38^*GEB9I/=>J*
M@TZ.7T)\(^NOC)WIVMVGTEFLULCKWN'KCIO:&Y_CY0QPS=8X_>?1FV8>MMF=
MJ[52J>;);;W/5]/8G#[7RT-.PI<I1X#&SSAJFG\C^ZT23QZ!OHCX"=J?'[Y)
M=K]U[4^8V[LKL+O3O7L#O/M[J7<'2'2]?F=^5N[<=D<7M/9V9[P;!_Z4O[H]
M/XIL9C-KT\=2@QV$PU/0*#$TI?W6R01PST#>S_Y1$^*ZC[LZ]WM\L^Q=[;S[
M#^7^)^?G5?;U-U=U+M/='Q]^7&+W2F]9>P]IX3'8.LVMN_:V6SM'3TU7M[.T
MM92S8.2MQ[2Z*QI8O=;+5ICRIT8_ISX-;DZIV;\I<WD/D%ENP/EA\OYZ&M[9
M^36YNK.OUH:>3:>PZ3K#J_ ;2Z,IH?\ 1]CM@]:;+HR*7$5SY+^(Y.NKZW(5
M%4U;)&ONJDU^SH>/BI\6NMOB%U/#U9US/N+.S9+<FXNP>QNQM\Y"ES/9/</:
MV]*Q<EOGM7LK.T5!BJ+*[OW57JFM:6EH\=CZ*"FQ^/I:3'4=)20>Z\23QZK
MIOY5'8W7O:'QEZCV;VS4]@_RQNIOD)EOD3COBGN2KQ6R=W=#]C;:W1E>YNE:
M+;?8F"VCD<SWY\>-D]S9:LJ:;8^X*K%UV(,6$*Y;)T&*?&R>ZWJXD_%T,'='
M\G[I+NK,?S$<SE^PM_8*I_F$;&ZOVAF!@J7;=/\ Z$,AUM#25LV[NL)_X:M9
M-GMY[QPF)SN2;(R5&G(XJ%J<P@M?W6]9&GY='5[,^*/6?:GP^WA\*=Q+7KU/
MO+X_9'XYU<U**,9G';1K=A-L"ERN,>6FDHJ?/X:@$=522^(I#60HX7T@>_=5
MU$-J\Z]$OPG\M_>W96W]Q[M^3O=517=]]H?RS<M_+8[;S75M#CWV-DL769[>
MU95=_P"UX=U[?BSM#O\ W'%NK[V?%59J,30U+-3H*E(_N)O=6U$8^=>CS8GX
MP]/S?'SK#XV]G[)V?WIUUUELGKC9U)B^X-E;3WMB\Y/UE@,7@\!N;*[:S6(K
M=N#/(V+6J62*F04]0Q,.@ 6]U6N:]8LQ\3?CS6_'OM;XL[=ZIV7UAT?W-LGL
MC86^-D=/;;P?5F,JL/VSMO);6WS6XZFV7CL128S<&8Q64EU5\48J?-ID+%E!
M]^Z\"0:^?5>FV?Y;'?O6,FT^TL7\KH^_>^_BU\9.T/CE\ 8>U>L-E]4=8=.K
MV?A=E[=R&]>YDZBPT^>[DST6+ZTVY#.J1XS%-38ZH%+C*:JK35P;ZW4$Y'V]
M6%?$7XV[3^'WQCZ-^,6QZ^LS.W>D^N-N;%CW'DH(Z;+;NRV-HU?<N]\S3PRS
MP09S>^Y9ZS+UJ1L8EJZV0)Z0![UUIC4D]&-]^ZUU[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__];?X]^Z]U6#\M?G!\#^@^_L#U'\
ML-FSKNK(]=[3WK0=D97H',=N;#VOU_N7>^X]EQY;L#?6T]K;T/3FSL%O+'+%
M693=*X7!1MDXY8ZJ18ZYJ3W5@"1CUZ4'0WSN^)>X?DYOWX6]5;%WIUUN/;.X
MNR,1A-V2],R]>]#=R]B]0KMVF[XVAU#OFF@I,7O;??3TN<H8-PPO34SMHF:C
MDK8:&LDI_=>(/$]%X_F4=Y=!9/&4N8IOD-V)\=N^_@?\G>L<KM/LRC^&G>WR
MBV7@.V>W>A=_146U-R]7;,V%5GMGK[??0_8><HJ_*[=R5(^V<G44[?Q:@R44
M=/-[KRUR ,GH+?Y;O;N+^5WRWR_<O:?R^D^2'>?57Q^W=L;KS9&P?Y=_R:^#
MW4/6W6O9'8/7>4[+W!D-S_(O%YW<':^^]Y;@Z^VQ#343;D2FP]'05,E+BRU3
M5U@]UX@J*$=6G_+_ .)^TOF1U;A.K-Y[X[$V#B]N]J]6]Q8[+=<5>TEK*O=?
M3^[\=OS95%N7";]VAOO96\-HP;LQ%'6U.)RF+JZ.JFHX2Z'0 ?=:!(-1TB]N
M_#K=F+JNF:_<GS8^9F_,AT[O#M;=4L^;WQUGMVD[6H^T-B5^QZ+:/<&"ZWZE
MV/MS>6U^K9:_^,[6B^SIYZ#-Q1U,\M4$5![K73!T!\#*+J+O.I^2?:'R,[]^
M5O=..ZJJNB.NMX=Z5765%#U?T]DMQX?=NXMO[;VSU!UOU=M7(;KWUN';F+J-
MP;DR-%5YC(KBJ2%):>"-XI?=;)J*4QUD_F77_P!E/R O8-W_ /"U"+?56^:/
MQ_#*?ZAE-B/S[]UM?B'1]_?NJ]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0,K_Q:\E_U 5G_ +CR>_=>ZJY^
M+W>^UOC/_*+Z3[VWC35F0P_7?QIVAEH,#C S9G=NXJNFIL/LW8V 1(:@R[CW
MWN[)4.'QR:&#UM=$"+$^[L*N0.MGB>AM^&GQ5INK?CK1X'N_:NQ]S=R]O]@Y
MSY._)%Q@,17;=R/R3[*S5/O/<F1Q=)+'5T#)U]6P4.%PM;$%E6BP=),I63U>
M]$YQPZUT>CW7KW2!WOL; ;GV/V#M2;9NS-QTF^\#GZ#/;9W5B::?:>]*G+X1
ML1)0[VI4HZ@Y3%92ECBI:PR132-2+ILP55][J?7KW6NKU#_)B^9_0V_/C1W/
ML3Y%?$S.;XZ=VUE,COCK#<?QYW5CNE]U]KT>S<=L_:>^Z%*+>>5R[]E1[=HW
MP4O8TE)3;MI,0P"I50EZ%G"^JH)-.M=8?EG_ #9NL=U]I_#[XZ;^Z<[BV7\R
M.H/YAW3%5W7\:MM;:RW9>2VKM7#]<;ZW)7=G;!WQMS"0[?[CZ^J=K;BARF/C
MPZ#<E;205(;$P2TTR+71QIP/6Z8)].M@GH+Y ].?*'JW;W=?0>^,?V1U9NQ\
MFFVMZ8FBS%#B\T,/DJK$9"7'IG,=BJV>GI\E12P^41>-VC.EF O[J01QZ]T5
MO^5G_P!D2]=?^)%^3?\ \%+W1[V_$?8/\ Z]TQY?^:)T9@=TX;8V8Z?^9]!O
M+<[;J;:.UZCX==]+F]XTVR'I1NS(;6H_[G:\UCL%#7TLT\T-T6&JA<$K(OO?
MAG^)?VCKW1U<3V=B]P]1IVU#MGLG'X>KV76[Q&T\GL+<^&[5AHJ?&U%>^';K
MFLH8MVTV\7C@,<.,-.*QZ@K&J%V ]UIFE>O=:9?RA_F-?$[9O957L_JO^9A_
M-?V!G,/U)\C/[R]<[U;N9-T8?Y'[:CVQ)TKMS(8?L/J&LW#2[>;+5&<@SJ4X
M?$TT5' M1-3*'D]WX88"O^KY=6"L<JF/]7SZL%_E,;)A[-[:^.>>PWR([G[^
MV!TULKY7_(G-KV#N7;NY]EX/MCNWOWL3J7JC.89\=M+;6=BW9O#K^/L+.9"?
M(5->D\^59X8J;BVF) ^9_P!5.JTZV?\ W3KW6KY\\^Y-W=793Y^;.@SF4V-U
M'\@?E+MOH_LSLK8^X,+2=F-OO>WP?Z'Q?2_0&T!E(GH>NX^]MS99:7+]@5DC
M4FT,1#,\L5-]PN4H'% .G^+_ &>O>?2?^'_;>_\ L;J7X.]=5.6RO8'3WQT^
M?OQYZ7V!V=NC*8S);_INR=@_'[N[ ]Y] [CGP\?\/W_M_H/<U$M+@^P:5DH-
MV8BJI_ *K[5LG6[*CO\ 6G^7KW5UNWHI1_,[[9F,3B(_!?H9!+I.EF/?/R%L
MH;Z7])_VQ_I[I^#\^O=,W\J?_LA#IO\ [7_>?_P0G:OO<G]HWV]>ZL"FQV/J
M*.JQL]!1SXZN2LBKJ":E@DHJR+(F5LA'54KQM!41US5$AF#J1*7;5>YO3KW6
MMU_,+W;NO^5YUKVOTKT'U7VQWA\;?F!TE\EL'UW\>]H[4K\CBOB[W#-USN++
MY-NJ=\&J>GAZ?WK15]?E)NLH:>HR^,FH*NLVK%+2?=8F!P=YJ?B'\^O#CDXZ
M/K\$/DM6?+GXTU'1V(V_W5\;NWNF>F>F=A=A]AXK![+W1LG;6_<[UAMO-QCI
M+M6I3?G5G:T^,PU335DJ_;5+XZ&N@BR-+35;-3I4C30GKQR3]O2'ZOZU^4V[
M_E3\E.D,K_,,^2']U.A=O?&S<NWZJFV#\7:?-9Z?M6B[!RVZ<?N6N_T$RP5>
M-;^Y4$-,*:"CE@CGF];L4=-UP#I'6NK&_DMLGM[?W3>[\!T/V=E.I.VA1G([
M(W7CDVPU.^=QZ23X["Y]]V;)["H*?;&8JPD5?)#BYJQ*?5X"KV/NH(!R.M]:
M-G8_R]_GXUW=7R>^(6?^9?Q[WM_HEH:GKSLC'[BZ8V=0X'>^(['Q6XMHU-%C
MJ_;6R,9EUG2,5#AXQ2-'((38^M#<@D<!2G3@\(TPU:^O6S=_)HPV[-T=9=H]
M_P"_=R;2W;F=X574G1&R]P=?X;<&!V-D.HOC!U5@=E[<J]O8_=&1R^5AJ:W?
M6?W,V39*AJ27((Y@"QA5&GQ1?3IOHX/SX^2^Y_B]TQC=X;:HL5AANK?.!V#N
M'N_?%.TW37QCVQG8<A+E^^^ZS3U=)7'8VTHJ$4\$*-#3UF;KJ"GK*K'T,M37
MTVE%3GKW6NK\8.]=]U7Q-VC\/MX9K.]DCICY%_$K?]9V!N;8M/U=V+U1E>PO
MG'MK+;?Z@^1VR7J*7'X7=?:6W=P4N\-@Y'%QO'G=M9$"HIZ9J>&HKG ,L:YH
M?\'6F.:^5>K_ #(,H_FN[14RQ!W_ )>G8K)$9(Q,ZQ_)'JX22+"6\K1(95#,
M!I4L 3<CVW^#\^M]$?W90TS_  3_ )V$L]'2S2GOOYJ"-ZBF@G98Y.L-AFP:
M5)"!?D?T(!%B![L/CC_+K1X'J[7KJDHZ?8^SY*:CI*5Y]I;9,IIJ:"GUZ<-1
MA PA2,%8P;*/HHX'NAXG[>M]+?WKKW6IO_/$V1V+O;Y8]88RO["^2/84?4&Q
ML'\SOCWTK\1^HZVG[8V_7=/=B[,PO;>P-P]M[8VMN62+']N8Q8<_M/)9QDQ>
M$W)M-XZVBR,$M/X'%^'\^O5 XBO5J/PLVOM3^8U_+\Z4WG\L.SL1\NVWMF*G
ML]LGA,/7=(S=?YZ*HKZ&EZDW1@^LLQM>N3??3Z5$^#W"*Q:9JK-05,C4=/'X
M88JU*DTZ]TD_Y;OPK^-&*??G<E#U]E3V1U;\OOESL[86X\GV=VUGI-O[6VIW
M'OG9.V<%#C<_OO)X>KQN"VC''04T=33S".*-6_SGK][8G&>(ZUU='[IUOKWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__U]_CW[KW
M6OE_-8VC _?U'%AJ#^:K283O;X\X_JGY14/P,^,&TN]>L.[^C,#NSL+^ ]7;
MNWQNG!9K(=0=EXV?L#<*C(X T^4EV_G98F:S020^ZNO#)&/7KG_*_P#C+0]D
M=@4/RFR7=OR[R]#TMVW\DJZHZ#^5?QVZY^.O8&(^6??--0U'<_<.:P>TJ>FS
M='LG+=?;KBQVU=M2P04-!!4U%='+5I-1O%[KS-B@I3Y?+HQ/\U'<7RTZFBZ3
M[[Z@^=GQ-^'/1?6O8=+5]QR_*W;&8AV9FDK]C=FX#'4V0W)ANRMGU&_Z+,YC
M<.-CIMF(N-J9LK24N3AR9-$U#4^ZTI7-1T"W\N;Y<;D^4GRQR*[I_F?_ !-^
M7-3LGH3>_P##NB?@UU!V3M+K>B@SV^^KS7=K]V;LW1VKW!@TW;MY\7#B=J4!
MJL94U%)FLQ+"E0D-08O=;(I4::?;QZOJ]^ZIU[W[KW7O?NO=$(_F6_\ 9)]=
M_P"+!?"O_P"#1^/_ +]U9?B'1]_?NJ]>]^Z]U[W[KW2*[$[!VKU5LC<W8N]Z
MROQ^TMGXF?-Y^MQ> W!NFOIL=3:?-+2;>VIB\WN/+S+K%H:.DGF;\(?>P"2
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M9'"S4[U%),L6\NO#&.KD_;?6^BK_ "H^)FR?ESBNJ=O=@;R[.VI@.JNW-O\
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MZJ/XZ^'Z2WKV?W9DY:K>.Q=S/BH]M]GX\8?#Y%ZFHR&;@AJ,A4T\"SQ1C=
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M5+L7<?Q]^<N\_E/@>L^JZ;J"'M39^#WWU_MGXBX_LFF[#PNY=ZY?=%'NC/\
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MQ23U%!YX\M4XY6UUI?750](#^7#T?B.N/DOGMR=3?R:=N?RV.M9^D]T8+?\
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M]>]^Z]U[W[KW5>WRV_[*M_EG_P#BP7<G_P "QW#[NO!NO=2ND/\ MX?\^/\
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MVMU!N3$;BZ%^,GRS^4]-V5MO;J;#Z&^26=^/R=!_&_M6DH<?0IF.S\'M/K?
M[BSE)U-434>)BSL-#F(:FE6MJED<K12Q.> ZUUL@?&GH+:?Q<Z)ZSZ V+E-S
MYO:W6.W4P.,S&\<U59_<>3:6LJ\ID*[(5]6Q6%:G)Y"9X*.G6&AQU.8Z6DAA
MI8884:)J:]>Z'3WKKW7O?NO=>]^Z]T6[Y@=?Y#M3XO=\; P_4.Q._,[N3K/<
M])MKIWLO.U&U=E=@;IIZ"2OVO@LQNVBC?(;1D?<%)32TF7I6@J\76QPU5/44
MTT*5$=EH&%33KW6JY\0N_-_?";Y(Y#?>X/DOVQ\DZ#O/L/KBO^7O:?<U%D*.
MA^/W4.RMET/4NZ\'\\NO*&FRN<^'GR7Z/[%Q Q.U,Y$M1M/L3;[11UDD @?,
M1WTDCA_J^76NMB3Y\9;$[HZ>^->X-M9?%9[!9SYL?!?*X3.8?)461P^8QF5^
M0W7\F,R&*RE)/+0Y&BR455&U/+#(Z3"12A8,+U05U ^AZWT:;O*;Y$0[5Q[?
M&G'=+9+?!SU&N4A[SS.^<)M1-L?;U?W\N.J=@X+<&7DSRU0@$,<D*4[1F0LX
M(4&HIYUZ]T3'XF=[?/7OC<%9G=][%^(6V>IME]Q=P=-]@-M'?/<69[#GRO4&
MZ]Q;!R>:V;2Y39-#MF;'YG<^#$U/'75,,J8^2[_NV7W9@@ XY'7NK+ZJEIJ^
MFJ:*MIH*RBK()J2LHZN&.HI:JEJ(VAGIJF"97AGIYX7*NC JRD@@@^Z=>ZKE
MW%_+[3K+-9?L/X%]IY+X?[XRE7+E\UUGC\0=\?$KL/).YJ*A=X?'JMR.-Q&S
MZ[*R(L4N9V55[:R<:LTCFI8E&OKKAQ4?SZ]U@P_SVS72^6HMC_S!^J7^+F5J
M*NAPN'^0V&RT^]_ACV%E:R=:*D_AW<?V5!D.G,GEITEECQ/8%!@3'$FF*MK"
M [:*@U*G'\^O=6/4%?0Y6AHLIBZVDR.,R-)35^.R-!4PU=#7T-7"E125M%5T
M[R4]71U=/(KQR(S(Z,&4D$'W7KW4SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=?_]+?X]^Z]U5W\_?EO\$^K,]LWIGY8],Y+Y%5M4FUM\93:F/^-%1\BML=
M+[.WEO(=9[<[@[<K:W;N7V?U3L[+;M:?'4N0KZB&JK&I:O[:*:.EJ6C]UL \
M1T<_I/?_ $SG7[(ZEZ=Q^/VQ%\:]\4_3N\-@8O9\NQL;L?./LO:78>'Q^#P/
M\,Q6.DVSE=F;ZQE?05F.C?'5$=0RQN7CE5/=>(."?/HE?\UWI_LCN7I_IO#[
M,ZH[M^1&R<'W]@LYW?\ &WHSO7%?&S/=U=8MU_V+B(\;N/M_)=G]0-AMI[$W
M[E,)NB7'IG*>/-5>%IZ.8"*5IH?=;4@5KT!O\LSX\[.ZE[LW_N7;G\LGY/\
MPIJLMU:N%D[1[J^:V*^36S]Y4(W5A,E#LO [6Q7RW^0=-BLM.ZC(IEX\;2JU
M-2R0&K'D6&7W6V-134#^75W?OW5.O>_=>Z][]U[HA'\RW_LD^N_\6"^%?_P:
M/Q_]^ZLOQ#H^_OW5>O>_=>Z][]U[JM?YP[FPFR/D!_+ZWUNBL;&[5V3W!WUN
MS=.5%)6U_P#"=O8+XF]RU^6R;T>-IZS(5,5#1Q-(ZP122:%)"FQ]W2I#@=>Z
MUQ/GU_,=ZD[1[?\ EGC.BL#\E-Z;\[FP/\MW(_#/^XN.[5V-U%\NO[RYOMG:
M,N![7R&V,ALG<=;\4>P8]]-CJ@U]1C7SXI*J?!3F6E$XL!32/]6>&>O4J :B
MF?Y=%XQ/\HCYQTG;]1T3/\4>V\ST3U[UQMWM?9O4.6W5T;)\)5[JH]PQYUWP
M]-_?O$8ZLRU?DYZO'9&>BIL9O.KP9AU5E)4*^5FV&6@%<=>S2I_V>A0^-?S\
M^6GPXWOUKW'\@/C)OG"[<Z<ZC[3^,?:. [][ZJMV]H[]^37:/<G6>[:_9?6_
M96XZO=6"ZDV3LRFH<&NT]K;CJ8,;!LV9IVS=75 22>TU!\NO&E<&O6SQ_,"[
M'VINO^5K\KNR4W)L]-M9;XJ]C9JJSN+WC@MR;/HC/LRL>L@I-Z8JH;!YFDHZ
MQF@2J@?QU#*"@]07W111Q7KW1N,SA]V;]Z+H\3U/VD.L=T;AV5MB3:/:N(VY
MMOL*/!B6FQ5:F8H-O;C6?;6X:>OQJ/$GGU1%)_(O*J?=<5X8Z]U6_P!)X+YW
M[V^1WR/ZOW#\_P"MJMM?'#?O2-#%%3?%KHZBJ]]8+?/6>VNR]P8O-UT<+MC7
MJ9,I-CXIZ)(9(*>T@U2^H6[: Z>/7NKBO=.O=>]^Z]T!?>GR6Z)^,^'P&X.^
M>S=N=98;=&9;;VWJ_<;U:0Y?-I1S9!L;1_9TE7))5"CIWDMI%PO'/'O8!/#K
MW6MID][?%3Y__P X7_1_L;OG+[MVY+A-N]\4%;TCW'O[84&?EZEZ#W7L3!KC
M,KL2KQ0FWOMG=N^:Z<5<DT<U)1TT].K^J:!KG$9! J.MT89I@]'O^,.7VG\6
MO@9U7\YMZ=@_)[NWM_?'26R<%B]@[^^1?:W9*]R]T=GY'$X;8VR-G["W9N3)
M[4IM[;\WW54=!2U-+CP]!2SRRL13QSM[J14Z:#K1).2>C:_$[^7YUYU1F]N_
M)CN?;V W_P#.S==#G]T]V=UP56=?&Y#L?L"*G3/)M7;-5E9=L4-#UWM6*'8^
MULJM!'F:/95"F/$ZP5-7%+XMY#X>O=+O(?RZ_B7'U#G^F-@=:ITC@,OV=E^[
M,3N;I#+Y+KGL387<69FJWJ.R^M]\8F=LULG<M-1U\^/IEHG2AI\+,^+2G&-9
MJ0^U-Z]>ZUJ,CVWWI\*^\<+N7X3_ !GJNR/Y=?P8R'SLV9U-MBNP>=I=T;)W
MW_#]COW?T+O/<M*]15=%; I=\451N[8>X][T33;@PLE;3F=X*G"SO<K6E?BZ
M\.!J<XZ&G^79\N.VJ7YHXC-4>_NP>X=R_P Q_=&U>S,UU/VC%L3;U'7=0[&Z
MIH=M]@_(+K-MNY7(#XZ9KX];OP(VU5=1;GGJMRYK:HHJN[9>"MD73A:#_5_J
MKU[JY/Y*_)GYP]$;YV5C<)T-\9MV[$[@[^VUT1U/F<CWUV-@-T+6;QQ6=RN#
MW%O_  <?2.3QF)I8(MM52U4&.KLC*&>+QE[OIT I'G7KW1Y>FZ_NK);-2J[]
MVOUMM#L Y7)1R8?JK>.X]];37"I*@Q%4F>W3L[8V5;)5$.HU$)H!'$P 61QR
M*FE<<.O="M[UU[H)<MT)T?GJ'?F,SG3W6.9Q_:66HL_V72978NV<A#V!G,8D
M$6*S6\UJL9*-S9;$Q4D*4=16>::D2&,1,@10-U/&O7NA4)BI8"3:."GBN; D
M1Q1)^ +L0JK_ (GWKKW6MCVW_.__ )3W1NZ]N]74_P 4OD3O&@VSOG=G:&S,
MML3X(;CQFUHNQMDUE;F-[=E; _OYA=AY?+;GP5+'-E\GN/&4DC+12M4S5>B1
MS[N0:Y85ZV%)X<,?SX=</Y(7R!VC\].Q^R?D/L7:>_*'I_X\UWR)V)U3N#>>
M-P-#'F]^_+;Y);F^2?:57-04^7K<WAMV;<ZZ?8V,D66".*2GJ9@DCB]],05%
M/]5.O%2IH>/6RO[KUKKWOW7NO>_=>Z][]U[KWOW7NM;[OO\ E#]ZMF,UUI\;
M*_J_']156V^V#B^S.PLWEY^U\ITWV]O&EW[WA_+Y[-E;#9RMW_L7N3LB?^\>
MT^VJFJ;>W5D]/,:1:VK6GJ*AP,,$\>M=#MVS1_&3YA?$GOCL#(;&[1ZI^3OP
MU^.'9NP]Q=.YGNGMG:/:7QNWUM7K;-[HVK2Y^EV1V+C<'V'C*ZKQD&4VSO-U
MRM#N?'*E3354@^XABT*A@*X)ZWT=_P"#GQ<Z<Z8ZSZ_[,V+@MW46_.R^F>M)
M-]9G<_:W;6_FS%54[=Q>=K*AL7V!O?<^'Q==49BLEEEFHZ:GE<L59BME]U+$
M\3U[%<='L]ZZ]TB.R=\TG66P-Y=A9#!;KW/0;)VYEMS5VW]CX.7<N[\O1X>C
MEK:BBVWM^"6&HS.7FAA80TZ,'E?TCDCWL"IIU[K5N^:?_"FCX99'HON[I_K+
MJ/Y'[@[4[*ZIWKM+8>.[!ZX7KG:E=3[NV7FZ*JW;G:RKSM9NW'[<V]CY)ZJ:
M./%-5U7V_@C$;N'2VFA KGJRJ3FF.K _Y&/9E/O?X_[HHNT=KY7KSYE9&GZH
M[)^177N<I<8LF&V3NKK# ;4^,.2V9D\15Y*"NZKR?2'7=!'BHJFH7)TV0I\D
MM9303,WD\U30TQU4BA(K7J\7W3KW7O?NO=>]^Z]U[W[KW7O?NO=)2CV)LC'9
M7>.=Q^S=JT.;[$..;L#,T>WL1397?+8C#Q[>Q)WCD(:-*O<QQF A2AIS6O/X
M*-1"FF,!??NO=:I?\S+X.X'J'MB*3(39+KGX493L'JSM+HCXY[6Q79^Y/BMO
MOY'8C-2MO;JK<NT^K\@G9OQO^2/=5=EHH.K]Q[(C&U89XYX3BX\[+'/5W'<,
M?%_JSU[JR7XY_P PG>/Q6Z-Q6WOYL>V.ROC1N? '+3;;[B[%QZ=E=<[CV%65
MM36]9;-WOW_U52979V<^16*VEXJ#.I4X[;[YS+TKR44%1+->3Q 8]G#KW3__
M "COE?L+MO:W<&S)]M;RZMWIN_Y+_+#N?K[;'8L6&CE[+ZJW9WMNG*1;RZ]W
M!MW)YG:F\(MJU.6CQ>Y*.@K9ZW;V63PUL<:S4TDWF4@+C%.O=7-^Z=>Z][]U
M[INRV)Q6>QF0PF<QF/S6%S%%4XW*XC+4=-D<7D\=6PO3UE!D*"LCFI*VBJZ>
M1DEBD1DD1BK @V]^Z]U7%E/@?N[HJNR.\/Y>';:_'.JJZZIS.6^-.^,?D>P?
MAEO.NJ7DJ*N&CZU6OH]R]!UV1FT*:_8-?BJ*(*&FQ-;;1[MJ!PPZ]TZ;7_F"
M8K8>X\3UC\Y.M\E\-.R<O7Q8;;>[=V9REW1\8.TLF^I85ZS^1=%28W;%-7U^
M@-'@]UT^V=P R)&M),2';VFN5-1U[JQ6*6.>..>"2.:&:-)89HG62*6*10\<
MD<B%D>-T8$$$@@W'NO7NLOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__3W^/?NO=:]W\W
MSX];MW]V,FZL%U__ #!]N[#WITMM+8?<O=WP3KOCAVMB]RX[87:F7[!V+L?N
M_P"*?=LLN\<]%U?DZNNS>#WALZCJLG2)FZ_'5"O33>/WOJZ&E.'1T?Y4^0^*
MFZ.D>RNP?C/\D]]_+O/[Z[KSN2^2W?G;-5&W;6X^_P#';.V/ALIM;?F!H]H[
M#PNP'Z\V!18##XO;.,PV/QF$P]-3111N[2U$^NJFN >FS^;'TSEN[.I^C-OT
MFV.I^ZL3B?D5M_/9_P"'7=/< Z1V5\T:>CZ][(_AG2D&[GIZ^@S&[,!FGI]Z
MXK Y2CKL%F*C:ICR,(IU-33^ZVII7HFW\J[HCY-]8=M] ;3^1W7G5'Q6J/C-
M\*^V^D]B=&8#Y'X'N/M7NS9V\N\>KMW0=EU^S=H04.T]E=-]&?W?I=NX:4+7
MY23(YZ>.:>FIQ%%5;ZVU!73D8ZOYW=@)MT[6W)MBFW'N+:%1N'!Y7"P[KVC4
MT%%NK;<N3HIZ),[MNLRN-S&,I,YBC-YZ62>DJ84G16:)P"IUU3JM'^3AV+V=
MV?\ RM/C#V!V%O3=?:G:&7V1O_\ B>]=_9VHS^[MW93"]G=@87$UNY,_D&,M
M?D9Z3&4\<DSZ4]/I5$ 4>ZLP 8@<.BJ_RMZ_?G2'=>UOC?\ +3$?-C!?+KLG
MXDX_MZ3/_(;Y@Y7Y,]0]LILC<FSL+WMF=C;/I.PMT[1Z5WGM;L?L#'A,5#0Q
ML=NY&FCAK)EIZB*+?7FH<BE.AN_F5_)>B?:M5\>/]!_R76LE^1GPFI!W(_2^
M>7X\1&?Y4=!;I6JJNWC-_ X,= B?8S3%"(LD?MR"_OW6T&:U'5QOO75.O>_=
M>Z][]U[K3F_FU?,?Y+]8?-S$X#(?*_J_J?=?PVS>Y/DWTYA=H=89K,;3EZ([
M!Z8[$V<^1^1]=6YK.SGLC^*3U&V<;02G!;5KTS$&1>JCF04OMY0A&32O6LUX
M5Z67P8V/\)/C=/\ %3?6X_YPO5O9O<&R.T-S]R]Y;/1]CY+J#M+L7NS:>X-G
M(=D8PXG%[ZV#CMJTF]IX=H2M5OBUA4FEQ=&)76/QU$,-!QU[SK4?ZO3J['Y>
M=_?.WH'+Q;DZ_P"M_B=NWJ7<_;'3?4FQ6WAV/VWM_L0Y7MW=.W]A09C=5%BN
MOLIMBEQ^#W-G/-)'25<\LU EUM+Z?=%53ZUIUOI)]:_RR.F-\2=A;_\ E;\8
M/CCC^\][?(.@[^J]^=+[U[:W=E,GO;!# UV$W94;N[%H=N[DP<D.4Q(0[<I(
MVVW]G#$C4\FIU'M5*:3CK5*\>B,?S5?Y2>T>W<YT9C?BMT%V5B8^R^QMX0?(
MO:'0_;.&Z)Z"RVT8^O<W68'?/<FP<]'ENJMPYK =D18B6B2+;5=6Y2%ZV&6.
M1C#+!96!KK..M\,C_5_FZ$O^3I79/XW5.^?C!\L>M=Z?&;Y<=B;WW;G=G]>Y
MG>^7W'\7.R.M^NU;'X&B^!LE=NS=FW]N;.V?LJ2FKL[M!:B+<%+6U55D'@;'
M>,4>GJ<^76AT?WXT!A\U?YE)((#;]^,.DD&QM\9-E@V)X-C[J?A7K?01_.'-
M_.+IFIHNRNK/E-UE@]A[\[TZ'ZBVWUMN7XT4NY:S9M!V[OK:?6V4S=1OF+L[
M'5FY:W"UF9FRD$+T%+'+84[&P#FR@-BAKU[H^O1NT>Z]F;2KL7WOW'@>[MWS
M;@KZZ@W9MWJRDZCHZ/;LT-(F.P4FVJ+=>\(JNKH9HIG>L^Y0S"8+XUT7:AIY
M#KW6LC_-&_F _P Z?^79W'A L/QDW_\ &[MSO/;G6?1/8U3U;44^9J,EV#-6
M5&U=@[KP]/VI!7Q[IP<M.:*IR(@H\;4P!:E9$?R1I>BE1IXDTZV #6M:@5ZJ
M>_E<?+WN/J3Y&=H]T;S[BZLPW<7=O9=)\=-W=:Y7JG)]F8FIZUZMR78_;6_=
MG?%O^X6;PN7W-VC6]F;YEVQM3:5#4Y&*OR=<U9D],%'"7V1J!+_ZJ=;8  *H
MQQKY]; /\H3=FU/G=MKX[=ATLF5HNGOY>?6^"ZLVAU-O04E-O&?YAY;;>1PO
M:?:^[L'1UU7CZS;/5NTJJ7;&Q<F@FI<C7U^X*V"0-34Y33&@QY]5(H3UL;>V
M^O=>]^Z]T3+M7X&?'GN/NW =Z;PPVY4SE*^W*CL'9&"W/7X7J;O[(=?U461Z
MAROR%Z[I0,%VSE>ELO&U7MB?(*7HI&5)ON((*6&#88@4Z]TZ=M?!SXT=N[>[
M6QE;UMA=C[K[?W7MCLK<?;?6-)1[%[?QW<.PJ"CH.N>YL!O_  U+%F:#LSKY
M<;3G&Y!VE!CC>GJ(YZ6>I@FV&(IGAU[JD[Y5_.C?/5_:OPM^&7R<VENKN/Y4
M]5_,_J'LV+>/Q[V='F</WY\?ML[-[0)[JI=EXVIF?9O<5)BA4U&YNLZ1JG,%
ML;5Y/!056&FI=&Z>:\#UKJ\7?/8W<_9'6_6O8GPBK/CKV3@M[BESTNY>U=W;
MYQNU*_8^3QGW.,RVTJSK[;6Y:O(9-ZJ1/)!5)3*D8969905&@%R&Z\:^71=?
MA%\@OF[\E<3L[MCLKKGXM[+Z1S^1[7P.4I]C]A=J[C[3HLQUQO;=?7%)/0T&
M;V!A=I5.,S.Y=I33OKK4EAH94LK2AE]^(4>>>O9_+I^K_P":K\(<7FZ/;61[
M&[$HMQY1]PIAL#4?&KY/)ELZ-I.B;GFP-!_H<-3FZ3 "6-ZJ:E66**.6-RVF
M1"WM#>G6^CB87M[8NX.IH>[<76YN7KNHV?5;\BR%1L[>6/SYVS1X^?)U%2VQ
M<C@*7?4>16CIG*X]L:,@[@(L!=E4ZH:T\^O=:<G\_;YC_%WY"=R? C$[1^1.
MYNIGV3L+YM[TW3E=Q=8=U=<96?![KZ4PN/V'L[,X/=^T]C;DK]@=\[BVW5;7
MK:JC#P0*[FI/A21&N 585&>MJ"RL0<8_P]6<?R4NA>R=[;<ZE^<69ZNG^(^
MW_USV)N'<'76(;$0[E^6>Z.]=\UO8M+VGVU08N-L-C.J.I<+44N.ZIITA@ST
M^.JZNLJFI:">DHIM,V*?ZAUJF>MC#W3KW2'W1V9UOLBOH<9O3L#9&T,EE(FJ
M,9C]T;KP.WZ[(P+,E,TU#29:OI*BLB6HD6,M&K .0M[FWO="> Z]T1O/_P W
M+^7#MK?FY^L<E\KNOZC?VSMR5&S]Q;6P%!O#=>4HMSTS,DF$BCVMMG,QY+(,
M\;B-*5IC*8Y FKQOIWI;TZ]T(^0^9='NWK79G:OQ>Z8[2^6>UMV[JSVU:F7K
MM-L]=U>V)MO>6&MR6<HN^L[U96?PTY.$TJO3QS,7]8'B]?OVGC4TZ]TD?BE\
MX]W_ "KJ-JYG#_#WO_K?JG=M/O1J+MW?^9Z6&W*/(;(S&2VW7XJOP.V.S]P[
MTAJJ_<>&JJ2F9<>\3F+R,R1LK'Q6E:D=>ZL#]UZ]U0)_.\^/>YM_8+:G8.!W
M._QYV1D^LNV.E^_?ECLBERE9N3:VR-ZX=(]F]>?)?"8J>@FW#\#\_N6JJ9]\
MU]/,V8VG4I25U+)18Z;-5:N(<$>?6NF+^5E\H.U:_KOLGXO;:FVSM[<&Q.MM
MD5OP3Z^^36]]U5V4[0V+@<!+M_>V]NM.VJ+#U>:^0/PGI]S8N&386[8*.7=D
M.&JS!EJ*"FCQ4M3YE&">'GUOHU6ROD'_ #-=Y=W]L]'0=4_!RCS'26+Z7S^\
M,_/VGWR<3F<7W#%N:NAI=KP)U8U6<CMZ@V?6"5JKQQ3S20Z=*E].J)2M3U[J
MP_O"O[LQNP*RNZ!H>I,AV!35^.E$7=F?W7MG84.WXYB^X*NMR^SL%N+,P5M+
M0*7IQ]MX6<?N.B\^ZBE<\.O=?.2^?_S8WW\XOYBW8.Q]L]?=8[EW_G,[\8_A
MWMGN[XW[JJ=Z8_$9'K_O+/;LS^[^@LUV#0;4Q.8W%VGBMRY;9\6-R<U+BLV*
M04RSS)4KKO6A  ..G52D>IOF:=;_ -\#]K?'O"?'_";A^/&ZLEV/A]^Y/)[C
MW_VKNZIEK>U>P^TZ:;^[^]\CW%-6TF.RN,['P&6PSX>OPE12T/\ =HX]<3#1
MT<%''315:M<]-="?WQV[V+U/2[4FZ\^.'9WR(J-PY.NH,I1=:Y[K# R;1@I:
M6.>FRF=G[,WOLJEDHLA.YAC^T>HD1T)=56Q.@*^=.O=%U^+/SKW+\H:?;V[*
M3XB=^=6].[DP>\<U2=Q=B9?IK^[E*^R\ID,'7XROV]M3LS<F]H*VLR^'JXJ<
MC'-&RP^1F5'0G96GGGKWY=3:G^:9_+NHY8J:M^8/25%5U%-][!05F[(J3(S4
M&OQ'(18ZHABK9,<LQ$9G$9A$A"EM1 ]^T-Z=>Z4.QOYD7P/[-WGMGKOK[Y5]
M-;QWQO+.1[9VSMC;^[:3(Y;+[BECDF3!4]-3ARN6\43,U.Y255%V47%]4/IU
M[H[?O77NO>_=>ZX,BN '57 =' 8!@&1@Z, ;^I'4$'Z@B_OW7N@3^0WQ_P"O
M_DSU9FNJ.QH\K%B<A5XG.8/<&W:\8G=>QM[;8R%/FME[_P!G94PU,..W9LO<
M='!7T$DT-13&>$)/!/ TD3[5BIJ./7NJF^K/Y0N_]K[VF^0E;\C,#U%\I=I9
M7<N/ZBSGQLZGPVV/C=A\#F::# ;GW]O;XN;IJ<GL+*]U=_X#'4T^_LGA), &
MGA@I\7+31TWW%1;4.%,=:Z,^?EK\G/C8WV7S=^/,V?V%2*3-\JOA_B]T=G];
MT5''J>7)]H=%S)D>].K8*.B0RU55CH=W8J-KWJXU OXA6^$_D>M]'HZF[FZF
M[ZV5CNQNENQ]E]I[%ROHH]T;%W%C-R8@U0A@GFQU54XRIJ!C\O11U""IHZ@1
M5=,[:)8T>Z^ZD$<1U[H3/>NO=>]^Z]TGMU;4VKOK;N7VAO;;6 WCM//T<F.S
MVU]U8;';AV[F\?,5,M#E\)EZ:LQN2HY"H+131.AL+CW[KW5=4OPA[8^-\TV=
M_EY]SKUM@5E-34?$GOJ?<G9/Q4R0>0-44NPJI*NI[4^.U3.\\\X.W:ROP"SE
M <&R CW?6#AQ^?7NE9L/^8'M/%[LPG4?R_Z]W#\+.Z,[7C#[9Q_:>4QN6Z1[
M1RICDG6'I;Y'8A(>M]Y5,\'B,>(R3X'<_DF$1Q6H'WK3YKD=>ZL*]UZ]T7SO
MKKGO?L*GVI%TA\CY/CQ-B*W)S[HJ8NH]D]K-NZBJJ>ECQU"(MYU$$6WSBIXI
M9!+3AVF\NEQ91[V"!Q6O7NB:?RXZ[Y@=P]9=5_(_O+Y8T78FVM[;:WBF5Z?Q
M7Q_Z^V'BX<U0[MR^W,5EJ/>6&R-9N6./'P8,R-3-K2>2=M3!5519J"H Z]U:
M=[IU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO_4W^/];W[KW6N_\LNC.]OEQO/I/,]X?RTOC_\ )+M3;/3V/W#V#\<-^_S6
M.P]M]+]2Y:?LSL3'[<R$WQ^Q'165ZX[H@W;AL8LHW=GL&FN>GEQ4<)&,\TGN
MK*:<30=6I?!W);N3JK/;(WS\<?CO\2]R]:;WJ=IMT+\;>V]O=L[.V?A:C;&U
MMS[>JLU-MOJOIVCV5N+.XO<*50PS88,F->DJUFDCJT5/=:/'C7HMG\VZIZUV
MWU5T%V9G_D/O/XT]V]7_ ".P6X_BGOC8'0&?^5^Y<_W'ENM^S-GYWK\_&7:N
M)RNYNXL#NKIC<FZ5R-)CGQM=C*>$Y*#(4;T8<^ZV"<@>?1=/Y=.Z<[W_ /+_
M #_<G>7R*[_^0';O6_0.Z-C=5T.?_EB]\_R[.B.N^O>P=]==Y7M":DF[JCW1
MF>T>T-Y;@V+ML(D^Y#'CL9C9S1XY?)65/O?7F! X#J\7>FV(M[;1W-L^HS6Y
MMN0;GP64P,VX-EYVMVMN["1Y6BFHGRFV=R8UTR&!SM"LWEI:N!A+3S*KJ;@>
M]=5Z(STM_+$^,?0>W.@-H[ J^\5VU\8MS]M[GZ<P^>^0/;6>I-N2]U[/KMF;
MUPU<M=NEGW%MV*CRE568JDR!J5PV3J9:JC,,DCD^ZV23TJ?CA_+]Z3^-?9NX
M.Z\9NGO?N7N3-[*CZMQ_:?R5[OW[WQOC9?4L>;I]ROU=L7-;ZR=?)MK9^0W+
M1P9#(")6KLM64U/+7U-2U-3^+W7B:FO39_,M_P"R3Z[_ ,6"^%?_ ,&C\?\
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MNO;&\DP_PWV!\U]T"H_AV<W1M+9.-.[MH;"V^ZU6U<W'/5;B@&C&&:['2/\
M!]G56))S\7 ];I/MGK76C#W[\G/DYD=C;Q^<.T.W^Y^Y]U=<;/W'T=O??+]
M_'KLWXR])=K[E^=^T<!2]%9O;.Y=AT-?N2CI>J:5?O9MO'(9J@S38VFGRT#U
MGA]NM3T%#3_5]O6TR1ZT/^#J.W6WR$K^Y?\ 15N#XQU6!ZX[ZP_\QC95-VKM
M7^6SCMI]WKMW>/=&P^Q\INSIKJ'='80W?/52PSXZGQ>3W6M)C=HT5?)34JY.
M8*XV*#@>'6B:Y)S_ *OY]-4&8^;^)R?R?^:F;ZLWAM[;75'9G\P2OVSOG8GP
M@Z*RVTH-R===+=2[#VSCNT.D\WD=T]N=246XY^HY*?<F3KJG)X;'RT4TT5;
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MC?*+M[L'9I^5.SHOF-\@NB/!E/C;//B\9FNQ-N=G4/:>Y33;)QT'@JL?CVI
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MZ+#=TY*+KZ&HV3N[I%ISE-X86+)29!GI]GRUSPTTTL"M.B*=KI.-/7L] /\
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M[X;?TVQ-I;3K=RY?;6+V1@H]JX+;F+H<9GMUU5:8)*6:.>0JK@QC1[:+$BA
MI7KW6MQWS_,\Z-P_S4R_PF[Y_FT9+<_6?7VU]QMOWM;>?PI^*V]]@;+^2>U*
MV%Z/8TF>;I7,[4>JH]I29.*::FQ<K4^<\="*L2S/3BU0!P ;\^MA&*Z@I*]$
M7VY_-3^"'5_Q=[V[B^/WR<[(ZD^3.%[S[PJ.G.K=D?$?XT8O>._)^U-]9_<&
MR>WZF+=_2&4RNW-L9G:E7IS\&,SV-H,(97H8Z*,"&.79=#0D]GVG_!U?1)J
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M\3N"OHMY5>VJ*DAVU1[BD:FIZG)+033 H6B1FT^]:2:E1CK5>E)T)\U_BO\
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MEIV1V7MN+XO[7ZZP?]_\GTK!F\5M?<'864VA4;?QB44]'4R4N-AG=&JG=SK
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M<!E,U4R4F0BWF]##+64X$,]5JH=(V2&I0=;B95#A_P#B_EU<3\IA_/5^'_\
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MD_B.[/BSWGUKVXE0HU"&;&[![&_T);ZF:8@:H8X:@QKSK8^D;HODW7NLM/\
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M )/XD46[^NLC_+Q[-[+I.C-N[2Z3F^7GQZV!TQV_V!D]Y4..HLCVITIOG?\
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MHQ2Y4T,#4J4]7M&GI97F\A\>@7H0!Q0CK?0T=!_,#Y)[:KMV;M^2NTNZ=_[
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MO=OSZ]_>#^:+_P ^D^ W_I1'R'_^Y>]^Z]V_/KW]X/YHO_/I/@-_Z41\A_\
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M^&Q>]/\ O</_ #0/_0A^(/\ ]R+[]U[6O^^QU[_AL7O3_O</_- _]"'X@_\
MW(OOW7M:_P"^QU[_ (;%[T_[W#_S0/\ T(?B#_\ <B^_=>UK_OL=>_X;%[T_
M[W#_ ,T#_P!"'X@__<B^_=>UK_OL=>_X;%[T_P"]P_\ - _]"'X@_P#W(OOW
M7M:_[['7O^&Q>]/^]P_\T#_T(?B#_P#<B^_=>UK_ +['7O\ AL7O3_O</_-
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MW_#8O>G_ 'N'_F@?^A#\0?\ [D7W[KVM?]]CKW_#8O>G_>X?^:!_Z$/Q!_\
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M0?\ [D7W[KVM?]]CH<?CM\)NSNBNRZ;L#=?\PSYN_)'$T^#S&'/6/>^9^/\
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M=U]N'K7N7LW9V)S^9V]U7NCJ+N/O+;,.3?%&''YG:D8KY*>CEJ'ACUUO0*T
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DO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g790774g72d51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g72d51.jpg
M_]C_X1H517AI9@  34T *@    @ # $   ,    !&K$   $!  ,    !&&4
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HP,SHP-0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   &IH , !     $   &$          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MWO\ 2]&STOIH''(=MK5QA[1)83>J=0#0'6,<X ;G!D F/<YK2Y^QN[\S>_\
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M;ZUOI5L]3T-_Z%5'48XZ1>X=5ZB<NN^W#&4;[&D6#?:VUF%9E,KM911[MO\
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M/S:K/^+14DE//4_63JCVUFSH^0&O=2TV%CQ[7BLY=GHBNVVO[+OL_1V?S_\
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MKJ\%PTXX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <L            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    !XX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M              &$   !J0    8 9P W #( 9  U #$    !
M              $              :D   &$                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   &$     %)G:'1L;VYG   !J0
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !A     !29VAT;&]N9P   :D    #=7)L5$585     $
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MGTA9I[MF9ON^GZ'I^G^B]1:?43DNOZ"<IC*[SG.]1E3B]@/V3/T98]E+W_\
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M69^#1F,;L%S XL.NT_GUS^=L?[%@_6ZC/MS,)U%=]F.VJ[>*&VOBPNQQ7O\
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MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI,OE9))3]4CA0?\
M3K^C]+\[GZ+OYO\ E_\ HM?+*22GZ:PO^4^H?T3FK^8_I'T7?\H?^ZW_  :O
MGCMR.?BOE9))3]5*'^%'T?HG^MR/^BOEA))3],]$_HUO]#_G[/Z#_-\_X7_N
MS_IEHKY5224__]D .$))300A      !5     0$    / $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
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M(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &1
M ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M_\  $0@!A &I P$1  (1 0,1 ?_=  0 -O_$ :(    & @,!
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MIJ.NI*#=&!I,L[U"8_*Q5M$))9#XOW)-2W=.5.7=[O+3<-UVF*>\@H$9@:@
MZ@IH0'4-G2X9:DXR>@W[??>%]ZO:GEGF/DWV\]Q=PVKEK=M9N8(632SR1^"\
ML;.C/;S-$ C3VS13%50:^Q:38/AW\8Z7;O7&TJ7IC9M+MCJ'M*I[JZRP5-2U
M=/B]E=HU6;R>XY=X8*DAJTBI:]<UF*FHCCL::%I+1QJJH%V.5N7E@L+9=IA%
MO:W!GB4"@CF+%]:BN#J8D>0\A@=)Y/?KWBFW7FS?)O<'<'WC?=E7:=PF9E:2
M[VY88X!:S,5)9##$B,V)& )9R68E5?[+ET?_ 'L[CWS_ *-]O?WM^06V\9L_
MN?.&.J-7V'MK#8&HVOC,1GP:KPR4U)MZJ>D7QI&YA-B3864_N+9_J=UO/W?'
M]3?1A)VS65%70%;/ *=.*8Z)?]=CW&_<G(/+?];;K]Q\K7<EUM,-5TV-Q+,+
MF26#MJ&:=1*=18!\@"IJM>N.N=D=1;%VMUGUMMVBVEL396(IL#M;;>-:H:AP
MV(I 13T5.]7/4U3I'J)U22.[$DDD^U=A86FV6=OM]A (K.)0J**T4#R%:G]I
MZ#O-G-?,7/7,F\\W\V[K)?<R;A.TUQ.^D/+*WQ,P4*HKZ*H &  .EM[5]![K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]+?X]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6[M#N/YO=U;N[W;J.D^*
MNW-B=4]];[Z5PL'8U!VYEMW95-ATN!^YW!E*O;.:QN&B;*5F5D\=/% !#%&M
MW=F-@+:[IS9NMSO!VU-NCL[:\D@7Q!,SGPPO<2I"Y). , <3UEQOW('W<O;S
M8O;->>I^=KOF7>^6++=I6L'VR*UC-ZTVF"-;B&24^&D2U=G[V8T50!5?_;_S
M*?\ G;?!S_T'N^__ +)_:VG/?^_-I_WFX_Z"Z"_B_="_Y0?<C_G/LO\ VS]>
M^W_F4_\ .V^#G_H/=]__ &3^_4Y[_P!^;3_O-Q_T%U[Q?NA?\H/N1_SGV7_M
MGZ]]O_,I_P"=M\'/_0>[[_\ LG]^ISW_ +\VG_>;C_H+KWB_="_Y0?<C_G/L
MO_;/U[[?^93_ ,[;X.?^@]WW_P#9/[]3GO\ WYM/^\W'_077O%^Z%_R@^Y'_
M #GV7_MGZ]]O_,I_YVWP<_\ 0>[[_P#LG]^ISW_OS:?]YN/^@NO>+]T+_E!]
MR/\ G/LO_;/U[[?^93_SMO@Y_P"@]WW_ /9/[]3GO_?FT_[S<?\ 077O%^Z%
M_P H/N1_SGV7_MGZ]]O_ #*?^=M\'/\ T'N^_P#[)_?J<]_[\VG_ 'FX_P"@
MNO>+]T+_ )0?<C_G/LO_ &S]>^W_ )E/_.V^#G_H/=]__9/[]3GO_?FT_P"\
MW'_077O%^Z%_R@^Y'_.?9?\ MGZ]]O\ S*?^=M\'/_0>[[_^R?WZG/?^_-I_
MWFX_Z"Z]XOW0O^4'W(_YS[+_ -L_7OM_YE/_ #MO@Y_Z#W??_P!D_OU.>_\
M?FT_[S<?]!=>\7[H7_*#[D?\Y]E_[9^O?;_S*?\ G;?!S_T'N^__ +)_?J<]
M_P"_-I_WFX_Z"Z]XOW0O^4'W(_YS[+_VS]>^W_F4_P#.V^#G_H/=]_\ V3^_
M4Y[_ -^;3_O-Q_T%U[Q?NA?\H/N1_P Y]E_[9^O?;_S*?^=M\'/_ $'N^_\
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MM=*OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4;U/\
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M -H_Y35_8W^;KW^S*='_ //?X_\ \]^<_P#K7[]_4[F7_HU/_O2?]!=>_?\
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MT]^_J=S+_P!&I_\ >D_Z"ZW^_P#:/^4U?V-_FZ]_LRG1_P#SW^/_ //?G/\
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M5J#T#]VM[6SO7M;5)5\/#"0@G57BI'X2*$>?5"'\ROXA_P L+XB[_P#A]L/
M=C=@;%W1O/Y);*R/RBVCG?E'V]NS<.U_B%FL?D'W#OW,XZEJ:VHV%C*K,>(T
MU>B_Q22*\D$$L1,GL!<P;;L>V7NVVZ3LNJ=/$&MB1&2VLGN)'X?PKQPS9"B?
M9;W=KV'<I6C#(L#!#H4#Q/("O$\?EZTZV%?B;\5?BI\4=@;RW!\6,EEGZB[5
MHMO=K9KL/>'>63[6V7E-JX7$9&/;F^L7V%O#)-A\!L[^!Y.5IZMJJ.F:P\SJ
MT(1![M5EMFU6LD]G+_B\H#EM18$!2:BK-Y5."<>O'H*WUW>WDT<=XO\ C"$J
M%TT8$G*T&:U\NM,C^<KVQ5]X?._?O9=-O"?L7H2OV_B]N?%C?\%!GX.J-P=5
M[3V]C\;OI>ILSGL7B\+NBAH=^ME$S^3Q)J**OJCY?//#XW]Q'S9=R7F\SSF0
MM9$4A.=!50 V@G# /JJ5)%>!IU(O+ENEMMD4?AA;L&L@J-08DE=0!)%5I0&A
MI3&.MD?^0/3=RTW\NS"?Z5(]Q0[,J.V-Z57QL@W2E5'D$Z1FH\.6EPL->!6Q
M=>56^!D9-O @4YIS,U,/ R$R+R)]7^XZW1;1XI\*M?[.@X?+54CSI\J= WFG
MZ;][$6]-8C DI_'4_P P*5_+H4/YW_\ VZA^87_AO]=_^_3V?[7<X?\ *M;I
M]B?]7%Z3\N?\ERP_V_\ QP]6?X#_ (]38O\ XCOKO_WA\![/[?\ L(?](/\
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M\>%HS^@XT@D&O#/#A_/JW#XN]A_+7M:GWKDOEW\.Q\3:_%[DP4&TL/M+L?\
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M\_7M$G^^G_WEO\W7OL,G_P Z?.?^>/+?_4?OWC0?\I$7^]K_ )^O:)/]]/\
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M'8F$[#K<WES78BFQ/7]'DL>F H-L#'.Q=):K[YZA/TQH']U04\_]7\NB7?\
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MGY?X>M@/WOIKKWOW7NO>_=>Z][]U[KWOW7NJ!O\ A19_V2/\6?\ QIK\%/\
MWZ,OOW5E\_\ 5YCJ_GW[JO1)/YC_ &WU=TO\&?E-NKMOL/9O6NW,ET5VOL[%
MYG>VXL5MN@RN[]V]?;EP^UMJ8F?*U-,N4W+N3*SI34%!3^2KJYV"11NW'OW5
ME^(?;U05_)?%+\^OCC_+IZEI,SB\S\3_ .6MT[TQO/NW$TU6Z2]I_P P.GQ5
M3G.L^IMQ8EH*;)1[3^(6&JH-VY6.=EH\EOC)8-$6?^!5:CW6S5>/$]7C_.C^
M95T5_+ZJ^KJ/N?8WR(WB_;2;NDV[+T1TANSN*'%ILL[=&5.Z6VNKM@6J?[S0
M&D616:J$<Q06B>WNJ@5ZUPOY*_\ -OZ%^'_Q:H_CKW'T;\V:/L3=ORJ[UW1C
M?X+\3NSZ[;E/@^Z>Z<CE]E5N2S];18RDH@V/ST,E6I!>GTNMF8*&]7J[+4UK
M_A_S=;HWOW3?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7_]#?X]^Z]UJ8_-OK;=O2G\V'Y-_(3;'\E'LW^:'M+O\ Z'^.^#W!NO?>
M!Z7K=A=>]C=8X[,X5H>C:W>VW]ZR2[=W'L6JQD.XTK**DR$.?Q/[,DE'*H'N
MG%./B(/Y?YQT>;^5[V1G]X?('>&.RO\ (8@_E>P0]1Y6L7Y )A^E*"3=\L6[
MMIPIU(T_6_6NS\RZ99:ELN$DK)::^()>+7XG'NM-6@[R?]7VGJ^CW[JG7O?N
MO=>]^Z]UB,\ <1F:(2%M(0R('+$7"A;ZM5OQ[]U[K+[]U[J@G_A.1_V0QW'_
M .- ?F__ ._IROOW5FX_ZO7J_;W[JO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=48_P#"E3_MR+\\/_#/ZN_]_P"=4^_=67B?L/\ @/5R?5W_ #++
MKK_PQ-H_^\_C_?NM'B>J ?\ A13_ #7-M_!7X\M\8-O["7LGNOYI=6=P[(HH
M,AEYL'MCK+JJOVZ-B[P[)SU1345;79O+_=[QBI,)B8!"M75+--45$$--HJ/=
M7C74PZ S_A,3_-)V[\E.AL-_+SW-L%MD]K_"_H[9--M;<>.R[Y?;G<73>$K*
M?9,&[_M9Z.EK-H;RP&6FHJ;+8QY*RF?[V&HI:AD>2&#W7I$TGY=;/O8/_'A;
MW_\ #0W+_P"Z:M]^ZH.(ZI=_X34?]N0_@A_X:7:W_P $!VS[]UYN/Y#_  =6
MD_*OY5=&_"OHG?/R.^16\X-C]6[ HZ:7*Y+[2JRF5RF3R=9#C,!M?;&"Q\<^
M3W#NG<F7JHJ2AHJ=&DEFD!8I&LDB>Z\!4T'6JI_PG\_F^_!?9^)^9W3?<':D
M?0.Y^S/F#\L_F_LW,=WC$["V'D^F^S<Y@LW38Z;?E7F:G;&-[&VKCJ/R97"5
M51#.%D#4;UBI,8O=./&PIBN/\O1_/YD'=GR*_FC? [Y0?'K^79\7>ZMT;'[-
MZIKH&^47;S57Q?V)V!@L?58#=M;LCX[[+[$QM)W/W5E>UL%CJS 4]=68';&Q
MJB*N+_W@FA?0_NM*%!&L_EUHS_RTOA5\Q.\_Y@/0G7/3G4G:^P.R.@OD)U-O
M/M[/;AV;N384OQ=Q?7V],5N/<E9VC-EJ#'?W$W$-N86LI,=A:AHJ_-R3+3TD
M4T4I;WK/3TC*4_U?ZO\ 5Z=?7/\ >^DO5 _0_P#W$??/;_QG+\5__?AY_P!^
MZM^'_5\^KT=[;2Q6_MF;NV+G6JTPF]=L9_:68:@G%-7KBMQXJKP^0:BJ6CF6
MGJQ25CF-RC!'L;&UO?NJ]?+;W;_PGL^9>WOY@F%_E@8W=74M?E]X=9YSMO9W
M=M9GJRGVJ_Q:PNZSU_5=DYW:B4$NX:7L7%S30TDVUHA+'49+4T5?]C_E(UTI
M$@$8IQX=?3/VKAMF?$3XN[;V]45V=R?7OQ@Z#P^&GR<>-J<UN;(;,Z5Z\IZ&
M6N3#XJ*>LRV=JL)MHR"FID>2>H;1&I9@/>^D_$]:BWS%_G/_  O[R_F0_P H
MOY.]?T?R1KNH_BAGOEMENZ<S6_%GO.BR&"H>Y>EL5LK8TN)Q+;+DJ]R?>9RE
M83?8B8016<D@^_=.J"$=3Q-/(];57PM^;O1OSXZHR_<WQ^??TFRL)OO-=<US
M=C=<;MZPSHW)@<5@,SD%@V]O/&XO*U&-6BW)3:*I8S"\ODC!UQ.J^Z:((X]&
M[]^ZUU[W[KW7O?NO=>]^Z]U0-_PHL_[)'^+/_C37X*?^_1E]^ZLOG_J\QU?S
M[]U7K3'_ .%>'QK^3'9NS?B5WMU]M;>/8/QYZ+?MVG[=PVS\=D\^.N-V;OAV
M7+M'MC=&W<1#55C[:APN RF+DS#0O38.2H7RR0+6ZFT>G8B QKT5;_A(E\<_
MDA0?(GY!_*>7;&[MI?%?<W0]'UC3;GS-!7XK:W=79478&)SNW:W9,5>E-3;O
MQ_76"H<Q'+GJ(5-+#)EOLXYB9)57PZM,5./Q=;\/O?3'7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]'>'^2O1F-^
M2W1/9O165WWV3U?3=D;;EP<78_3VZZG8_:&Q<E'54N2PVZ]C;JI(YI</N' Y
M>A@J8'*21.8]$B/&S*?=>ZHTRVVO^%-WQPE79'6N^_Y>/S_V)0JM'MSM?N?;
MV]NANZJC'T\ABIY.PML;)SN&Z^FRAI%3R38ZHJFF<,\C%V]^ZOV?G_J^W_)T
M)?3?P[_F]_)KLSK7LO\ F:?+WJWJ/J/K/?&VNRL;\-?@+CMS[;P'8^Y]FYZC
MW#M6A[Z[LW@S;UW#L>BR.,B?([7H'GQ.95@)IHS$-7NM54<!_J_U?9U?C[]U
M7KWOW7NO>_=>ZUX?G+\/OBSW+_,G^(/2'6_0/5V+[[[/[!'SO^9'?>&V]0P=
MJ8?X]?%O+;2AV5A9MS(]-F\56?(3ON/:^V35451%/)MW"9J/Z*"/=7#,%.<=
M'E^:7R\^>/0/:VU-D_%K^5WO3YN[#SFR*+/YSM+;OR>Z;Z0H-L;OJMQ9O%3;
M$J=O]E4,M;6RT>'QU+D'R*S1TNBO2,#5%*R^ZJ #Q/\ J_;T2;_A-!D<MF/Y
M>?8.7SV!EVMG,K\Y/F3DLUMB>NILG/MS+5W;-;59' S9*C"T>0EP]9*].T\0
M$4ICUKZ2/?NMOQ_U>O6PE[]U7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NJ,?^%*G_;D7YX?^&?U=_P"_\ZI]^ZLO$_8?\!ZN3ZN_YEEUU_X8FT?_
M 'G\?[]UH\3U0K_PH<_E3[%^=OQOK_DK1;ZJ^L^\/A?U1W%O[;V7.(&X=M=A
M=<8S;;;[W?U?NK$K7XNKHI\C5;-@FQ&7IIR^+JGE\E/513LB>ZM&VEAU7A_(
MS_E#]U]%_%+K/^9+\7?D]MZB^6?R;ZAV[NFCZM[8ZX@R'QCR71VYZ2EW7C^@
M=^5F#FJ.W,9N2KW-1T62?L' UM--C:F)8CM_)44<E+5:ZLTFK!&.KENROYP_
MQYZ5Z=[:Q_S\P.Y_@?WQLK9E5'ENENRXJW?%/VA49ZDAPV*ROQ+[(V1AJC;W
MRIVGD<[E(Z<M@((-PX4 ON+#8(!E7?5 I)QD=5G?\)]/YH_P.Z7_ )1W2?3/
M;/R&VML'MWXRTN:VIV;U;FL=N2H['K\UV=W'V#N'8-'U5L/"X7*[M[RJ=ST>
M;AB@@V;1YVJ6K#P21)*ND^ZLR-JI3RZ%C^:9T-\YOYV?Q0RG4O3/Q?F^+?56
MRMZ;9[TZ[W3\Q-V?Z/\ O+OO>/7])N6EPFQ\%\?MJ4>Z*OI':FXQEIO]S/86
M5Q><IY33B3;4".U;3>Z\I"&M:GK7S_X3W_RA_D%W3\VMH?*KLW!;;V3T-\&/
MD#OS;>\X<KG-O[CW1NSY/]0X^OV[/UIM[ XR?+4L.)Z^W-N&FR5;N&9EI*DT
M\<>,:61GGI]#IR5U( !_U<.OI!^]])^J!?Y6/_;TW_A0%_XLI\2O_@<)??NK
M'X1_J].K^O?NJ]4#]#_]Q'WSV_\ &<OQ7_\ ?AY_W[JWX?\ 5\^K^/?NJ]4#
M=@?]Q,_Q\_\ &/?;?_P4N,]^ZM^ ?:?\G5_/OW5>O>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NJ!O^%%G_9(_P 6?_&FOP4_]^C+[]U9?/\ U>8ZOY]^ZKT6
M?YI_]D<?+/\ \5G[W_\ ?6[J]^ZVOQ+]O1-OY%7_ &Y]_EW?^*Q=?_\ N+/[
M]UX]6P^_=:Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO_2W^/?NO=>]^Z]T07_ &=NJ_X<]'\NG_1FOV?^R._[.-_I
M@_O8NO[G_3C_ *'/]'7]R/X%JT^/_<C_ !3^)6_W1]M_NSW[JVGLU5\Z='Z]
M^ZKU[W[KW7O?NO=!QBNH>L\'VEO#NW%;+PE)VSO_ &KM'8V[]_+3M)N/-;.V
M'6;AR.T=LS5LTDAI\)@\ANO(U$5/"(XVGJY)'#.0P]U[H1_?NO=4$_\ "<C_
M +(8[C_\: _-_P#]_3E??NK-Q_U>O5^WOW5>O>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>ZHQ_X4J?]N1?GA_X9_5W_ +_SJGW[JR\3]A_P'JY/J[_F
M6777_AB;1_\ >?Q_OW6CQ/1>_P"83_V0+\X?_%0/DM_[YC>OOW7E^)?MZ+O_
M "2?^W1?\N?_ ,5(Z:_]Y.A]^Z\>JR?^%0O\OWY+_-3XU]"=@?&C;-7V9F/B
MYV!OO>N^.HL/74-'NG=FS-Y[,AP5=N39]/E*NAQ^?W!L9\8)/X9YHZJLHJRH
M^V\DZ)!+[J\;!6R.J<?^$J'\OWY!YGY/4G\QC<.UIMG_ !DP73?96Q.J]WYA
ML:]5W=N_>^=P^W\N^R\.9Y,Q0[0V1!M2N6MS$\5,M3DBE'3+.JUCPZ'5IF!(
M \NOH%^]],]4"_\ ">O_ )DA_,,_\;"?/_\ ][/:WOW5F\O]7F>KGNY>_P#H
MKXZ[<QV\>_\ N7JSI#:67SE-MG%;G[:W]M;KO;^2W'64E;7TF!H,QNW*8G'U
M>9J:'&U$T=-'(TSQ02.%*HQ'NM $\!UK;?RXOG9\(^O/YCO\\SL'?OS"^+VR
MMA]E_(#XQYSKC>FZN^^K,!M7L'";<Z!GQ.X<SL;/Y3=5+B]VXG!9133UE3CY
M:B"FF]$C*W'OW5BK:1VG_53K:3PV9Q&X\/BMP[?RF/SF!SV-H<SA,UB*RGR.
M*S&(RE+%78W*8S(4DDU+78_(4<Z2PS1.T<L;AE)!!]^ZIU0ST/\ ]Q'WSV_\
M9R_%?_WX>?\ ?NK?A_U?/JXSY'?(7JSXH](=C?(GNW-9#;O575&!_O+O;-XO
M;^=W57XW#_?4>.-33[?VU093.9(K55T89:>"1E4ER JL1[JH%<#K4*W9_.Z_
MEX9C^=UU#\V*+LKLQOCEM'^7)V+\>L]O:3XX_(2.NH^V\[WC1[^Q&V$VBW6G
M][JJ*MVY3LXKXJ)\='+:.2=&]^Z<TMHX>9_R=;;_ ,6OD_T[\R^BMC_)#H+.
MY;<O4W8JY]]J9O.;4W-LG)UR[9W/F=H9=JC;.\,5A=Q8Y8<[@*F.,STT8FC1
M98]4;H[>ZH13'1@O?NM=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5 W_  HL_P"R
M1_BS_P"--?@I_P"_1E]^ZLOG_J\QU?S[]U7HL_S3_P"R./EG_P"*S][_ /OK
M=U>_=;7XE^WHFW\BK_MS[_+N_P#%8NO_ /W%G]^Z\>K8??NM=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]/>8^0'
M;76'172W9/;7<^_J7JWJ[96ULAD=Y]AUOWG@VCB:@)C?XS_N/I:VN,U-55T?
MB$44CF4K8'W[KW6C-#MO^6-#$D0_X5F?.Q@BZ;MWKO!R?]=IL++*?]BQ/O=>
MG=1^7_&?\W5I?\ESJG^7Y2?.??G;W0'\X7N3^99\AY/BWG.NLEMON/.S;SS.
MU.GH>SM@9Z?,4.Y\IMZDR]+B\+NP4E/%0K6"F5\M(_B+,&776F8E:&E*_+_)
MUM7>_=-]>]^Z]U[W[KW7O?NO=>]^Z]U03_PG(_[(8[C_ /&@/S?_ /?TY7W[
MJS<?]7KU?M[]U7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ,?^%*
MG_;D7YX?^&?U=_[_ ,ZI]^ZLO$_8?\!ZN3ZN_P"99==?^&)M'_WG\?[]UH\3
MT7O^83_V0+\X?_%0/DM_[YC>OOW7E^)?MZ+O_))_[=%_RY__ !4CIK_WDZ'W
M[KQZL8[!_P"/"WO_ .&AN7_W35OOW7AQ'5+O_":C_MR'\$/_  TNUO\ X(#M
MGW[KS<?R'^#JUKNKY2?&?XVR;6B^1'R%Z1Z'?>\F5BV:.X^T]C]9C=4F"6@?
M-KMYMYYS"KF#ADRE,U5]N9/MUJ(S)I#K?W7@"> ZUV/Y$7SC^%O6?5'S<V]V
M-\N/C/L+<'8/\V7YH;KV'@=Y=Y]9;:S6]=K=@;WVM#L3<NU,3F=S4=?N';^\
MYO1BZVDCEIJ]_3 [DV]^ZLRG&#_J)ZV,.^/C3\>?E)M7%[&^2/275O>^S,)N
M"FW9A]J]M;'V[OW 8O<]'09'%TFX*#$[EH,C14N8IL;EZJ!*A$$JPU$B Z78
M'W502.!Z*M+_ "@_Y5T\,=/-_+K^&$L$4;Q0PO\ '+JMHX8Y+F1(4.V;1*Y-
MR%M<^_=6UN<%C3JP' X'";6P6%VQMK$X_ [<VYB<=@<!@\1204&*PN$Q%'#C
M\5B<904R1TU%C\=0T\<,,,:JD<:!5   ]^ZIU0[T/_W$??/;_P 9R_%?_P!^
M'G_?NK?A_P!7SZOW(!!! (/U!%P?]<'W[JO7'QQ_\<T_Y)7_ (I[]U[KD  +
M  #^@%A_MA[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0-_PHL_[)'^
M+/\ XTU^"G_OT9??NK+Y_P"KS'5_/OW5>BS_ #3_ .R./EG_ .*S][_^^MW5
M[]UM?B7[>B;?R*O^W/O\N[_Q6+K_ /\ <6?W[KQZMA]^ZUU[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_4WJNYLATU
MB^L-XUOR$K.M*#IB/%K'V#5=QS[7INL4PE35TU*$WC-O1DVJN*GKIH8[5I\+
M2L@^I'OW6Q6N./6L/\C.G][_  8_F*=^_*3;/\I;&_S%_AY\I.C/CYM;I^A^
M,W6W4FZ<Q\=,OU-0[B_O;MV3JZ?;4\51A>T,QN+^//FZ.+P3 4T1J)&A,,/N
MKU) &JA_U?/HR_\ +:H?D9W;\^MT?*O%_P NC/\ \K;XJ8GXMU/3.YNOM^X/
M8>S>P_D_VQ-V+B-U;%W/F.LMH8?#R;9Q?3&W?XW3TF5JD:HJ/XZ]-%+-$TL=
M'[K3' !:O6Q?[]U3KWOW7NO>_=>ZUM/EC\T^X*'YA?*3N/.=:=J=@?!W^4EE
M>I1VAL7J3N[#=49'-[TW=U-B>[NU>^NP-FULN(ROR"PW1_7>^,(-N;"J,GC,
M#6SP93(RMD<@F+I:;W5P%IQH>K OEU_-7V!\1M_[!V'/\1_Y@/R2C[&ZWPO9
MN!WQ\2?BYF^[=A4^*W!F<OB,9@,OG*+/X6HQ^\95Q/W;8XTS21T=33R,09E7
MW[JH'S _;_FZ)M_PF@ST6Z?Y>?8.YX,=E\/#N/YR?,G/0XG<%"V+SV+BS';-
M;D(\=F\8[R/CLO0I4"*I@+,89E9"3:_OW6VX_P"KUZV$O?NJ]>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U1C_ ,*5/^W(OSP_\,_J[_W_ )U3[]U9
M>)^P_P" ]7)]7?\ ,LNNO_#$VC_[S^/]^ZT>)ZJ&_F2M_. ['?O;X]?$SXR_
M$KL#XU]N=&9OK1.S.T>\-R[$[-HLGV3LO/;5WQ+#MVBQF3Q)7 ?Q4-0&2,)*
M5!<N"RI[K:Z10GC_ *OET$_\JS9W\Y7XS;2^)7Q#^0?QC^(6W_BUTGUG1]7;
ML[>V7WWN7=O;+8O9FR,G2[3R]#M)L'C<%55^8W)24%/61BT<5/--*I!15/NO
M'3Y<?]7RZO=[!_X\+>__ (:&Y?\ W35OOW6AQ'5+O_":C_MR'\$/_#2[6_\
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MZ__1WYLSE\;M_$97/9FLBQ^'PF-KLOE:^?4(*'&XVEEK:ZLFTJS>*FI87=K
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ!^A_^XC[Y[?\
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M]C_'[MO^/SUG:&_L!U]BZR%L]NK$XX4N-R6X89Z@-*',"/H!<*K>ZL-!-/\
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MB!(897CU?0D<GW7CHK_J_P _1BQU'_PI3N+_ "]_E8 ?DCX_=Z$_[ ',"_\
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MJ6IH*?*8C,K/NN+-OD<J<@IIV@IGB72=9'%_=6HE"?\ 5_AZ.;_HC_X4J?\
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MO;:^'WSUEL2;;^QOC[VU_'I:[L_?&&V+C*V-L_NO$X\4N-R&;BFG!E#F%6T
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MLS=%N+:'8^'[KZAWGM_M_85-OW TNT^V]OX/;>'RN_\ 9-/*^/WA@XJ5_P"
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MJ>-I9ZBHGE9(H8(8D+.[$*J@DD >_=5ZJB_E/=J?&7<>R>^NE_B+\>\I\?\
MHGH[M_[OK_[[-93)8_N#;/>6WJ#NC&=W[<Q6XJFKW5M7;'9+[JFR&*H<BXDD
MQ,M+5PQPTU3##'[JS XKT;GY9?)\?%?;O3VY:CK'<_9&-[5^2?0_QVR%1MS-
M;6PT'7S=[]@8KKG#]@;B&XLG1UV4V_A=P9RDCFI,53UV0E:H4B)(EEFC]UH"
MM>B@=<]M_%SXO?/[+?#'X]_'^MQ.X_ECO[N'O[Y*]P;>SE:-GXGY-5?7>W>U
M*G [BQ^X*O(U&3[ W_UG)!G*NGQ#4U'B:*>@FFBU9*/W[K="17H^_P AM_\
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M[UZ\P6-SC/TWV!2;,WML3<+]?Y[==3B\AFJ&*L\&=H<8^)K4DQU=612^ZJI
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J^,?N_=^6_P"YK]^ZL=5!6M.C>>_=5Z][]U[KWOW7NO>_=>Z][]U[K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g790774g75h77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g75h77.jpg
M_]C_X0]Q17AI9@  34T *@    @ #0$   ,    !!14   $!  ,    ! AD
M  $"  ,    $    J@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    L@$;  4    !    N@$H  ,    !  (   $Q  (
M   >    P@$R  (    4    X $[  (    )    ](=I  0    !   !
M 3@ "  (  @ "  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C U.C$P(#$P.C$V.C,T ')R,3<W.#8U       $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   +5H , !     $
M  $N          8! P #     0 &   !&@ %     0   88!&P %     0
M 8X!*  #     0 "   " 0 $     0   98" @ $     0  #=,
M2     $   !(     ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1" !# * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M#K?5+_ES'C4^G9IQV78=9=9^S+I9M^AWG\]JY#ZH_P#+N/\ \79_U*['K?\
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M-:3<Y\4X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <L            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    !XX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M              $N   "U0    8 9P W #4 :  W #<    !
M              $              M4   $N                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   $N     %)G:'1L;VYG   "U0
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !+@    !29VAT;&]N9P   M4    #=7)L5$585     $
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M>P/L>WV5/:WV.68>@9H:Z_UL9U=;WU.+;'NBRO<^VOVT?28VMZ[K*Q+/L^W
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M,B(-;7--K>6OV:_^J_YQ99RLZNO>Z[IU][-:-SF@,:UMCKG;@*O?O%#7[/\
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M[?LL>K_VCG;]"O\ G=_^%_\ 1/I+YG224_52XG ^R^C7/[*C:)^R_:.-UO\
M1X]WJ_N;?TO\ZO"TDE/T+3Z/[2KV?8-WKGZ?J^IR?YKU?9]I_G-W_H'_ -UE
MTJ^54DE/T5]:/2]?#]3[#]"^/MGJ;XVMW?9O0_\ !_\ P-56_9?2,_8_YP3Z
M?VC;$6?0V_\ :O;^[^D];_A?27S^DDI^F>AQ]B='V:/4?_0Y].9U^E^?_P!\
M6BOE5))3_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 4P V     0 X0DE-! 8       < "     $! /_A&]!H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @
M(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O(B!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN
M<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O
M<B\Q+C O(B!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&AO=&]S:&]P+S$N,"\B('AM<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T
M<F%T;W(@,C4N," H5VEN9&]W<RDB('AM<#I-;V1I9GE$871E/2(R,#(T+3 U
M+3$P5#$P.C$V.C,T*S U.C,P(B!X;7 Z0W)E871E1&%T93TB,C R-"TP-2TQ
M,%0Q,#HQ-3HT.2LP-3HS,"(@>&UP.DUE=&%D871A1&%T93TB,C R-"TP-2TQ
M,%0Q,#HQ-CHS-"LP-3HS,"(@<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB
M<F%R>2 Q-2XP,"(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7!-33I);G-T
M86YC94E$/2)X;7 N:6ED.CDT-3,S.3@U.#<P145&,3%!1$9&13A&,4)#,$$R
M0D,S(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C<Q,&-A-F4W+3$S-F4M
M.&4T."UA8F9A+61F9C-B86(P83AE82(@>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/2)X;7 N9&ED.C$V-4)%0C)%.45%-D5%,3%!,D0Y.3(T-C0V1#0Y1D4V
M(B!X;7!-33I296YD:71I;VY#;&%S<STB9&5F875L="(@:6QL=7-T<F%T;W(Z
M0W)E871O<E-U8E1O;VP](D%D;V)E($EL;'5S=')A=&]R(B!P:&]T;W-H;W Z
M0V]L;W)-;V1E/2(T(CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CYG-S5H-S<\+W)D9CIL:3X@/"]R9&8Z06QT
M/B \+V1C.G1I=&QE/B \9&,Z9&5S8W)I<'1I;VX^(#QR9&8Z06QT/B \<F1F
M.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @
M(" @(&1S<# V-V(N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(V
M,34U-S F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(Q+4UA<F-H+3(P
M,C0@,3 Z-3$Z,S(F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C$M36%R
M8V@M,C R-" P,3HR,3HS,B8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R-2XP+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @1FQO=R!#:&%R="8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @06UP;&ET=61E+5)E9W5L87(F
M(WA!.R @(" @(" @("!!;7!L:71U9&4M365D:75M)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C
M>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S<U:#<W+F%I
M)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R-C Y-#@P)B-X03M,;V-A
M;"!4:6UE.B @(" @(" @(" @(" R,BU-87)C:"TR,#(T(# Y.C0X.C,T)B-X
M03M%4U0@5&EM93H@(" @(" @(" @(" @(#(R+4UA<F-H+3(P,C0@,# Z,3@Z
M,S0F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,C4N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03L@(" @(" @(" @06UP;&ET=61E+5)E9W5L87(F(WA!.R @(" @(" @("!!
M;7!L:71U9&4M365D:75M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S
M(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!"
M;&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S<U:#<W+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R-C$T,C8Q)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" R,BU-87)C:"TR,#(T(#$W.C0V.C0T)B-X03M%4U0@5&EM93H@(" @
M(" @(" @(" @(#(R+4UA<F-H+3(P,C0@,#@Z,38Z-#0F(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,C4N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R
M="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E
M+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P
M97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A
M<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @06UP
M;&ET=61E+5)E9W5L87(F(WA!.R @(" @(" @("!!;7!L:71U9&4M365D:75M
M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN
M('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @
M(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @
M(" @(" @9S<U:#<W+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R
M-C$U.# R)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R-2U!<'(M,C R
M-" Q,CHT,#HT-28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R-2U!<'(M
M,C R-" P,SHQ,#HT-28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV
M)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R-2XP+C F(WA!.T=R87!H
M:6,@='EP93H@(" @(" @(" @0F%R($-H87)T)B-X03LF(WA!.RHJ*E1H92!P
M<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N
M=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[
M)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D
M;V-U;65N=#HF(WA!.R @(" @(" @("!!;7!L:71U9&4M4F5G=6QA<B8C>$$[
M(" @(" @(" @($%M<&QI='5D92U-961I=6TF(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.SPO<F1F.FQI/B \+W)D9CI!;'0^(#PO9&,Z9&5S8W)I<'1I;VX^
M(#QD8SIC<F5A=&]R/B \<F1F.E-E<3X@/')D9CIL:3YR<C$W-S@V-3PO<F1F
M.FQI/B \+W)D9CI397$^(#PO9&,Z8W)E871O<CX@/'AM<$U-.DAI<W1O<GD^
M(#QR9&8Z4V5Q/B \<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T
M.FEN<W1A;F-E240](GAM<"YI:60Z,38U0D5",D4Y144V144Q,4$R1#DY,C0V
M-#9$-#E&138B('-T179T.G=H96X](C(P,C0M,#,M,C!4,34Z,3@Z-#0K,#4Z
M,S B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HY-#4S
M,SDX-3@W,$5%1C$Q041&1D4X1C%"0S!!,D)#,R(@<W1%=G0Z=VAE;CTB,C R
M-"TP-2TQ,%0Q,#HQ-CHS-"LP-3HS,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RDB('-T179T.F-H86YG960]
M(B\B+SX@/"]R9&8Z4V5Q/B \+WAM<$U-.DAI<W1O<GD^(#QX;7!-33I$97)I
M=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)U=6ED.F9A86%F,C,Y+34X,60M
M-&(S92TY9F$Q+31D8V(P,38X86-C,2(@<W12968Z9&]C=6UE;G1)1#TB>&UP
M+F1I9#HS96(U93<S8RUA.3(U+3%F-#0M83=F9BUB8S4Q,F8Y.3%B83$B('-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#HQ-C5"14(R13E%139%
M13$Q03)$.3DR-#8T-D0T.49%-B(@<W12968Z<F5N9&ET:6]N0VQA<W,](F1E
M9F%U;'0B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM
M<&UE=&$^(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TB
M=R(_/O_N  Y!9&]B90!D0     +_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,# P,!
M 0$! 0$! 0$! 0(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# __  !0( 2X"U00!$0 "$0$#$0$$$0#_W0 $
M %O_Q &B    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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M\N-LXS?FQ=_U79V>S S.T-L5,>WWPWAFGH/+CXY*?WOW7NB;T[;YH/Y)\_\
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M[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO__3^?\
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M]^]^Z]T:7W[W[KW6N!_PI!_YDQ\1?_%C]P?^^-[-]^]^Z]UI\]\?\R+[J_\
M$4;^_P#>:R/OWOW7NEWMG_CU=H?^&?M/_P!YW&>_>_=>Z#?:VT]K9K<';U;F
M-MX++5O^EG+P?>9+$T%=4F&+;&T_%%YZFGDD\4>HZ5O87X]^]^Z]TC=[;'V7
M%W3\=*6+:6VHZ:L_TZ?=TZ8/&)!5?;[ Q$E/]Q$M,(YO!(2R:@=)-Q[][]U[
MI6=G[#V13=9]A5-/L_:\%13[/S<]//#@<7%-!-%2L\<T,J4JO'+&X!5@001Q
M[][]U[H9(233TI)))HZ0DGDDFFBN2?Z^_>_=>Z!CIO\ XO'R$_\ %B]Z?^\Y
ML_W[W[KW2QSO_,P^KO\ J![1_P#='MSW[W[KW22^1_\ V3YW3_XCS-_[W3^_
M>_=>Z&9/\S2_]05#_P"X<'OWOW7NMS?_ (3\_P#;OF/_ ,6&^0G_ +W]7[][
M]U[J[KW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=5B_/S_LHO^4?_ .-!
MMP?_  "'S2]^]^Z]U9U[][]U[KWOWOW7NJG/A%C^QH/G=_-&Q&[/D+WSVELS
MK/MOI[;?6/779.[,)FMC]<X;M7HKK_OG<%)M/&X[:^&KZ<4&ZM]5>/Q[5-54
MM2X."FI;NT;3/[W[KW5L?OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][
M][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[JJSXV?]O:
M_P":3_XK]_+/_P#<3YD^_>_=>ZM3]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=5+?R,/^W6'Q:_X)W3_ /!#]M^_>_=>ZMI]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>][H/_  CR_P"/R_F#?^&%\>/_ 'KNRO?-
M[^\/_P"29[3_ //5N'_5NVZF#VC_ -SK_P#T\7_5NYZJ?^87_97O5O\ XK+V
M?_[];JKWN]>^8W607577\T?_ +(3[C_\.WXW_P#P4G2WOP^H_P!?W[KQX=6-
MY/\ X^:O_P"UY4_^YS^_E-?SPO\ M[1\[O\ Q.F8_P#=1AO?>3[LG_3@_:[_
M *5:_P#'WZP^YK_Y6#<O],O_ !Q>C4_RY?\ LD78?_A[]_?_  0W:ONJGW.W
M0>Z/#[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO\ _]7Y_P#[]U[K
M;X^<'\Q7K'X#4>'SG;/2GRSW[LRNP&4W)GNQ>A/CUN[MSKSKS&8O(4.-<]E;
MNP3PXG9M575&00TL54X>H0,4!M[][]U[H*.J?YM'6_:';76'4&1^'_\ ,>Z5
MR?;NYI-H;1WI\A_ACV-TQUA_'TP.7W)'CLOOS>$M'AL96U>+P=2U-3NQJ:J5
M/'#&[W4>]^Z]T?+OWL[=O4/6&<WGL'IC?WR"WQ%/B\/M#J;KBHVUC,[NG<>?
MR-/B,3'D-R;SS. VGLS:=#5U:U&8S60JEI\7C8IJCQSNB02>]^Z]U6/4]A?S
M\J&6H[!K/C__ "IXMBTM&^;J.D9/DA\F:;M6FQ\*-53X2H[QJ.D4ZJCST%,-
M#U+;?7&+(I?R^/GW[W[KW5EOQV[;W%W=U/M[L#=_3V_.AMV5\F1QNY.LNPJK
M:^7RN"S>&K)<;7SX3=6R,WN+9N^]DY6:G-5@\]C*MZ3+XN6&I"0M(T$?O?NO
M=:TWR ^>?Q+^8/SQWATG\Z^^\UT7\5?AQ\I*+KKJ_P"&J=4=RY+<?S1^1/56
M8P4M-WM\A=P;:ZWS^)_V6'9O8M4*78FUZ>K3'[HRF*GS69J'I::CH1[W[KW0
M=_S4=X_!3;^Y?F/3?"KO;Y-8S^=)O'O;K#+].],]5[M^36W=V?[,C@(^J^NC
MDMI]2SX["=-;MZPW=U5M6"GW)F<M2YC:U?B*:55JU=$C7WOW7NMLO+4W:%;U
M]10;=S.S-N=G28O!-69/<6V\MN_:%)EE%&^XD_@>(W3LW)UM-+:>.F9<C#XV
M9'8.%*-[W[KW0+?!I:A?A[\;UJY(I:Q>HMG+6S4\3P4TU:N+A%7-3022SRT]
M-+4AFCC:21HT(4NY!8^]^Z]T:OW[W[KW6N!_PI!_YDQ\1?\ Q8_<'_OC>S??
MO?NO=:?/?'_,B^ZO_$4;^_\ >:R/OWOW7NEWMG_CU=H?^&?M/_WG<9[][]U[
MI+[$_P"+OV]_XE[-?^\OM'W[W[KW25WU_P SQ^-?_E>?_?>X?W[W[KW2O[6_
MYE;V/_X96?\ _<)_?O?NO=+F'_@/2?\ 4'1_^XL7OWOW7N@8Z;_XO'R$_P#%
MB]Z?^\YL_P!^]^Z]TL<[_P S#ZN_Z@>T?_='MSW[W[KW22^1_P#V3YW3_P"(
M\S?^]T_OWOW7NAF3_,TO_4%0_P#N'![][]U[K<W_ .$_/_;OF/\ \6&^0G_O
M?U?OWOW7NKNO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U6+\_/\ LHO^
M4?\ ^-!MP?\ P"'S2]^]^Z]U9U[][]U[KWOWOW7NJPOAQ_V7K_-Z_P#$[_%+
M_P" =Z,]^]^Z]U9[[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>ZJL^-G_;VO^:3_
M .*_?RS_ /W$^9/OWOW7NK4_?O?NO=,^X-Q;?VEA,GN7=6=P^V=N82DER&9W
M!N#)T6&PF(H(!JGK<GE<E/34%!20KR\DLB(H^I]^]^Z]U!VCO79V_P#"P[DV
M'NS;.]MNU%15TD&?VCG<7N3"3U6/J)*2OIH<KAJJMH9*BBJXFBF02%HY%*L
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M];JKWN]>^8W607577\T?_LA/N/\ \.WXW_\ P4G2WOP^H_U_?NO'AU8WD_\
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M]%OQMZ,ZZ_O1L^MBR6TMR?W(ZPVOMG^/[6R,$<,&0VYF/X9]Q0SHB)+32(P
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MZEWM!!CL;15,<+23U@EEF#D1J@4L('^RGUW_ #W6-_\ /)7?_57L^_UKI_\
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MZ][][]U[KWOWOW7NO>]T'_A'E_Q^7\P;_P ,+X\?^]=V5[YO?WA__),]I_\
MGJW#_JW;=3![1_[G7_\ IXO^K=SU4_\ ,+_LKWJW_P 5E[/_ /?K=5>]WKWS
M&ZR"ZJZ_FC_]D)]Q_P#AV_&__P""DZ6]^'U'^O[]UX\.K&\G_P ?-7_]KRI_
M]SG]_*:_GA?]O:/G=_XG3,?^ZC#>^\GW9/\ IP?M=_TJU_X^_6'W-?\ RL&Y
M?Z9?^.+T:G^7+_V2+L/_ ,/?O[_X(;M7W53[G;H/=%/FZDZH/\^J@['/6'79
M[$'\L?)[B&_SLG;1WL,^GR&Q?7J9L;K_ (9_'AEDV%.^$%1]QYAB':CU?;DQ
MGWOW7NKD??O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?\ _]?Y_P#[]U[K<X^?
MNROD1V+\-?D-LGXG[FJ]I?(3<?7U;0=;9?&;IAV)G9J_[VAGS&W]K;^J*:K@
MZ^WCNW;,-=B<-N!XRN"RE;3UY*BGU#WOW7NJ$_C!\:X\=\I?C?G_ (*?RXOY
MAO\ +]W/L_MK&9GYB=T_*?NS(3=3]E=#4FW]RTW8'5V<V]FOD[W^?DEO'?.X
MCCCA<G3XJGEQ.02/+_Q."*&6"H][]U[K:L]^]^Z]UI4=1]?;BAH^X8-O=1?\
M)V-M8FE^4ORX5,!_,=R=5O3YOX^KD^1O9E7D7^2>Y\;AZFDJ]W9"JG:JQJZY
MY:?:LV*CDEF=6D;WOW7NMP_K27^$]0[ GKH-C1?PSK?:LM93=/TU1/UK%]GM
MB@>H@ZNHXH35S;&3QE<)$L9D:@$*A;\>_>_=>ZKXZ-_FT],]O_(+KKXV[R^/
MOS,^+&_>\,5O3+_'FM^6?0-5T]MSOV+KS$C<6],;UY4ON3/9BBW)M_;!_B<^
M+W!0X/("A*N(B[I&?>_=>Z2\_P#.H^)T'9TVUVV5\DVZ+INZ%^.E5\Y8^F*Y
M_A/3=W'<Z;#.QY^Y1F?XBE#'V'(NWFW)_!O[H#,L*?\ BM_5[][]U[JW?W[W
M[KW16OA'_P!DC_'C_P 19M;_ -P5]^]^Z]T:7W[W[KW6N!_PI!_YDQ\1?_%C
M]P?^^-[-]^]^Z]UI\]\?\R+[J_\ $4;^_P#>:R/OWOW7NEWMG_CU=H?^&?M/
M_P!YW&>_>_=>Z2^Q/^+OV]_XE[-?^\OM'W[W[KW25WU_S/'XU_\ E>?_ 'WN
M']^]^Z]TK^UO^96]C_\ AE9__P!PG]^]^Z]TN8?^ ])_U!T?_N+%[][]U[H&
M.F_^+Q\A/_%B]Z?^\YL_W[W[KW2QSO\ S,/J[_J![1_]T>W/?O?NO=('Y09?
M&8?X\]N292LCHDR6T*S!X_7'4S/6YG*21)CL9314L%1-)5UK1,(QIT^DW(]^
M]^Z]T,^&RV,S^$PF=PE=!E,-F,-C,ABLG2^44V0H9Z.'PU4 GCAF$4FDVUHK
M<<@>_>_=>ZW1_P#A/S_V[YC_ /%AOD)_[W]7[][]U[J[KW[W[KW7O?O?NO=>
M]^]^Z]U[V?SXQ_\ ,N*[_P .JN_]UV-]SK[;_P#*O3_\]3?\<3KI3]T?_IUF
MX_\ 2YF_ZLP=%)Z7_P"RG?F?_P!K[HC_ -\]C/9AO8^ZR>Z+W\_/^RB_Y1__
M (T&W!_\ A\TO?)" P)^G/\ O1][''JR$!@3PZ/%WU404?1G=%752K#34O4_
M8M143-<K%!!L_,2S2L%!8K'&I)L">/=;M7T=VO+5U4J;+R+))43NC"HQMBKR
MLRD7K0;$'WCQ+R7S0TLC#9Y*%B>*>O\ INN5-[]WKWGFO+N6/D*Z,;2N0=<&
M06)!_M>BF] ?+';E/T-TC!'TM\J*N.+J'K1$J:;XX=ERT\Z+LO"!989$Q+(\
M<@Y!!((^A/N/_H*[:_YXK(_^=&-_^KO;?]2>:?\ HSR?M3_H+I-_P.OO5_TP
M-U_O<'_6WHG_ ,2_DKA,7\V_YK6:?J+Y*5<>X>\OC!-#08_H+L&MRF.6@^%_
M2^->/-8^GQCU.(J)WHS-%'.J-+2RPS+=) 0Q;BZOW[M/&G,;BVW68O&BHAI3
M5SS43H*B<.88M,%3+)=Q&UN+<>T>X<M;YM=L;N_VYXK?4%U$J14\!@DYIT'>
M:/:'W(Y+VH[YS1RI/9[4)5C\1VB(UO72M$D9JG2?*F.K,=I_*G8VZ=^;4ZYJ
M]D]W;&W#OG^.Q[3E[(Z9WYLG!YJMVYAJG<65Q=-G\SB8L5'DXL'0U%4D,LL;
M314\FC45(]H+V1=1OT9GW[W[KW7O?O?NO=>]^]^Z]U2O\_.F.J=Y?S//Y+N]
MMT[#P&;W=3=T_)6A@W#6P3G(K0]>?%'MWM?9-%*T51%!5TNV.RL-29RB29)!
M39*F2:/2P-_>_=>ZNH]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U59\;/^WM?\TG_ ,5^_EG_ /N)\R??O?NO=6I^_>_=>Z0?:?\
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MWOWOW7NO>]T'_A'E_P ?E_,&_P##"^/'_O7=E>^;W]X?_P DSVG_ .>K</\
MJW;=3![1_P"YU_\ Z>+_ *MW/53_ ,PO^RO>K?\ Q67L_P#]^MU5[W>O?,;K
M(+JK[^:'%++\$^Y1%')(5W9\;F81HSE5/RFZ40%@H-@78 ?XD#WX?4?Z_OW7
MCPZL8RJLFZ,BCJ59<]5*RL"K*RU[AE8&Q#*18C\>_E-?SPO^WM'SN_\ $Z9C
M_P!U&&]]Y/NR?].#]KO^E6O_ !]^L/N:_P#E8-R_TR_\<7HU'\N7_LD78?\
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M=>Z)C_*5_P"W7W\OG_Q3OX]?^^PVW[][]U[JPKW[W[KW50'\T?JGJOL?N?\
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M7WOW7NC^_)O_ +)M^0G_ (@_MC_W@L_[][]U[K'\7O\ LF?X[_\ B"^I/_>
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ME^?GI_*).;H/C0NYU[M^6_\ =%<9E^U&P\E4?A#W*,F,^]3A%JH:1,1]P8S
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M_P#"/+_C\OY@W_AA?'C_ -Z[LKWS>_O#_P#DF>T__/5N'_5NVZF#VC_W.O\
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MMI?^Z#'^_>_=>Z7/OWOW7NO>_>_=>Z][][]U[KWO?>Z@_P"9/=._^(BZP_\
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MZE_^SCW-7_!U_=>_\*.W_9!N/_;)T!O]8'W6_P"F9'_91;?];NA#'RLJB?\
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M'TL&5RM)B_B?ML8JDRN2BA6KKJ;'FID^WCF=TB+MH N??O?NO= 7\[,1\O\
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MK3'C,E1D8ZUY/^%"&U<COG8?PFV;B,AMK%93<GR>W#C:')[SW)C-F[2H9_\
M0'VM5F?<.[,U)#B-OX_Q4K+]Q4,L?E9$_4ZCW+S7569P6*K<O4[DZZK(*&-)
M9*7$=A;4R^3F#RQPA:/&T&3FK*N0-("5C1B%!8\ ^WK_ ).O]NLY[V7=-K>.
M,5*QWMO)(:D#M1)"S'-: '%3P'2S??:+?-@VB^WFYYFY:GM[=0S);[QM]Q.P
M+!:1P13M)(:L"0BDA06. 3UJT?*[XI]B]?\ Q@^0>\LWO_XRY;%X'I_?=768
MW8WR8ZMWQNVLB?!5=,(\'M/ Y2HR^;JE><,T4",RQAG/"GW+QW3V=R5%05T6
MZ>L:>/(TM-5Q0U_9>SJ&L@2JC25(JVDJ<M'/15,8>TD<BJ\; A@"/;UMR1N%
MU!;7";OM*K*BL ]];(P# $!U:0%6%>Y6 (.#TKVWV5Y@W2QVZ_AYLY5CBN8D
MD59=[VV*1!( P66-[A7B=:T=' 9#4, 1T*/77PZ[/W+UUUMG\?V1\3Z&BS_7
MFP\O1TFXOE;U%M[-T=-DMJ8>J@I\Y@\CETR&$RD$<H6HI9U$U/(&1QJ4^V?
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M48H]/DE%/2U,LOC34+M:PN+^^6'ZFS6:Q=!EJ?<O6])#D(!414V5[%VEB\E
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M!=V*&"30WBW,<08CSC+&DB?TUP>K$/<+ ]BX&OVED-Q0X??\5!M[P0UU'6[
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MG=ZI!16%K:RO-X2TK)+IT1BA8T/7MYY/W;E^Q.X7VX[3-;^(J:;6_@NI:L:
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MD_X^W/[B?_CO-_U,?_BOMCP(?]\K^P=:\*+_ 'TO[!T&\L47_#IV.?Q1Z_\
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MK 5\KZBUQ8D/_0.'_)O_ .\7-V?^E$][?_9O[E#_ (,C[Q7_ $W$'_9!8_\
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MH/\ F3W3O_B(NL/_ 'A<![^=#G7_ )7?G?\ Z75__P!I<W74SE__ )5_E_\
MYX+;_JRG14_@Y_V21T+_ .&#C_\ W)J_8A>PUT;=%8^-G_;VO^:3_P"*_?RS
M_P#W$^9/OWOW7NA[^9G_ !=OAK_XNQU1_P"\7VC[][]U[HS_ &@CR]:=B1QJ
MSR2;%W:B(HNSN^ R"JJ@<EF8V'OWOW7NB8_RF8Y(OY8'\OA9$9&/PX^.T@#
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M_P#BZ_QI_P#>PF]^]^Z]T=?W[W[KW57'\DS_ +=,_ '_ ,5LV%_[B2^]3O\
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MT&_OWOW7NIN-_P"+C0?]1M+_ -;X_;=B_P#@/-_U'Y/_ -V%3[>G^,?Z5?\
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MNO=<6944N[*J*"69B%55 N2Q)  'OWOW7NM.3<O\N+<E1O[N6N[U_D)[F_F
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M?^'57?\ NNQON=?;?_E7I_\ GJ;_ (XG72G[H_\ TZS<?^ES-_U9@Z*3TO\
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M?O?NO=>]^]^Z]U[W[W[KW7O=@W\J7_MXQ\0O_$QX/_W&K_>-?WP__$8?>O\
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M>_=>Z][][]U[H/=B?\7?M[_Q+V:_]Y?:/OWOW7NA"]^]^Z]T@NUO^96]C_\
MAE9__P!PG]^]^Z]TN8?^ ])_U!T?_N+%[][]U[K)[][]U[I"YW_F8?5W_4#V
MC_[H]N>_>_=>Z77OWOW7NO>_>_=>ZW-O^$_/_;OF/_Q8;Y"?^]_5^_>_=>ZN
MZ]^]^Z]U[W[W[KW7O?O?NO=>]G\^,?\ S+BN_P##JKO_ '78WW.OMO\ \J]/
M_P ]3?\ '$ZZ4_='_P"G6;C_ -+F;_JS!T4GI?\ [*=^9_\ VONB/_?/8SV8
M;V/NLGNC;>_>_=>Z _Y-_P#9-OR$_P#$']L?^\%G_?O?NO=8_B]_V3/\=_\
MQ!?4G_O ;?\ ?O?NO=#I[X-^N+_@S_\ 6MO=6^).FW^.'[3_ ,=/1)?D'_V5
ME\ /_#\^0?\ \#IO;WS]VZ<Z.U[][]U[KWO&GUE_Y:?]$)[T.+?;_D'34?Q3
M?Z;_ "#HIOQZ_P"9R?-C_P 6 V?_ / T]$^\GO?3O1LO>&J_X!9#_M6Y+_W!
MJ/=)/[&?_FF__'3TQ=_[@;G_ ,\D_P#U9?H"_E#_ -DS_(C_ ,07VW_[P&X/
M=0?O$_KA_P!+OK#_ )EKUY_X8VTO_=!C_?O?NO=+GW[W[KW7O?O?NO=>]^]^
MZ]U[WOO=0?\ ,GNG?_$1=8?^\+@/?SH<Z_\ *[\[_P#2ZO\ _M+FZZF<O_\
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M;N]D0]RGT0='C]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?__1^?\
M^_=>ZW^/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW6I7\U>AO
M]E!^0?\ ,1_F6?*W^6!\6?F%\>9>]^A.T).VM^[RV'G?D#L_HS;/2_2'3$U=
MT=U_NCK+=%+#F>N]^X6NS63Q^4W%MQ<M#;[,^1$E/O?NO=;2VX.S=H;9V%'V
M7DZG,S[1FQV)RT-7M_:FZ]WY6>@S8I3C9Z7;.T<+G=S5GF6LC9A#1R&)"6<*
MJL1[W[KW0)?!J>.J^'WQOJX?)X:SJ/9U9!Y8I:>;P5>+BJ(#-33I'44TQBD&
MN*15DC:ZNH8$#WOW7NC5^_>_=>ZUP/\ A2#_ ,R8^(O_ (L?N#_WQO9OOWOW
M7NM4[W[W[KW7O?O?NO=![L3_ (N_;W_B7LU_[R^T??O?NO="%[][]U[I!=K?
M\RM['_\ #*S_ /[A/[][]U[I<P_\!Z3_ *@Z/_W%B]^]^Z]UD]^]^Z]TA<[_
M ,S#ZN_Z@>T?_='MSW[W[KW2Z]^]^Z]U[W[W[KW6YM_PGY_[=\Q_^+#?(3_W
MOZOW[W[KW5W7OWOW7NO>_>_=>Z][][]U[KWL_GQC_P"9<5W_ (=5=_[KL;[G
M7VW_ .5>G_YZF_XXG72G[H__ $ZS<?\ I<S?]68.BD]+_P#93OS/_P"U]T1_
M[Y[&>S#>Q]UD]T;;W[W[KW0'_)O_ +)M^0G_ (@_MC_W@L_[][]U[K'\7O\
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MW1*/FU_Q:_C#_P"+K_&G_P![";W[W[KW1U_?O?NO=>]ZG?\ PHB_YG[\=_\
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M?^X-1[I)_8S_ /--_P#CIZ8N_P#<#<_^>2?_ *LOT!?RA_[)G^1'_B"^V_\
MW@-P>Z@_>)_7#_I=]8?\RUZ\_P##&VE_[H,?[][]U[I<^_>_=>Z][][]U[KW
MOWOW7NO>]][J#_F3W3O_ (B+K#_WA<![^=#G7_E=^=_^EU?_ /:7-UU,Y?\
M^5?Y?_YX+;_JRG14_@Y_V21T+_X8./\ _<FK]B%[#71MT:SW[W[KW1)_F9_Q
M=OAK_P"+L=4?^\7VC[][]U[H['OWOW7NO>XT?_ NN_X+0?\ 6B7VZW]C;_[?
M_".J#XY?]K_@Z)WT]_V6!\S/^U'\9/\ WCM\^Y/MKJ_1Q/?O?NO=('M;_F5W
M9/\ X8.\?_>=R/OWOW7N@V^(G_9)_P 8/_%>.E?_ 'VVVO?O?NO=&']UJ_S=
MO^R$-^_^)%ZI_P#=QDO>5'W+/_$A^7/^E7N'_5I.H;]_O^G7[I_SV6O_ !]N
MBP]\_P#,TOB'_P")VW#_ .^"[E]ZA/OM9U@#T9[W[W[KW7O?O?NO=>]^]^Z]
MU[W8-_*E_P"WC'Q"_P#$QX/_ -QJ_P!XU_?#_P#$8?>O_I1R_P#'DZD[V8_Z
M>GR/_P ]R?X&Z+#\M/\ F6VT?_%@/C3_ ._YZ^][ZGOYUNNE/1GO?O?NO=>]
MQ1_Q<7_[5L?_ +FS>WO^(H_YJG_CHZ;_ -&_VG^4]$\V_P#]E^=K_P#BH707
M_OY/DA[E>V>G.CA^^:?K7_@R_P"]CWIOA/V=;'$=>]P,;_Q;Z/\ Y9-_UNE]
MJ+K_ ')G^W_(.FX_[-/L_P O1/\ X"_]D?\ 1O\ X;.0_P#>FSON9[8ZOT<#
MW[W[KW1*/FU_Q:_C#_XNO\:?_>PF]^]^Z]T=?W[W[KW7O>IW_P *(O\ F?OQ
MW_\ $&Y#_P!^+NCWV/\ [LO_ *=Q[F_^+ G_ &A6_6%/WI?^5FY6_P"E<?\
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M_?Z5^HO^?Q]-_P#HVNNO_LF]^_J=SK_TP^^?]RZ]_P"M'7OW[L'_ $T.W?\
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M:>*:>6221P J(SL38 FP]^_TK]1?\_CZ;_\ 1M==?_9-[]_4[G7_ *8??/\
MN77O_6CKW[]V#_IH=N_[*K?_ *V=!_\ &#^91\"MM?&GX[[=SWROZ9Q&<P'1
MG4F%S.*R.Z8J+(8S*XO8.WZ'(X^NHZJ*&II*RBK('CEBD19(W4JP!!'OW^E?
MJ+_G\?3?_HVNNO\ [)O?OZG<Z_\ 3#[Y_P!RZ]_ZT=>_?NP?]-#MW_95;_\
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M^RSW[^HO/W_A/>8?^Y7?_P#;/U[]_<O?]-'MO_97;_\ 6WKW_#H7\O3_ +S
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MZ4)T[_\ 9K[:_J+SS_TQ&\_]D-U_UJZ]_6K8/^C@/]XD_P"@>C%_[/%\,?\
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MGP+Z[^0V.D[L[FW_ -4[>P/6>'['R_0V!ZOV;1[/ZS[(=JK#4VVL<M%)5F.
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M_E%;KP?QW^678.POC%G?EED^Y^R^K_C+V_V+UKM.F^2'Q['5?68;?&U=L9'
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M^S?*B'K>'H?O#X<_S*Q\)-B;.DV-TOB^O,-FOE!UE)O';>?WOOC9VX*0U?\
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MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW6OS\*/Y_\
MU!\MOAQ\]?EGN'IK,=,S? JAW+N+>O6.2W_C]UY/>&SXMBY;>/7.=Q.X(=K;
M?I\;-V=D-OY#$44#4M2D=73:A+*KZ5][]U[H/L-_PH*R.>_E>T/\Q3&_"K<,
MFZLE\M*+XC4/QOJ.[\)09.;>F0W)3[5I,C-V37=>P8VA1\U5+3O!-BE$4ER\
MPC!?W[W[KW1@^C?YLOR&[ [G^0_PW[E_EX[G^/OSTZI^+&6^6_470-5\B>N^
MT]A?(3KJAS;;0Q]#@N]=E[=@P6SLYF=]S4V(1*W&3QPRR2R2,%IY%/O?NO=8
M?C=_.RVI\M:3^7AA^C>@-S9WM+YK9#NBJ[9ZWRN\Z7&5OPZV/\:\Q!M?O/=O
M:M9_=B6LKGQF\J^BQ6W:2>BPQW#45\.F2FD(A;WOW7NDANS^;S\L_CU\E?CI
ML'YL?RW:WXX_&_Y:?(VD^+/2W=.(^3O7?<.]Z/LW<N7J,1UI6=B=6[0V]!'M
M_;W88I_NP8,K4RXFCU-/Y)4,)][]U[HTWQ?_ )GU+\E/GE\O/A!5_&SM?I"L
M^)>SMM;MR&_.X,CMS$5G85!N3<%?AJ#.[?V5A9\V,9L7-T%",IA\I4Y4U-?C
MIXWGHJ*0F(>]^Z]U7M6_\*"]Y4VR*GYL0?!3<U7_ "CZ+O(]'5'S;3NO:HW[
M/0IV4.I7[_Q_QS7;;YRKZ3&_R,:ELL,S(S"7[=7#4P][]U[H?/D?_-\[WP'R
M$^5?2WPF^"=9\O<!\ ]G[0WE\QNP<OWWM7I.GP,V\=I5G8=#L+I? 97:V[<A
MVIO*'86,JZV4ZJ&!*RD>B :22G>;WOW7NK6?B9\FNMOF7\;.F?E)U#)E&ZZ[
MNV-BM\;;I\Y304>=Q4=>)(,CM_/4M)55U'!G=MYBEJ,?6K!// *JF?QRR)I=
MO>_=>Z,/[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z /Y5=Z0
M?&#XR?(/Y(U6V:C>E-T)TOV7W#4;0I,I!@ZK=$/7&S\ONV7;]/F:FDKZ?%3Y
M=,28%J'@F2%I-91@+'WOW7NJ<,;_ #^NM,G_ "B*O^:-%T/G%W12=H_Z"#\5
MCV)CCNB7NZ3MFEZYI=A1=@':B41GGV_6Q;E,IQ =,>6C\1D74?>_=>ZR]@?S
MN>QJ?H#^5WV?T/\ !K(]Y=L?S1*3<[=;])5'R)VGUA%LG);7VMC]VU5!E>RM
MS;"K<%E8IL34SR">2DQR*M*007=$]^]^Z]USP?\ .U[0S'QG^?O8-3_+^WY@
M_EE_+/S^SU^4GPZJ^Z]GYBHI=@[IQ]1NB??_ %WW9MC:V:VQO2AQ'7N'RV=:
MF3%Q2STN+=(B[3T[2>]^Z]T9'K3^:UB/DEW'B>M_B'T=G?D'M=/@7M;YP[RW
M_0;YP&TZ?:M;W!B<MD?CG\<*G'9.@JZ&F[D[=&#JY98\AD,=382CII)9C*4D
M2/WOW7N@4Z._FU_)FF^9O7/PM^>/\O?*?$_L+Y#]0=D]Q_'"3KWY!;'^2YW9
M#U3@LANC>76N[8]J8+;%)@-]X[ 8J=HY8)ZB@JJPQ01MIE6<>]^Z]T*'P[_G
M$]=_)CI?Y\]^]H=(]D?%#8G\O_LOL;8G:>&[:R&%RG8\%!U;L:GWONZOW#M/
M:XK,?MO=&/C>6C.%I,EF2]5&$BJI6D"CWOW7NB^]&_SK>ZL_O_X;93Y4_ 3/
M?%KXL_S&-UX38WP[[TJ.]]G=E;EJ]W[YPLVX.G-O]W=7X3;F+K.NZ[O'""&H
MPGVM?D_M)*F."J'$\T'O?NO=(?L#^?;V7@\;W]\G>N/@3N3LW^6?\5.^LI\?
M^[_E/2=Y;.PG;$V6VIN?"[-W_P!B=8?'&LP$V1WCU[L_<6X:-$DFS=#4Y&EF
M-1II5@JUI_>_=>ZV+=M[APN[MO8'=FV\C!E]N[GPN+W#@<M2ZC2Y/"YJA@R6
M+R-,75',%;0U,<B7 .EA<#W[W[KW3U[][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][__3^?\ ^_=>ZW^/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW6OE
M_/B^-,_RSS?\MGHVNVONO/;&['^5G9'7?8V9VWMS/YVDV1M?LSXJ]V]>INW<
M-3@Z::/!8W%9O<E)(E75R0TR3JFIK CW[W[KW6L#L?I/Y;=W[3^ /RD[:Z,[
MUQ'8W5?\Q;^3G_+\&UMT=5[T7=6&Z:^$W5NZMS]P]L9-*K#2Y2FV%N+M_>U-
M)-FW(QU154,I>42*ZCWOW7NC8_._K_J=?YH7\[Z3Y*;._F=TV,[FZN^,6U_C
MI2?"/:GR/IMB]YY_'?%N?$[JV[V/+UCB!L#L>CQ>YLGB*2A@W#-48F%ILA!(
M.:A/?O?NO='5WMU)\LOGK\%?Y6/\GWY#=-9+H[M'MSKNG[Z^:78FR.G*#;.V
M/BIT+\?,CN-^A\/@(*;"4.P]@=Z=O;GQVV,=48G$3PU^$BAR]-44-)2UBE/>
M_=>Z:MI_S&_FA\:OY.G3OQ^QW0._NAOF+TW\B<)_+/[2[)P/QH[([*V/T+U_
MU]19*DK_ )I;(ZNV7M')5/<.W_\ 1E@(CBUH(#C<MNMIY@)*58J>J][]U[IY
MRV9^%?4_\B+^8-U3\5MI?-+>F]^W]K=G;"[ [$[M^+GR/'R%^47RX[ZZZSLL
M&_=TTN;V ,[E*;<=3B_%49)(H\'@XQ''43+/,9*KWOW7ND%N9-T9/X!_\)[/
MF=LKJKO7>6T/Y7?8W2^S_F!UU0])]EX;N'8>$HNE]F];=L;WQ/6F?VYC-X[U
MVUU9N+"+]S-AZ2MAR%)4?<0.U/%420^]^Z]T-/5?0W6/\Y/Y]_S*?E1N?8O;
MN)_EU=G_ ,OSKWX,;4['WCL3=_3&<[ASB;VP/=FZ>S>K=O\ 8&VL=NUX.H<[
MM>F2ER>0Q*P'(K$BPU,:RQK[W[KW3'\!OBIWY\M_Y@GQI[IW?W1\H^Z/@U_*
MCVWV)L_X\]R?*7J+9O16X_D-W-O?;%+L&&#K+K_"]?[%WGG^I^KMC4-#)5[X
MW&'R&XLY2110K)&*N1/>_=>ZV\??O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=:2G\T'J3NG9O\SCY??/[K7JGMW>&=^$78W\H;OS9F
M,V9U[N_.S=L[,D;M?IKY!;)V-)C<9)#NFHI]H]A4$V7AH&FDI8*4O4-'#%-;
MWOW7NL?\HCXC]J_'+YK;N3>77W:B9W?/\AG$;[[2WGN38>ZZ.@R/R5[_ .\&
M^0':NQ9=PU.+&-K]\83/]BRTDF.$S5ZBB=!$%A8)[W[KW59WP?Z_WC@.B_Y4
M&V/C+TM_,4W]_,<Z>^4&W<[O/JKY&=8]XYWX&=-=>U^\NS5WWN^EV_W3@%Z6
MZJGI]E9^AK*;<&VQ29G&Y2>>JIZB*L(8^]^Z]U:S_,GZX^2ORW^4_>G\UKHK
MH[<N7HOY+O9G2'77QLZPW%U=7TF8^;#]8]A3]B_,[+''Y_:\&\LSLWKU\Y0P
M[%K\7]Y0U53BLAD<2YK9%]^]^Z]T*G\SWYO8GYB]O]7?%3M>G^:_0_\ +4W?
M\<^J?D5W56=+?$_O_=O=GRZS'9TU!N'"?%*MS>R-CYINDMB;0VPZ5.^6ED3+
M5E:L^%$<14SCWOW7NO?S3N].A-O[^_D'GI7J'OS =+?';NCIKY0UFT]F_$SY
M!UU+TY\4Z7;E=LO:?\7PF ZYR<V"S^#_ +JO2R;6M)N.D@C26:C6.6!YO>_=
M>Z&/=7=^W?Y8G\Y#YM?+_P"1VRN[ZGXT_P PKXU?%_+=']I]7](=G=J8X]G]
M([9BV%DNB]SX?8FVLWG-K]D;HIYHLCBDRM/14<E/*(Y*B-UD">]^Z]T4/X^_
MR]#T_P#RKOCK\R_E#OCY+?"WY;])_)OY-?,3H2NZ2ZC3N7O/K$_+3+QX=^BZ
MWX_Y39F\<9NFM[2V7MS%25V'R%%31XNIGT9&>DIX\A%[][]U[JV?^2+\0OD/
MUJ_R^^=OS BWKB/DC_,*[)V/N^JV3V8VV#V=U_T=T]M>NV;T;@NT:?9>'P&T
M\-V76[=RL]3E,5CJ.GI\1 U)1M'%4PU$,?O?NO=7R^_>_=>Z][][]U[KWOWO
MW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z^;/\7?A]\FAL[X?]!_Z .W\5U-
M_-LVEU/T_P#)R67KK>N!EZWH/A'_ #0>Q-Y[XSO9BY7'4TVU$W=\68Z5:!<E
M'2)D8\A)#$K02$CWOW7NC&;IZB[1KO\ A/WO+;^=Z8^0.(R5;_.ES/8N7V?L
MWJ_LG&]KXWK.H[L.XLAN_:>V\9@(]V4,-%MUGFH<A30".*H1!&XD4#W[W[KW
M1YO@!V33]!?/[Y??*/XY=1_/7L'^7_B/@A2;C[\[J^:_5_;V[/DOO?Y)]=[L
MRM?LSJ[X_;S[CPW^GS>^+SFTLC!3G;FJ?$IE?-4R+!:A>3WOW7NF#^79UA\I
MO@!\_P#X^?-/Y ='Y:3 _P \':G8F0^2F*V+U/F,DWP@^0N^>V,OW#TKLW*3
M8C;LFXMA;&W7LW>6'PVY8\FL(DW135F0RLX_A:-[][]U[I6?%_Y6]9_.?^8A
MUO\ )OY_;/\ F/1=B;#[]RW6O\O;X:K\.ODCC^AOB]#F=U0[&VEW[W=O]]@)
MLW=?=N^J=X,K49BMJ_X'LRE*RZHWIH3C?>_=>Z&CXQ=P;,W[_P *!_YE@CV[
MWGA=I_)CX_=7_'#JWL'-_'#O/";$SO8W1NS\UC>UZ(;RSNPL;MC&8W ?W=JV
MH<E7U5+BLVR(M!4U!FIQ-[W[KW55]-)VQ@?Y(N9_X3NP?'_O2K_F65?<E?TW
M1;-EZ7[(?J&MZ]K_ )AQ]X?[,A!W@=NMUA2])C8C,PRQR1FBG'E-,( 9A[W[
MKW5EO\QCXO=@?%_NC?!_E\=P_+RN^;W\Q/IKK+IWL?X[]4]7;.W#T-V-D>KN
MN)NFMN_([N/N_?\ USG=O_&+;^R=L+/5Y2>@RT&7W!/"T<$<:U%;6P>]^Z]U
ML#_R\/B-C_@=\)/C9\1L?G(MSR=(=9XK;.=W+302TM%N/>5=4UFX]^9_'4D]
MZBBQ69WKFZ^II()"TL--*B.S,I8^]^Z]T<WW[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]T0/\ FLX3/;E_EB_S#-N[5P^7W#N;._"KY-X?;V!V
M_CJS,9W,YK(]-[PI,7B\/BL=!4U^2R=?6S)%!!#&\LLC!54D@>_>_=>ZTJMM
M?&CY)))G/B4OQV[2I?CQ2]5_\/9TU3)U=O X63MN?^4M#U_3]54U-6X>6LJ.
MQZ?Y;9Y(VVXP?*,V/,K0?<@*OO?NO=#_ -U]9Y+ ?!;_ (3(R=S[%^9&TMB=
M0XGM"H[WRGQEV9W=B?D%U)2/U7A<7C*FEJNKL(>Q=BY6JW')!!>-:>JGI#.(
M]2"0CWOW7NC*?![O3O?X;_'[^;YVAT/\5?DMO_XW[Z[2V+C_ .7'C?D?TKO;
M(_+#Y-?([MO:]=L_>]9VQ-N7$P=I=E=083>YHZ\YG=Q5Z7;L$](M6U0)J>'W
MOW7NEI_+(Z\[?_D)=G?+_P"('8W4&^^^^O=\_$3$?/KJ+M[JWK'+Y&7L'O7I
M_I!,3\@?BN=V[=VW6T-)D\QN?8]94=>8.I,:8_&,JJLE7EXXY/>_=>Z6_P#*
M:[XZ=[F^4W^SE_,EOE?V-_,H[8ZFW?!20;D^''R4Z]^,_P )NF\+MW)]AY_X
MX=)5NXM@1;;BRN'QV)J*3)[BFJ:G(;JR[O3T4LTM?,^3][]U[HM_PNVWD_FC
MT!_PH\^,'6VTNWMK]F_-CO'Y8?(;XV)VST5V[U'MOL#KC>N*PV)Z\R2[J['V
M;MO;^&K]S;LGIJ*3&UE1!EJ."9JIJ4PQ2M'[W[KW3C+VKGOYC>Q/Y%GP%Z:Z
M<^0NS>^_@G\D?A]W5\X5[.Z&[)Z^V_\ &7'?##K2;;6[L?G-_P"]-NX?:N5S
M6^,[(\>VHL955IR-X1.()'$?OWOW7NI7SD^ _8V6[;[_ /Y6G\NCNKY7G8GS
MN[MF[X^6/7.7Z@V9'\./B!MCL/<.W-V]U[Y/R%W%U_0[NSN:WK2X^GAV[UEM
MO,O&TE2\M5/3F&*.K][]U[K<9Z^V1@>L]A;(ZWVM#+3[8Z^VAMK9&W()Y/-/
M!@=J8:BP.(AFF"IY98\?01JS6&HB]A[][]U[I7^_>_=>Z][][]U[KWOWOW7N
MO>_>_=>Z][][]U[KWOWOW7NO>__4^?\ ^_=>ZW^/?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[_??\4]^]^Z]U[W[W[KW77Y_/_$?\4O[][]U[KOW[W[K
MW7O?O?NO=>]^]^Z]U[\_X\?\3;W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]UX_0W^GY]^]^Z]U[W[W[KW7O?O?
MNO=>_/\ CQ_Q-O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW71_WW]?]A_L/?O?N
MO==^_>_=>Z][][]U[KWOWOW7NNA]/S_L?K_O//OWOW7NN_?O?NO=>]^]^Z]U
M[_C7OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>
.._=>Z][][]U[KWO\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g790774g75q33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g75q33.jpg
M_]C_X0Y517AI9@  34T *@    @ # $   ,    !*:X   $!  ,    !$;\
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HQ-SHR-      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   (ZH , !     $   #_          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
M 7X" @ $     0  #,\         2     $   !(     ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1" !( * # 2(  A$! Q$!_]T !  *
M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M       !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H # ,!  (1 Q$ /P#U58N3TWJ%)R\UO4KF2RU[*V"0TSZE>QN4
M[+H]K*]K_P!7^G_,_9ZG^@KO[2/[6_9OHF?3]7U)'T3INV_N;F^G]+U?4_P/
MH_ID+JG4^GUXV9CV9%==E5+S8'N#0V6MV[WOAC=WKT_YZ2FYB6.MQ:;'ZO?6
MUSCYD E2H<Y]+'.^D1)_U"A@@C"QP="*F:?V0I8O]'K^'E_WWVI*2H=;G.?:
M#PUP#?AM8[_OR(LW"OK9F]1#[C9%[0*Y<[9---FW;[MF[U-R2"0-W20RYWKM
M9^:6N)^(+/\ R2B<JH=K/E6\_P#?%1?F_P"6Z:Q98*W8UKC1Z+M2U]+?4]3T
M?4_PGT/425Q#N'420ADT\DEO]9KF_P#5M:AW]1P<?T_6N8WUK&TUZS-C_H5Z
M?O0DKB'<-E)!^U8_YK]Y\& O/_@>Y4NL]69A=,R<ACS5:RMQJ+V'Z?T:_P!%
M8:76;K"U)5CNZ:2!@WC(PL>\/]06UL?ZFW9NW-#M_IGZ&[]Q'22I))))2DDD
MDE*22224_P#_T.Y>W=]<:^/T>#N_.GW6/9I^D]+;[?\ 1?\ ;GJ?H+N?A8C:
M,O+%+/M#J;9LCW>YC6/_ ,YE%+/^M5K/LR-GUKKH92RW>W<Y[?I5_HWS8]KL
MCZ7Z.JKUVX7\U?Z/VC?7Z=A>H=2Z@1FXS>GO=4RJW;=NVAT-;JUUS*ZF_3=_
MA/ZGJ,24Z>!_0<?_ (IG_4A2QOZ/7\/+_OOM4<'^A8\&?T3-?[(4L7^CU_#R
M_P"^^U)25<[TKH=U75.LY#KBUN7D-=#7V$R&[]Q;N8QGZ"ZBGV_Z!=$L;IF3
MD?M'JH.'8&B]NUX-</'IM;O&YU?[G^OZ1+BK3OX6NCCE(2(KT"SKP[GA;9Z5
M6[Z5UQ_M#_OS2LB[ZO=+/UHQLEU]GVD8=K!3ZD'8'MUV[MVQSKG_ )GTZEN_
M:XG=3:V/Y.[_ ,]EZIV=7H'6*L(5VFQV.^T'TG<;FMV[G,_D_O)<8';739,<
M4Y742:!E_@QW2_L?& AK[!_:G_JVN69UWZJU=0;@ACWSC95>1N :2"R=MLM=
MC_S7_7?^)6UZ^2[Z&.1YVO:T?^!>N[_HJIU&CK-_V;[-<S'#,ACKQ6-SC2)]
M5OJ6PW_P%+C(UJ_HJ./B(!E& /4R_P"]XE9&%T^O]&\Y%UED$4-ON),'M5ZS
M:ZV?R_T=/[ZI]2Z'19T7.JO-E%%E%DTT6/D>TG<ZUQ=ZMG\G9Z/[]=ZVJ<>J
M@$5M@N,O<22YQ\7O=[WJ;V,L866-#V.$.:X2"/,%+4[GZ*X@/E_QC\W^#^ZA
MZ?C58F!C8M)<:J*:ZJS9J_:QK6,]3Z/OVM]ZKX_2GT=1NSCG95K;VL;]EL>#
M2S8"W=35L;L]2?TBOM:UC0Q@#6M$-:-  .P5&CH^/1U&[J+;;W67M:UU;K'&
ML;!M&VO_ ,FAKI00.$\1E(@U<=.+BEV09/0K;\A]@S[ZZGOW^BUQ '\VYC6N
M#@[V7,NN_P#0C9]"FI+&Z+DT9-5[NH6O;49>S@6-VO#&6#=LVU.L_1^E76S9
M_.,LO_6$]_2\2U^0XYCZ2^TY%GHO%9:6UUX]F^/S?2V^IO\ ](HM^KE LEV3
M?;46ECJ;7![2TCWL]P^C_P"IO],BM==)83>@?H[,1W4[CO<'5N:Z+@UE/V1]
M;W[W-?[;&V6.955^D?\ \6GR_J^TU/%74<BA[B7%S["]LD.9[]:[-FUS_P##
M,_\  TE.XDL3_FYCEFPYET-:YK1N$-:XLLL8T1_-V._G?WZ?T2T.FX+,#'^S
MLNLO&XO#K7;W .^BW^2QL>S8DI__T>^:\L^LCV.R'O%E(<W':R]S6:;9LN9>
M_ IW>E[?6PZ;'[_T5SU?ZC_R?D_\39_U+EF>E<?K6+F46,I%!8^W8-CG'8[?
MZNW]T-J_GO5WU?T;TOTZ/UG#R;:[KZ\NS'K;BVL=6P-,N.VQM@]86T_18^OW
M46?SGL]))3=P/Z#C_P#%,_ZD*6+_ $>OX>7_ 'WVJ.#_ $+'TC]$S3^R%+%_
MH]?P\O\ OOM24E0JOYR[^N/#]ROP14*K^<N_KCP_<K\$E)4%S6_:V.CW>F\3
MY36C(3OZ2S^H_P /&O\ M)*2I)))*4DDDDI2K5X&/5DORF[_ %+ T$%[BT!F
M[;LK<[8S^<>K*S\?IN75U*W,?G66TV3MQG?1$BIO[WH^STG[/1QZ+/TWZ:RU
M$ &[-5L@@::6TLOIG0[\K(R,C)].YUH;87N8P-M;6VREK6VU[7^G1^E_PC+F
M?TGU_1J]&%^!]6K7/O.3N);ZDU6EQ#6-%+;:_2W6-?LJ]-EG\XH]0M(RLFH]
M).4SU!9ZSO5(<[96WU=*K?;1LV/KI_\ 06N[]/Z:L%&/E%]?1+7.80XO9WEC
M=^S7TWV;OT3O=LM^ST?I/T5/IA*K>C] LPG4MS@P,#MMOJL]F^JUU@VMV,]-
M]+K<CT?H,8S?1Z+,>GT7S.E_5O.BS(RV%U-+,9SFVUM %8L>S=7_ #3;&LLR
M/S?YI]JIV#"Q\*Q[^CV_8]SK+:'&S;6ZJES,=]5;VM;70ZFKTOH_H?5Q/YOT
M_P!6EF,Q[[/1'1+'5$LVY53K -MK*W^M6ZBIS_T+K,AC_P#B_P#NQ[$IMOP?
MJV^EK7Y0](MNM'Z0-T>^K(OM<]@98UC<BBNSZ7H?X/9Z?HULN])Q^F8[K+,/
M(]4Y42"]IUK&NVM@9M>QCV-L;_@V>DLPMJ%=9_8C]]S:WV .L_1O<;MWJ.%?
MT\:W&I=ZF/ZMGK9'VK_NQ?I]'HPW5%[.GC"./;8VEKV0X!^US[*=P]C+F[=^
MS_BO\&DI_]+U54.JYV'3C9./=?77:<=[PU[@WVD%F[W?RU?0'X6)9D#)?4UU
MX9Z8>1)VSOV_YR2FK@]4Z8,+':<RB14P1ZK/W1_*4L;JO2Q0P',HF/\ 2UG_
M *AVU63C8P!<*6$C6 ULD_-4^CT8[^FT%V"W#(!:,=P+BT-<YK?=:RNWW-]_
MO8DI/^UNE?\ <RC_ +=9_P"20ZNJ]+#[IS*-7B/TM?[C/!W_ %2M?9,7_0U_
MYH_N57#Q<8W9I.&VH^N)>X$BR*J&BYF]K=K=K?1_1_H_T*2DG[6Z5_W,H_[=
M9_Y)#/5>E_:&'[91 8[_  M?C7VW;E:^R8O^AK_S1_<J;L?&/5JV?8VD-Q["
M<G:0UNY]7Z"-GHV.L]/U/YSU:?1_X9)2;]K=*_[F4?\ ;K/_ "20ZKTL\9E'
M_;K/_)(WV3%_T-?^:/[E3ZECX[1B[<)N1.34(:"-FI_6/8QW\S]+])^C24F_
M:W2O^YE'_;K/_))?M;I7_<RC_MUG_DD;[)B_Z&O_ #1_<J_4</&/3\EHPVY.
MZFP?9V!K'62UP]%MAV[/5^AN24W4D+%>ZS&JL?6:G/8USJG:EI(!]-W]1%24
MI))))2DDDDE*22224__3]527RJDDI^JDE\JI)*?JI9_4L?J]EK+.GY#:FM8X
M.JL +"\OJ++#%;K?93]I_P ,QF_TE\RI)*?H_P"S_6LTW,?DXYLBL8[Z@6F9
ML]9UIL9:S\ZC_!?S=:3*OK8T[76XSFB"'&2XAOIS798VNEF^W]-^E9B_\+Z+
M/Z.OG!))3]28;<AN)2W*<'Y#:VBYP[O ]YTV_G(R^54DE/U4DOE5))3]5)+Y
M5224_522^54DE/U4DOE5))3]5)+Y5224_P#_V?_M%>!0:&]T;W-H;W @,RXP
M #A"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4      !#-S_I]
MJ,>^"05P=JZO!<-..$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,]    !@              _P   CH    $ %  ,0 S #D    !
M                  $              CH   #_
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   #_     %)G:'1L;VYG   "
M.@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    _P    !29VAT;&]N9P   CH    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     #.L
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MNSU)_2*^UK6-#& -:T0UHT  [!4:.CX]'4;NHMMO=9>UK75NL<:QL&T;:_\
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
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M Q$!_\0!$@ !  (" P$! 0$           @)!@<$!0H# @$+ 0$  @(# 0$
M             0(#!00&!P@)$   !0," P4&!@(" P$    !!08'" (#!  )
M$" 1,$!0$A,A,3(9.0I@(A0T%19!,W 8@) 7)1$   <!   $ P()"04%" ,
M 0(#! 4&!P@ $1()(1,4(!40,4$B%A?7F#E 4%%A([-T=;@P<3)")&"!4B4*
M@C,TE=4F&!ER0U42  (! @0" PH'" P,!P$   $" Q$$ "$2!3$&02(3$" P
M46%QD:$R!T!0@;'!(Q3PT4)B<I*R%6#A\5*"HL)CHR0T"-)3<X.SPT1D=(0E
M%G" D#-#I+0V_]H # ,! 0(1 Q$   #W\  J-6U(6AHW*C)0
M                     >?=?2Q:DI&ADNV8QT)IDD(  #1AL0R\  $64RF0
M                        !Q"EEDNQ8QU9@1M$  &N3)SOP  :6-T@
M                    '$*662[%C&+F@24P  (WFTDY\@  0K3-1
M                  '$*662[%C'5F!&T0  5(8=#O):?N;>  "G[#HYR3FD
M[EVP      K=ZG[5.WLODV:Y]<             .,4B+3/1/5 '$*662[%C'
M1&IS>H  *OM[@D=5+/29P !39O,-H6!M'59@     !YC.P]7]&6G[+L'C7
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M*]        \P47LZFMH: .(4LLEV+&.K,"-H@  KCV>.1!)369  !66M9HJ
M !6#ZAJ+ //]EGVORB%_5O=^!3DS?[9\_BD/K_L%RVY\UR;/J0
M  !UAY]%YOHL_5 XA2RR78L8Z U ;^  ! 6+2/F-UH  %&':^)9-I\TJ=9E
M  &B-1Z)'+2>HS/[1X1FO*T(%'TVN,BN:@$4>N>R[EVO1-D\[JL;DY C:!PS
MD&@4ZM):HYIS3Z'7').21O3)E$4T\PDPC(  4D+6!HEH@#B%++)=BQCHC49O
MD  %2'>^!NS59; ^L\H  1E3)I   'EL^?/V"L-[M\OST[C\X22WGE@   &B
M-1Z-X^/F3]Q[@_3OAN^7V#\XXCY.'$A-)B^+1.0(V02SE 8L;5T<F*:>L3S#
M1\3,J:]VG6YKH[A'M(8@.L/'FR2Y1Z9E*K5H))EB8ZF[!C'5F!&T0  >;_Q+
M]1-S['I5['KGYX?T  KNZC]$S$W_ )'LWG]2U_PNRQHT7K'$KFY$XOC&3S9>
M%?JWZ1/<_P JIT]N^=P     !CQW1QP< ^ABQKI.JB6Z/V=J=20R6WPC;R/D
M?0XYD@!UAY V231Z=6.IY:,2;XE*:F2[%C&+F@24P  /.'XA^I'?9>#:%W[Y
M%[+)Q>OIRN9;C]93E]SDX/D'^:/V^M,]#^.[F/4?A#.^7UV3N_\ (_I-0-(Z
MGT#8W.ZME'(U          '1GS/Z=^     #K"C]:R1$KT <0I99+L6,=68$
M;1  !KDR8R   %<_2_IF7G8O&]N;+I0        U'AZ_3GHOG6PO9^NS+Y_H
M\)9Y'GD7^Q:$K'%/Q2-,)L_4KY3]3T+*>*.,TM)COE?0VI3:R=&:H+I%+-E0
M/'(OZ859=( XA2RR78L8QXTR2'  !HDV&9F  "**97(         $9.'TK;6
M??;!R[>,R8P)R-&SS#D\<[LTF2--7%6:WHZ8ZU%N8;11MDU&GOT:&3*A$J4
M5X)WR260!Q"EEDNQ8QTAJLW>  #3YFQE0  (X)D>@             < XYV9
M]   < YYU9]3G@ ZX\GK+:&K<@H!Q"EEDNQ8QU9K\VH  #6IE9WX  -*)W6@
M          ""Z=))@ZG"$[$-=0RR7[1*@P$CBGB)V2C C#2;Q"%.+&T$67(G
MBKL]'3'EG9+,U;?E1YT%Y#HXZUV#&,7-#$H0  1S-GISU   A>F:"
M  -&[WC^;KZ3ZQ+7J7+OM\![''W%;@$?$_0Q R [4C"G)222.G/H:Q(!+SV5
MR5'X.L-EDRT;*0!Y3%[+D7"JBI)>V-2EADNQ8QU9@)M(  &MS*3OP  :5-U
M         IV]CTDL^I<R:W2>?&Q-9J>Q3)M'R/VCN2+"TJT:(3G"/Z:Z3KHR
MXDJC6)M,PXLO5 'G+6GV6<J@<0I99+L6,8X:4)'   T&;&3FR  !$=,N$
M        086IQ3V*9\JQ.6ZQ(UN6+JP>37_%KAII%E;5$1+>8D.0P3(Q%=2?
M6@Q_H   '$*662[%C'3&KS=(  -2&:&3@  CRF0R                -'IW
M@@       #B%++)=BQCJC7)ML  &KS,#(   :-3O)
M      '$*662[%C&+FBR3@  (\&RTYX@  0V3,E
M   &-'EP7L.36BM8.J.B-3F]0  :8,[,L  !&LDH   8,9R   9>7/,8
M           'R*?5KAU0!K5,-RQ)   @82'3NQ   JC3:X@  "JY:U%4  "J
M5>UI0                  "*B=9)GPJ  (*)G6@  " "TJ%=K@  J\39RCE
M   K36LL5                   JZ6P$N#5  %/JULRO>   HZ6M_1L9
M\\R_H 4[D  'FB7]("G>@
M                   'GL7R!&N3M4S_ $4>K3B5Q1.UD:V/1&J
M                     *^$XJG1Z(E+W2*4NK;,1E"<2-8H]+:H
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M/2(!V%-0!1X. ==5!TYP#KV !U[   >PII&KPB@>@CST].O.'30^_FI'H'.
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MT?HS<%'?OXR>CF;'!\Q?,_9F:$K*(C*R\Y%\TIC]0)AEO 4=&2-K=N!W'/\
MV/VZ/T9N![BF6:2,,G7'23-<SV$*^5+0)/".BU*\TC4F[2V:CQ//_8_;H_1F
MX+>@CN(N&%AE,6*G-+>PT>5&!JZ$I;;#FGSBQTS(Q^(K138Z+1T>)C3<3J9<
MC=_5J(7>U;/-\X'P'^=:LM?.M66E/O?K<F349-^]T77C_P#.M66OG6K+7SK5
MEKYUJRU\ZU9:^=:LM2*WYW+;%AT'OCKM2(;YUJRU\ZU9:^=:LM?.M66OG6K+
M7SK5EJ6WW #LLRQOSK5EKYUJRU\ZU9:^=:LM?.M66OG6K+7SK5EI;;_Q"V5?
MSK5EKYUJRU\ZU9:^=:LM?.M66OG6K+7SK5EIEMYY*.C)OP'(Q[&588?9Q:YC
M7'Y'F(3A4L_M*L:ZD9]MGFW1F9<N1.W3&I)J)!1RYMZF-[V2Q@!S[H,=7KD*
M:<\S(WO6ZNXQX/,F6Z%A<R\,9S52B5?-/F=Z4@$VG/.>8SS1#3S$/.AY&LGS
M3QW%%_ VY@YN,987-N"[GC1;?6?X/NS1I>*13#P)9I^E5-'FWL6JD*_<1DR:
M&!XF^;=O04Q7S5C/T7;;3<V\PR<@Y.&Z<L'F*GN;<XVJISNZ;I?!/2Q,_C?>
MO5DXX\91DXRJBY.UK=YB9SSJ/'WV<U?1TCON/HJ16VM<=F<*8A*P$QIULL\A
M'OGKS CQ++>=S8[**:4E)(-E'[Q[<:A,=3I;5_H"'ST36CEM3*=BESA;$+A(
M:.+1QNR"J(B<VOIT+B'B\V671>!BF@VRUVR]J!\$)5H#9[)MGUZ46R7XS__:
M  @! @(&/P#_ ,F2*D&I#Q-0*?(<S\F'[6 I0Y9@U]'?]DQ.NE?98CIZ0*='
MCQKC)*UIF"/40#X<64NS;H9V=U33:3,)-&;&-@M&6G6!K0C,8AN.QDCUJ#ID
M4HZUZ&0YJPZ0<Q\7[AMZ[383BX!':30+)+'52OU3DU3C44_" /1BQ1MJL+7L
M$T_U:!8=>2BLFDG41IR)X5/C[][&;ERUFNRX87#O<"0#4IT:4F6+20I6IC+4
M<YZ@I"W%CLL%A"$ [.)IF4FI.JL\LKU-0*!J4 RK4GPVUPR\GV#/&I$E9+O^
ML$KH5I:7 TD/UU[+LP7-""O5%Q/;V:6\#N2L:%RB G)5+L[D#@"S,?&3\7Q4
M([1Y%1?.3F?D%3@216;-F0:%0*@T/%J^;+AC*P]+K]%<?V1!YW^\F,HX1_"8
M_P D8S, ^1C](QG<1#S(3\[X_MH'F0?23BVMZR2P49F;2H4$*VD5&=:Y^CIQ
M&\\S1S#(JZ#HRK4,*@\1T^//&3PM\C#Z3C.WC;S.1\ZXZ]@WR,A^<C'6M)A_
M!K^B3CKEU/E1Q_)QE<H/.:?/3&W7R;_:".ZE"A5NXF>,#)FFC6K6Z TK))I7
M.M:'#V$^Z6T\B<7AGCN$-<\I(R5:E:&G Y=&*QK(_P"2C'Z*8^KL93Y]*_.U
M?5CJVT:G\9R?4%^G'6GB7S*3\[?1@*][(2>A0JU]"D^O"FVY<W&2%A[;B2..
MAZ>T?1&!Y2V.<DV;G+EZWL;1[6!K>R,E=OEB5$>.YBDS:5;A66XGUF*:X8B,
MF.A%U=;#<;=-M,UO:21RV"/'93![2!C/;1R 2)%,Q:55<!EUT(%/B^UO;FR8
MQ:RL<C*P0NH#,J-DC.H*LR@EE4@D '$EW;6+)9O*5,@5NS:4 %DU^R9%4@LH
M.I05) !'?#[+MMQ+7]Y&[?,#C:+^^V:ZAMIXF+.T,ZHKB:1 CNZ*@D*JK*JD
M@HRGVB1C:-TCY<OV>Y,I*BVN-2HC*(W8&/3IE4ZD*L:J*D*:UK+RY?J/+;RC
MYTQ];MMPOGC<?.,4="I\HIW:, 1BU6ZA15N+2*X5@C*K1RKJ%&=%UZ/9<KJC
M#@J&)!IM4,6W.]Q>6B7"11Q2=HL<A8(&30IJ0NH%0R,C*RLP-<=O+RY+:VO3
M)=/#:(/+6YDB:GF4X47>[;;,"1E:W N3F*GV$"9<#5QGP)%#A&O%WN\ONE8Q
M:VT0SX%W>Y<BG2(P?(,(^S^[ZR$@'M7<UQ=GSZ0\,-?\T1Y,21;9>0;?;M^#
M9V\%M3S-%&LGRER?+A?UMNES>WY4M'$\QEGD _Q:2/4^+5DHZ6&>.=M[YBOW
MMMYY@NC/(D2H4MM,O:1)D2'84':A6"C-4)(KC8[3<WC:\M;&WMV,8HA%O"D"
MD9GBL8->).9H33XOM]JV;EO=+V!.8)[J>6"W,MK!#%:Q F>8'ZIU-'TZ<X@7
M+4%,<E[/S%R7S3:6EMN%PT,=ZL%F9.UBA8R1R+%,DT; 5&E%=*C4[:@!1>0)
M7/CDW"4_Z."+&JR]WFW*?YV:^F]1NE'JQ2#DS8$\OV37_I9)/7C596VV6W^2
MV^R7UF GUX"KS%)&O\VD47^CC7!,O-VY'R?:9@/0' ]6-FY6YEV7<KO>[&21
MDN1>E4837*2R!XRC,[=DIBC9G^K8AER&G'+-ER?:;CMFU[;;20JLEVTTC!YG
ME!:15C)TZRN8X4 H !@=GS-N"^:XF'S/@%.;]T'_ #4_^'C+FV_/Y4K-^D3C
M_P#HY6_*2)OTHS@]KN<+_E6EFWZ4!Q_6(=ME_+V^Q/S6XQRGND'O*V*&ZLMH
M@>:WN;57-H82Y>*,1VI1;-3*&-NVM.U>0T*L -IVSEWWCW&X;=%M=LDLT$AA
MC>=582*%B2"D:9+$A7J1A%S(.&FN)GDF;BS$L3YR:D]V6[O+A(K5!5G=@JJ/
M&6- /EQIY?B-IM9_VN9.LX\=M;M0L#E268*G2L<HQ++;HTE]+3M)Y6[2:2G#
M7(<Z"G51=,:_@JHPTDVG455>JH0450HR0*!U0*D"I-6)+$DR7$Y7M6XZ55!D
M*9*@51D.@#XOFV^SW>ZBL)*ZXTED6-M0TMJ16"MJ&1J#49'+$$&Y[O=7,,7L
M+++)(%R ZH=B!D ,N@ ='A]XGW/G"&"ZOMLGM^R^SW3M$\C+I+LD10K1*DHS
M$:@*5J!+;V&YI>6JTI*B21JU0":+*J.-)JIJHJ145%#W9=KV"T-]NR&CA3I@
MA/\ O$]"J$9GLU#S&F4=,\1;CS+="^W!#J1-.FV@/\U"20S"N4TI>3(%2@ZO
M=O\ 7/+6V8"3ZBX-"6T#32+K];I34 ,R=.>(;JW8F"10RDJRFAX55@&'F(!\
M8^+R2<O )-S+O>X1/5P8K>VC?+3]6PF>=?PS5U[/V5(#5:H6/9MSFNK4H"7E
MA$#!JFJA%EE! %"&U"M2-(I4^ C-[,3/(2(XD!>:5OWL<:U9CXR!I6M6*C/&
MK=Y&L-G/^S1/]?(*\+B=#]6"!G%;FM#1ICFN(K*PM4AM$%%1 %4?(.D\2>).
M9S[PCH[U['<]]MH+Q0"4=PK $5%0?&,_-A;W:[R.>T8D!T.I20:$5'B/Q5MF
MZ;EN^V0;9:WT!FCNIE1I(@ZO)IC8'M%T JPZ2=-,\!X]UV^YAG>1E%K,)@@#
M9!Z :*@]4$9@'A3P\VWM9;D+V&YB:=H[B1(Y(C&&*(HG 6H*\%3,$USJ;1>4
MMMELML;56YNV,K+UB"(4,CM,P-:/(ZQ(1IZ]"@ENE+S[I(*27$IUS..-"U %
M0=$<82,4R4'P4!V_?)+-5!U!8HI-=:4)[16(I0\*5KGT8OIHMNO-P0QQ#MUA
M4!J)PH@5.K[.0KEGBVADWBYVV3M9?J6MX25J['561&8ZO:S-,Z#*F(DEE,DJ
MJ 6( +$#-B!0"ISH!0=&7?#OQW!W!\(L+6\V(W-W/:S".43O$8<P 0%'6(9@
MP-0:@#@<;O\ 8=F6QE1XU8&=I3*=)(;KYBF?"M:YFO?R[CMTUF;-3$NB2.0O
MJDD6,G6LJB@U@@:*Y$5SJ&&ZSP27&HT,2,BZ:"@(=Y"36M34"E,O'@-?W\,"
MGID=4_2(PT=G=R74P_!MXI9Z^8QHR^E@/+@-MO*-XPKQG:&W'H9WD_H\"@VV
MTA/^6N7'_P"=*CY1@KN7-UVP\4"0VX](223^DQ)=0;_:]A=7$42B:9WG5FC
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MYD'8K\E*85K78[59!^$8U9_SV#-Z\  4 [R6YN=EM)+A_:=H8V9L@.LQ4DY
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M:TN]?H[;,6K.4Q(#:(W2E-+5B6J_TH W%!8X.Q*U^<<O\YO?\(Y_N3^.*_\
M)]H_U'[%^&7=0,<WF)QM%R#B&B';_P"ZFDI*HM%5(Z.=2GTSW[M;OGA2)'<?
M)6^24PG]!O+TC0+%N6>P>3Z],5I@^T+-ZU<TM$@:;9EB"+^#B[LA%0B%D:M3
M 'DY(U2*81$ ]0!ZC?:T3:N=;KT13Y#'><MCO+=SFFG<_P!3RAO;*C O[3"2
M^H4[4\OO]VN*,6$4*JB$,JW3<L2JMA+\Y4BA9V<W"S]#6:2N,-G<Y&*[IJ&$
M:1'-7#FO.74\3/ Q3.\^4@H91\])\\LNFNLOZ411^44BA1^U86%%XQT'<RP;
M+*)$+X:YP5*S!4-#T&/IK^#<2Y6%CLC>PQJ+L/ITRQBJ*[QRV(<Z:1E%"3EU
ML>'Z'@;^&N4I4R5#2G$ YG)%O&Q\2]+8FBE=?R+'[I>J29D4O4H"@G;G$0\A
M*(_[9UFE@S+HS]*@LEKJ\*W8Y<V=M+8_IGU*D\YK;P+.1)S'(,6IG1%7'TPJ
M-Q Q2^H?3XJ6@1<38(*.N$$PGV4/:XXD19(UM(HE72:348FY>$8R"1#>2B8*
MJ 4?Q&'^6NY&1=MF$>P;+O7[]ZNDU9LF;5(Z[IV[=+G30;-FR"9CJ*',4A"%
M$1$ #P_6Y!X.]PWNC-8M\^CU-[Y^P)JSPVQ+QSE1D\-F]YU&UT(VF,T7;=8A
M7L2U7C7 $*HW<K)*$4&Z4>FQFL8_NV9,H^3T_F;I'-)[&-]H<1*N%&4=89&D
M6$IT9RIOGR1D$YB&=R<9\_TI&7(H<I!_"]_PCG^Y/XXK_P GVC_4?L7X;$BM
M/N*HBM!2Z2MI:.&+1U6DU(]P0\^V=2B#F,;.(8HBX(HX340(9,!4*8@" Y'&
MPF]2_440SI,0C'="SUCJEOE]>: D(HW5]9Z,T95*=5E2#Y@Y8I@BH4 'S,;S
M,;[75FBO=TVW)?T!Y&Z&.2/H6G_H=GDT=+.K'+)'OU8?M7%?LZ+E9J5DJ5V)
M2J,EU$ $OK P5R2:[%MNO%O%&SB5%]L&GN=(;QP-:NB8BU0$S9M'0K*8"0^:
MX*T#Y"XD3$H 4A0^WHMY8].ZIFU11N/+,6;.JY'Y"UJA94_4>2L&]A"Q6&@/
M[RE**/I-NL" 31&BJS1)/Y(IJ+)JOH>Z;%=]KDW4TZDV]GOD/GL++1S!=NT1
M1@&K7-J;2(52.9J-SJD46:JNS'7.!U3% A2_[;@>D6B_5.,L_4VG]8SZL>MS
M-QR\^D<+95)2T4$\=W@:Q;I]\6Q^E'1[JWDG7;E^<5$E@? 9QXH^9PZ[=U%T
M:M1=98.&M:I]-;+-8IL1LDHA5<^K]4I%?3,4GF#6*C6+)$/S4D2%  _EKN.D
M6C9_'OVR[)\Q>H).F;UFZ2.@Z:.VJY%$'+9R@H8BB9RF(<AA 0$!\2?,S3W5
M^3O:<PZA<VX]>,GB[CAN5;9:-ED+58]&K=P3?L+K:(!CD\)F*%*BVL5')HM_
MO9O(&7;"N1JZ*UN>E3/N!XK[G%PA]$L%';='9-B6:XZ%%K*T%2K ?$7;+/)>
MP(/18OE$II951R0[@)%#UI>2*1Q\<&9C7L(AKOFO8'3%:YUM>Q2^EL()3-)^
MQP5KL\;&Q&;M8J0LMOD96 IDBX*^^:TBV)FQ$5SF4<I 78>>:HVX.KN4XMTM
MH^$S57N72EM8]JW*O9;2:Y/6K1L_P*/S^0A):!;SEH1;_-<2[5,B#9P<_D!4
MSJ7+/[GWYRS5KI39NPTVV5J<UNL,9BNVBO/G<+.P<LP5>?4M9*(E6BK==(2^
MM-5,Q1#S#R\<3B(" *P6Q+IB/XE$''16OKMUB?TIKH*%.4?RE, _ALIY"O.+
M:P) 3!GU4:,&4JZLS,L<Y%S7FT7)*H1TDXFD0,V(W7.1%8R@$.8"B(^,9=T/
M )[E:G.*'"*UWG2T4:N9G8<=C#(C\BD2]!J+I[6ZJ]B?B!VC14R:?J_(81 /
MM=/1$I'P,_9=LRC0L6I%8L+%I+QLC*W6E3S67F7\.Z-Z'T;3*R1Y*J>93D%9
MJBF/Q5+XQVS99RM=+8WA:+6*581KETQ6I5.(N-1K\7$6&#@V-DO\5-M(ABZ2
M 6958] 19*)&*7TB B -.+G3<H_\\YT+EK/T_P#\RPJ%C$/_ &?5X\D^:,LA
MS#^)29Z4>+E+_1ZTH7$9 ?\ ?Z3CX]3*E<JQ!3 /D1_I>M3BJ8_D XM<J@DC
MB']0AX'YTER+$E$?@*4)LM@$H?U@>P5D#B'^\O@/JMMY\KQ1_P"((/ +Q+G+
M_2)%)K>4B&\OZR>/,>PJ]' (_$(;FBK)>0?T$&:OT_Y?]_J\!C;BQZYNV2NI
M?*KII%V;9?GN=T:,L@[51(++ZI&V"L#'2\A.&LC@SM=!0ZK=!R,:<HBIZOEP
M5HTG8I;)K[&NI.LV//=>YMK,BH=Y .1:LY^(F8"^U>3FZ]8XP4'*;M53YYEC
M+%,'J(/@A&-GY0MJ1/(#*25+URBNE@ ?B8XL;O?6Z9S!_P"%/R#Q_P"981AE
MT6 OF)Z;OMHKPF'S^(%9V[&/E@;R_(+KR\_^;P8UFXMT!)NGYBHXIFNX?;!$
M \__ '#26N5,?+B/E\ ^4 ^/D3G,/74$ &$IE_U.MK4@7R'R]7KSRUW(QRC^
M3T@;S\ -J>Z;2%OSOF-KI@VY5U1'T^0"*J[W/"L2E 1_&"PAX*DVZ&REBL;\
M3>Q6Z,J;GS_\)FUI5AURF#\H"4! ?#&.K;#W)G=<MV]Y_F\9?<:O6#R7/6M(
MV"I-7SRG\\O3Z,^D/TC=.%$4A^M;17RI!%V!ETBF*8]3D[_?]&RJRJR%M;/L
MUZRN5$F^FH=2/M<PQ*%T@<XM%X(1%\1 %XLB:RAQC%6_J*4_F0!<T6%VS3P
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M'X1":&[;-'%;AX]2R'9M5WJ3<Y52G?+&B8M14R#E4YU8YFJ*B@IG.8ZGS$3
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MY+M>2SB=0M-&P2/T^/RX+'/R21JR]>KRMIOV?9Z\&(@I9RX(2<=*))BF)FQ
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M)D9*KRU76?O8B:K3_P#LY1M\Y^S>K/ODMW/CVZ>(FQDWM8AU(WOCHJ,0?)I
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MD\Q#)Y9+"9/F))]2XA=/GZ8CJE$262IBD()TQW%T1T\J,>>+(4 !)@I\DA1
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g790774g77b51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g77b51.jpg
M_]C_X1#817AI9@  34T *@    @ # $   ,    !!2T   $!  ,    ! S$
M  $"  ,    $    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q  (
M   >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @ "  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#(T.C U.C$P(#$P.C$T.C0T   $D   !P    0P,C(QH $  P    '__P
MH ( !     $   +5H , !     $   &_          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M4&AO=&]S:&]P(#,N,  X0DE-! 0      !H< 5H  QLE1QP"   "   < @4
M!F<W-V(U,3A"24T$)0      $(Z^@)B'0;(J-N*P=5!$L,8X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ $L     0 ! 2P    !  $X0DE-!"8       X             /X
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      T$    &              &_   "
MU0    8 9P W #< 8@ U #$    !                          $
M         M4   &_                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   &_     %)G:'1L;VYG   "U0    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !OP
M  !29VAT;&]N9P   M4    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M%E;; " \!P!YU$I*9))))*4HNL8US&N< ZPD,!Y) +X;_9:I*A2_]#T_<Z3
M+BYTDS4_5SGG<Y)3?0,[^@Y'_%/_ .I*.L#ZS=;=TG"RKG5G(8[92VL.#-OJ
M,MW/W;'?N(QB9$ :D[() !)V#MBQ@<RHGWN:7 0>&[0[7_KC$/ _HP_KV?\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
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M P,# P,# P,# P/_P  4" &_ M4$ 1$  A$! Q$!!!$ _]T ! !;_\0!H@
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M7DRL6U=P97;)RF-@JWEJJ6BKHX)I)98VD?WOW7NA(ZM_[+ ^6O\ X8GQ@_\
M=?V_[][]U[HV_OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z]
M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_
M=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOW
MOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][
M][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO
M>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[
MJL'^5E_QXOS,_P#&GW\PK_X(W=GOWOW7NK/O?O?NO=5-?SQ_^W7GR3_[6?Q_
M_P#@FNFO?O?NO=6R^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7
MNO>_>_=>Z][][]U[KWO_T/G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=4<]R==_-++?SG_ (Y_)3:?P\R6Y/C/T_TAO_XU9[MY>^NE<14Y
M"A[XW#UIO'+=IXSK?*9^#>IV]U54;0J*#(8Z2),KDY)!+00RQJ/)[W[KW1)M
MQ?"#^8IUQ\4?EK_*&Z:^.>T-R=#_ "8[;[WEZN^=E=W/L;$;!Z<^.GRA[#S>
M_M_83M/IBLRM-W9N7M[K:@W+D\1CX<%05.%SKU-)4/64<<-3$?>_=>Z-QN'X
MZ?*K^7]\SNS?DO\ #CXK2?-/J[Y+_&+XX]&[WZYQ/=?5_2O9'6/9?Q)P6[-G
M=6[MK,MVU78#9^:ZMWML?<T%!E9,=+4YK%UU&:B/'U,+:#[W[KW1N/Y;_P )
M=X?%WX*83X_=U;I6L[?[ W+W!V[WKN3J3<^ZML4=#V?WYV5N?L_=F-Z\W?05
M.'WC0X[:4NY8\51Y)9:>LJ4H?N?VS+H7WOW7NA ^-VP,5US\I_EYA,/F=\9R
MFJ-I?&'(O5[_ .P-Y]CYE)WP?:5$\4&<WSF\]EJ:@*T*R"FCF6G2:21U16D<
MGWOW7NCW^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][
M]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KW
MOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z
M][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[HL>Q_FK
M\/>S>TZGH[KGY2?'W??<]%6;JQU;U-M#M[8>XNQZ.OV-*\.\J.KV7B<[5[BI
MJG:TL3+7H].K4I5O(%L;>]^Z]T9SW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U6#_*R_X\7YF?\ C3[^85_\$;NSW[W[KW5GWOWO
MW7NJFOYX_P#VZ\^2?_:S^/\ _P#!-=->_>_=>ZME]^]^Z]U[W[W[KW5*79G2
M%-)_.=^/$T7<?RAQ^VMY_&KOCY#[CZMQ7R=[KQG3.4[,Z5[&^-6Q=C551U-2
M;QCV.NVX=N]@9-*W"QT<>)R=1,*BKIYIAK]^]^Z]U=;[][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>__T?G_ /OW7NM_CW[W[KW7O?O?NO=!KW)C>QLS
MU3V%B.HM][;ZN[-R>T\U0;)[*W=M4;XVYL'/U=')!1[QRFSGS6W8-S1;;9S5
MK135M-35$D*I,_B+@^]^Z]UJ%[YS/_"?>HW3N*G^27\P7YX?/ON?;574R[Y[
MZVIV[\]^UMK;0S<\S5U=)M;)_"K;^(^.>RMOXVJ=VHL3A(9J7&TT:1:6T!G]
M[]U[JZK^52-A9B#=.[_B1_,VW+\\_A%D,!#0X/KCNC<T'<7>GQY[7_BZY%<6
MW=F4?"]N4>R,IM&H,"[-W]BZG,XIJ6FJ**O2FEFIW][]U[JY3W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW12.K?^RP/EK_X8GQ@_]P.W_?O?NO=&W]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW51'Q<VMMBD_F[?S3<A2;<P-+7T
MG2G\N*HI*ZGQ&/AK*6HRV!^6$>5GIZF.G6:";)QP(M0RL&F"*')L/?O?NO=6
M[^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NJP?Y6
M7_'B_,S_ ,:??S"O_@C=V>_>_=>ZL^]^]^Z]U4U_/'_[=>?)/_M9_'__ .":
MZ:]^]^Z]U;+[][]U[KWOWOW7NJONQ_\ M\9\3_\ QGU\T?\ W^WPU]^]^Z]U
M:#[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>__2^?\ ^_=>ZW^/?O?N
MO=>]^]^Z]T&G<O7?6G;75/8/6W<N"H-T=3[RVIF,'V+MS+3U]/B,[LZJI)/X
M_B<PV,J:2LFP]?CD>.KA#A*BG9XI T;LI][]U[J@;XP[^_G"?+CHGKCY!_"3
M_AM[X0?#G=V*GR7Q3^.F^.F.S][[U'25%D*[';#R/9]5UWNC96P=AU&\,;CT
MR5/A]K4;08K&5T,+RR54<MO>_=>Z.K_+6S6U^_-U]]]_]O\ QIZ?Z/\ YB/2
M'9.]?A%\O-U=*SY2?9G965V53]?]DX/=6WLY6T^'S&]MA[QVAN?;^;P$NY:6
M?<. @K)L:TR::@3>]^Z]U;?[][]U[KWOWOW7NO>_>_=>Z][][]U[HI'5O_98
M'RU_\,3XP?\ N!V_[][]U[HV_OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=
M>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWO
MW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][]
M[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>ZJF^,O_ &]J_FJ_^(._EI?^Z/Y:^_>_=>ZM9]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=5@_RLO^/%^9G_ (T^_F%?
M_!&[L]^]^Z]U9][][]U[JIK^>/\ ]NO/DG_VL_C_ /\ P3737OWOW7NK9??O
M?NO=>]^]^Z]U5]V/_P!OC/B?_P",^OFC_P"_V^&OOWOW7NK0??O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W_]/Y_P#[]U[K?X]^]^Z]U[W[W[KW2:WG
M'@YMG[LBW/6#'[:EVUG8]PU[3+3+0X-\75+EJPU#JZ0"FH#(^L@A=-R#;W[W
M[KW6H+NKX?\ \NCXN_!?XW_(_8/\PS^?!)T)W;'U[L?X=]!?'WY5]J1]E=H5
MO8M+D,QUSUKTAT%0[2VS-35N:Q%)45E'0LF/IUIQJ+!Y8UD][]U[JX_^2?@?
MBUA_CMW%D?C9NKYC9_<.[/D?NW<GR9PO\P&NR]5\PMA_(<[%ZXP6<VEW93[@
MQM#F:/.P;$P> J:?R39".:DJ8Y(ZN56TQ^]^Z]U<A[][]U[KWOWOW7NO>_>_
M=>Z][][]U[HI'5O_ &6!\M?_  Q/C!_[@=O^_>_=>Z-O[][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][
M]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KW
MOWOW7NO>_>_=>Z][][]U[KWOWOW7NJIOC+_V]J_FJ_\ B#OY:7_NC^6OOWOW
M7NK6??O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW58
M/\K+_CQ?F9_XT^_F%?\ P1N[/?O?NO=6?>_>_=>ZJ:_GC_\ ;KSY)_\ :S^/
M_P#\$UTU[][]U[JV7W[W[KW7O?O?NO=5?=C_ /;XSXG_ /C/KYH_^_V^&OOW
MOW7NK0??O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W__U/G_ /OW7NM_
MCW[W[KW7O?O?NO=!!\@=W['V#TAVOO'L[";GW'UO@-A;FK>P,+LS:VX=[;FK
MME?PNHAW2N*VGM.EKMSY^6'"2SR/3X^&:L>)&\*.^E3[W[KW6O+_ "]_B-\?
M\CO'XD]YU?\ -^ZO^</Q.^ ^T]YX?X%]48G#]+;%EZ<I=Z[078V*J>^=][6W
MI5Y/L[>_6'4LJ8''PY7";>K,9/#]U-3PU?GC?WOW7NC^? #L?XNU_P MOY@F
M!Z0^1.*^579W=/<E%\DNW-Y=1;6J,KTETA@L?UUU?T-U;T-F^W]N9+<G6>6[
M6H\#UM/6RX^')KG*A%K*BIQ])%"A?WOW7NK???O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=%(ZM_[+ ^6O_AB?&#_ -P.W_?O?NO=&W]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW54WQE_P"WM7\U7_Q!W\M+_P!T?RU]^]^Z]U:S
M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>ZK!_E9?
M\>+\S/\ QI]_,*_^"-W9[][]U[JS[W[W[KW537\\?_MUY\D_^UG\?_\ X)KI
MKW[W[KW5LOOWOW7NO>_>_=>ZJ^['_P"WQGQ/_P#&?7S1_P#?[?#7W[W[KW5H
M/OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][_]7Y_P#[]U[K?X]^]^Z]
MU[W[W[KW7O?O?NO=4U_+/X@_R'/]+!W)\R^J?Y<.R^Y]T^3>%;5]PUW2/5>^
M=[_<U31S[HW#297+[5R>^!55<!CDK:^.L$C*49S8CW[W[KW1_P#XI9'X?3=3
MTV"^#^1^-]5T?L_,Y#;M+B_BS7]9U?5VVMQ+%297+89*7JB:7:V*SQARD%55
M062I(J4ED!\BLWO?NO=&5]^]^Z]UKR_(7^<QWEUGF/G'VYUK\<.H]T_$/^6M
MW/MKI#Y//O\ [MSNP_E-OS-Y=-B-G]S=#]9+UWE=B' X5M_TZX&/<.>H3OAZ
M:6.@FII2B>_>_=>Z-CWY\Y_D_FOE9N'X;_ 7X_\ 4G</9O3_ $KLKO[Y#[R^
M1?;>Z>FNO=C8;LK,9B@ZOZ9V]!M#KGL;=V6[D['QFV<GDHYJRCHL%A**EC:J
MGEEG\,7O?NO=&Q^#'R\VG\Z/C%US\D=I[8SNPCNQMT;=WEUSNB:EJMQ=;=G=
M=;LS?7W9NP,O6T2I2Y.3:N^=LUU+3UT:0QY&C2&K6*-9A&OO?NO==]6_]E@?
M+7_PQ/B__P"X';_OWOW7NC;^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[
MKWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=
M>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWO
MW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][]
M[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[JJ;XR_\ ;VK^:K_X@[^6E_[H_EK[][]U[JUGW[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U6#_*R_X\7YF?\ C3[^85_\
M$;NSW[W[KW5GWOWOW7NJFOYX_P#VZ\^2?_:S^/\ _P#!-=->_>_=>ZME]^]^
MZ]U[W[W[KW57W8__ &^,^)__ (SZ^:/_ +_;X:^_>_=>ZM!]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?_UOG_ /OW7NM_CW[W[KW5#'S^^0'SWZ]^
M4>S>@NB(^]Z&F^0>X%R?0.X]A9?^7Y#B,T>M.F\EG>X.KJ'"_(C&U&[H::DD
M@&Y)LGD3)72U<9I*$+CUE*^]^Z]T._\ +(WG\P^RJ[MO<WR#[RS>]<'LC=&Z
M>C]X=-=D[.^-T?9'4O>O7V7Q.2JZO%]E_%6*@ZUW1LW=6P-U4<U3CJR*?*8N
MO5(VEA<5-,GO?NO=5[?)+XE?(;:'SN^8W<.S_P"27\=?YFNR_D/GNG-V[?[?
M^4??_P 6]K;BV35[.Z;VMUYN+8&P,+VAUCVINO'=:15>VX*JEIYWQK19)ZUU
MBEIY:=H_>_=>ZM8_EE_QJ@ZC[(VQNOX$_'/^7%O';7;N0@W#\=OCCVATQV?@
MY3E-D[(S&,[#WG5]);(V!@MN[PW5CJU(A0U]"<DV,H:2I:5H)X%3WOW7NK(?
M?O?NO=:1WRVZ<W?NSL7YO=G=G]"?.BG_ )TN'^4F<KOY<G:'QSZ-[$R736YN
MG=AYS%-\-H(=Y[=VAE/B-NGJ':6-=*K?>1[1<;HQ,\M<LE13K%10Q>]^Z]U:
M#1[J[+_EU?S%OD7\IODMTKWMV5LOYX?$;X?05^^?BOT?V+\@\1M;Y3_&#;.\
MMD;UZ2KMH]68/<V[]M/V1'O*EKMJ9/(TL&$K&6:GEKH9(I OO?NO=&Y_E+?%
M[N#J3^7E2[+[JAW7T;W)WUV9\B/D+O# [<R& _OMTW6?(?N/>/9. VQ#7U&*
MS6WH=W[8VGG,?'7H]%-!2Y/SP>-A'<^]^Z]T8+XS['KM@_*3Y>X?(=A[_P"R
MIY]J_&*O7.]C5FW*[-TT38+M&C7&4\NV-L[4QXQT;41F :F>8SSRLTA!55][
M]U[H^OOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][
M]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>ZJF^,O_;VK
M^:K_ .(._EI?^Z/Y:^_>_=>ZM9]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=5@_RLO\ CQ?F9_XT^_F%?_!&[L]^]^Z]U9][][]U
M[JIK^>/_ -NO/DG_ -K/X_\ _P $UTU[][]U[JV7W[W[KW7O?O?NO=5?=C_]
MOC/B?_XSZ^:/_O\ ;X:^_>_=>ZM!]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?_]?Y_P#[]U[K?X]^]^Z]U47_ #<-M=T=G=>=6]-]4?$KX\_*.AW7
MD>U=^;G;Y/=*[J[XZSV7D>FNI]Q;YV-AL=M+:.X=FY#;_8_;.XH?X!@<^^7I
M8\=42O$(JJ6JCA]^]^Z]TH_Y/^0R=9\5<[3#8VQNO]@X;NOL#$=/8;K#XB[X
M^$'7E1UK#1;9JH*_:GQ^[.DG[,P,/]\*S,4U?D,[)+6Y7,4U94QR2TCTTC>]
M^Z]U51\__P"57N3Y(=U?./Y'=_\ 1%1\FMV;7[M^)&Y_@WM#._(.MV3BNUOC
M'M79W6[_ "3^*/7VT\?V+@L+L#=>YLSC=W$U&2HZ9]PY;(4,GW*Q/++#[W[K
MW5A'\EGXZ2_'KK'Y.+M;XA9KX0="=I?)G(]C_'GH;LF?%5_?>)V14=6]:;;W
M'G>XJ_$[Y[)6FJ<_V%M_*S83%56<R%5AL/XJ82+2K21I[W[KW5T'OWOW7NO>
M_>_=>Z][][]U[KWOWOW7NBD=6_\ 98'RU_\ #$^,'_N!V_[][]U[HV_OWOW7
MNO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]
MU[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>
M_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z]
M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>ZJF^,O_;VK^:K_P"(._EI
M?^Z/Y:^_>_=>ZM9]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=(Z?L3K^ESG]V*G
M?6SJ?<GWU)B_[O3[GPD6<_B>0C6:@QW\)DKEK_OJV)@T,/C\DBD%01[][]U[
MI8^_>_=>Z][][]U[JL'^5E_QXOS,_P#&GW\PK_X(W=GOWOW7NK,JS(X_'+&^
M0KJ.A25BD3UE5!2K(X4L4C:=T#L%%[#FWOWOW7NJD_YW^:PU9_*_^2R4F6QE
M4\=?T!+(E-7TL[)$/DYTNAD=8I6*QAY%%SQ=@/S[][]U[JV"7<. ADDAFSF'
MAFA=XI8I<G11R121L4>.1'G#(Z,""" 01[][]U[IR@J(*J&.HI9X:FGF4/%/
M!(DT,J'Z-'+&S(ZG^H)'OWOW7NJQ>QE8_P XOXH, 2J_R^OFAJ(!(6_>_P -
M0+GZ"Y]^]^Z]U:![][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>__T/G_
M /OW7NM_CW[W[KW0%=Z?([J;XX0]75O;VY(-HX?MOM;%=.;;W#DI:*AV[C]X
M9K:>\]XXX[HS>2K:#'X##U.,V+60K53/I-9)!" 7F7W[W[KW07_$WM;L3MO(
M_(/,;A[F^,_=G76 [QW3M7J?,?'6AW1!4;-VM14V/S&.V!VKFLONK=FV]Y]B
M8?;^=QTU?D\(]!0&>H>$4JE"1[W[KW6NE_,X^-'>>W_F?V3\A]U?R_?D5\Y]
MV5/R-^#W;?PR^2'1M=@>PY/C=TAT5N[JG='=GQU@Z?SO8>UINJMQY#.[.W)E
M*;.4&/K*/=TN[4%?64K4;K%[W[KW5V7\LW8_?M*GS%[Z[QZTW7T!0_+3Y79?
MO#J?XX;[W+@MT[ZZGZ\I^INJNKX,COR?:N9W#M;;&]>ULUUY5;GK]O8VOKZ;
M!G(I#)4259J53WOW7NK0/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=%(ZM_[+ ^6
MO_AB?&#_ -P.W_?O?NO=&W]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW54WQE_P"WM7\U7_Q!W\M+_P!T?RU]^]^Z]U:S[][]U[KWOWOW7NO>
M_>_=>Z][][]U[JN7YT?.WL'X:;FZ+P>WOA]VA\C,;W_OW"].;-W'L#LWH[95
M%3=V;L7-5FS>N<O0=H[[VIE:8;@PNVZ^K.86%L32+3B.:999$4^]^Z]U87BJ
MFLK<7C:S(8V;#5]704=378>HJ*2LGQ59/3QRU.-GJZ":HH:J:AF=HFDAD>)V
M4LC%2"?>_=>ZG^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NJ1
MNT?BY\9\K_/%^,O8V4^//2.2[!R'PN^3/:U?OBNZMV35;MKNT>O.ZOB5@M@]
MDUNX)L*^4K-_;(P>7JJ+$9B65\CC:2=XJ::.-BOLW'P%Z_V9VQ\W_B/UCV+@
M:?=.P>P?D7T_L[>>VJNHK:6ESVV=Q;ZPF*S6(J*G&U-%D((<ACZJ2)G@FBE4
M-=64V/N/_=?=]RV#VQ]P-[V>[,&[6FSW<T,@"DI)' [(X# J2K &C CU!Z-^
M7[:&\WS:+2X0-!)<QJP]0S $8H>'1_?GQN[=FQ/AU\@=V;%W-F-F[MQ&PJI\
M)NG;\T%-G<%55>0Q] ^1P]54TU9!2Y*"GJG,,K12>*2S $@>_I.U/\A_^40E
M34(GPAV"JK/*JJ-[=P6"K(P '_&1/H /?&1?O4?>"*J3[F7=:?[YM/\ MGZR
M0A]ON56AB9ML0L5!.6\Q_INJ\:C:F\8LI/31_)?Y=B&*OD@16[WJW(B2H:-0
MS-MHECI')/U]X?\ AB'^45_WA%L'_P!#;N#_ .V)[M_P5'W@?_"EW?\ SAM/
M^V?IS_6\Y4_Z-:?M;_H+HB/P*VYNN7K[Y(3TWR ^3N&9?Y@_SCHIDP/<D^,C
MKVH^Y*HG*9)5V_,U9F\C-4235=02HGG=GT*201^^//\ +7^!WQ1W!NBNZ"^+
MW6FR*G?. HJ'=3U]/E]_1Y.EP>4%3BXHJ?LC+;NIL5]O/72,S4:4[S$CR%PB
M:0GS=[T^ZG/EG8Q<U\[WEREK*S14*0:2ZT8UMTB+5"@=Q:F:4J:K;'E#E_;9
M'^EL NOC1F'"M*]V1GAZY\NACSG6^(W3\F-MXOL[<.^N]<92_&7L#,8C'=][
MBI.TJ';.7_TS]4XVHRNUJ7+86FAPF1R..D\%5,BM)-"B(2%6Q-9_H@Z=_P"?
M.=/_ /HJNO\ _P"QWV _ZQ\Q_P#31;A_V4S_ /0?1K^X]K_Y1?\ C3_]!=%A
M_F>=(=,83^7]\E\MANI>M\5E*+']+M1Y+';*V]15U(:GY-=(450::JI\?'/"
M9Z*JEA?2PU12,IX8CW[_ $0=._\ /G.G_P#T577_ /\ 8[[]_6/F/_IHMP_[
M*9_^@^O?N/:_^47_ (T__075A>Z_CST''NG<D:=)]4(B9_,(B+L#:ZJB+D:D
M*JJ,8 JJ!8 ?3V53=W\L_P#EV=K;KW)V#V3\(OC?O/>^X\S5SY[<V5Z^I8:_
M*S4>C'4TM1#BZG'8]&AH:2*(>*",%4!-VN2.]N][/=_8;"SVC9O<O>+?;(8P
M$C6X;2H/<0-08Y8DY)X^G1+/R7L%Y-)<2VBZV_H1-P%,L\;.3CBS$] %\>^K
M]LQX+MREQN4[(VUBL=\I/DAC<5MW97;_ &IL?:6$QM'V)51TV.P&T=I;OP^V
M\#00@DB&CI88M;,VG4Q)3W_#1G\K/_O7W\7O_0"F_P#KM[6_\$'[Y_\ A6-[
M_P"<_P#T+TU_4'ES_E$7_G'!_P!:N@?WOUWB4_F4_&2@&Z.WS%4?!WY95;5,
MG>W<LN6BDINX^@XT@I,W)OA\O0XZ99B9J6&9*>H=4>5':-"I:/FG_*S_ ):V
MR/AI\N-Z;/\ @M\;]M;NV?\ &7O3=&UMQXC9$M-EMO[CP/6NX\GA,WBZDY-S
M39'%9&FCGA< Z9$!Y^GL:>VOOK[S[I[C<@;;N/N?O$VWW&]644L;SU5XY+F-
M71AIRK*2I'H>BO>N2M@M-IW*YBM$\1+>5A^G",K&[#(C!&0,@@^A'1F>U=N3
M;"Z]S.]MI[^[NQ6YML;CZDK\+D6[^[JKTIIZKN[K3$5:S4&1WU5XZOI*W%9*
MHIIX*B*6&:"9T=65B/?RZ??<7K&7K8L]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W_ /_1^?\ ^_=>ZW^/?O?NO=4Y_P Y;MOXF;2Z(VULSO+LCXPX+O"GW70=
MP_%W8'R>J,SF>O-Q]D[ CK<.,UOS86U,'NS<6>ZUI<-NRNQ^1FDQDM#'-7Q*
M)8:HT\B>]^Z]U8%\5-S?%K>?2.U-V?#2HZ<JN@-P/E<CM2?HG&;8PW7[U\F2
MJ$W"L&)VG1X['8O.P9J.:/)T\L$-;!6I)'4HDRNH][]U[K60^778G36;_F-?
M.7:_RA['_FY]VXWK[/=#XOJ';'\MNO\ EBG3_P ?MJ[AZ1VUGLYU;V'B?CS5
M87;]!W+EMV/69^MJ:Z?(3U^'R>.TO \$])![W[KW5V_\IRIZ3JOCUO.3HC$_
M/+#[3'<.?3(T_P#,+?O%^Y)-P#:>RC53;9/?F0R6[O\ 1NV/-,*3[9QC_P"(
MK7:5$_G)][]U[JT+W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW12.K?\ LL#Y:_\
MAB?&#_W [?\ ?O?NO=&W]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW54WQE_[>U?S5?\ Q!W\M+_W1_+7W[W[KW5K/OWOW7NO>_>_=>Z][][]
MU[KWOWOW7NJF_P":I_Q>OY7G_C63XP_^\!WI[][]U[JV3W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW57G87_;Y+XL_P#C/#YD_P#O
M_P#X<^ST_P L+_MXU\%O_%L.A?\ WY6W?<7>]W_3G/='_I07W_:-)T?<K?\
M*R[#_P ]D7_'UZ&;^9%_V0W\D/\ PPO_ ).8?W]=JK_X%U7_ %$3?];&]_/H
MGPK]G67]O_N/!_I%_P  Z*36?\7NK_[6L_\ [EM[C^[=.]$(^ 7_ #+CY*?^
M-%/G=_[^67VWG_B[1_\ :KJ?_<VC]O?\1S_IQ_@/39_M%Z'6I_[*FV]_XJIV
M%_[_ $ZD]N'MGISHN/\ -0_[=W?*'_M7=(__  4G1/OWOW7NK'-W?\?7N?\
M\.'-?^[*I]M^._S=5_VM,I_[FS>W9OB3_2+_ (!U2/@>BR?'O_BS=S_^+8?)
MG_WX]5[</;75^@7WS_V\W^+W_BB?RZ_]_/\ '[V4OY]_]D'?-O\ \5'^1/\
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M,W\R+_LAOY(?^&%_\G,/[^NU5_\  NJ_ZB)O^MC>_GT3X5^SK+^W_P!QX/\
M2+_@'12:S_B]U?\ VM9__<MO<?W;IWHA'P"_YEQ\E/\ QHI\[O\ W\LOMO/_
M !=H_P#M5U/_ +FT?M[_ (CG_3C_  'IL_VB]#K4_P#94VWO_%5.PO\ W^G4
MGMP]L].=%Q_FH?\ ;N[Y0_\ :NZ1_P#@I.B??O?NO=6.;N_X^O<__APYK_W9
M5/MOQW^;JO\ M:93_P!S9O;LWQ)_I%_P#JD? ]%D^/?_ !9NY_\ Q;#Y,_\
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MG_C13YW?^_EE]MY_XNT?_:KJ?_<VC]O?\1S_ *<?X#TV?[1>AUJ?^RIMO?\
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MO>_>_=>Z][][]U[KWOWOW7NO>__6^?\ ^_=>ZV0OYI7R<_F?](;^V!MKXC=
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MK7HYWCA>:E>II6,;LB%D() ^GO/+9=UMM]V?:=[LU<6=Y;13QAQ1PDR+(H8
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MUF\S@:+)97+9.NJ%>HK<AD*^IDFFED9G>1R2;GV(?^@'H#_GP71G_HGNN?\
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MZ3#Y:7#Y7:O8E'E,2]?2)'4MB\E33%*BGU>&<!=:L40KI)>^]_7/;JQ'-?\
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M:E:U/39&NI,!62PP2,LDL=.[*I ]G0_EQ_$7Y7[2^?\ \+-S[J^,/R'VUMO
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MU]N6*P0JP_XR5L7D,$!!_P!;WG?]3?\ !F_WL^Z#@.EB_"OV=&FR/_%_KO\
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M+:G8.^M@4^8S&WZ/J^DP-9EZG8>XMMY#)_P>'/UOV\4TSPQO4,X36%9=@?\
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MPKS_ )I/_P =/3L']O#_ *<?X>K9/?S;>_?^9Z]U?^):['_][',^_J4]N?\
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MV?;(X#JZ_"OV=&DR/_%_KO\ M<5/_N:_OKW[K?1!?@%_S+CY*?\ C13YW?\
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M]U99[][]U[KWOWOW7NO>_>_=>Z][][]U[HI'5O\ V6!\M?\ PQ/C!_[@=O\
MOWOW7NC;^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[H@7\T+ [TKO@G\D
M]X]==X=R_'_?'2W4?97?&U=\='Y_;>WMS5NX.HNO=U[QPVU,_4;IVCO3&Y'8
M>X<GCXH\O1+2Q3U5.H6.HA/J]^]^Z]T*7PBV=N#97Q7Z5HMU]O=M=Y[CS^Q\
M+OO-=C=VY[ [DW]E,EO^BAWA6X^KR>V]K[/Q'\&P51F6H\9#'0QM3T$,43/(
MRF1O>_=>Z-7[][]U[KWOWOW7NO>_>_=>Z][][]U[JKO^7U_V41_-I_\ %_L9
M_P# <?%/W[W[KW5HGOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[JL?^:;_S+7XE_P#C3#^7;_\ !2]?^_>_=>ZL
MX]^]^Z]U[W[W[KW57.R_^WS_ ,B/_&:OQ-_^"7^7OOWOW7NK1O?O?NO=(+M'
ML"DZJZ]W;V+7[7W]O2CVAAZC,U&U.KMF9OL3L+.QTY0''[2V1MNGJ\[N7,2Z
M_P!NEI8WE< V'!]^]^Z]T 7PW^:G4WSGZYR';/2FW.Y,7U_39F7"XG</;/4&
M]^I:;>,E*9J?(Y'8Z;UQF,FW3A<5E:6HQ]55TRM%!D*:6!CK0^_>_=>Z-U[]
M[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>ZJ@^4G_ &]F_E.?^(H_F3?^\3\:O:]ZKP6,W1V?UQMG-0R5&&W%OW9^
M"RU/#.]--/C,ON''8^OABJ8_W*>26EJ'577U(3<<CV'><-PN]HY2YHW6P<+?
M6NW7,L9(# 21PNZ$J<$!E!(.#PZ--CM8;W>MGLKE2;>:ZB1@#0E7D56 (X5!
M.?+H]WR<W9N'8?QP[[WMM+)/AMU;2Z;[*W'MO,1T])5RXG.X?9V8K\3DX:7(
M4]7CZB;'UT$<J)/#+"[(!(CH2IVRZ_\ E%_ N"NK((NM=\".&JJ(HP>UMT,0
MD<SHH)(N2%'U]\:[?[Z7WBI+>"1^:MOU,BD_[K[?B0#UGA+[!>URRR*NSW6D
M,1_N5)Z]!_0_&W=KT=&\GRX^5$DC4U.[R-G.F-3N8D+.P7I%4NS<FP _P]Q/
M^&D/@=_S[;?'_HU=S_\ %/;W_!G_ 'B/^FIV_P#[E\'3?^L)[7_]&>Y_[*9.
MJVOY;/1NY-PU?\Q$0_)'Y![=_A7\T'Y28^9MO9+JFF;,U$>"ZH,F8RQKNI,B
M&R50" RTXIZ5%4>.%+L6';H+X8_'CXM[GRVY.E-K[@V_EMVX&HVWG9LSO#*[
MFAJ,13UM!EHH8*?(KHI9A74D;&1;DJNG@$WCWW']]/<SW=VFSVOGS=[:YLK*
MY6>$16T<!60J\9)9,L-#$4.*FOIT*.5?;KE+DB]N+SENREBN)XC&Y>5I 4!5
MJ -P.H#/Y='"?KS/==?-CXQT^1[C[7[1H\YTY\J&%%V76;&K8,15XO)?'PQ5
M^(?:.Q-G525<\.0DBD\\E1$8R-**UV)K?<.]#KIM_G$_]NM?GG_XK/V;_P"Z
M.;W[W[KW5BV)_P"+5C/^U?1?^XT?O4/_ )NW_9=O:?\ VH^N/_>!V_[[4_<L
M_P#$>>4/^>B]_P"TR;K /W]_Z>?O?_-*W_ZL1]%7^)G^=^3_ /XMQV]_[A;1
M]UG^\J^H9Z-Q[][]U[KWOWOW7NO>_>_=>Z][V%?Y2?\ +@^+OS$^/?879'=^
M-["K=T;;[AJ=E8N3:6]X]LX]<%%LW;6;1*BB? Y4SU@K\I,3+K6Z%5T\7/-+
M[YOWHO=OV0]R^6N5^0;K;(]HNMD6ZD%Q:F=_%-S/$2&$T=%T1KVT.:FN<90>
MR/M1R?SWRQNF[<PQ737<5\8E\*7PQH\*-Q4:&J:L<^E/3)**M^UNTODAW?L/
M#]Y;XZLVMU=L[I&JP>)V1MSJK(QU^0WY#V-7;BR.:J]^=?;QRD]5)_ J**!8
M*BGIX8H6_:9Y&<6C_P##&'\OG_G0]U_^C9@_^PWWB/\ \G!?O*?]''8?^Y<?
M^VGJ8_\ @<_;#_E&W#_LI'_6KJOS^99U/V+A<[_+.&7^2W;>ZVR7\U7XT4=$
MV4VWT91'!3_Z.>^Y6R^-&(ZAH5GR:1H8T6K^YH]+L7IY&T%.C_(O_E]$$?P/
MNQ;@C4O;--J6X_4NK9CKJ'XN"/\ #WX?W@WWDP0?WAL)_P"I<W_;5U[_ ('/
MVP_Y1]P_[*1_UJZLY;HGN!D91\Q^\4)4J'79GQQ+H2" ZZ^DF4LIY%P1_A[M
MAVGB*+;VU-K;<Q@F7%[;VU@=N8M:B7SU"XO XJDQ..6IJ-*?<5"T5&@>32NM
M[FPO;WAQO-[/N>\;ONEV5-W=74T\FD47Q)I&D?2,T74QH*F@Q4]37901VME9
MVD-?!AA2-:Y.E%"K4^9H!4^9ZY?"96C^'WQ@B>1II(>A^K(9*B0(LE3+#LW$
M12U4JQJD2S54B&1PBI&&8A55; /WLNZ4]%%^,O\ V]J_FJ_^(._EI?\ NC^6
MOLGGS\Z)WM\FOB3VET7US/@*;>N_:G9,&#FW3DY,-@4?![SPNXZW^(9.*DKG
MI0V/Q,HC(B?5*57B]Q-WW<?</8?:CWGY0]PN:([EMAVY;HRBWC$LQ$MK+ NB
M,L@;OD6O<*+4YI3H">YG+>X<W\D;SRYM31#<+DPA#(VE.R5)#J:AIVJ:8.:#
MH=_G'E<MA,=\8,K@ML9'>>6I/F%TZ:3;&)K\)B\CE?-C=Z4U2M+7[DR6'P<#
MT='-)4G[BIA5UA**2[*#K2_\, _.;_G?_'C_ -&CDO\ [#??53_DY!]WW_HW
M<S?]D"?]M/6)/_ R^XO_ "E;7_V4-_UJZ5N6[H[Z;%959/ASV1$AQ>1O)_I5
M^/[@$4<Y6ZKV7JLS  D7(!O8_3W[_A@'YS?\[_X\?^C1R7_V&^_?\G(/N^_]
M&[F;_L@3_MIZ]_P,ON+_ ,I6U_\ 90W_ %JZ(/\ RFNV>Z,3_+$^ >.P?Q6W
M]NO&4GQ-Z4IZ3<%%V1TCBZ+*P0;*QD-/74E%FNP:'+04];31I,JU$$,R"32Z
M!E/N^G^57\0>UOA3T5V+U9W#5[-K=S;B[:_OWCY=C9Z;<6)7"5>SL%@HDJ:V
M?&XIH:_[W#RDQ"-@(RIU7-ASK^^![U\G>_/N%RQS?R1#?1[5:[-](XNX1#)X
MJW,LI*H'DJFF5:-49J*8KUDI[,<B[U[?<N;KLV^R6[7<M[XR^"Y==!B1,DJM
M&JAQ3A3/1O/C9N;=>ZOE-\O,CO#KC-]89.+:?QBI8L!GL]M#<-94TBX/M*?^
M)QUNRL[N#%1TSU=1+ L;S+/>G+E%1T)LT]XH]2[T!G\U3_B]?RO/_&LGQA_]
MX#O3VY8?_B[XK_M8T/\ [DQ>TM]_N%>?\TG_ ..GIV#^WA_TX_P]6R>_FV]^
M_P#,]>ZO_$M=C_\ O8YGW]2GMS_T[WD/_I367_:-%UR>YF_Y6/F#_GNG_P"K
MK=%@^%'_ &2'\:O_ !"G7?\ [S./]A+[&?1)T9_W[W[KW7O?O?NO=>]^]^Z]
MU[W]6W^2)_VZ7^"W_B(LC_[\/>OO@W]YS_I_ONA_TL%_ZL0]96>WO_*K[=_I
M1_@ZH=VA_P ?7\C_ /Q;KY&_^]FGNT[W!/0VZ*OO?_MYS\9?_%"_EG_[_'X_
M^VS,_P#%JK/]:F_]S:;V];_V\?Y_X#TW+\(^W_(>A6^8'_9*_>G_ (:^W/\
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M^]]K*?\ %SR/_4=5_P#N1)[^=*T_W$M?^::_X!UU+F_MI?\ 3'_#T8B@_P"
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M^E'^#JAW:'_'U_(__P 6Z^1O_O9I[M.]P3T-NBK[W_[><_&7_P 4+^6?_O\
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M>O92_GW_ -D'?-O_ ,5'^1/_ +Z?=7L?^T__ $]3VS_\6#;_ /M+BZ).9/\
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M]_Z6I_ZL1=%&ZK_[+ ^7'_AD?&#_ -U?;7N]CWSUZR/Z*I_-2_XO_P#*W_\
M&LGQI_\ ?9]_>_>_=>ZMD]Q,?_P!I/\ J'B_Z$'M^Y_W(F_TQ_P]4C_LT^P=
M%C^%?_9(GQH_\0?UI_[R>+]R_;'5^BA?&7_M[5_-5_\ $'?RTO\ W1_+7W%J
MOK0_]K.D_P"A*CV]#_Q(_P":3?X1U1_]#_TX_P O1EOEU_P.^)__ (N'U/\
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M3W_O_NI_?Q^/?T-]8<=;!/OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>__0^?\
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MDM3;D^7AJ(15=0?'M:<R+YVC[_[!$@BOZ]!_V764!]/T]+<_CW[_ &5#*?\
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M/?O?NO=>]^]^Z]U[W[W[KW7O>X%_PGQ_[(_[@_\ %C:W_P!]MLKWQ,_O*?\
MI]G)/_BKK_VG776='W8/^5%WW_I:G_JQ%T4;JO\ [+ ^7'_AD?&#_P!U?;7N
M]CWSUZR/Z*I_-2_XO_\ *W_\:R?&G_WV??WOWOW7NK9/<3'_ / &D_ZAXO\
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M8_[V?;(X#JZ_"OV=&>S/_%XRO_:RKO\ W*E]]>_=;Z;?;>?^+M'_ -JNI_\
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MGQ@_]P.W_?O?NO=&W]^]^Z]U[W[W[KW7O?O?NO=5??!;_LKO^;Q_XN3U%_\
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MAQ.Y=O5DB*4^YH:JGJ!&S*K@,P*'_P!$?5O_ #P>"_V^3_\ KC[)OZJ<L_\
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M9C$::^;'8V;<51.M.'$3SA&<-H ]WQ?\-U_!G_O&G97_ )^=\_\ V5^^=_\
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M2["Q,3'_ / &D_ZAXO\ H0>W[G_<B;_3'_#U2/\ LT^P=%Q^%?\ V2)\:/\
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MWLI*DKMC;JDJ0RFW9>QA=6'#*?P?S[='_4W_  8_[V?;(X#JZ_"OV=&=S/\
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M^9^6O_B\/R&_]SMO>Y/MKJ_0 _*3_M[-_*<_\11_,F_]XGXU>XM=_P  ZO\
MZAYO^M;>WK?^WA_TP_P]4D_LW^P]',^97_9(_P G?_$!=N?^\)G?<D?0?ZP]
MM'B>K]#O4XR+-;:GPT]3D*.#+8.7&35F(R%5B<K2Q5] U+)4XS*T,L-=C,A
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M\]O[W*]L]7Z-AFO^+-EO^U97_P#N++[][]U[JN_^3M_VZJ_EY_\ BH71/_O
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M]/NKV/\ VG_Z>I[9_P#BP;?_ -I<71)S)_R0=W_YY9_^K,G0/?(3_F26^/\
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M8VO3R:?)!MC;L+Z6#+KCPM"C:6%PRW'!'U]^]^Z]T%G4O_'[?)?_ ,3?3_\
MOM-C^_>_=>ZNR_DI_P#;SOHK_P 19\C/_>6VM[][]U[K>K]^]^Z]U[W[W[KW
M7O?O?NO=>]BQT9_S-G9/_:SE_P#=?6>Q3R5_RM.S?\U3_P =;J9_N\?]/HY
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MZ][][]U[KWOWOW7NO>]P+_A/C_V1_P!P?^+&UO\ [[;97OB9_>4_]/LY)_\
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MX5^SHSV9_P"+QE?^UE7?^Y4OOKW[K?3;[;S_ ,7:/_M5U/\ [FT?M[_B.?\
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M^*C_ ")_]]/NKV/_ &G_ .GJ>V?_ (L&W_\ :7%T2<R?\D'=_P#GEG_ZLR=
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M #C'_0?6>/\ P5GL_P#[^W;_ +)$_P"VCIQ_V;[Y=?\ >JOY0?\ H]?@I_\
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MPHQO>OP;84>V-[U&'FPM+E#4?)V P9V,44OW5/&)H8?1HGEU'3F_X>1^$/\
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MOV&EIXGR'?6N.&-'T]2X8C4J@&Q_TBBXO[=F_N]_O)/-(ZVW+NDL3_R49?\
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M^ 9]]_X-D_[+'_[9NK?Z[>S_ /*(W[6_ZU]"7]_\X?\ O5U\A/\ TI;X/?\
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M]^Z]T&>Z?YAWQ"V+OGY9]?;X[<HMGYSX/=>]?]I?)FKW'@=S8S;_ %YLOM#
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M_=>Z+_\ &#M+Y'_+[J#Y-_*[:D>]C\D/Y<7\E#*?!O8T8AGKMQT_\QO+;3[
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MDOO?NO=7%=S="=&_(W9XZ]^0?3?5O>6PURM#G4V7V]L#:O8^U4S>,\HQV83
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/[W[W[KW7O?O?NO=>]__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g790774g80i17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g80i17.jpg
M_]C_X0W#17AI9@  34T *@    @ # $   ,    !!50   $!  ,    ! D8
M  $"  ,    $    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q  (
M   >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @ "  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#(T.C U.C$P(#$P.C$Q.C Y   $D   !P    0P,C(QH $  P    '__P
MH ( !     $   +5H , !     $   $U          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M!B8@<3'#E8QD)"1T<?ZY3D_5?J5&,UUUSZ2&5UM+G.,MT8QHW.7D7[%ZW/\
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M^&V?X/\ ?_P:WE\JI)*?_]G_[15<4&AO=&]S:&]P(#,N,  X0DE-! 0
M !H< 5H  QLE1QP"   "   < @4 !F<X,&DQ-SA"24T$)0      $"F9MGY6
MKA%>['(_C6VV0) X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              $U   "U0    8 9P X #  :0 Q #<    !
M                      $              M4   $U
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   $U     %)G:'1L;VYG
M   "U0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   !-0    !29VAT;&]N9P   M4    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     $X0DE-! P
M#%D    !    H    $0   '@  !_@   ##T &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( $0 H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M$3N;#AL_D^[W)^+(<<^("V:6,& A>U?\U\G'3^HQ7^IY.G/Z&S]W^HB8V!U
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M ]B9_$*__E=J_P#SIF_Z/]D6A/X!^SHZ^DM/^46/_>1_FZ"B'(Y#_AQS*/\
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MVQ?]HL'65'MS_P JO8_9U1!M/_C\OD[_ .+B]_?^Y&U/=K7N!.AUT7CY!?\
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M5WW;_P#PLVP_]E"_YNK_ .M#[F_],3N'_.,]5^0_)[I\?S;,GO$U^^_X _\
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M;DV]5U-*RRBGK*>&<1NI*BX]^]^Z]T(_OWOW7NJ[OYFO_,B.J/\ Q=OX&?\
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M7RT_^!!WE[][]U[HW_\ NJJ_Z@,C_P"X-1[][]U[HMGPT_[)!^+W_B"^OO\
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MO[I/)Y/(_%#Y%4./QV/[5V+65U=6U?4&\*>EI*2DI\])/4U-3/(J1QHI9W8
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M^(1WQ_[@+[][]U[HRR?YJ#_J'I_^M$?OWOW7NN7NGC^?[_VY]^:?_AN]3_\
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M(_\ N#4>_>_=>Z+9\-/^R0?B]_X@OK[_ -TT7OWOW7NC)>_>_=>Z+/\ -/\
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M+_)BLQ6<P.2HLQA\G2/W1O!%J:#)XZ>IHJR!G0C7&[+<$7N/9MO<,=#WHO\
M\I?^WCG\J[_@_P W_P#WPV"]S,=_P/H_^HF'_H<>V+K_ ''G_P!*?\'3D/\
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M )1[LW_W#QOO#/[]O_3BO^IW8_\ 'GZGG[N?_3Q1_P!*^X_P+T6CO;_F9OQ
M_P#%@]P?_ T_(+WM;^^._6=/1E_?O?NO=5G?R<_^W:GQ5_\ #2W7_P"_+WM[
MH>_GI4M55;/^-"4M-45+#<7:-UIX)9B"<=LM@#XU:S%8V('U(4G\'WT/_N^)
MHH=[]U6EE51]+8<2!^.Z]?M'[1UB]]YQ'DV_DQ8T+'QKG@"?PP^G0R[SW=M/
M9OS5V77;OW1MW:M%6?%OL2FHZO<F;QF#IJNHB[:ZPDE@IILI54L<\T4;JS*A
M)4,"?J/>NG_!,S_SJ,G_ .<%5_UZ]].OK['_ )38O][7_/UB+]+<_P#*._\
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M5]#D8(:NGD9&>GGAF"L=+B_OWOW7NAR3^9U_,:2&F1/FCVTJK24:JJ[8Z0
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M;_V2Q\:/_%?^FO\ WW6W/:+]GW1;T8#W[W[KW7O?O?NO=>]^]^Z]U[WLR?\
M"<C_ (N_S$_\-GI?_P!Z#?/OE-_>@?[A>R'_ #U[I_U9M.LN/NJ?[D<^?\T;
M3_C\W16LA_V6QM'_ ,5:[%_]^SU;[V=O?)OK+_HTOOWOW7NO>_>_=>ZKX^/O
M_;P'^8G_ .&U\+__ 'WO9?OWOW7NHO\ ,U_YD1U1_P"+M_ S_P""[Z?]^]^Z
M]U8C[BTGZ:G_ *CZ_P#]R7]O3<8O^::?\='3<7!_],?\/1#_ (%_\6;Y7?\
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MK_[UF.]N/MGISH:/?O?NO==_[JJO^H#(_P#N#4>_>_=>Z+9\-/\ LD'XO?\
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M[_A1?_V4G\5/_%?^[?\ WYW37OWOW7NM9GOO_F1?<7_B.=S?^X1]^]^Z]T+
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M0U>-W7FZALE4BM\D2&$(T<,I+ J 37^Y1ZS/ZL6]^]^Z]U6]_*!_[=E_"_\
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M07>1F=CRQ)-_<6D_S<G_ %$U?_N3+[>F^)?](O\ QT=4CX-_IC_AZ)3\$O\
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M@/N/_P!]WN+V.?:[_IZ/MC_XL>V?]IL/1!S7_P JIS5_TK+K_JQ)T5CYN_\
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MH[>_\6$[7_\ <C">_>_=>Z>-X_\ '[=)_P#AY;P_]]KN3W[W[KW0DP_YQ?\
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M_P 5Y[I_]]MN7W[W[KW7S=MI_P#'I;2_\-3;7_NCH/?O?NO=(7:?_,YN^?\
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M'T?_ %$P_P#0X]L77^X\_P#I3_@Z<A_M8_\ 3#I@W7_QZVY/^U!F/_==4^]
M?LG_ )F)O[_P]-T_^[RN]_1[RM_RK'+G_/!;_P#5I.N5>\?\E?=?^>F7_C[=
M ]\3?^R6/C1_XK_TU_[[K;GM%^S[HMZ,![][]U[KWOWOW7NO>_>_=>Z][V9/
M^$Y'_%W^8G_AL]+_ /O0;Y]\IO[T#_<+V0_YZ]T_ZLVG67'W5/\ <CGS_FC:
M?\?FZ*UD/^RV-H_^*M=B_P#OV>K?>SM[Y-]9?]&E]^]^Z]U[W[W[KW5?'Q]_
M[> _S$__  VOA?\ ^^][+]^]^Z]U8/[][]U[KWN+2?IJ?^H^O_\ <E_;TW&+
M_FFG_'1TW%P?_3'_  ]$/^!?_%F^5W_B^'RL_P#>\7W*]L].='P]^]^Z]UT?
MH?\ 6/\ O7N+0?\  *D_ZAX?^M:^WKC^WF_TQ_P]-Q?V4?V#HM7PS_[)+^-O
M_B$^M_\ WE<9[E>V>G.C+>P:^2'_ &3?\B__ ! ?<?\ [[O<7L<^UW_3T?;'
M_P 6/;/^TV'H@YK_ .54YJ_Z5EU_U8DZ*Q\W?^R3.^O_ !'V4_ZV4_OYQ7OZ
MA.N4_1I_?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_1#_X2<?]NY.WO_%N=W?^
M^LZN]\@OO\?]/BY?_P#%?A_[2;KK(?VC_P"2)/\ \]$O_'8.J9^V_P#LLGY.
M?^&7\8__ '2=L>]GCWA%U+?3?[][]U[KWMNQWTK_ /M;Y'_K:/;TW^A?\TU_
MP=-Q<#T"_2/^9[[_ /%P/DK_ .]9CO;C[9Z<Z&CW[W[KW7?^ZJK_ *@,C_[@
MU'OWOW7NBV?#3_LD'XO?^(+Z^_\ =-%[][]U[HR7OWOW7NBS_-/_ +(]^4'_
M (A'?'_N OOWOW7NC+)_FH/^H>G_ .M$?OWOW7NN7NGC^?[_ -N??FG_ .&[
MU/\ ^_\ .J_>1/W3?_$AO;;_ )K77_:#== ?W&_Y5+=?]*O_ %<CZ2N=_P"/
MV^-O_BV71O\ [E;C]_++]]T>L5>KTO?O?NO=>]^]^Z]U[W__U/G_ /OW7NM_
MCW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]T5#XE_\6GOO_P 6
MO^0?_O;3>_>_=>Z-?[][]U[HO/RZ_P"R4/D]_P"*\]T_^^VW+[][]U[KYNVT
MO^/2VC?Z?W4VS>W_ &HZ#W[W[KW2'VMM[?F.[3[.W1FZ?9*;2WI2[2I\.</E
MMP5.Z*8[)QU7B<:V5H:[#4F'C7+4N0DEJ?#4RF"6-%CUJS,/>_=>ZR=S_P#'
MA'_P]^K/_?E;6]^]^Z]T+-6=,]6UF;3)4/H47=RC.PCC!(#226LH) +$<CZ^
M_>_=>Z!'I:3.-#V:V<V1O;9+9?MS>>\,3%O3%8[&2Y/!;IDHI<=-1KCLSF%:
MHIA0,*J-RAA9T +ZB1[W[KW2DWC_ ,?MTG_X>6\/_?:[D]^]^Z]T),/^<7_6
M?_H1O?O?NO= Y\?/^9#=/?\ AAXO_K?6>_>_=>Z5O_-4A_XAZ7_WX]-[][]U
M[I,=]_\ ,B^XO_$<[F_]PC[][]U[H6!_FX/^H6D_]QHO?O?NO=;9'_"<?_LG
MWY1?^+-0?^^0ZE]^]^Z]UL4>_>_=>Z][][]U[KWOWOW7NO>Q.Z8_YFGL?_M>
MT_\ T)+[$G*'_*S;+_S7'^7J7/8;_I\/M[_TL4_P-T63Y>_\R3D_\2S\<?\
MX(OJKW9I[R/ZZU]&;]^]^Z]U[WP;]<7_  9_^M;>]'XE_P!7ETV_QP_:?^.G
MHK/=W_,^/AC_ .)6[2_^!P[=]\_>^G.C3>_>_=>Z][][]U[HA,G_ &]!I/\
MQ0G(?_!"XSW[W[KW1EN\OC_TK\F-@5?57?\ UIM/MOK?(9/$YC(;)WOC(\SM
MROR."JUKL345V,G/V]9]E5H)%20-&6'*GW[W[KW2NZ\Z]V5U/L?:W6O7&V\9
ML_8>R<-1[=VGM;#1-!BL#@\=&(:'&8^%GD:*DI8@%1;FP%O?O?NO=$R^,O\
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MWE[E>V>K]'?]S,=_P/H_^HF'_H<>V+K_ ''G_P!*?\'3D/\ :Q_Z8=,&Z_\
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MIHO?O?NO=&2]^]^Z]T6?YI_]D>_*#_Q".^/_ ' 7W[W[KW1ED_S4'_4/3_\
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M+BGST(="*2H]^]^Z]T9[XM]-_(K?GR?^:_S+[2Z_SWQ-K^^>J?CI\>NE^O\
M/Y[K#L7M#;.WNAZ?MG<F;[4WK%LK-]A]605FX-^=U5=+A\7%E,C_ +C<*E36
M+&]8*>+WOW7NA]V%\5.X^N:'<-%@/F5V;)_>K>V[>P<Y49'JKH.HFJ-R;TRT
MN8S+4ZQ==T\-+CTJ)--/"%)CC%F=SS[][]U[I<_Z%OD'_P!YD[^_]%#T+_\
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M V1-N>'>$E#_  3_ $!?PXY YZG5_N]/D$/[=K<^_?[,[V5_QRVO_P">,?\
MU5[]_KD\Q_PVW_./_H;KW_!<^Z_^^=H_[)/^NG0A_P"RS?*?_O8_WS_Z([X;
M_P#W/GOW^S.]E?\ '+:__GC'_P!5>_?ZY/,?\-M_SC_Z&Z]_P7/NO_OG:/\
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MVW_LG_Z'Z6O^RS?*?_O8_P!\_P#HCOAO_P#<^>_?\/7?,O\ Y4NDO_19+_\
M7SW[_@#/8S_E(W__ ++O^N77O^"0]Q/]][;_ -D__0_7O]EF^4__ 'L?[Y_]
M$=\-_P#[GSWU_P /7?,O_E1Z2_\ 19+_ /7SW[_@#/8W_E(W_P#[+O\ KEUO
M_@D/<3_?>V_]DW_0_2'V_P#!_OC:^\NP=_X3^8?\@:;=/:,^UZG>M=+T_P#$
M2JILA-LW IMK -18^?H)Z7%B##QJDHA4":0:S8\>^_\ AZ[YE_\ *ETE_P"B
MR7_Z^>_?\ 9[&?\ *1O_ /V7?]<NM?\ !(>XG^^]M_[)_P#H?I<?[+-\I_\
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M#;[5=,]*;_0M\@_^\R=_?^BAZ%_^P'W[W[KW7O\ 0M\@_P#O,G?W_HH>A?\
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MI_\ 9#[]_P FXON\?\I/,G_<Q_ZX]>_X)CW(_P!];9_V3?\ 0_7O]EF^4_\
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M?N%N6WW^VW$>W?3W$+Q/IMZ-ID4HU#KP:$T/25WO\+^_^R-IYW8N]?YA_?\
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M)'+$_P#QC/XF<QS1M%( ?] '!*.1?\>_?]!67\T;_G6?%C_T1]5_Q.]??O\
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M^Z]U71\N?^&Q/XCVS_LZ/^RT?Q3_ $:?'W_3'_IC_N]][_HK_P!.&Y_]EO\
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M^^']W/\ 1[_>[_2'+_LQ/^C/Q_M???Z2M7]X?M_3_$/\[ZK>_>_=>Z-GU?\
M\-/?=S_Z(?\ 9._%_LC$%O[D_P"C[^['_#>G][=X>?\ A?\ #/\ ?K?[+A_?
MC^-?Q+[7_<3_ !/S?>?O>_>_=>Z(AVO_ - V/]X_C_\ Z8_]D3_O1_HDZ(_V
M7C^]_P!G_%?]#7V<G^R[_P!U/NOWO[I_PK5_=WR^C['_ #/['OWOW7NC7;)_
MX9P_X<,[*_N1_LL/_#D7BWW_ *6/LO#_ *</X=_<G#?W[_OG]QS_  #^X_V?
MF^Z_R+[?_-^K7[][]U[KK^6Q_P ,U?QKY ?\-=?[*K_>+^*4W^G3_9=OX?\
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M] ZWA^*G^S:_\-^_8?[+SU;_ +*7_I<_N;_"/]E?U5?^BG^Y'\9_W&?Z'_\
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B[][]U[H5O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g790774g80w10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g80w10.jpg
M_]C_X0Z017AI9@  34T *@    @ # $   ,    !/EH   $!  ,    !%=0
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,CHS-SHS-      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,,H , !     $   $6          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MK-TA^)ZO5BYSALR7_:&VO!8T!K3O#-K&55O9[D^"WI#>H4CI8H#!1<UWH;>
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M24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M 0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $6   ##     8 9P X
M #  =P Q #     !                          $              PP
M  $6                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $6     %)G:'1L;VYG   ##     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M!     4X0DE-! P     #28    !    H    #D   '@  !JX   #0H &  !
M_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)
M"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,
M# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #D H ,!(@ "
M$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!
M  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS
M 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1
M R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54E!EU-F\5V-?Z;BRS
M:0=KARQ\?1<J&)ATX.;3CXIL%+J;G%CGO>R0^G; >YS&N_26?124Z2K]0?FU
MX=K\"MMV4!^BK>=K29'TG2W\U%]1NW=K!.W@\SLXC]Y/O;N+.[0"=.QGO_92
M4Y7V[ZQ[W1TRHM@;6G( U!A\V>F_\US=GZ/_  5G[ZBS.^LCKFL=TVNM@VFQ
MWK!PAQAWIF&;WTM:]W\M:XLK(:0X$/\ H&1KIN]O[WM2-C 'N)TK^G&I&F[@
M?R4E,DE'<V0V0'.$@'D@<Z?--ZM>TN+@&@[23H)G9&O\M)3-))"MRJ*;::K'
M0_(<6U""9(&\B6C:WVM_.24E25#J&.QMC,UKK&W"RBKVV/#2PW,#FNI#O1=N
M;:_=[/\ OBOI*4LG[7]8QM8<"DDD;K1=[0"1N_1$;W>E7_PGO>M9,2 "28 U
M)*2G)LS/K&UQ#.G5/&Z&N]<#V@NW6.EOMW,V;*_>M'$LR;,:M^54,>]PE]+7
M;PT_N^I#=ZD[(H;=70YX%MH<ZMDZN#-OJ%O]7>Q$24UNI6^ET_)MVW/V5/=M
MQANO, ^W&9^=?_HOY:IYCO4JQ;-V?4'5.<?1;[N&.VY5>Q[VW_N>S_2K1R*3
M?192+'TFQI:+:R ]LB-]9<'MWM_JJME=-=D-J S,FGT@034]K2^=ONM_1NW.
M;L_Z:2FIB]0KQVO.WJ&4'N$FVAYVG^;.V*J_W=]G^K%L*B>F/-IM^V9()F&[
MV[!N&V-FS\WZ;4S.EV-+#]ORG;"TD.<R';?S7Q4W^UZ>Q)3_ /_0]"Z2T^IU
M,/:YK7YCR)!$M].EFYO\G<URJ5].HQNJXMG2@P8S<>]KJ&$;''U<9S_3L!W,
MM9^9_@?\%^C_ )RLW2'XGJ]6+G.&S)?]H;:\%C0&M.\,VL956]GN3X+>D-ZA
M2.EB@,%%S7>AMX#\<-#O3_M[$E*P6X&9@[*2:VUY)<ZMSK:W->V]UGZ1ECF7
M?I'_ )COT-G^#]2A7AAL&39>'/#K&,9]-_YAL/T'.]/_  O[B#G=)HR:ZVM!
M997:VQMK7N:\18+W_I6G>]N[_ 6?H/Y"&RWJ>/F7^LW[5BLJK-;J@19N_3>H
M7U.VT6[MM?\ 1K-__=='R1?=,S"N;5AL^T6DXY'J$N:XOBM]7Z5[J_TGN=O_
M ,&GLZ>'UY;'66'[5,?I7C;-;:?T>S;Z'T=WZ/\ XQ0Z7U;'ZA@XN4)8_*8P
M^DYI#VN<SUO3M9[_ $O:UWTU=#V$N <"6&'@'@QN]W[OM<@E [%?]IJL;;8V
MMC'M<P.!:2[T]I?O:ZUSF^G_ *1#. \8[JF6VM<ZXV[A:28-HOV!]C7[6;?T
M?I?Z/]$KJ9SFM$N(:/$Z<I*76=U)KG]0Z7 D,O>]VH&@IN9P?I>ZQ:*R^K-J
M?G]*;97ZGZPXAQ)]A;798Q\,<W_",9]-OII*2=2INW,N%[A5ZN,WT &P2+VR
M_<1N]V]GT?\ 1*WZ+_5?9ZSP'-#17[=K2-WO;[-^]^_W>_\ ,53J7VN61Z?V
M;U<;F=^[UV[_ .1M_F=O_7%H)*:PIRV-H:S(W^F1ZS[6 NL :YO^"]%E;_4V
M/^@H65YAKRQZC1N!]$BLNC]&T?1-CO5_2?F^Q7$DE(FTLV0[W.=&YQT)(_._
MD?\ ?%G=5^V4],MWBS-N=:T448Q;38YIL:YC6V6^SU*JFNLM^AZC&/5G*SC3
MU'%Q RVPWUW/BM@<P>GZ7\]<XM]#^<_1?Z59U-.3U?[55E5OQ6UY%E8(L%CA
M6RQEU9:X#8Q^7L8Y]7O^RX[&5?3?ZB2BWW]4]-^WTS8US1Z5HT#["XU-Q=OT
MF7[F_I?]%[WV^EL3]%HRL?IE-.60<AN[U"  )+W.T#8_-06=)(Z_^U'.<\#%
M]$2=-Y>7FSTVEM?J>E^B]7T?4]+]'ZJU$E*22224_P#_T?0>C@.LZHU[26',
M>"QVNAKIGV^[V/\ I_VU'!R^F96;CNZ:ZMU0HOTK&V)LQ_S(:YNYP<KU.+BX
M3;WTLVBY[K[H)<7/<!O=[B[]SZ#5GU]6PK\W&NJ%OIFF\ >C;.EF,WZ(K24[
M"2H_MG V;]UFS=Z>[T;8W[O0].?3^GZWZ'9_I?8I#JN&7FL>J7M <YGHW2 [
M<&.+?2_/]-^U)3#+Z-A9-F'86-:[!=NI>-P>T;'TAM=E;ZW-_G/S_5_J*GD]
M*Z@S$ZO]GR[G69@<[&;86VAA]%E36U,L9M:WU6?S:NMZS@.;6]KK"V^/1<*;
M8?+3:/3_ $?O_1,=9[?S$CUG :VQSG6!M,^J33;#(:+3ZGZ/V?HG-L]WYB-H
MKZ('4]0'4L)QM<65T7-M&RHASCZ&QSG_ **ZKZ+_ &4,]/\ TBK?8^L6=-NJ
M-WI7'-=8Q]=;6GTAE"T?HWMM:_=0'?I5I'JV&'BL^J'N!<UGHVR0W;O<UOI?
M1;O8H_MGI^POW6; [87>C;&_=Z/I[O3^GZOZ+;_I$K\%4>[>6=U+_E'I9V[O
MT]@',M)IN_2>T_N^SW_Z17ZWML8U[9 <)&X%I^;'AKVIGT4OL9:^MKK*I])Y
M +F[AM?L=])F]OTD$M/J5M@VU>BXU^MBGU@6[9-PW ASFN]GI5_1_P!/7_PB
MMB^@VOI%C3;6T/LKW#<UKMVQ[V?2:U^Q^U4>JYV/66XSM_J"S&L]M;W#:<BM
M@]U;7MW;F?15=S\.WJ618YC2+::FN'V2QUYUO_GGNJ_F'-_H^]G_ '(24Z3^
MH8+#CAU[!]L=LQ?<"+"6NN_1D?2_1L<Y+.S*L'$MRK9+:F.>&-$N=M:7^G6Q
MON?8[;]!JPL?&Z55A=*HKL>:\79Z'ZO+7Q1;7^C_ %/]-O8Y]OZ/TO9^E35X
M_36NZN[(.RC+,9!JJO!#/L]5;VY&]GZK[1ZGI4O9^B].W?\ I/31KQ1?@Z&-
M7EYF17E^H:J'L=ZS1.YV_P!,TU5/_P '5CL:_P!1_P#.?:++?2]%:&+B8^(Q
M[*&!C;+'6O  $O>=]CW;0-SGN_/=[U79U/!K].D>HT[?T;!1:):S;NV-]+Z+
M-S$CUGIX8ZPNL#&.+'.]&V X'86.=Z?TM_L02WDE3_:V'ZGI?I?4C=L]&W=M
MG;NV^E]'<BXN;CYC"_'+G,'YQ8YH/;V^HUF_Z/YJ2DZ2222G_]+U5!--ARFW
MBYPK:QS#1IL)):YMITW[V;=J,DDIKG'N-(K]=P=ZOJ>I G;ZGK^A_4]/]6_X
MI3%3QD/M-CBQ[&L;5IM:6FQSK&_RK/4:W_K2*DDIPZ^M8+:<=KLK)-F(SU;B
M^A[7VM;66/\ 6BEE.[=:R]WI?X1$Q^J8699?BTYEQMRR[T1Z3F&F*PUPK>ZI
MC?:YGK?I-_Z2Q;"22D+J+#DU7"Y[:ZV/8ZG3:\N->RQYC?OJ]-VS;_I4"[ R
M;,5]%>;=6]]CK!< PN:UQ<[T&>S;Z=>[8S_"?RU=224I))))2')ILN8UM=SJ
M"U['ES "2UK@]]1WAWLM:-CE(,>+GV;R6.:UK:X$-+2\N?\ O?I-[/\ MI$2
M24UF8US:L5AR'N=CQZKR!-T,=4?4_=WO=ZWM5',ZEC8UF9C7Y5]3[H%3A2YP
MJW5LK_5WTU.W?I/TOZ;_  SUKI)*<6SK_3F9+2[+M8,<6,MI]%T6.!:WU-_I
M>WTG,?MV/_PBT+<2]^-957E65V66;VW -+F#>+/28'M+?3V-])6DDE(30\Y)
MO%SPPU^GZ&FR9W>M]'U/4_,_G-BCA8]V-CBJ_(?E6 DFZP-#C)F(K#6^U6$D
ME*22224__]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4 9$     !_]L
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$'87?\
MTMU/F<+M[L?LO:6SLYN$I_",9F\I%35=4DDH@2=X@'-)2O,=(FF\<1:XU<'W
M8*S5H*]:) XGH6XI8JB**>"6.:":-)89HG62*6*10\<L4B%DDCD1@58$@@W'
MNO6^LGOW7NBJYSYK?&K;6!^2&Y-P=DT>(Q7Q)SM%MOOZ6NQF8AGV'E<IB<-F
M\/%449H#59*#-8S<%'+1RTB3Q5'G 1B00/=;H<="G7=W=846*S60&[</69'
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M5V])4=R]?=>;GZLVKN89*NCBQ^RMX9*DR^?Q;8I)UQU0]974,3B5XVD0+92
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M- '^'/O54_AZ]GUZUG_E%\9_F?7_ #;S=!D]O;[WOVMO7?&*S_6/:6W9):'
MU6 P\^-:AS>"R'WOCV=A-C4Y45]#<>'20!)Y02J1HQ'Q[>J$-J'KULWXG;_R
M\QF,Q<%3V%T?GJVFQU'!72Y+8N\:5JNLAIXXZB=JB@W:I9JB52Q/C3DWL/I[
M3=E>!ZN:^77.>H^8D!/BH_CUD #QH3?] 6'_ $]RU7H)'^O[UV?/KV>M9[^8
M%VI\R,?\Q<E'NW.=B;1WGM.KP,O0N#ZS_O'+M<0U]-2QT^0V'#3PR0[BR&>K
MB8,J)M<H4O%*%B4>U4:QZ!P^?39+:N/6Q[LS=OS+J-H;0J=P]6=4'.U&U\-4
M;@%1OK+4%4N;EH(7KDEI(L%/#2R^<_N1JS+')J520![3$)4Y-.G,^G2JCW7\
MK $\O475;DWU^+L_)II_H%U[5>Y/O5$_B/7L]:[?\TWY _*_#?)'$8/<^>W+
MTWB-F;<PF[NIL5L/)5^0P=1N-@ZU&[J/<%-BJ!MS;FI*]_M?L6C9H(FT*C!R
MQ4Q(A6HR>FY"13TZN]Z!^2G=\O3/6^8[Q^/';3[GJMC83([AW)M7%X'*QY6L
MFI%;^)3[<&5QF4P]3D8-$\M-XV:%Y"MA:P895J=#"G3E<<.A@H/EUT_)'+)N
M$[YV)X1>0;TZ]W9BD4W *&II<9D*,,/\9 ./K[UH/EUZHZKZ^>?\R;HS9$77
MFQ]FTV5[=S;;FVAV?EVVA-3T^.P. VAN*DR8H:^LR$8==PYL4[)34GC5K>MR
MHX]N1Q,:DX'#JK,!3JRGI[Y+=.]V=;[/[.VEO/!TV%WCB(<I28W.9;%XK/8R
M0L\-7B\QBYZT5%#DL?5PO%+&P_4EP2I!+3*5)!ZL#7AT+5/NS:U7;[7<NWZF
M_P!/M\SCIK_ZWCJ6O[U0^G6^J^_YD?R=Z@Z8Z?H]H;QST\F[.Q\ABJC:.V\%
M1G+Y3(X_;>;QF6S.6>**1(J7%T=-3E?-(X#S,J)J)-G(D+-4<!U5B ,]&TZJ
M^1/3';W6>UNU-D[_ -OU.S-TT)GQM=E,C1X6JBEIG>FKL?DJ'(SP3X_)XZJA
M>*>%Q='7@E2&-"K E2,]6J.GG+=[]*X.(S93MCKRE0?C^]^"GE_V$%-6S3'_
M ))]ZTMZ'KU>JKOYC_\ ,4V1LSK*BZQZ:&![.W)VQ3Y?&Y;+-5UT.!V9MJA2
MG%7E)BD-.V5R594U"14T,4EETN[\  NQQ$FIP!U1FIT,WQ%_F/[0[KZ6H=R;
MRV7NG;^^]O92IVCN?;>RMM[@WEB6K,9%']ME,1DZ*DEB2@R5(R.(9Y?N(')5
M[\$U>,JU*XZV&J/GT9B'Y9[8K'$>,ZH[^RC,; TO6%7$I/\ P:OR5$!?WK1_
M2'6Z]5Z_S//FEW%U[T=@L=UOU_OWJ>A[*W+/LG='8O8NV,/314&#K\55>3"8
M6(93,4U)F]RH7BBFJDC\:(WC)D(LY%&K-DUZJY(&!TP?RQ?G5O3/=,9_;O=.
M(WEO/$=<[DH]H[-[*V9L:?,8^;"1XZ(G;NY9<$+29W;3H(WFC@<R1L#(VL6.
MY8QJ&GB>O*V,]6G8_P"5GQ[R%?#BF[/P6)R<V@"AW+#E-JU".]OVYO[QX_%Q
MQ.I-C=N#[9T-Z=6J.H/>_P CND.K^F-[]A;O[)VM3[5I</78O[[&96DSDE7E
M<M1ST>,Q5!2XB6LGK,A75,@6.-!?ZDD*"1Y58D #/7B0!4G'0.? /Y%].=L?
M&_:XV=O/'2U77-%#MG?.,RK#"Y':^9:6HJ8*;*4]>T2QQU=/('AE1GBE'Z6N
M"!:165LCCUX$4Z,]G>^.EMM0-49OM78%$BDJ5_O5AZF?4!<@4M)5SU)(_P $
M]TH?3K=1Z]$J^7_\P_8?3W0.Z]]],UV*[(WQ]WC-N;>I:K';CI]JX_(YV<TJ
M9C<&7;'4=$,=CX]3B):A)*B32B7N?=TC+,%.!U5FH*]$W_E@_P PO+YN@W=T
MEW=CJ=(MB4 W/M3>NT=N9VN:HQ^X<W75F5Q&Z,+B*7*2T-1392N>2DJ0L<<L
M&I""R7]N2QTHPZTK5KU;*_RZ^.44@BJ>T,502$VTY/%[CQA!_HW\0PU,$/\
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M ?L'LFCZ]P\TD,K[3ZCAD7)M3FG99:2NWWF8?OHY?(]G^UI@A(]+6L?;%5'
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M&PU-CZ+M>C$/B"SB2B9-E]L01T"/42+2S4>XBS 246KCVU-L,LB/<;)<B^M
M*E0--P@_IP\6I_%'5?/I^WYPMH98;'FNQ.T;DQHKNVNRE;_A5SP0GB$FTMFG
M15OF#_/+_ED8OMG9NVLAN'=>1W%T9O#:W</;TT/2.XJUL;L6GP5<*ZEJ:FIQ
M"55;G<9)7Q0U&-($T3@@CT@^U.P7UQ';;]$EQ(%6R<@!B-)U+7%10UXG'2/G
M+9+6:^Y/N);"!FEW6(%BBMK'AN1W4.L4X $_9PZOT^,O>O5WR:Z#ZL[\Z5-:
M>J>U-JTFZ]C'(X&;;%:<%633Q0-4X"HCBFQ<AD@<^)E!'U_/L..[R,7D8LYX
MDFI/VD]#:*&*WC6&"-4B44"J  !\@,#H=?=>K] !V%\K/C7U-NF;9'9W>?5^
MPMW4^/I<M-MS=F\<-@\O'C:T.U'6-1U]5#+X:L1MXC;UV.F_OW6Z'C3H2NON
MQ]A=L;5H-\=:;OP&^=GY5ZJ/&[EVQDJ;+8>MDHJF2DK$IJZD>2"5J:JA:-P#
MZ74@\CW[K5*<>EK[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HK7S)^1_77Q7Z%W)VIV7M;*[^
MQ#Y;:^R,#UU@\;C\KF.Q=\;]S]!M?9>R,=2YB2'"I/N#<&1AB,];)%24Z:I9
M75$/OW6P*G'11/B5_,0Z:[(W5T/TW1?'?<OQT[%[]I_D-40=>O0[&DI=G[B^
M->=I\%O_  6ZZ_8U2V*?(RBJ2:DJ(%EIIEN@DU"WO76RIH:GAU;![WU7KWOW
M7NB\?)_>WR)V'U76YGXN=)[>[Z[=ERV(QV(V5NWL7%]7[8I\?6503*[ASFZ,
MG#5.M%AJ0&0T]+#+53M98U)O[]UL4)R:#H!_Y>/SHHOG%\=\CV_N#8K=.[MV
M-VIV/T9VCM.LW%C-Q[9QG9?5&XYMK;J;96^Z%H\/O39U7DH"U!D:<A9E)4@.
MC#WX=>(IPX=$[^:>2QN1_F\_R>6Q^1Q]<(Z?YE"04592U31_\8FQ%C(L$KO&
MK'@$@ G@<^_=>'5X?OW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!CO;K#<'
M;6Q_[L;;[=[%Z5KX<K0Y=MX=856+H]RR4^.\LDN',V7Q^2I?X=D"P$P\>M@H
M 8>_=;!IY=$@_EF[-[CS/56W^^>V_E'W%W5EMY0=C;:J-H[T.VJ?9N+?:O;.
MZ-KXK.8G&X;$4E33Y?\ @VV(HY6:=TD:61M()%O=6<C@%IU:-[]U3KWOW7NJ
M/^K?D=_LL/0'S W?B<#+O+M+>OSZ[JZNZ&ZX@+"K[&[HWE7XJCV9MJZZ7IL-
M33I)D<Q5<+0X:BJJ@W\=C[UZL1D>E.K!?A;\9YOC1U&V,W9G/[[]W=E9VN[1
M^0W9LZK]YV#V]NE8I]QY)6"J:? 8<*F.Q%(MHJ/&TL4:  &_NM$UZ!OY<]K]
MD=G;MKOAK\9WRDG855M:FWEW_OG;N5H\+DNI^H:V9HX=L[8W%D&3#XKNGM](
M):#;XJG1,=2FHR<MD@0D[VVW@MXUW._IX.K3&I%0[^I R43BU.)HHX]!7>KR
MZNYGV+:JFY*:IG4@&.,_A4G EDX)7X15SPZ!WX6_'3>?Q][1[OAIO@;U]U3U
MQW]OK;];7YK ]A];YRHV_L;;G7N&VY3XS>.)AK*VOW+5U>?QE35RI2>6*6?(
M2327<L?:K=+R&\M[0_O=Y)X4."K"K%B:J< 8(&?3I'L>W76WW=\#R^D5K<.N
M1(C:45 H#"I+9!-!Z]&]WS\"OBWO?(U^X(>M:?K_ '?D/MC)O/J;*93K/<<4
ME(RM#,DVTZK'8^652HN9J:75]3<\^RV+>-PB54,^N,?A<!A_.I_GT<7'+>SW
M#-(+3PIS^.,F-O\ C-!^T'H/LE\=OEEUG0Y^LZ1^5&0[*HS$LV*ZL^36VL7O
M#&9&"EIY-6W9.S,(F+W+C:?*@"!IWI*G0KZF#%>7A>[;<:5N]N"'S:(D?GH-
M0:>E1TF;:][LP[[=O1E7B(YU#5IY>(*,*\*T/6K/\ >\/FSW7_._WY@>Y?BE
M@+[>SV#K^U.D*3;N)VSL7XE4NT,;+@MC]M[;W3/BJ<;HS4% K18Z1GC;-+6/
M- @< @2W=CLMGMFY-9W0!,$&EL%I"P)9:>0KQIPIZ=!.RW'F+<-YV9-QMRRK
M<W)*#4J1A"%1OFP6M-5:U]2#UO.^P#U*77O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=?__0W1/G-LSM7?GQ5[GP'37R#HOBYOEMC;DKJ7NS*8>BS&(V;C:'!Y&?
M+UN7%;-3MB,:E '>;)4\B56.5/N(CK0 ^ZV" 02*CK7'^*WR7S_>G:/P\ZBW
MU_/ D[HP^+[)ZNRE'U[U#\ ?D%UAD^[=P;,16PNU\C\D-PTU7@\CU_N')0!\
MED*I$I\Q2H6:10]_?O/CU<TIA,=;=GOW3?7O?NO=>]^Z]U[W[KW7O?NO=4@;
ML_[B&>FC_P""N^XO_@@.N?>NM^0ZN_\ >^M=>]^Z]U[W[KW7O?NO=>]^Z]T1
MOM/XT][=@]FX3L+%_(O$[8@V)N#<.>ZWP(ZCPV4BPG]X\/'A:NCSU=+G:>;<
M4<-/$&C<K ^OZDCCV*+#>MIL[*6SDV4N94596\4C5I-05&GM_GCJ/]XY6YDW
M/=K;<X>:EB6VD=X$^G5M&M=)#'6"X'$?":]'(VS0YC&;>PV.W!EH<[FZ+'4M
M-E<S38Z+$092NBB5*BMAQ<,LT-!'42 L(E=E0&P/L.3-$\TC0QZ(B31:UH/(
M5\Z>O0YM4GBMH([J<2W 4!G TZF\SIJ:5/E7'4G,X7#[BQ=;A-P8K&YS#9*$
MTV0Q.7H:;)8VNIV(9H*RAK(IJ:IA+*#I=6%Q[K%+)#(DL,C)*IJ""00?4$9'
M6[BW@NH9+:Z@22W<496 96'H0:@CY$=:>'\R'^5?VI#\OMX[ZZWZ;Z^S'7WR
MLW!LSIS9\M)N">OR[3UNUY*?)8OL2'-TJ-MC9JUD4S0O1SU8AAC],:65/<X\
MA\S;#+MN\OOUJG[TCB)FE**3<6_#1C\:X!K0L:$MCK%#W?Y$YMMMZY5AY0W&
M4<O27"BUMUD=5L;XU)E[B:1O0D:25054(*Y/Q\3<S\QOY=_5G67Q:R=+U7O_
M !76V!J]L[7Z>[)KLAU#F\C2T\U148C%=#?(^:+-=:]IX^0RE*+%Y_'8'/E@
M8Y&MI<1=N&Q^))=;AL"B?9F=F55):6%"<)*A[JKYL-2T_%U/VS<W".+;]GYR
M8VG-"QJDDCJ$M[J0 ZI+>04CH]!2-M$E:]G5F>S/YB_0=;FZ;9'=L&\_B9V7
M/638U-E?)7!Q[ HLC7TT,,LZ[8[*CK,GU/NNGD:6T!HLX\\XL1""0/8<Z')4
M^6>B'?S5_DM\*,/N+8_4W8L76E;W#A>ROCOW+EI=P8S8U5D:OJ7;>^*3/9/*
M093)51RE9C*?"T-1I5E%,P:VK22?9UMVQR[G&7@W"U20!B4=RK!4%6:FDX S
MQ_+H*[SS;#L%P([O9-QEMV**LL40>,R2'2D8;6#J+8X8]>K9_B_VQTIW?TOM
M;LSX\QX-.I=QRYA]L2;;H<)CL+5?99>LH,G54--MZ:HQ6B;)TTVIHV)9P2WJ
MO[+KNW6UF:%;F.4 #NC.I37."0/SQT=[?>/?VJ7,EC<6SL36.90DBT-.Y06
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MW"8]Q5N)IL]7_P"5PTF6I,I22-*K^6%+*I+/O=CO\LEQS#;NNXR&IN(J:B<
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5)2UE7\WOFI4Y:DJ)*GXL?
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M?K/J7ION;9O8O8_3'76"C[2VEMVJJY\KLF3,9'*28V/-)44=-%$]4OZ0C/\
MX^_8\NML"":CJW+W[JO3)N*?'4^'KY,G-004_P!M4*KY&2FBI_,T$OC755,L
M.MK< GW[AUL5)%./1%/Y8%5@Y?AAU%!CZC$/71S]IO404$U"]3' _='811Y8
MZ9C(L37%B18DCWH$'@>K.I#&H-.K!O>^J=$Q_F!?,[:_\OSXH]G_ "PWILS<
M._\ ;'5L&&JLOMC:]52469K*?,9N@PBR4U37QR4D8II:]7;6+$"UP3[>MUMW
ME5;J<QP^;!=9'^UJ*_MZ37;WB0,UA:">ZQ1"XC!SGN*M2GV&O#JD3^3)_-UZ
ML[V^06Z?ACMOJ?L#$[I[6K^Z_F)2;TS%;BEV]A=I[YW-0[BH-HU=+##]Y4;@
MH8LZD4LBL(BR,0+6'LTW/;;#;A"D>Z&:XDB20+X14:)!458L:$#RI^?1'L>]
M[QO1N)IM@6VL8;B6!G^H61O$A;2P"! 2I/!JC[.MHGV2]"7KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[JGS^=%V]T1LSXR8OJWNC=>]>OLGVYN["U_6'8NS
M?C=N'Y,S; WKU-N/;&^Z+=DFS,/B,QCJ/(XZ>"%:.:OC,+22, K:6MZM.K+6
MN.B@?RKOE]NOO#Y/U>S<Q_, [C^3- G76=RPZ_WU_+9PGQ2PL=125%,B9@=G
MX_8.V9Y:NAC:ZX[S::C66L;6'NO&G6R%[]U7KWOW7NO>_=>Z][]U[JDCYP'_
M +&]_P G7G_E'^9/_OIL3[]UL>?5V_OW6NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB
M+?.WO?>?6VQMH]-](2)-\G?E#N&IZFZ0C\$]4NT3-0-5=@=SY>&G>)HMN].;
M1DERCR.RQR9$T5,;_<6]^ZV*5SPZ><!U1N_X??&+874OQ5ZKP/;>7V?%C<1D
M,;O'L*'K:7<<V1$]5O7L3/;LGV_N=LAN?-9J:2NJ5D@:2IFG8&10 1X#Y]:)
M\]->BO?RLM[?(?'_ !ZV[B>YNF]@=:=2;=I>X,[1]H4?<U%N&IJ<J>Y][Y'*
MX_+[7FVQAX\#BL4M56:J^2ODC9*4.402>E1/:2VTYMI"&FQA:FNH BGK@C\^
MD=KN-O?6JWT09+<ZLO04TDJ:^F5)J?+H8,S\P=^]ZY7*;#^".R<;V/)CJV3$
M[D^2?8,>3Q7QRV741RP0U?\ =NII&I<[W3N"@$Q/VF&:#'\!S7LH9/9DFVPV
MBK-N\I0$5$2T,C?;Y(/FV?ET1R;Y<[B[VW+EN)2#1IWJ($X5TTS*P]%HO]+R
MZ[I.@NMOC71Y?Y4_(G.=A?)[NO 4JRUG9.:VW-NW+;4@R4L=)48?I7JC;U.<
M!UY@E:HL\6(I$JYXUUU,TSZF/C>3WQ&WV2)!:-^ &@-/.1SEC_IC3T Z\NVV
MNTA]YW226[W%/]$*ZBM?**-<(/DHJ>))Z W^73W-L*CW7W/UI3=4]H;#W#VQ
M\C>Z^WMO5>;Z:S6T-OY7;&9DQ571;AR&>DI(Z&FJ<U'$_BCG99G92-(]K-\M
MIFCM+AKB-UB@CC-'#$$5P!Z#HOY6OK:.?<+-+2:.2XNY9A6-E4AJ'42< GYY
MZN"]AGH<=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U__U-[+N')0X;J7M#+5&4W#@X,9UYO2OES.T&IDW9B4I=N9
M*=LEM=ZU)*-=QT(3R4)E5HA5*FH%;^_=>''K4^^ ?P]^4_8'RUZ8^3^Z_BL_
M=W6N(WIB=T_[-7_,8[)V+F_F)L>EB!ECS74^)Z5S^5Q$$T%&R&CI\K3Q  KK
M"$7'NG6(I0'K<']^Z:Z][]U[KWOW7NO>_=>Z][]U[JC_ ';_ -Q#/3)_K_*\
M[B'^V^0'7'O7GUOR'5X'O?6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJQ_F&[N^9N26'IWX_?$(=V
M;!W/@\3G,WV>.UMK[.?;>XL)N>AR46WEVUEY8<AD16TM /\ *$;QIY.1Q[$W
M+$=O%?Q7]UN5O#;H'!#ZM9JI ( !Q4Y/ET!>>Y;FYV:YVBQV6]N;Z1HF5H@G
MA@+(&;4[$4("X'F2/*O1M_BKV3W]VEUK/N+Y'?']?C=OR#<>4Q=-L!=]X3L(
M3[?HQ3C&9XYW 7H4.2UN/!<O'HY)N/9%=6IM)!&;N&8TKJC)*_9D UZ%MA?I
MN$/CQV%S;J#33.H5^ J:*2*5Q6N:5X="'V#T?U#VK T'8776U-TLTL4XK<AB
M:=,O'-!Q#)!FZ04^8IWC_!CG7\?T'MZSW3<; UL[R2/Y X_WDU!_9TDW+E_9
M-X4KN>UPS9K4J-6.%&%&'Y'J@'^;W_+ 3*[-Z_\ DOTS'G=Y9CXVT>ZXTV'O
M'<=9N6HP6RMWSX^3+UG6-1G'FDH<GCJND1Y(*B68S0$Z&#( 9+Y YBVN3?H3
MO=C"-S(TP7 0 HV:ZU':=0P&I53]O4$^\7)/,%OR==Q\J;Q='E]6UW=BTA82
MH"-)C=CK 0Y:/40X^8Z'K^6Y\0?D;\"OCI+MG!=&=/;V_P!-F]Z_N?L[:>(W
ME)MG<F)SV[:#%+/C*U=P4TNRLM74-%0Q1M)!-#&TBD%; -[(^9)>3=UWO<+G
M;WELPS&IT:HI'!H9%4'5&&XE0/GY]"OD>'W1Y>Y5V2QWF*VW,H@TJ9=$\,1H
M5A:1AHE,8- Y8'RR!7HUF[=W?&C)8G*0?([X5Y;8F/%4E+6Y#=/1&$WAM^9V
M9AYTWALS&9JCC0$$^3RI=;F_LC'+LDY4;?N5K<$BM X5O]Y?2>A9_7B*S5WW
MO8]PL@IIJ:(R)_SDBUK3J@'^=3\ ?C_WCU)TGV;\"-U?&OJG"=!]B93L;ON:
M?L3+[9J\EMB>@Q7]WMMX?;,61F-5GLOEJ.6""E6FCD>I>-3P3:^V\O;]^^=J
MMDV^=9GG2E*J"%8%B6% 5 %34\.O;USORB.6.8K^;>;.2VCLY0=05V#21LJJ
M$(+!V8A0  :\>E=_(K_E/YN/KWY =P=P=SY');5[SWOMO=75F3^.7>>Y<5/C
M<?0XVJASNW]^T,"F3&[LPF1:.&:GE :$AU *%3[3<R65_8;YNEON$<B3>.Q
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M4A98UHR'_"I_$/LZBWVH]Q^7^:X]\VFS:2'=!?W-R(I  SP32521:'-,!U_
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MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4@;L_[B&>FO_&7G</\
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MH\WM_/8>NC$M)D<5E<?-/1UM).AX='(O<'D$>_=:ZIGW;_W$,],_^,N^XO\
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M*%K+_P 9X_EA7_/_ !B[OK_;?\#O?J?/KW;Z==?W%_X4+V'_ !GC^6%]>?\
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M<7_A0M_S_C^6$?\ #_1=WU_]7>_?GU['IT57YJ]^_P ^#X-?'/>GR6[ [/\
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M-+5UF/AJECDEC"QNX)46L3[S^77C2O#H6_[B_P#"A;_G_'\L(_X?Z+N^>/\
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ME2P"&?(4OJ>0QEO?NKL<*",CHN7RAVI_.$@_F-?RS*/LCMKX)5W>5;%\H?\
M0IF=K=?=MT_76"2'KW'OO<=D8[(5ISV6;(8'QQXK^'-'X:H,TWIY/OSZU5:'
M'5F_]Q?^%"W_ #_?^6'_ .BN[Y_^KOS[]^?6NWTZ]_<7_A0M_P _W_EA?ZW^
MB[OK_'_IN]^_/KV/3HJ'R4^0O\]SXO[X^*FP]W=G_P N;<N2^6_?N+^/6T:W
M ];=U4U)L[<&6P.6W!3[EW E;D!+D<1'3X>2-H:<+-K=2#:]O?GUL $,:<.C
M8'8G_"A6]AWQ_+"(O;5_HN[Z%Q?ZV^^N+CW[\^JX].NCL7_A0M^.^/Y87^O_
M *+N^>/]O7>]9]>MX].BJ_+[O[^?!\,^O-C]C[W[._ER;SH=^=X]1=$8[#[:
MZX[JH*RAS7<>[*/9V'W)5U62R'@DQ6#R%<DM3 @\TD0.@W][Z\*&N.C62;#_
M .%"BNRQ]]_RPY4!LDIZK[ZC+K;@F,Y!]!_PN?\ 7]^_/KU1Z==?W%_X4*_\
M_P!_Y81_Q_T7=]6^G_4;?W[\^O=OIT5[YG=Y_P ^3X0_&CLSY1;^[0_EP[UV
MKU=!MJ?*;4VOUQW909W+KNC>&!V;3"@KLE7?8P-1UNX8IG\@.J*-@.;>]=;4
M!B !GHR>-VI_PH/RN-QN4I>^/Y8WV^3Q]#D81)U9WRLB1UU+%5+&X%>P+1B7
M22#8VO[WUKM\QU-_N+_PH7_Y_O\ RPOS_P TN[Y_Q_Z;OQ[]^?7L>G0(?)7?
MW\_+XN_'WN;Y&;O[=_EM;FVUTGUSN;LG,[:P/6?=]-F=P4.UL?)DJG$8VLKL
M@M'15E;!"RQRRAD5[7%C<>],]>QZ=*_J>K_G_P#<'5G6G;6![K_EGXS#=G[!
MVEV#CL3D>L.])*_$4>[\'1YZFQ%;/3Y P5-7CH*Y8I)8[([J2HM:_J'UZWV^
MG0@?W%_X4+?7_3Q_+"_UO]%W?7^WO]][UUKM].DGOZE_X4#==[#WSV#EN[_Y
M9E;C-A[-W/O2OH*+J_O9:S(4FUL)6YRHQU))+7K##4UD-"T:2/Z$9@2"./>^
MO8J!3H(OB1VW_/J^8WQHZ7^46QNUOY;VTMJ=W[(H-]83:VY>M>[JK.X"BR$U
M3#'CLG68[(-0U=4GVQ)>(!?5:W%SKK9 4D$9Z,3_ '%_X4+7_P"9\?RPO_17
M=]?T^G_ [^OO?Y]:[?3KA-LO_A0?3Q35%3WY_+$AIZ>":>:1>JN^Y65((7F)
M$8R"EBVC3P>+WYM;W[/KU['IT5SX8]]?SX_F[T!M[Y#[#[._ER;(V_N+='8F
MU8ML[HZY[JR&7HJKKC?.>V%D*R:NQ=?]G-#E<AM^6HA15#1PN@8EKV]3Y]>-
M >'1IO[B_P#"A;_G_'\L+_T5W?7Y^G_*=^/?NO=OIUR38G_"A0NJOWU_+#1"
MP#2?Z+.^G*J?JP05ZZK?TN+^_?GU['IT4WXE?(3^>_\ ,/#=WYG979O\N79Z
M]#_)#M;XS;AI-Q]<]U5TF=W-U'746/S&Z<3+CZ[QT^#S$M<K4T,O[Z*IUGZ>
M_=;( ICB*]&P_N+_ ,*%O^?[_P L+\?\TN[Z_P!C_P IWOW6NWKL;$_X4*\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g790774g82i98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g82i98.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!'0,5 P$1  (1 0,1 ?_$ .(  0 " @,! 0$!
M       &!P4( P0) @H+ 0$!  $$ P$!              0" P4& 0<("0H0
M   %!   " D'!0T& P8'  ,$!08'  $""!$2%I;65PD9$],4%9755A=8(=*4
M59<8&C&R<S14L<$B,G(S4[-TU#6EIT%182,V"E(DM8&10G4F=G%#8R5E9C@1
M  $# 0(*!P0'!@0% P0#   ! @,$$071$M*3TU4&!Q<8(9%2$Q055C&A5)1!
M42*24Q8(87$R(Z34@4*RE;%B,W,U0R0T\,%T)?&"HO_:  P# 0 "$0,1 #\
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M(<B*;C6.0*4L-41FNQJ,XX5,)Q^3"!L,JR%A1/8."P9,X8'\(3ND!G\;F\@
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M1R/%<@:Z.-W2NSG2VM7HRD2&H_3D)A+#?7W$RW: W0$=6=ZH<>2RFXN-,!0
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M%%TV7CII+B])V*BB1Y 7F*]66^++ILPS(]8SV/'&6^C.*$W"3.:^#E%$S4U
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M7>HD=%6ZNJAQ2E!_23&;81Q6XMDU<-WQ%BX,Y#3U]/-DP3#<";8;;,9"C'+
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MJ=R*C'W J-1LR0KH)-K+BT62$LP-:Q<?, ;P.6(0HF?%QN!%D'>B!E]DO:4
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M&VI-/!JN1MM<H57$-00<1R0 YY7,"*!H?,$!++A%A!<KX'@,K@9EE;NZ_O\
M>_(9OK;H\.H!/P1ENA48CM2&%)^<6"&09*+1@]%!) 0GJ:9(I,6QS H+E?/
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MC:M"]R)4=TQ"RCNMNLT[ZZ1\_6JYW<O+BXJOAKHB3&TJC-E4CY*(-D=$/HX
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MI95C-HER2B<$:QLZ=3S0F.*>$(!X,R;$R$#! BJ/HYLDXX_,LF1%*&486,-
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M)$YN7%6CRY8J,2P7KV)!!W'Q,&<K^ L!N]0"@% >?$MZ-HD[;>G)HE*P:S$
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M%^,)X("M71I[M&X]BFQ*JRK,9YIL>[;"3.UW YYPE0(V)"RH16T1,BI%BJ[
M6V QE&-DY:R%P.$A[Y+HF-_#9@YBB"W K=8[-^9G<WIP:*-C'6OL>NINLPRR
M(7:$U3#*$4*$Q,N7D24O>+9/7&DR34/M]?2TK-#S3FZ")D5Q-9&L,+Y%@,1
M/0G5>'W#%C<?RHY8N8$</Q].$JJJ@+1F.49GQ<0:(W$Y!0CSK>4GH:6NX*1?
M IF7P"+AC@@I^(&-LKYX98V I"#M;YR2MKE781Y,Z!X&;YMBN=NO1F:_.1P+
MI>>GXXG("X+2;(X1^/8Z(9JJ6.,;$ /&03RT**:SP%&L'?*^8'I+0"@% * U
MKEN''._9VU/D]'/()9 @EXRJX7<44C2@"L*))\PR\([20FX7*I9PD;-%UMP
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MJJ7/MT0_$?,KX473]K23T#IRIWAKJ'Y9VF',;1ZJES[=$/Q'S*^%%T_:TD]
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MJJ7/MT0_$?,KX473]K23T#IRIWAKJ'Y9VF',;1ZJES[=$/Q'S*^%%T_:TD]
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MJJ7/MT0_$?,KX473]K23T#IRIWAKJ'Y9VF',;1ZJES[=$/Q'S*^%%T_:TD]
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M]'(U+/Y<?2C3S[D1BK\72 ^HS=898%TQV\7.Q7*"3,6-DPE]HK9YOK 94U;
M.QDL&HIXEL!.+CQ\;6OP6X:[.NN\::^+LIKWHE5:.J@CFC54L562L1[;4^A<
M5R6I]!U_>-#477>$]V5:(E53S/B?8MJ8\;E8ZQ?I2U%L4AM3B&* 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M38C41.DU2KJIZZJEK:IROJII'/>Y?\SGJKG+T?6JJI'JDD<4 H!0"@% * 4
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MH(Q]_MGV/I)K2^[3FU7<]&WV5T+;LJIB1&JE.=V[92PY@VR37M=4@\F*B",
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MAFRIXBC9K:5@,.9*)HN.  @'H_0$6?/_ $4\/_M9P?\ I)NIEW?^0@_[S/\
M4A%KO_A3?]I_^E3^<'7UV/F:* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% 2)H\H.5C8Y)^4\JN4*+R:\BXWEG*#SD6\S>2<3^'Y
M3YQ\'X/@^7C\'!46O\+X&;QUG@NZ?WEOLQ,5<>W]F+;;^PDT?B/%Q>#M\7WC
M<2SVX^,F+9^W&LL/Z4=?(<^F8H!0$9<'\<K_ "1?W0Z CM * 4 H!0"@% *
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MJ>I@K35.YJ>0@=RQ07 D(GF3!$4$0F9' $ KT]V;&IIU'14()HO%)3TYE)K
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M$U' RJ*(8_@@-O\ 1V I[CW=B9)C?6L:) [;EJ-'NE2 H1JB:_-".'5)Z%L
MX'$QG4?"CV3W+*,K.9VQ<Z;&\W6YD[%0R.Y* (X23<3 A0&A,E=F/LZ_TW;
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MH!0"@% * 4 H!0"@% * 4!CU;_##W]E&_,O0%3T H!0"@% * 4 H!0"@% *
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MQ*7,IA'?4[Q?7L;_ &>I_P#>Z<N&[/\ "K,^[ ..NWWXE+F4PG(%VUN\H(F
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M#[8+*GA=V1?TZON6V&\9C:)B-VQ(+NBPXY(=8S1;IA(:\\1ZZ&)%! BK);[
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M3HY+%D>]%:Z1$7_(UBN1%]CG.M:OV5/TV5XN/58H!0&=0/UD;]!?^LPH"5T
MH!0"@% * 4 H",N#^.5_DB_NAT!': 4 H!0"@% * 4!F4[^8R_2Y?F84!^=F
M?=C%XUN=&:](\^.@FH:W[\;,%D34=IMB(SCA9L-L+L?=Q76@S^BMDXR<9O?;
MD>1EQ"#D3AI=%9IG)P%DS C8T!@/D!6S'W)D.3S3"!=>\[B*1U'?:,0*FY2J
M.^=,SZ\>@F8M*G/)K;1YC>,40RVH%,)!F94HXE$LB*07#Q4+CIV1Y1/$BQH
M#=[2#=!QS5NM+\86G%>D2+5N,'Q(+'8LFG=<@9%CAU1ML(Y(H=[;2VS![#9;
MJ:;5*D!266*6]CSE=(!6Y$<Z9)F1S);,#SC<>X^TS00MPBD5R\5AXO#,:_\
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MS4(81@N*3K1E6&=53VQ\=RT<=@LG!HR[D5425DHZB>92X!TKG<:QH(3@M8"
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M!HHO*3J*F4MH-X@.6="RW^2:NY"XQ1."$!7E5K6\V&3F-[&!T_\ \OGGD#_
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M70T=SOP=N%3)%O#O->3B)=5= R$2.C DLCPH^14(7/ *^..65K@3.@% * 4
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M/F4 \S.OZB!],%/F4 \S.OZB!],%/F4 \S.OZB!],%/F4 \S.OZB!],%/F4
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M+']I!S];(>G[RST. =]=%W4D_N<#>\73RQ_:0<_6R'I^\L]#@'?71=U)/[G
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MU)/[G WO%T\L?VD'/ULAZ?O+/0X!WUT7=23^YP-[Q=/+']I!S];(>G[RST.
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M284,K)<EQNK-<LBRXHJ[Z+6?(#<0U*#2I,_)*$H%SS,*N(0VE)A\(V6%+$3
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MHV7H(5HF3T-<Q=C6?;:6UYWM"SA:.#D"(D'FPC1 JZVV< =#?;JA<<C95+#
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MG^H4J=.*>.JNU[DP#E'_ $]>G_ZZ\O[P=W)IGU.?ZA2ITXIXZJ[7N3 .4?\
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MTM;@WM5J[.4]B_5/5HO6E0BI_@2'NZ=,^I0ESRD;IA7/C:GM>Y,!8Y4OT_\
MIV+YJN_NAW=.F?4H2YY2-TPIXVI[7N3 .5+]/_IV+YJN_NAW=.F?4H2YY2-T
MPIXVI[7N3 .5+]/_ *=B^:KO[H=W3IGU*$N>4C=,*>-J>U[DP#E2_3_Z=B^:
MKO[H=W3IGU*$N>4C=,*>-J>U[DP#E2_3_P"G8OFJ[^Z'=TZ9]2A+GE(W3"GC
M:GM>Y, Y4OT_^G8OFJ[^Z'=TZ9]2A+GE(W3"GC:GM>Y, Y4OT_\ IV+YJN_N
MAW=.F?4H2YY2-TPIXVI[7N3 .5+]/_IV+YJN_NCI'^SVTZ(E[F"T+)V(ML\<
M.$5UO\SAQ<N'A_Y1EUC!</R?EX.&U/&U/;]R8"IGZ5=P,;L9NSL-O[:FM<G4
MM2J&$^XAJ7U,HGIMW=(:X\94]M?=@+_*YN$].4V>JM./N(:E]3*)Z;=W2&GC
M*GMK[L Y7-PGIRFSU5IQ]Q#4OJ91/3;NZ0T\94]M?=@'*YN$].4V>JM./N(:
ME]3*)Z;=W2&GC*GMK[L Y7-PGIRFSU5IQ]Q#4OJ91/3;NZ0T\94]M?=@'*YN
M$].4V>JM./N(:E]3*)Z;=W2&GC*GMK[L Y7-PGIRFSU5IQ]Q#4OJ91/3;NZ0
MT\94]M?=@'*YN$].4V>JM./N(:E]3*)Z;=W2&GC*GMK[L Y7-PGIRFSU5IS(
M)V@&H*@+F$:A=*RPP#\)C8%R/@KEQN-CC\N95S@YY6X,OR7O>U<^,J>VO4F
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M?<$U"ZE$/TX\>D=/&5/;7W8!RN;A/3E-GJK3C[@FH74HA^G'CTCIXRI[:^[
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M>[Y7).8ZXO/@L=*R\JN1Y&3XCD+QJ&I"*HH9E8,*ZD&FWQ#S%-"X!Y =2>-
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M<D34_9T]*VEM3EV=#HFUP;4I!G8TPTH+W&>,=.J9(Y1(F1CC[S+,**XMBP9
M:DK+#M.DF^4<2?%1,P*8Y-CFRN1@7$ 3'.V MH5W[3Q4$5&]*5'WA0L>V)ZR
M*C/MR226NC1J*Y6K(J68Z(MB6I]!?J;H?4OG:LV+35#FJ]J-2W[+6ML1RKT6
MXJ?Y;4^@G<@Z$%I >[PF@U+*LG;!&9XBB7XKE<LUP+YQ(T(;3U%N-B$4] !7
MRF3BCQ<:+U>9->#&.E[JQAZJ1B^ 7 7""CTVT2TU.RA2%JW:E/)')'C?]1TJ
MHYTJK9]EZ.;$K+$7%2)J=/2JW);K261U0LBI5]ZU[76?PHRU$99;TM5%>CNG
MIQU7ZC9R8]<84V S:8LOL,B\QV(;5C[0-&5)=2S;?.+Q()-6#"<;051*,A"J
M">#8 2]\[\(5\L?R996OB:&]*^[<=**18TD1$=T(J*B+:EJ*B^Q>DFU%)3U6
M*M0U'*VVSVI9;T+[%0T)1^R^M'\2P-$\13*F-I&A>9I!G563GU%AZ3F9)K]<
MR@>-,95=#+-2FW0L1HD"- B(^-S@Y:RJ1*J5P,#@ 8EMB?M;XFLJ*RM@5\D\
M#(D5DB1NC8U$1Z-<D;O^ITXW0BXJJRW%54,6VY>Z@B@@D1K8Y'/6UN,CG*OV
M55,9/X?HZ;+41UEJ&TDQZT/.?XB:$42A+*(+?!5$'E-Z,^*23==3K0Q,SH1A
M(C ^JO!TC0:JJB2:\WFEPCFI+017(7-.,)QK,,R#B:&]8+MK7UE)"[V?RVND
M5S6KT=,B(UO>HB]*,7%:JV8R.2U%G5%')54[8)I$]OVE1MBJGU-M5<153H5R
M6K]2HO2F$?>I3B5IEU-?<:26UHMC#4PD(EM*'BT2^?P5!'56R?CQQ(Q1V8R
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MT;4)FLP*_L PI3BY@$_/>O6Q4UE'ZSU$TVBHLHHQ$S!P147!*%L!F&H6MD9
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M;^ \B\%:V%@-KR1(FFDRB<G%"I!/(%0"1 @2 "*DR1,J%@ 5*%"H& 8!8J6
M#QP##PQQPPPQM:UK6M0':H!0'$/_ # WZ(3\R] 1R@% * 4 H!0"@% =U._7
MBWZ7']^@)W0"@% * 4 H!0"@,0M_J-_TH?[] 0Z@% * 4 H!0"@% 9U _61O
MT%_ZS"@)70"@% * 4 H!0"@(RX/XY7^2+^Z'0$=H!0"@% * 4 H!0&93OYC+
M]+E^9A0'?H!0"@% * 4 H!0"@% * 4 H!0%T4 H!0"@% * 4 H!0"@% * QZ
MM_AA[^RC?F7H"IZ 4 H!0"@% <)@N ; '*F@ 3)4R"(7,EC > P!@ ;#(,8
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M 4-B/8ZKKS"?#^2XL9!5";B:@G7"MOAYR*N$49);Q0J,LJ"B=   +9B"X8W
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MIUX6H[6H#EJ.I$:J_+B;BY6RY5MDR SD!S6;"BS0C!TB9"*"!G31?(CQ@C.
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
%H!0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g790774g83a26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g83a26.jpg
M_]C_X0X517AI9@  34T *@    @ # $   ,    !.SP   $!  ,    !%SH
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HQ.#HS,@     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,,H , !     $   $R          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M)4<< @   @   #A"24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      ST    &              $R
M   ##     0 4  Q #0 ,     $                          0
M       ##    3(                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   3(     4F=H=&QO;F<   ,,    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $R
M %)G:'1L;VYG   ##     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     3A"24T$#      ,JP    $   "@    /P   >   '8@
M   ,CP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@
M    !P ( 0$  0$ _^$-?6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M%@B"PG.#D[/#TS0U<$-35-0E%X"0HV2$=)2DQ(75)C88_]H # ,! 0(1 Q$
M  "_P #5Q.LY)RB,M/,F8SL!LT@
M           "N$O#JM984@J6W!1&ZF85'7S,I.VH
M                       !'ZG\'8D]<1]AF,YHSZBN4M8U5 '3=UN(I\B=
M[E^QGC[J.YW%7[/^;;">%L2<QITAYR;D*8/&6/<F;#9=WVFVY"E!IYV;L.U'
M7N"YO2TP                                     !7*6GQWNYT^[-V&
M(?)60)B,98]ZIN-> '+69;'F&<']0T^8JU;/Z+W!]K\T\G5X2J%W7VU9HZWX
MS^NE>F;O<\#K:O(:=*TN9\]2V](Q9O'U'K7TQ'&WO[8B.;O'<.1I21;H_3_D
MO;L^WT,E[#9]FV^AJYV'G-\NG]6 '5=QKX>Y/D=B.$X?]@
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M\G_IXVRCONGY8Y+H^0=YU;YKJT^5?1EB_&7GKNNUVP
M  _)1K:EKU3=E$)ZTRBM29J;^(U6-\438JU:>1Y? '>_8^A_SO\ M#9JSA\A
M)F\J?/L            <3I[[C=/=]HW'# #'VR[1"5B;Z*SUYD^9.,./[EC'
M8=QQEL.XD5A?/WV0NA>J/SX]MW/!@                   #P44&K;.:>\2
M(-5^\HAU3(::F&_Z,"D=O(90QGAK[ 6E^Q?-&0/N?EL:][;'4"W ?/JP;V+Z
M+\+78P5=?\$3;\][G]LWKC=:^:4V7-^Y]I=WE7ME^8[A?FN9MO8A>%\<;=;W
M,6X&]S*                                !^#^><U;QC3VH0/C/L  *
M3FT]/91\Y?4RSOZ._.'&QQGF+?SD?0V!=MT"&?A/$ME_M'U!Q]I]>KH=:^:M
MDOL_TXSUN,@P7\#X)ENY?V'D+5[%U:G$]6IQ76J\57=ZW\WY#>2]'2,\EZ5]
M#3^R=;YXTX&^ ^?WVMQ.KS_OCWSJ>F-/LU^5UZVV.->MMCB9_F_;H
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M,:%K'_FC(GSVCW5G]&KW:N,U*[AQ5@CSOWW(?&[CZZ2."UZ1=Y6ZS+#B+M(
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M6^),*29Q3856/Q?7=&Q2=W%<''[1"6M.$:*'<8M:'G1R6#4!-91:QTKO@@
M ?SON\_*"P3V[W%8XPQGT                        ?#3<0NXI^A,PV4?
M!':MQPHK(M20Q$=:)5D?LQ&MMVKI*GYS-2,.IE65B(6]".83VM&?SV)@H6S
MB4M7!:>QHP6G,B,:IVX1N@C)(/! DM,TKE0   '\N3Z)X$O?>1LHRNXE[4
M                                  /!Y     **C6N=-+.*   !0RS5
MAF[#ASOV;-#M                         X>NRBNXCR;)GROJ+NVISH@H
M7Q"G!:)7U<AFMJTQBD$BV1"3A76A.SY$TGB"0]& S\IY=&WQIH<F:L)WV1B,
M^A.#2:E4 =1*F;4L8J;DH '@^<^D%+;+_5K=V..>RWP^[
M         ^*-#2;8X,JT]3^4%F#M/U"D Y#T1SEM_P#SD6O,.B(=6?-$F2NC
MZ^]JE>9>16(^V6MB;-+3K"+YIB=D9KK@G1U/6TVF&G#RGJ:=)SN:<XIW84ZX
M3^J@#35-11>W INJ@ 5PEL>)VK1A9/!EEI0
M  8B3V%&+TY?1\YT9/:D<P8I3D-&/DY51B9/Y-@D=,.*3$>G?9'=3[S*R/)B
M9.64= 3FI  _)1U:UGUI2'H $2R>.3N@C:I%<M:QHJ
M         .*/2?$<J?L]A]9Q9])]APAS9\9UP[>   8:,R@'%G*  \%5AJ63
M5,MH   %<I:QJJ                        ./U*Z"9"X*H_["Q1; \C93
MD&QSS_9=MJ4;VM[$Z&12Q),2=*QCKSVM.K(OM!"16:Z0)GV5K^K8I6WD5U=3
MA1.8$2HJQTI_"=+3:$Y!/?%<1ILRJ ##":J[4LFM/<)    KE+6-50
M                  /Q*O)Z-Q_8'\[]]Y?1N*?[5E*5C71+,=V1@];:Q6,9
M?,RN8$8=3,TK"8OQR)$$:R)UI3&Z6/U8^D_$<R=A,6IW[5PTF9U4 >"D*U;>
M+3V*0   *Y2UC54                                   #69.R"/I
M   /!0E:UOUI;O(  Q$=].P%<I:QJJ
M            /R59%YRU=TD  0L)D9(2EN)++*@
M                     \'\_&-6[-.GM2@ #5M/=C-R*Y2UC54
M                                 >"A\U+>ZFY:   !7*6L:J@
M                                    "+A.+T[3HWP0   *Y2UC54
M                                        ?.1Z)D30   !7*6L:J@
M                                           #$Y%TMO"C*YF5%<I:
MQJJ                                             (E5HAT[8F_R-
M"4Q Q:8":"-=:2A41J+25JB-E:2941GK28*B-U:2)41HK27*C0U.WQW1&IZ>
MRIV+5Z@G3E.^JHC26DM5$;JTD2HC'C4DXG3$:JTE2HUD3;"4
M            '"'Z/N/K(S4R9(  C63)2@ ",],F"  (TTR6(  U1.P)V.0
M!&HM)6J !&*M)TJ !&>F3!                          &J:=-$R[J@",
M9/*';#?E &%$Q=IYPF35 Q01!+\XB;A4#'B835MR59+$ :CIUK3KD;"$JJHQ
M*:SK:ZG'DQBH$9*WV(TC3/6KS8                        !"*MI2M:0:
M8 K'M3FD=D+&2@$-RT"ZW)1-V>=(#XRN:OJDFW6TP,9IJ'KZ(IO>M/-J!&6M
M VOT0WX5LMJ#"::@T:NPTQIZ7H6D!3QC4C_F>KHOMJ9;0
M          /!Y     !X/(    !X/(  /!Y    !X!Y
M                  (:E\X*[)':T<V1[+9/1RIOD@
M                          5ZEO@A!*M\\S/XKKFG3")ETFD^*H
M                                      XT'QGL/A,3IRZC&AFX
M
M              '_V@ ( 0(  04 ^*0^+,*C#N966A2[ ):PH"O!I]67_;K&
M_(LA/'M[(!+J4>%#/YN80Y"74F+=N%AE:Y7;N6_%-I$\5=R_8O8U[X/P"TP-
M+Q4GU27Y:A3!R5E_Z/NXG,;+19%DFSOIN\04K=16N75:OS( >)]A5@F*JQ>
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M96WJ*.L:V*-L<!)7Z.?IX]HY^2JVGBM-E0CR-JU4?570OKRWRHV6%O@*!0T
M*MOT<+%]@X&4521PC,[I7J.NU6U6E[O+1F6W^ ("%%(5UX:XQR$OS<>C$RO>
MI:;9)1>=M5Y;<MVA4\!L?XS/)'#ROXJ[9LW@HQ,6W5Y#+%O9V 4,WAD9C511
M6%TG*+_+B22MT*D CJA!")R@#0D7XJG#OUY6)[U**$J)I2#<KS*Q$.7X5[PS
M+U>/BB=Y75.18$+N3;HM?GN5Z+>78JMCFX@<_-L_F'GVJ\8,O%'@7[(\"JD?
M"\<T6;^%F!FT?!RH1;AGI&TY$J, VS,G\)9I.Z:JQS*:ARL?.R,82HPZ#&Q_
M3>Q+ V?RHP]-C&M4V0HH#GY$/,;&#'QQLV1X.+C#P<+$'@E^&/,G"R?Q)9B7
M/Z7X6X'/Z&6'/1G4\[SPX;57AR2FY71D?C!#GXVT'/Q^)P,W$'F88T8]O%-J
M\G(^ C5:N&U2/3EXU3J<JO7[H6K%X;H  !_!Y9=:R[F(76L.YXC335PTQ*KE
MO$+\FG)_ V Y^$$.?T,H.>G.#A@.9^!"JL:OQ&0'/Q58<_&<_&4<_'6 Y^;9
M_,.Y<NXOL,9MU'E)KW8Y+DUX.*<G^6JZDNF\E4GRKCJL$D1X!(=&O$JSRR/#
MHT91MC$ENM4X5JFZBECCW/\ 5PZ_*;2.5M^Y8:UP[])*Q;<EQ&I6<4I2H?[4
M+X>5-2XE/*VR<.WRM +N@6]CQ:/2)R6YSV^4/D3R84"KS3]-GR6S_99-BG)L
M?DUGOR#WU^47^\2W59QO-;N5V;@KQ55#CO+;I3HKU5U5963>S,CP_P"/X ?*
M'\$;I9)X1A']*D:P=0PP4JGL99O@AR],9CA+K/X4'(81YG2;R#'#JO>F^FU:
MK<,W_NRB?P"B6*PR3:]?OY%1)(Q;DY&8&&::YWA1EY5KEL\.[7&Q=Y.DR5<U
MU3_/45#KN%2 N>JKHTN->ZJ6Q3?&/RF2V?@2 .D*-JK':J^/Z:;^[32A"_(Y
M_;)07A2#%JX]/'*C]:3A'>(SO'Y7;N6Q\,7%R<[)/F.<9.DGOL [' -$:ISX
MF:<E9L%2^YHL2C^%*U>J23$-5:ISS%\C0JFPC5$YCQ$JA3]MP%Y9&VZCBV^"
M["^K#^Y*AN<;9P,JZM#LTL%Y-^JD>-5:@;RYRG-:Z]P0:.L/P#7WN)Y()/!3
MJS+RLI5OO6/RJ3J:<YZ3@B+&Y]T6JJ*+N$\]DL)S;)P<PQ\URL;=L%.9B&<Z
MV7870J<S ,:]7D8_L1]PH%MF]7ZI7RP;)PL_WE<H_J6Q99$"&)C486)[K9](
MILA0;VI@D2;@?$#4+98D15E9AB8Y?O*JH**:3S"JIM7*;UOW6D<1(E&*=EV
M69?O$0["YB5!;IQLGTXV)6./33Z:?8CY_P#CRA_Z%V;5=^[::M7W<BPP#96"
MHS:558!GFXE\OR_,/B/PJ B XTF5KCDN1D7\O(]D/_R7?\?_  P?\?\ H/\
M_]H " $#  $% /)T/.A\/35P*1$.AX("'PYW_+\QK /YO_MS_BK_ *^JGE?7
M?PSZAZ]0]>K^4:A$ $0X B B(B/*O+B48M>1DHW!PBFL*0KPZ>\G]"8_Y-?(
MSF[?!.J >%;69>42WTZ?XURLN,+?*K=='B0)<X4M=ZS=Q[OP=5S"+\XQNEI(
MH\')/4\:EV#^E;N-S'R4D39!XKZL9%4J\]M\3ZLR\E0"W[34QY49MCB?@89]
M53;M$XBJCSEFACC95*D45'*5>IZ> M%-U4KCRL6OH5:DL*M0959D!P0U\_&)
M2Z/2*K#\ D[G$6DDZ9&BQ11=AFHI7/'@(U1U!<2:FM<N$9U9#&+<_+RU,D31
M+U^3&Q<G,O GC\1$! ?> ?+GSX/U]A5PF+#(X,# @RTZ"K<&]D$A*1':E,T=
M$-98BC<F,K;8L8[KV-)@5$LC34S. ?!@[30'DO)*DIW7,V3M8(#87%9)HM?2
M_=W"60RR=N_RU*$ZY=D>6Y04O:UV5R ;?-C804F6@BLR3M6D%%<Z&W'M)G%R
MU$)ZC.H[C9(-.BTB 4JK<YX4R8H1?^%N_?L\MGAU:!,*)8#G+@[4MJ@%5FU#
M4H[-SE)P0U<'/2MSF)=1P7U1:35"6 L3%?!)B(> GL>O@I>[RA*&X5X*/O9)
M0;?UOS+W6(TU"/L:N-04)<X51_'<N567*^+[(M@R9S*MS/RQ(K94(15TS:E%
M13FY>089A6:FA&9?[$R!_K&AH9GAE[1.N O$A5!R6J;2V/-*5;8'YC:E"<<N
MR0*<KG]ZFDR^?W3C=>ICJWD?9+NKL"CBR91@W2B'^:-EMXRY85LRRV55:C<4
MY86(UJ?!RW-@@YR:9?-A])[##-CN_P"7<,4(N"?E5-5%5%(55IQ+KR^U&78H
MQLGW6(TCRKKOE(4B/.J>=!2'IZ$>NN%>488N0P[29KLNS)YT+"(:P_V6R04Y
M#_%8)F9%=S*4:AS<?R(D_+THKG)V;JIUT/CY63B7"YSW*)^84DI#%U=B94G;
M--R7CX9=2"=V'81\4Q1C$"B]U]T]#]>4==]?+NGOU (>H!$1#KUCQJG76S1*
M62CRNS&E"*.6*S597X.VKS% MK=FZ[%%O#<%$Y&.IG%3A0F/]Z5[_1(7<0N:
MG<EZ6CQ@_P!M'Z[:5_D<=-]:==KKW+"V1F5RP9%V5X+N81(AEDRKQX+SD7P)
M5\A'Z^PBQ0WJ:>S90YK%'Z'>)S :5%ETW\(Q,LIZ2TTR7*;YZW!05V)K^U6\
M-M$!<P5LTR*RT<,4) CBH1N4T5I"R2E&-2$$:^VW;O"02"OHU(97+C7MG>')
M91H<KE<?6;K%S63<2AQ8SLVHJ4P#6GV* HAV[57Y4^F'33DO_C\E@;+/)<.)
M2E.B5>UO!=L5?WL2UGG]_P!I*:L9ZVAR^/'(TC;U/-3+0Z<9PO?'U$?K["),
M<4 XRPW@W3+'1F>KUZJ;241"LS%5C8V/AX_\&ZL<$D[JE:>.:3:!1>.65%A@
M$HVBSU*G&HCNXV(XP,8A,8*6ARL:JM#.G9&HL?G"!\S%Y\-GRT[/[9K_ '!7
M]K@NF=60!XAIY2\92 5OB@[0?[:/WQHE$:JYL?86$"?9"?\ &ND*1JI .?RC
MP [ >N4@ CP0  H *N '8CP.#T(=!3ST@ ] ( '?/3\O2/.OD "/.N 'S&GG
M7 I[X%(=>3Y]>QALD9$E#:235*L696A642'ZG3R*3M1S?S,/&X9JLIP\/&6"
MAQ\NE3$50TG!373_ ')Q/Q51L5T4UJ4AH'+6A_D9A<K"_*P/U.1\!3D(\I41
M#5P#PEJX>KRK"S4\?V#W \F<8X)99P3'!,['LE\DJ5TE,:'*:P\R@*J:?')J
MNT8PQ$755]JB#,2K=>:W<KM7!6BD$;#KVZ2(5HI1'(R+V7?Y4(#6(]A_-P!]
M("'SH ?4'\M78>FW]:!Z'Z4TAV-5-0<$!JYV CT-(4\_^H?,:PZX'S  '@#T
M <Z]0#UW2 CY ^O\W*OK[#8[)(^7,(V"+[1B[5!@>&E90C3G(,;)"2V.96)_
M6PK+=6\>\%/=!@5%=[%_3!Q_6P"DIMXM-%% 9B!)\O-L6+.+8\*K5JKE6%AU
M<426S\LS3J9P;. *8(AY^G"RG@D%' )\J@%T7F5B^AL,Y"L*U-0'Y@>TB)W?
MHY^HL&GAJM"K"PD\N:C#,HS<.YP*J:@\+MRW9MX2S(,_,]R@/7!'V8 (CZ:O
M4/U\?2'HZI >@I"H.N5?RTGD1%2<-0TK((O$P2U%8Q3E_P +DE1;F7<8K+<.
M[Y%265FV G4GEX&=41$E?*DR05<!+D8#^GL"GBA([5)1AXU5_+_+#;H,$^IY
M_14E'/\ ]2'/ZZDHYG&II>,"B_DY17[7KG0\Z'K@ (^/0^3Z<Z\.O8"'7L!I
MX/U\?4'H[ >=@(5#WSUUAQ6K9M\!5)HLRC(Z]T5!4--Y(U9.7BV[UJQYL''M
MY>;4P2#IJ2NNQ/&T1Z6#0=0GQ;CDQWR[T(U<#Y#2'?*A[&U_W .Q$*NJ1$.4
MA\^NPY4/?*_ES_FD.Z*?K\AHZ#NKY4TA\@ZJ$?F B C_ -*:0#NBKOR!USK@
M]>Q4R%1R[?%B5C86B/\ >6'D?@\NC:%*JT*D/<E3J'P&Y_-ZOD @'.^"/?**
M@I'OH?75U2(!P!Z'OH."(#SOGJ^??R >N>K^0![$:>@ >@ >N=_+OY]_(*OF
M B'E]/7!^7L548Y>4>(W/R3(C^%@_F ?K[ X;:FSGI),UI0K]Y&6?8*BZF;;
M-56TPH<!6IWPKH]/!HZX 4#SKL!Z#E%(55<&GH #O@!WP>@X'78A2(=  "'0
M^D>#2(<Z'@AUSH>=#P*1'G0\Z'KTU=#3T'E'YB/U]@;W37+NX=^_D6O>.39'
M)QC]I,ZTG<=KG2#";5IS2ZWA7@B6%O*OG6(@/ [Y3_+P?K;^58= /\O5(#RG
MY"/8ASY^FH1KY7_VY2/0TTB(#]1 1YT/!^@C_*'R$?H(#UY ^M5/50_7R4CS
M_K35]?0/*PZ'WQV/?8\['Q 1#Q 1#P[$>?3@B(\[$/'L0YV \$>Q['G8AX]B
M/AV/F$**>5==^0!Z !X(]CRKX8$/F/U]A5[SKJ"BFI3%5-NXN%%7DXRH++^/
M9NT7[7+@=C5P/ERG^8*A^=K_ +@'8CUU2/*0[$0$?"H>^5AZ>5!T(!3P IJX
M !U5UW\@X'I#@=  @'/2%7!Z *A#KR!URH J$?K["KWH( (7&[**\NW;HM4>
M UTC5Z@Z 0#G?0#T/*!"FH!](_U*A"GK@#USL #E7I$!$! 1['L.4U=#\^A^
MHB \[ >=_+U?R^KK@CWP>A#RCZ*A'Z^PJ^"@$0]MV TC]?+]?&KX8'TB(_7R
M@/7!^O\ )RYUW\+CP?KY0J&G@B(CRKX8^0<'Z^PJ^%Z>NP"K@_7V%7PQV/LJ
MOAT/GST\ .Q$.AY5\.T_7Z<H#JNO_OZ@Y54'/4'/4'!$ #U!SU!P1#T^H.>H
M.=AZ?4'/4' $!#U!SU!P!#GJ#GJ#E(@//4'/4' J#OU!SU!P*@[J$ J]0<"H
M.ZA !]0<]0<J$ 'U!SU!P1  ]0<]0<JZ"GU!SU!SL/3Z@YZ@X/0A[V$>_-W\
MO* ]!Y0'KSU#V/EJ'L?*-0B'E[^7O4 $>" =>0  >==B(=>0 $1&D0$:0#R^
MD.AI#KQ .Q]/RZ\@!V/I#OT_,0 /$/GRJD:1$.N>GY>(T] (=<](>]:!Z'YT
MT>2FD1 !  KZ[\0$  0I[J[]/D'@A4 >(#T/JZ#NH0'KOPH_[#3ZJ_G2(AZ0
M\ ^8UC2-RH0&GND0\>N@^?I !Z'KO_Q131Z@ZYT/.AX("' I[YT(<$.OANGZ
MA]!&K@"'=0@(!]0^= _(/A_L>N"/?_A__]H " $!  $% /(WTUXI.S(C,W*Z
MU,"2-==%NAF-Q^MF0;^2JVV:^(5.=)">,1XELS%&8\;)O-I\-MDD<9*_</X6
M8@?_ .-2;;Q9!]KYD/GH ZT7P@.D41/EK2LJPE7FNB@Q,MUU.N_[@<.: I*2
MEDE&_P"&4UJLUYH^1&1JGUUY4FD9!5LDQ/\ :'5-KJ81_9.ZMM?,S'(D-#>+
MDKFAC7%J/4/6OY]ME_@GR.#GKLK1J(V4.NY<@BZYG72]R<VG'1-.UM8U232<
MI8V$"6KF1$.V#X[YF^0TF4O,J)*S)RYXFB..81L5&5/A+>=<=(3EB;4B?6*?
M^#OMLO\ !+ENXUC,D3TR@ABZB)BQ,)@WB='_ 'T)%N"P0^PF2B2CQIY>2_-[
M,UTQ3.>.# Z%C:-F#",-<F:T3,LNH&QN,^TQ?B2O9YB3?8BWS$,XM4#F0IAP
M84YVNR#!@-6LZ#OJQM>$6BZC:C'EE2%XM?<3&^L,7>CC+/ X#;S]([7]79N7
MWJG8V!$M.S#8-,IE6)UP;.7D<1A;,]VGQPN[)X78=PHV!P?.ZB>449E#4LGJ
M:1OD#"+8>Q$ZROR+1=HAMT]>F#$G&L6[EN];]X308M_Y&MJMDQ]KRW2TUDXR
M^_U:]A]ME_@F2;WLO'-HFBEJW\R+VOK48CDY)Y5*Y*(0@?\ V!M*XS1M/)%S
M59+(KB3(S+P55!].D"9JB=,2_)1):UH)JI*T:NH#VQ>+2SL-<5T6:UHQL-&O
M#7+&[$Y?@ EN8\'#S &Y%*0& .XEZW^R7C@7);8=*R.5]X=AJ6"]-1QDS:O[
M+HK$5*4G7"Y;AL,Q<E41SUV)94X[&^!NE$LH*3:+<93ZJ<L-]<=AK]:$1(CV
ME!<@.V>-1BPP494&1'"66)RRTT^"BA?$.R*^DX+GDVC.=]U[IS%XV)(RIQJ;
M\Q%B746IV$=%1G/R.]XM=78PGT7(>/M*:%E?=55(54LHT&V:#:"AFY!T[T6/
M8?;9?X)V+*TM1T5(MLX91/+-=$U9BOM+5+Z[F&$^<IJ&^=YN[FJ77_<K*BS"
M)2Q0)X@5I%_I/#/\,GT\0)(C]HM699]RJ=LNN%<N#G:L]>#^H\FR( )GF/!I
M2%_ BM) MY_KY.7%JFV]4SH(1XTUSDE<ICK'4NS(K#*?*>A:-J4<IL"C(G,H
MRT7)EXAG10T>Y7QI5,MB?9? 7-ME<V(:G8DCO-,I>6[EN[08Y5S!+W[0,?W&
MV%-VJC%;HOW54 U4XNG$K95M];S3NZQ,#N;T)>31A)%Q3*$K2*;KV8[.B>!S
MLR/G1,[821[FI52+A] N44KTO.[FB%J4 [$8EB][>E!;"5D3-Q7S2&B*#:#5
M_P#%&Y"1*"S@(A%E6;Y'81ATXK:,;H2;V.[L9A?@&-H[8)B5+PU@Q"LZMYFK
M^ V7<LZU(FEM#OQMV;5S,02ESEDB/=50"-+71<FI"&3&M*.[CQ*@'S?2PTNI
M813-)8R^<>;0Z]=H!YKM<QC9M07V0)O3Q+N,\0X+QHDXY<]Z?M:]9M(:G8"I
MV4VKS4O K!F:_")US-<WA_X2N=E1,5'/)W0REM6"I^6:SL!R)!-ZDVV'=P_'
MY:AY6LB<M^93%BD74!M1G0-449VM0KF!QI1QFS.8+RM 9\PE$GS+GUX]6W%'
M,N[\-Y=DTPT5\!W!ZHC_ ),#7+;N#V(@\&(7A27X%&?Y83N6M&QUJ:(F3E<G
M'7EQ(^B*K.I[=(2J!1F4QDXIS&1["3.?EB<S5A.VO%*(YL3?)GFBLS1HT0ZM
MIYB5L?'MNDTTN(CDF76PT?WPJCM'XH8QBLYH6G,^9$9XX9=1A#2)QF%V!<0[
MM4D(;2!MR$UP1%<"AMZ8R+DLIJ9>56+<_3$VBBW:,9X%_-IBH=\RD!JJ<18(
MU];LMLG"N!,QL<4 G?%6BX6S*B>:C+K80BV#0$7MJ2RD*_OO>4LQH^0M32+A
M.^;,MWKADHWLDXX>P-'/%/L4QSM'!!#0[=A\W,Q6O9ATS9T"\N+RG!_@Y0Z\
M6KE>XT6M?#61+7_B:IE-GM.S**)XXC>Q;@!(0ID)3"9D"^FU$XS+J[[*2<PZ
MKB;G(3TS;/9@%L1R!7+>VI@?I]\;E4G5EBA3+BN@;<NDL%-Z:K'8M'[J4Z.1
M.7ZJ=6-7L%7MMB<D)=>.@O:%(B8"4UC[4)ORM;0GFIMF8: <FYNO% K8YK#7
MLKGIB_O?E#L0AK'/*RL;!QHB[,)5REVK[6I.[&(L/A.>8S=P.C-JZ?%V7U)Y
M!)AZEFSC+N]/2)>U]*NGLBV:NEG[C'YD7K^85ZYDQ V/S=FZW$#T"2[HUD:N
M99W11T,(91HV>+-^Y4S=GXCX:YZRVDE[2QM)MC6))!G=;FW<W;"(,B]J&.UK
M[.'N+BVD&6DUMRF*E'(2YMFGZ:\%6DDJO$WCZ9-#E+J)M-)Q&D'L$ >1_N8C
MZN^CI 1"+(\1Z8VJ'VP^%\@I#KEZ6=;&F46W&(++LTVNY38PWSQ%>T> AC>+
M)EQ$/, /N;&A%TC.744B3 .MG6O\EOO!NUV&."],<-O$<G38,=IL$J.6-I.O
MR]S"V30 S^8L\8/9M,^ON #1DWNUS["D+/9@@$!#Q?V2S!Q:1K#R,8J3R(]D
M^[3V'R:O!U#ML6FMJFNBUXF-S*M%]6IY[J\V+J#.&NCWYC<JP#XILZSX4X]A
M4Z!#?+E79UFPHQ\9&I!/(!*<0Z,>UEX+,,T>*T#]M?8A&6Z]=BC)*_<3)'47
M+QSI6Q1^YPD*TN!!"3O];;UKH(F'V.-INDW^2Z8#!4VY;].S5@.TJVB9,'<[
ML\ERK8,P;U /-KIQ'CB;,ECM+RT2L.G_ (-:\F[>UM=HVZ/?(3G1RRZ/*#JC
M[CS'+SQ*:NM4[E-.?3>V>*TMB+LUG;*]F9"'92O4U/*=*X2JMJT6H*7;*ZEM
M@S QM>YA(T[G7$1\?9=)%5I]>)/PW"VVP+H957OM-:D-JY0I2C8G^P8!DR@[
M;-S7+73+I5&N/+*0Q_#_ $JS57\E$A .$"%%V6?J63)HS[;)/M^KL8IJOD4B
MXI155K4AJOFA^MH^Q$B,G&L*20E(<5Y/MZH7.V]*!0:/:U$<$ J#-2B7,N9[
M),R:<V2ZG9!.Y*#6UJ\8E%1^R]6, \BNC6C& OIOZ]">FNQ#!U"6UOICC)Q#
M+O0RSLVK1KC'VT4BM_[&3T++]V<2_(J1V2L&4T2RW=119)D]=.^@VD*]90]K
M,*#F'GX!A;\%.ITZBDVQ^Z_7Q(%Y_P"-IHIH#P&BFH>6[=NU3X30A$EYB8<:
M-<..SK_U4TUTTTA2%---%/*K=%?FV0/TPL8H2&,V8I*HW@6KC!>PP\4?*.:N
M'OR,IM[(WWARL9=2DV,S1T_3)>>3#-?OYZ;^H=ONV"5B/'XN)9TE$9-';9Q'
M=C^%<J)L8GD53913C0RRG\FV2,)[+U@-;^HMXV!?DQ@7!TVI,-7NO<RJM:K8
M)8EP-=+ X7-C$"TN60W9QM3=?.V,89<4XV*PVP O&\CMFI3RFO:[AU@NMF)1
MQ^Y82D6S_P .U\YCJ13]HP$H([RK3*$F5%)S\]I=K>M1]UZ0R 9-3O*W#X-
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MFF@)ADUL:V[QTV'R[,ITQ!DOL%@@B8VSYF1.MUC1RR5M]7<<-D<99'#&?9;
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M'>^YUO"6))$,-K ,S7("%B!W@#D,ABXN+C?MWGT(6TM>O$&H*TK&8E6O"I(
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M"@  R  H/PM+[;H)A]N-'^\#C;[7D_E*!(JF2:6+L8:D5"1:=25&9=CI(J$
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M *0OEE.U*:=-.M$,F:A4JA8*6.YBI-?Z&#_=8GN[E]5Q(Q9C0"I)J30  9]
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M>=Q]&/2;'=Q#[%RK?0\!\N/K;I&WB@D_''CT?,-S'^?:@_2D[>3#3-O4=[%
MNOL.SDC9Z'BX<#5&OY80DG(-123BNV[M9VR2KK,$TFAHZG\@D$&-N*:B& RS
M%"?07MA*?L7=O_C2+BL>WA_S)87^[(<5;8;HCP1LWW0<5EVBZ4>&*0>5<06-
MM9R-=R,%5=)J2?'\Y)R S) &+?UW1);RJ*2)4IKH"\9) HRFO$=9:,M0<O>+
M;V=O)+.:T5%+,:"IH%!)H,SEPP5&QWA8<?0R?S<$$9_"713Q_O\ X(=W2<0[
M?M4;-=R5X&@"C-F9OR449L3P [^-LYBAW*>9=LL@CQQJ:RD%\R34+;G61*S
MNJ#(58%;"UVR P37UN6F:M2BEGC:).D!BA)8];00N1U'%ILG+FSW6X;S<-IB
MM[:*2>:1OXL<42M([>!5)QRUMWM5YKV7E'=MQNH(+7;;NFY;Y<271$<*IL%E
MV]Q'J=P"=S-@B4+,U%SVCV66_(UKS-)R58O>V$';^H2;E?PH\E^QGM5=D?<@
MT\A@2J/(+:%I%51(-?*_]U+E6%^@W]_S!N/\EMUMXS_H\^G&S;+LGL?]F^S^
ML7,47;P\KVU_+")'"&14NUW"XE,8)<)&'D>FE%+$ BVM-\WFVY)T'9$NX>6+
M^-XK[U7MO6XMM&UF.,K(?7U861MA/Z,*7ZN-WVB+VI2,MK=21!QMEA;%Q&[*
MKF&2PCEB+@!NSE59$KI=0P(Q3_U=OU&?U8K1./'ZMN,<I\M<P\_\Q;SNMG9)
M'>74VTMKO9W!:YD<"15"R,S)&A5NSA6.-FDT:FYFL>1?:P^[\B)>2"QGO]GV
MAIY+4FL7;I<;>Y$JJ0DAH [*7"JK!1_YI:\IWPZ?6.5^7'KXR-K4GY\$WOL:
M]F=R3Q+\K[9&3\MO% ?FIBEW_=N]F;]_3ME]!7_[MND('R 8_P#./[JO)\A_
M^7O.8K3YM&].!\V)_;?M_LJV3E;>M_2:T@A;=)[[MMJCE"S-)'N=Q(\"W5U"
MT91#Z6" ,_5D0G>N2=^Y;YWL]NFC2[L;K;-RVG<+6>TGK1EM[BUAEA,$RS6S
M0R7KM6'7K9'1V,FV_P!X7?\ : 1E'NG+1DTGO--MFZ7E:=)6#Q#HPQY2_O-^
MS^[@IU1>3[GM$I\!7<=L@B4^.>GAP3RG;<O[_!2H?:^8-CO=7YL<>X=N2>@=
ME7P5Q(=W]B?-,42\9!MEW)%X^VBB>(CPA\<D^S7:^5[F+GS=-TB@@>9IH%AU
ML \L\0B,G86\8DFN",^P63++'.?(G,^S/!SCM6Z36]S(9GD21HF9=<2NBGL9
MET2P,2:PLA%00?=K%,ZGP$CR8I%O%TH\$L@\C8[>TW W,<0!>.XN%5'1LBM9
MI%S/04.I>/# AL+*.VL8X8Y9.V>V>1^TC21?12$DH%D!1EC/:J1*A,;*<5GV
M[;I3]JT@\JHN/2\M;8?%'(GW)5\F/3<I0U^Q/<+]!=QCK<NW"?F75?H>!O+B
M)M6ZV_6H65X7*@Y$Y)&3EWL_ <6QEW%H+!%'JLD+L\A+4)T@L#*&&<H<C2<Z
MHU 21S3(I^U:O_BR-BD7-L%?M07"^2-L>CYFVTCPO,OWH1CT>][8_BNHQ]_3
MA'A]3E (-!=6Q!\!':@D'$DUYL^UQ;[( T2"&L2C.BR%9""9*BC+41T!JU6I
M>K<6<5O<+(5:.,41&7JD* 6'$=!()J0?@RIU5_!#NZ3@0<U>T*YY:M8X'DBN
MX=OEW)NU0J>S>"*>!EB[/M)))2S(J1D.A#$CD/E'E7VD;GN6^<U[%%NNVV47
M+5^BW%K<336\%Q?7,=^?4K6.2,23R%9(((2MPYD5HU'(?/TGLOO>8(N1-O@V
MVXMK._%A'>07$CN]_N%PD$MU+#%N4TCTM1#,5O0'EBBCU1W7+?LU@VWD/E&9
M0CVO+L!L))U7(>M[D7EW:])6BOZS?21N/^K -,;9SORKNS6O-5G*TL-P4CE9
M9'5D9RLZ21LQ5VS=&S.H=8 BV0>U>?LX7+1J;/;BJ,:%BJFS*@MI750=;2*U
MH,7=_=N&NIY6D<T"U=V+,=*@*M22:* !P  RQ8;SLFY7%GN]K*LL,\$CQ30R
MH0R212QE7CD1@&5T8,I ((./6/\ UTYQ]8I35^VMRU4K6FKUFM*Y\>.>+[>=
MZW&>\W>ZE:6:>>1Y9II7)9Y)99"SR2.Q+,[L68DDDD_A0W*?.V[[6PZ;2\N+
M8_\ P9$QSES#_>9_O(;Q<7FE+3;-OOAN.Y]FK:9+B_[7L+DH^E5M80)T<*]R
M71E9".4><?8#SCRYO5[,CVVZ6=_RS:7$C&( VUZ+G==K:1PT1-K)&+@Z!!"5
M0*S$'U[V+^S*Z8\2_*^VQD_+;)!]%, 7O]VCV92#IT;=N-N3\MMNT('R#'_F
MW]U'E-CTFVW#F.U^8#>)5'R@XI<_W5>S/?M^9MT3YNWANOIKC8/9KL'L+YJV
MYYM4]U<P\QQ7,-I9PT::>6.38T<KFL**)D9YI8HT<,XQL7MTYOY1YHM-KAAM
M=HN1L(L4B@C@C$.W3W$-ZFHKV*IMZ/'(J(MO:Q/1GCU%;+GKVB6#=!GV;:+I
M1XS#O,#'Y%&*Q?WFMQMB> N>5KE:>,VNYW?S@'Q8*;/_ 'LN6V;H]:VGF*U^
M=AM<ZC](X9MN_O+>S*4= ?<MPMB?DN]J@ ^4X$VU^T3V:[N5!ZB\S[/I:H(S
M2XN[5LN(K2A&>/8_S)RSR=8[E[09A<_MRP,L(@L?69!+MQMWDN(X"##Z*X*3
M2"2Y:/LBZM7#.WL1WV51_P!W@]9'R>KM+7Y,.;_V'<WPJO$ML^X ?I&WI].&
M_:W)NZVM./;6EQ'3QZXUP4=2''$'(CY,*I8*"0*G@/":5-!X <<\<U[/NEO+
MR;LEU8VT]ZO;4M6W!IUCB4F$.1(T0!9%(@[1:E#-'66".ZCF13DZ:M+95J-2
MJW@S49CX,.67BP:</<H:^YIZ>_\ )W'Z/#@$CC@][N\V*@>XYVZV669EH084
MFRU="NCT-:"H /17/'('LVWB*':MNW<1&\D>%;9_4[:/UG=4BD[-:7=PBK:0
MPU']+*X4"(D#GSV,>T_E.PYRY?LC=V5A+>6+V^Z;/V36[VL%L)T-T+=8Q-MG
M9AX6N+>6-5:5U*;YRQOMORO<;'N5G-:W$3;5%IEAG0QR(U'S!!KWJ@$@T_=<
MDNV;A/;RNNEC%(T9*U!TDH02*@&ARJ >C$MI>;[>36KTU(\\C(U"&&I68@T(
M!%1D0#Q'O>6^9=UY<MMXV^PO(IWLK@L(+D1,'$,^CK&)V $BCZZ50Y,<<W>S
M_G'V(<LS[!O-H\,P$M]J5B0\4\6J=E2:WG6.>!@O4DC6E!@2VMP\4O?1BI^<
M$'"_LCVA[Y:TX=C?W45/%HE7"O9^W3F]*='[7OV7]%K@J?E&-#^V'<[A.D7*
MV]U7Q^LPRU^6N*[ON6P;@G2+KESEV<'QE]KU?RL'V1^T#VO\F176_;5(-\7;
M+'U"![Z[0%IH(+.QCM^ULM-ND$X5&D>T21@A8J-]V.SWJUW*SL[N6&.[MBQM
M[E(W9$N(2X5^RF4"1-:JP5@&4&H^#&[^7NU+4Q7%?!^]A03D,'O=WGP .[NK
MC^'SXEW_ )(YBW#;KNZMS;3M9RF*62!G5]%<PU)$21584+J.'$<J;CS1S+)N
M7/7-?*&T[?;[7?J+JRM^P@+<R;IN%O)&(Y-QO'GM]LCC9JA#>3OFL:NNT[[[
M..0)H(MM:PMW_LYMJRV=JPETQ6<@B#6XB>:66$I0QRN9%.KW><><MIMX9=RV
MZS::-)0QC9@5%'",C$4)R#J?",.R\K\OE@/XEW_XC%O(_.6T=LR*6"WEN0&(
M!('I#T\,<Q;UMF_[9<W]I87$\47K45))(HG=(SH<M1V4*=()SR!..V_]/MIT
MZ=7_ !%S7A7ZNCCX-7'*O3C8-UWOG39+/<;JR@FEB:^MU[*22)7>/KR*W49B
MO6 ;+, X8/[3=BU4/U;VW?Z$D;#_ /\ )K"FHT_4(> )IT](QRM?<^>T/9X.
M<I;<FZ22:"V99-;T#1ED52$TUH #Q SP.Q]I.P-7O;A:'_;8'JO-NV25_BW4
M#>20X'JU_#)^:ZMY"?<YCY.GY"W"ZN-NN>Q:2.:!58Z%<$+(5855P1QR(SK4
M#>-\L-AN-OCL[WU<I,\;LS=E'+J!CJH%) *5)\GQ%I6GS_@N2^<?;79;HG(N
MU2K>HD%A-=>MW<;JUE R+II"92L\C'4LB1&$@"74NX^R#F_<[^W]L^VK:[SM
MA]2=HOUR,%X)+@,*+>6S4E%-$5S!&6+-$5,W.3[&VX0QW4$+1+*(2!/((PX8
MI(#I8KU=.8-:BF-MVU?9M-&US=0PAWOXU1>UD2/M'8VX"HFK4Q8@!5)) SQ<
M;7[,N7KWFG=(V*M)::8MMC=>(FW2?3:Y9U6V-U+E01$Y8YIMMXYBM([VXM2D
M&T;:%CMW=G4#US<;Q>VN55"Q>**.QBD*A36H.' Y5LJTZ-PMZ_)6@KXR!X<6
M1OO9YL@N^R36#96C4?2-0U"*AH:BHR/$98YKM>7O9MLK;_+MMREL$L[.)^W>
M%UB*RM&HC82%2'+#21JJ*8[+^QL';=G2OK]IQI2M>U[^.5;;=N1=K@WZ+;K9
M+@>KVKN)TA19=4J(1(2X8EPQU'.IK@K:[5;199:8D6GS*,.?_51LV8_\O7I)
M/_>^BN.6N2+J:+</V=;]EVSPJG:==GKV9:33]:E-;<*USP?6N5=MD_.MH6\J
M'!,WL[V)R>_86I\L6#VOLTV3_!LX$^XBXJO(=JA_JWFC_P!7*N.=5Y1]F.\2
M<K"_86K)&SJ8E1%JLDLA=U9P[*Q9JJ1F/JKS-%S<_-/+FZC<@T:074MDDL1@
MB <QJ6BE<.KJTA5CIT)7JT%=L]LW-4;?UK[?<K\T^WLQ^5L5M?;>[KWKC:+&
M3YS ;4^3!6WYSY:O?#/MEW ?GAW%Q_)^3!,VS\H7:C^)=;A;,?$&M+@#Y6/C
MQR^>9MN&TWXV90L5IN$MQ%(@N9Z2EUBM2C%BR:#&310=9R YHN+?9=VWNNT
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M<\4;<D0_;U)]\+@LFYV[ "N4B'+CT'%/V;)^SZTUZAJI_'[.G"F=-6JG17+
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MOE6AO:S%YC8(1*8T%[JTK=& 2E1B\JK6=QEJL^D/[)%F!TT)"LWOF-.KCJ"
M"H#C6^,&HQ6GTR-L<G3+$=O&S]:LE-ND(1NI,4V]4BX1-?N=(M4:D\14582C
M!HY\E9-4I3)*$.;^S?/EEEM:K=3FIKVJLOL3%.N0<- (2N@6+:K&^6LLP6.:
M-$I.>F+ H"KM\Z!1PX, "H<P '2SP<J5F.KEM4_5)J'>B171U.61N?0NB1IV
MA1/9%-6%8Z+HB8 ,C\N J@!Z7X^.9?&VD:S3Y;GE6?;AT:XV+(8*YP;_ &>(
M?S6+S$<:T*4V.?*V9H$M/&439.@;E [I=N*9NJR(G_R^L7C!X1QHTGRB]L1#
M"V5?5CE[674:^DX;:,YKQ8_O=DG8:71EB3RR?06[HRH.S H80'_,YM-W?UQI
M8F6\3ECT9"XN(U%__AK=<:Y'^%CRP$E#%6-GX47UA&)E^K(&YU"DZ 8W7_*B
MN=Y!ZVJSCC#[A[/,G%T%0D.C?Y]A)N\L18K2?1DC.S.-KQ*=>*(@LNV%,C/N
M'H'CW[9+/%R(Y"9_PG@)9_&>G6K!N0L7ATFC=Q9D1,+1:T1"2@$G2I]%"NS$
M(Z_;=.ANOOQTLW510P";@)D?4"G4,8I [9@H=J91 H=>H] ^(B/41Y1+<N=K
M_C[IF(\\-^X[Q^A%I=4H3>0JN51]$BV0,Z]48:%9-F;N6<O7B?J"+.R%=^6H
MJ<"%Z?V9+RTK/%/,H;DD70;-JG\8V:,V6YGOUR3EDK-85GYYDZ2ZLJ2==]Z!
MTS-2"L(D2*(%$ YB..(^2*\B?O,G>1OAHI_Z(^@)&\Q/1U:&$D&<+:61U_Q(
M6,T0,V#O_B/5>?\ M/&U>X:Z:UYQKVGX3F_'6$&&JC>!=P5#ITL]LUHEK1.(
MR+E:]W2\S7RAF=^N@W-'P-8BV"("4BQU'_)_'N(^1T+<7KV<DFESAHJ0%"KR
M=G25;V.3S^I/9)W2<UDYYLX51>.*]&QBSE!91-0QB*'*:N:]R<XJYAKFDUA@
MPB&5MGFDNQDI6#BGY92+KMR+7Y:'::#68Z0+YJ$;/)R3!$PF[$@[C=6."\@\
M/H6E9)#+PSNMTV3BABVM-?5UH:/@)*A25=6AYN@RL+&J':M74,Y8N$&BAT"'
M!(YR"PQGC-DU1QW-F$@^F?N[4V:Q#2D])^4$E8[+-2#A_8+99I$C=(B\E*.W
MC]9)%(AU1(FF4OCW$_\ JY\UO^?HWXLZ_P RK==M][;-DCURMVRSO*9795V+
MMN19"3L\?7;:\B$4V1E5"G)'.A,H0I!* &$Y;]Q;HF;\69O9J!&)/%8T>5MF
M2K-ME$47"MHJE'L:/'MT2QVK-P32^\;--$%(_P!1]GS10= @Q5E&S=G)J,VR
MDBT9NCO6C5\=$AG;9J]4;,U';=!P)BD5,BD90H 82%$>T+0W2T1AE4D\@95"
M+OSXE=<EJ+Y1FL5O8RQ]J ]?D/DZO1?R7A#MC]G10!+U\?PM#G5HY^.QBEJB
M?)Q/CEQ[,D;0AE1:C9_N]]V.TV#BUZ(%ERMQ>B\_XSL^5_MO%=A[5S%P*YV*
M,AX^/F[>^U3(H%U9Y9JT23?3:\-"3S6&BUY-8IEC-VJ9$$N_M(4"@'CJIRIX
MWD "]_4VXYB7[/T=WQM ?9Z_7XK%.RBH--8XTUEV]A=DU6%5=.IZ?D72B+4)
M3#F:#A&/LD!GJZ2IY!9<#EL)A40C#%\@CAU$3M9Y-8-*1T[&LI6-,35Z0V=J
M,I!NFZ:BXC'LTVE(]R*2H HW<(I.$3]2*$*<HE ORC4\XE>_IV?+KQ67W=U^
MCM]-**]W7\W@#QTG'ORC]!F3ULZ*/U_ 4%% ^C\-+?[I:7[!W?+ TAH*NUF)
M5LUH&+]4W1L%V>0+)4K]"CTIHX!S*O@*<4T@!-!-=RHD@I"6RIS<79*Q9(MC
M-U^P0CYM)P\U#R;=-W'R<9(-%%6KUB]:JE4343,8IRF 0'^Q_N)_]7/FM_S]
M&\-;/K>B4O-*X^E&\&RG+S9(FKQ3N9=HN7+6*;/IATT;+2#ANS5.1$IA.8B1
MA .A1Z'K:?/RHY+Z9\RLJELQC?,XKUS,TA0<.%HL'KY&SIK1,@3J#AN5J*RW
M:4"" ].NQP>A>X!S7RJK4>V(V[$9W3M:SZH5[3,BKD?6PE4YEROF:"Q[(_N#
M*3<FB70MI-S7))D1(@K).02(CQMX_<C^20O4C?*[36\X<9?DSAP';]E;5=S=
MYM7UV90, F7C"2@=H@)"GZAXL])M=BQCAE0KO OX.0=Y?,6[;^1$1'R;=5H\
M)"WATVS'.:9.*-E1*5ZV83AFIA[T3=Y2F\6+#[+=T:3G'&Q[1]+E-@S>="&O
M$[4[7(6)7*4<Z0;K'FJ-?;4%3E49=\J(EA?1N3MU'0N6ACE-:ZQI5Y7 1,HX
MO/(CD/:S+F-^L*[>7U)RQ.!NH]0\D"CU^CQ?[A7>.?&>+FJQ3K#.1]FVJEJW
M:C0KJ+BW+U*6NX23A],N*RP,CYK[R5B+"W*?M, _'P>LCR)X2'J(58-J"H&:
M;'_AG/85)0[0<2)*A<0N9R)& +-\D];Z?Y08&/;Z0!+XSVRR63\<)B5GJ=7)
MM[.YME]?94.8<RD2U=GE:8A+QSJ72K+\%O,9 X546],8G<8P_'PX6C<@SE5P
M@V64;,VM+J3,[I5-,QT6J:RD:D@B9=0H% QQ A1'J(@ >,%J5ZXHZ'DMLWX9
M:SW_ (R0.VX$VK>J3R)?+H0M+)!6L\/F!=*FX:28SC87C(]B]*FFP!-XLY65
MKLCHG#W),VG56:C5WG-@IF0W-S66[!RO'Q[,\U5V4Q6GB2\:V263!LNH5)-4
MJ9NARF*!BO.)_&U?N^DQL/S,JG]X*DK)5 '^X? F5XJ8FW,/7[492(J&,'7_
M &31"3$Q/]'3P)FV#1<481Z]8&XZ17N@_E+\BN4=V=/JZ=.GCLA(#5J\(  $
M4@.2_):),F ?1V%:ZX1$ #_N^"V["][GK=9V=BKF(:=F^XV'7[%,T2P?-@C(
M"7J6KWR$G%)2BMGLH)IB*)(/#L_MOHX' G6;%8T_!N??*)60H;D&^@HYX9A5
MLJBKY8TQL<HWI&>[5CL\I$5HYW@F22:JF34'N65[7"JH>"EK?N#Z*9%,1\M"
M\X%QYM?<'U%<.H*F49^L ?6(*E,/Y?!31/*7C]=E2_\ R;WQ:L<(4_3ZCNZ1
MOK+XF_*5N7I^3P/5CP2MK8O40[)3?\]<J@ ?J@0T3IB*)C?E$QP#P));AUBE
MP,7Z7%"Y:.6'?T^D4V5YPN!^D/H[G!?S]/#*OL^,ERXS3VK2Z])_CRO?Z#I4
M#3FSEBX.O'5&5H[Q_P#(=/L*("2&<3+9F@B5-=9L#AVBFF'I]LX^\C-GD,_F
M1HS/>L6S)6^PNA)Q+-N*X6UJSD(YXUT. *JFA+J,$'3)VL8%>J*YEFR8#:LQ
MY8T(O;W'4MO$?D(D@F'UB9S!T"=;F /RE.8/'E2^P.JV?N[1^]^7;%3B%-UZ
M=%%+3G\0FF(#]/<(=/!2L^6&"(',(!Y<QIE6KR@&'Z"G3GY&,.0WYA !\%)
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MJM>K1(Z:T=O7"/W*<G-MVL(@=*.<)E?).!$4JOL?,&CI"'0J-9Y=;R=!,/J
MK:QW2PMQ /\ >*;P(P7-KFU'G /V)9/2,WN*"8A]'F$NV16%=P4/K[U1$?K'
MP!*[[A.D%2(/[-.XX'QTM ]/J*LXB*-3G:P?E'S"B/Y? &8\Q\<M1R]>B-RX
MDJ,P4_V04=T_=H3I^<2H!XGF96/ K8O)BW3MA5;'3MDIS6Q2K!(SN*9KEE+=
M?X5JJN_13[#K=$DU.AA.F =Y;LV@<<@]-UFP2KXW*_+]BIL!2Z!%QM<]2R:#
M8I!G5YB/R5]67!BM:DI#M79'R(E2*B_9G4<$*FKP/J,BDF4"]:SRZIS@.A0
M !%&QY?4P O0/@!A+T#P!Y[V]M723 ?VAJQN7&JR&*'UB1!YI5<<*_F#L 1\
M?^<\'N:#14/_ !"Q=/QVTHE_+V*UO;I)14.OY$_CX$LMQ=YR079\5#N>+&@3
M*28?6(K5 EE2.!?K$@F\2$=82\C<_.]8NV9GDOQ6Y,PLC'"Y040%VT>DR-^V
M:/6O?WI*&[BD4* B @'B&KN<<BN=UYXJTM:1K^LWR2VE"-U"V/B^E;/+7G\-
M-9[%NH>.S%9HX%=A(D:.[$HHX3$K7T[4ZV;.J;HMWUNI2U686"LZ3H\DYE[K
M<(*Q@>=BI>>D'D/7WBSA5E(D*F59DV530(0AR 8H_P!5B4P 8I@$I@'X@("'
M00$/K 0\$XO8]9/8)I63YK:= _A?1=AT7DC8-*I-#ME\LESJU1MUE<LJU)6B
M1@(NP)MOF#MDF[<IIE%8ZQP%=3"M(LMSP+0K-:\]A7]FN?%B1FI;CI/V5$BC
M&P/,;D;'_P"?.J&68:+)L3//^(\LG13[0#_0^XG_ -7/FM_S]&\7Z0LG'RN\
MF:7)&C:U;LNL5P:T[YHUM#HM?KQ*ZY6A)M[*W23N\C%QT,S8>EDCR3Y$[5PD
MLF01W+<[H% K-UX[[$YQJP;[+;#CUM1Q:7JU?K=JNE-RG*K]2UF&AZY<6LJM
M'M)#ST9A8$OES,C9;Y@JM<<F9<LH3$5N45JLFH.[-;<1K5_DIF[UVNP\3'5.
MI0;R6C:U2+/)YA6$"@FX4>1P'A!32375$A%H^\[N[O7+[28U=1Y'W#E%8R:3
M%0#M?M45&DY01A$8M0T47("HW&*KK9RB(A^W,8.[Q.Y/H=<0GL]LK!I%S593
M>2<*U=QS!VS?-&1'5?>Q4BS;HN6"0@5!9,!*3L'J01*+]4W':(\^4;)LY%P2
M\:BFZ>M42KD00<N4[P5PJFW*Z4\L!-^S\PW;TZCXC8:-2,WCHE@SC&"!EEW)
MD63!NFU:I&<.E5W2YDT$B@)U#G4-TZF,(B(^)>KVJ#A[-6K!'.X>>KM@C&4S
M!3<3((';/XN7B9)!RPDHYZV4,FL@LF=)0AA*8H@(AX]%_A(XQ^C[_,])_ 7*
M_3>9Y?E>9Y'W4\KO\K[/7IU[?A]'B(J]5@X>LUJOQS2'@:[7XQE#0<)$QZ!&
MS"+B(F.0;,(V.9-DRIHH(ID23(4"E*   ?T'_M]?Q'_W^.O_ +?^WQ_$,31<
MIS6_D/U[B76BU>U%-U#H/<6=BWX#U#QE]+X&\',RA(OS7UTUC3,]6RS)C2KI
MJ+F+K&;!#&L%5*]CTUEU9E\<\>NB99!B"2I#IJ@.E9ES&S';<KB8YVPM6/7K
M-^6USJ\>V2ECJH6VA*57&]?:Q3 [:63+,-G1HT 6._=%45$Y2 8/E/*7GG %
M)_X:;+EYJ<HFF'U "=K?V,ABA^0P&_/X$T3SPYYLC?\ RP>ZGF%E3)^0!):\
M6G#*@'^\81'\O@?NY[BO(I( #H4ELS/BU<"]/H#S#*8?$KG'\X'*/CJQ]PWU
M90'X$LO$O()$!#\AQKDU3S#U^OIV^+CNMQY<<>KJG&^CKU.JDYQ9EJE.W:\S
MYCMH.O0\G%<@G[!!X $6>K*J,5D6[)FNLHF*:9@\6SB3G&EX+:+#+2%OVNHK
M\DG6BR,O8Y6?D33.HUZKSU"?>6BX&:<KV99LZ:JK+*2#]=(!(DMV%/*Y%PGM
MY0_\1.N;KM=1<GZ?4F2=PBQ-B";\ZP]/ %<<"Z3. 7_Q%*ES#JB_F=/I%NC;
M<FIOT_4!SD_./@%+-[<NXH)A\5#5#9^+EP,'3Z?+06UZNNU?S!Y91'P4LWP1
MYYQQO_FG8Y5FMM13$/I[3TK9;$JL7\@D3$1_)XD*?-4+W'>/AI5S&'"[4SBS
MLL+<8H8^1;/C(QT]$9UHD6@@_!OY#D!05\QNH<I1*(@8.5T/9>9G,K+Z!*'H
MJF6;2PN*1[CMO\.HA:M6Y.^Q\?CLS-)*P+@PJ0A#1K(R$(FOZL"*DZ>&[8G+
M')6:A4TT@-:K&-6=*"0I2"=P%F:0IBJFZ=3B)2_$?H#PD6(Y9\:I$ZP]$D6F
MYYBLN<W^R#<EG%8#_F$O7P7[N:AG<_W].SY)=:U*]_7Z.WT,FOW=?S>"J)*$
M53.'4BB9BG(8!^LIBB)3!_=X?/D6+N359LW3I*-CP;B_D%&Z!UB,60.W#1H+
MMV8@)I^:JDGWF#N.4.HAQYT.[\"N049>-!J^F7FX85*N,&:#N5KS1&ENZ==Y
M2I1^T/JQ/*4U*1?'FR/7S,)GT[+S$I!-FX($#:9:B6W,Y"7;++.:+>BUTELK
MID7;AH1K,$J<_::\599)N58GIG[@GDJDZB4W<0O]5& #"01*( 8  1*(AT P
M 8! 1 ?C\?AXXV2FE^W+Q\]Q3F/!NN859YQ8BXY.4VM;[NJ.L:NRMV'\PXBX
MVBYL$6;Z&C89))^S6*F[CHZ[+B5,5695$N*&/;RA2&>N9SBE,JUUC,Y8PC"F
M0LA&QX)M*_#)UMNU@'?W?BA;LG#QF3T[]TW5<D$Q5@,/BH;;Q+>87#1'\7<U
MH6MV+48FRVB^1,9H^B4NF5G^$=39HHTF3?N'<R[&6<3SHI&K$@>E05<* HWL
M%LG%S-H2L0<M89AR4@J&;Q<*P<24@N5,OVE#)-&QS 4/B/3IX@O?7F]?R!3B
M#+Z9&2TE[<K?"8H9F%XMS6\AA;2P-N3"=H&[/=V:,U4IU0AF?W>.H<P V A?
M1FY*\)N"O)3/.'=1X08YAUZT[4K5@$+R#LFQ:MR,K;R]T.BMH:VS\%!4[-(*
MCMVZT@]:E4FCO%S$)^S$HI>WQ1\CC<LQWGMS?Y5Z?PUO6@RE>D+UD6)3/&][
M,DWC9J71)"19N;JN]@HYB]K\!(O4VJ2\J9!RZ5*U Z_)GVQN:&J4ODCH.38K
MG'*''^2E.R^-Q23O637R<5IU@JVC9C7Y69JD):*5<2HI,W46OY,@R5%14B:@
M 7\'N!PFES-L@8.O>\;S9L:+ZH:E>,D=D?-DZJR5"2L5"L]5D)"*28N53F:.
M5U&@'*582=Z93EU':<VM>T\@J]Q0VS8;I#+.M=TW0Z(SMTI=STOV_D)B*MU_
M5;3N;U6092]SD9MDT?.!7AHINLJH1\8/#K-N3G&[D]IV<:W;F=,OUSIE$NT=
M>LNV]Y98V>1N,O9)&+2C*DK+J3:J5R!XNU?I0SY)?N!)+REZG?*D]W^%ME'L
ML);JO---GF0=Q,_7Y!"2C'S8YF!NQ1)=  $0Z")#& !#KU_[6BWGH6)FV[9?
MU+="7CF<DB@Y\M1'U"*3Q%8B2_DK')WE #=IA#KT$?#>1C*A5XZ0:BH+5^P@
M(EF];"JD=!46[INT371%5!4Q#=I@[B&$!^ C^+>:%7KS.YG,7&LRU;97^L(,
MW%DJ1IAJHQ6FH K\IVJ4RS;K'%LL8!%!;M4+]H@>,VV7,N6&\1-QR^Q,9Z!5
M4ALZ%J[;IIJ,)F EP:U]HZ?PEH@';J/D$15#U#9T?NZC\? H2#)H^0'J HO&
MR+I(0'Z0%-<AR#U_N\'^\>*Y+8/,Z^9\[SBG2O?W?3W^OAE^[K]?7P=.2XD<
M:W'?U[E"XAFS=Q\?IZ.FM;1<E'^XX>/-2XRT.&4 1,4]5<6:G&((CU$4QJD]
M#>5\1_U>G3QVUN#V*G' 1$BU/Y2<H*^9,?J%-%CL!6A>@_0'E]/!>26-<9^4
M3YCC^AQ:_'AUK.@$T>R,<_I+]4C&$G[!=]"D[*:&OY74FO(1RBRR39&:50**
M@$*8U1MLI59ZBR=EK<+.25*M*3=&R5*0DX]N\>UN=39KN682T*Y5,V7%%11$
MRB8B0QBB C_51@*;M,("!3= 'M$0^!N@_ >@^,JGFWL[:SR8Y$TG/N<F9<C^
M45*U+/I&B^X9;>2\U47.::]?=)N]G^<9W7#M8J34EXJ401<0)9@Z"! 21%(>
M(_&O7K QLVEXOAM'HERDHMXM(Q#>9B(PA5H"%D7"3=:1A*HFH6+9.!32\]JS
M3.":8& A?%5XU<4.-A]ND[AJF=Z-;+DYV;+\KA<T0Q'1J-H4;&24=?Y!E*6M
MSI#9@^8-#1A3DC5T 6=B"9B%/Q<X97/BUGE$Q?DIP>UO9.5D.^UJ-NV]<:YZ
M-<N*,6N23VBO7V:2=3G+'9(B'B9!N9Y]X'2LNLU.BE N2N*]["TYQIJS/#(C
M58JL3/N/MMRSW[@3'$N%WT-Q1EHW$DUEMA:[H]8I)U_Y&K'A%E63%R,B5 X+
M$Y4<TN(?$4G-[-N<^*8+3[3GT%N>;XE<<>VKC?5W6>TN0F76L/8V!ELHN-,4
M;@[?QZSR58O4E!.S%,J9E_;GU+.HVA;MS?X1\N=:YEZIB<?;VM#INOEY-OY@
M=IQ_,="M10A:_9ZU7WL:UAY28,E%NW,<X65$A5D4O'*CW-^6F*I\5Y36\$SC
MB;BO'!QH]1U#08'+Z7,JW"W7[3+?G3V4H;.9N%O.B:)CXUXY59,DSE="54"&
M5$ L_,S[1U%!_P#[67L/M*J&4-^J@ "/<<?B/Q'Z1$1ZCXYZ<8JK8_NFZR#W
M7^42V.6*Y#]Y2)N\SA*+4X.)OLRJW^<.HVSUQ(64S)-/*?F!8Z_14.]NK;9B
MTS3^KY3QME4'5DFLWM"+&PV+1UY5R.>URG6B,4*LWJ4,I75YT9=LD8K@&[)-
MOV><J=)6Q5+<.8\6[D;PTT:SM Y4:JM%7BX('B0=R]WC5I<[:RJ33&":,WY%
MP$CID@5$X=@=/PZ]K]280TI9,_I[RP0\?84WJL*[>-EFZ94I)..=L'QVPE5$
M1!)9,W4 ^T'A51+-,(.H0O4I/0: ;N'J'P[2V_N'_1X8K*Z]E'K%FC51TBVT
M*I*D2=*H$462)VS*@B4BAA /B(]/K'QH-PK=ZSBQSE4H]LLT+"_?:#.E,RD#
M!/Y./BU!8OEW8)R#QJ1$PI$.IT/]D!-T#P+T,"R@5/0^J!$+A<Q,)_(\WRP3
M"&[Q,)OAV]>O7X>*)9[EL6,5&PV6F5BP3D \T^HM/DLO,PC&1DXD"R<PU> 6
M->N3H_M2$4^Q]H -U#PJ"W)+$?-*0W:#72ZE)"!^T>W]G'2KLYOC]0 (CX6_
M^Y-&[0<NBI]<IKOQ1(Y5*@8/^(#J!D0*(#](@/C+YG>-_P CA]BDH Z]\CY:
MP5NE+LYCYF_(1%>$<O&J$:<K$J/4I?LC^L'T^"^EY$X8X$_3L!'6J"H8W7Z
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MC&_[PJ0)A'P(.N.6,EZ_3Z+/:U&#_H&-CV@@/]WCO)A]98F#X@,2_LD*)?\
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M^_IX#OY39LQ^C_ZPI.08!U_VAF(9B!/]/3IX#R.9'')/KT__ 'NKU"-Z=?\
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M=TKCQA?);D,ML&LK0%CG*OGA;QQLLM=I8V8U9B9I^P3L]@+Z-J<41(9;X&$
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M255,NB#9)4Y?ZHDFD;(FB)%TP>-V$L1JW?'BWJ[=1)K(E9.@%J\,R7,54$E
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MO$XQ.[S7:?;>U'W):NFN<$6$KJ7"[;]QX^;E66("NB4]BMID:LH9$!*HLB5
MY1ZBH(>^5E>@H.4=7C>"/$*\[<H]."SM]MF[<1]ZY"Z<_>*]B8JO/O'K"C=4
M1 .AVPEZ   'C@3FVR\%I+BCQZCB<1'TY[N,C(X??VV)P]>T.KR3/98//LFE
MY+D)!N[W)MDJPF^DV,:@P+."M(. 2ZG/PS]T/C<R877F31XS;L68XO$_-7CC
ME;Q>?XM?M5T-M/EJR#^3D*CQD7KI="3<^6#% "*D44\YPR#QQPJV-: VV:O7
M"A1VR6/>DQ<JO>0.C;.7^)6B;9*.9(Z\THYT*UV-R]01?*K.XY@9NQ,<0:E
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M=D@(%VO(TFO4BJ+!$S4>^2;&0="+-5(%4%")^^H*0MSK![A-<(J=,$A7[$\
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M)3M]AUC"ZQO6$W=[.TF"LMO;U"EVBP4BU5U11H_=-X=%S'+2 J)H.@:@1QQ
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MC&%$B*'><SANO[7ND>UG1N)5Y]N'B30TM3PC$N2=LY#8::=WR$6E:9E>HV>
M5P^XW5^&+5U%Y)0)I9-E(N+1,.9-V"RJ#-?Q?VFM46FTZD#R2W>7S=Q'R=Y'
M19J=L&MWV6U@;]7+?7XMI"PT59UVZ%:<M'+A:4B^JSQ%JX 2J?AX?J<;X3C#
M>,%P+33\A-0R+D%J>M9>WUW::(0 X^-9N1R[.+RO(YSE5H>*6Y6+<]S67L$9
M&$=-SH-Q$?>^GO\ "UD>JRL]S8Y)29LU<U;0=A>V6YZ9L-78\O7PY5:H:J(Z
M9CF:YK+*S--=H/59&>69+^M9HF1\I3C)3/:OY"[5STXJVOC+=*;RHG.0]-M%
MK=<':51J^,MDU;R_;+U1JA.Y<GI&DKBG)YRU*1--4A#NFYNUD>/_  OI21<)
MLX^-9N7[]VL/:BU9LT3N'3A4P (@F@@F8QA_('CW(_?1VFH75)GMSNY4_C'4
M'55F$+W7^!_$EG-)ULE=J4FS83K*P;;:8!Y,.XLZ/5S(M&ZJ0B"X>,SY<\PM
MSM=Y]PW1:M?:[Q,XDPV <B(3 N!65RT%,V&QT.&TRP9-#Y_<]\L%#B%#V^X2
M,HV*Z<+FB8]/TZ30#_AU+#-+CUI7/-BSVXYC>(YNX,S=/*I>:_(5J>09O2E.
M=D\-&22GDK% 3(J]IP^)0\<+^"&?\I=2Y=<#?:3Y#5':KQN=ZX^4S'L^I=CX
M\1KVO\=^)%*OL8R-,\HM8KKM94MGGV1HZO1-<(W!0CF15[3>[[DG*X.2U8]W
MFT\X.06[<!$\OEN4L1-[ ^T\L&OQ;TKCQ&Y$Y;9]:S)*J*1<D9=%R]A(Y(S1
M4[<2%33X_I[P<RFXIXGE1-E.<S0YSZJ2BP1=",<\>(L#G-;0>"(H?L1']3[/
M3\/,1;0YU["_Q0P'7L0H+>-K-LMDC9]5U7,;A6<]IK"+IT'/R9'EIGW";1)=
M5%-FD=0!753)]KQ[7&1<<M'<9)HVIT:E\2M:Y/VW ]DO<+PE?X1C=35Y!V1_
MD[*A*V'0M9JC^3:0M6BO3#!2TVX,N9XHS:*B?A?M_MO/MWY&8Q[?ONRX]RRY
MBVJXY7LZ.\;%.1/E.N1&[VRI:-1Z7>="NL-&7F,DUG,=%K,T(Q%9-(Y4V*_E
MT7F7Q*D)W0^)_%#@-<,=N.^'IMQJ=!MFWZWIIYJ.RJDO;E!5YW:I>M4\!DY9
M5HBJVC3@1NN8BZB93_@TW9-DM(4G,Z/67+VUVH8.S60(5G(K(0C5T,'38:PV
M>1 TE)H$[&;)PL'?U[.@"(9=P+XAS>?0^K5'5K'2>=6=[TZW3"'S; +YL6KZ
ME-X[$W&"S.5EFLEO5%=14:^D8M-XDTK$T_)WE>"1(OO!L66&\0\QTA'C)Q-J
M2S" M6Q*8)3K]1>-MIC.)%<QB3<9G6#W++G N$$K^ QS)>N>E3;1I%S>80WL
MI99=<@XCW'58SD/S.UTFN5K6-YMC/?MMUK.&,KR:VCE=<'>*UA>E6R?932CN
MK%:$F"KNVS:*$J<<S#I^'_,0T'CK>IYUI_-^@P$GPREW6?ZI2(_1Y+*N)MIR
M^VS5>L]OIE<B8@:%J$VR8*G>.6BAENBK8%D0!7Q[*>9<% Y.TCW;,?W3 LGY
MX9RZ4Y),R9?QKIIK23E[$;Y1KVHWQ:KY@63>G>1#9H@V<._7"+3S79UC![DV
MH:GJ>O<7?=.9\PI8V$\!\WP:X3V&\V<LQRPP:G$I76L <4ZYY[R[?["9N65E
M[<[=&;I*>4<T:DW;E*]Q6Q[)5F5&UZ?R7.9O5*5&AVQU0T>5I\.^N]78%]0[
M[6<!9EW31(/-5Z$2 .\WZP_UIT   .HC\ Z?$1$1'^\1'J/]*/:4"]1$P]
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CF']AL$S,V&RR4U9K)/ST[)N';V0D7CIXZ<+&.HJ8?_P?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g790774g84m86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g84m86.jpg
M_]C_X1 I17AI9@  34T *@    @ # $   ,    !.KT   $!  ,    !'2(
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," P.3HU-CHR,P     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,6H , !     $   &(          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MWVESM"_UG>ZIU%GMW;:/?^B_1*LSH^2',W.I+:]I9!O$$&UT ?:'?Z1OO_\
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MC&S0W\&S=9Z=;G@;B!PJ3^IO&#3E>FREUI:'593S26[F[_3=L9?^G9]%U?\
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M'USK/N$S^>C856+6;/0<QSB1OVD$]]N[_IH\0"""4F-B8^*US:&!@>=SH[F
MV?\ HIP_>[3@:)[RX5.V@DG33S4*  T)A-G5> !&_HF40Z70G=PHL^E*2'__
MV?_M%[A0:&]T;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (
M   X0DE-!"4      !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !
M+     $  0$L     0 !.$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -!    !@             !B    Q8    &
M &< .  T &T .  V     0                         !
M  ,6   !B                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !B     !29VAT;&]N9P   Q8    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   8@     4F=H
M=&QO;F<   ,6     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M,&#'91O=K'9HDQJJ_J4M'JO'IEW .A=\6?\ ?TE\86.K;]9GFIM<'"1P55W
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M%5 NNR[*A<2"*0 PM!=$.>QS_?>YO^BKV>DQ[_YQ2P</)R+&TW8VX.M%U^1
MGW2VP;W^[Z7OV+<&/TN='USK/N$S^>C856+6;/0<QSB1OVD$]]N[_IH\0"""
M4F-B8^*US:&!@>=SH[F V?\ HIP_>[3@:)[RX5.V@DG33S4*  T)A-G5> !&
M_HF40Z70G=PHL^E*2'__V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (     0$
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M(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4
M9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P  1" &( Q8# 1$  A$! Q$!_]T ! !C_\0!H@    8" P$
M        !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D
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MD4QC/3K3V\,D9NMPA2!E)(KWBGK]OE\N@$W5\@.O*3<>(DS^)GR^0VSD*R;
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;:[4B.X>XM^C@*I'&HDW/\
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MGU-''&JN[O(PBBCC1=3.SL50(JBY)/ ]U +T* E^J'P85#'CUP*JT)E1T=;
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M^Z]U@F@69;7T$$>H %A;GTWX5K_GZ^]@D<#UZ@/$5Z1F:V1B,QJ%1$8&9?\
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MN0?=+E/EF>]WN"7EJREMVG_4"J&2/3^HE02%4$LII48; /0\_$#>7S1^(_R
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MV!NG*4V:JE&2H,?'5P>=S$Z%W+*]QYSW[=8I8;N6$K(5,A6&)&DT?")'5 [
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MA8Y-5/,RH2L50NE6])LK?3V$>C7HS^V,G)F,!B\C-;SSTP%1:UC40LT$["W
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MOCM-U.Q:EI*>MA=V9UE6?2>;>;5J;R'U.7<$DFY/MR!@P8#UZ0\P0^'<QM0
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M7>QMS;9RTPCJ9II5KLA&\,/\,E:3W5M/;7_5_J_V.K0" 00?H>#^./?NJ]>
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MR?6O1@MJ;0QNT<9+24UIZB81^>L;2TD\B?I 9?T1J/HH/LVC00+&D*U3S/\
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MG6:W$^WV$+!KB&/OS\)]#Y5_R=#&R@$ "W]?S^?\3[T>@BK55B3UCG_4LT!
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MODKKK*!"01<:JA;76X++<<@>TE[_ +C2="GDU0V_6_"H1S_+HN<4XC(!8("
M%!]5[@DV(O>WL.VZ_I&G"O4M21@TH/7IP616*6878V 'Y:WTY]JD1F(,:UID
M_P"3I*RE20>L\]?3XRGFJ:EU2*./4Q8V'IYL?S=OH/9@2-(U-3JBV\EY-'#"
M"7)\N@?R6X*[=$IAA=J;&)(3&$++]P3<6>UB!I/M.)YI9?"C6J>8KFGJ>AM:
M;7;;0@ED77=D4-:47[/GTJ\%M@S0+^V$LP(<K86^AO\ U-_:]8,APHK3HEW+
M>-$A[Z_*O0@T.VX85.F=0S@>164/&X!!&J-U*,%(N+C@^U)A+J%24HU:U'^#
M[.@M<[J9>V2#5'7@?7_/U/?"%R769I95!(U6OI'+:2QX 'XO[U].5%6DKTPN
MY#"M'1.FR2D\7UMJ'XTCD'B_UM;W4Q+0GI8DXDI3AU&DC5K+Z5OSJL./S_7\
M^T[J@!SGIT\":=-M11Q1B_D*ZB#86 X_()-_="XT::YZL#I!]:=-5?64L4?B
MB.L@6+O;D'ZO<?CW1&!H/(GI3!*JL-3?EU2O_-:W3NGN:;H#^5UTQGJK;O9_
M\P'.9@=S[RQ))K^G/@QUE*F6[_WN\JP5,5#7;_CHSMS&K.J)6+]W K7D'M4L
M"@&6@U'(KP 'G^T5-,@+Z'HNY@W*:Z:WV.VE93+AZ&ATD=X!) JR,(T#521I
MB*AD!ZM8ZAV;TSUCM_9O5VV=E4VU^O\ KW;.!V+UWMNBG>##8':6UL=!A]NX
ME:>.X)I:"G0RDD^:=GD;U.3[1 Q.R&205)I_Q>./F?4DGH5WUEOEMM$$6S72
MK$B"JJN< #M)SI  5*DE5"K4TZ.1&M :"(4\<5-1:(Q"(ETQ+I&E$2-!Z1^!
MP/Z^U[(H)$&<>6.HI)N1<.9F+7%36N3GC6O4,HI5@;AU-ASS]/I_0C5^?:4H
MY%=.>E2NRE2/@/4;\?\ $?[Q]?Q[H.E!-!\NEILS(K2U4F*F94^Y)D@4\:98
MD4% ?T_NI]!<DE3[602*PIJZ"6^V=52]B!*<"?\ 5G_8Z$6MJ5HJ.KK'%TI:
M:>I8?2ZP1-*1?_$+[4]!CHIL]5/7U$]?5N9*JME:IJ'/U+R<A!^ D2610. J
M@>_=>ZKP[C^>]#U)\]_CG\,WV+09C:/;N.VYBNTNY9,W502=-]I]RTW8]3\8
MM@-B88VQU=)VY_HERYE-2ZRPQ/ 8;NP5A58<KS7_ "WN>_"?3)#J:.,C,B1&
M(3N/Z,8E!)J*$4H02037.\PVVZ6FVLA/B%0S^2&02: ?Z3%* 4R"36H -A3*
M>0=2,"""+H\;J0593]4D1A<'Z@CV%>CGHSVT\I)F=OXVNG(:I>$PU1'YJ::1
MZ>5R.+&1H]7_ "%[]U[JJ#Y3KVYO;^9C\9.JMJ2=E[BZV@^+W9W9^\MD[5^2
M/9/QRVKBLK@/D+\?L#1=EYB3KVBJ4[7S>"P6:KZ.#;61DIZ.II*JH#N%E8CW
M5Q303\^JZ=V?S#^]>V5^1&%V%\I-X;!ZUIJ_XN]G;,[*W1UGTSM/L[JC;-?_
M ##Z+XZ]X[5S6TL14U<6UM@8'93T\U?#OLT^Z*.CC:KR?VM)7M3P>ZMI I4?
MZJ="CD_F3\O>B\!\J>S8>XJGNW'[#_F'=I?'*OZLW!UO@JW<NP,1W-UU@-@_
M"G+XF/!U^%R^*ZVS/R,W)M9JF>HBD@R&#SE54TC%8@S^Z]I4D#Y?\7T8S^9)
M\Q>[_B+L/I#![>[A-%WY@.H<KV[O^>3K/KRDZ5[HH^KLUU+M[LZGRV2WSDX=
MQXN6OGW55UE#M78\LVZWH:B6J62.GQY,WNJJ :XQ7I)YKY'[W[%R^[*S>';7
M6O8^;VW_ #.^E>G<7\4ZOKW&T65^.NP-I?-#%]<]==LU%1B\[1]D9O/]O=?4
M>+W3BL_FG;;*39^GGH::2E@"S>Z]3_CO1,]N?*GY.YFO[/\ DC@_DIMC.]FY
MKXD_#W=G8=+6P]6]/[8^.6&W#\GOD2G>?QKZ\A[>S%/TH/DCLJ*CBPV*/8\R
MY.H_ALRU\D355+X/=6( Q3S/_%]6&?(KN?/]CYS^5UN?%[@["Q?5?;'6??7?
M$-5N#:E3LG<>XNZ-I?$W_2+T'B^P-GTHIX\5N6AH,ON;<R[8E)IQFMO1MXG:
M@C*>ZT!36//HF6V]Z=_8?^6#\;=EUNXOE3L3Y#?/K"]%X>B[AZY[T[E^77R)
MQVVY.@*#MKLKY'[.VMN.CQF0ZSRE\-)#E,!B@M#139A#Y6D:-1[KU!J;T'1P
M/A!\C<K\A/E1T9VEBZK<&)K._OY8F(['^4O6=319C&8;8??G6O=VW^L=N"NV
MYE5;^Z.[HMR5/9VVYT AFR-/M55E\HQL13W6F% 1\^JV.N/EWV7\2>ANITV]
MW?NFJ[:[&[\[U^0?;53V!U+UCBMF=L[%R?\ ,&C^/F\9-^;XW-746_-Q[JV_
MM2.::EQNS%?+8S%FFJJIZ;$T=)!4^ZM2IX8_V.CO_P"S&]C=E5_7F;W]V3UU
MV-NZI_FF;1ZFR'QFJME8)-P?#;:>S^[N_>M=I;CJ6VMF*'L$[PWWL[9^,R=)
MG-T^?$U3UK5N,IC0STZC75: 5IZ=%+ZN[@[:VUMGX;XW:W:F0Z4I*S;?\DS%
M=J]O2;?;-[OW[LGLWK3Y0OF=B]L;P[$KZ[#G;,VY]O8VCI)S#2U\%3DS3SS5
M,M33J-^G5B!W?G_DZ5&XOY@W>'<,GR PNQ_E3N[JWK.'</Q"[.V;V;N_K/I3
M;'9G4&T-S_S$%^.O>&TMQ[/QM374VV=@;3V8E+-D:??9I]U45+%)/E_M:2O:
ME@]U[2!Q&?\ 8Z/Q\1?E?\I>Z?F[WIUUNO)]9#J+KW?/R,V-ENO:S=/7.'[(
MV9A>K]\;0VOT'V!M/KS&M/W+E<9W'M:HK\[GLIN)8<!+'E,5+@2M*]I_=58
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MV^$FI_;3H4J?*T4" >6,#_4@V(XX^G^'LUP$%6IT#)K.>1R=!ZS_ -X*9?\
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M+<_Z]Q?V720*6+4J!_A'4H[7>LZM&Q[!P/KT/'7.YI&I?X37'R.H7QM(UW
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M[.X?-9Y4^[:2FEI0TL9<.QB;W7@#TJ.N?G3\7>Q<OW)MY.U-E[+W7T!O7?\
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MEHH]11PWB/'0B@HBJ6"OJ)H"64$D?#?U\._F)COD3U//U;A?CG\MNE=]=8]
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ME _%(@/[*U_ET)74G4.YNV.RMKUL&)%1LW!U0R-75S,IIJVIB16H(H22PD@
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M *PMQ[VI (H.W_4.D3+BA^+IZIB0!;ZW;_8#\6_V'LR_AZ+IQW9'3FC:O\.
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M59*B:&GIX/),XAIJ.BHX$15CBC2"FI**C@5(:>FIX45(XXU2**-0 %4<)?\
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MD9H[ZDLK$@BWN67N;>T@VBX@@!M- JBX!;U('F.-:=8:<QV]Y<;WNJ;VS?O
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M0>#S^?QS_C_7W1J \/+JM2?/K*JV^A_UO]8VL?Z<6]T^SKW7?TL!_C_K,?\
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MO=>TT'SZ0E%_,@[_ .X-V]08WH?K7K'.[EH/DUO3IK?NP,-W&,MU5W+MZO\
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M?EUEAC4DG2+#TG_; _[:WO75)&( %<]9BMPP%OHP L.!8@<_X'WL'2P/H>F
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MH&7DQ\O\_4.2NKI 1).X&O4-'H_%K @ E>?I]??@*GIZ.QB0ZF6I]#U&=C(
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MW\R.!ZQ%V_FZ_P!YYQO;'?=B79[IR&@$\)DB:F"DE3G4>#H10G@1CJU7X?\
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M[]ULF@-30=2X8V"WT/I)5OHW*N %(/ULQ^G]3[UTT[+7B.LA N-(/]+<WO\
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M(S F[LOMJ:Y@ME!F>C<0/,C[.A?RA[><]\\AIMBV+78HI5I7.A-?'#'XJ#R
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M#WNOKTH,P/G@==6/]#]?Z<\?TXN??A]N>O=<0@;D*#?DG_7]^_/K=6]>NS&
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MG^STY'$&DC+ X[OLKP_D.EBY%R;BU[6L1?BX/]2/Q_K^S,M4D+P_U5Z-E%
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M_;J,R!G6FH<.D[ D"AS7HN3M)N7>>4R54%J8J*3[&E#K>*-82+L%'!.HVO\
M7VPNOZEI5GD#L,]QI^SJ555-IY?M+2 Z))!K:G$D_P"QT+>*HM**R(D1L8]4
M2B-F1K:D)M^EK<^S14\15$KLXJ#1C45' T]1Y'H$7MP-1!8MFN36A\C]OITJ
MH\=0U,?CKJ*FJ U#5XT&>)9)11UP JZ42M=A2U=OW$_M >SNTW'<(V\*/<)5
MC )(#$#M'H.@/O>P[#OMQ#>;QLMM>7,?PM-&LA /$#4#^73!N3JS:NX\/+B8
MZ"BQF2_ADE'C:O'T@A-.L<$D= 1X-#*E"SW('+(-)O>_L8\N^Y6Y;='<?6))
M<Q $>'6E:XP>( XXZAOG_P!FMCYKFLK[9EM]KDBP9$C&03D:!1>X8^5>D5NK
MH""LJ-F5>W<XVU,9MG P8F?,4M1+CZC!Y*BHE2BS444;^3_*LDGFEEC(G!(%
M^/8ZY=Y\VO=[.:QN@%O-7Z46*^I%3QH*\>/41<Y^U-_RLUE?;9>>)M<8_68B
MI_A!IY L1PZ#3NK:F\L;ELINS*Y2'<.7J,%'4;MW/AZ:EI\#49*HQ]/@VW$N
M*CABI*;/U5# L$X920SF6Q9B?8EL[7;S83SV"$:%(T$U/ICCZX^6.HXFW&:T
MN8H=VN-18]M$T_M/01=0X#+90[TWIMO:^3WY6;1P4]!N3;T\<E9(FU\_54_\
M5C2DI6-;E)YZ:E$%-21IIF<EN A]KX=BL]IDM3O.XJINV&C(&GSSY8Q7T_/I
M/-?[G/#<-M-JSQH#7MKCA_Q75HOQ<ZCRFQ*/=?8V[9\S1;][DJ:'/YO9E54L
MV'V+AZ8L-O[>@I \D$F8AQ9B%7-972PA^B>XKY[YBCW?<8]OL@O@6HTAZ#N
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MW>1P;7"98RUNS:OZ56\J^H-<T^><&R+XU=/Y3I'!=Q8/)U^WJZ+LCY6_)'Y
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M%04Y\"-*"XLOC@Y!_%AR>/9%N5RT\Q"DUK04\Q7_  GHSLXUB@&H]I%3]O\
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MI'^P)%[VX']?]<CW[KW64)P+FQXN/Z?U%_?NO=8C3 ZO6XU?T-A]> 0/JO\
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MXNGDI2U5E52OAD5I,E) !#2UPA#"- P8H + B_MF[Y?(W2/<9)%,:D$H,\.
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M8VQ\GVCUU58^FQN/:!\E504!;(X%JAEI/XF*@2%T5#+Z9 "NM@&M<>RO;]Z
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MEP@8>!I120*$''D3]OIU>1D4JJM4D<>B3CY85V'EH:1(YCFO.TL-(TS 0MY
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M([GW5"2<GH5<W%4SX;+0T4:2UDV-KHJ2*33XY*F2EE2".360NAY2 ;\6/MV
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M%./6>)#KYL;"U@.!?_$_ZWNR&H)ZM(1V@"G4E5TWYX]VZ;\OGUCFTWBU:O\
M.@BU[7 )!-B+@?[;W[KW6;W[KW7O?NO==$@<DV]^Z]UB!:0_1HU'XXNPX*L&
M'(^G(_H??NO=90 HM^!_7W[KW7?OW7NO>_=>Z__6W^/?NO=>]^Z]U[W[KW1<
M>\<1%!4X?/QQL9*E9<96%197\*M4T;.;@>07=1]"1_K >R'>8P#!.J]Q)!IY
MT&.I1]N+UF_>.VN_8 )%KP!)TM3^1Z P?V3QZD#\7X!_!X'/LEA(9#*,"M,\
M:_YNI//F/0]=^W./7NLD3%'#+];$<V*LI%F5U((9&7@C\CW=#1L]4= ZE3_J
M_P!GIKJL0C2-58V-K %Y**Q)CL/W)*6]]<(/!7DK_K>WXU)/:>/E]GITI@OF
M2,07C>= _P#@#?/Y]=TLHOXVN#8GFX -_P!.GZAA^?:I%8D]U:]:E0BK =O3
MW3C]!\B_DZ+FYX((_I<7]VHQ.G2:](9FKJ'AG[>G6'DK;Z$_XVO>P/%_Z^_(
M:$=%\APP(KCI[AX2Q'*L0?P+@V/^\^[D@-7U Z0GC7IS@?\ %C] /\?K?W8B
MC!O+I+,II6O3U2R:2;ZK6%A^ /\ ;_6P]WZ+95K0^=>E715*>-;1M= O)( Y
MY!!_'NQR1T37,3!FJP[NE)#,7%K>H#GZ?TM^?;^G25)Z*)$TGCT\T\@&EK&U
MK<?4'_;_ $'M400*5[NB^X0T\J#IY1K@WN?I;_B?]?WY:@DEJ]%S*,4%.LQ)
M^O\ 06)/UY'TM];6]W'GTUU,6^@7 / L/]@+>V3\1IZ]-'B>L,D<86TBJ\9<
MLRR*KJ/J;@,#;W:-O#),9(!ZTX64 2(II\NJA?D.-^?Z6(^N\9MZO@QF/R-3
MGL3E)Q/18C+8;-N9H8L541#0KT%1*T+L&U1NMB+'WD'R7^Z1R\MXUXAN"@#K
MQ97'&M?(\?SZACF0;@F^2*]LPMQ(2I' KY4\NK$>@QN:+KW#0[RPU)B-PTTE
M5CZD44T53'EJ2EET8_-.T2+HEK*33Y%;U!T)_/N(.:6B;=YVM96:U+8!\J\1
M^1R/D>I,V)%6QMWT%9'6N>/Y_/[.F#O[Y#0]%;=J,K4;-W)NBKFKZ;%8L8BB
M:3%0U=;2F>FGS>1U 4%(&5@.-4K)H6S$'VUM^S_7*LOU2*E"2OX\&A '#\^G
M+G<V@EDA6U=G7S_#D5^W_5QZU]>Z^U^X.]JS.9/?&X<I7T-/6B./#8VF:CP6
M(@J7D&-HX,7#))4ZBJ7+'6]_\XU_9^Z%HIX-LM'CB@IJ!IJ:OG4<?SZ1QW6?
M'O&PW!?,4]?+YBG5KW\NNHS&V^HZ.DS&+CQL!E$?GJJ3^'R>$.29YG8+='4@
M@O\ 7ZFWMG=;(R;=8+W"Z 8E3QR:C \Z=.Q7GA3L *PXS\C_ )NF[YL_)CJ7
M?/6NZNEMDID.R]Y9<TNAML1J^+VI7XK(Q5<&8R66G"1***>D/$.N]R+B]O:?
M9]LNK:;ZJ5E4@$:>+&HX^@'3T]Y%.HCC!I6M3P_S]43[FVUN3"[U7(9Z9HTW
M9,):>;4WEJ6I48FHB*V$AB6(JQO>]K_7VY-#-;W#/,X*DUIYYZ?\56B"A<@=
M&)Q?5.U]S[9Q65:HDCD:ID-5^Y4R2R(.+U@U!)%9_I:UCQ[$,%E;W$ G.*?S
MZ34*EB3T7SMG+KL?-4M%LG)SR82L>GH=Q9A()%QL,M/.#244%5$5A>8,65M+
M7%_K[#NZSO;.GT2L%IFOF:^7RITLM@K0S?Q5_9CI?[5[8IJW+E=W96)V:C(&
M4J9(XZAX)%2BA@6.+13UJA0J1,5#* ;D\GV86^YA[:.-FH[#-?/RZ1*D@9]7
MP@]!+W1U_C\'N^EWOM*LJ*K%BDAEKZ'+HM)*LP4_=G%S.X7*A5(D6)!J1/5]
M/95?V?TX2X$@4-7CY_9TOAGB9EB1M3G&/+I$Y/+Y+>^#BQN-E-5202I+3"HG
M%)C::>%3^[YIQ=9O5R5#&WM%)*\\"JS@KY?+[>GEMEMY'(()8=-F*VSN"+'4
MN*R=3CFIWUT;O#Y6I7J9I'DIC451C#M32$Z%LNDM87M[9AM'FC6!)5#UXYIU
M=F '2_J(EIZ3&XQJ2GC3&T@BFT('AU0AG:T;%F\X87!XN?Q[-4C:U1+9R&8&
MM1P_S]%<KAG:G'I_I&*"&JC=:6J9 3&UVBFC,:#PP)ZM-3,=3/SP/I[5_P"@
M\//JE :>E.E)3T$%51UM6V1J*MO*9H*6M>!,9C$L5*4-D!2:0'2TK&Y%@/?C
M"-&ISV5\N->F&E[@ IU=)[%4U9BJZ>OIZ:%)4:TCLWVPDAD4I-ID6R-5KK!0
M$<VY]LLL:BJZM7^?JT;'4!7'5GG7?4?1W:WQVQ^3VW05]'V9B\='C-^;XVIX
M,3)0UX\\+/+CJB5J:MD8R*)H&ATR :U(]G=JCG1%*R?32)08.K5Y@^7V'ILK
MJ<:3WU-?3HM.S?C=O'J;#;E3 Y/&9N?).[8G='V\M'6FP<KBYX"LU+3_ ',<
M)76H :=P"![?V_8[BS6]#W"-*X[*5QGSKGAZ=(MQF#*"BD%?/I7],R[B[8WE
M1=9X2IBKLQF(3/4U64<T_P!O+111I,M08P==.\K^-C^K2I Y]BS;=PCVRSFO
M+Q6:. :FTTJ0/(5\^@ONIDNYK>QA:EQ,="D\*GS-,TZO:Z&Z4PW1VT)=NX^M
MDRN5S&1ESNY<S(OB%?EZB**'QT=/R*;%T4$0C@CN2$Y)N?<2<T\Q3\R[H;V2
M/1 BZ(TK4JH]3ZGB?GT.N7=CBV+;5ME8-.S:G8<"W^8<!T.(0@@W_/L-]'O6
M3W[KW6'R:M.D7!N-0Y /(']#8WY/X]^Z]UR1&4W9RW  '^]D_DD^_=>ZR>_=
M>ZQ3P05,4D%3#%402KHEAGC26*13]5DCD#(ZG^A'OW7N@TS/2'2VXF9MP=0]
M7YUGOK;,[ VIDV>_UU&MQ,Y:_P#C[]UNI]>D'4?#[XE5<GEJOBY\<ZE^?74=
M(]:327/U/DDVTQYL/]M[]U[4?4]>@^'OQ(I7\M-\6OCG3R<?N0=(]9Q/QR/7
M'MA6X/OW7M3>IZ7.'Z,Z3V\5; =.]68-DMH.'Z^VEC"EOII-%B("MO\ #W[K
MU3Z]";3TU/20QT])3PTM/$-,4%/$D,,:_P"ICBC540?X >_=:ZS>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NB^=U?&OKKN]8JW<%/5XC=%'2M1X[=F"D2ERL
M-,6UI25RNCTV6H8I266*=6*$G0RZC<4<N\W;MRWXD=DRO:.P+1N*J2/,'BI^
M8QZ@]$>[<O[?N[+-.E+E10,./YCS_P!6>B*[T^*':?6!BK]H;CW)O!?0*3*X
M6C!KZ">%K0ID<,:J5FADC.D20ET4?4#W*VT\][%O1,&X6Z6S 9UD:6KQTM0<
M.-"!7R/47[WRSO\ MCK<6B?41$FGA U6E/B!]> (KPS3H<L9N^DZWZW9LWA(
MYYLWD:+&[NP=1(80N3EB6.MR#4]0ID242:7FA(! ]2^PW+9Q;[O+FPN@8H 2
MKC_CO^;HQM)[K;-LAEO8"AN6TE6X@KFO\^@7ZG^-6;[*>JR&;R7\'ZZR>2R=
M?0X3"52Z:J&MJY9DEILDD9DBCB7TJ +$7!M[UOVYVVUW"4!:XB TCAI:E#J!
MZ$%@D^YP+"M H-:\1GJR/8/76#Z^VU1;3Q6N?#XV83T$-6L;M!("KE[HBJ\I
MF&LM879B;#W'.Y[K<;I=O>38F84-/3H6V5BMI"(M6H U_/UZ)E\QOF/LSJ_"
M9_KW:V57,]C/!]M6TN+M5Q8%I+$T^0GCUPP5Q%M4;<QCAK$V]F>RV*1C]YWA
M B7X%\R?(T]/3U^SI+N$[2GZ:!P"#5B>! _"/GT!?\OG<A[1;-;H[!RD>4SM
M)65:4U B24T--XY5>"::)'^WGJ(XB=,B!;@?3V(=VW*XN-ECEM(@M9-)( K2
MG#I!&(YKI%G:L(IC^EY='X^56V]N[J^/':."S^8QFW*&IVI734>8RDM-3T=#
ME:"+[_$OKJ62(O)5TR( #J.LA>;>P9L[W"W\9MU+.:@T%<$9)^0P2?ET=7RI
M],5J :C3]H]/RKUJR[US^6S&\*3<4E#;'YG%8A S!GIHJF"E2E@JXG.D1JUA
M<_3GGV?2R7$LPAN%/AGB?LZ+Q"6A8:A7H?=O=;U.\L%4Y>'<-33U<$\"US4C
MPTD)B,062%(D'D\:K_NP:;7X]G-OMT3Q:]50.D3+X9H>@\[>IJKJ2CI1L_*B
M7*U-+]IE:>E1ZF&BP;Z91D*N:,7A1:A+JSV+M?\ 'M#N,#6+(8GR>!\@?GT[
M'$7TD&B_/J-MKNJ2*7!U&X\O%6X]4BI:>OJG7711TE%Z8:":/2\D:1*5$4H8
M:S<&Y]^6_1D1"W=Y_,>@ZM):.6#AEQGS_E\^H_<VV-B[KPN([!P,M1MN?'1F
M2JS,TWW5+45=5*II(JG%H#613U,YTZTL$!!;CVUN-O:M;I/ I5QG/RSU:"8,
MS0*I#G%?*I_R= EMPY;?E)60)35"4E#,:*KJ:8"JEEE#_P"5+0TS66&0LH(D
M<$ GZ>R>/ZJ[6A4M'3R\OG^72E(EMC5C67@3T\0=:1[<++'1Y:.5:DF*/,RR
MU,IGFT,::1(41*?[Y7"#0"P)%K^_(@@(5Y :D#%?\W5]:G D%.C2;_\ BKW7
MUKL3$]B;CV'+M_8D\%+5+KR=!)48DUH1HX\YC#4-DJ!7=K!W4\6+!?9A.T#*
M]M:-KD7B5X?ZOF.D<BM$XC<'/ ^70(4*-"BTM-,D==)')J8#7$[3A^(V"F*1
MW@+(I(&B]_:E9 X "GIEX_#KJ..GC%2YF*FKEI8@:E:*HDI(O').B2HNF%)(
M[GRE#SH4BYMS[?@:ZEM9)  )1PZ:\&W*\#UBDAR])CZ:KJXJ*/-M'%'64D,A
M-303^&TLA:P#2U%[LHL(SQ]?=!+<4%::NGM8 I0TZ$'IOM+>G5-/V)EMJU<D
M63KL%&KXUJB=5JQ2UFF:FIJ<I*)JZM281J+ ,Q 8V]O07KBWF,D.ME-0"*Y'
M _EUID9G257 I_J_9T)'6?RXS&Y*?<F-K<1D\+E*U9J7[7)4+L\LD<;?<(@E
M55A?5=6^G(-O9C:[U<7(@#6A#J,$^OY?RZ]/;P,&.26X_GT#M/ELY2;@Q>_*
M&&?'9A<Z&FHY&E:.GK'J1',\4Q_=$592N9-5[I?Z^QURS&UY.TLT1)G,D7V,
MHJ2?Z/IY]1QS5(%2WAA!4K.!GS_9UMC;;D:;;V!F>43/+A<7(TP)(E9Z&!FE
M!-R1(3?GGGWCU> +=W2A: 2-CT[CCJ9K0DVML2:GPUSZX'3U[3=*.O>_=>Z]
M[]U[KWOW7NN#NL:EF-A_MR3^  .2??J@<>O=-;2F9O)8 J2H!8LH^AN+$K?^
MI'^P]T9@,=/)$2*D=<ED$=[AC<_6]_\ >2;^])&TH/<,=6E 0B@ITY)] >.5
M7Z?UYO?W<"E>D_'KG[WU[KQ /U_K?_8CZ>_=>ZQHK*6):]_H/P!<GZ?2_/U]
M^Z]UYA(0X!53?TD7)TV'U_HU[_U]^Z]UTL5CJ?UL1:Y^@O\ 4 ?3_8^_=>ZR
M^_=>ZX%@#8@_[;CWNGGUJHX=># FP_I_L/K[]2@ZT...'7/WKJW7_]??X]^Z
M]U[W[KW7O?NO=!]V?BSD]G9,(ADEH53(1*H!;_)C>4K?@$4[.?:6\B$MNX(J
M1G]G0AY6O/HM]L)"^E&;2?L;_9IT40*S(K\6'[>K\DCFX_P(_/L)HH76H&"Q
M/4^:@K%?S_+KRJ1>X!)' X/Y^O\ K<>[\/LZW7UZ[B'[EB/H#Q_0_P"/NT>6
MH1Y=>;A4=9]+BWB'[@]0<'2R$?VE:UP1[51*@< UITTY6A,@JOIQZS-34E00
MU1&T52!_P*@4"1[?B>.X28'\GAO:FKEAII7U\_SZ3"6>*HB-;>OPL<#[/,?X
M.L8QM0C!Z9Q4JMR/&QU&_P!1XSR+7^GX]NZ7I3%?7J_U<+#3,I0_/A^WIQ@9
MT-GCD0_6Q6P'U^A-AJN?Q[;"'54D4'2:32P;0X(^WIT6=2%"K)^ >/JWY/!Y
MO[<"]P.H<>D9336I!/3G#)S]'YM:ZGCZW'O8C:M2XITF<8Z?*;4UPH)#+:]C
MQ<  L1PH'NW'SZ*YB%J#2O2DQZ@ ZR2%"J=)N+#\CZ?7^ONP'#[>BJ[/P@#)
MZ5%)*MOH1<<<W)Y'U)_/M4V: >O1-.AXUQT\P.60@< 7L?\ 8\BX_/MSQ*BG
MGTAE4].T<ZV">K4?KQP3^+F_T'NP!H,T/184.3BG4_4#:P(X'UMS^+_7W>N.
M&>D^@YX=2UF%@/43^>!_3\<B_/NI0DU'3.@UZR^EQ8@$<$@BX_J+CZ>VR"*5
MZIT7SN&MRT.<V=CT1I-OUTF1>5O"DD2YFC$=13Q5,S*TD-Z5F:%;JK.I)N0+
M"OEE(1%?L';ZBF/2AX]$>\/66T26&L1/$"IKT)^TY1]K"TAN'@B )Y%[ BY)
MX'^/LLO4(+ FI!Z,HM(8*@H@% #QIU-WQM:CWIM#<FU:T1B#.XBMH/(\,<X@
MGEA84E6(I 4=Z2I"2+?^TH^GM/:7#6MS!.ARK#]GG_+IR9 \;K3)'59OQ.^+
M.?V[O;<^:[(VUC%HJF&2@>FG85"5E2D_E:MHD,=J9*F1;M&. ";-;W(&\[O%
M9V<S6<ZFYG*GLS0!:'5]O^'H+6UN+^[/BH5"\0<?L_(=);^8?\AZ38V(QOQ_
MZDJ*'&Y#,P?Q'?N0P>E:S$;?D=X(,+CZV*\-)DLI4+^\;ETBTCC4?9!MWU9=
MKVZD8S-@:O3S/R]!\J^O1M<FW*B*(<*9&1\L]$>Q^8VML#;>X:R2IHJ'?V9V
ME()\<'D,-)5P4"OY!Y6E=,A7A \Y#:&D)T@+Q[$HF@^E^HEQ=5(^5!P_/UZ+
MH8I!\1''HFF3WAELEC\#D=V91I:I:<)C8BC&GQRR%Y[^148>.I:Q=1^;<\'V
M&[J\,RZY3E6H/L'1J%(H//H:<5V>]!TWNFCPWKS7\/:%A&+S4-+D:B*DFK8P
MPU.U/3RO(/P.#^/9RFX1_NX00D^*3^5*=5*%J"O0Q;MVWU/GNGXNL\2\8KFC
MH(*26!H)LE-/31)-'D6DG.A7$HUWYU:R#^/;]R+2[V_1&*W '\^K*63!X5SU
M7/N#86XMC[KIIMRPXS[6&H@H\5.LXE.4HZEO&E1C:,CR?<4DC$R?5(_J/8*D
MM;N!E>=2-/"G#I>IBEC>@[.!\CT^=NTF\UVM@X\GC8ZVGFFJ%VG'C*E\KDIZ
MJ>..DBB@I:835,E;7/,D44"*9)'<*!]/:N_^JN;:W,^(UK2GSI6O^3I+8K8Q
M33/")*XU5'[*9_;U;#\4OY>&]\KU!B=P=K[7JMGYV2D6HH-B;A6*DSRH41H:
M?(0P/.<:YOJ:.0K*&]+ 'Z*+*YV>VBBBF5GD;B1P3YGU)]!PZ?E\1I9'!(0\
M/7_8Z'CK'^6G!/V+C]Q=CM%%L/"::D[8CJ?-7;NK!(TL-)DWA"+086G>VM01
M-)I55*@E@Q?7>WPDFP)9S\L#_/\ 9^WJL2R.6UBB]$F_F 9[IW&]@UF!ZGZM
MP&W6V-4)3;LS^WW^QI<['*Z4_B>AI;TAGHY[D3Z1*"IU$@^S'PVBLH1=2$W1
M(?-*!2/AJ//Y=(24EE<1BBC_ #\>BGX7 Y3/K^QCJFJ2JBC-'H1G;U*ND1R!
M1'I :S?0D^WXHI[F(?3V[N=7D,_;]G3;2!&:O0@Y3I+=*;9J'RM-68?&L:6H
M:=(M-4(Z6827I(AP9K@!6/H7ZGZ>S1MKOC;DF'2!0Y/#Y&E<]($N%DG*!&#4
M/$8Z0F1H7R#LF$DJ$\$4LU?#,XG+R GR53,+MYWCMY3]"?T@#V2,"NH'R/2M
M" U3PZ56VMQ]H;5Z_P I!UI19:NR]/G_ .)YO#4%+*YJL;'0)]W43U,;!X4I
MXE7QA@R,2>0?:Q+F[C@;Z2-C(. I_J\NJHRM=1U:@S_@Z$S;WR&WYF.M<E05
MF)RN,S+Q&:;$5*&..>61]017=ED+E5/Z?HQO[--OW"[N59I[<JZBE2,_ETW>
M*ACD :O3S\5US&.^1_5<.%EDIVW7G\;2U,DS/'-1X^IF6NG#?4L:>2F*$<B3
M5SQ[&+V^GE+F*XDB.@6K$&GS%.HZGF9^;-ACBD'^Y"@BOR/6SXH(OJM?4;$#
M^S^+WOS[Q[ZFORIUR/'/OW7NL1.IP%;@#U"Y_K]001<^_=>ZY(I50&TWNQNJ
MZ1R2;V_J1]?\??NO=<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5[?+WJ;LW<N7
MQ.0V/CUK-IY66D?=M10R1IEL'D,:&:GRII'\2U&.GID"SSAF>,J RZ;'W+7M
MWONQV,-U;;B_AWPKX9/P.&XK7R8'@*4/46\][3N\DL5[9(TME6K*N60\*@>8
M;S/ET+?QJV7G-B8#(TN4W/4YBAS+T&2QF-J*>*-<'5K%(F1:FD1V=XLCZ':-
MP%#(2/J1[#'..Y6VZ7IDM$&I"58^H' ?D:TZ%?+%A=VEC')=QE0Z@BO^KTZ%
MKM7;6_MU;4S.-Z[WD=CY^OPU138_.&BAK&HZLLLL1BCE5OMVJD!B,X#/ &#H
MI86]ARPFLXI%^LB+)J'#T\\>=/3HVOH;R73])*JX-:US\L>O6O=)U!G\EW+)
MU]N&::?.Y3*9#!97*5-5&HCW3%Y(I*NOG@1?N:F*9=9#_P# DL&)LWL?-8PW
MTVJI_=@A,E0/2E,?,'H(3S3"18B")=5/E^WJT3J'X][>^'_76^NQ]][G(IL9
MCYL]F*QE++&M+&%BIXX(?29JJH9(D51=F< ^R67=[5S%MFWQ,;<DDDT%!Y_R
MK3]G1T=LG,!>1U#BA&?,<.J_LGV7O/Y5[MHMQ[RS,TO7T-;4&KZ\J*IEPN%I
MZ=]>$>:E 2@R%5DJ9E>ZEYH9%(;\>S_:[:"HEL(E2W13JU88XXGC7]N.BQC<
MM<J9Y=4H!IZ<,_['13>S-[8K/3[GV;0X&FQ]!M[<SJ^29#"E.E'ZHZ:FL$7P
M'TW7^B#CD^RBYN/JWF6(J-)\\?LZ.8/$H-7#I;='[VQ]'4Y*CKFCE$[*8Z20
M*KR3B,_M0 ,4/F5-37) )M[,-KN$ H[@JO'[/ETU*C,"PZ7O4C=<YKK;<^:W
M<T+Y_?-9NN7(1U\BM]D),C68Z#!1036+>&")53G2FJX]^:XM+F&[64F@!\O+
MY=.02!>THW^3\^B,=B])9O:J1Y6BKZ+^Y6-$E8,GD#JJL2(Y%>DBKTIU:GJU
MF%HT92O%BW/L.7FVR1!;F($Q#..E8D6O=6G4HT.4RW7V5W#'N+'T./@QXK:K
M;U3'*:FI5=)DJIG53$D CN][@  7]J&22YLY"C !4)-33%,T^?2..2"&Y&H,
M=3 "@X5ZMJ_EL? C/XG9<?:_>46-6CWO!!G-C;.C,W\8IMNUX6KQ.4W3,+4=
M/49.ED6H2CB\K1QNGE</J0%-MO$UE&8[<=U.)'#\O7HV>W\1JFFG_5GJS'&_
M$CJFFW3C-V93'R9JIPN27+XO'5PA.-@R4#JU%65,"1J*V2A*@QJ_H# 7!M[=
MN>8KFXA,0MXD8BA8#/Y>E?7B/+IM=OA#AR32O#JL3^8QV?\ Z2>UZ'J+;M;4
MY/"[,HPFZZ?%5+-22Y3(1W>CK!&PB:?':E+ZKA"MC[,MO4V>TEQ$WU#FO#R_
M#_+/1?<OXU\0IP!2OE\\_;U7]T7U[2YS)R[7S]6])745?/3XRTR":OH/,4%6
M!*ZE@=.FPY'^M[-=EA6:8QRGNI^73=[(L41E/P_+CU=9LKX0[?I=ET=;2U-#
M_&,I0K50B5+3>J(L$27U())0 /\ "_U]^DYEL;.^D@6R/AHU"?+'$]53;II$
M5_&6C#&:<>JJLWUBT/:.ZL6U;%34.U\HE-54[CR25.0ETR3TPL6!^U8C4YMR
MUB/Q[7W-H&W&&6-T%NP!I7.<\/L/3".&34#VK@_EBO0H;2ZJ%%N[;F[J26CA
MI:3/P2(K2Q/_ !$K.K34%5&\;PB.=T =[%4'-KCV<0[-WO-J3P:$T_%3UI2G
M\\]$KWTJ2E3$XC+4!H*<?MZ-=N'IS%YC)96+([?VY/N'+T\];05NTXEG6"J6
M05#Z:2G19ZR.*)@KNBD J3;GVIM9+(0K<&)H[=&TL9%"D^50>''(Z*-PWV>)
MV@@K))J( C[J'TI\O/HM]%\9.WMT9+^Z>!VI7U--7[@&/?/24\E+B,71S5$3
M3YVKK:F.)TIJ2B5P/2TGE 0*6/L40\P\O;#:+<27L9TZGT U8E@>T >9-/E3
MSZ)C9;SS#)# EN5=)]3%J@!<>=.(\QUL#8/%QX/"8?"Q2/+%B,7C\7%+(;R2
MQX^DAI$D<GDNZP@G_$^\9KF9KFXGN& #2.S'[6)/^7J<H(A!##"#4(H7]@IT
MZ>V>G>O>_=>Z][]U[KIF5068@ ?4GZ>_=>Z8*JN+N55F  X"_@AC]?ZAE%C_
M +QP;^Z,14#SZ606KOWFE >L,$H56U DW&D+]  MK?@6]U U<#^WIRZ B*!3
M3'^7J8G+I]6#*2 >?]>X/]/=XS16IQU?Y/\ 4>DDM>VIZ<86M<$D\@ <FWU_
MVWNW3;D"G4GW[K77O?NO=>]^Z]U[W[KW71-A<^_=>)IU'ED":F)8*"!Q?F]A
MQ_7W9?2F>J5J:#K":N.UK,3_ %*\W_V)O[MX<AX+CK>DD&A'62"59')&H#2!
M8CZ$%B?\/=""./7E%//J7[UU;K__T-_CW[KW7O?NO=>]^Z]UBGB6>&6%@"LT
M;Q,&%U*NI5@00;@@^]$5!'5D8HRNIHP-1^71'\OC),/F,ABI3K^QJ9J92#Z;
M(Y,9T_ZIX6!!_(]A*0)%(\!KXJGTQ3RSZ]9#;7>KN&VVEW%\3J*U]:9_('IN
MN!?_ %_K87M_3^O/NF*UZ,=)(%<_Y_7KFB:CJ51?GFX'UM>_N\0#/0<<]4+E
M/B8GY=9@C!K\&P/Y_K_4?4CVI0'5TV\@84%>L@X(_P!8@_7_ %A:_P!+>WXZ
M:QTW7U/GU/BN&0#BP^G %])OS8>WSTFD ())ZG":;@>GZ_4^HC_#GZ^]4&DC
M4>DI5>I\,I) *KQR"40DGZ?6WT]Z45SJK3IIDH#DC\SU-68W'I6Y/! "_P"W
MM_3W:OSZ3-&,]QZ<H95T-?42590?]JM^>1^;^]AM7 ](Y(R#2@K6O3]02HJ:
M?4"VD?3^E@;G\>]C%/6O1;=1L> &.E%3RHH-[\7'^W/%O;XD&*''15*C,"!T
M]TTEOJ2023;_ %_Z@?T]N'#5Z02*?3IR%Q<@FXY'^'^M[N'"_%TB=>&D8\^G
M.*9"NKFW ^AO<#D?ZU_;H\^D3*02I'4WZV(XX'/ _'^O_3W8=)C2N.I*RII
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M'3W1^E9 02=0/I_UAQ_L?;FAAAL=)Y."]3C_ +W]?>@/BZHI\NLRDE03]?\
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M_/I3^T?2OKWOW7NO>_=>Z][]U[KHFPN?H/?NO= WNS.K55CTT+W\#Z-2%BH
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MU#(QTE*_+'6=&*L"OU) /T^E^1S]/;X &F@X])' )(/"O3HA%^;?I^O^%_\
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M/).S2,27D-A]+D7_ ,."VGV5E@Q+*V*]2E)&D$(11VCI2XU7>10BEE4BQO\
M0  \D\\6]O(I*X'GT$]Q=#*"IQ3I=TBL62RD@&_T'^L;_P"(]J(AI4ZN@U.Z
M=YJ.'3_3CDL1ZN!_AJ"_[;VJA&?E7^716W\NGFD^CD#FP_WC\?[S[<EXL/GT
MVXX'J61_OOZ>Z@_MZ]3K+I0?4?[R?^*^ZU/5J#K"?K[N.J<:=1JD^A>0!J/!
MX^E[F_U-_>TPQ)XTX];7B03TW2M8'^OU_P!C[N[A5ZL!Y=-,TA!'-[7#$_ZH
MCCVF)#"H.>G8\-GJ#+)8L%/KO?Z7_P"#7_%[>VJ U(..G*5.,CKG$2X!)O8\
M_C3S_3Z< CWY31A09IU1A@^72GQUS*I/^HY_U[./?EH' IU4Y6O3[[>ZIU__
MU-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=!9VAA358Z#,P(6EQ9;[FPN#0S"TKD
M?JO!(%;C^S>_LMW*$M")47O4YIZ?ZJ="OE/<?I;YK662D,JT%>&NN/VY ^?0
M",BW)2[6(N0;VO:X/^-_9(&U=I^+_5QZE6-V&D-@$=82G' 8D_3Z<V//NAK4
MXST\&6F&ZX$$?52+_2_^O_O7MR'$@KQSU8$'@>NH[ZU'XY_WH^UR?$!TW)4*
M<=3$%W7_ %_^(_Q]O-6AITG/#K.1I86) ^OX_P")X]LBND4X]:&5/68-^1;_
M &-[G_D7NRG2M-617JA%*@\>I"GD'Z?2_P#QOW<5TU\Z=,D>1ZGHZ\#4#?G_
M &/'^V]Z34* C!Z2,C9-#CIWHY0A.ME75] ;C_?<^W1TBGC+"H4GI3T3+9C?
M@W_XCG_8>_-4CHGN :@4ST\TTB*>6 X_/]/\+?CVJ^($#I!,I(J!T[0LH!N;
M?D?ZP^OT]Z0G()STC8<.I8O]1?\ !7C^ECQ_KCV\KC@3TDD"^7'IS4ZD#7'(
M4&W !L"1_M_Q[\<&OKTD."1U*4\?7FW^^^@_I[=%*+Z=,,#4GY]=_P"QX/\
M3W;JI%./'J#EJ>&LQ=535,(E290$# >J164JR_[7&1>_UX]N6[,LRLM01TGG
M560@GCY=!C5[>D,J*K'3(J^8%OVU8&YTH;N!;Z"_U]F;R:F+&E>DL,>F, #
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M]AQ_3W4CA_JX=/'2N//J92+JL6Y!)'U(!(M_O%Q[WDUIQQUYS5,_+I48Y?W
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MO>_=>Z][]U[KWOW7NNM2_P"J'UM]1]3S;_7M[]U[KOW[KW4><$JP0>HBU_\
M;<V/OP^S'7L>O3:1*CJ2\BLMBVEM(*@W ;ZW2PYM^/=SHH36AZL QR%J.G.G
MF\T:N5TL1ZDYNI-[7O\ U'/]?=.M$$<1UG]^ZUU[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]TGLS":J6")T_;A/D!-K%F]))/U 7Z6_-_:NT?PV9AQ(ITENU
MUQJ/Z0/2+J<'3I-))X(P2I8&U@Q<GDB]C:_']/:UI2X&H_GTVB*J:D8:_3_8
MZ:%VW3%M=3 U54&37")40QP6Y N>5'Y%_P ^]"32*JV?EUYES\!)^?3UC=K4
M4OG6KC6I68W(J;MJC(MHFCN%=X[D!K7L?=))V5*DFO7A'J.C1@^O3ZNTZ"BI
MZC[6FABO!*D$2+I6*T9$:D7]9'_$>TZW3,ZAO/JYMP@U+Q'0:8+:-()'>KHT
MEG=V4AN3YD9@S.C>@R,2#_2WMV)BC2D&A/3*QY[E[>EG-M"DIJ>*.\3.Q8GP
MQHDI5N2I( N!?Z^[K<NY.3CUZ<,,:@D <.@SR>S88ZXK21RQ!V2\K/KB92VH
M^<$,K(GU^G'X]O?5N.)Z;\(E@ #3ITHMD5,ZM!31BGCC\DA,>E0ID'J9==[J
MUKK>Y'X]U-W(#4D=6^FCX5_U>?3K2;*I,31?=33F*JF8A$C0>9TC),CM(/4K
MO^D?Z_O1NI"Q%<#]GV=6%O$HQTD\Q%#+Y)TIEIXCJB29U:1U:12BF,Z3>1&-
MS_0>U*71!H6Z:9#2H4](H[+CER$<4L4S05E71/4Z 6E>)Y8DJG#W!B$W(O\
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M%EQB%F?2A6P_4C.?KSI4&X ^GY_K^/;JRD"E,]49*D$''7HD\+N(H5AT6 (
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MZQ;_ !(;CWZ,4!ZK7J4J$#@$_GZ>[=5Z[L?Z'_;'W[KW6%TTM959A8FXL+$
M'^EN3[]UNI\NH+*Y4A5<$L23="0#?CZ\6/O;T;3PZ\.F^6X!X/I/U(L/J0;G
M\ >VRNHU/5EIPZ;G9CJ:VDGCD->W]?I]./=3Y46N*?+I\%D&.'4/Q*Q8WL6N
M38?D_P"N!_3WJAX:34=4!QPZS0QLHLMV]1/'#$<"Y!M[VJ$Y(QU8=HZ4=#"_
ME1K$64?TT@#FU[WN1_A[N":C!ZK)4QMD5/\ GZ>@Q$C)8$?JO<W7BYO<6-S:
/UO\ 8^[=,=9??NO=?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
